<?xml version="1.0" encoding="UTF-8"?>
<rdf:RDF
   xmlns:ao="http://www.w3.org/ns/oa#"
   xmlns:dailymed="http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/"
   xmlns:dct="http://purl.org/dc/terms/"
   xmlns:dikbD2R="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/"
   xmlns:domeo="http://www.w3.org/ns/domeo#"
   xmlns:foafx="http://xmlns.com/foaf/0.1/"
   xmlns:ns1="ncit:"
   xmlns:pav="http://purl.org/pav/"
   xmlns:permissions="http://vocab.deri.ie/cpo#"
   xmlns:poc="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#"
   xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
   xmlns:rdfs="http://www.w3.org/2000/01/rdf-schema#"
   xmlns:sio="http://semanticscience.org/resource/"
>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:7C3ED630-095E-46C1-9254-E12EC01A6C0B">
    <ao:item rdf:resource="urn:domeoclient:uuid:AAEFE98C-39D7-46CB-BE01-0CEE69109804"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:070E2A64-30A3-49B0-980D-E6D564CF7473"/>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="N0dccb356d55d459d873dc136f1c35557"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4B204B72-F327-4522-814B-751D36B88B82"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:A4F26A0D-380A-4D5D-9B97-3201413D165B"/>
    <pav:createdOn>2015-08-26 16:11:31 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB05F5-AF88-4B04-87DC-5826864F9BE3</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:deleted>false</domeo:deleted>
    <pav:lastSavedOn>2015-10-09 13:39:25 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:BC9BF70A-8C2D-4C02-85CB-CFA09829ED3D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:47322827-ADED-4C7A-AA4D-868F6BE857D6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:F179D434-4611-4764-BC78-8C0904DFF47C"/>
    <pav:previousVersion>urn:domeoserver:annotationset:9D7FFA51-EA63-463A-80AB-A9778FCB751A</pav:previousVersion>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:D6FC87AF-703F-412F-B64A-DDC21D3C4AA9"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5d103551-978f-472a-9c62-51e6e4dea068.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E8A26B3A-BA52-4768-BB64-F9A0C1CB4C22">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> The effect of</ao:suffix>
    <ao:exact>Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated. In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2015-09-14 11:11:20 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E8A26B3A-BA52-4768-BB64-F9A0C1CB4C22"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/62ad31c0-8ba1-47f3-8e3e-79498dabd5cb">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:71031431-0ea2-438e-b8df-774b463de764"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f31345cc-fba0-42e8-aa14-e28a07f49b91</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <pav:createdOn>2015-08-27 14:50:35 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-08-27 14:50:35 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AAEBD83F-900E-4F14-BC7C-D209DB8140F2">
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7-10% of Caucasians are so-called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>AAEBD83F-900E-4F14-BC7C-D209DB8140F2</domeo:uuid>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-01 10:31:00 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AAEBD83F-900E-4F14-BC7C-D209DB8140F2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:08734296-66AE-4F6B-900A-DABA586B8C92">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:E4BFF5E7-45AC-492F-A97A-ED4CF92B8A10</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-08-20 11:45:06 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:F87055E3-1DB3-43ED-9639-5EE3B5AD76E4"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N3873be13859a4697998c760b17f4f3df"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2A4C0943-7004-45BC-BF7B-43DF1B68143A">
    <pav:previousVersion>urn:domeoserver:annotationset:BA4A4F06-DE8C-4B66-8918-920D0399D744</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:439B2109-3D9C-4904-9DF7-41D812AC5AC7"/>
    <ao:body rdf:nodeID="N5bdb3440ca47451ca905e91e6c4a6209"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-08-20 12:47:40 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0F3E0C6D-FB96-49CF-9B4B-7212D3477613">
    <ao:body rdf:nodeID="Nc30c99df41c64bb4970ec8f94a53a9b8"/>
    <pav:createdOn>2015-09-03 15:42:35 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <pav:lastSavedOn>2015-09-03 15:43:15 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:01EDBAAB-9298-4A59-9A65-0993A50EB1B1"/>
    <pav:previousVersion>urn:domeoserver:annotationset:005E135C-72AB-4FCB-BCFB-DCD15A9EAE0B</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E9FA0611-C81F-43D6-83F4-5B754AA98ADB">
    <ao:exact>In healthy, male, Caucasian patients (n=24), coadministration of the potent CYP3A4 inhibitor ketoconazole (200 mg b.i.d. for 6.5 days) increased the peak plasma levels and the AUC of a single 30-mg dose of mirtazapine by approximately 40% and 50%, respectively.    Caution should be exercised when coadministering mirtazapine with potent CYP3A4 inhibitors, HIV protease inhibitors, azole antifungals, erythromycin, or nefazodone.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <ao:prefix>  Ketoconazole  </ao:prefix>
    <domeo:uuid>E9FA0611-C81F-43D6-83F4-5B754AA98ADB</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E9FA0611-C81F-43D6-83F4-5B754AA98ADB"/>
    <pav:createdOn>2015-09-25 10:40:38 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5E8D3357-55CA-4AE9-B960-B847060273F7">
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7E5D8A38-C152-42BD-9C9C-C8C5B1FF2384"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/57A6491F-ECEC-432E-80B5-4DDD07163F42"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:auc>3</dikbD2R:auc>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6DE7B434-B945-4A30-BC7E-EF02CE863E97">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <ao:exact>The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).</ao:exact>
    <ao:prefix>, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6DE7B434-B945-4A30-BC7E-EF02CE863E97"/>
    <pav:createdOn>2015-09-29 09:47:01 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4A116AFF-7CEC-45FB-AF0B-551A5366DF25">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <pav:createdOn>2015-09-29 09:03:19 -0400</pav:createdOn>
    <domeo:uuid>4A116AFF-7CEC-45FB-AF0B-551A5366DF25</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>s) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA ).  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4A116AFF-7CEC-45FB-AF0B-551A5366DF25"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CCB3CF0F-1CEB-4E3A-ADA3-5966ACE51668">
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:C6032A1D-A583-41DE-A677-CB9F1CBBFA3A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="Ndd42df00f30649dea4fd6f19c5a70d0d"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">13</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:E84A8D67-35F4-4284-BEF8-3DC391CC6D79</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <pav:lastSavedOn>2015-10-16 10:38:06 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-03 15:49:53 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C45AD04D-3270-4CC3-863B-3DC449CE3508">
    <rdfs:label>haloperidol</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/12A44C8D-D655-4384-A103-30D2CB254809">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10318</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>40</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>tacrine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/752A858C-B0B5-4369-8D1C-B88B6B159BCD">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>olanzapine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D61B6D49-7337-4057-8729-3F46826F0EE4">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <ao:exact>Fluoxetine-Switching from fluoxetine (20 mg once a day), a strong inhibitor of CYP2D6 and a moderate inhibitor of CYP2C19, to milnacipran (100 mg/day) without a washout period did not affect the pharmacokinetics of milnacipran. </ao:exact>
    <pav:createdOn>2015-09-30 10:43:11 -0400</pav:createdOn>
    <ao:prefix>) following multiple-dose administration to healthy subjects.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D61B6D49-7337-4057-8729-3F46826F0EE4"/>
    <domeo:uuid>D61B6D49-7337-4057-8729-3F46826F0EE4</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:81B69CC2-6CFB-4E8F-BD18-1440CA86A9C8">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N3f1b59dc267c4c09b31b8bf5ab553020"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-09-24 15:55:00 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:8CA484A8-1B26-42B7-A330-C05AE757E2AD</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:A68DDD07-EF29-4F4C-9784-72EADBCD7BA5"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:85AD6EA1-D560-4FFB-A685-3F21B0B4208E</domeo:belongsToSet>
    <pav:createdOn>2015-09-24 15:49:35 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:AA18BF65-3F61-4179-8A1D-B73034A9E587">
    <dct:description>A specific variant of a gene, including the wild-type allele, or a patient phenotype</dct:description>
    <poc:Variant>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#poor-metabolizer</poc:Variant>
    <rdfs:label>poor-metabolizer</rdfs:label>
    <sio:SIO_000628>poc:Variant</sio:SIO_000628>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EBDB43FF-AE87-4F7A-851A-39FD29796105">
    <ao:exact>In a dedicated drug interaction trial, co-administration of ketoconazole, a strong inhibitor of CYP3A4, had no clinically meaningful effect on the pharmacokinetics of abiraterone [see Clinical Pharmacology (12.3)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-08-20 11:06:07 -0400</pav:createdOn>
    <ao:prefix>Clinical Pharmacology (12.3) ] .  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EBDB43FF-AE87-4F7A-851A-39FD29796105"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>EBDB43FF-AE87-4F7A-851A-39FD29796105</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:62527B5F-7EB9-4A81-9165-73E4FCE2C6F9">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:hasSource>
    <ao:prefix>). While all the </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>selective serotonin reuptake inhibitors</ao:exact>
    <domeo:uuid>62527B5F-7EB9-4A81-9165-73E4FCE2C6F9</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-29 09:23:52 -0400</pav:createdOn>
    <ao:suffix> (SSRIs), e.g., </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:62527B5F-7EB9-4A81-9165-73E4FCE2C6F9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:58248057-768C-4323-B6B0-8DCF7930B044">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E965E51E-54F7-4BC3-BA85-B2BE1A92A6A1"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7A6ED409-6373-4CB8-9789-8A728A13C5CF"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A2DE45B0-9514-40B5-B411-F5FC6B9D395D">
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/814FE517-D865-4846-BA0B-338F630FF375"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BDCEACD0-98B1-4AB9-A3E9-72B4C3E4FB45"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0E5A5D2B-7003-483D-B7D1-DF89B8CEF564">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>clarithromycin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/68158035-A75F-4817-A8AF-B67C8EF43857">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>verapamil</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11170</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/a35c52ef-9af1-424f-abf1-58cb7ae4aeff">
    <domeo:belongsToSet>urn:domeoserver:annotationset:0185AD47-6E7B-4C92-8A3D-A2876CC95002</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5717d098-1d24-4a72-8da4-62bb13482a06"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2015-08-27 14:50:19 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f39a9e3d-316d-4f11-875b-be07c238984a</pav:lineageUri>
    <pav:lastSavedOn>2015-08-27 14:50:19 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:933223C7-983E-49F8-9C5E-9729630CBD5D">
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3CD92FB3-F293-4A2C-9F16-10772321FFDD"/>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/71BE88DB-5E8D-4962-A6C5-9EAFD7D55E92"/>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:auc>4</dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:47ADA4F9-1416-4A25-9B67-082755D374F4">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="Na0cf34fbec244d24bbd1aca8d1a7d1ce"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0185AD47-6E7B-4C92-8A3D-A2876CC95002</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-29 09:25:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:2F5CD38D-ACDF-497A-B31B-191BD5E31A57"/>
    <pav:lineageUri>urn:domeoserver:annotation:3A8E7BC3-4C41-4BA4-9786-98F50BDA4CA7</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F270973E-DB55-40D2-8C87-2E60338AD366">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>EMSAM</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9F3C3FE4-7308-4AB5-AFD4-095B9C07E8B3">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:25BA553C-55CB-42A9-8E94-9B05C7471880"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4CBDF6F2-E04B-477A-B3BF-FAAFD610AECE">
    <ao:body rdf:nodeID="Nd431148f817448108b584b102427c9c9"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2E0AD717-67BC-4D7C-AF83-5F1037F99712</domeo:belongsToSet>
    <pav:createdOn>2015-08-20 11:31:12 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:411EA8FE-947F-4575-905A-CFC5ACC4BD70</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:2BF29D63-16DC-413A-B043-2D784BEE08D7"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-08-20 11:32:27 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1E97C862-CD4B-4655-AA5A-73C5C1C3260D">
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8EDCFE51-FD29-4AEE-9B50-B418C03E22F1"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E04E68EF-0690-42D3-A066-0A02D642ABDD"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A3366D2F-9B7F-4577-8711-EE1CB7233531">
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:2B72E799-44E0-4434-B7E3-346160B5FB5C"/>
    <pav:previousVersion>urn:domeoserver:annotationset:6B50E664-BD71-432E-B7FA-E7313EFF76E1</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-20 10:18:11 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-20 10:19:28 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FC2163A0-83DC-4C95-B395-886C91DB61AE">
    <domeo:uuid>FC2163A0-83DC-4C95-B395-886C91DB61AE</domeo:uuid>
    <pav:createdOn>2015-10-01 10:30:47 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FC2163A0-83DC-4C95-B395-886C91DB61AE"/>
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7-10% of Caucasians are so-called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/39747b4b-4ab4-44a9-a6d3-fd1e87c3b18e">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:cca05e8d-7ce9-43fd-8acf-b19fd67fb9e0</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:28071b68-eb46-415c-b53c-52b3a4a35218"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-08-27 14:50:14 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-08-27 14:50:14 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DC54EBE-B2A9-4AE7-A174-F0074ECE4050</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7BDF9237-F361-436C-9F38-F65B2E5D8BD4">
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptFormulation>transdermal</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6947206C-641A-4D07-8C99-0099CAA79C39"/>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/752A858C-B0B5-4369-8D1C-B88B6B159BCD"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptDuration>10</dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/76FDF091-BF17-4173-8FBA-154825C19086">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:77D3CA28-823A-4BC7-8DFD-034B9C5C8959">
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/158BBB77-5CB2-4D1E-B6AE-C1D5F5B22362"/>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmax>37</dikbD2R:cmax>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3A80C62B-7836-44FF-B64E-77DA92F605DE"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:auc>35</dikbD2R:auc>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B95EF06F-2E7B-4ADD-BAA5-16482A25FC49">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3407</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>digoxin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:91941771-D879-47D4-A033-6E979797C3BE">
    <ao:exact>Antineoplastic, immune-modulating, or immunosuppressive therapies, (including corticosteroids) are expected to increase the risk of immunosuppression, and the risk of additive immune system effects must be considered if these therapies are coadministered with GILENYA. When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating GILENYA [see Warnings and Precautions (5.2)].</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:hasSource>
    <domeo:uuid>91941771-D879-47D4-A033-6E979797C3BE</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Antineoplastic, Immunosuppressive, or Immune-Modulating Therapies   </ao:prefix>
    <pav:createdOn>2015-08-20 13:55:05 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:91941771-D879-47D4-A033-6E979797C3BE"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FC5D8077-E799-4A20-AEB7-F5A53906040F">
    <pav:createdOn>2015-09-29 11:18:42 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:D5DA46CB-DED1-422E-BD1B-E4AE4E7D33A9"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:76A3F097-D0FC-4AED-92E5-AF23875139C7</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD84C196-D687-44A3-9825-9D1276283E75">
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:6D353708-61D5-4483-9392-C64EE4CE14E1"/>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-14 11:40:00 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2C2CF26D-06E9-49D5-9141-8C8D332BC314">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7BDF9237-F361-436C-9F38-F65B2E5D8BD4"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D4075F76-8042-4477-9D20-5D1A7749FAC9">
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F5FCFDEA-A058-4B82-B10D-81427E8E5243"/>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>38</dikbD2R:cl>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clDirection>Decrease</dikbD2R:clDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/28AABF38-58C8-4949-AFF2-702FAC5913CD"/>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:clType>Percent</dikbD2R:clType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>6</dikbD2R:numOfParticipants>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A116A539-CE24-4247-84A9-FC06FC8CF84A">
    <ao:prefix>(100 mg/day) without a washout period did not affect the pharmacokinetics of milnacipran .  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>A116A539-CE24-4247-84A9-FC06FC8CF84A</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <pav:createdOn>2015-09-30 10:43:58 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Lithium-Multiple doses of Savella (100 mg/day) did not affect the pharmacokinetics of lithium. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A116A539-CE24-4247-84A9-FC06FC8CF84A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:3D046132-84C4-4ABF-8B1C-EC07A0D07CA1">
    <sio:SIO_000628>dailymed:ActiveMoiety</sio:SIO_000628>
    <dct:description>the ingredient is active</dct:description>
    <dailymed:ActiveMoiety>http://dbmi-icode-01.dbmi.pitt.edu/linkedSPLs/vocab/resource/ingredient-active</dailymed:ActiveMoiety>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Active ingredient</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:351D2822-3970-49BE-A42B-2DB8E7DE6EB8">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptFormulation>transdermal</dikbD2R:preciptFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7DB97C61-75F4-4C62-9D15-4FDB96A0D78F"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DE55F02D-63B4-42D7-B53B-C851E6782F76"/>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>10</dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectDuration>7</dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354">
    <ao:item rdf:resource="urn:domeoclient:uuid:E7183CA1-C2BE-48A3-B739-A4EAFA4C115B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C0D15D7C-8D72-4FB1-BB34-3C5B3BAC9CB3"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/71bea6cd-1e47-40c9-935d-423d03992201"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BA36415B-432D-4246-9872-A79B94700E76"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:682F4BFE-93E6-4136-A9ED-25937FE7BCB3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B8DD9C99-B398-4DCF-906A-3A7539D03923"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A1828EE5-809D-4FD1-AF38-3101C913DC5E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:97961C84-B101-47B0-9F36-4124A7C5BB29"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:933A2B5E-1527-47CC-AF30-1F82C9D93E43"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9A9C6311-750C-4A5B-AEC1-96022DC1FE62"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:22DB0824-2A61-4B05-8B21-324FF990CCA0"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:annotatesResource>
    <pav:createdOn>2015-08-27 14:50:03 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:79D4A775-77C3-4208-A3B6-6DD5F6BB9ABE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1D5A6A7E-B5A8-4307-8524-83E87C344BCB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4F689C05-33E7-48FB-8155-7196CDB2E6AD"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:8B629F70-4030-4225-8953-D8624D66FF43"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:198D1084-D78B-46D0-BC19-BB2AA690A15F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:53F487DB-0EE0-421F-81CD-A66E1F9F18BC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:36E11325-AFC8-4648-AF0D-040A27E4391D"/>
    <rdfs:label>NER Sets</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:5AE531FF-D6F3-4A08-A8A3-8B94B005D306"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A98E10B7-3877-4E84-BB0A-2738C21E4CDD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E89A7C7B-5319-4A9A-A702-2E60FDB5A0B7"/>
    <pav:lineageUri>urn:domeoserver:annotationset:2933b5f6-bb2f-4961-86ed-e09658163628</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:FC5D8077-E799-4A20-AEB7-F5A53906040F"/>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <permissions:permissions rdf:nodeID="Nfcfb4a62b7b8452ea7101d5ef807a955"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:025816D5-DA6C-4827-903A-181524F7812E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:77E5C5F7-F081-480C-88EC-AE783CBA6721"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6E5C050B-2B08-43BC-9C40-CD73FFE5B61F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:CB5CD621-E9E3-4987-B430-DAD1C01273E1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:726B758C-5D4A-423D-B28E-4C51148D9F39"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1A5D2B03-C402-4744-9427-79753A2FAD8D"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B8304FDE-AD6F-4F41-B61B-4F88031B0A85"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:ce1a9885-7839-4b9a-91b9-ec27924a0c98</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:324585FC-3C7D-4ECD-A8FD-34EFC3850977">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/276A334F-EB95-4B3D-9EDC-93CDFA8BAAC1"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/AF23E222-97FD-45FB-875D-197B209CA9FB"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:88388447-F89B-497E-AF01-6E474B27B54C">
    <pav:createdOn>2015-09-29 09:03:01 -0400</pav:createdOn>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:88388447-F89B-497E-AF01-6E474B27B54C"/>
    <domeo:uuid>88388447-F89B-497E-AF01-6E474B27B54C</domeo:uuid>
    <ao:prefix>s) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA ).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A5AA05FC-8ED5-46DB-8B18-4A6154EBBA93">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:7C1C174C-14D5-469B-8D3C-57A63B16E0E6"/>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdOn>2015-10-14 11:40:16 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:75C5BEDD-5FBA-4417-A356-74879D603274">
    <ao:exact>fluvoxamine maleate</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-20 09:56:50 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:suffix> (100 mg q.d.) and alprazolam (1 mg q.i.d.) were coadministered to steady state, plasma concentrations and other pharmacokinetic parameters (AUC, C</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:75C5BEDD-5FBA-4417-A356-74879D603274"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>When </ao:prefix>
    <domeo:uuid>75C5BEDD-5FBA-4417-A356-74879D603274</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D759793B-B538-4560-A802-3EEF1915F24B">
    <pav:previousVersion>urn:domeoserver:annotationset:CE124242-AD57-4D32-9A25-1EF5E6126E23</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:1A62DFA9-A3EA-44F0-938A-C311F8F17963"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N5fcf5887708c4c10ae00f8ef21237ab1"/>
    <pav:lastSavedOn>2015-10-16 10:46:08 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">14</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-09-03 15:56:13 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6194C9B7-CA7C-48DD-961C-3D30385A3B65">
    <ao:exact>A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction. On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone. </ao:exact>
    <ao:prefix>   Lorazepam  </ao:prefix>
    <pav:createdOn>2015-10-16 10:55:32 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6194C9B7-CA7C-48DD-961C-3D30385A3B65"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CF5E3D34-4BFF-41D7-83EC-62FDB08127EA">
    <ao:prefix>, </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CF5E3D34-4BFF-41D7-83EC-62FDB08127EA"/>
    <ao:exact>quinidine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>CF5E3D34-4BFF-41D7-83EC-62FDB08127EA</domeo:uuid>
    <ao:suffix>, methylprednisolone, cilostazol, and bromocriptine.</ao:suffix>
    <pav:createdOn>2015-10-13 12:03:18 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A6B2FC51-C9DA-42D2-90FA-0DF0DBCE925F">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <rdfs:label>EMSAM</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23924823-F3F1-4104-A9B9-313B8D1C035E">
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:0A2D817D-4EA6-4B9D-91A5-3EF21D457EE1"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-14 11:40:43 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:882DF60F-84B8-422C-8907-B1B444911B5C">
    <ao:prefix>Drugs metabolized by CYP3A4 ( midazolam )   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:hasSource>
    <domeo:uuid>882DF60F-84B8-422C-8907-B1B444911B5C</domeo:uuid>
    <pav:createdOn>2015-09-24 15:37:52 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In vitro, desvenlafaxine does not inhibit or induce the CYP3A4 isozyme. In a clinical study, desvenlafaxine 400 mg daily (8 times the recommended 50 mg dose) was co-administered with a single 4 mg dose of midazolam (a CYP3A4 substrate). The AUC and Cmax of midazolam decreased by approximately 31% and 16%, respectively. Concomitant use of desvenlafaxine with a drug metabolized by CYP3A4 can result in lower exposures to that drug. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:882DF60F-84B8-422C-8907-B1B444911B5C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a2e50e41-1d1e-4107-b919-264beca55b9e">
    <ao:prefix>e.g., beta blockers or </ao:prefix>
    <ao:exact>diltiazem</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:a2e50e41-1d1e-4107-b919-264beca55b9e"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-08-18 11:35:24 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4347507D-3A50-47E1-AA6A-6B116D6C9151">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E628D4CB-EC21-4420-BF42-AF61D6850848"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0C2D9A2F-489B-4509-9364-A8B5F2617D8B"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F24B102B-A1DC-4C9C-B227-BC36875F31B7">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/203143</dailymed:activeMoietyRxCUI>
    <rdfs:label>fluvoxamine maleate</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5EC2CAD7-796B-481D-ACFA-AAB2C664BE23">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <ao:prefix>). While all the selective serotonin reuptake inhibitors (</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-29 08:58:58 -0400</pav:createdOn>
    <domeo:uuid>5EC2CAD7-796B-481D-ACFA-AAB2C664BE23</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5EC2CAD7-796B-481D-ACFA-AAB2C664BE23"/>
    <ao:exact>SSRI</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>s), e.g., </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:454518AA-5617-4ED1-85DF-11BF34E8E45B">
    <ao:exact>calcium channel blockers</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:454518AA-5617-4ED1-85DF-11BF34E8E45B"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:hasSource>
    <pav:createdOn>2015-08-20 13:56:54 -0400</pav:createdOn>
    <ao:suffix> such as </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>, or heart rate-slowing </ao:prefix>
    <domeo:uuid>454518AA-5617-4ED1-85DF-11BF34E8E45B</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:19AED2B2-1A29-4270-A1F2-C94D2FCACAFA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-08-20 13:57:12 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:19AED2B2-1A29-4270-A1F2-C94D2FCACAFA"/>
    <ao:exact>Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited. Because initiation of GILENYA treatment may result in an additional decrease in heart rate, concomitant use of these drugs during GILENYA initiation may be associated with severe bradycardia or heart block. Seek advice from the prescribing physician regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating GILENYA. Patients who cannot switch, should have overnight continuous ECG monitoring after the first dose [see Dosage and Administration (2) and Warnings and Precautions (5.1)]</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:hasSource>
    <ao:prefix>Drugs That Slow Heart Rate or Atrioventricular Conduction (e.g., beta blockers or diltiazem )   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>19AED2B2-1A29-4270-A1F2-C94D2FCACAFA</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9C8C57C1-AB82-4BCD-81EB-63037E21E979">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>duloxetine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CD630185-AE1F-4834-939A-B5DE7FE4B1C9">
    <pav:createdOn>2015-10-14 11:41:38 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:D3363696-62ED-4C7C-916C-75F08DDF9E4B"/>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6E2F72BD-DCE6-4B9F-8A11-C0C47CD56B18">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:C9EFCE7A-9214-4308-A7B3-CE8E69647709"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1A678E14-BBD7-4207-8D4A-FA358A7E562C">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-30 10:48:09 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N38b642101e3b4a46b41a96f4334f69aa"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:2B3292B2-ABE7-48BD-BE53-147BC1F6B363</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:545F2613-2A5E-4333-A651-CBA80268D6ED</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:C8B13C68-DA2F-459D-B4E3-A4ABBDFF42DC"/>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B2450468-903F-4AAB-B77F-AD3AE1736E0E">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>paroxetine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>40</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6488D76E-6BAD-424B-AF80-2CD63E0D8E94">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>bicalutamide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N52ed874a00d541189c99c2a8912086df">
    <domeo:sets rdf:resource="urn:pddi:uuid:F54CC42B-7295-44A9-964E-C8915B707342"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:913AC9D4-9D38-4FF1-9ACE-F74820A0C732">
    <pav:lastSavedOn>2015-10-16 10:55:51 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="Ne70e30db8a9a45759ff3699348fb0808"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:80A2D9C2-BBE3-4073-A25D-8B748388D720"/>
    <pav:previousVersion>urn:domeoserver:annotationset:0DAF5666-9E53-42D5-B92E-DE2C00764986</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-10-16 10:53:43 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:68F33E48-4A8D-49FD-91B4-DFA00C9E1732">
    <ao:suffix>-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, suffi</ao:suffix>
    <domeo:uuid>68F33E48-4A8D-49FD-91B4-DFA00C9E1732</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which </ao:prefix>
    <pav:createdOn>2015-10-01 10:27:29 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:68F33E48-4A8D-49FD-91B4-DFA00C9E1732"/>
    <ao:exact>SSRI</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FFF83E1E-53AA-4146-9554-A201722DC7AB">
    <dikbD2R:dose>50</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>lorazepam</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6470</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B81D5E26-E66A-4C11-9AC2-C774F994E2AE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:comment>Maprotiline plasma concentrations may be decreased</dikbD2R:comment>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F8ED774F-FF92-4E0A-8F8A-A921A3B0C159"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4886337B-6379-4434-86D1-B467989AB11F">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>400</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
    <rdfs:label>ketoconazole</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:77CF1A27-F7DB-4B5F-9F59-6E2E483DEA12">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:comment>Decreased TCA levels</dikbD2R:comment>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:AE5043A5-A6D7-408B-8086-D164EAE3A3F0"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CCC07A28-6FEF-4F41-B9EA-6A9DB36C0D7F">
    <domeo:uuid>CCC07A28-6FEF-4F41-B9EA-6A9DB36C0D7F</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CCC07A28-6FEF-4F41-B9EA-6A9DB36C0D7F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>fluvoxamine </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:suffix>reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic coadministration. </ao:suffix>
    <pav:createdOn>2015-10-20 10:08:58 -0400</pav:createdOn>
    <ao:prefix>is generally not advisable. Because </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:56ABE48E-674F-4C83-AF35-5A83F88C35E9">
    <ao:prefix>, increase plasma levels of concomitantly administered</ao:prefix>
    <pav:createdOn>2015-09-29 11:18:37 -0400</pav:createdOn>
    <ao:suffix> through competition for the same metabolic enzyme systems. Concurrent administration of </ao:suffix>
    <domeo:uuid>56ABE48E-674F-4C83-AF35-5A83F88C35E9</domeo:uuid>
    <ao:exact> tricyclic antidepressants</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:56ABE48E-674F-4C83-AF35-5A83F88C35E9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1C2BDB81-EC13-4226-BD06-76F19AB38CCF">
    <pav:createdOn>2015-10-13 12:03:01 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:B51F4BB3-6BDB-45E7-9399-D93DBC4324AC</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:7E62BBC1-074D-4EF0-8E18-207BD15D07C8"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="Naa2e7d7a337642edb4054b417e240f43"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-13 12:04:13 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7354A25D-D05D-4C91-BB76-5928D1D5DE96">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>40</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/7646</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>omeprazole</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DEAE2EA6-BFEB-4C59-AC1F-5CAC23D48A04">
    <ao:exact>darunavir</ao:exact>
    <domeo:uuid>DEAE2EA6-BFEB-4C59-AC1F-5CAC23D48A04</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <pav:createdOn>2015-10-14 11:39:58 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DEAE2EA6-BFEB-4C59-AC1F-5CAC23D48A04"/>
    <ao:prefix>, </ao:prefix>
    <ao:suffix>, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:23C51101-74AD-4D98-B40F-6E13A74A4065">
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/39C4C7DB-94E1-481E-BBD5-D5081A9637DD"/>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/AB94710B-440E-41E2-9FD0-6A5EBBC5576C"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:auc>46</dikbD2R:auc>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C264D646-7C64-4346-92EA-657FF860711E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Drugs Metabolized by P450 2D6 under PRECAUTIONS ).   </ao:prefix>
    <pav:createdOn>2015-10-09 13:31:41 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <ao:exact>Hypoglycemic DrugsIn a placebo-controlled trial in normal volunteers, administration of sertraline for 22 days (including 200 mg/day for the final 13 days) caused a statistically significant 16% decrease from baseline in the clearance of tolbutamide following an intravenous 1000 mg dose. Sertraline administration did not noticeably change either the plasma protein binding or the apparent volume of distribution of tolbutamide, suggesting that the decreased clearance was due to a change in the metabolism of the drug. The clinical significance of this decrease in tolbutamide clearance is unknown.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C264D646-7C64-4346-92EA-657FF860711E"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>C264D646-7C64-4346-92EA-657FF860711E</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N20de6a39ff334519ac07d79d1e145c1a">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:2E0AD717-67BC-4D7C-AF83-5F1037F99712">
    <ao:item rdf:resource="urn:domeoclient:uuid:A63FF147-259B-46E0-8A9F-F286872F35DF"/>
    <pav:createdOn>2015-08-18 11:34:40 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:21DF6087-5773-41B1-BBF7-AC1630C52D00</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:6BC11E2A-50E1-4200-BFC5-0613C6D28799"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <rdfs:label>NER Sets</rdfs:label>
    <pav:lastSavedOn>2015-08-20 11:32:27 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:9060017D-193D-4DE8-9E11-175889E42400"/>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="N2bc3b068ecf4443492ab9ab282a8b80e"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:64737b65-8582-4b76-8095-85ad69e2cc47</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/50540ab3-4d5b-436c-afe5-9e16c16ef1fe"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D4E167D7-7DE2-4653-B03E-8E1AFFCB78D1"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:A61914F5-07DB-4846-9A3F-17EF69E195B0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:56B057CD-6ECA-42DC-8F93-C29F590DFE4F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:197A4281-DC53-4B3B-8219-112150CFECF8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4CBDF6F2-E04B-477A-B3BF-FAAFD610AECE"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:084ACFBE-6C19-4F8C-BF54-035F58B7A68F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3CEE72DB-95D0-4667-BC57-4876C3F279A5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:545F2613-2A5E-4333-A651-CBA80268D6ED">
    <ao:item rdf:resource="urn:domeoclient:uuid:39EE729E-3704-418F-A9A4-F96C867889C0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E57AD432-E66E-4C87-85DA-FBBE0F227CC7"/>
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/c13b7a77-fc02-4fd8-af6c-68bc656ceab5"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:5639E7F7-47BE-4F6B-A2CD-C2D4930B731D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1A678E14-BBD7-4207-8D4A-FA358A7E562C"/>
    <pav:previousVersion>urn:domeoclient:uuid:d486e3fe-9d07-487a-ad77-dfa932ae7d6e</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:61B625CB-8C56-4E12-A6F4-0DC653A10AC0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A34BD5C7-51DC-49B8-89D0-61837CDAF19C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F198FC07-E8F6-4F6C-81F4-B0FABE8FBB2E"/>
    <pav:lineageUri>urn:domeoserver:annotationset:78f86ce8-5c0a-4d81-990b-ae1d0753efb2</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:80D2A1C4-6072-405B-A4F4-2432E0B3EB53"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:21FE036F-53ED-42FA-8560-F8A1B7D6AB20"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5451B70C-E690-43BF-8F3C-2F7A9D7DAC4B"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <permissions:permissions rdf:nodeID="N852e2b072c224ca982a367b08175c17d"/>
    <rdfs:label>NER Sets</rdfs:label>
    <pav:createdOn>2015-09-29 16:04:14 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lastSavedOn>2015-09-30 10:48:17 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:FAE68D9F-031E-4AE3-B4EE-5DF90C7DC714"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CF4E0D8B-79B9-41DB-990C-A041462A7C73"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:973101FF-2CCF-4B2B-981D-8B49DF14D876"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:2797DF94-AA41-40DA-89AC-2B6FE32F26F4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E49ECA25-B2B5-4EC3-B3DA-562B43C387B4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:24D70E0D-0D6C-44CE-AEFD-72CE05F7E586">
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:60383C47-9637-4716-B18F-42EABF19C871"/>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdOn>2015-10-14 11:41:29 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:44696D7C-10B2-4F4B-AECE-CD7E954AEF97">
    <domeo:uuid>44696D7C-10B2-4F4B-AECE-CD7E954AEF97</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-13 11:23:22 -0400</pav:createdOn>
    <ao:prefix> and </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:44696D7C-10B2-4F4B-AECE-CD7E954AEF97"/>
    <ao:suffix> were increased by the concomitant administration of</ao:suffix>
    <ao:exact>14-hydroxy-clarithromycin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/1F3648EF-BEFC-4824-927E-20EC7DA1AF8D">
    <dikbD2R:dose>60</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>pseudoephedrine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:024C9E53-7441-497A-B8F7-2F037AF42C36">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/56F26685-0744-419E-BE42-AEF9BAEBF7CE"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A39C05D9-C1FF-4348-B163-BEEEF07CDD0F"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C67B7283-20BE-427C-86F2-7D5C4E9D5799">
    <dikbD2R:dose>6</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <rdfs:label>EMSAM</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:18CB9938-6266-493E-A282-DB819CD3E51A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-02-19 12:41:40 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-02-19 12:38:23 -0500</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E9F13BFE-1A17-4FDF-99A7-13B89F697635</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:E73D6B7D-A3A8-4817-A2C4-32DE510299C5"/>
    <pav:lineageUri>urn:domeoserver:annotation:E28A51D7-37BE-4BCB-B3E3-5F03A528E03B</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:CBC29E8F-3018-4FB3-9D06-66D1FC3641AB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:80427841-8733-4D31-B75E-C7B5AC762B29"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6A939209-7E68-435F-BA58-C4A802640148">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>mirtazapine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0E0A4DC0-6734-478B-AC97-93CC2B52C521">
    <ao:exact>phenothiazines</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0E0A4DC0-6734-478B-AC97-93CC2B52C521"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, and the Type 1C antiarrhythmics </ao:suffix>
    <domeo:uuid>0E0A4DC0-6734-478B-AC97-93CC2B52C521</domeo:uuid>
    <ao:prefix>) and many that are substrates for P450 2D6 (many other antidepressants, </ao:prefix>
    <pav:createdOn>2015-09-29 09:02:32 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BC9BF70A-8C2D-4C02-85CB-CFA09829ED3D">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB05F5-AF88-4B04-87DC-5826864F9BE3</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7C3ED630-095E-46C1-9254-E12EC01A6C0B</domeo:belongsToSet>
    <pav:lastSavedOn>2015-08-26 16:14:07 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-08-26 16:11:47 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:55511E97-34AB-41C6-A461-E5D7312F99C8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3E8F5287-A48D-41C3-9170-862531EB5307">
    <pav:createdOn>2015-10-16 10:26:56 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Clinical Pharmacology (12.3) ] .  </ao:prefix>
    <domeo:uuid>3E8F5287-A48D-41C3-9170-862531EB5307</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3E8F5287-A48D-41C3-9170-862531EB5307"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7F836356-3F1C-49C3-B669-D269E5E6E11B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-08-20 13:06:20 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N2d08b2c0616449dbb9a5d3a342b2cef3"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:19657071-B127-4578-BE8B-15EFC45BD573"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:EF2BE243-8979-4220-A29B-AEDCBB584D94</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BB6BF730-3D6F-4A51-B2C3-17BB46FA8AEF">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-09-29 09:00:38 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:2D247AB0-07B6-4A5D-9514-AE9569AE6192</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:BD81BD31-90E5-4609-93C7-7E22524EEC3E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:10D95FA3-6B6D-4F9C-ACC0-0B6692EDAB63">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9444B9C5-5E86-416E-9833-D136BC2A2458"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:47436655-2C70-4BE4-BDF4-E0E6BEAC2364">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. </ao:exact>
    <pav:createdOn>2015-09-03 15:41:34 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:47436655-2C70-4BE4-BDF4-E0E6BEAC2364"/>
    <ao:prefix>Clinical Pharmacology (12.3) ] .  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/16D1170D-A133-48B2-B0FC-5F7C5D9A592D">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4053</dailymed:activeMoietyRxCUI>
    <rdfs:label>erythromycin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0F1FE74C-5115-43D9-80BD-8EF1DFFE72EA">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <domeo:uuid>0F1FE74C-5115-43D9-80BD-8EF1DFFE72EA</domeo:uuid>
    <pav:createdOn>2015-09-29 11:18:54 -0400</pav:createdOn>
    <ao:suffix>. Other substances, particularly barbiturates and alcohol, induce liver enzyme activity and thereby reduce tricyclic antidepressant plasma levels. Similar effects have been reported with tobacco smoke.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>tricyclic antidepressant</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0F1FE74C-5115-43D9-80BD-8EF1DFFE72EA"/>
    <ao:prefix>, which may result in the loss of the therapeutic efficacy of the </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A526E65-670D-456C-907B-1D272F1FA1C4">
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:6F7DEC5B-F0F1-47F1-9E89-42D1748BDC63"/>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-14 11:42:00 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:99F81799-FA1E-454E-8912-AF54614E5794">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/75B841AC-9362-40F7-8C11-26139D521425"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5D90DAB9-EA1D-400B-9D40-5E1082910AEE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9E39C9A0-7D4C-4A57-B963-787FA1EC899A">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:867AE862-C429-41C4-A327-DC5851C4562E"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8A6540FB-AF9F-4436-89D0-CBFECC25ADC0">
    <pav:lineageUri>urn:domeoserver:annotationset:3ee8b0e2-8d9a-4983-9455-386905b69964</pav:lineageUri>
    <ao:body rdf:nodeID="N24a4f3a6a618470899b3ee88060a6760"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:createdOn>2015-09-16 15:26:12 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0468AC6B-4F06-4CA4-A0DE-A389E3B0E59F</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:F230AB9B-627D-4C94-AAA4-4B76239F5D6E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-09 13:32:08 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:B87113A1-7EBA-41D9-8585-5F374FF62A02</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/107EDD01-3DB7-41CE-B570-FA04C3B4DF7F">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fingolimod</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9CCD590F-A14D-4E82-9365-527B1627BB84">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/5691</dailymed:activeMoietyRxCUI>
    <rdfs:label>imipramine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8A0049C0-151B-4CD9-A5F2-E75FA2BE6A24">
    <pav:lastSavedOn>2015-10-20 09:49:40 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-10-20 09:49:36 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:925378B3-0BCB-4EA3-AC47-5DD55DEF8970"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="Nea286e88440846f186e68cb78198880f"/>
    <pav:previousVersion>urn:domeoserver:annotationset:5E07BB54-F7DC-4B40-AB14-1C917FA43F1C</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:38C04CDC-DC8F-4124-8366-315F41D3B360">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:comment>Increase TCA plasma levels</dikbD2R:comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:B15CEE3F-DFB6-4C26-92A9-6BC508FA3986"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/AFEEA39C-D805-4CD9-8B57-D9547F6C801E">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>paroxetine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8">
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CB9F0709-26F3-45BC-853A-0EF0ED89BE81"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:59142E57-1816-4AB7-B582-C415EBDF37D4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EA793A2B-1519-4053-B8E2-E9076266C705"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F9FC75CB-1715-4671-A6A7-A61B56C05A2F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4FC117E6-6D99-4A02-88CF-028C55B050BC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:59737256-6A10-41BA-BB40-6E36BA8080A6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F101E45F-9436-4E81-BE2F-72CF34EBA947"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6E37F34F-43A6-4730-9D49-4EDD55028BA3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DB1C7584-93A5-4911-B42F-53E0E14CE25F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AFF477E1-4F09-4E06-A825-1632395DB0AC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:325E3C9C-45AF-42AD-ADE5-CD3F4CBE61D2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:09A51DE0-D723-43D1-89AB-43B028E5D01C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0ED91940-C0DD-4195-AE7F-B43AB1E4E117"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E6515473-8F32-47FB-9F82-4E1CCCA670BB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1885A697-957C-4329-B524-9B683EC6620F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8A1A74BA-5924-4B41-96D0-B7199CD1CFE9"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:3ECB7CC0-8270-4447-8B64-0A0EA6011D97"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:47308EE3-1269-4178-8530-2A71DABC486B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:23424B36-5284-4228-B373-655A516BE9D1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BE062828-3F8A-4772-9461-387A35112F5A"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:C50E8ACB-18FB-4CA8-96D7-3DF57419D60C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1C2BDB81-EC13-4226-BD06-76F19AB38CCF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1056244F-7147-456A-9240-D224C911F3B0"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:63051F23-7F57-41C0-B92B-AB7543774011"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8844EE85-76AF-4E48-94F9-5AC9DCB442C7"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">9</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:637CA4F6-3E10-4E98-927D-ECD68FD6717C</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:4F6BD35D-C4EC-4D3E-9493-DF86504ACC41"/>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:22F5BE19-3AE3-412C-B0C3-2FE0F519DBCF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D333F5B1-1DBC-435B-BA4E-8EEAC5D7230F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3246EE9D-08F9-4FD7-BEF4-BE9102B9FCAB"/>
    <pav:createdOn>2015-10-12 13:20:27 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:576A1DD4-4A0B-4632-821C-5F4FB1B06214"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:44046A29-7959-4E62-9332-5C8CAF559886"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CDB3561D-BB5B-4F02-87A9-F4E5B9DA7530"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0C8A8CBC-D82D-4B57-90F2-3B6A5EAE5CBA"/>
    <permissions:permissions rdf:nodeID="Neb13e42d900240deae3092573c8c79c7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FC81AEC7-EA2B-41F4-BF9B-F01EA42A0D31"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:556C3C36-929F-4F59-8BB9-033A8897C16D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D61A1061-76F8-4260-8644-9EAD2CB79E2D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9D13FD7D-56D6-4D7B-BC33-67B4C98F472C"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E6EE8106-6DE2-4E80-BA46-2BFB8DD87999"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8CB0EAF5-2143-4515-B447-2EA1A8508235"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0C61A3F4-A4B7-4756-BF49-512FAED37378"/>
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/fedc5c0b-24e1-406c-939b-28950ffdc9ec"/>
    <pav:lastSavedOn>2015-10-13 12:06:23 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:2CD634EB-128A-462F-A28B-C5244A2351DA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:091FB1B6-AFD7-417A-B142-19C55B590655"/>
    <rdfs:label>NER Sets</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3A91906-2294-4B18-8A8B-10D1F233BC34">
    <ao:exact>Ketoconazole    Seven-day treatment with ketoconazole (200 mg per day), a potent inhibitor of CYP3A4, did not affect the steady-state pharmacokinetics of selegiline in subjects who received EMSAM 6 mg per 24 hours for 7 days and no differences in the pharmacokinetics of ketoconazole were observed [see Drug Interactions (7.4) and (7.5)]. </ao:exact>
    <pav:createdOn>2015-10-16 10:38:05 -0400</pav:createdOn>
    <ao:prefix>   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <domeo:uuid>F3A91906-2294-4B18-8A8B-10D1F233BC34</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F3A91906-2294-4B18-8A8B-10D1F233BC34"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/07F5A746-6968-4B5F-95FD-3D3B0D64AD2D">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdfs:label>digoxin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3407</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7488FD20-D665-4B23-9EC8-75E05A10A3F4">
    <ao:context rdf:resource="urn:domeoclient:uuid:0693FC56-21C5-448E-A068-8F71FB6D5E24"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:0DAF5666-9E53-42D5-B92E-DE2C00764986</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N6ee84d643f974750940e775c5dbd8205"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:createdOn>2015-10-16 10:53:33 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-10-16 10:55:51 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AD9C90ED-946A-4A47-B3E8-0E11D226FCB3">
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/1C17697D-A00B-4699-9B4E-956A463E764D"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/70D5F376-877B-4127-9822-34F169B5B9CA"/>
    <dikbD2R:objectFormulation>transdermal</dikbD2R:objectFormulation>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectDuration>10</dikbD2R:objectDuration>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:auc>Unk</dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:79D4A775-77C3-4208-A3B6-6DD5F6BB9ABE">
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:B2109108-581E-4CB0-9BAA-BCB518613C2C"/>
    <pav:createdOn>2015-09-29 11:28:11 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:CF9F1ECF-6E59-4249-9473-03E25D6E37FA</pav:lineageUri>
    <ao:body rdf:nodeID="N51188617479245079c00b9949eecf225"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5717d098-1d24-4a72-8da4-62bb13482a06">
    <ao:prefix>uman serum is approximately 90%.                   In man, </ao:prefix>
    <ao:exact>amoxapine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-08-27 14:50:19 -0400</pav:createdOn>
    <ao:suffix> serum concentration declines with a half-life of eight hour</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5717d098-1d24-4a72-8da4-62bb13482a06"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B173B596-3E40-4B44-970D-6B5474DB30EC">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D27274BE-720D-44F5-B604-55E09E9A68B0"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FE948543-6157-435A-AB3F-21C650D1AF18"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8387503E-E4C2-4442-8F5A-ACAC8F2ECB58">
    <ao:exact>A multiple-dose study has shown that there is no pharmacokinetic interaction between paroxetine and lithium carbonate. However, due to the potential for serotonin syndrome, caution is advised when paroxetine is coadministered with lithium.</ao:exact>
    <pav:createdOn>2015-09-14 11:20:15 -0400</pav:createdOn>
    <ao:prefix>does not increase the impairment of mental and motor skills caused by alcohol, patients should be advised to avoid alcohol while taking paroxetine .  Lithium  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8387503E-E4C2-4442-8F5A-ACAC8F2ECB58"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3EC59A94-8BF0-47FC-BD50-FB02548C9994">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:EFD279F0-5D61-4016-8F33-A1DE9ED6D796</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-09-24 15:38:09 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N31235d9575214181b73cae0ec93105b4"/>
    <pav:createdOn>2015-09-24 15:36:49 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:DAD02F8C-D0CF-4D03-A113-8C242E8A7E4F</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:D0977829-85CF-48FD-9F4E-40132B488710"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E9EF0517-2E1D-4217-8D3E-05CF7B6973EA">
    <rdfs:label>EMSAM</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F52BCCB8-8F0D-4897-A41F-8C949DAE470C">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>GILENYA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8FEA5EE6-6737-4181-AE96-5FBC6B3F9EF7">
    <domeo:uuid></domeo:uuid>
    <ao:exact>ethinylestradiol</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8FEA5EE6-6737-4181-AE96-5FBC6B3F9EF7"/>
    <pav:createdOn>2015-08-20 11:38:44 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> may increase the systemic exposures of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CFAE29BC-FF25-428D-B782-0D804503CEE7">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-10 14:44:45 -0400</pav:createdOn>
    <ao:prefix>tizanidine ), CYP2C9 (e.g., warfarin ), CYP3A4 (e.g., </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CFAE29BC-FF25-428D-B782-0D804503CEE7"/>
    <ao:suffix>), and CYP2C19 (e.g., </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:exact>alprazolam</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9B2FF7B9-6C2B-4473-A30C-C87F7F14558A">
    <pav:lastSavedOn>2015-09-10 15:01:13 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="Ne85bc6278ff5488788452d54420a24fb"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:42FE8003-EA53-433E-852F-817D0BE4BDD8"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-09-10 14:51:09 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:53B33BA1-0DA1-469C-A2D1-8C7886E87CB8</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EDCA5EA5-9888-43D6-9944-71BD1EFBDDF6">
    <pav:createdOn>2015-10-14 12:06:25 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:A39CA8D6-8728-4BBC-92CC-0C2F2A887E44"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-14 12:07:40 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:C91289D7-45EC-44D1-A933-E79E770CFE71</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:10303B76-B21D-40E5-86E2-AC2A99F114BC">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:33DCD3EA-1199-4A8F-A11A-7A31E00D95D5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:711B5807-B1E3-4D14-8643-F10FED5E3371">
    <domeo:uuid>711B5807-B1E3-4D14-8643-F10FED5E3371</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:40:59 -0400</pav:createdOn>
    <ao:suffix>, progestins, quinine, tacrolimus theophylline, tricyclic antidepressants (e.g., amitriptyline, nortriptyline) and zidovudine. It may be necessary to adjust the dosages of these drugs if they are given concurrently with rifampin.</ao:suffix>
    <ao:prefix>, </ao:prefix>
    <ao:exact>narcotic analgesics</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:711B5807-B1E3-4D14-8643-F10FED5E3371"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8E88E5BA-8C1A-4A07-9CC9-EF3A4AD313F1">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:BE71BBF5-9A2D-4EBE-83B0-1E019FA0E0F8</domeo:belongsToSet>
    <pav:createdOn>2015-09-25 10:40:38 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N08dadf9cb8c64c588148c0641d0edcfe"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:8AD42C28-4155-433A-B448-C0FFCF388F5D</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:E9FA0611-C81F-43D6-83F4-5B754AA98ADB"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-09-25 10:47:09 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AF394279-7325-4C60-BB1C-C81BA104ADB8">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <ao:body rdf:nodeID="N6c1c41f3b7fd40babadd6c298bd1e72f"/>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:16EF4E16-7784-4EB0-8FE0-6A31A48EB623"/>
    <pav:previousVersion>urn:domeoclient:uuid:a7f59b4d-3ada-4384-adb1-665a4a1743c8</pav:previousVersion>
    <pav:createdOn>2015-09-03 15:39:33 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4F6D9D8B-BFDC-48A8-8B68-2FBD87B23A1C">
    <ao:exact>pimozide </ao:exact>
    <pav:createdOn>2015-10-14 12:08:04 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4F6D9D8B-BFDC-48A8-8B68-2FBD87B23A1C"/>
    <ao:suffix>administered alone. The increase in pimozide AUC and C</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> compared to </ao:prefix>
    <domeo:uuid>4F6D9D8B-BFDC-48A8-8B68-2FBD87B23A1C</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F198FC07-E8F6-4F6C-81F4-B0FABE8FBB2E">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-30 10:43:11 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:D61B6D49-7337-4057-8729-3F46826F0EE4"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="Nd42aad590fa44dc3a399324cbb36ebce"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:545F2613-2A5E-4333-A651-CBA80268D6ED</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:4BE6B852-1D17-4F08-A718-7C40709FFFB4</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F54CC42B-7295-44A9-964E-C8915B707342">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:911E45A5-C8CB-408F-A048-AE764254BB06"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:01E7137F-16D5-480F-8DCD-C6BDA1E72B3D">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-08-20 13:06:08 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N0b46291164f44de2ac3f50ba4e03f1db"/>
    <pav:lineageUri>urn:domeoserver:annotation:FF8F0A7A-47D8-4CB4-819A-9A30DD325D13</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:DA322BDB-92B7-4631-8DCB-DC725BBAC9ED"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5B9289C4-6EAC-44C9-9AC8-BB5217DE4EBB">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. </ao:exact>
    <ao:prefix>Clinical Pharmacology (12.3) ] .  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5B9289C4-6EAC-44C9-9AC8-BB5217DE4EBB"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-03 15:42:21 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6769FF26-4593-4ACE-85F4-0082EFE3DBD6">
    <pav:createdOn>2015-09-14 11:12:22 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-09-14 11:21:10 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:17CFEF69-CCC6-4ACD-8A24-0425991EC98C</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N45499dc0bb9d4ba58f69059ccd27aaf5"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CE635F27-A391-4A6B-9D87-339FA2F114B2</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:fc9e17d3-1b0d-4635-9936-0d1d94cb01f9</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:C8874E61-E80C-4C3F-A900-EA53216C53E0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D63FFAD6-2B46-4448-A854-4D6C6595A64A">
    <pav:createdOn>2015-10-01 10:46:50 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>)</ao:suffix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <domeo:uuid>D63FFAD6-2B46-4448-A854-4D6C6595A64A</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D63FFAD6-2B46-4448-A854-4D6C6595A64A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:BE71BBF5-9A2D-4EBE-83B0-1E019FA0E0F8">
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/c1a88987-fc21-4e81-bc38-6b7a3a75ed81"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:67F51C12-D1C6-411F-8150-60DF549C5DD6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9EEDCD84-BDA9-4C83-841A-EE1AE5760F6A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:39094284-467B-4880-8053-BC4887FD4C6D"/>
    <domeo:deleted>false</domeo:deleted>
    <rdfs:label>NER Sets</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:F74FE5C1-B9CC-46B7-90EB-735E4E3F42FA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B49657E4-FB9E-49F2-94A4-CE875B099051"/>
    <pav:previousVersion>urn:domeoclient:uuid:6950c3f8-2a13-45a4-9e41-29a725b25ff4</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:D1A189B6-4854-4795-870C-B1CE5202D07B"/>
    <pav:lastSavedOn>2015-09-25 10:47:08 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:58783000-8223-4301-92B8-F448905DE2CA"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:E7D49F0F-4C2F-403D-B408-E33808B2D70C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9CEDBF4C-4695-47F9-9724-88EEA750A041"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AC844597-827C-46D7-BC10-F1AAEFD7FCDB"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:8E7ABB1C-FA5F-4991-B571-7869CB72CA87"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9479B4BD-59A7-4AC9-B221-E9869B952571"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:29B8806B-B5D6-4242-81BF-2BC2D594B831"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8E88E5BA-8C1A-4A07-9CC9-EF3A4AD313F1"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdOn>2015-08-27 14:50:29 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="N8b00c7a1223d42a3be4be3486cd2e2b5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8135BF3B-C859-4C1E-B730-D48B1E7FD2D4"/>
    <pav:lineageUri>urn:domeoserver:annotationset:cb74bb03-5ad2-4eea-b083-973424b3737a</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:8FDD37CC-61CA-46A4-BB15-912B0623A178"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E2D98F3E-AF53-4C93-896B-04F390D2B2AB">
    <rdfs:label>fluvoxamine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2C5BC3F9-D707-470F-AE11-8D6ADC1C72A9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <domeo:uuid>2C5BC3F9-D707-470F-AE11-8D6ADC1C72A9</domeo:uuid>
    <ao:exact>rifampin </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2C5BC3F9-D707-470F-AE11-8D6ADC1C72A9"/>
    <pav:createdOn>2015-10-14 11:39:52 -0400</pav:createdOn>
    <ao:suffix>with drugs that undergo biotransformation through these metabolic pathways may accelerate elimination of coadministered drugs. To maintain optimum therapeutic blood levels, dosages of drugs metabolized by these enzymes may require adjustment when startin</ao:suffix>
    <ao:prefix>is known to induce certain cytochrome P-450 enzymes. Administration of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B9DC837C-AB49-496D-9AA3-389E4BDF49F3">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <domeo:uuid>B9DC837C-AB49-496D-9AA3-389E4BDF49F3</domeo:uuid>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-29 11:26:07 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B9DC837C-AB49-496D-9AA3-389E4BDF49F3"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/32B97A0F-D811-4EE0-8AAE-809811B56CA2">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>ketoconazole</rdfs:label>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AB8ABE6E-51A7-45D1-AF71-817381650071">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>AB8ABE6E-51A7-45D1-AF71-817381650071</domeo:uuid>
    <ao:prefix>Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required. It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.  </ao:prefix>
    <pav:createdOn>2015-10-01 10:49:37 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AB8ABE6E-51A7-45D1-AF71-817381650071"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf3057e84446041fb8290288f80b353ca">
    <domeo:sets rdf:resource="urn:pddi:uuid:84E732E9-EFA8-44B1-ACBD-AC557E774425"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:340B2835-DC58-47CE-8C11-F79C36CBF1FC">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:42165BEF-D9B6-4885-998A-9300570F3ADE</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N246ac54b0cb7495ba8289a2ebb7874b7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-10-01 10:29:56 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:7A6AE117-70A3-463F-9A39-4FA23E86E199"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:33B17719-DF97-48EA-AFA2-01DE8A8887B4</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:63C4B236-094B-4C60-BF4B-DBE1FBD6A88C">
    <pav:createdOn>2015-10-13 12:03:22 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:exact>bromocriptine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:63C4B236-094B-4C60-BF4B-DBE1FBD6A88C"/>
    <ao:prefix>methylprednisolone , cilostazol , and </ao:prefix>
    <domeo:uuid>63C4B236-094B-4C60-BF4B-DBE1FBD6A88C</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F5B6DD30-DEBF-478A-9551-5FBF24BBB5A8">
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FC1DDD53-7473-431E-8950-A5A9D07425CD"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5EFEE67C-83D9-4028-B5EA-AF8C3696A1C4"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:numOfParticipants>32</dikbD2R:numOfParticipants>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0">
    <ao:item rdf:resource="urn:domeoclient:uuid:08E23EDA-057E-46A0-B028-3EF188F39525"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D3BA1581-32CA-4E00-81DC-2B8825244D7A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:16EA135F-CDB0-4142-91AA-B23FC38A3199"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:134D7CB1-E742-45FA-8436-98DA3480170A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1F07C92E-D96B-4283-8F92-81EDB88E913D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D7EE7058-D1E8-4EC5-82D5-9A47FEA2B052"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AB12B3EC-41EF-4DDE-98ED-2155A0A4B9B3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5F55ADCB-AA08-466C-A32E-2740BFF6F508"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4F32B034-EBC5-424C-BBC6-52AAD0D32DD9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7B448242-40AA-4BE3-BC6B-DD6ABF8F5FDB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D9E71616-7D16-4C2B-9A4D-B3AB4AEB4BA1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C20EF95A-DAE3-4E18-9A61-1035A52F81F2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FE761BDC-F49F-4756-8D07-F41A55DC5220"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AD84C196-D687-44A3-9825-9D1276283E75"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B5BE8416-9D18-4716-A9B6-856792123329"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:69D1F873-6483-4406-A61C-98BC73C5A620"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CD3A7AE7-5E99-4E1E-A75B-5E0A94EBD675"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9B62559A-7BF8-4CF1-882E-ED54C0B36733"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E8F7D750-35CD-45CF-9A08-E121B19CBEF2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C2915845-B6D5-41CF-9AA1-083F459B7EB1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D39AD412-5269-4737-9C8A-D705002B9E48"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:82EE3E7D-2A34-4402-ADF2-A3E0372E3BEA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A5AA05FC-8ED5-46DB-8B18-4A6154EBBA93"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B9E961DB-D430-4F4F-B9A8-070D3943C9B8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:536084E1-4894-4FC8-8485-806ECB576ABF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B3CB5756-91BE-46FD-8A2F-18EB0E55096E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7D8FA781-27E9-4FAE-AC8D-B8ACEBA61475"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7E489E1F-6E43-458C-BBF5-3C3B620C3CEB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B01048B3-7D98-4B92-9E98-C160BFB5F6B3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1B360D7B-CD91-4FAF-9476-97FA252DEF85"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3C3D5B64-6A65-4CBD-82E4-8EBB9BF0F6F0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:325955E2-1A3F-45B4-83DB-34472FDD97AD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FB5E27FC-759D-4791-A1E0-1ECF6608F328"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DEF93588-2EC9-41DC-A3ED-F69C039BBCA9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DD3E3032-727D-4A53-AA39-EF11B585F4CD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EBD564F1-FBBC-4657-A7D1-CC931904D2E3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:897BE155-74FF-42F2-801E-97BC586FF1AB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:400DB10E-975D-40DC-8BBE-672C89C7A710"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B0391606-0172-43C1-A1C6-0F166427C843"/>
    <rdfs:label>NER Sets</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:59432D4C-310C-4958-A609-270395DC845D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2575BC9E-F40E-48B7-89B0-48D528CEC745"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:722C7B42-FBCE-42D9-A86A-C13624023A28"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:23924823-F3F1-4104-A9B9-313B8D1C035E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FEE0B14A-3D15-4C79-8CEF-3A7B1C94EF08"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F28D6516-9703-406F-96F8-5B421154E605"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:44C1B3E0-7D35-4769-9BA7-FF9B4301F514"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D14AD1F5-2795-478C-B8D7-016316593E1D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:76ED8A68-6744-46EF-B9C0-3A017F20A451"/>
    <pav:lastSavedOn>2015-10-14 11:57:06 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:24D70E0D-0D6C-44CE-AEFD-72CE05F7E586"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:29D74A78-F777-4518-A420-AC4CFDABA48C"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:FAA59BBF-F495-4115-A3D4-7A5302A3CEFC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8B8ED38F-25A3-4CF1-9385-E137098DB26E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1D1F4E1A-B9D4-460F-AC11-4ABA88DA72D8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:74D645EA-3445-4B52-8137-F45AC68F5792"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:26716B9A-81D7-435A-B33A-D6B56849F816"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:351F9CC4-DE7F-4409-B049-B3529F081B4C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:85AD7C92-23BA-409A-88A0-4C9FF4A6A25B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D118C509-DE8C-4A8E-BB86-21CFE1955841"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CD630185-AE1F-4834-939A-B5DE7FE4B1C9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:ECCC345A-BE75-43BB-88C2-F71C6FDBFC7B"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5000D962-57F1-4EEE-9643-6544E28C0C68"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:ED1DC53A-6D91-4B39-9733-9EB4AE8830AF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BA210D49-0C81-471E-A555-2E7822BB82B5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:08D9F2FC-8AD3-4B76-8722-A9EEEF1233AB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:91B50784-905F-495F-AD8F-E62C27217707"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AD69FEE2-142E-4170-A583-B4791A2C9D5B"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:1004CB50-F4B2-47A8-8632-F333D20F2E67"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F0A8DF45-E947-4CC6-90D2-D34891139FF5"/>
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5f8f7830-34e2-4a38-9ee0-8113b6f2c0af"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:11CFFF93-99D0-4CF8-A9EB-EE1BEDF2137B"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1922C8FD-FDAD-4FE8-ABD0-4CF2A15D66F2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7A526E65-670D-456C-907B-1D272F1FA1C4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:ADAE5737-442E-4008-BD0B-9B62E45610C2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1CD72A3B-02EF-47C0-BB78-1E8CA3D998CA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B979097E-7BE0-4BBF-8151-F28FB534A2D2"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <pav:createdOn>2015-10-12 13:20:27 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:3C93BED4-244B-4EC4-9CCF-4225C5B87905"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CCF3DB31-ADF0-4361-A2CF-40577E0CC470"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3A225FC5-5620-450A-9EE4-3DFE36E2CA3B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:694C8CCE-50B6-4BBE-8E15-E6D2CFF02130"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D90EDE5C-86B4-4DA8-A1F6-3088500295D9"/>
    <pav:previousVersion>urn:domeoserver:annotationset:DD3A3AB6-4E96-4C4D-A44C-2769AD2CAA22</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:3E018E90-4D51-4344-AD05-A49492C9B566"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EECADA2C-8278-48A0-8F4E-925B892A34EC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C7933EAE-B8B1-4F90-A63B-E0A4E34DFAA7"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:78FC1706-B6D7-4F2D-BAAD-579DA6D22143"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D765C020-2D34-4D0C-8D4F-8E19DF6E645D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FDF0015E-54F5-4BAC-A5B5-4239D0E27D0B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FBFC7A2E-312A-4BC0-9A3A-832DBFC6DE79"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C1CD89FB-FBD9-4B6F-BB85-C88A3AC629E3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CECE7ED3-4A39-47F8-9B3C-F78361B4F3CC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B853D0D5-2744-4039-91BC-E2D7933A2A5A"/>
    <permissions:permissions rdf:nodeID="Nea4583a18e6846d5981d0a3ca717aad9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A5789EB7-E220-4F2D-9D56-323B392EAC5C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EADDCAFC-F127-4D8B-AC67-FA06B0EADDA5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:017082FB-C40B-493A-B2B5-09825691F4C8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3EB5B0BD-9D35-4A8D-841B-4134C25EEC8D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:817F1189-E5B6-4610-A044-B745728634D9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D9DFF99C-370B-4655-9E62-B8B725F31F30"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6E30469D-53FD-4CDA-980B-4DCB18DA1EA9">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CE37B0DD-63CD-4244-97C1-41BECC806657"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/63B9442A-C267-404B-B347-4599E7805D8C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F">
    <ao:item rdf:resource="urn:domeoclient:uuid:AA23F94A-9F0C-4106-8D8F-F55C8CF08515"/>
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/f0293991-7014-48da-8dc8-9cd6abfc858b"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:66EBEC3F-5FA6-40F3-AE9F-8F714C95AB68"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9C7E3E66-E1B5-4AA1-928E-76684151DE67"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">17</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:4DFFE47E-5452-452E-B101-770AFA41F372"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BD5D8B9A-4999-49AD-96CB-C8A98B37C861"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:58900B65-A479-4EC9-9B5C-D08181AEBB76"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:CCB3CF0F-1CEB-4E3A-ADA3-5966ACE51668"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:55FCD9DB-B74B-4058-9EE3-E31E5BBA0A4D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BD891937-2C4A-475C-9F12-D68CA41C44BB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E9FC935E-A71B-4526-809B-94CC04024810"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4269EA24-F80D-475E-9FA8-528F69AD0C63"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2122DCBB-B3C5-4E30-A80B-86AB95C590B3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2B5070FD-9D65-4C0B-B084-C8BC8912D195"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CC5831BA-A457-4A1C-A105-E4571054D878"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CC0EC292-D57C-4733-ABF5-90BEF67B1DA4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6E810DEC-906B-4BEC-8621-DAB36D645A70"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5917C0F8-C7F3-436E-9D49-46C5F4C600CB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D759793B-B538-4560-A802-3EEF1915F24B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:50F3FA34-07BC-42B4-A034-5917E4C79B90"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D027B9BB-84B8-4AD8-98B6-E6B6F9BAA7FE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:37FAC892-00AA-4A61-815B-E0670FFEAB15"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:16EF1A8D-F411-462D-B908-B935CB267C22"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EE774587-230D-4340-8F4D-CD0A0BAA721F"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:73C70409-2A07-4743-B1C9-4841D5E27EBB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A33EAE5A-8DB5-4457-BF16-9974AE27B18F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E1B06E0F-5C33-411C-96A8-189B2513F62C"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:9B16807D-97E9-4B29-81DB-7EE66CEB3FF0"/>
    <pav:createdOn>2015-08-27 14:50:16 -0400</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:9AE53DD6-BF07-4ED3-925B-66A877E065CC"/>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:EBC7D022-C17F-4F68-99DD-1C481A89BA04"/>
    <pav:previousVersion>urn:domeoserver:annotationset:9A112604-A4EE-4E15-AAEC-AE44AB44CD5C</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:252EBC69-6A12-474B-90A8-CE817A36D4DB"/>
    <pav:lastSavedOn>2015-10-16 10:46:08 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:DC117877-091A-4B88-8576-9668C2E6FCD2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:50448CFC-87BB-4F11-9507-87FA713CD169"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1D929373-D289-4A98-9888-F4FF30674B8E"/>
    <rdfs:label>NER Sets</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:AEC0D894-25D8-45C6-B259-D0D000221245"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9D3B0238-804D-4D71-9897-88C5A623B997"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:166AA3D7-46F5-42AC-9272-8A6A40A86DBE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0F3E0C6D-FB96-49CF-9B4B-7212D3477613"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AF394279-7325-4C60-BB1C-C81BA104ADB8"/>
    <permissions:permissions rdf:nodeID="N4537cd741edd4782bd34faae3e12d1f4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B2D07C5D-738B-4B2E-BF50-1CABE0AFDADF"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3ABD276B-6BC1-4B1F-AFA1-B2CC5A0B0C4F">
    <domeo:belongsToSet>urn:domeoserver:annotationset:CE635F27-A391-4A6B-9D87-339FA2F114B2</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-14 10:25:06 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:fc9e17d3-1b0d-4635-9936-0d1d94cb01f9</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:7E008BC6-EC9B-4F1E-B537-D4CF660033C7"/>
    <pav:lastSavedOn>2015-09-14 10:25:07 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:nodeID="N70d230cb157b4f2fa4772ce0f7e8c0f5"/>
    <pav:previousVersion>urn:domeoclient:uuid:e382d7cf-3db6-429c-b6c0-e231f2492215</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:48174C77-8AA2-4177-A9C8-F0F6197B6446">
    <ao:suffix>. (</ao:suffix>
    <ao:exact>ests are available to identify a patient's CYP2C19 genotype and can be used as an aid in determining therapeutic strategy</ao:exact>
    <ao:prefix>T</ao:prefix>
    <domeo:uuid>48174C77-8AA2-4177-A9C8-F0F6197B6446</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:48174C77-8AA2-4177-A9C8-F0F6197B6446"/>
    <pav:createdOn>2014-02-19 12:37:38 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/Clopidogrel-1086a7b4-b89b-4bee-8120-5f752626c046.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AA23F94A-9F0C-4106-8D8F-F55C8CF08515">
    <pav:previousVersion>urn:domeoserver:annotationset:E84A8D67-35F4-4284-BEF8-3DC391CC6D79</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="Nff262b54d49641179b6e64b202db20e2"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:89D1253B-FCEB-49A4-B78E-F745CF9C9BD7"/>
    <pav:lastSavedOn>2015-10-16 10:38:06 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">13</pav:versionNumber>
    <pav:createdOn>2015-09-03 15:50:31 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CBD3826C-96BE-496D-94F7-B5EAD1383423">
    <pav:createdOn>2015-10-16 10:55:50 -0400</pav:createdOn>
    <ao:exact>A study of multiple doses of fluvoxamine maleate (50 mg b.i.d.) in healthy male volunteers (N = 12) and a single dose of lorazepam (4 mg single dose) indicated no significant pharmacokinetic interaction. On average, both lorazepam alone and lorazepam with fluvoxamine produced substantial decrements in cognitive functioning; however, the coadministration of fluvoxamine and lorazepam did not produce larger mean decrements compared to lorazepam alone. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>   Lorazepam  </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CBD3826C-96BE-496D-94F7-B5EAD1383423"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:82534F38-12A3-4093-9D06-C2F7DE554A10">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N9140882ddcf54c1f8c7b84d3cd98177b"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:0DAF5666-9E53-42D5-B92E-DE2C00764986</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-10-16 10:50:50 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-16 10:55:51 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:1D19C3BD-7842-460F-8255-BA31A9C6A907"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BA210D49-0C81-471E-A555-2E7822BB82B5">
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdOn>2015-10-14 11:41:49 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:0551D423-1699-48B1-BBE9-B1E946BDEEAA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3928749E-2902-40CE-B487-8BB453887F77">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>phenothiazines</ao:exact>
    <domeo:uuid>3928749E-2902-40CE-B487-8BB453887F77</domeo:uuid>
    <pav:createdOn>2015-09-29 11:18:33 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <ao:suffix>, increase plasma levels of concomitantly administered tricyclic antidepressants through competition for the same metabolic enzyme systems. Concurrent administration of </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3928749E-2902-40CE-B487-8BB453887F77"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>and the </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:38F59318-D228-4A94-844A-705774A95918">
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-16 10:54:08 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:38F59318-D228-4A94-844A-705774A95918"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin. If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached [see Contraindications (4) and Warnings and Precautions (5)]. </ao:exact>
    <ao:prefix>metabolism have not been studied.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EFDE0C08-E26E-490C-BCA7-40A754BD7790">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>risperidone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:56B057CD-6ECA-42DC-8F93-C29F590DFE4F">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:createdOn>2015-08-20 11:19:49 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:606EFCDA-E3C6-4BAA-AC91-61A3C06FE137"/>
    <pav:lastSavedOn>2015-08-20 11:30:25 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="Nfe1978203f6d4b7fbf8618845abddddf"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2E0AD717-67BC-4D7C-AF83-5F1037F99712</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:64737b65-8582-4b76-8095-85ad69e2cc47</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:77088A85-ED77-4524-B35C-2DDC054C7684</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:812800E2-CCBF-4D26-B127-DE7CAF212FBE">
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>s) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA ).  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:812800E2-CCBF-4D26-B127-DE7CAF212FBE"/>
    <pav:createdOn>2015-09-29 09:03:38 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>812800E2-CCBF-4D26-B127-DE7CAF212FBE</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F63AD193-B301-4138-A56A-8F0E9F879B07">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-14 12:07:40 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:2323BFC3-8379-4C7A-8617-A93A9B3A33BE"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:C91289D7-45EC-44D1-A933-E79E770CFE71</pav:lineageUri>
    <pav:createdOn>2015-10-14 12:06:17 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:682F4BFE-93E6-4136-A9ED-25937FE7BCB3">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:3265DCD8-9E57-4CA5-B3AA-1EF86E51A44A</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-09-29 11:25:03 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:BF935E8F-19A5-413F-8C9F-6AC24A383B4C"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:33B17719-DF97-48EA-AFA2-01DE8A8887B4">
    <ao:item rdf:resource="urn:domeoclient:uuid:4C18F359-19DA-409F-9FC4-923939D24EFA"/>
    <permissions:permissions rdf:nodeID="N0ee07473d75c487090f7f6c667a1835d"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:153EB93D-9546-417C-9EA7-6C2412E5C256"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:340B2835-DC58-47CE-8C11-F79C36CBF1FC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:48CBCF3A-2676-4D9E-8A2A-3E1ABC922C14"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1D47EB00-D7BC-4588-9793-29047B520FE8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3299957A-4DD8-42F0-880B-EFF809AD45A4"/>
    <pav:previousVersion>urn:domeoclient:uuid:e0852c87-45db-4900-afce-82b5d0323a45</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:BE0D460D-5292-4CD4-82A3-E2116AA49A01"/>
    <pav:lineageUri>urn:domeoserver:annotationset:9bb6dd0f-3b72-4a0d-9c01-71e7c9ec8d9b</pav:lineageUri>
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/c89cfc94-dee3-4cee-a24b-f02fe9626e23"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1F4995A3-461C-4944-8BDA-B9103E6977BC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A2972AD3-DCB1-4A60-AF1E-7FA59D903AC9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8E653C68-3DB9-4CF1-9868-60E3738D25E5"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:417C0B18-0863-4B8B-AECD-13BFD8C1F3CC"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:DF0440E2-4532-444D-95DA-006D988DA65E"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:C3B195E3-DE80-4547-ABB5-CF768DE087E5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <rdfs:label>NER Sets</rdfs:label>
    <pav:createdOn>2015-08-27 14:50:17 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:97EF39D9-0073-404C-B1F0-D472528A3FAD"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:18E274E9-2A42-4B5A-9D95-37B595098FE2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3C3B2204-6D66-446B-9AF5-5B5931422E80"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:7ECC86B5-29FE-4D9A-B4F6-EDEED30CB6CD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B089E97E-4E63-40D5-8643-27B261116AD8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7C45F870-951A-49F5-9A73-F41F546A8D5E">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:024C9E53-7441-497A-B8F7-2F037AF42C36"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1084FB4D-C3D9-4F51-AB79-67D422116DA7">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectDuration>28</dikbD2R:objectDuration>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/35096440-E02C-4177-B446-A1169CA8838F"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptRegimens>TID</dikbD2R:preciptRegimens>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C8525E3E-20A2-4497-88CF-376153FB353D"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/450B8BE6-DF2D-4179-BEDA-7E0B3280E265">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>desvenlafaxine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:67F51C12-D1C6-411F-8150-60DF549C5DD6">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-25 10:47:09 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:AE0DD04E-5F6C-4F42-A871-E61AF88ED79B"/>
    <pav:createdOn>2015-09-25 10:43:28 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:6321D7DE-96A8-45E3-BB36-EB04DDBABAD7</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:BE71BBF5-9A2D-4EBE-83B0-1E019FA0E0F8</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DF0440E2-4532-444D-95DA-006D988DA65E">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N5bcb65e85b9d41f3b42b12cfb1d9b7d6"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:33B17719-DF97-48EA-AFA2-01DE8A8887B4</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:8BA4C59B-CC51-42BB-AF4B-D94EDC879DAE</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:8C2AB037-A9A0-4C62-A473-F7A147EA3C04"/>
    <pav:createdOn>2015-10-01 10:29:06 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B3AD5EB9-79E0-4CA2-B026-05BA753A2E7A">
    <pav:createdOn>2015-10-20 10:18:00 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>B3AD5EB9-79E0-4CA2-B026-05BA753A2E7A</domeo:uuid>
    <ao:prefix>    Clozapine   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B3AD5EB9-79E0-4CA2-B026-05BA753A2E7A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Elevated serum levels of clozapine have been reported in patients taking fluvoxamine maleate and clozapine. Since clozapine-related seizures and orthostatic hypotension appear to be dose related, the risk of these adverse events may be higher when fluvoxamine and clozapine are coadministered. Patients should be closely monitored when fluvoxamine maleate and clozapine are used concurrently. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EE8109C6-F996-4992-83CA-022BC0576074">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7DF66C96-E6C1-4D67-886F-3A5C59D7E087"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:640B975C-9A37-4C61-94BF-4F6DC0BB40FF">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8F9227EB-64B6-48B6-9996-6D860AB88B63"/>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EC181D09-9FBE-4D67-B527-812C5BD1E031"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:48C9C8A6-75C3-4FE1-82EA-C0CFD252021A">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N3908dc2259d242f091573a59d6525eb2"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0468AC6B-4F06-4CA4-A0DE-A389E3B0E59F</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-16 15:31:12 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:841A93FF-C9A7-4ED4-9B08-BBB942ED30A4"/>
    <pav:createdOn>2015-09-16 15:26:50 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:3B6BD446-38AE-4A35-94E7-9373995DF256</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B089E97E-4E63-40D5-8643-27B261116AD8">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-10-01 10:27:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:76C532D0-95A1-4E30-A106-B7BD8D283D3A</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:33B17719-DF97-48EA-AFA2-01DE8A8887B4</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:4D7DBAA1-48DE-4BE6-BBEA-286BD33E89EF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BF935E8F-19A5-413F-8C9F-6AC24A383B4C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-29 11:25:03 -0400</pav:createdOn>
    <ao:exact>TCA</ao:exact>
    <domeo:uuid>BF935E8F-19A5-413F-8C9F-6AC24A383B4C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BF935E8F-19A5-413F-8C9F-6AC24A383B4C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F179D434-4611-4764-BC78-8C0904DFF47C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7C3ED630-095E-46C1-9254-E12EC01A6C0B</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:A18FE7A7-6258-4E81-9924-B53727D3AE53"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-08-26 16:14:17 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-08-26 16:14:17 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:60BF701E-474F-4B58-8774-3E450D3C23B5</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BE9C0041-BC8D-43A3-994A-A07CF600971A">
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B0209F2A-C65D-4890-9D82-B304338F4E6E"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9C8C57C1-AB82-4BCD-81EB-63037E21E979"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49">
    <ao:item rdf:resource="urn:domeoclient:uuid:52165ABE-00FF-41BF-BA2A-5938CA339FD2"/>
    <rdfs:label>NER Sets</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:AC05F8B2-F9F9-49D3-A70F-921EA23EA476"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AC99C46C-859B-46C2-AE16-9C1D260E1BDC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9B2FF7B9-6C2B-4473-A30C-C87F7F14558A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:317AD3F8-0D57-4139-8BB0-76A296E48D86"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:29C9F4E5-4A2A-4693-AF94-46A5CC1A21D0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D9409E4E-F16B-4055-8C9B-10D5E4BF8361"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E42630A7-EC0A-4840-A981-7D700D64CB85"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4A1F947D-E4F9-4B43-9991-96915301A3C1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:82534F38-12A3-4093-9D06-C2F7DE554A10"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C9EE9367-E702-41C6-AB74-3024CEAAB71B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:267DFD0A-5B3B-4F41-9DB6-8A24E410471E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4A04CDE4-D2EB-43B5-8A0F-ACB912CEA762"/>
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/940d0fc9-6876-4714-abf6-541abdf7fa67"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:961DD3B0-9056-4A8E-BA5F-F77A157F7F8F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:383EAF23-ABAB-4AA4-BDB3-988974B6D1ED"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CBAB79B3-8313-41B5-999B-25D4F9959A13"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E8D5C85E-AD89-4E93-B371-0678DA230E33"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:145CADDF-092E-409D-83DB-7E09303108D6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0ACB8BDE-E592-4270-9AC7-42A62B893693"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8A0049C0-151B-4CD9-A5F2-E75FA2BE6A24"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4B590F9A-D21F-41D1-93B2-7EF2747AFDC4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A7EDE56B-7E2D-45DD-9B69-71AF93CE4A54"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C7E772F6-875F-4637-94E9-DE4BCB9AAF16"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F0161B4E-C364-4202-B596-E59C9581CCBF"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">13</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:FF695BC4-C82B-4848-9B16-ECAF10060C47"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B37F2903-12F8-44FB-92ED-CC6B5B8369E0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7A2A2345-C764-4C44-81DA-580C2885BBD7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2D74C846-D521-4E4D-ABB4-735D9E78A6FC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4E812EE5-3B86-412B-99DB-84E15DEFF8C6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0E6D27D1-BB58-44E7-A985-E844B9108BFC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A953940F-4A5E-4451-8F60-7585A9F3A6B8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C1556E7D-4545-45DC-96D4-2458BD08DA75"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:563B4DF4-2A90-4A3F-BF5D-40F5E36A5D8F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2FA865F9-7395-4DC0-AF33-84D72F77EA3F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:49746603-5E54-4D89-8C88-A0A5870FA4E2"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:D6350C48-AC2A-4106-82F4-E2F7CF2F561B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:783BEAD9-A5E3-4C83-964D-B264DA1D580D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:560ED62D-D32F-4146-B047-7AB9DBB6F516"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EE531387-2630-404A-90E4-6A4B382FFD4F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4180C419-788E-4700-AC18-62022C0E5751"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6F48A090-E4BB-49EA-BD4B-621FCACB423E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2015-08-27 14:50:19 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:F429D0CF-A31E-4429-8092-5584CF47A264"/>
    <pav:lastSavedOn>2015-10-20 10:37:41 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:4488333E-90FB-4227-A529-CB398D9751C8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C4DC6294-3B81-4921-9633-75583A1E42C5"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:657BFDCD-CAF7-4E5E-9671-C1747114E769"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:FF895082-0B10-4D32-ABF2-77A3ABFE3D80"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CED8BF4E-8391-4512-AEA7-FEB082C4D59F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2E43AF44-F0BD-44A5-9C65-D35E3D54601F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7EFBE050-F23D-4AD7-9613-BEDEC8EE79D8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D827C70D-8527-4B67-BD81-4007E2027108"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2DC230E7-7D25-49FC-8899-90D905A84DC4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9FE667DC-2842-457D-97A1-7440687F7955"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:14569B66-469D-40B5-9FED-8E8591F749CD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E45E25B8-DB5A-4994-8764-AEBEB1B5F0BC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:21C5AF10-BD7A-4667-9B9A-6DFB1A3BB881"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1CEB3C6B-7B47-4609-9F0D-697A3AF5EBC5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3C72AF03-DEEA-4C38-9BC8-C328532DA55C"/>
    <permissions:permissions rdf:nodeID="Nd2415601d5354e6ea3d0aa6834999adb"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:59AA3350-6C71-4B9C-83AC-E3303FC1EFC3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BE494201-423E-4C4F-A4B0-44644A531896"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C0EAD6FC-7563-4352-8B33-AA84146C6C74"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:14A50529-D7FE-4475-8383-CB1135DDAF7D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:48D927C3-381C-4356-93AD-214B71B23DB5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:19CCE768-6894-484E-BE0C-E22478C924A2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A3366D2F-9B7F-4577-8711-EE1CB7233531"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:40DAB383-D55F-4575-9AFD-BAF1EDCEBB4F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D6C46F99-3BE0-4FA3-938E-3706A46FE0C9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:711DC06D-073B-492E-84BE-F4D429C68659"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:82843431-618B-411A-B745-998E072E8D0F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:236D5197-CE0E-4A75-AC7B-062499B37679"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E39A0DBC-CEE5-4BB7-B57D-BE7FF66AB57C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:46D60EAD-7099-4467-8AD4-8B299E24C6F6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3028A14C-3DC4-4F10-9879-34B89C52406C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:282346E4-30F0-47C2-98DE-CDAC179DA92A"/>
    <pav:previousVersion>urn:domeoserver:annotationset:B5F05A36-0042-4985-BDA0-C0BB93B51AD7</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:F67BC663-6A59-481D-AF2C-EDB9936FBFD4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B1ED0446-7473-4E86-95CF-113D6813129E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:09EDF778-A166-4AD9-8A4F-9CDE1A48385D"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:6EF09AAD-D99E-4078-9139-493C415E346A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:913AC9D4-9D38-4FF1-9ACE-F74820A0C732"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F416F666-81A3-4F10-81DE-F6B6E34655AB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F7AA104A-110D-4EA9-88E0-99F6DE345461"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B163C0BF-9476-44C8-8119-F9FE4A9488A1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:42201ABB-753C-491E-9EA9-45A742B4D21B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4F2A9C24-89DE-431D-B9A0-9DB593BD82C5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B549982E-B184-45EA-8F52-24E289C3EB5A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AB53D00A-B8AF-48B0-82DB-9F7EB166BE7D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7488FD20-D665-4B23-9EC8-75E05A10A3F4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:065AC336-D88B-438F-86C0-C1846BB09A35"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5A57003D-C40D-429F-9ED1-02CAF7EDC52A">
    <pav:lineageUri>urn:domeoserver:annotation:76D59973-438D-48A3-9680-9DA36D52E574</pav:lineageUri>
    <ao:body rdf:nodeID="N19f433bce14f4f9ea5c2551540b3ad07"/>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2ABE5FA2-BA00-4AF9-A2EA-1305FAECF3DF</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-08-20 13:57:12 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:19AED2B2-1A29-4270-A1F2-C94D2FCACAFA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8B629F70-4030-4225-8953-D8624D66FF43">
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-09-29 11:21:05 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:C83ADD65-1FE4-472E-ADC9-CB830E45EC4F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="Nbccee63e20f24a9c939eb0ff73202072"/>
    <pav:lineageUri>urn:domeoserver:annotation:A932FDAB-72C4-40A6-8559-14FDB4695121</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:37C29721-E01D-492D-B896-DA9BCD64DCF8">
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:FD24FF99-6DB5-4760-B922-D6B873DD71B6</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:C331A888-80A8-4A77-8B8B-9B4659235EBF"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-09-29 09:25:46 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N1ae090ec8f9c471da7836b9872e575e1"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0185AD47-6E7B-4C92-8A3D-A2876CC95002</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4F7C83D7-4B68-424D-B57D-EF9997ADAD18">
    <domeo:belongsToSet>urn:domeoserver:annotationset:2ABE5FA2-BA00-4AF9-A2EA-1305FAECF3DF</domeo:belongsToSet>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:8829FC35-C588-40E5-A075-03B89B92A252"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N9f5b2469596a452cbf0f8ea661a1004e"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:7B69210F-FE8C-4B77-95F7-6A3F57C1674F</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-08-20 13:56:05 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DD827BEA-0D7A-42FA-B33E-FD565FF369B9">
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:t12>35</dikbD2R:t12>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptDuration>14</dikbD2R:preciptDuration>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A89FC92C-5A67-42A6-A421-D569274EB522"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/96425A47-B57A-4120-9BE9-A9BB35F407E3"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:auc>50</dikbD2R:auc>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Type>Percent</dikbD2R:t12Type>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12Direction>Decrease</dikbD2R:t12Direction>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:741F8D04-9EC1-4483-80FF-2D5626EA5BBC">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <ao:exact>TCA </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>treatment in a patient being withdrawn from </ao:suffix>
    <pav:createdOn>2015-09-29 08:59:10 -0400</pav:createdOn>
    <domeo:uuid>741F8D04-9EC1-4483-80FF-2D5626EA5BBC</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>s and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:741F8D04-9EC1-4483-80FF-2D5626EA5BBC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9EB813C9-4F23-4FDF-80E7-60BE4ED6AC9A">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9EB813C9-4F23-4FDF-80E7-60BE4ED6AC9A"/>
    <pav:createdOn>2015-10-01 10:29:22 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7-10% of Caucasians are so-called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).  </ao:prefix>
    <domeo:uuid>9EB813C9-4F23-4FDF-80E7-60BE4ED6AC9A</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:201A57BB-94B3-4FE8-942E-4EE00AF39EB8">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/96535AFF-63A2-4ECA-A193-C044A8E5A042"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/16D1170D-A133-48B2-B0FC-5F7C5D9A592D"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A72BD722-4ABC-4E15-8572-3DEEEBD77214">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7993A459-EE66-4E96-8A86-86C5B2BB1378"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F0CE3DA6-955D-446E-9A5E-15F4DDD90DB6"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A9FB662B-B83B-4917-B9B9-EA3D95D5A7B3">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>methylprednisolone</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A3511B53-47E5-4DC5-8429-E8BAC40EE89E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>ketoconazole </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5d103551-978f-472a-9c62-51e6e4dea068.html</ao:hasSource>
    <ao:suffix>in healthy subjects decreased the bioavailability of ketoconazole by 30% and increased the AUC and C</ao:suffix>
    <ao:prefix>(20 mg daily) and </ao:prefix>
    <pav:createdOn>2015-08-26 16:11:33 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A3511B53-47E5-4DC5-8429-E8BAC40EE89E"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A0DC074E-17D3-4D1F-9EF1-1C00163EB257">
    <pav:createdOn>2015-09-25 10:03:31 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-09-25 10:05:58 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:AE00EC22-1231-4A33-AE87-FACD45762D44</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5808C4F6-3D20-4064-BA30-F1F80E74C108</domeo:belongsToSet>
    <ao:body rdf:nodeID="N4a04021bc8ef4b5aa69cf3cf5737dbc2"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:A70238ED-3B41-4B29-A0BD-932D1A199E36"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4193FEF6-81CC-421D-8342-A5481CFF1DC5">
    <rdfs:label>TCA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8566158B-84F1-4845-B2E8-3CA5B143414E">
    <rdfs:label>rifampin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:5808C4F6-3D20-4064-BA30-F1F80E74C108">
    <pav:lineageUri>urn:domeoserver:annotationset:7ee8c071-c115-4ead-b481-d5d30c6f9300</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/f371258d-91b3-4b6a-ac99-434a1964c3af.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:A9CBFF9A-EF56-4A42-95EE-9A1D317628A3"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:previousVersion>urn:domeoclient:uuid:9d7dfc4b-055d-4d41-bf8d-659860b332b6</pav:previousVersion>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/a3687c1e-976c-4ef7-9091-ac466a583bf8"/>
    <pav:lastSavedOn>2015-09-25 10:05:57 -0400</pav:lastSavedOn>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:A0DC074E-17D3-4D1F-9EF1-1C00163EB257"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:00E9D06D-C90C-4069-974A-596169F16DF5"/>
    <pav:createdOn>2015-08-27 14:50:08 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="Nc45b52497fe54dbfaf9c19b10aafffb7"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <rdfs:label>NER Sets</rdfs:label>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E1B06E0F-5C33-411C-96A8-189B2513F62C">
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">14</pav:versionNumber>
    <ao:body rdf:nodeID="N8c003dc6a2d740f287117c5cd5756f73"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:20A4F13C-F9D0-424D-9960-73CDCA576AD1"/>
    <pav:lastSavedOn>2015-10-16 10:40:14 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-03 15:54:29 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:CE124242-AD57-4D32-9A25-1EF5E6126E23</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:BDA149A4-7480-419D-95B4-B8534B0D597B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c00d1607-ac36-457b-a34b-75ad74f9cf0a.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:EA373C68-45B7-43A7-8318-89A087B0443D"/>
    <rdfs:label>NER Sets</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:22bfb0a5-43c0-4a07-a42c-fe959741f5a1</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:0E920D43-C030-4524-9A28-FCE987721FAB"/>
    <permissions:permissions rdf:nodeID="Ncaf5e839ddfb43039aa5188559dbc0c7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2250D858-35D5-4CB1-B540-384475386972"/>
    <pav:createdOn>2015-10-12 13:20:28 -0400</pav:createdOn>
    <domeo:deleted>false</domeo:deleted>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:2dde803e-2aa6-412f-b00d-eae0772b9fcf</pav:lineageUri>
    <pav:lastSavedOn>2015-10-13 11:13:09 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/e2c85362-b41b-4e30-b3ec-3e9a1e57d381"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:48E05987-C3A7-4E43-AEE7-4A150AB4A2B1">
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-29 08:55:49 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:85B341C9-81D6-4E4A-A34C-2D651EADEDD9</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:1C418A3B-A13B-4CCF-A73C-F688A08DBC67"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B48B1E77-F1D1-4DD5-8343-F0BDDFEF55BB">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BDC69264-3F54-4B1A-A8DC-4EEAB55EE6C8"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:89D1253B-FCEB-49A4-B78E-F745CF9C9BD7">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-16 10:37:33 -0400</pav:createdOn>
    <ao:prefix>   </ao:prefix>
    <ao:exact>Ibuprofen    In subjects who had received EMSAM 6 mg per 24 hours for 11 days, combined administration with the CYP2C9 substrate ibuprofen (800 mg single dose) did not affect the pharmacokinetics of either selegiline or ibuprofen [see Drug Interactions (7.4) and (7.5)]. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:89D1253B-FCEB-49A4-B78E-F745CF9C9BD7"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>89D1253B-FCEB-49A4-B78E-F745CF9C9BD7</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DF275A70-03F2-44A1-918B-D8D47DBC823E">
    <dikbD2R:dose>1.5</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Savella</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:152B2F3D-4E7D-4FD4-87BE-DE4DCF3F490C">
    <pav:createdOn>2015-10-09 13:18:56 -0400</pav:createdOn>
    <domeo:uuid>152B2F3D-4E7D-4FD4-87BE-DE4DCF3F490C</domeo:uuid>
    <ao:exact>In a controlled study of healthy volunteers, after paroxetine was titrated to 60 mg daily, coadministration of a single dose of 2 mg pimozide was associated with mean increases in pimozide AUC of 151% and Cmax of 62%, compared to pimozide administered alone. The increase in pimozide AUC and Cmax is due to the CYP2D6 inhibitory properties of paroxetine. Due to the narrow therapeutic index of pimozide and its known ability to prolong the QT interval, concomitant use of pimozide and paroxetine is contraindicated (see CONTRAINDICATIONS).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:152B2F3D-4E7D-4FD4-87BE-DE4DCF3F490C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <ao:prefix>CONTRAINDICATIONS and WARNINGS .  Pimozide  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:27CDD1F9-58C1-4AE2-982C-582882E7AE76">
    <pav:createdOn>2015-08-20 10:29:57 -0400</pav:createdOn>
    <ao:exact>In vitro studies have shown that R-bicalutamide is an inhibitor of CYP 3A4 with lesser inhibitory effects on CYP 2C9, 2C19 and 2D6 activity. Clinical studies have shown that with co-administration of bicalutamide, mean midazolam (a CYP 3A4 substrate) levels may be increased 1.5 fold (for Cmax) and 1.9 fold (for AUC). Hence, caution should be exercised when bicalutamide is co-administered with CYP 3A4 substrates.</ao:exact>
    <domeo:uuid>27CDD1F9-58C1-4AE2-982C-582882E7AE76</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:27CDD1F9-58C1-4AE2-982C-582882E7AE76"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7c295b64-ec39-42ec-9f02-da5b42e775e1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>bicalutamide induces hepatic enzymes .   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/a3687c1e-976c-4ef7-9091-ac466a583bf8">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:7ee8c071-c115-4ead-b481-d5d30c6f9300</pav:lineageUri>
    <pav:createdOn>2015-08-27 14:50:08 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:1ef67243-4467-4109-8d15-a36c39140f24"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5808C4F6-3D20-4064-BA30-F1F80E74C108</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2015-08-27 14:50:08 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:51ADF4A4-36F4-4036-8C39-A4E2F13682BD">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/ADDBF2EC-65E3-4DD5-A161-4E2BA5648C57"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptDuration>9</dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptFormulation>transdermal</dikbD2R:preciptFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/51FDDB98-A5CE-47B1-A192-61AC33B13E17"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C3B195E3-DE80-4547-ABB5-CF768DE087E5">
    <domeo:belongsToSet>urn:domeoserver:annotationset:33B17719-DF97-48EA-AFA2-01DE8A8887B4</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-01 10:27:40 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:6F3A4A7F-7DA6-4F16-81E8-4ACD20ED3D91</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:F2FF4BAA-E6D7-4190-A266-56C578E40ACB"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EBD564F1-FBBC-4657-A7D1-CC931904D2E3">
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-14 11:41:39 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:87AA3A89-7CF0-4741-B125-89652FE3943C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:701DB538-7BEA-4445-90B8-94717DA942D2">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:DA6F7D85-DD9E-4845-BF51-0263865BEDD4"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2A1BB431-B923-4C57-AA3D-4E5343A75E5B">
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-10-14 12:10:56 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-14 12:08:09 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:FAA60182-D523-42BF-8B80-10BFEF6C9D55</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:1D5A637D-5D0D-4828-BA8F-B06362C87321"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:45E2683D-3B8E-46A3-B025-28C2F533D051">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:04B80DF1-D3FE-4E2E-859F-732C816CB3FC"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CEA91607-0BA5-49A7-8FEE-F739EA74F261">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6E30469D-53FD-4CDA-980B-4DCB18DA1EA9"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4715C7DD-0005-4C0F-88B4-99A266D94C43">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-10-14 12:10:56 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-14 12:08:08 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:F9C4EC72-87AF-4115-91A2-612EF6702030</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:74319367-2778-4836-A36D-C8518AEC7C9D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/99E8881C-1ED6-4ED9-A748-04DA06BDF07D">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:325955E2-1A3F-45B4-83DB-34472FDD97AD">
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdOn>2015-10-14 11:40:27 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:89BEEE9E-FD9A-463B-9C3B-DF66ABFD0923"/>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D9409E4E-F16B-4055-8C9B-10D5E4BF8361">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-20 09:22:28 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:7F58F36E-9F7A-4CD6-9AF2-A18AC685705E"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:8D286017-0AEC-46C4-AC51-641E2F31DE1A</pav:previousVersion>
    <pav:lastSavedOn>2015-10-20 09:23:48 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6FB3EE06-1EF2-4970-9924-E3F72D0AFA10">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/91E89437-3D47-4B7F-B4B2-43FBAEFEF1F1"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A304BF07-A56F-40D4-9D69-89D42C824C17"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:338217AE-916E-466D-8467-B99AFFFF05E5">
    <ao:exact>ketoconazole</ao:exact>
    <domeo:uuid>338217AE-916E-466D-8467-B99AFFFF05E5</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>), barbiturates, beta-blockers, calcium channel blockers (e.g., diltiazem, nifedipine, verapamil), chloramphenicol, clarithromycin, corticosteroids, cyclosporine, cardiac glycoside preparations, clofibrate, oral or other systemic hormonal contraceptives,</ao:suffix>
    <pav:createdOn>2015-10-14 11:40:20 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:prefix>, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:338217AE-916E-466D-8467-B99AFFFF05E5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:25BA553C-55CB-42A9-8E94-9B05C7471880">
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectFormulation>IV</dikbD2R:objectFormulation>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cl>16</dikbD2R:cl>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A75C324F-9F88-48E2-884F-44D03DA0A982"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BDA75F87-E8CD-4109-B8B9-9272AB22F777"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptDuration>22</dikbD2R:preciptDuration>
    <dikbD2R:clDirection>Decrease</dikbD2R:clDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:clType>Percent</dikbD2R:clType>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DFC29412-859C-45A5-BB5B-240CED90D299">
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmax>18</dikbD2R:cmax>
    <dikbD2R:auc>55</dikbD2R:auc>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BCA7C5D9-76C4-4313-B0F4-D885A239D20C"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C01F7ADD-2F57-4B50-8835-5CE1DF41F6AD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0340691A-566D-462A-991D-4B1EB2FC98B2">
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clDirection>Decrease</dikbD2R:clDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/23E27A87-DE2D-420E-9D6D-98BD122107FF"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:objectFormulation>IV</dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:clType>Percent</dikbD2R:clType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptDuration>21</dikbD2R:preciptDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cl>32</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0F426060-C04A-472C-8743-8DAC80A34F49"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5B26DDD8-ECAC-43C2-8187-556E17A58793">
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/56B626A1-FA5F-41C3-941C-7FC2F0DFA6B6"/>
    <dikbD2R:preciptDuration>11</dikbD2R:preciptDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4A18152D-98CB-4161-B63A-8E64236DE720"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EAAB95EB-FAF6-4447-BC17-C540B6BDF6A7">
    <ao:prefix> (e.g., </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>EAAB95EB-FAF6-4447-BC17-C540B6BDF6A7</domeo:uuid>
    <ao:exact>amitriptyline</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EAAB95EB-FAF6-4447-BC17-C540B6BDF6A7"/>
    <ao:suffix>, nortriptyline) and zidovudine. It may be necessary to adjust the dosages of these drugs if they are given concurrently with rifampin.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-14 11:41:08 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D5C58383-272E-4040-9840-D67FB821F7A2">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>duloxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>20</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:27542EC3-2E5D-4711-97F9-3700D71B59D2">
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmax>1.58</dikbD2R:cmax>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:auc>1.54</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/46BB7B1D-CA69-484C-A2CF-827E4D97C26E"/>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FDAE890E-049A-41F4-9F30-53EF368E9E98"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DC117877-091A-4B88-8576-9668C2E6FCD2">
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:A906518C-A45F-43E6-88EF-1DCB10E013E1"/>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <pav:lastSavedOn>2015-10-16 10:42:46 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:5BEA2001-CB06-4507-A35E-7F6F162CB5CE</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="Nb6874c23d10746bb889eadebdc134433"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-03 16:13:00 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:39EE729E-3704-418F-A9A4-F96C867889C0">
    <pav:lineageUri>urn:domeoserver:annotation:9608F159-3D37-48BF-92DB-B6327FA47DC5</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:545F2613-2A5E-4333-A651-CBA80268D6ED</domeo:belongsToSet>
    <pav:createdOn>2015-09-30 10:39:28 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N1fa0d25fb1ad46a4ad7f514b67f3f06c"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:282837CD-372D-4A39-ACC1-B9E420E7A591"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:0185AD47-6E7B-4C92-8A3D-A2876CC95002">
    <ao:item rdf:resource="urn:domeoclient:uuid:E01D6A81-E98C-4BA7-936C-B4D6127192C7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:101726AC-4079-4A15-B511-8EB870DB4FF4"/>
    <rdfs:label>NER Sets</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:C18ED82D-257A-4F8A-9E43-CA2E44AB5086"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1B29206A-BBA8-4584-BB32-267808C9854A"/>
    <permissions:permissions rdf:nodeID="N15a6777be34a41c2b1cd7efb166ae35c"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:37C29721-E01D-492D-B896-DA9BCD64DCF8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CFF7A244-CF86-44AD-A33E-ACF701E2EFFE"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f39a9e3d-316d-4f11-875b-be07c238984a</pav:lineageUri>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:47ADA4F9-1416-4A25-9B67-082755D374F4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdOn>2015-08-27 14:50:19 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:D412315B-36D6-4C34-B6D0-D6A7021E28F8"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:6853CD49-9E30-472A-9DD1-6C5F009A7AC1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4D4628C4-27FB-4DDC-B242-E679B66BF887"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:annotatesResource>
    <pav:lastSavedOn>2015-09-29 09:27:09 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:d4cbfe9d-e841-46a7-81dc-20313ff2e4f1</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:D960C312-4566-45E1-8A58-E9EDCE19C1BC"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/a35c52ef-9af1-424f-abf1-58cb7ae4aeff"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:195D49D1-2E5F-403D-9BB9-0471ADA92D3A"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D4D62777-76E7-4FDA-83C4-0D64C053920E">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>darunavir</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:45751E42-6FAA-4771-A8B8-F08AD42C83D7">
    <ao:prefix> Absorption/Bioavailability -  </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-09-29 09:44:12 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:45751E42-6FAA-4771-A8B8-F08AD42C83D7"/>
    <ao:exact>CMI</ao:exact>
    <ao:suffix> from clomipramine hydrochloride cap</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0dccb356d55d459d873dc136f1c35557">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DD3E3032-727D-4A53-AA39-EF11B585F4CD">
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:0AEC087A-B27C-4CAE-83EC-666698AECFBD"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-14 11:41:09 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C546DCD8-3F2C-4E34-BF95-7720097AE8F3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E2A044D2-76E2-4DBD-9969-C882DC1E4E30"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:comment>TCA plasma levels decreased</dikbD2R:comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B01048B3-7D98-4B92-9E98-C160BFB5F6B3">
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:3B4BB6C7-ACA6-48F0-BA61-967A67720DED"/>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-14 11:39:50 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0E920D43-C030-4524-9A28-FCE987721FAB">
    <ao:body rdf:nodeID="N2579bc32cc3b48cc8b8e42a205c43b23"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:BDA149A4-7480-419D-95B4-B8534B0D597B</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-13 11:13:09 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-13 11:12:58 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:6D4E55B4-6B7C-41BD-8D0F-70EB7D9C1BE0</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:7A49A875-16F9-4412-9863-8314AFC3BC55"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BED03FA5-9E57-4FE6-B474-FBD6C633C54F">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:B173B596-3E40-4B44-970D-6B5474DB30EC"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A66F97CF-143C-4929-85A7-8F2A4BA0AF3A">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>EMSAM</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dikbD2R:dose>6</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7284D267-7184-465F-BA7D-6103BCF19E06">
    <ao:body rdf:nodeID="N8784e7551f604001a50ec1b139326131"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-29 09:04:23 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:1FE06F45-1F25-4B8A-BCC6-643822373F72"/>
    <pav:lineageUri>urn:domeoserver:annotation:190A87A5-9529-496E-ACB7-C5575B16B534</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8D869AC5-11A1-47C6-B72D-5D0285ABE2A1">
    <ao:body rdf:resource="urn:linkedspls:uuid:BF13ABBA-974C-4D13-B3D9-09EF5A6BB2FA"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:CAB63AF9-D23A-4109-A615-275C9421E6CB"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:BFDA94B6-C3E3-4254-B29F-1D8EE09A501D"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <ao:body rdf:resource="urn:linkedspls:uuid:16FDB844-0908-4D9D-9647-601A4C547C45"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:3D046132-84C4-4ABF-8B1C-EC07A0D07CA1"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:82327B05-8BB1-401E-ACB4-42C3E0930D57"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:23530D0B-F4A5-407A-AED0-EE99C0B30E6D"/>
    <pav:lineageUri>urn:domeoserver:annotation:E07CBE6D-93C5-4C75-8C1F-2BADEA50F654</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:0768CA5A-42B5-4AEE-898D-336AADC10B13"/>
    <pav:lastSavedOn>2014-02-20 13:49:40 -0500</pav:lastSavedOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:AA18BF65-3F61-4179-8A1D-B73034A9E587"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:56EA7F48-3179-452B-BB6A-F74C96533A0D"/>
    <pav:createdBy>urn:person:uuid:080e1430434f70e501434f711b6e0000</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:2615D048-46FA-4557-B691-24297A4787D9"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:resource="urn:linkedspls:uuid:7F46AEEA-D7F6-4F1F-A426-9F20EDEB76A3"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:CBE2B329-4E6C-4915-91A7-775A43D4D87E"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:94611C47-47D7-4D38-8EEF-17379EF5BB78"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdOn>2014-02-20 13:49:37 -0500</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:8EBC3A86-CAF7-4AEB-8718-D2C34C496981"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8AD21D6C-B585-4986-9335-FAD5A45407B9</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4FB3483D-36F7-4ABD-BE96-8AED148EF544">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:bea6ab45-b167-4aa7-899d-2dad3f303256">
    <ao:prefix>e.g., cimetidine, </ao:prefix>
    <ao:exact>fluoxetine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-29 16:04:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:bea6ab45-b167-4aa7-899d-2dad3f303256"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na0cf34fbec244d24bbd1aca8d1a7d1ce">
    <domeo:sets rdf:resource="urn:pddi:uuid:1DD7B543-078B-4F0E-8C2B-7D10EF933612"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2250D858-35D5-4CB1-B540-384475386972">
    <domeo:belongsToSet>urn:domeoserver:annotationset:BDA149A4-7480-419D-95B4-B8534B0D597B</domeo:belongsToSet>
    <ao:body rdf:nodeID="N4edd194f0db44a5a8305511b5046df5c"/>
    <pav:lastSavedOn>2015-10-13 11:13:09 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:C06230C7-FA16-4D25-BB25-03C809169038</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-10-13 11:12:39 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:3E3F5537-2CCB-43FE-9963-2617094F1725"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3B7BC994-0AD3-4AB6-8772-CF4F3FEF6C4D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:34C21368-2A4D-43BE-A6BC-F2D131B07F2D"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:770C9DBF-86C8-4FC9-ABEA-6B185AB873D5">
    <dikbD2R:auc>1.41</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>1.33</dikbD2R:cmax>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F924CECD-3BCA-4F07-B76D-4F30EB2A95EA"/>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4E539308-4FB5-4CB6-814C-CFEA1D7EF6B9"/>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:351F9CC4-DE7F-4409-B049-B3529F081B4C">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdOn>2015-10-14 11:40:08 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:AC2087DA-3178-4243-9BA8-82C69F3AAF6C"/>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:48834AD2-4A59-4451-94B1-2750AA9B63EE">
    <pav:createdOn>2015-09-14 11:31:57 -0400</pav:createdOn>
    <ao:exact>Coadministration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine. Any dose adjustment should be guided by clinical effect (tolerability and efficacy).</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:48834AD2-4A59-4451-94B1-2750AA9B63EE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>levels be monitored when these drugs are concurrently administered.  Fosamprenavir / Ritonavir  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DB1C7584-93A5-4911-B42F-53E0E14CE25F">
    <ao:body rdf:nodeID="Ne6b115537dd64ecca390f3c189617d86"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-13 11:27:39 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:BD8AEC57-8E65-4689-A734-08C52656A65C"/>
    <pav:lastSavedOn>2015-10-13 11:52:38 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:58BD31E4-F1E7-44DA-87A9-5298EBD36BEA</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BD68DA44-7F86-4048-99B9-16558FF32E07">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>BD68DA44-7F86-4048-99B9-16558FF32E07</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BD68DA44-7F86-4048-99B9-16558FF32E07"/>
    <ao:prefix>were approximately twice those observed when </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-20 09:56:55 -0400</pav:createdOn>
    <ao:exact>alprazolam </ao:exact>
    <ao:suffix>was administered alone; oral clearance was reduced by about 50%. The elevated plasma alprazolam concentrations resulted in decreased psychomotor performance and memory. This interaction, which has not been investigated using higher doses of fluvoxamine, </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/48BBB7B3-7B05-4159-93FE-71662573AF67">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>olanzapine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:37DDEDB4-2423-46DF-880E-A2D411563078">
    <pav:lineageUri>urn:domeoserver:annotation:0B909215-7514-42AE-8D33-022CB8C17D3A</pav:lineageUri>
    <ao:body rdf:resource="urn:linkedspls:uuid:A26A390E-AB65-462C-81C3-438BDBA41B70"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:1ED20ED1-FB0C-422E-8105-1ED7D0D52049"/>
    <pav:createdOn>2014-02-19 12:41:17 -0500</pav:createdOn>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:C3D5761B-F1E9-43C2-9D22-5854F1ED38ED"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2014-02-19 12:41:40 -0500</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E9F13BFE-1A17-4FDF-99A7-13B89F697635</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DC123E69-3401-4E56-B96A-77AF52AFAA21">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-30 10:39:45 -0400</pav:createdOn>
    <ao:prefix> (75 mg once a day) to </ao:prefix>
    <ao:suffix>(100 mg/day) without a washout period did not lead to clinically significant changes in the pharmacokinetics of </ao:suffix>
    <ao:exact>milnacipran </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DC123E69-3401-4E56-B96A-77AF52AFAA21"/>
    <domeo:uuid>DC123E69-3401-4E56-B96A-77AF52AFAA21</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:8AD21D6C-B585-4986-9335-FAD5A45407B9">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:F9D4CB21-4899-4A2F-B0CD-7E645C1D09AE</pav:previousVersion>
    <rdfs:label>Default Set</rdfs:label>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdOn>2014-02-09 21:25:30 -0500</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8D869AC5-11A1-47C6-B72D-5D0285ABE2A1"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e1430434f70e501434f711b6e0000"/>
    <pav:lineageUri>urn:domeoserver:annotationset:6B63AAA7-56D3-4CE3-85CF-8ADE045F53A7</pav:lineageUri>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/Warfarin-ab047628-67d0-4a64-8d77-36b054969b44.html </ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <permissions:permissions rdf:nodeID="N6e60f74aff7c4797877c83ea8d8efdd1"/>
    <pav:lastSavedOn>2014-02-20 13:49:40 -0500</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:deleted>false</domeo:deleted>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:65A96884-F27A-4B18-94D1-983AFF5A5C47">
    <pav:createdOn>2015-10-20 10:08:56 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <domeo:uuid>65A96884-F27A-4B18-94D1-983AFF5A5C47</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>fluvoxamine maleate</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:65A96884-F27A-4B18-94D1-983AFF5A5C47"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> tablets and diazepam is generally not advisable. Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic coadminis</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6D3709FE-1151-4CCD-8ED5-6577EE09D4D5">
    <ao:prefix>   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Alprazolam    In subjects who had received EMSAM 6 mg per 24 hours for 7 days, co-administration with alprazolam (15 mg per day), a CYP3A4 and CYP3A5 substrate, did not affect the pharmacokinetics of alprazolam or selegiline [see Drug Interactions (7.4) and (7.5)]. </ao:exact>
    <domeo:uuid>6D3709FE-1151-4CCD-8ED5-6577EE09D4D5</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6D3709FE-1151-4CCD-8ED5-6577EE09D4D5"/>
    <pav:createdOn>2015-10-16 10:31:35 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:812B7CD3-0806-4CD6-ACCE-D738EF8B5B63">
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:body rdf:nodeID="Ndf5c7015115a486da6516c5be87cb76f"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-08-20 11:43:54 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:7084298F-F868-484E-9091-B9ED9E4588DB</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-08-20 11:41:14 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:3002A6AB-D0C6-4851-8086-5F1EA0F6A084"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E4F1D2C6-857D-4F82-B085-04A9A96FDCDA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:4C8F7669-6070-492F-8BF7-54DFF7BD7341"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N1c6512802de44c9783a76192729e400e"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:85AD6EA1-D560-4FFB-A685-3F21B0B4208E</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-24 15:48:28 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:6DAEABBA-523F-4EFC-B55C-70FC920F6265</pav:lineageUri>
    <pav:lastSavedOn>2015-09-24 15:55:00 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FA8CCE60-3C9C-42F9-BDC2-0668957F1AA1">
    <rdfs:label>mirtazapine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>15</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0040B2A4-9CD1-49A8-B3D4-BC8547FC2363">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DD604848-4BDA-4DA2-97ED-ABCA8265DA7A"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A42CEB18-FBDB-4BA4-BF6F-D8F2A839D949"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:575EE166-E25C-4355-A63D-3ADB011F3371">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>hydroxylase) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <domeo:uuid>575EE166-E25C-4355-A63D-3ADB011F3371</domeo:uuid>
    <pav:createdOn>2015-09-29 09:26:10 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:575EE166-E25C-4355-A63D-3ADB011F3371"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CCEEA6AE-2E77-4C46-AD3D-D81508E6C690">
    <ao:exact>Carbamazepine is contraindicated with MAOIs, including selegiline [see Contraindications (4), Warnings and Precautions (5.3) and Clinical Pharmacology (12.3)]. </ao:exact>
    <ao:prefix>7.4 Effect of Other Drugs on EMSAM  </ao:prefix>
    <pav:createdOn>2015-10-16 10:25:33 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CCEEA6AE-2E77-4C46-AD3D-D81508E6C690"/>
    <domeo:uuid>CCEEA6AE-2E77-4C46-AD3D-D81508E6C690</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7E7F4E8D-E33F-46C2-BAA8-8364523ED1DC">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1084FB4D-C3D9-4F51-AB79-67D422116DA7"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:comment>Steady state plasma increased 50%</dikbD2R:comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2CD634EB-128A-462F-A28B-C5244A2351DA">
    <pav:createdOn>2015-10-13 12:05:17 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:1B142529-AD77-4271-A130-905880ABE202"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:2E530504-9AD1-4B4D-B852-0172AAE4FD45</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-13 12:06:23 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="Nf3ddbea522b24c04bfee0ef13daa9900"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FC30EFD3-8B33-4D31-8F77-295276999DDB">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>selegiline</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>6</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/02ca3ccf-111a-444f-9d13-aed4fb51ea37">
    <domeo:belongsToSet>urn:domeoserver:annotationset:0468AC6B-4F06-4CA4-A0DE-A389E3B0E59F</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:bae50ce2-5965-493d-becf-e26e57748704"/>
    <pav:lineageUri>urn:domeoserver:annotationset:3ee8b0e2-8d9a-4983-9455-386905b69964</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-08-27 14:50:28 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-08-27 14:50:28 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97EF39D9-0073-404C-B1F0-D472528A3FAD">
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:33B17719-DF97-48EA-AFA2-01DE8A8887B4</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-01 10:31:00 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:AAEBD83F-900E-4F14-BC7C-D209DB8140F2"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:C1FCF784-1A13-401C-B669-CAB28F86A66A</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="Nd378fd2dffd04831b6a8d1cb826cd7e5"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/10724B60-7F03-4798-8C06-530A4F0C6687">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>abiraterone acetate</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>100</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B4234013-1118-4769-8D2D-47E93AB98ED1">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D0914AB8-595D-4D40-89C9-70508FAEB8EE"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:51FA01A1-09E3-4C6A-BCCB-682D02F9460E">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:51FA01A1-09E3-4C6A-BCCB-682D02F9460E"/>
    <ao:prefix>on organic anion transporter 3 (OAT3) substrates   </ao:prefix>
    <pav:createdOn>2015-08-20 11:45:52 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BDFA1B4D-CBB4-4F2D-BFA2-EDADB4C2A92E">
    <ao:context rdf:resource="urn:domeoclient:uuid:8B1C920F-48AF-42CB-B4DA-DEBE5FB38829"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:C2A94A4E-5139-4C8A-B41E-C417F307A4EE</pav:lineageUri>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-09-29 08:59:33 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E881763B-51F8-43BC-951D-E3A87053E98B">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>omeprazole</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/7646</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D699E8C5-EDCC-4757-9BC6-9A6D2E036FD2">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>25</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluvoxamine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndd42df00f30649dea4fd6f19c5a70d0d">
    <domeo:sets rdf:resource="urn:pddi:uuid:06CA4F5E-AE2F-4CAE-8104-B4DBFD00AF22"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F4D9193F-6630-4EDC-8181-3955EE5FA89E">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <ao:exact>citalopram </ao:exact>
    <ao:prefix>2 mg coadministered with racemic </ao:prefix>
    <pav:createdOn>2015-10-14 12:06:21 -0400</pav:createdOn>
    <ao:suffix>40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Racemic citalopram did not alter the mean AUC or C</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F4D9193F-6630-4EDC-8181-3955EE5FA89E"/>
    <domeo:uuid>F4D9193F-6630-4EDC-8181-3955EE5FA89E</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FB3767C5-D6B4-44DF-BBC5-B1CBB19D8547">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>50</dikbD2R:dose>
    <rdfs:label>desvenlafaxine succinate</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9C7E3E66-E1B5-4AA1-928E-76684151DE67">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-03 15:47:29 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:0C9EA96C-0867-4B4B-A1A5-99A165881EF0</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-16 10:35:58 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N4d3d0bcc6e264aa8bc5a66aa73fc61e0"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F3E418AD-A782-4293-B4D8-8CB1E09D8D1A"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:94197DC2-E08A-4657-9AF3-3A137868DE30">
    <domeo:uuid>94197DC2-E08A-4657-9AF3-3A137868DE30</domeo:uuid>
    <pav:createdOn>2015-10-20 10:18:39 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:94197DC2-E08A-4657-9AF3-3A137868DE30"/>
    <ao:suffix>(50 mg b.i.d. for 7 days) on the single dose pharmacokinetics of mexiletine (200 mg) was evaluated in six healthy Japanese males. The clearance of mexiletine was reduced by 38% following coadministration with fluvoxamine compared to mexiletine alone. If </ao:suffix>
    <ao:prefix>The effect of steady-state </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>fluvoxamine </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F230AB9B-627D-4C94-AAA4-4B76239F5D6E">
    <domeo:uuid>F230AB9B-627D-4C94-AAA4-4B76239F5D6E</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F230AB9B-627D-4C94-AAA4-4B76239F5D6E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-09 13:30:56 -0400</pav:createdOn>
    <ao:exact>Drugs Metabolized by P450 3A4In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertralines extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).</ao:exact>
    <ao:prefix>CONTRAINDICATIONS, WARNINGS, andDOSAGE AND ADMINISTRATION .   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:219BB0B8-6710-493E-95C9-B50BA0F64342">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-08-20 11:44:53 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="Nb6330ddf9113434d998c0dc43fee3a23"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:146FB10B-DA65-48DB-A614-AA04320BBE75</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:0DDCC14D-1691-4186-9766-064E8F5C0851"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:92C6B48C-4C9D-40DD-AADE-25C9BFCBA081">
    <pav:createdOn>2015-10-14 11:41:14 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>92C6B48C-4C9D-40DD-AADE-25C9BFCBA081</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:92C6B48C-4C9D-40DD-AADE-25C9BFCBA081"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Rifampin </ao:exact>
    <ao:suffix>has been observed to increase the requirements for anticoagulant drugs of the coumarin type. In patients receiving anticoagulants and rifampin concurrently, it is recommended that the prothrombin time be performed daily or as frequently as necessary to e</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2918DC5D-AFBA-4BDD-AF7C-FF0561F45663">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0468AC6B-4F06-4CA4-A0DE-A389E3B0E59F</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-09-16 15:31:12 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:A03CB02F-4CDA-4B3E-AEA7-159714857FF1</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:292DDE04-C612-4FA1-8DEB-1912DE56BEC2"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="Na1229c9b766d4ac38a11fc1d734d73e8"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-16 15:26:37 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F0161B4E-C364-4202-B596-E59C9581CCBF">
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-20 09:56:51 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:9B8FBF72-9A52-4632-A51A-8B711C78D73A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:64AA2313-E589-4938-99DC-2A49A60E0242">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>The Potential Effect of Other Drugs on AUBAGIO   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-08-20 13:06:38 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:64AA2313-E589-4938-99DC-2A49A60E0242"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Potent CYP and transporter inducers: Rifampin did not affect the pharmacokinetics of teriflunomide.</ao:exact>
    <domeo:uuid>64AA2313-E589-4938-99DC-2A49A60E0242</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8D611268-C3CA-4B8B-8BE5-CCEE1B802599">
    <rdfs:label>fluvoxamine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4A194B83-BBD0-4A1F-830E-1D3CE2352E73">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>temazepam</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix>, </ao:prefix>
    <domeo:uuid>4A194B83-BBD0-4A1F-830E-1D3CE2352E73</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4A194B83-BBD0-4A1F-830E-1D3CE2352E73"/>
    <pav:createdOn>2015-10-20 09:54:10 -0400</pav:createdOn>
    <ao:suffix>) is unlikely to be affected by fluvoxamine. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD78AF4B-DBBE-4FF7-8F6B-FFE1682428C5">
    <ao:context rdf:resource="urn:domeoclient:uuid:0D5EB926-B056-4F85-B631-59CE9E122B9A"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lastSavedOn>2015-08-20 11:38:24 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N321e7762d7ab45389edf893ea84cf636"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-08-20 11:37:03 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:7d2027ff-e85b-46f3-befa-3f8f5cf7e88f</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5E066C8D-C35D-4E0C-975A-46B22FCAB24C">
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-29 09:03:19 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:4A116AFF-7CEC-45FB-AF0B-551A5366DF25"/>
    <pav:lineageUri>urn:domeoserver:annotation:1E92F0D0-6CF4-4B0E-9893-02F7D1D6F892</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="Nd85fd1cb75074465be16877532c01d53"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C1CD89FB-FBD9-4B6F-BB85-C88A3AC629E3">
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdOn>2015-10-14 11:40:53 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:9A74732C-FABE-471C-972C-0CC6549B2961"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:680BB734-E110-4953-A6ED-937A50138C7D">
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:t12Direction>Increase</dikbD2R:t12Direction>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0799F45C-AB26-4C6A-A508-17349BB26B01"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:auc>6</dikbD2R:auc>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/277BE7D5-53BD-4070-8A37-193202BDA762"/>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:t12>3</dikbD2R:t12>
    <dikbD2R:numOfParticipants>40</dikbD2R:numOfParticipants>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptDuration>16</dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12Type>Fold</dikbD2R:t12Type>
    <dikbD2R:clType>UNK</dikbD2R:clType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/22ADA332-6E7E-4B45-8F2C-28B248EFAFCB">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>temazepam</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8389E685-A055-44DE-BC64-186CEE64B7E7">
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DC54EBE-B2A9-4AE7-A174-F0074ECE4050</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-10-01 10:46:20 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:751E61B0-AEF5-4076-A23C-E7295C3E518E"/>
    <pav:lineageUri>urn:domeoserver:annotation:D565B618-0539-48A4-89EB-14250F9E0753</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="Ndd982fd9e8044af4a717251246ceb697"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:634E3729-1931-469D-85FB-EFC61E128CC8">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A689156C-7D60-4A20-9DD0-285100C9AF39"/>
    <dikbD2R:preciptRegimens>Q12</dikbD2R:preciptRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:auc>20</dikbD2R:auc>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E5B17E24-8354-4EB7-BCE1-276BD496416C"/>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>20</dikbD2R:cmax>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6DE261AC-3364-4AC2-985F-E44D2C662600">
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C7D731E9-DEA5-4D63-891D-A09D631C9A48"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CFD26E3B-E2AD-445C-AB09-BDB891F85FBB"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:auc>6</dikbD2R:auc>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmax>6</dikbD2R:cmax>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E57AD432-E66E-4C87-85DA-FBBE0F227CC7">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:545F2613-2A5E-4333-A651-CBA80268D6ED</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:C4300A0B-08B7-4D4A-8588-00AE7F2C370E</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-09-30 10:43:21 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:606C68F7-F825-49F9-BF2A-E2F8035F1E52"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD0FF3B7-1403-44E2-8BC1-C8B62A3F6AD0">
    <pav:createdOn>2015-10-14 11:40:19 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, ketoconazole), barbiturates, beta-blockers, calcium channel blockers (e.g., diltiazem, nifedipine, verapamil), chloramphenicol, clarithromycin, corticosteroids, cyclosporine, cardiac glycoside preparations, clofibrate, oral or other systemic hormonal c</ao:suffix>
    <ao:prefix>, </ao:prefix>
    <domeo:uuid>AD0FF3B7-1403-44E2-8BC1-C8B62A3F6AD0</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AD0FF3B7-1403-44E2-8BC1-C8B62A3F6AD0"/>
    <ao:exact>itraconazole</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6EF09AAD-D99E-4078-9139-493C415E346A">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:createdOn>2015-09-10 14:47:41 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:0DAF5666-9E53-42D5-B92E-DE2C00764986</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:6194C9B7-CA7C-48DD-961C-3D30385A3B65"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-16 10:55:51 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="Na0bfd2f416534568ac32f244cd9a90e2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DE5DD0C7-8157-4179-B542-7367D2140BB7">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A4589B70-A162-4462-93A8-A4C5E8552C5E"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C2DFE403-9A62-41B5-A780-CA8820026119">
    <ao:suffix>) is necessary when these drugs are used in combination with </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-03 15:40:01 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <ao:exact>ketoconazole</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C2DFE403-9A62-41B5-A780-CA8820026119"/>
    <ao:prefix>, or strong CYP3A4 inhibitors (e.g., </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:6F5C24D1-EA99-48CF-B498-A0D89C02B290">
    <pav:lastSavedOn>2015-09-30 12:41:51 -0400</pav:lastSavedOn>
    <domeo:deleted>false</domeo:deleted>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdOn>2015-09-29 16:04:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:previousVersion>urn:domeoclient:uuid:c29cf054-0272-4dd7-8a1e-d350757231fb</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:578FF25A-B6C6-474F-8C61-2BA421EF9F4B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FB7C3E1A-9374-4DF5-80E7-43CE698CF7A9"/>
    <permissions:permissions rdf:nodeID="N8231b1f294eb4f65bd1a8380d39d9fc4"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html</ao:annotatesResource>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:B1388FFF-1D80-4A68-B45E-724DC48B5687"/>
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/775c860a-4753-45b9-a371-85faaac32a56"/>
    <pav:lineageUri>urn:domeoserver:annotationset:39fc80e2-49c4-440e-bd50-1aa2413f2f32</pav:lineageUri>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:653058FE-C140-48A5-AA68-61D05E0E3436"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AED9E760-9BFE-446A-9218-8F3850610388"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <rdfs:label>NER Sets</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:206B49CD-CF07-4B4F-A06A-33227D2DF298">
    <pav:previousVersion>urn:domeoclient:uuid:fc4fbf7a-d657-4f63-8f25-373c29656475</pav:previousVersion>
    <pav:lastSavedOn>2015-09-24 15:47:22 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:d5d1f96a-f1c4-422f-a8db-6afb741bb0fc</pav:lineageUri>
    <pav:createdOn>2015-09-24 15:46:01 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:AB525967-9BA3-4C51-91D6-7D8F6B0AE214"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:85AD6EA1-D560-4FFB-A685-3F21B0B4208E</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="Nf5aedc926fef4936925ecbe51cb2c67a"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D6C46F99-3BE0-4FA3-938E-3706A46FE0C9">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:42971738-8B34-4ABD-87F1-61C34140F478</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:F4F7005B-B14B-4AE3-97BC-106FAA25D6CA"/>
    <pav:createdOn>2015-09-10 14:49:48 -0400</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-10-16 10:56:33 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="Nc375534964cd457ca8e489679bcd7b1c"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8275AC8D-C197-4A2D-B764-130348A5DAFA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so-called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).  </ao:prefix>
    <pav:createdOn>2015-10-01 10:46:05 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8275AC8D-C197-4A2D-B764-130348A5DAFA"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <domeo:uuid>8275AC8D-C197-4A2D-B764-130348A5DAFA</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9122E29C-7A46-4528-95FC-A1AD9EC754EE">
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptDuration>10</dikbD2R:preciptDuration>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2E88862A-E48A-4E4D-9585-9598A488A431"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0A57B9F6-33D2-4DC7-AB9A-6EDB728D7FDC"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectDuration>18</dikbD2R:objectDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6221399c-7475-4504-b9cb-e9341e023700">
    <ao:prefix>2 of </ao:prefix>
    <ao:exact>rifampin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-10-12 13:20:27 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> averaged 2.9 hours. It should be noted that in other studie</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6221399c-7475-4504-b9cb-e9341e023700"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C5C3EE46-D5E6-4F78-9D98-8A8299E4AA84">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-08-20 11:12:46 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C5C3EE46-D5E6-4F78-9D98-8A8299E4AA84"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:hasSource>
    <ao:exact>In an in vivo drug-drug interaction trial, the Cmax and AUC of dextromethorphan (CYP2D6 substrate) were increased 2.8- and 2.9-fold, respectively when dextromethorphan 30 mg was given with abiraterone acetate 1,000 mg daily (plus prednisone 5 mg twice daily). The AUC for dextrorphan, the active metabolite of dextromethorphan, increased approximately 1.3 fold [see Drug Interactions (7.2)].</ao:exact>
    <ao:prefix>has the potential to inhibit CYP1A2, CYP2D6, CYP2C8 and to a lesser extent CYP2C9, CYP2C19 and CYP3A4/5.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>C5C3EE46-D5E6-4F78-9D98-8A8299E4AA84</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:259CFB0F-7ED5-4494-A634-F548DF83F2C9">
    <ao:context rdf:resource="urn:domeoclient:uuid:0CE28007-B024-43C8-906A-836ED3FB7ADA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-29 11:41:50 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:A7E736B9-61AE-4DFC-8F6F-737EA5FBC28B</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="Ncebeea2da3cf4a46bcffcbc18cecaa1e"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-29 11:40:55 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:432B18FD-15F2-4A92-9083-0A0B230A9CC3">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:1898BF1E-CE40-436B-968F-1154C1CF097C"/>
    <pav:lineageUri>urn:domeoserver:annotation:2A0AC9C3-45A5-48F4-90F0-AE22D718B812</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-29 09:56:53 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="Nca59f240375e46828239339903e74612"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-09-29 11:41:50 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:97943AA2-332D-4556-8948-4D75AFC7615D">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8A8A6EC7-7E6E-4019-9747-DA99D46ECB77"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/519D3E74-400D-4120-8E9A-19D15499DE3F"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D07DC343-AB19-40CC-A629-36FC562D0314">
    <rdfs:label>antiviral drugs</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:46978DF7-54C6-4DAF-AE2C-288EC912B983">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-09-24 15:47:22 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:d5d1f96a-f1c4-422f-a8db-6afb741bb0fc</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:nodeID="N7a98df939d53483b863c5db71965bd3a"/>
    <pav:previousVersion>urn:domeoclient:uuid:fc4fbf7a-d657-4f63-8f25-373c29656475</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:85AD6EA1-D560-4FFB-A685-3F21B0B4208E</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:4ECC45D7-1009-41EF-81E5-A2A40E7750D7"/>
    <pav:createdOn>2015-09-24 15:47:21 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3C3B2204-6D66-446B-9AF5-5B5931422E80">
    <domeo:belongsToSet>urn:domeoserver:annotationset:33B17719-DF97-48EA-AFA2-01DE8A8887B4</domeo:belongsToSet>
    <pav:createdOn>2015-10-01 10:30:31 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:7AF8594E-0C2B-47B2-A28B-F52D124B0239</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:736AE15B-A2FB-4A1B-837E-E60FC4298542"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97B31FC7-E5D1-4758-A47A-54242458BD93">
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:5EC2CAD7-796B-481D-ACFA-AAB2C664BE23"/>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:88825191-7121-4AEB-A942-F720922EC59F</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-09-29 08:58:58 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:0468AC6B-4F06-4CA4-A0DE-A389E3B0E59F">
    <ao:item rdf:resource="urn:domeoclient:uuid:DA552785-0C49-4973-AE28-18F7D1CA2A44"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:75A2813A-8AB3-4071-ADBF-240FB84F8727"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B09769E1-4079-4AD7-8C38-999FD9B34833"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:7625FFE2-5AD2-45D5-B529-281159B83AF9"/>
    <pav:createdOn>2015-08-27 14:50:28 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:3ee8b0e2-8d9a-4983-9455-386905b69964</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:48C9C8A6-75C3-4FE1-82EA-C0CFD252021A"/>
    <pav:previousVersion>urn:domeoserver:annotationset:5219A0F7-CF6B-4B44-8DAF-61E03E87FB8A</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:69C234A4-460B-4AD6-A14A-389E8556B5B6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8A6540FB-AF9F-4436-89D0-CBFECC25ADC0"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F6B22400-8582-4873-A0AA-10081BF04B0B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:056BEDA8-97D1-403C-B251-9FA6D7AC07F5"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <rdfs:label>NER Sets</rdfs:label>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <permissions:permissions rdf:nodeID="N7023dca4c49f439082bf1b793c2bc17a"/>
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/02ca3ccf-111a-444f-9d13-aed4fb51ea37"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:D1506DE0-38C5-44C2-A094-5E512962C351"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:lastSavedOn>2015-10-09 13:32:08 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:2918DC5D-AFBA-4BDD-AF7C-FF0561F45663"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:annotatesResource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f6b80764-86f8-46c7-9dc5-dbe24be3c79a">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:suffix> or dihydroergotamine is contraindicated </ao:suffix>
    <ao:prefix> system. Concomitant administration of clarithromycin with </ao:prefix>
    <pav:createdOn>2015-10-12 13:20:27 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:f6b80764-86f8-46c7-9dc5-dbe24be3c79a"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>ergotamine</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:236D5197-CE0E-4A75-AC7B-062499B37679">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:2A650F26-E819-46B8-9C4C-7A57863D6C6B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
    <pav:createdOn>2015-10-20 09:56:54 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:21FE036F-53ED-42FA-8560-F8A1B7D6AB20">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-30 10:46:02 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:1924F5F7-8583-4786-B72F-85FFB4524425</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:545F2613-2A5E-4333-A651-CBA80268D6ED</domeo:belongsToSet>
    <ao:body rdf:nodeID="N4c1b798e95a44a2292ecba7934d2be7b"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:13042343-0C29-4091-AB6F-07240E4CB24C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A0A9E06E-7395-4665-ABB3-4C779A9747CF">
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:auc>19</dikbD2R:auc>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/66B73E5C-5979-4966-8079-A2F5CA13ADF5"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>29</dikbD2R:cmax>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/36552645-2A49-4B3F-A83B-AD6CC9F3BA5B"/>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D412315B-36D6-4C34-B6D0-D6A7021E28F8">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:257DF3EE-4154-45D5-A69C-2B759389FC95</pav:lineageUri>
    <pav:createdOn>2015-09-29 09:24:56 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N0170eb3e769341579de44a9f948555d2"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:6013A870-1D33-411E-BBD0-3607ADB2CC11"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0185AD47-6E7B-4C92-8A3D-A2876CC95002</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7B300AA8-9780-472A-8138-C7B919A828B9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:DEF3C7AE-E9D3-41C3-A16A-F50BAE3C2CD1"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:147C7E33-CA71-4007-9D0D-0D74BACD2105">
    <domeo:uuid>147C7E33-CA71-4007-9D0D-0D74BACD2105</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:exact>enalapril</ao:exact>
    <pav:createdOn>2015-10-14 11:41:34 -0400</pav:createdOn>
    <ao:suffix>. Dosage adjustments should be made if indicated by the patients clinical condition.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:147C7E33-CA71-4007-9D0D-0D74BACD2105"/>
    <ao:prefix>, the active metabolite of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3E2FDD29-E848-4894-A2E0-F79CFB2AEE6A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>imipramine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/5691</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:2ABE5FA2-BA00-4AF9-A2EA-1305FAECF3DF">
    <ao:item rdf:resource="urn:domeoclient:uuid:5A57003D-C40D-429F-9ED1-02CAF7EDC52A"/>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <pav:lineageUri>urn:domeoserver:annotationset:41206bdb-e025-4044-9968-b0f3d6d02da8</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:38A7D6C5-26EA-4A09-8B05-90EB95AB376E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2EDB9905-6E9B-43FA-A7FD-B370A762BA9E"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:68AE10BB-FBC8-40C9-BEBC-132102208892"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:2AD0F96C-ABDC-46F3-B9C5-6E19DD3A7B92"/>
    <pav:createdOn>2015-08-18 11:35:24 -0400</pav:createdOn>
    <permissions:permissions rdf:nodeID="N20de6a39ff334519ac07d79d1e145c1a"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:4F7C83D7-4B68-424D-B57D-EF9997ADAD18"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B6766B06-895F-4173-AC6D-9B856461E828"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/29e13672-e729-4f8d-b7b2-18b3cb4ede4a"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:9694E9DF-C9D1-420E-B4D5-5F7232AD8335"/>
    <rdfs:label>NER Sets</rdfs:label>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:92525BCC-1D61-4C74-B180-DB03E1413601"/>
    <pav:previousVersion>urn:domeoserver:annotationset:1E9BF9A1-74FE-4B4E-8AF9-DBCC49EBE88D</pav:previousVersion>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:650291E4-CD2C-4F63-8D8B-5FE81B6C6AA2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:89812278-2FE3-46D0-9045-6F889ED70543"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B80BB047-F0B6-4152-AC1F-06F914DD8AD8">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N642afa43b37d4d489844a9925543a6b0"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:815D89AC-B96F-4285-825C-F8781E00E27F</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-29 09:58:21 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:33161C4B-1CB3-4645-BAA9-C29F6292D51B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BA3E44F7-5E41-42CE-BB2F-E0110DE96C1B">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FF5BE84E-7934-4808-AD2F-6F207D312D09"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A2B36B62-4E42-4EFF-82B7-1B9A77823B1B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9EEDCD84-BDA9-4C83-841A-EE1AE5760F6A">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-25 10:46:33 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N29fc2e1686d2481da9aa49a4d1fdb237"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-25 10:47:09 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:C42E4470-8D91-4DA5-847F-EA1C13DE5740</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:1E892F99-BD17-4A3B-BDCD-58AA050D0BAB"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:BE71BBF5-9A2D-4EBE-83B0-1E019FA0E0F8</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5451B70C-E690-43BF-8F3C-2F7A9D7DAC4B">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-30 10:43:58 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:8A70700D-0594-47B4-810D-0F585F093F84</pav:lineageUri>
    <ao:body rdf:nodeID="N01dc3ee44d12415ea8a38ca18db3d50f"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:A116A539-CE24-4247-84A9-FC06FC8CF84A"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:545F2613-2A5E-4333-A651-CBA80268D6ED</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5798CBE8-708E-45A1-88F9-BB02BD866FEE">
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>12</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E4462C4A-DCA8-486D-9F68-B5E79858E901"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0E5A5D2B-7003-483D-B7D1-DF89B8CEF564"/>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:24DCF383-153B-4640-8043-7C4632C5F4AA">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:24DCF383-153B-4640-8043-7C4632C5F4AA"/>
    <ao:exact>Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam, etc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine. The clearance of benzodiazepines metabolized by glucuronidation (e.g., lorazepam, oxazepam, temazepam) is unlikely to be affected by fluvoxamine. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <domeo:uuid>24DCF383-153B-4640-8043-7C4632C5F4AA</domeo:uuid>
    <pav:createdOn>2015-10-20 09:54:44 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>    Benzodiazepines   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A18FE7A7-6258-4E81-9924-B53727D3AE53">
    <ao:exact>ketoconazole </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A18FE7A7-6258-4E81-9924-B53727D3AE53"/>
    <pav:createdOn>2015-08-26 16:14:17 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>by 30% and increased the AUC and </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5d103551-978f-472a-9c62-51e6e4dea068.html</ao:hasSource>
    <ao:prefix>in healthy subjects decreased the bioavailability of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FF63AE48-3767-4170-B8D4-9949D561C3B9">
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8897DB69-A04A-4BBC-8B42-D8F0B553B267"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D699E8C5-EDCC-4757-9BC6-9A6D2E036FD2"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:numOfParticipants>10</dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BD5D8B9A-4999-49AD-96CB-C8A98B37C861">
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>urn:domeoclient:uuid:a7f59b4d-3ada-4384-adb1-665a4a1743c8</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:F1A26F99-9F60-4059-AA7F-419F4852F52C"/>
    <pav:createdOn>2015-09-03 15:41:17 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N0d554189f939461d8ce6d9abf7e93c22"/>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AD775091-85D8-4B77-9121-BF7A457ACD7E">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:DA6380EB-F552-4705-BC0B-02B1DDE88B31"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2453256F-56D4-4235-89E1-77477041E2D7">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F5B6DD30-DEBF-478A-9551-5FBF24BBB5A8"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AB53D00A-B8AF-48B0-82DB-9F7EB166BE7D">
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:5275F184-7DF1-4DF3-B8B6-A543AE2EDAE7"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N74f190382db54789a03f29e6ba19ca5b"/>
    <pav:createdOn>2015-10-20 09:58:05 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:606C68F7-F825-49F9-BF2A-E2F8035F1E52">
    <ao:suffix>. </ao:suffix>
    <domeo:uuid>606C68F7-F825-49F9-BF2A-E2F8035F1E52</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>lithium</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <pav:createdOn>2015-09-30 10:43:21 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:606C68F7-F825-49F9-BF2A-E2F8035F1E52"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> (100 mg/day) did not affect the pharmacokinetics of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6F80331D-77B9-473C-9E85-DFDA8F1062C4">
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:numOfParticipants>21</dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EB23C209-ED58-4EFD-BDBB-82B5E438C421"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>18</dikbD2R:auc>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/77B85D6B-14C5-474E-B9E1-1D425AFB1FF6"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:8DC54EBE-B2A9-4AE7-A174-F0074ECE4050">
    <ao:item rdf:resource="urn:domeoclient:uuid:B9B2E4B1-156C-4FBA-846E-AFE80466AEC7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CC0D693F-5965-4DC7-80CD-62DED563C67B"/>
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/39747b4b-4ab4-44a9-a6d3-fd1e87c3b18e"/>
    <permissions:permissions rdf:nodeID="N8407dba312a64477bccbd16e58e48fdf"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EDD4DE44-60E0-4BF7-9358-79D622BDEFA1"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdOn>2015-08-27 14:50:14 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:a30cd523-66b2-4a27-9b4e-230db0895cc9</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:331EA73A-B17C-4129-8E97-A6D6195AE89E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:23F1AAA6-DEFE-4DC7-BBDA-BF4E31C4CF53"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B9DE1B2B-7900-412C-B470-BF5A3E25597F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:52478B04-68BB-4BB3-859E-ADC37C8058B8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8389E685-A055-44DE-BC64-186CEE64B7E7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E9EAE4A5-B8D4-445A-B9C0-EA6DEABCC480"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:B2AB6C73-4A35-45BC-AB2B-24DF13F02726"/>
    <pav:lineageUri>urn:domeoserver:annotationset:cca05e8d-7ce9-43fd-8acf-b19fd67fb9e0</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:7DC95F37-31D6-41FA-934B-50B98ED51CE9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:702A8854-7BC5-430E-87FF-62B857C38A13"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:6AE59F0B-03A0-4731-8439-9C5065EB73EC"/>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:annotatesResource>
    <domeo:deleted>false</domeo:deleted>
    <rdfs:label>NER Sets</rdfs:label>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:B00FB515-BCD9-4CDA-92E1-542F90AA2984"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D93184E6-2126-4874-BB5B-16B99244195C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D205191B-E949-4BF3-B844-951C38D31E80"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:20F56425-0E58-4E30-A035-E5253468DFF3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F900845F-B29D-42EA-8707-2DD6BAE279C9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-16 10:57:41 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F900845F-B29D-42EA-8707-2DD6BAE279C9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Propranolol and Other Beta-Blockers   </ao:prefix>
    <ao:exact>Coadministration of fluvoxamine maleate 100 mg per day and propranolol 160 mg per day in normal volunteers resulted in a mean 5-fold increase (range 2 to 17) in minimum propranolol plasma concentrations. In this study, there was a slight potentiation of the propranolol-induced reduction in heart rate and reduction in the exercise diastolic pressure. </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:17826D3C-609B-4BB6-89A9-ECE6035061EA">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-24 15:55:00 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-09-24 15:50:22 -0400</pav:createdOn>
    <ao:body rdf:nodeID="Nff25cb610a4845b6878ab4ffe8c7b454"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:045492A1-0E37-4C8C-9485-7E11134C582A"/>
    <pav:lineageUri>urn:domeoserver:annotation:D2350554-6BA1-43FD-8BE5-F0364240EBE4</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:85AD6EA1-D560-4FFB-A685-3F21B0B4208E</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:36E11325-AFC8-4648-AF0D-040A27E4391D">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:4655D30A-B652-44FA-9DC7-0015C67E66B7"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:F35D1FA7-6952-4425-BDDF-C93AF0B65655</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-29 11:24:21 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1c27b48856f74687a3a0c4b7714fa501">
    <domeo:sets rdf:resource="urn:pddi:uuid:D2ADEC8E-3FB1-43F1-9101-6807EA638559"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E8F6706A-E20A-4DBA-8CE1-B71E6F17FEA6">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>selective serotonin reuptake inhibitors</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F15CC0C5-8322-4829-AE1E-EDD48EC6F753">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BFE2309E-0451-4F6F-B065-4457A24B1C0E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DCB77F24-1F8C-45FE-B693-B2FADB64AF47">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/40D0E198-1AC4-473D-8BB1-FE2877A636AC"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B853C546-5169-4BDE-A71E-82BB708405C8"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:850E1DB2-54CE-4C03-8CAF-FC518D4668BE">
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-09-29 09:44:12 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:45751E42-6FAA-4771-A8B8-F08AD42C83D7"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:CD6A0730-2B1F-4730-981B-07E1ACD19934</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/15706B7B-7757-4106-93E6-5173979D3824">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>rifampin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:040AAC68-C089-4D0C-82F0-E37CEE99917B">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <pav:createdOn>2015-09-29 09:46:34 -0400</pav:createdOn>
    <ao:exact>CMI </ao:exact>
    <ao:suffix>has been reported to increase the plasma levels of </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>as well. Administration of </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:040AAC68-C089-4D0C-82F0-E37CEE99917B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D95D2B8F-17FC-4A88-971D-B666AB43725E">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:16A0844E-3F03-4029-B7C2-1E174B6032F3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C9EE9367-E702-41C6-AB74-3024CEAAB71B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:CF22FF83-C1EE-443C-8E6C-7FF613D550D2"/>
    <pav:previousVersion>urn:domeoserver:annotationset:6B50E664-BD71-432E-B7FA-E7313EFF76E1</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-20 10:19:28 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <pav:createdOn>2015-10-20 10:18:18 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B2BFE0C5-595D-4142-B0E1-1A2851105B5E">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>mitoxantrone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4C18F359-19DA-409F-9FC4-923939D24EFA">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:9966E472-7F69-441E-900C-832EE2412A01"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:86C7B6BD-4656-42AC-AA3C-33C66CFE8259</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:33B17719-DF97-48EA-AFA2-01DE8A8887B4</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-10-01 10:29:37 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N636778f2c58b42e29276fd20ed255a92"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1D929373-D289-4A98-9888-F4FF30674B8E">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-09-03 15:51:41 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N17aed261ab2c4946b850e66d7878dfa0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">13</pav:versionNumber>
    <pav:lastSavedOn>2015-10-16 10:38:06 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:F3A91906-2294-4B18-8A8B-10D1F233BC34"/>
    <pav:previousVersion>urn:domeoserver:annotationset:E84A8D67-35F4-4284-BEF8-3DC391CC6D79</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BB1D9014-52E7-49C4-9887-45F5FBCF2FAF">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds. The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available. Based on a finding of substantial interactions of fluvoxamine with certain of these drugs [see later parts of this section and also Warnings and Precautions (5)] and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>7.1 Potential Interactions with Drugs that Inhibit or are Metabolized by Cytochrome P450 Isoenzymes  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BB1D9014-52E7-49C4-9887-45F5FBCF2FAF"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-16 10:51:55 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:30A55376-DA35-4F14-84D6-CC542F7CCC15">
    <ao:context rdf:resource="urn:domeoclient:uuid:A82B1C2D-CBC6-4B0F-A77B-5C0B065E335F"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <ao:body rdf:nodeID="N61120de9a93941ddb85ef30afa63453e"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lastSavedOn>2015-08-20 11:38:24 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:7d2027ff-e85b-46f3-befa-3f8f5cf7e88f</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-08-20 11:36:33 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AB9646D0-69B7-463F-B535-B0682D7E6F8A">
    <ao:prefix>. In these subjects (N = 8), the clearance of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-20 10:09:09 -0400</pav:createdOn>
    <ao:suffix>was reduced by 65% and that of N-desmethyldiazepam to a level that was too low to measure over the course of the 2 week long study. </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AB9646D0-69B7-463F-B535-B0682D7E6F8A"/>
    <domeo:uuid>AB9646D0-69B7-463F-B535-B0682D7E6F8A</domeo:uuid>
    <ao:exact>diazepam </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/77FD8774-B176-4E5B-A87B-ADDC76548A56">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:person:uuid:080e1430434f70e501434f711b6e0000">
    <foafx:lastname>Boyce</foafx:lastname>
    <rdfs:label>boycer</rdfs:label>
    <foafx:title></foafx:title>
    <foafx:homepage></foafx:homepage>
    <foafx:picture>http://www.hcklab.org/images/me/paolo%20ciccarese-boston.jpg</foafx:picture>
    <foafx:firstname>Richard</foafx:firstname>
    <foafx:middlename></foafx:middlename>
    <foafx:name>boycer</foafx:name>
    <foafx:email>rdb20@pitt.edu</foafx:email>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9730CBBB-7089-4CCE-82A1-294E965F9063">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6E803E7E-A17A-45EB-B29A-24A2605495C8"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/18A4B509-B850-400E-8EE9-780AA264AFDF">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>L-methamphetamine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:111E0CE7-7420-49E7-A976-43E417CA03FD">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>7.1 Potential Interactions with Drugs that Inhibit or are Metabolized by Cytochrome P450 Isoenzymes  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds. The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available. Based on a finding of substantial interactions of fluvoxamine with certain of these drugs [see later parts of this section and also Warnings and Precautions (5)] and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:111E0CE7-7420-49E7-A976-43E417CA03FD"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-10-16 10:51:45 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:09EDF778-A166-4AD9-8A4F-9CDE1A48385D">
    <pav:createdOn>2015-10-20 09:22:32 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:CCBB1912-2615-4C30-A634-859FECE23236"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:8D286017-0AEC-46C4-AC51-641E2F31DE1A</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-20 09:23:48 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3C93BED4-244B-4EC4-9CCF-4225C5B87905">
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-14 11:40:54 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:D7A9CF59-FA8D-4C9C-B9B1-11165D8D02AA"/>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:19657071-B127-4578-BE8B-15EFC45BD573">
    <ao:prefix>[see Drug Interactions (7) ] .  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:19657071-B127-4578-BE8B-15EFC45BD573"/>
    <ao:exact>Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), and metoprolol (a CYP2D6 substrate).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>19657071-B127-4578-BE8B-15EFC45BD573</domeo:uuid>
    <pav:createdOn>2015-08-20 13:06:20 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2A1F7A1E-6D01-428F-B598-26E80043C4C2">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:836A9ED8-3168-46A8-8BFD-D0B77AB5A1E1"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3ABCA7AE-0EF6-44D5-8F82-AE7C89B7ECF6">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:suffix>, oral or other systemic hormonal contraceptives, dapsone, diazepam, doxycycline, fluoroquinolones (e.g., ciprofloxacin), haloperidol, oral hypoglycemic agents (sulfonylureas) levothyroxine, methadone, narcotic analgesics, progestins, quinine, tacrolimus</ao:suffix>
    <ao:prefix>, </ao:prefix>
    <domeo:uuid>3ABCA7AE-0EF6-44D5-8F82-AE7C89B7ECF6</domeo:uuid>
    <pav:createdOn>2015-10-14 11:40:37 -0400</pav:createdOn>
    <ao:exact>clofibrate</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3ABCA7AE-0EF6-44D5-8F82-AE7C89B7ECF6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/40256306-A3CF-446C-9E11-97451E784EEE">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>phenytoin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:031D9FFC-DBC7-457A-AF73-FF8ABED1AA23">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/668924AB-96EF-4B98-80A9-29AFE755C7ED"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F7FECC4C-1169-430B-AF75-887972E7499C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeo:software:id:Domeo-2.0alpha-040">
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Software"/>
    <foafx:name>Domeo Annotation Toolkit</foafx:name>
    <foafx:homepage></foafx:homepage>
    <foafx:build>040</foafx:build>
    <foafx:version>2.0alpha</foafx:version>
    <rdfs:label>Domeo Annotation Toolkit</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EC10971E-3E24-45DA-A543-556459171054">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <domeo:uuid>EC10971E-3E24-45DA-A543-556459171054</domeo:uuid>
    <ao:prefix>   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Olanzapine    In subjects who had received EMSAM 6 mg per 24 hours for 10 days, co-administration with olanzapine, a substrate for CYP1A2, CYP2D6, and possibly CYP2A6, did not affect the pharmacokinetics of selegiline or olanzapine [see Drug Interactions (7.4) and (7.5)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-16 10:40:22 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EC10971E-3E24-45DA-A543-556459171054"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A587FCF9-0C88-4D93-AB10-FF3AB8EBC24F">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5F07294B-DDE9-4785-BAD5-2E3C0D58F502"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CC3BD481-4C31-44BF-BC22-EA9082344830"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EFA928C7-C58C-4CE6-B9F7-4B61069AEC50">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>pioglitazone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:633CA52C-A1B8-4DA1-936D-70D2F0106564">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:resource="urn:linkedspls:uuid:1135EFA3-67D9-4B8E-B010-CD51438236F7"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:48174C77-8AA2-4177-A9C8-F0F6197B6446"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:2DCBAB84-202D-41C3-B8EB-9CD9D668C3DF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdOn>2014-02-19 12:37:38 -0500</pav:createdOn>
    <pav:lastSavedOn>2014-02-19 12:41:40 -0500</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:8A890B84-DFB5-4F1E-AA94-2BFCA03E6EF0</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E9F13BFE-1A17-4FDF-99A7-13B89F697635</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:417C0B18-0863-4B8B-AECD-13BFD8C1F3CC">
    <pav:lineageUri>urn:domeoserver:annotation:DE3FBC0F-298F-4A24-A331-06E7842AC311</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="Ndbb83f681f364abdac51215ebbb878ef"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:DDEE74D5-2F0E-453E-9FEB-EC6BE327A439"/>
    <pav:createdOn>2015-10-01 10:28:22 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:33B17719-DF97-48EA-AFA2-01DE8A8887B4</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FF724A23-834B-40DF-BD93-6C05A7E222C2">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N633f1fc2e80348c39edaa213b91ccc69"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:1B289B57-9720-41F9-BBFA-D4E32800CCDD</pav:lineageUri>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:88388447-F89B-497E-AF01-6E474B27B54C"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <pav:createdOn>2015-09-29 09:03:01 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/29e13672-e729-4f8d-b7b2-18b3cb4ede4a">
    <pav:createdOn>2015-08-18 11:35:24 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2015-08-18 11:35:24 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2ABE5FA2-BA00-4AF9-A2EA-1305FAECF3DF</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:a2e50e41-1d1e-4107-b919-264beca55b9e"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:41206bdb-e025-4044-9968-b0f3d6d02da8</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/349151D0-9CA1-4F4F-8A0A-2B09C91D8963">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3247</dailymed:activeMoietyRxCUI>
    <rdfs:label>desipramine</rdfs:label>
    <dikbD2R:dose>100</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9D3B0238-804D-4D71-9897-88C5A623B997">
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <pav:createdOn>2015-09-03 15:39:59 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:a7f59b4d-3ada-4384-adb1-665a4a1743c8</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:DC4A9FC2-1018-4E06-8B45-3BBBB5D59DE7"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/655C69F9-AAD6-4BDD-B6CE-34CD426FF16E">
    <rdfs:label>cimetidine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F2C6F9E4-8CE7-4261-BFC5-E81DFEE2EB11">
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:auc>46</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CBE54F32-8CD8-43A0-9C0B-347A34E16D47"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9B6AB25B-F52E-4B8D-A2F0-9BB0DB36E039"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5230D4C8-6846-4BBF-9B52-C9DE46AEA077">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>100</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/203143</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine maleate</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EC39377A-FCB4-4984-B555-5FB229E17906">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:7B94E3B6-6BAD-475F-A7E2-4A243AB3EAA2</pav:lineageUri>
    <ao:body rdf:nodeID="N62ced0d0f7ae4f37aee621edfdf09715"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:DAD02F8C-D0CF-4D03-A113-8C242E8A7E4F</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-24 15:35:57 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-09-24 15:38:09 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:3545E07C-1260-4EE4-B446-28CBDB1E6555"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1D6FB298-54BE-445A-852F-BC90F8821EF0">
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptDuration>14</dikbD2R:preciptDuration>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EAAF690D-73CA-4E97-9ABA-228A16082AA5"/>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:objectFormulation>transdermal</dikbD2R:objectFormulation>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:auc>2</dikbD2R:auc>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/759E5BCD-B74C-472F-A849-36EAF4A6B901"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmax>2</dikbD2R:cmax>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CFD26E3B-E2AD-445C-AB09-BDB891F85FBB">
    <rdfs:label>fluvoxamine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>40</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:95C9BC91-F173-4DEE-BB26-1A7E789A3C91">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-30 10:46:40 -0400</pav:createdOn>
    <ao:prefix>(50 mg) and lorazepam (1.5 mg).  </ao:prefix>
    <ao:exact>Pregabalin-There were no clinically significant changes in the steady-state pharmacokinetics of milnacipran or pregabalin following twice a day co-administration of 50 mg milnacipran and 150 mg pregabalin. </ao:exact>
    <domeo:uuid>95C9BC91-F173-4DEE-BB26-1A7E789A3C91</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:95C9BC91-F173-4DEE-BB26-1A7E789A3C91"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6035449E-44B5-4AC2-B5D8-E1F87722C1D1">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42351</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>lithium carbonate</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B1712E9C-0C41-4680-B97E-4A8DE5131457">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>maprotiline</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A61914F5-07DB-4846-9A3F-17EF69E195B0">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:64737b65-8582-4b76-8095-85ad69e2cc47</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:5D7970E2-6A55-4380-A2F7-06C554DD3F1F</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N1ce14d6bd7334650b1bd7ed53f17effd"/>
    <pav:lastSavedOn>2015-08-20 11:17:13 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-08-20 11:12:46 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:C5C3EE46-D5E6-4F78-9D98-8A8299E4AA84"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2E0AD717-67BC-4D7C-AF83-5F1037F99712</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:51BD9699-910E-4FD0-A63A-D68388FDA719">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:AD9C90ED-946A-4A47-B3E8-0E11D226FCB3"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:26045A64-6643-4302-9B53-F35F498DCEBD">
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CE635F27-A391-4A6B-9D87-339FA2F114B2</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:fc9e17d3-1b0d-4635-9936-0d1d94cb01f9</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:CEA4E0A9-4D52-4D06-B7F7-888CAB312880</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N4f9c82096f7e449885747a57995cc781"/>
    <pav:createdOn>2015-09-14 11:26:11 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:DB4D4254-04A2-4C48-9D60-BFF38A50B47C"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-09-14 11:31:14 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23424B36-5284-4228-B373-655A516BE9D1">
    <pav:createdOn>2015-10-13 12:06:19 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N13fc23429b9b42838f46ef83c8ada125"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-13 12:06:23 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:3B53C1B5-5C35-4E08-A864-123B2D5F20CF</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:109EA3A8-973A-4DA9-80A8-7662CE097F39"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:50707EE2-1666-4851-9265-5CDF0B590D9B">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:auc>55</dikbD2R:auc>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4E825338-5822-401F-8440-DD2F9EEC6845"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8974378E-D90C-48CD-9BD9-AC7D446F8C75"/>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration>6</dikbD2R:preciptDuration>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/79BF090F-C54F-4CF8-A3CD-86ABA82B1EDC">
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8E653C68-3DB9-4CF1-9868-60E3738D25E5">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N50ce90acbbbb4490bff71ed0bb22fe6a"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:5F6FAEAE-2608-4CF1-B828-CC054D0F8A37</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:9EB813C9-4F23-4FDF-80E7-60BE4ED6AC9A"/>
    <pav:createdOn>2015-10-01 10:29:22 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:33B17719-DF97-48EA-AFA2-01DE8A8887B4</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:115D6BEA-61FB-408B-BE9D-158A3C4A672C">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:52DB4DDD-6B99-4C2A-B8AE-C74F18D1C9C8"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/94C4A489-0A9A-4F53-95D1-B370A11CA8D5">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>6</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>EMSAM</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D027B9BB-84B8-4AD8-98B6-E6B6F9BAA7FE">
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:97E4CDE7-633E-4188-9846-10A00E9A78AB"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-09-03 15:57:06 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:1B90596E-FA6D-42D1-9A32-310F1BFE4639</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-09-03 16:19:40 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9C8684F9-A126-455C-B66F-EB4598A5F120">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>AUBAGIO on CYP2C8 substrates   </ao:prefix>
    <pav:createdOn>2015-08-20 11:37:19 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <ao:exact>Teriflunomide is an inhibitor of CYP2C8 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP2C8 as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9C8684F9-A126-455C-B66F-EB4598A5F120"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C868D749-332F-412D-9C19-B3F12AE868BB">
    <pav:lineageUri>urn:domeoserver:annotation:413A4750-DA5C-403C-9C4F-8852C8994333</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:68710CB3-2621-4C81-8B39-86CF50BE9127"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-09-29 08:59:27 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C306E6D1-CDCA-463F-8574-026E2775C5BA">
    <pav:createdOn>2015-09-30 10:41:45 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>, monitoring of patients during treatment switch is recommended.  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Digoxin-There was no pharmacokinetic interaction between Savella (200 mg/day) and digoxin    (0.2 mg/day Lanoxicaps) following multiple-dose administration to healthy subjects. </ao:exact>
    <domeo:uuid>C306E6D1-CDCA-463F-8574-026E2775C5BA</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C306E6D1-CDCA-463F-8574-026E2775C5BA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4B204B72-F327-4522-814B-751D36B88B82">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7C3ED630-095E-46C1-9254-E12EC01A6C0B</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:03B26142-76BF-4602-9917-090D6E864169"/>
    <pav:createdOn>2015-08-26 16:11:55 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-08-26 16:14:07 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB05F5-AF88-4B04-87DC-5826864F9BE3</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2BB9235C-F6FC-4F92-A5DB-3F6E5F01D13D">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CDB3561D-BB5B-4F02-87A9-F4E5B9DA7530">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:AA54A62B-E215-4EE0-9098-64C4976AD18F"/>
    <pav:lastSavedOn>2015-10-13 12:04:13 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-13 12:02:08 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <ao:body rdf:nodeID="N0b9e880cd9154cb5a167fd952f5daf90"/>
    <pav:previousVersion>urn:domeoserver:annotationset:B51F4BB3-6BDB-45E7-9399-D93DBC4324AC</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:13042343-0C29-4091-AB6F-07240E4CB24C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:13042343-0C29-4091-AB6F-07240E4CB24C"/>
    <domeo:uuid>13042343-0C29-4091-AB6F-07240E4CB24C</domeo:uuid>
    <ao:prefix>(50 mg) and lorazepam (1.5 mg).  </ao:prefix>
    <pav:createdOn>2015-09-30 10:46:02 -0400</pav:createdOn>
    <ao:exact>Pregabalin-There were no clinically significant changes in the steady-state pharmacokinetics of milnacipran or pregabalin following twice a day co-administration of 50 mg milnacipran and 150 mg pregabalin. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:01727474-D904-451D-8C6B-E656DAC891F1">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:669A4336-8FAC-4F68-8C83-5C820CEE68E7"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:86BE9337-A28D-474B-88DB-D20A43681D40">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:DD827BEA-0D7A-42FA-B33E-FD565FF369B9"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:58783000-8223-4301-92B8-F448905DE2CA">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-25 10:37:43 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-25 10:47:09 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N80b54cbfb19f44c696c6b51dfa2d4e6b"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:BE71BBF5-9A2D-4EBE-83B0-1E019FA0E0F8</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:5820B0CE-2CDC-4CE4-B4A9-68B408C39343"/>
    <pav:lineageUri>urn:domeoserver:annotation:BBCF376F-65C0-417B-A2EC-C362AC7FB24A</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9D1C1206-9096-4B3A-ABDF-BA78B56F1359">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8566158B-84F1-4845-B2E8-3CA5B143414E"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8B9FABA3-122C-4B5B-8C64-FBDF38F32EEE"/>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:auc>55</dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2C0CC855-B0BF-4638-8FCD-B61F16128202">
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-09-14 11:01:50 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2C0CC855-B0BF-4638-8FCD-B61F16128202"/>
    <ao:exact>Phenobarbital induces many cytochrome P450 (oxidative) enzymes. When a single oral 30 mg dose of paroxetine was administered at phenobarbital steady state (100 mg once daily for 14 days), paroxetine AUC and T were reduced (by an average of 25% and 38%, respectively) compared to paroxetine administered alone. The effect of paroxetine on phenobarbital pharmacokinetics was not studied. Since paroxetine exhibits nonlinear pharmacokinetics, the results of this study may not address the case where the 2 drugs are both being chronically dosed. No initial dosage adjustment of paroxetine is considered necessary when coadministered with phenobarbital; any subsequent adjustment should be guided by clinical effect.</ao:exact>
    <ao:prefix>on cimetidines pharmacokinetics was not studied.  Phenobarbital  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5CB83113-A43E-4CB3-A4B1-780E0F45EDA8">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/27D73D78-3872-4F3B-B360-73FB6DD1644D"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/94C4A489-0A9A-4F53-95D1-B370A11CA8D5"/>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation>transdermal</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectDuration>7</dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8B9FABA3-122C-4B5B-8C64-FBDF38F32EEE">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>abiraterone</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:f89a7ada-fcb5-49de-886b-0c52c297a6f9">
    <pav:createdOn>2015-08-27 14:50:29 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>somatization factor and sleep disturbance factor. The mean </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:f89a7ada-fcb5-49de-886b-0c52c297a6f9"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>mirtazapine</ao:exact>
    <ao:suffix> dose for patients who completed these 4 studies ranged from</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:33161C4B-1CB3-4645-BAA9-C29F6292D51B">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:33161C4B-1CB3-4645-BAA9-C29F6292D51B"/>
    <ao:exact>The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.  </ao:prefix>
    <pav:createdOn>2015-09-29 09:58:21 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:070E2A64-30A3-49B0-980D-E6D564CF7473">
    <domeo:belongsToSet>urn:domeoserver:annotationset:7C3ED630-095E-46C1-9254-E12EC01A6C0B</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB05F5-AF88-4B04-87DC-5826864F9BE3</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:3444A96C-4C33-4FE7-A291-3713BB14BA26"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-08-26 16:11:31 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-08-26 16:14:07 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ABDB3F0E-3768-4FCC-A328-2E9C2D56FEE2">
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <domeo:uuid>ABDB3F0E-3768-4FCC-A328-2E9C2D56FEE2</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:ABDB3F0E-3768-4FCC-A328-2E9C2D56FEE2"/>
    <ao:exact>Probenecid </ao:exact>
    <pav:createdOn>2015-10-14 11:41:42 -0400</pav:createdOn>
    <ao:suffix>and cotrimoxazole have been reported to increase the blood level of rifampin.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/625296F7-1267-4ACF-B45F-0D20A05D262B">
    <rdfs:label>paroxetine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3519E134-7F5A-48D2-B805-99B992459417">
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F9897809-1242-44CB-AC4A-03EDD6A34BDB"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:auc>151</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F7688443-E658-446B-95E1-BD1EFCD05CC4"/>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:cmax>62</dikbD2R:cmax>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D452A095-9171-4848-9B0B-6E03D7A7A8B7">
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42330</dailymed:activeMoietyRxCUI>
    <rdfs:label>terfenadine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A9F76EB7-C4FE-41DE-ACD1-B9A7AE8B5D1A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:41:00 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A9F76EB7-C4FE-41DE-ACD1-B9A7AE8B5D1A"/>
    <ao:prefix>, </ao:prefix>
    <ao:exact>progestins</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <domeo:uuid>A9F76EB7-C4FE-41DE-ACD1-B9A7AE8B5D1A</domeo:uuid>
    <ao:suffix>, quinine, tacrolimus theophylline, tricyclic antidepressants (e.g., amitriptyline, nortriptyline) and zidovudine. It may be necessary to adjust the dosages of these drugs if they are given concurrently with rifampin.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B96681A4-AD78-4B86-8548-E64E89BD1CC2">
    <ao:body rdf:nodeID="N08a343800fd4450fbc90450a7acae9a4"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-08-20 13:05:10 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:C9DE974E-8A48-4DD5-B1FF-FEF3E4AFB8AA"/>
    <pav:lineageUri>urn:domeoserver:annotation:2DD4C337-455A-40EB-9DEE-41A9C8A2C5DB</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:025816D5-DA6C-4827-903A-181524F7812E">
    <pav:createdOn>2015-09-29 11:18:33 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:0F756DD8-D53F-4BAE-AFA7-2FCA7F3B987B</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:3928749E-2902-40CE-B487-8BB453887F77"/>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:87EC29F5-C3E4-413C-8BA1-9DF5AE1CBBCA">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="Nd152913a9f13445f93efeecd6f93e8f5"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-29 09:58:01 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:6E7C2A4F-21A9-4598-8E5E-04652137E639</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:D557BF69-26AB-4E39-B394-E926CC17D66C"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2CEEDAA8-C06E-4CF2-BC26-160763C76B7B">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:71FB4725-2639-4306-855D-E6079CA204F4"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/c1a88987-fc21-4e81-bc38-6b7a3a75ed81">
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-08-27 14:50:29 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:cb74bb03-5ad2-4eea-b083-973424b3737a</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2015-08-27 14:50:29 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:f89a7ada-fcb5-49de-886b-0c52c297a6f9"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:BE71BBF5-9A2D-4EBE-83B0-1E019FA0E0F8</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:153EB93D-9546-417C-9EA7-6C2412E5C256">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:FC2163A0-83DC-4C95-B395-886C91DB61AE"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:33B17719-DF97-48EA-AFA2-01DE8A8887B4</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-10-01 10:30:47 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N2631e625a678462d9291c12e4677d0c9"/>
    <pav:lineageUri>urn:domeoserver:annotation:703D9DE3-AE6D-4331-B60B-A5F4995128F2</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B9BE6515-0D51-48A4-A122-164A661EF83C">
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/74817592-9344-43E3-B8EE-DF8381C29BE5"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>4</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/51F74AD9-CFE6-402E-9742-65FA5B4711E2"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:auc>12</dikbD2R:auc>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F559702E-86B5-4B89-9DBF-F04A75B3360B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>times should be carefully monitored while patients are receiving clarithromycin and oral anticoagulants simultaneously.  </ao:prefix>
    <ao:exact>Elevated digoxin serum concentrations in patients receiving clarithromycin and digoxin concomitantly have also been reported in postmarketing surveillance. Some patients have shown clinical signs consistent with digoxin toxicity, including potentially fatal arrhythmias. Serum digoxin concentrations should be carefully monitored while patients are receiving digoxin and clarithromycin simultaneously.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F559702E-86B5-4B89-9DBF-F04A75B3360B"/>
    <domeo:uuid>F559702E-86B5-4B89-9DBF-F04A75B3360B</domeo:uuid>
    <pav:createdOn>2015-10-13 11:58:14 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0A57B9F6-33D2-4DC7-AB9A-6EDB728D7FDC">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>30</dikbD2R:dose>
    <rdfs:label>paroxetine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B37F2903-12F8-44FB-92ED-CC6B5B8369E0">
    <pav:lastSavedOn>2015-10-16 10:55:51 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <ao:body rdf:nodeID="N2a382ee0360b4ef78da0a27bdee45686"/>
    <pav:createdOn>2015-10-16 10:53:55 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:0DAF5666-9E53-42D5-B92E-DE2C00764986</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B55EDFB0-3526-472E-8B0B-8583AFB2A081"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:48D927C3-381C-4356-93AD-214B71B23DB5">
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="Nef87126d43a8431ebe77b1e291ef3f73"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-10-16 10:51:55 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-16 10:55:51 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:BB1D9014-52E7-49C4-9887-45F5FBCF2FAF"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:0DAF5666-9E53-42D5-B92E-DE2C00764986</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C0B51BBF-1076-4E1E-B22D-E07C0777D467">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <rdfs:label>warfarin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>200</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5ACB2517-A52D-4E82-AC3A-47C6A5641B6C">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5E8D3357-55CA-4AE9-B960-B847060273F7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:60A0F07C-2172-4677-A782-F6408A598554">
    <pav:createdOn>2015-10-13 11:56:23 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Concomitant administration of clarithromycin and ritonavir (n=22) resulted in a 77% increase in clarithromycin AUC and a 100% decrease in the AUC of 14-OH clarithromycin. Clarithromycin may be administered without dosage adjustment to patients with normal renal function taking ritonavir. However, for patients with renal impairment, the following dosage adjustments should be considered. For patients with CLCR 30 to 60 mL/min, the dose of clarithromycin should be reduced by 50%. For patients with CLCR &lt; 30 mL/min, the dose of clarithromycin should be decreased by 75%.</ao:exact>
    <domeo:uuid>60A0F07C-2172-4677-A782-F6408A598554</domeo:uuid>
    <ao:prefix>were not significantly affected by concomitant administration of fluconazole.  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:60A0F07C-2172-4677-A782-F6408A598554"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CD253487-2236-4233-8018-9CDB85F89040">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D4C98CB4-FEB5-4061-B1B8-36CE8BD2B5FE"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:07CA9796-0E8D-4505-828E-323AC16E6EFD">
    <ao:exact>No dose adjustment of FETZIMA is needed when co-administered with a CYP3A4 inducer or substrate. In vivo studies showed no clinically meaningful change in levomilnacipran exposure when co-administered with the CYP3A4 inducer carbamazepine or the CYP3A4 substrate alprazolam (see Figure 1). </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>ketoconazole (see Figure 1 ).  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/f371258d-91b3-4b6a-ac99-434a1964c3af.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:07CA9796-0E8D-4505-828E-323AC16E6EFD"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>07CA9796-0E8D-4505-828E-323AC16E6EFD</domeo:uuid>
    <pav:createdOn>2015-09-25 10:03:05 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D13DE50A-38BE-447F-ADB1-4CB68F14A56E">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/950759E6-F9E3-48D0-8AFA-7A8C5114B86E"/>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C906081F-115B-4532-B6DB-49330D1E7159"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12>Unk</dikbD2R:t12>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6A2C2680-8895-4D3E-941E-1212437B892A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6416BB2E-E31D-401D-80C0-9136D4AAEC24">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10767</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>triazolam</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3C72AF03-DEEA-4C38-9BC8-C328532DA55C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:createdOn>2015-10-20 10:08:56 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:65A96884-F27A-4B18-94D1-983AFF5A5C47"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/259BC540-3D43-4F99-B96B-5CD172299B1D">
    <rdfs:label>clarithromycin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/58ABF8B0-22B5-41E9-8E53-F8B7B2752222">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>paroxetine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2730D7B3-31C9-4A50-B560-5142B96A3A23">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4347507D-3A50-47E1-AA6A-6B116D6C9151"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:325E3C9C-45AF-42AD-ADE5-CD3F4CBE61D2">
    <ao:context rdf:resource="urn:domeoclient:uuid:518FD360-703E-4F95-B396-CCB179716873"/>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:DD53EE65-079D-4C5D-8248-EE332FEE3EDA</pav:previousVersion>
    <ao:body rdf:nodeID="N5493b2edd21b497aaca51d8a66e04fc7"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-13 11:24:27 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-10-13 11:24:28 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2B21D2D6-E6EE-4F7B-8F60-4AA923FC48D2">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/112AC08E-3C63-4C04-8E28-AA93CC8EDA26"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FB6B82F4-1EBF-4EB5-AB9F-F7E58FF8DE43"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4F6BD35D-C4EC-4D3E-9493-DF86504ACC41">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:58BD31E4-F1E7-44DA-87A9-5298EBD36BEA</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:89B0316F-0588-408C-A123-319062AB06EE"/>
    <pav:createdOn>2015-10-13 11:52:24 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-13 11:52:38 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FDAE890E-049A-41F4-9F30-53EF368E9E98">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>ethinylestradiol</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8754B1EE-5CF3-4B07-B663-694229AB8CE6">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>and increased concentrations of </ao:prefix>
    <domeo:uuid>8754B1EE-5CF3-4B07-B663-694229AB8CE6</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8754B1EE-5CF3-4B07-B663-694229AB8CE6"/>
    <pav:createdOn>2015-10-14 11:41:27 -0400</pav:createdOn>
    <ao:exact>rifampin </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>were observed.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:83F941D4-E688-4E2C-8F5D-9129F179A240">
    <ao:exact>CYP 2D6 inhibitors: In healthy subjects, co-administration of pimozide 2 mg (single dose) and paroxetine 60 mg resulted in a 151% increase in pimozide AUC and a 62% increase in pimozide Cmax compared to pimozide administered alone. The increase in pimozide AUC and Cmax is related to the CYP 2D6 inhibitory properties of paroxetine. Concomitant use of pimozide and paroxetine or other strong CYP 2D6 inhibitors are contraindicated (see CONTRAINDICATIONS).</ao:exact>
    <pav:createdOn>2015-10-14 12:09:47 -0400</pav:createdOn>
    <ao:prefix>is contraindicated (See CONTRAINDICATIONS ).   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:83F941D4-E688-4E2C-8F5D-9129F179A240"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <domeo:uuid>83F941D4-E688-4E2C-8F5D-9129F179A240</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:29D74A78-F777-4518-A420-AC4CFDABA48C">
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:338217AE-916E-466D-8467-B99AFFFF05E5"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdOn>2015-10-14 11:40:20 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7">
    <ao:item rdf:resource="urn:domeoclient:uuid:67CA9779-E6E3-452A-9E09-AC09514B67E2"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:995850CB-4152-4213-9360-B739CC078262"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DBAA205F-D763-4B3D-B200-B0A15F0FEEF2"/>
    <pav:lastSavedOn>2015-09-29 11:41:50 -0400</pav:lastSavedOn>
    <rdfs:label>NER Sets</rdfs:label>
    <ao:item rdf:resource="urn:domeoclient:uuid:F6C8FEF9-A572-4C72-BBD0-306FDD15972A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1EAD1B21-BE15-4960-B81D-9B59CFD37A6E"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:CA2DF16A-BCF2-4417-9D8F-6A88FE885D86"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:47711889-AF38-45A8-A424-6E73BA96C377"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:681BADBA-A7DA-414A-9E7A-F48859411242"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B7913381-B93C-4BAE-809C-0230467183DB"/>
    <pav:lineageUri>urn:domeoserver:annotationset:148461b1-b4b4-47d1-ac70-e21d1f8f267d</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:52CD5AF8-2C2A-4A5A-B02F-0C46D5CE209E"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <permissions:permissions rdf:nodeID="Ne5e50011ec9841728b0502ce9511293e"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:259CFB0F-7ED5-4494-A634-F548DF83F2C9"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:850E1DB2-54CE-4C03-8CAF-FC518D4668BE"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C1ED112D-54FC-4EED-9310-75DAA13EFFBD"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:93272F80-7133-4FFD-819B-B60FB135C380"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2B412587-C38D-429C-82F8-6FA6FF610C62"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:64DF4E01-7FD9-4C44-BD7E-89C3DAB13158"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:87EC29F5-C3E4-413C-8BA1-9DF5AE1CBBCA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:47795914-06B1-4C55-864C-EBC32AE4358E"/>
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/c1bdce77-66e3-4473-a4af-d20ec6534ce4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:59A8EA1A-1C4A-4895-A91B-B43DCABB6E99"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:432B18FD-15F2-4A92-9083-0A0B230A9CC3"/>
    <pav:previousVersion>urn:domeoserver:annotationset:1DC72E94-8B98-4C69-BC20-1CADCDBD7388</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:538E06C0-D3EE-4DD3-BE7D-E3BA133FC18E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F7D91396-F847-4D3B-8DE6-8BBDAF06324F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:175D6051-88AC-4656-9272-BBF63B1F9C81"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdOn>2015-08-27 14:50:29 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:F7A3EC7C-8A47-44B3-8A00-2C5D20E6B0D1"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B80BB047-F0B6-4152-AC1F-06F914DD8AD8"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/276A334F-EB95-4B3D-9EDC-93CDFA8BAAC1">
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>carbamazepine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E60849B6-3467-49C6-8A41-614417EF3801">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/07F5A746-6968-4B5F-95FD-3D3B0D64AD2D"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/28590323-92ED-4F77-820A-CFD9FF7E1D99"/>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FC3BDA4B-6797-4E69-B2A2-8D02E551D5DE">
    <domeo:uuid>FC3BDA4B-6797-4E69-B2A2-8D02E551D5DE</domeo:uuid>
    <ao:prefix>s) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA ).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-29 09:02:21 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FC3BDA4B-6797-4E69-B2A2-8D02E551D5DE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:20F56425-0E58-4E30-A035-E5253468DFF3">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DC54EBE-B2A9-4AE7-A174-F0074ECE4050</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-01 10:49:37 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N81c54f25f6ef4bcaa93b1ea0607c2c4d"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:DFEB4A11-A3FA-44D0-BA91-2CB9EDC71DF4</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:AB8ABE6E-51A7-45D1-AF71-817381650071"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/fedc5c0b-24e1-406c-939b-28950ffdc9ec">
    <pav:createdOn>2015-10-12 13:20:27 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-12 13:20:27 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:f6b80764-86f8-46c7-9dc5-dbe24be3c79a"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3855DAFA-7CA1-473C-84D0-9686D6BEA028">
    <ao:suffix>and Celexa or Lexapro is contraindicated (See </ao:suffix>
    <pav:createdOn>2015-10-14 12:06:28 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Pimozide </ao:exact>
    <domeo:uuid>3855DAFA-7CA1-473C-84D0-9686D6BEA028</domeo:uuid>
    <ao:prefix>. The mechanism of this pharmacodynamic interaction is not known. Concomitant use of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3855DAFA-7CA1-473C-84D0-9686D6BEA028"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/64047647-342E-418F-B80F-5F03217AE2D4">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>cimetidine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AA119F40-3DF5-414B-A9BA-D5DA54DF8259">
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants>13</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/1C28BB6C-3609-4CB3-A98F-B198460C640B"/>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/12A44C8D-D655-4384-A103-30D2CB254809"/>
    <dikbD2R:cmax>5</dikbD2R:cmax>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:auc>8</dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1579053D-B51B-4EF6-A468-58C48DBFB64E">
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:numOfParticipants>12</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4FACBB8A-BCA1-467E-9A16-53A7A8E95D18"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FA8CCE60-3C9C-42F9-BDC2-0668957F1AA1"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E8F7D750-35CD-45CF-9A08-E121B19CBEF2">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:AD0FF3B7-1403-44E2-8BC1-C8B62A3F6AD0"/>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-14 11:40:19 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FED6DBC4-B992-4231-9B50-CD74271FF94D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A8AFAC88-B784-485A-B795-6D633633106E"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76ED8A68-6744-46EF-B9C0-3A017F20A451">
    <ao:context rdf:resource="urn:domeoclient:uuid:3C5E11B4-8675-4671-9460-F973D9BB478F"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-14 11:41:03 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5E8D0ED9-202F-4A41-9961-E4207967C162">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/358262</dailymed:activeMoietyRxCUI>
    <rdfs:label>fosamprenavir</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D7EE7058-D1E8-4EC5-82D5-9A47FEA2B052">
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:D47B67A6-F253-4F81-A37E-89462D176513"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:createdOn>2015-10-14 11:40:29 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:14E22AEC-2057-4B75-A8C0-143FE90E9159">
    <pav:createdOn>2015-09-24 15:53:57 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-09-24 15:55:00 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:1EDA01E1-6C70-4B3D-B5D8-F39C62662C21</pav:lineageUri>
    <ao:body rdf:nodeID="Nd3a86f2ce691499eaeb58c290157d5a6"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:85AD6EA1-D560-4FFB-A685-3F21B0B4208E</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:449680C4-EDC0-497D-8F7B-7F0CDE1A79C7"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E39A0DBC-CEE5-4BB7-B57D-BE7FF66AB57C">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:createdOn>2015-10-20 09:54:09 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:lastSavedOn>2015-10-20 09:56:31 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:4E9A3236-5738-496E-91EE-4C23AF5C9EB2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:659993FA-47A6-4170-A1F4-37E021B93D40</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E89A7C7B-5319-4A9A-A702-2E60FDB5A0B7">
    <pav:lineageUri>urn:domeoserver:annotation:78A9FDE3-96DB-4CCA-B598-82ADCB29B121</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-09-29 11:24:12 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:21FFFD1F-27FA-48ED-9946-A15455B6663F"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F101E45F-9436-4E81-BE2F-72CF34EBA947">
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:58BD31E4-F1E7-44DA-87A9-5298EBD36BEA</pav:previousVersion>
    <ao:body rdf:nodeID="Nc394ce39837a42e7894e92d63c546a3d"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8F8E9C64-8696-4ACD-9B24-35D4C06DD4F5"/>
    <pav:lastSavedOn>2015-10-13 11:52:38 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <pav:createdOn>2015-10-13 11:43:21 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:57B389D3-D73D-4A28-8728-A45DCC6DD30C">
    <ao:suffix>, </ao:suffix>
    <pav:createdOn>2015-09-29 09:46:31 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., </ao:prefix>
    <ao:exact>barbiturates</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:57B389D3-D73D-4A28-8728-A45DCC6DD30C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B7913381-B93C-4BAE-809C-0230467183DB">
    <pav:lineageUri>urn:domeoserver:annotation:11FA1948-DC5F-4220-85C1-ECA1D3ADB4AD</pav:lineageUri>
    <pav:createdOn>2015-09-29 09:47:01 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N724f723091d44a39ae1549104b0b234f"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:6DE7B434-B945-4A30-BC7E-EF02CE863E97"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:197A4281-DC53-4B3B-8219-112150CFECF8">
    <pav:lineageUri>urn:domeoserver:annotationset:64737b65-8582-4b76-8095-85ad69e2cc47</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2E0AD717-67BC-4D7C-AF83-5F1037F99712</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoclient:uuid:be10a7b6-9093-4dc5-bd8e-7c1619eb41b9</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:EBCEFCFC-427C-49EF-AFE9-1274D4001C7D"/>
    <ao:body rdf:nodeID="N0d052c11e4f1402584b8ad2ecda40e61"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-08-20 11:07:28 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-08-20 11:10:08 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B6FED040-B249-4D05-9B5E-3F9E803BE417">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/02C6A4C3-181E-469F-8BC8-C562E075204E"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C53DC362-8533-4B85-8AA7-6D92A5C9C174"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D0CCAC05-2FD9-4C0D-B712-4B325A19A640">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>D0CCAC05-2FD9-4C0D-B712-4B325A19A640</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <ao:prefix>Certain drugs, particularly the </ao:prefix>
    <pav:createdOn>2015-09-29 11:19:53 -0400</pav:createdOn>
    <ao:exact>psychostimulants</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> and the phenothiazines, increa</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D0CCAC05-2FD9-4C0D-B712-4B325A19A640"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:41A964F8-890F-418E-9391-8D77BE8A2F18">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:962077F2-FB00-4675-9E3B-C57F6D350EF9"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/26BAC204-CD2B-49BC-B2C6-3A5AB3B24726">
    <rdfs:label>fluoxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5ABAC940-00EC-4BEF-B1DF-86B5E2019EA3">
    <domeo:belongsToSet>urn:domeoserver:annotationset:CE635F27-A391-4A6B-9D87-339FA2F114B2</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:0FEB7FDB-C1D1-4B92-A18A-533B592A321F</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-14 11:31:57 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:48834AD2-4A59-4451-94B1-2750AA9B63EE"/>
    <ao:body rdf:nodeID="N64bebd049c334ff7a5fbb50431b9d964"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-09-14 11:32:07 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:CE635F27-A391-4A6B-9D87-339FA2F114B2">
    <ao:item rdf:resource="urn:domeoclient:uuid:6769FF26-4593-4ACE-85F4-0082EFE3DBD6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D1FBAABA-EF88-4FD0-8C4A-3447C135D2E1"/>
    <rdfs:label>NER Sets</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:864ED026-5998-4414-A057-6FCA60ABC131"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:088CBC7A-07AE-43E0-881D-4C1B0A051F3A"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2B6DC982-E12E-48B2-ADAE-398E867DB33B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D1747B58-FE13-4FA5-BF30-708A5FB7E514"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CAE8468A-B375-41C4-89B1-057EB6FF0781"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:8A1F4F2B-48FC-473D-BFAA-23C03BE4EEBF"/>
    <pav:createdOn>2015-08-27 14:50:27 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:3ABD276B-6BC1-4B1F-AFA1-B2CC5A0B0C4F"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FE241EF8-F507-4CE3-949F-DD4EBE848652"/>
    <pav:lastSavedOn>2015-10-09 13:18:59 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:DDEB9FF7-9051-4C5C-B5F5-3024924A4C1A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A7312858-A9CC-433D-B9AC-C691A114786C"/>
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/ae020e7f-0797-4a91-b8b9-d041676f17d3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:091ADEE2-BD39-4316-9D9D-D0737D6F7CBE"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:E7675671-AEC9-4A92-BAF6-0E3954752675"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5ABAC940-00EC-4BEF-B1DF-86B5E2019EA3"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:annotatesResource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:99AACB16-26B2-48A8-A0C4-B33A03BB516E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:91DE19EE-708B-4249-AD26-81B70675D3C3"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:26045A64-6643-4302-9B53-F35F498DCEBD"/>
    <pav:previousVersion>urn:domeoserver:annotationset:B7E1F169-A1DD-4966-9CF4-5B4DC0ABD372</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:E742A8FE-5600-44EC-A3CD-70667F10AE25"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:985767C6-2BB2-44CE-8DE9-89EAD47F6E74"/>
    <pav:lineageUri>urn:domeoserver:annotationset:fc9e17d3-1b0d-4635-9936-0d1d94cb01f9</pav:lineageUri>
    <permissions:permissions rdf:nodeID="N82b2db7d810e437fab5859ee4db2e95f"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:071BC921-234F-46F2-B81F-373E3EBB5348">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4D429DDD-AB90-41BB-896E-0ADE524E7210"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4BC94603-2CAA-4991-8D85-B103CC78103F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4BC94603-2CAA-4991-8D85-B103CC78103F"/>
    <ao:exact>Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam, etc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine. The clearance of benzodiazepines metabolized by glucuronidation (e.g., lorazepam, oxazepam, temazepam) is unlikely to be affected by fluvoxamine. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-20 09:56:15 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>    Benzodiazepines   </ao:prefix>
    <domeo:uuid>4BC94603-2CAA-4991-8D85-B103CC78103F</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A8E93953-0B7B-4984-90DD-EF7F2278F39D">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/454FDA85-31D5-4267-A049-34D9A53C6A8E">
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9B0F9D3A-740F-4C2E-8BB9-79934B636019">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/203143</dailymed:activeMoietyRxCUI>
    <rdfs:label>fluvoxamine maleate</rdfs:label>
    <dikbD2R:dose>100</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0331BE00-9791-4997-932F-FAB3E4507C8F">
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2DEF71E7-518E-4AA5-92AC-A020B088D299"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3750C2AF-6026-4CF2-A9F2-7BF65EADDC13"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4FACBB8A-BCA1-467E-9A16-53A7A8E95D18">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3322</dailymed:activeMoietyRxCUI>
    <rdfs:label>diazepam</rdfs:label>
    <dikbD2R:dose>15</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8960E120-1B6A-4612-AC01-B56565F1DBE1">
    <domeo:uuid>8960E120-1B6A-4612-AC01-B56565F1DBE1</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:exact>There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, and bromocriptine.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>dosage should be considered. (See Viagra package insert .)  </ao:prefix>
    <pav:createdOn>2015-10-13 12:03:13 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8960E120-1B6A-4612-AC01-B56565F1DBE1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9009A542-077B-4E59-90E4-B89CB4F865D4">
    <ao:suffix>and rifampin. This finding may be the result of alteration in the colonic bacteria responsible for the reduction of sulfasalazine to sulfapyridine and mesalamine.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>sulfasalazine </ao:exact>
    <pav:createdOn>2015-10-14 11:41:55 -0400</pav:createdOn>
    <domeo:uuid>9009A542-077B-4E59-90E4-B89CB4F865D4</domeo:uuid>
    <ao:prefix>may be reduced following the concomitant administration of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9009A542-077B-4E59-90E4-B89CB4F865D4"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8B9CE845-DC5C-4C1A-B610-A49E5EABC515">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:5DDF6D10-A992-43D4-B1C2-B010E34F248F"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E9F13BFE-1A17-4FDF-99A7-13B89F697635</domeo:belongsToSet>
    <pav:createdOn>2014-02-19 12:41:37 -0500</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-02-19 12:41:40 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:05D1E91D-8E58-4E8E-995F-9FE6DBC6A3C3</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/790BC479-B26F-4F08-A851-B17265810340">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>phenobarbital</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8134</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5820B0CE-2CDC-4CE4-B4A9-68B408C39343">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-25 10:37:43 -0400</pav:createdOn>
    <ao:exact>In healthy male patients (n=24), carbamazepine (400 mg b.i.d.) increased mirtazapine (15 mg b.i.d.) clearance about 2-fold, resulting in a decrease in average plasma mirtazapine concentrations of 60%.    When phenytoin, carbamazepine, or another inducer of hepatic metabolism (such as rifampicin) is added to mirtazapine therapy, the mirtazapine dose may have to be increased. If treatment with such a medicinal product is discontinued, it may be necessary to reduce the mirtazapine dose.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5820B0CE-2CDC-4CE4-B4A9-68B408C39343"/>
    <domeo:uuid>5820B0CE-2CDC-4CE4-B4A9-68B408C39343</domeo:uuid>
    <ao:prefix>  Carbamazepine  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:141C618E-2C93-4B79-936E-2FDE2CC233F3">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-08-20 11:45:24 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N032c31791b6e45f9b7c08f3fd125f575"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:4D6AB109-FA4A-4D5D-8346-F94208BB97F6</pav:lineageUri>
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:4ADCCB67-AA24-4C5E-A116-A1A8EDA0C259"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4ABBFA3B-0EB4-4F06-813B-0A31BDF7073E">
    <rdfs:label>EMSAM</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>6</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/98DF7C52-806D-4BBC-B646-D50272400CDF">
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>bromocriptine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:898943E1-8373-4EAD-AD6E-A4B90C2E9F95">
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-29 09:25:58 -0400</pav:createdOn>
    <ao:prefix>hydroxylase) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:898943E1-8373-4EAD-AD6E-A4B90C2E9F95"/>
    <domeo:uuid>898943E1-8373-4EAD-AD6E-A4B90C2E9F95</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:76846948-A201-4FB8-8CA0-B7E0EF641A9F">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BCEC36F1-A3A6-4CAB-A507-D8DA9D9D2228"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/57BF8DDB-2F8F-4E27-9FD5-634619584FB6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5A2106C1-9FB8-4E59-BCA1-1E2909B77C1B">
    <pav:createdOn>2015-09-24 15:32:02 -0400</pav:createdOn>
    <ao:prefix> (200 mg BID) increased the area under the concentration vs. time curve (AUC) of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>desvenlafaxine </ao:exact>
    <domeo:uuid>5A2106C1-9FB8-4E59-BCA1-1E2909B77C1B</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5A2106C1-9FB8-4E59-BCA1-1E2909B77C1B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:hasSource>
    <ao:suffix>(400 mg single dose) by about 43% and C</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8A87388D-69CF-46EA-98B2-17F5863DF318">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/83395</dailymed:activeMoietyRxCUI>
    <rdfs:label>saquinavir</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/55569A80-4A18-47C6-804A-8B13AAF0A793">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>ketoprofen</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C265B1AF-4653-46CE-B70B-A0B180ED58C4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>dosage should be considered. (See Viagra package insert .)  </ao:prefix>
    <pav:createdOn>2015-10-13 12:04:12 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C265B1AF-4653-46CE-B70B-A0B180ED58C4"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, and bromocriptine.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>C265B1AF-4653-46CE-B70B-A0B180ED58C4</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FD084F05-42CF-47DA-9169-B3816C94F3CB">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="Nbe8b1a59a50747a4971bfdf0f3eb4482"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:BA4A4F06-DE8C-4B66-8918-920D0399D744</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-08-20 12:47:54 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:D2922D3F-3CFA-4786-B2D2-F1EDB6C89271"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B2AB6C73-4A35-45BC-AB2B-24DF13F02726">
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-01 10:48:53 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:4B873ED7-0EE0-49FF-92F6-C55C5743F86D</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DC54EBE-B2A9-4AE7-A174-F0074ECE4050</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N6327cf99c497425ca63616d61f499a55"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:CDDC9E8D-62CB-4BF0-9812-9185A18E1C54"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FB5E27FC-759D-4791-A1E0-1ECF6608F328">
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdOn>2015-10-14 11:41:34 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:147C7E33-CA71-4007-9D0D-0D74BACD2105"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F6C8FEF9-A572-4C72-BBD0-306FDD15972A">
    <ao:context rdf:resource="urn:domeoclient:uuid:83F3CE35-1D1E-40F7-AFD0-669A8DC32134"/>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N3774f0c52ae44c3892768487ed9b6b3e"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-29 09:47:31 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:3DA62A8A-89C7-45E3-A67C-E69EF01F228E</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:34A2128C-DB02-437A-A05C-C462C499966B">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/990A8EFD-9234-41D3-A475-48D0CA0DB9D7"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/82F5D709-515F-4442-95C8-DD289F45E850"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:85AD6EA1-D560-4FFB-A685-3F21B0B4208E">
    <rdfs:label>NER Sets</rdfs:label>
    <domeo:deleted>false</domeo:deleted>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:lineageUri>urn:domeoserver:annotationset:d5d1f96a-f1c4-422f-a8db-6afb741bb0fc</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:46978DF7-54C6-4DAF-AE2C-288EC912B983"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:41DBC941-97B7-4F69-B88D-FB36F19C347A"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2015-09-24 15:55:00 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:81B69CC2-6CFB-4E8F-BD18-1440CA86A9C8"/>
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7bbf62d7-595f-481e-b910-419c53446301"/>
    <permissions:permissions rdf:nodeID="N2c8b797d6bb644a2b915c60b9c8c7fd8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AEBD2BB2-1ADA-4FE3-8B12-5993B86C445C"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:14E22AEC-2057-4B75-A8C0-143FE90E9159"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:06BC474E-3024-4DCB-97FA-F3A2B0984C23"/>
    <pav:createdOn>2015-08-27 14:50:34 -0400</pav:createdOn>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:17826D3C-609B-4BB6-89A9-ECE6035061EA"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <pav:previousVersion>urn:domeoserver:annotationset:A79FD8DE-2645-4A33-992C-1B3E6A06E9A0</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:E4F1D2C6-857D-4F82-B085-04A9A96FDCDA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:206B49CD-CF07-4B4F-A06A-33227D2DF298"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/c89cfc94-dee3-4cee-a24b-f02fe9626e23">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-08-27 14:50:17 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:33B17719-DF97-48EA-AFA2-01DE8A8887B4</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:2d1a4a7f-6ab4-4b36-a625-a116e1deb204"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-08-27 14:50:17 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:9bb6dd0f-3b72-4a0d-9c01-71e7c9ec8d9b</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F7A3EC7C-8A47-44B3-8A00-2C5D20E6B0D1">
    <ao:context rdf:resource="urn:domeoclient:uuid:C21EEA0C-88D7-44F4-B790-38B97282D2BF"/>
    <pav:lineageUri>urn:domeoserver:annotation:2AB80A41-C626-44C5-8212-222E02B558EF</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-29 09:46:21 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D4E167D7-7DE2-4653-B03E-8E1AFFCB78D1">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:be10a7b6-9093-4dc5-bd8e-7c1619eb41b9</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:64737b65-8582-4b76-8095-85ad69e2cc47</pav:lineageUri>
    <pav:createdOn>2015-08-20 11:08:37 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2E0AD717-67BC-4D7C-AF83-5F1037F99712</domeo:belongsToSet>
    <pav:lastSavedOn>2015-08-20 11:10:08 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:FC641720-6E94-4C53-951F-25C1172B97B8"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N4fee2038a0bc49d7bac96c39d604c780"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3B88446F-BBBE-4200-B520-7533B65271BB">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E15ADF76-9E3C-4FE3-A2F3-750E2C5B7A0B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:71031431-0ea2-438e-b8df-774b463de764">
    <pav:createdOn>2015-08-27 14:50:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix> transmitting activity. This interference with reuptake of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>norepinephrine</ao:exact>
    <ao:suffix> and</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:71031431-0ea2-438e-b8df-774b463de764"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7BA4CEE0-5F5F-4215-A94F-CE87E8E216A1">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7BA4CEE0-5F5F-4215-A94F-CE87E8E216A1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Clinical Pharmacology (12.3) ] .  </ao:prefix>
    <pav:createdOn>2015-09-03 15:41:51 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CDEFF0EB-79DD-493B-A381-6343E24BCF9C">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2BB39737-8A55-4CBA-A991-8E44E5F10B70"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/62FC9A11-0C8E-45AF-A806-C55FA3506D96"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5DF6AE9B-949E-46A3-A206-985DB924A453">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>lorazepam</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6470</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>4</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C114DF72-D510-44D5-BB77-FE602EB2056C">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4441</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>flecainide</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EC6731E5-3BC9-4D46-9885-9EA2C74CB23B">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:58AF5A91-0D92-4C34-8B7B-E2AB8D21A53A"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:69D1F873-6483-4406-A61C-98BC73C5A620">
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-14 11:40:45 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:EFB0903F-21FF-4FB3-A116-4DC0F441A4E6"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:91B50784-905F-495F-AD8F-E62C27217707">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdOn>2015-10-14 11:40:36 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:8B2AEBA4-2FFE-4044-8357-29D8859AF7D7"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4F689C05-33E7-48FB-8155-7196CDB2E6AD">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <ao:body rdf:nodeID="Nfa4ed7eb852f4f488795fae3a5c71e06"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B4FE1A5F-829C-4CC5-BE0B-4AEA61773EC2"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-29 11:27:03 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:0FB41B40-5994-4234-8BA3-B6A0B4EB87CF</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:55170CF8-8D68-4114-B3E6-DDA4F59726CC">
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D5C58383-272E-4040-9840-D67FB821F7A2"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:auc>50</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B2450468-903F-4AAB-B77F-AD3AE1736E0E"/>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1CBC63B2-8B2E-4ADB-B5BB-A9F2750B2A50">
    <ao:prefix>on BCRP and organic anion transporting polypeptide B1 and B3 (OATP1B1/1B3) substrates   </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <pav:createdOn>2015-08-20 12:48:25 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1CBC63B2-8B2E-4ADB-B5BB-A9F2750B2A50"/>
    <ao:exact>Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)]</ao:exact>
    <domeo:uuid>1CBC63B2-8B2E-4ADB-B5BB-A9F2750B2A50</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B627103B-63D6-44FC-8F4D-CE5F66D98218">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EC0DCB16-B5A8-4E6B-85E2-B89C1EDEE563"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BEDEB324-5B51-4438-99BD-9D06CF61A26B"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/71BE88DB-5E8D-4962-A6C5-9EAFD7D55E92">
    <dikbD2R:dose>4-8</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>risperidone</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2575BC9E-F40E-48B7-89B0-48D528CEC745">
    <ao:context rdf:resource="urn:domeoclient:uuid:8F76EE37-C22C-4ECE-9F52-CC13D26D2DE0"/>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-14 11:40:41 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BA36415B-432D-4246-9872-A79B94700E76">
    <ao:context rdf:resource="urn:domeoclient:uuid:C22B15D4-ED74-40DF-92C3-16732E7180BC"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:50ECB447-54CE-479C-8336-99977B926324</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-09-29 11:24:52 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/285EAC7B-9DBA-4700-B619-67A16BEA39A1">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6960</dailymed:activeMoietyRxCUI>
    <rdfs:label>midazolam</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>400</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:88D5A9D8-13C2-4F7C-889C-FE89812C70E5">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <pav:createdOn>2015-09-03 15:40:17 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:88D5A9D8-13C2-4F7C-889C-FE89812C70E5"/>
    <ao:prefix>Clinical Pharmacology (12.3) ] .  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:98C3B339-EE74-4B6A-A71F-AF2F032CDA0D">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C6618B4E-98E0-4726-B821-3577879C7B57"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6D04824F-3FE0-4EDC-853E-99A452259A65"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:81318619-7AC8-45CC-8689-2D147CE9F211">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D964DDC3-EBB1-45B3-B394-996F56299C7A"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6B4D7751-1D0A-4847-A1B2-6E0366E2003C"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:252EBC69-6A12-474B-90A8-CE817A36D4DB">
    <pav:createdOn>2015-09-03 16:12:07 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N4a0128b05aeb4778a4499bf1f87fe130"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:5BEA2001-CB06-4507-A35E-7F6F162CB5CE</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-10-16 10:42:46 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:9F260B07-A582-4AC8-B337-2561E714CB8B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2DF1511E-C967-4532-AE40-EE4DE4EA8451">
    <ao:prefix>) and decrease by concomitant administration with hepatic enzyme inducers (e.g., </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>2DF1511E-C967-4532-AE40-EE4DE4EA8451</domeo:uuid>
    <ao:suffix>, </ao:suffix>
    <ao:exact>barbiturates</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2DF1511E-C967-4532-AE40-EE4DE4EA8451"/>
    <pav:createdOn>2015-10-01 10:48:58 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:322EB9EE-02D4-4A14-930C-8B461AFD4B02">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-14 12:06:18 -0400</pav:createdOn>
    <ao:prefix>and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>322EB9EE-02D4-4A14-930C-8B461AFD4B02</domeo:uuid>
    <ao:suffix>: In a controlled study, a single dose of pimozide 2 mg coadministered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Racemic citalop</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <ao:exact>Celexa</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:322EB9EE-02D4-4A14-930C-8B461AFD4B02"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9694E9DF-C9D1-420E-B4D5-5F7232AD8335">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:2861ABC1-22FB-4FD5-88C2-532AD5E8650E"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:1B12B01A-FEB5-4B23-91C8-C762EB613C92</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-08-20 13:56:48 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2ABE5FA2-BA00-4AF9-A2EA-1305FAECF3DF</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:DAD02F8C-D0CF-4D03-A113-8C242E8A7E4F">
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:2F975366-FD56-48D6-9A1E-37798B03E721"/>
    <pav:lineageUri>urn:domeoserver:annotationset:01207605-4e40-4784-b7e8-7c296bff1d72</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EC39377A-FCB4-4984-B555-5FB229E17906"/>
    <pav:createdOn>2015-08-27 14:50:21 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:B2B52CA8-8E9F-4EF1-BC60-4C0C672DFABD"/>
    <rdfs:label>NER Sets</rdfs:label>
    <pav:lastSavedOn>2015-09-24 15:38:09 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:CC573065-1EFB-432F-8729-8E859D2CB33E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3B7E6C06-0481-460E-9625-E6C11AD727AB"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:79A8DE39-E57A-4966-B6CC-4915B089F4CB"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:3EC59A94-8BF0-47FC-BD50-FB02548C9994"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/fabc04a0-b02c-41c0-8e2b-48837615d6eb"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:ED0570CC-A3F9-493A-8A74-1A7C60C8F3DB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:13AB40AB-03FE-40A1-BD82-BFF7637C3EE5"/>
    <pav:previousVersion>urn:domeoserver:annotationset:629D5A75-90AB-47E6-9CBB-E92D12C215D8</pav:previousVersion>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <permissions:permissions rdf:nodeID="N7227be347b9644bf916a13a2745a3247"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E19D2025-EB93-4F07-9C83-7950D34A6BA5">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-16 10:42:31 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <domeo:uuid>E19D2025-EB93-4F07-9C83-7950D34A6BA5</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>   </ao:prefix>
    <ao:exact>Risperidone    In subjects who had received EMSAM 6 mg per 24 hours for 10 days, co-administration with risperidone (2 mg per day for 7 days), a substrate for CYP2D6, did not affect the pharmacokinetics of selegiline or risperidone [see Drug Interactions (7.4) and (7.5)].</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E19D2025-EB93-4F07-9C83-7950D34A6BA5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8512C3A6-C183-4355-A260-B5264ABB5227">
    <dikbD2R:numOfParticipants>15</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptDuration>14</dikbD2R:preciptDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/42DCD145-8643-440F-BB86-FC11DCEFA544"/>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0A70CC02-9A9C-4466-8795-549262C22BD3"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0CE9B7E7-ABBF-4E8E-ABC8-DB03865B9C2A">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:DFC29412-859C-45A5-BB5B-240CED90D299"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7A9393F1-19B6-4E41-ADB2-31F523C2DE9F">
    <dikbD2R:dose>25</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CECE7ED3-4A39-47F8-9B3C-F78361B4F3CC">
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-14 11:41:25 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:15766629-36ED-4174-9263-26C964E1791C"/>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B8DD9C99-B398-4DCF-906A-3A7539D03923">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <ao:body rdf:nodeID="N33c8677f23454807bb0dda53702cf9de"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-09-29 11:28:28 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:3354A146-56A1-4986-B182-B6BDC41E08D9</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:E0A97148-5D07-470C-82E0-B363A9DDE5C1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D1747B58-FE13-4FA5-BF30-708A5FB7E514">
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="Nda150563f7e74340897874a7daa865f5"/>
    <pav:lineageUri>urn:domeoserver:annotationset:fc9e17d3-1b0d-4635-9936-0d1d94cb01f9</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:lastSavedOn>2015-09-14 11:21:10 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CE635F27-A391-4A6B-9D87-339FA2F114B2</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:17CFEF69-CCC6-4ACD-8A24-0425991EC98C</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:3B94CA21-324F-4FD5-9C09-51793E04D748"/>
    <pav:createdOn>2015-09-14 11:04:17 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:90CC2977-9DCD-4239-AA94-3A12FFC5DDD0">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/07DE1A2E-9C4B-4810-98B6-ECB88FDB3846"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptFormulation>transdermal</dikbD2R:preciptFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/1F3648EF-BEFC-4824-927E-20EC7DA1AF8D"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:objectRegimens>TID</dikbD2R:objectRegimens>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>10</dikbD2R:preciptDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447">
    <ao:item rdf:resource="urn:domeoclient:uuid:5CBE087A-CCD5-48AB-A2A5-02B7E65BF8AE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BE2C964A-CE58-4522-ACC9-84E4B2D79E01"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C868D749-332F-412D-9C19-B3F12AE868BB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:92457D2D-BB01-4342-9F4C-B8414696872A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BDFA1B4D-CBB4-4F2D-BFA2-EDADB4C2A92E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:94128D43-4924-4E39-A5F6-73D94E8FB7F4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BB6BF730-3D6F-4A51-B2C3-17BB46FA8AEF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:651930E8-C119-47AB-B738-6EE574930E0B"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:24e042db-9c2a-4010-9672-0cb5e6e9d848</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:328B72FE-B10D-4804-A1C1-8D2A1FDFD05C"/>
    <rdfs:label>NER Sets</rdfs:label>
    <pav:createdOn>2015-08-27 14:50:35 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:8AEDE37A-F06B-40BE-82F5-302935994D48"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:15B838BA-9B8E-469B-94DB-33151EE847D0"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:f31345cc-fba0-42e8-aa14-e28a07f49b91</pav:lineageUri>
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/62ad31c0-8ba1-47f3-8e3e-79498dabd5cb"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7CCF7600-624B-4E6D-983F-C36DF12B9B2D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7284D267-7184-465F-BA7D-6103BCF19E06"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7512BAA3-D70D-40E3-926F-0CCE4EC533DD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:97B31FC7-E5D1-4758-A47A-54242458BD93"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:C2D1A9E2-B506-4537-B5A2-2EEF27B55BF1"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:annotatesResource>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:deleted>false</domeo:deleted>
    <permissions:permissions rdf:nodeID="N5a337b328ade444ea37a8e239a9411e3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:93080012-4C3E-4C4D-B2F2-4D326EFC7211"/>
    <pav:lastSavedOn>2015-09-29 09:04:35 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:BF221115-C0FE-46B1-96DB-A85C6065A7D7"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:DD8CDE29-8D81-4F72-9ECF-445BC8E8A5BD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FA9F1823-1C25-4EAF-AEB0-2D9EFD1A628A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:493863A5-4C9E-4F9A-8147-FB5D77E06771"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1C1632B0-E9F8-4E24-B931-122605DEAF64"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:39368375-C994-4FD6-8A23-3C959B1AE025"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:5E066C8D-C35D-4E0C-975A-46B22FCAB24C"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FF724A23-834B-40DF-BD93-6C05A7E222C2"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:48E05987-C3A7-4E43-AEE7-4A150AB4A2B1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5EE070F1-3108-4ADB-BC2D-46939EAADB10">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <pav:createdOn>2015-10-14 12:06:07 -0400</pav:createdOn>
    <domeo:uuid>5EE070F1-3108-4ADB-BC2D-46939EAADB10</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5EE070F1-3108-4ADB-BC2D-46939EAADB10"/>
    <ao:prefix>Since </ao:prefix>
    <ao:suffix>is partly metabolized via CYP 3A4, it should not be administered concomitantly with inhibitors of this metabolic system, such as azole antifungal agents and protease inhibitor drugs (see CONTRAINDICATIONS).</ao:suffix>
    <ao:exact>pimozide </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2F258F00-52DA-4240-8817-2F94CB72286D">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D9F21CF2-54DF-4227-99C2-9D21912431C2"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DD8CDE29-8D81-4F72-9ECF-445BC8E8A5BD">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-29 08:59:30 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:525D1DB9-82B2-41E5-BD12-6445387778A9</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:9D96C168-8C96-49B8-BE24-FFF9F32265AE"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C5D43AE6-6354-4E16-825D-D76367957266">
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectDuration>10</dikbD2R:objectDuration>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/11552A09-BA53-4E45-AA92-F279C2AA195F"/>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectFormulation>transdermal</dikbD2R:objectFormulation>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/840BE60C-29AC-4826-BF18-E10A79E5054B"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clType>UNK</dikbD2R:clType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BEDEB324-5B51-4438-99BD-9D06CF61A26B">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>maprotiline</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3A77AC8C-55BD-4211-8696-453B0B608637">
    <ao:prefix>hydroxylase) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3A77AC8C-55BD-4211-8696-453B0B608637"/>
    <pav:createdOn>2015-09-29 09:26:32 -0400</pav:createdOn>
    <domeo:uuid>3A77AC8C-55BD-4211-8696-453B0B608637</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:37625BBF-2140-442F-87E5-A81B89AADD1E">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A047300E-DCE0-4EA4-BBE4-81DA58D32E2D"/>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D3E06232-E03C-4122-AA3F-16AF5BA22690"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:numOfParticipants>10</dikbD2R:numOfParticipants>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptDuration>17</dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/fabc04a0-b02c-41c0-8e2b-48837615d6eb">
    <domeo:belongsToSet>urn:domeoserver:annotationset:DAD02F8C-D0CF-4D03-A113-8C242E8A7E4F</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2015-08-27 14:50:21 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:fd835697-0f94-4dea-8117-8b676123d889"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-08-27 14:50:21 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:01207605-4e40-4784-b7e8-7c296bff1d72</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1143E987-C388-4A42-B60B-6F0E31921471">
    <domeo:uuid>1143E987-C388-4A42-B60B-6F0E31921471</domeo:uuid>
    <pav:createdOn>2015-10-20 09:52:05 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>5.6 Potential Pimozide Interaction  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1143E987-C388-4A42-B60B-6F0E31921471"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:exact>Pimozide is metabolized by the cytochrome P4503A4 isoenzyme, and it has been demonstrated that ketoconazole, a potent inhibitor of CYP3A4, blocks the metabolism of this drug, resulting in increased plasma concentrations of parent drug. An increased plasma concentration of pimozide causes QT prolongation and has been associated with torsades de pointes-type ventricular tachycardia, sometimes fatal. As noted below, a substantial pharmacokinetic interaction has been observed for fluvoxamine in combination with alprazolam, a drug that is known to be metabolized by CYP3A4. Although it has not been definitively demonstrated that fluvoxamine is a potent CYP3A4 inhibitor, it is likely to be, given the substantial interaction of fluvoxamine with alprazolam. Consequently, it is recommended that fluvoxamine not be used in combination with pimozide [see Contraindications (4.1)]. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:98F48C7E-A6A2-4BEB-B11D-0403BA73E069">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:FD528EB0-2A80-423E-9AB9-52C00C5FD85B"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/09DAC383-A901-4BF7-8CAF-796BA2EA439A">
    <rdfs:label>cefaclor</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2EDB9905-6E9B-43FA-A7FD-B370A762BA9E">
    <ao:context rdf:resource="urn:domeoclient:uuid:D9DD0FED-8CAA-4C72-9C92-E76BA43781CA"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoclient:uuid:19520cad-8db0-4571-9619-586a168d6356</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2ABE5FA2-BA00-4AF9-A2EA-1305FAECF3DF</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lastSavedOn>2015-08-20 13:53:28 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-08-20 13:53:27 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N3f9bd300206e4ba6a647274b686f2d88"/>
    <pav:lineageUri>urn:domeoserver:annotationset:41206bdb-e025-4044-9968-b0f3d6d02da8</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9B156F67-B49D-47AE-AE7B-FD05838799AB">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A016C3D6-7FFC-4901-9BB0-E99C37F139D2"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:654B2AAF-79AD-47F5-BD08-D71977DBCDA3">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/740001AD-822F-4815-B1EC-95234A0FFEFB"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/66A95A4C-FA60-43FE-ABFB-A6C892784BBC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4D463EE4-B17B-4CA9-909F-2363279F7740">
    <ao:exact>diazepam </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-20 10:08:59 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix>reduces the clearance of both </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4D463EE4-B17B-4CA9-909F-2363279F7740"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>4D463EE4-B17B-4CA9-909F-2363279F7740</domeo:uuid>
    <ao:suffix>and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic coadministration. </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F626D8F1-EA9B-4130-B2D0-0D3B14D5B3DD">
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptFormulation>transdermal</dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0DE7B5FD-A576-45AC-9469-74E35BE93A3C"/>
    <dikbD2R:objectDuration>7</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0EB5CB42-9D8F-4FB8-844D-205FA00A437B"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1D19C3BD-7842-460F-8255-BA31A9C6A907">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-16 10:50:50 -0400</pav:createdOn>
    <ao:prefix>7.1 Potential Interactions with Drugs that Inhibit or are Metabolized by Cytochrome P450 Isoenzymes  </ao:prefix>
    <ao:exact>Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds. The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available. Based on a finding of substantial interactions of fluvoxamine with certain of these drugs [see later parts of this section and also Warnings and Precautions (5)] and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole). </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1D19C3BD-7842-460F-8255-BA31A9C6A907"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3844B79F-439A-48FB-AF88-12C049A4766C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>SSRI</ao:exact>
    <pav:createdOn>2015-09-29 08:59:03 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <ao:prefix>, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3844B79F-439A-48FB-AF88-12C049A4766C"/>
    <ao:suffix>-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>3844B79F-439A-48FB-AF88-12C049A4766C</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:13D01157-3069-48CC-ACE1-E94A30C5F6BA">
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
    <ao:body rdf:nodeID="N160b709ba9744be9a26078ce9762bf88"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>urn:domeoserver:annotationset:BA4A4F06-DE8C-4B66-8918-920D0399D744</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-08-20 12:47:11 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:8B1939F6-6CDE-49BB-B048-194206B6B33F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A8AFAC88-B784-485A-B795-6D633633106E">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6A3F34CE-0ADD-4185-9FD0-AD22A9BC0E52"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/ECBE5A65-EB0C-47B1-953D-BB063498E57E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FEE0B14A-3D15-4C79-8CEF-3A7B1C94EF08">
    <pav:createdOn>2015-10-14 11:41:52 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:E0B63912-C3DD-4CBB-9094-C6C18ED87698"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C18ED82D-257A-4F8A-9E43-CA2E44AB5086">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-29 09:26:32 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N5a72ffe47737455c9f06df07895ceba8"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:3A77AC8C-55BD-4211-8696-453B0B608637"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0185AD47-6E7B-4C92-8A3D-A2876CC95002</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:5CA1E491-07C0-4FF9-A71A-2FA819741F07</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D4D6F8F4-C4E3-4D62-81AB-AD4AEE2D078B">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6503C8AA-225C-4574-B860-C4FC53740246"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FB8D4A98-F29A-423C-891A-788B00C52757"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C6F6583D-9C15-411E-A389-3E7455E515BA">
    <ao:exact>anticoagulants </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:41:17 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:prefix>type. In patients receiving </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C6F6583D-9C15-411E-A389-3E7455E515BA"/>
    <ao:suffix>and rifampin concurrently, it is recommended that the prothrombin time be performed daily or as frequently as necessary to establish and maintain the required dose of anticoagulant.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>C6F6583D-9C15-411E-A389-3E7455E515BA</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11">
    <ao:item rdf:resource="urn:domeoclient:uuid:96C2E3DD-CFC0-4B5C-A927-479839774169"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EDF1BCD1-0EA0-41C0-AF73-88FEC7DE58F4"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <rdfs:label>NER Sets</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:8172FAF8-BA4C-4D30-966D-6B6A0E21D44E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3CE7BECB-91E5-4F43-B89D-2808A4114CE0"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:E919E880-47EB-483C-855A-01488949B792"/>
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8b8a3f8d-c9a5-4eb8-9823-d688fe4b13fb"/>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:58655709-DAF3-46BE-9EE2-996808369DAA"/>
    <pav:previousVersion>urn:domeoserver:annotationset:A537E5AD-C7AA-4D1F-813A-6358E308AD63</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:141C618E-2C93-4B79-936E-2FDE2CC233F3"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:715D4106-C790-47A3-8A5C-4C871F409FC1"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A2EA9703-A708-4572-8D00-D5F3074A2E43"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:658E7905-3AD1-4F91-9C83-D42021CD0345"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1C941DD3-7D28-477E-8CB2-B25161FAC382"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7F836356-3F1C-49C3-B669-D269E5E6E11B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7D1823C4-97DD-4615-A703-A22221EE4B5E"/>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:B2C1921F-B346-41F3-8ED1-A8E19B7280D4"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:17973D21-09C7-4844-9F05-10F6A9BBBF88"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0CB55CFA-6EBF-42B8-8F0D-DD87A96935EE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:2A4C0943-7004-45BC-BF7B-43DF1B68143A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B96681A4-AD78-4B86-8548-E64E89BD1CC2"/>
    <pav:createdOn>2015-08-18 11:35:24 -0400</pav:createdOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:BBB2B0E0-A5E7-4820-AFA7-2E6B6CA080E3"/>
    <permissions:permissions rdf:nodeID="Nfb7ae8caada24b9d97d8b87bace2b373"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:FD084F05-42CF-47DA-9169-B3816C94F3CB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:567622C8-3CF7-4D00-B6DE-58E98EC87767"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AF1A8348-FE16-499F-A909-18EF8BA4B3BD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7FCEBD33-3E98-4378-968D-722F31455BCE"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1B6C697E-067C-46AF-9C37-2EC0D7B07E53"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AD78AF4B-DBBE-4FF7-8F6B-FFE1682428C5"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:219BB0B8-6710-493E-95C9-B50BA0F64342"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:08734296-66AE-4F6B-900A-DABA586B8C92"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:AC1210E1-E4EE-4D83-B846-16A50CD7E108"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:13D01157-3069-48CC-ACE1-E94A30C5F6BA"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:A5236F24-CD6E-4FFA-9D2D-4F7D5C440691"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:annotatesResource>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:3C958806-DB41-436F-9C02-EE13E739606D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:30A55376-DA35-4F14-84D6-CC542F7CCC15"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:812B7CD3-0806-4CD6-ACCE-D738EF8B5B63"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:23C4B3E3-1FBE-4693-B0F4-59041161A2DF"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3434A6E3-7B0B-4EB8-B5C1-C85AB7A49A6C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:01E7137F-16D5-480F-8DCD-C6BDA1E72B3D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:D7C2D90D-6D05-4C42-8B82-0733CAA32B4C"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:ED38BE9F-16E3-44A2-9EBD-E2E7309A6222"/>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:2880880C-966F-4482-BBCD-B24A39E8870E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:06C3C17C-03D7-464B-84AF-2AC11924D8E5"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:E040159D-8A6C-4851-BA28-4759203426F5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6E5C050B-2B08-43BC-9C40-CD73FFE5B61F">
    <pav:createdOn>2015-09-29 11:27:40 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:E57B6DCD-0892-4561-97B3-345ABC4211CC</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="Nf01dc4fda0b540caa80ac44411374836"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:0CCAA492-719D-47DE-AA19-07E516423E35"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C8BE2022-72F9-4691-863A-1C67FE32A041">
    <ao:exact>Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam, etc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine. The clearance of benzodiazepines metabolized by glucuronidation (e.g., lorazepam, oxazepam, temazepam) is unlikely to be affected by fluvoxamine. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>    Benzodiazepines   </ao:prefix>
    <domeo:uuid>C8BE2022-72F9-4691-863A-1C67FE32A041</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-20 09:56:29 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C8BE2022-72F9-4691-863A-1C67FE32A041"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CC3BD481-4C31-44BF-BC22-EA9082344830">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluconazole</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:710D2A05-EC79-4BFC-BC3E-436C7AC80BD5">
    <domeo:deleted>false</domeo:deleted>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2015-08-18 11:34:40 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7c295b64-ec39-42ec-9f02-da5b42e775e1.html</ao:annotatesResource>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.1alpha-050"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:lineageUri>urn:domeoserver:annotationset:b0de7462-b5db-4bbf-8a8a-8438b37938a8</pav:lineageUri>
    <pav:lastSavedOn>2015-08-20 10:29:59 -0400</pav:lastSavedOn>
    <ao:item rdf:resource="urn:domeoclient:uuid:76A0A4B9-D178-4060-963F-C58B74C12622"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dct:description>The NER set is created automatically by NER annotation loading program.</dct:description>
    <ao:item rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/cd9425be-1f3a-4f04-9290-7f3e46a8c14f"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:EB001177-4AAF-4272-8E73-2F1A77A14CBC"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:03CF6241-C331-40D5-BC34-DB9E7915F464"/>
    <pav:previousVersion>urn:domeoclient:uuid:0b070dd2-0029-4aac-baf6-11685c9a1e3d</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdfs:label>NER Sets</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <permissions:permissions rdf:nodeID="N92629cea59bb4759806d7d6b965cd158"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AAEFE98C-39D7-46CB-BE01-0CEE69109804">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB05F5-AF88-4B04-87DC-5826864F9BE3</pav:lineageUri>
    <pav:createdOn>2015-08-26 16:11:50 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-08-26 16:14:07 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7C3ED630-095E-46C1-9254-E12EC01A6C0B</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:23572555-6B65-422D-90E6-045BE62D49C1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1BDA7B55-D91B-4590-9E64-FDB6FF77928B">
    <ao:prefix>  Paroxetine  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1BDA7B55-D91B-4590-9E64-FDB6FF77928B"/>
    <ao:exact>In an in vivo interaction study in healthy, CYP2D6 extensive metabolizer patients (n=24), mirtazapine (30 mg/day), at steady state, did not cause relevant changes in the pharmacokinetics of steady state paroxetine (40 mg/day), a CYP2D6 inhibitor.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-25 10:41:44 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>1BDA7B55-D91B-4590-9E64-FDB6FF77928B</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2EE97ADE-F18C-48A2-9F22-4B314409ED08">
    <ao:exact>cilostazol</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, and bromocriptine.</ao:suffix>
    <domeo:uuid>2EE97ADE-F18C-48A2-9F22-4B314409ED08</domeo:uuid>
    <pav:createdOn>2015-10-13 12:03:21 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2EE97ADE-F18C-48A2-9F22-4B314409ED08"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>quinidine , methylprednisolone , </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CA2DF16A-BCF2-4417-9D8F-6A88FE885D86">
    <pav:lineageUri>urn:domeoserver:annotation:A956C027-8ABA-4F6D-AC6F-78DE2005CB1D</pav:lineageUri>
    <ao:body rdf:nodeID="N885e26abebba4112b1955044b7d7b4a8"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-29 09:45:10 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:EA9DEED5-5AA7-4986-8D55-2BC114A21609"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:612CD415-340B-4E39-AB07-DD25B9DDDAAA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7-10% of Caucasians are so-called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>612CD415-340B-4E39-AB07-DD25B9DDDAAA</domeo:uuid>
    <pav:createdOn>2015-10-01 10:30:18 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:612CD415-340B-4E39-AB07-DD25B9DDDAAA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A49A875-16F9-4412-9863-8314AFC3BC55">
    <pav:createdOn>2015-10-13 11:13:07 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>The metabolism of saquinavir is mediated primarily by CYP3A. Additionally, saquinavir is a substrate for P-glycoprotein (P-gp). Therefore, drugs that affect CYP3A and/or P-gp may modify the pharmacokinetics of saquinavir. Coadministration with drugs that are potent inducers of CYP3A (e.g., phenobarbital, phenytoin, carbamazepine) may result in decreased plasma concentrations of saquinavir and reduced therapeutic effect.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7A49A875-16F9-4412-9863-8314AFC3BC55"/>
    <ao:prefix>7.2 Potential for Other Drugs to Affect INVIRASE  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c00d1607-ac36-457b-a34b-75ad74f9cf0a.html</ao:hasSource>
    <domeo:uuid>7A49A875-16F9-4412-9863-8314AFC3BC55</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FEA679D5-C7D7-4859-BA01-6F91997B0C9B">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:379E5FD5-5C78-435D-9C03-E9A46CD3F77F"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6013A870-1D33-411E-BBD0-3607ADB2CC11">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>hydroxylase) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>6013A870-1D33-411E-BBD0-3607ADB2CC11</domeo:uuid>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <pav:createdOn>2015-09-29 09:24:56 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6013A870-1D33-411E-BBD0-3607ADB2CC11"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/45B77EF0-BBF9-48C0-A832-B0B49A30671A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>valproate</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/40254</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E45E25B8-DB5A-4994-8764-AEBEB1B5F0BC">
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N0992d2909649421baf18c58eaaae728f"/>
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:550727B8-CA74-41DC-AB41-81D12CB47BD0"/>
    <pav:createdOn>2015-10-20 10:10:31 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:912F4CEC-E545-4E5D-8337-0DBA3B5B6E89">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-14 12:08:04 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:956B5E17-AAAF-4A75-90DC-5AB3120E1D18</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-10-14 12:10:56 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:AC689554-C03A-4E24-ADC7-2A36E35E8454"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DBAA205F-D763-4B3D-B200-B0A15F0FEEF2">
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:C53C44EA-1F3B-4486-8749-4D57906431CC</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-29 09:57:35 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:1E80309A-5BCC-4DD4-8CFF-B1EFB59AF65E"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0C52A656-613C-467A-AE25-2D73361F34BB">
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:objectDuration>10</dikbD2R:objectDuration>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectFormulation>transdermal</dikbD2R:objectFormulation>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A65865D9-F393-4D2A-BA99-A5CE604B3F8A"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/48BBB7B3-7B05-4159-93FE-71662573AF67"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DFB7BB80-D245-46D2-8E46-4C4F9E081D08">
    <ao:exact>atazanavir</ao:exact>
    <ao:suffix>, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DFB7BB80-D245-46D2-8E46-4C4F9E081D08"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:39:57 -0400</pav:createdOn>
    <ao:prefix>has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: </ao:prefix>
    <domeo:uuid>DFB7BB80-D245-46D2-8E46-4C4F9E081D08</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F8FEA01F-5802-49B2-9B99-748333B3B90F">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0C52A656-613C-467A-AE25-2D73361F34BB"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:629E760A-97E8-4496-953A-35F7C6732923">
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:cmax>45</dikbD2R:cmax>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E19DE6D4-EB73-440B-B7AC-CF7AED46AD2C"/>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:auc>45</dikbD2R:auc>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5522FC9F-6AFE-4610-91FA-84A7249FF0B9"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:90AF36A5-2ECD-446B-A9B6-CEC8F72AB133">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Rifampin </ao:exact>
    <domeo:uuid>90AF36A5-2ECD-446B-A9B6-CEC8F72AB133</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:90AF36A5-2ECD-446B-A9B6-CEC8F72AB133"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:39:55 -0400</pav:createdOn>
    <ao:suffix>has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:91DE19EE-708B-4249-AD26-81B70675D3C3">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-14 11:13:09 -0400</pav:createdOn>
    <ao:body rdf:nodeID="Nfe77b05c35d84781b7fba6f8f954a96e"/>
    <pav:lineageUri>urn:domeoserver:annotationset:fc9e17d3-1b0d-4635-9936-0d1d94cb01f9</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:4CD9A258-C2B7-483E-B951-7206B4F86B0C"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>urn:domeoserver:annotationset:17CFEF69-CCC6-4ACD-8A24-0425991EC98C</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CE635F27-A391-4A6B-9D87-339FA2F114B2</domeo:belongsToSet>
    <pav:lastSavedOn>2015-09-14 11:21:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/63424F66-F81A-4FE6-A06D-1FD33D4C0A09">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Rifampin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7F5CD015-B229-4833-9E8D-3F33212A7B38">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7F5CD015-B229-4833-9E8D-3F33212A7B38"/>
    <pav:createdOn>2015-10-01 10:43:34 -0400</pav:createdOn>
    <ao:exact>SSRIs</ao:exact>
    <ao:suffix>), e.g., </ao:suffix>
    <domeo:uuid>7F5CD015-B229-4833-9E8D-3F33212A7B38</domeo:uuid>
    <ao:prefix>). While all the selective serotonin reuptake inhibitors (</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:651930E8-C119-47AB-B738-6EE574930E0B">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-29 08:59:21 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:96356D4B-BE9C-4D1B-A933-FE5531AAEBD2"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:B47C25BB-2825-48BF-AAD7-C51D23013406</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7E5D8A38-C152-42BD-9C9C-C8C5B1FF2384">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>desipramine</rdfs:label>
    <dikbD2R:dose>60</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3247</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:25770759-4AAD-4B30-99B5-5DB4D34BA980">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>25770759-4AAD-4B30-99B5-5DB4D34BA980</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>1.6  0.8    Lung  8.8  1.7      </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-13 11:22:54 -0400</pav:createdOn>
    <ao:exact>Clarithromycin 500 mg every 8 hours was given in combination with omeprazole 40 mg daily to healthy adult males. The plasma levels of clarithromycin and 14-hydroxy-clarithromycin were increased by the concomitant administration of omeprazole. For clarithromycin, the mean Cmax was 10% greater, the mean Cmin was 27% greater, and the mean AUC0-8 was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone. Similar results were seen for 14-hydroxy-clarithromycin, the mean Cmax was 45% greater, the mean Cmin was 57% greater, and the mean AUC0-8 was 45% greater. Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:25770759-4AAD-4B30-99B5-5DB4D34BA980"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D5DA46CB-DED1-422E-BD1B-E4AE4E7D33A9">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> and </ao:prefix>
    <ao:exact>tricyclic antidepressants</ao:exact>
    <pav:createdOn>2015-09-29 11:18:42 -0400</pav:createdOn>
    <ao:suffix> can produce clinically significant increases in the plasma concentrations of the tricyclic antidepressants. Conversely, decreases in plasma levels of the tricyclic antidepressants have been reported upon discontinuation of </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D5DA46CB-DED1-422E-BD1B-E4AE4E7D33A9"/>
    <domeo:uuid>D5DA46CB-DED1-422E-BD1B-E4AE4E7D33A9</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DE4DCFF2-608E-4A8E-B5DC-8724F0BC8ADD">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>DE4DCFF2-608E-4A8E-B5DC-8724F0BC8ADD</domeo:uuid>
    <ao:exact>Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See CONTRAINDICATIONS.) </ao:exact>
    <pav:createdOn>2015-10-14 11:53:53 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>with drugs that undergo biotransformation through these metabolic pathways may accelerate elimination of coadministered drugs. To maintain optimum therapeutic blood levels, dosages of drugs metabolized by these enzymes may require adjustment when starting or stopping concomitantly administered rifampin.  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DE4DCFF2-608E-4A8E-B5DC-8724F0BC8ADD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2F975366-FD56-48D6-9A1E-37798B03E721">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:DAD02F8C-D0CF-4D03-A113-8C242E8A7E4F</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="Na19b0dd402df4cfeb76b22632a46c8f9"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D04F3D8D-1B33-4FA9-B0E8-7D32C2B5B39D"/>
    <pav:lineageUri>urn:domeoserver:annotation:4B2F5DB3-AA8B-4424-B873-B1C02C3CC396</pav:lineageUri>
    <pav:createdOn>2015-09-24 15:33:08 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-09-24 15:38:09 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7D8FA781-27E9-4FAE-AC8D-B8ACEBA61475">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:DE16DE17-5423-4599-A22C-72CD49682241"/>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-14 11:40:15 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FF695BC4-C82B-4848-9B16-ECAF10060C47">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:1143E987-C388-4A42-B60B-6F0E31921471"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:659993FA-47A6-4170-A1F4-37E021B93D40</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-10-20 09:52:05 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-20 09:56:31 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N90b6b580ee124c4ab59fdc9cb13eb53e"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5F377576-4DBC-4316-BC46-1E324C1A4648">
    <dikbD2R:auc>2.4</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E3C63644-36C5-476F-826C-B41250DC99E4"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/348DA3E2-EC77-40B7-9C88-EE9DF41C8397"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmax>1.7</dikbD2R:cmax>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4D429DDD-AB90-41BB-896E-0ADE524E7210">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BD7B24E5-5A0E-4E40-9F53-E994B2428043"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/AF18B468-A219-4E1A-9219-4955E1D0702F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4F32B034-EBC5-424C-BBC6-52AAD0D32DD9">
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdOn>2015-10-14 11:41:11 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:BB1AF37E-3BB3-44CC-A127-077E63066586"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3CF51461-26FF-4F12-A356-422C9C7A5D17">
    <ao:exact>PPA</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>)      In subjects who had rece</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-03 15:57:04 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3CF51461-26FF-4F12-A356-422C9C7A5D17"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>   Phenylpropanolamine  (</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D90EB4B6-E985-43E3-95F8-50682DE27976">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>and Celexa: In a controlled study, a single dose of pimozide 2 mg coadministered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Racem</ao:suffix>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:exact>Pimozide </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D90EB4B6-E985-43E3-95F8-50682DE27976"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 12:06:18 -0400</pav:createdOn>
    <domeo:uuid>D90EB4B6-E985-43E3-95F8-50682DE27976</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N38b642101e3b4a46b41a96f4334f69aa">
    <domeo:sets rdf:resource="urn:pddi:uuid:0EE9979A-3981-4AB8-95D5-7D7C96D70345"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:38A7D6C5-26EA-4A09-8B05-90EB95AB376E">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:D4EB247C-C176-4A5E-90CD-4E8612DA3BE7</pav:lineageUri>
    <pav:createdOn>2015-08-20 13:56:39 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:C471FFF4-C39A-4E02-8A38-863CF7D75C91"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N6e330c49c5ac4ea0ac3dae1c1925cc1f"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2ABE5FA2-BA00-4AF9-A2EA-1305FAECF3DF</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C91D2274-509B-49F5-B5D1-D7C7D0D29F8F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-29 11:22:06 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>C91D2274-509B-49F5-B5D1-D7C7D0D29F8F</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C91D2274-509B-49F5-B5D1-D7C7D0D29F8F"/>
    <ao:prefix>. </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Other substances, particularly barbiturates and alcohol, induce liver enzyme activity and thereby reduce tricyclic antidepressant plasma levels. Similar effects have been reported with tobacco smoke.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/07DE1A2E-9C4B-4810-98B6-ECB88FDB3846">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dikbD2R:dose>6</dikbD2R:dose>
    <rdfs:label>EMSAM</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EA373C68-45B7-43A7-8318-89A087B0443D">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:206594A1-662D-4501-BCA2-DBA71CD719C3"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-10-13 11:13:09 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:BDA149A4-7480-419D-95B4-B8534B0D597B</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:7A5AE9CE-6DF7-4BD5-B9BB-F73A3F29F92E</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N2993ba8f20054a72a7958d1dc10a61f6"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-10-13 11:12:12 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/ED5CDCDF-BB15-4F6F-9249-98BB2F3B1837">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85762</dailymed:activeMoietyRxCUI>
    <rdfs:label>ritonavir</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B9B2E4B1-156C-4FBA-846E-AFE80466AEC7">
    <ao:context rdf:resource="urn:domeoclient:uuid:0B998C8C-A7B7-4E62-9960-0D6A6C27D6D3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DC54EBE-B2A9-4AE7-A174-F0074ECE4050</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-01 10:43:25 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:D2350E4F-BA1F-4DED-A735-C34D2DCE9000</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:95F45B41-8CBE-45C5-BA13-0C5BFD45D7B0">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-13 11:55:45 -0400</pav:createdOn>
    <ao:exact>Concomitant administration of clarithromycin and ritonavir (n=22) resulted in a 77% increase in clarithromycin AUC and a 100% decrease in the AUC of 14-OH clarithromycin. Clarithromycin may be administered without dosage adjustment to patients with normal renal function taking ritonavir. However, for patients with renal impairment, the following dosage adjustments should be considered. For patients with CLCR 30 to 60 mL/min, the dose of clarithromycin should be reduced by 50%. For patients with CLCR &lt; 30 mL/min, the dose of clarithromycin should be decreased by 75%.</ao:exact>
    <domeo:uuid>95F45B41-8CBE-45C5-BA13-0C5BFD45D7B0</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>were not significantly affected by concomitant administration of fluconazole.  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:95F45B41-8CBE-45C5-BA13-0C5BFD45D7B0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:460FF567-9498-4139-B837-750F5B71C8E1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required. It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <pav:createdOn>2015-10-01 10:49:17 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:460FF567-9498-4139-B837-750F5B71C8E1"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.</ao:exact>
    <domeo:uuid>460FF567-9498-4139-B837-750F5B71C8E1</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CFFE1E34-CEED-4DA5-B793-B7016EED59B8">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6FB3EE06-1EF2-4970-9924-E3F72D0AFA10"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:67CA9779-E6E3-452A-9E09-AC09514B67E2">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:C1072875-A7D8-4D03-B976-47B245B17B9A</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-29 11:41:49 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="Nd15e0f008d6248e896039a9b95a43715"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-09-29 11:41:50 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:454F6C27-43B6-4A9B-897D-8EFBA3FD1A99"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:93B475C7-75F1-4743-8FFA-D944D75B1713">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:AAF525DB-3D06-4C20-8D98-BC035397D69A"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:89812278-2FE3-46D0-9045-6F889ED70543">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:7AB37698-54BD-4A66-919F-A123A6569141"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:57989A97-E28E-4A67-8540-AED84D0A27AD</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="Nc8ec8707c16148949c59626a7ff6e857"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2ABE5FA2-BA00-4AF9-A2EA-1305FAECF3DF</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-08-20 13:55:21 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B6666984-66C9-4A84-B678-A70C9359EECB">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Coadministration of fosamprenavir/ritonavir with paroxetine significantly decreased plasma levels of paroxetine. Any dose adjustment should be guided by clinical effect (tolerability and efficacy)</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-14 11:31:43 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B6666984-66C9-4A84-B678-A70C9359EECB"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>levels be monitored when these drugs are concurrently administered.  Fosamprenavir / Ritonavir  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D827C70D-8527-4B67-BD81-4007E2027108">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:659993FA-47A6-4170-A1F4-37E021B93D40</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-10-20 09:55:27 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:39ECB635-1D7A-41B0-802B-6080D29F84FC"/>
    <ao:body rdf:nodeID="Nb7b43f8781ad4837a26849f73605cdfd"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-10-20 09:56:31 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D4F8EA01-8DCA-4715-AF5B-0ABFCF10DFA4">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>phenytoin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BF3B52AD-C540-4014-83D2-FE29BD13CA56">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:suffix>. (See </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BF3B52AD-C540-4014-83D2-FE29BD13CA56"/>
    <pav:createdOn>2015-10-14 11:40:06 -0400</pav:createdOn>
    <ao:exact>rifampin</ao:exact>
    <ao:prefix>tipranavir . These antiviral drugs  must not be co-administered with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>BF3B52AD-C540-4014-83D2-FE29BD13CA56</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9BDECE31-1737-44ED-AAF7-892459C4A105">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdfs:label>paroxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E6515473-8F32-47FB-9F82-4E1CCCA670BB">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <ao:body rdf:nodeID="Ndde8c450a967474ba5386e60b15d3738"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:FE5041E0-D597-4A36-BF97-FC9EBBDB6AC9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-13 11:52:57 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:46B234F0-D68D-4DB4-ABE7-1BFB208B25F2</pav:previousVersion>
    <pav:lastSavedOn>2015-10-13 11:56:52 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:277F51B2-4AD3-4BE4-9460-4E4FB0C3B86A">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7C5552C6-29B8-4ED1-9F08-13DBD5700F83"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EFDE0C08-E26E-490C-BCA7-40A754BD7790"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6CDB2B96-4DA8-44C1-8B35-3E8DA8E089D9">
    <ao:prefix>), </ao:prefix>
    <ao:suffix>, oral hypoglycemic agents (sulfonylureas) levothyroxine, methadone, narcotic analgesics, progestins, quinine, tacrolimus theophylline, tricyclic antidepressants (e.g., amitriptyline, nortriptyline) and zidovudine. It may be necessary to adjust the dosag</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:exact>haloperidol</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:40:48 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6CDB2B96-4DA8-44C1-8B35-3E8DA8E089D9"/>
    <domeo:uuid>6CDB2B96-4DA8-44C1-8B35-3E8DA8E089D9</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:74D645EA-3445-4B52-8137-F45AC68F5792">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:0B737F90-D900-4EBF-A944-99042ABD0DBC"/>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdOn>2015-10-14 11:41:47 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4A18152D-98CB-4161-B63A-8E64236DE720">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8331</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>2</dikbD2R:dose>
    <rdfs:label>pimozide</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BB1EF57C-D181-4564-8CAC-FCE81C31CCEF">
    <domeo:uuid>BB1EF57C-D181-4564-8CAC-FCE81C31CCEF</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-29 11:20:39 -0400</pav:createdOn>
    <ao:prefix>may be increased in the elderly, most likely due to decreased renal elimination with aging.  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <ao:exact>Certain drugs, particularly the psychostimulants and the phenothiazines, increase plasma levels of concomitantly administered tricyclic antidepressants through competition for the same metabolic enzyme systems.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BB1EF57C-D181-4564-8CAC-FCE81C31CCEF"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8CB716C6-3DD1-4088-8B37-038F3FF1F8F9">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>simvastatin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36567</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8CC6D2D9-EC12-46A9-A31E-545B24323940">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F3F07E2E-E25B-424B-AA80-B08BAD54201F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B8BF66D0-3ECC-4CAE-8D2A-060A2E0912AB">
    <ao:suffix> (e.g., phenytoin), digitoxin, antiarrhythmics (e.g., disopyramide, mexiletine, quinidine, tocainide), oral anticoagulants, antifungals (e.g., fluconazole, itraconazole, ketoconazole), barbiturates, beta-blockers, calcium channel blockers (e.g., diltiaze</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <domeo:uuid>B8BF66D0-3ECC-4CAE-8D2A-060A2E0912AB</domeo:uuid>
    <ao:exact>anticonvulsants</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>has been reported to accelerate the metabolism of the following drugs: </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B8BF66D0-3ECC-4CAE-8D2A-060A2E0912AB"/>
    <pav:createdOn>2015-10-14 11:40:10 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A876D8F6-552D-4874-AE4D-80EF6F76EEF0">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:DCB77F24-1F8C-45FE-B693-B2FADB64AF47"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:37FAC892-00AA-4A61-815B-E0670FFEAB15">
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:a7f59b4d-3ada-4384-adb1-665a4a1743c8</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:7BA4CEE0-5F5F-4215-A94F-CE87E8E216A1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <pav:createdOn>2015-09-03 15:41:51 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N3c2cade066c843d7b58bad795b5e7586"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0D5EB926-B056-4F85-B631-59CE9E122B9A">
    <pav:createdOn>2015-08-20 11:37:03 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0D5EB926-B056-4F85-B631-59CE9E122B9A"/>
    <ao:prefix>AUBAGIO on CYP2C8 substrates   </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Teriflunomide is an inhibitor of CYP2C8 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP2C8 as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C9895165-E2F7-4FE6-9EDC-FE57A930607C">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7A07B4CA-31C3-4C02-85CD-DE48739EC30C"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/06A3E8C6-059D-4578-8210-CA5CE45CAE53"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CCB515E3-7272-470E-B7DB-F399A3A49062">
    <ao:prefix>   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Alprazolam    In subjects who had received EMSAM 6 mg per 24 hours for 7 days, co-administration with alprazolam (15 mg per day), a CYP3A4 and CYP3A5 substrate, did not affect the pharmacokinetics of alprazolam or selegiline [see Drug Interactions (7.4) and (7.5)]. </ao:exact>
    <domeo:uuid>CCB515E3-7272-470E-B7DB-F399A3A49062</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CCB515E3-7272-470E-B7DB-F399A3A49062"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-16 10:31:15 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:61047704-2B5D-467F-8EA8-1BEC048D756B">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5CB83113-A43E-4CB3-A4B1-780E0F45EDA8"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7FA8FD4A-5E33-4537-A903-16639AE0421F">
    <rdfs:label>TCA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D288D74F-9708-49AC-B474-30F89F6775D3">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3247</dailymed:activeMoietyRxCUI>
    <rdfs:label>desipramine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:63051F23-7F57-41C0-B92B-AB7543774011">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-13 12:04:13 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N0df7b1d117e04bf7b85d0c07d4c0900e"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:C265B1AF-4653-46CE-B70B-A0B180ED58C4"/>
    <pav:createdOn>2015-10-13 12:04:12 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:B51F4BB3-6BDB-45E7-9399-D93DBC4324AC</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3CE7BECB-91E5-4F43-B89D-2808A4114CE0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdOn>2015-08-20 12:48:39 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>urn:domeoserver:annotationset:BA4A4F06-DE8C-4B66-8918-920D0399D744</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:7C1B5957-4396-4B3A-BC64-186F5A95193F"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="Ne1ef6f53310740c699aca737730e391b"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AAF525DB-3D06-4C20-8D98-BC035397D69A">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/72BE13CC-4F08-423C-B7F9-CC4465B469B3"/>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2C1DEA9E-A8E5-482A-8B56-78ADB9F83C02"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:numOfParticipants>24</dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FF456A41-9E7C-4E63-AA74-8071591A99CA">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:25AAB2BB-7B3C-4E9D-BA17-0E800465FE42"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AC1210E1-E4EE-4D83-B846-16A50CD7E108">
    <ao:body rdf:nodeID="N0a5610e932214c25879ce499e927f6b3"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:750C3B61-90C0-4208-9060-F6C9E7875830"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:AAF76A51-792C-4754-85EB-8E18EDAEC889</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-08-20 11:44:41 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F3181AE2-E041-4E56-9E33-9A4C89FB7FEB">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>GILENYA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F8A4A60F-D73B-49D9-B507-647F30F97129">
    <ao:suffix> and clozapine. Since clozapine-related seizures and orthostatic hypotension appear to be dose related, the risk of these adverse events may be higher when fluvoxamine and clozapine are coadministered. Patients should be closely monitored when fluvoxamin</ao:suffix>
    <domeo:uuid>F8A4A60F-D73B-49D9-B507-647F30F97129</domeo:uuid>
    <ao:exact>fluvoxamine maleate</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>have been reported in patients taking </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F8A4A60F-D73B-49D9-B507-647F30F97129"/>
    <pav:createdOn>2015-10-20 10:17:47 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B9DE1B2B-7900-412C-B470-BF5A3E25597F">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:F8C9789F-06FD-4B9C-BC2C-5D2C1BAAF5FF</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DC54EBE-B2A9-4AE7-A174-F0074ECE4050</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:64A14B71-4AB9-4735-A227-D9A89F23C614"/>
    <pav:createdOn>2015-10-01 10:43:31 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:653058FE-C140-48A5-AA68-61D05E0E3436">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-09-30 12:41:52 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6F5C24D1-EA99-48CF-B498-A0D89C02B290</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:97D20613-ACA2-4122-9E8A-62810E745B08"/>
    <pav:lineageUri>urn:domeoserver:annotation:76418FD4-AC19-42DD-9432-4C4A452FC108</pav:lineageUri>
    <pav:createdOn>2015-09-30 12:40:33 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D2128AEB-ADBD-4C8D-921B-A08DE5625871">
    <domeo:uuid>D2128AEB-ADBD-4C8D-921B-A08DE5625871</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <ao:suffix>), e.g., </ao:suffix>
    <pav:createdOn>2015-10-01 10:27:23 -0400</pav:createdOn>
    <ao:prefix>). While all the selective serotonin reuptake inhibitors (</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>SSRIs</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D2128AEB-ADBD-4C8D-921B-A08DE5625871"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:929BF940-1099-4796-BBA3-341FACCD0F42">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/Clopidogrel-1086a7b4-b89b-4bee-8120-5f752626c046.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <domeo:uuid>929BF940-1099-4796-BBA3-341FACCD0F42</domeo:uuid>
    <pav:createdOn>2014-02-09 21:23:27 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>CYP2C19 poor metabolizer status is associated with diminished antiplatelet response to clopidogrel. Although a higher dose regimen (600 mg loading dose followed by 150 mg once daily) in poor metabolizers increases antiplatelet response [see Clinical Pharmacology (12.5)], an appropriate dose regimen for this patient population has not been established in clinical outcome trials.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:929BF940-1099-4796-BBA3-341FACCD0F42"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FE844157-DB14-4D8C-A5BF-15D63AD8C55C">
    <ao:exact>anticoagulant</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>.</ao:suffix>
    <pav:createdOn>2015-10-14 11:41:21 -0400</pav:createdOn>
    <ao:prefix>concurrently, it is recommended that the prothrombin time be performed daily or as frequently as necessary to establish and maintain the required dose of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <domeo:uuid>FE844157-DB14-4D8C-A5BF-15D63AD8C55C</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FE844157-DB14-4D8C-A5BF-15D63AD8C55C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CB9F0709-26F3-45BC-853A-0EF0ED89BE81">
    <pav:createdOn>2015-10-13 11:57:58 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2F0F6A9C-0E38-4924-B1BA-458A4EEDE554</pav:previousVersion>
    <pav:lastSavedOn>2015-10-13 11:59:07 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N736cb82c7897487a88e42e0f6f2ae419"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:8192C38C-8A64-4095-93F3-6ABB76394412"/>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/572370D5-AA12-4E2A-81AD-80A6CB30FB7B">
    <dikbD2R:dose>150</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>milnacipran</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CC5831BA-A457-4A1C-A105-E4571054D878">
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">14</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-16 10:40:14 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-03 15:52:39 -0400</pav:createdOn>
    <ao:body rdf:nodeID="Nf3057e84446041fb8290288f80b353ca"/>
    <pav:previousVersion>urn:domeoserver:annotationset:CE124242-AD57-4D32-9A25-1EF5E6126E23</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:E7C7BC74-CBB9-4D9C-A253-7ACB76FC97C1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CE1FA3D4-E8F4-4DC0-B989-6DC0656AB8AE">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2E756266-05D5-4750-8533-ADA293D4922A"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7A4989DB-C1B1-42C6-B4A6-0AAAD2673ED4"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:41D04F07-F1A4-4984-92BF-64D621B5DF2A">
    <ao:prefix>    Benzodiazepines   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>41D04F07-F1A4-4984-92BF-64D621B5DF2A</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:exact>Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam, etc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine. The clearance of benzodiazepines metabolized by glucuronidation (e.g., lorazepam, oxazepam, temazepam) is unlikely to be affected by fluvoxamine. </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-20 09:55:09 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:41D04F07-F1A4-4984-92BF-64D621B5DF2A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4180C419-788E-4700-AC18-62022C0E5751">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:createdOn>2015-10-20 09:56:50 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:75C5BEDD-5FBA-4417-A356-74879D603274"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9D1B526F-267F-4ADD-A3FA-F70A535B6D24">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6E19CC03-E03E-4213-8EA8-46AEFDCE0AEB"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:267DFD0A-5B3B-4F41-9DB6-8A24E410471E">
    <pav:previousVersion>urn:domeoserver:annotationset:8D286017-0AEC-46C4-AC51-641E2F31DE1A</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:createdOn>2015-10-20 09:22:33 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:840EADA8-9914-479B-86B1-4DD985E78FB3"/>
    <pav:lastSavedOn>2015-10-20 09:23:48 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:385F758F-56E4-4CEF-B518-C20BF7DCCF03">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:B9BE6515-0D51-48A4-A122-164A661EF83C"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nff25cb610a4845b6878ab4ffe8c7b454">
    <domeo:sets rdf:resource="urn:pddi:uuid:2056EE88-B9C4-43AF-A3D5-B309CF4BED47"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A89FC92C-5A67-42A6-A421-D569274EB522">
    <dikbD2R:dose>30</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdfs:label>paroxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BD8AEC57-8E65-4689-A734-08C52656A65C">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-13 11:27:39 -0400</pav:createdOn>
    <domeo:uuid>BD8AEC57-8E65-4689-A734-08C52656A65C</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BD8AEC57-8E65-4689-A734-08C52656A65C"/>
    <ao:prefix>   Drug interactions  </ao:prefix>
    <ao:exact>Clarithromycin use in patients who are receiving theophylline may be associated with an increase of serum theophylline concentrations. Monitoring of serum theophylline concentrations should be considered for patients receiving high doses of theophylline or with baseline concentrations in the upper therapeutic range. In two studies in which theophylline was administered with clarithromycin (a theophylline sustained-release formulation was dosed at either 6.5 mg/kg or 12 mg/kg together with 250 or 500 mg ql2h clarithromycin), the steady-state levels of Cmax, Cmin, and the area under the serum concentration time curve (AUC) of theophylline increased about 20%.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0F426060-C04A-472C-8743-8DAC80A34F49">
    <dikbD2R:dose>50-200</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>sertraline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:27E99368-C12A-4070-8F13-575F3DDF977B">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A66F97CF-143C-4929-85A7-8F2A4BA0AF3A"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:preciptFormulation>transdermal</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/73EB24BB-86D5-496E-9768-2CE6A3B494A6"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptDuration>10</dikbD2R:preciptDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B7B13A80-C001-4C0F-A3B2-68C41351BC5B">
    <pav:createdOn>2015-10-09 13:31:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>n a controlled study of a single dose (2 mg) of pimozide, 200 mg sertraline (q.d.) co-administration to steady state was associated with a mean increase in pimozide AUC and Cmax of about 40%, but was not associated with any changes in EKG. Since the highest recommended pimozide dose (10 mg) has not been evaluated in combination with sertraline, the effect on QT interval and PK parameters at doses higher than 2 mg at this time are not known. While the mechanism of this interaction is unknown, due to the narrow therapeutic index of pimozide and due to the interaction noted at a low dose of pimozide, concomitant administration of sertraline and pimozide should be contraindicated (see </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>B7B13A80-C001-4C0F-A3B2-68C41351BC5B</domeo:uuid>
    <ao:prefix>I</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B7B13A80-C001-4C0F-A3B2-68C41351BC5B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3CEE72DB-95D0-4667-BC57-4876C3F279A5">
    <domeo:belongsToSet>urn:domeoserver:annotationset:2E0AD717-67BC-4D7C-AF83-5F1037F99712</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:C503AA81-1484-4CA2-957C-6CEAAC917A62"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:64737b65-8582-4b76-8095-85ad69e2cc47</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:77088A85-ED77-4524-B35C-2DDC054C7684</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-08-20 11:30:25 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:body rdf:nodeID="N4c37bf8217334902b2f65314fcd39920"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-08-20 11:18:41 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BF9602B4-C193-49D9-B91D-95A5DB4FEC73">
    <dikbD2R:objectFormulation>transdermal</dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0E895E85-BDA3-4347-A8DE-4CFC5373CA38"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/76463211-BEC6-4BF7-80D8-E889485548E8"/>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectDuration>11</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5AE531FF-D6F3-4A08-A8A3-8B94B005D306">
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <pav:createdOn>2015-09-29 11:20:39 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:0110F720-3309-426B-8436-176B10AEBC36</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:BB1EF57C-D181-4564-8CAC-FCE81C31CCEF"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N58f1f52ff4ce4d998d644c9ea6c3f301"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D81E0F3F-E93F-4A23-9E72-F8450AA979D6">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:3962E670-2F06-46D6-A0E5-063E8F06D917"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:427D6518-2858-4799-A74C-646C32A98582">
    <ao:suffix>, etc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine. The clearance of benzodiazepines metabolized by glucuronidation (e.g., lorazepam, oxazepam, temazepam) is unlikely to be affected by fluvoxam</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>, </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:427D6518-2858-4799-A74C-646C32A98582"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-20 09:54:02 -0400</pav:createdOn>
    <ao:exact>triazolam</ao:exact>
    <domeo:uuid>427D6518-2858-4799-A74C-646C32A98582</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FAD581CA-962D-4430-9B87-BF3BEEDC8518">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
    <rdfs:label>clarithromycin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B7E725AA-4265-4E0B-959E-57A4D8586321">
    <rdfs:label>cisapride</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35255</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2CB05416-6F87-48E4-95B7-9FB7BE3D832E">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2CB05416-6F87-48E4-95B7-9FB7BE3D832E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <ao:exact>In healthy male patients (n=12), when cimetidine, a weak inhibitor of CYP1A2, CYP2D6, and CYP3A4, given at 800 mg b.i.d. at steady state was coadministered with mirtazapine (30 mg daily) at steady state, the Area Under the Curve (AUC) of mirtazapine increased more than 50%. Mirtazapine did not cause relevant changes in the pharmacokinetics of cimetidine. The mirtazapine dose may have to be decreased when concomitant treatment with cimetidine is started, or increased when cimetidine treatment is discontinued.</ao:exact>
    <pav:createdOn>2015-09-25 10:38:41 -0400</pav:createdOn>
    <ao:prefix>  Cimetidine  </ao:prefix>
    <domeo:uuid>2CB05416-6F87-48E4-95B7-9FB7BE3D832E</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E37C0FB8-8BF3-4E5D-9C4D-76A95F6FE4A2">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>EMSAM</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:09A51DE0-D723-43D1-89AB-43B028E5D01C">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-10-13 11:21:14 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-13 11:24:28 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:DD53EE65-079D-4C5D-8248-EE332FEE3EDA</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:25770759-4AAD-4B30-99B5-5DB4D34BA980"/>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="Nabe39f57d83c425b979bb56129ee537a"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:71FB4725-2639-4306-855D-E6079CA204F4">
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8FE246CE-5429-489B-A255-1BC9C23AA17E"/>
    <dikbD2R:cmax>24</dikbD2R:cmax>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:auc>50</dikbD2R:auc>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6C2CDE1C-3327-4F5A-9E88-D6B10FDAD89F"/>
    <dikbD2R:t12>26</dikbD2R:t12>
    <dikbD2R:preciptDuration>8</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>Percent</dikbD2R:t12Type>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Direction>Increase</dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration>2</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D9F21CF2-54DF-4227-99C2-9D21912431C2">
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2D6B6138-C5FF-4667-AF3D-AEF8EFB27C66"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/16368547-3DC1-476D-BEE4-4DCB59549293"/>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:cmax>50</dikbD2R:cmax>
    <dikbD2R:auc>90</dikbD2R:auc>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B1830459-C328-439D-A1E8-CCB65A945C9B">
    <rdfs:label>fluoxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3A25B883-250F-4B02-840F-4193D0A046CA">
    <dikbD2R:numOfParticipants>12</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9729AB6B-8C8D-4365-8A84-25CE10E6AD4C"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/51B5EF7C-E93D-4C1C-BC56-CB80905FE771"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3444A96C-4C33-4FE7-A291-3713BB14BA26">
    <ao:prefix>Concomitant treatment with </ao:prefix>
    <ao:exact>rabeprazole </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3444A96C-4C33-4FE7-A291-3713BB14BA26"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5d103551-978f-472a-9c62-51e6e4dea068.html</ao:hasSource>
    <ao:suffix>(20 mg daily) and ketoconazole in healthy subjects decreased the bioavailability of ketoconazole by 30% and increased the AUC and C</ao:suffix>
    <pav:createdOn>2015-08-26 16:11:31 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2E756266-05D5-4750-8533-ADA293D4922A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AA54A62B-E215-4EE0-9098-64C4976AD18F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>dosage should be considered. (See Viagra package insert .)  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AA54A62B-E215-4EE0-9098-64C4976AD18F"/>
    <pav:createdOn>2015-10-13 12:02:08 -0400</pav:createdOn>
    <ao:exact>There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, and bromocriptine.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>AA54A62B-E215-4EE0-9098-64C4976AD18F</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:73751559-D18E-4DA7-BFC2-99E35DB4EDF4">
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9FDA56C9-1247-4921-B59B-E5A47EC1011D"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C1CA1E00-6920-4F80-B42D-D1B0F64F3F45"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:auc>10</dikbD2R:auc>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:53F487DB-0EE0-421F-81CD-A66E1F9F18BC">
    <pav:lineageUri>urn:domeoserver:annotation:F3B8C686-6517-48A6-B672-E8CA53F6E6C8</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:0F1FE74C-5115-43D9-80BD-8EF1DFFE72EA"/>
    <pav:createdOn>2015-09-29 11:18:54 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CCE4C7E1-27C5-426C-9841-006979CF5915">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>methotrexate</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6851</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8231b1f294eb4f65bd1a8380d39d9fc4">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:57A59D65-4528-4D1E-957A-2E6348B38F4D">
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/42C2A2DD-0DF0-4E6C-B6EB-E9D5C3923DE2"/>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FFF83E1E-53AA-4146-9554-A201722DC7AB"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:17973D21-09C7-4844-9F05-10F6A9BBBF88">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdOn>2015-08-20 12:46:56 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:E7A45CEA-7937-491F-B3A3-4881D2AFA749"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N0e7d2ecdfdb740989cc612c342351af5"/>
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>urn:domeoserver:annotationset:BA4A4F06-DE8C-4B66-8918-920D0399D744</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5F179590-78B5-4217-A441-7F5608C0DA39">
    <rdfs:label>tacrolimus</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42316</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6E11779D-86CD-474D-B2C3-EE46C71E6B66">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:26D05FD2-9BAC-491C-95B4-B87DEFD0FF0D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:90833F3C-9567-46EC-B92C-320ACABC3374">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/35269557-A44C-490F-BBB2-239DF98060A2"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CCBD88D5-62C4-4179-AA6D-7DD3626FB431"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/822451DB-387F-4E83-99E3-9CD58089D772">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>AUBAGIO</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:92525BCC-1D61-4C74-B180-DB03E1413601">
    <domeo:belongsToSet>urn:domeoserver:annotationset:2ABE5FA2-BA00-4AF9-A2EA-1305FAECF3DF</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:A266CECD-08C0-4975-89B1-CBC11FC578B2</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-08-20 13:56:25 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:A9746444-48D7-4D24-AA87-51BAD09C5DC4"/>
    <ao:body rdf:nodeID="Ncd934dce7d34452b97c1a9852c232ee7"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:74E02DD6-AA1B-4C0B-A182-800A00272FFB">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:auc>100</dikbD2R:auc>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/178AEACD-1341-47E8-B148-E838EA4A19D2"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:numOfParticipants>22</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/ED5CDCDF-BB15-4F6F-9249-98BB2F3B1837"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1033C46E-C444-4DA3-A5E8-0C570A912181">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:comment>Clarithromycin administered 2-4 hours prior to zidovudine</dikbD2R:comment>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F321624C-362A-4F2B-ABC9-57424B1311F6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CC0EC292-D57C-4733-ABF5-90BEF67B1DA4">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:A23AA743-97C6-4DEB-8331-DD3025461806"/>
    <pav:createdOn>2015-09-03 15:39:19 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:a7f59b4d-3ada-4384-adb1-665a4a1743c8</pav:previousVersion>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N919d44e7323a46adaead59f8b626312b"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:235D11AE-12F2-493E-AA97-F800206B2FFC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:47BBF50A-23F6-445E-BDDC-661B7E310349"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:comment>iNCREASED CONCENTRATIONS</dikbD2R:comment>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E332D54E-7DD7-464B-B67C-B0A710888D13">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>hepatic enzyme inhibitors</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DA552785-0C49-4973-AE28-18F7D1CA2A44">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N1d328f4b8f0245f89fe440d3342b4261"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-16 15:22:57 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:618B8046-3259-449E-A54B-8223F0C8075B</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-09-16 15:31:12 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0468AC6B-4F06-4CA4-A0DE-A389E3B0E59F</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:C5DFAF2F-C905-4201-BE99-FBC74F059988"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BDA75F87-E8CD-4109-B8B9-9272AB22F777">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10635</dailymed:activeMoietyRxCUI>
    <rdfs:label>tolbutamide</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>1000</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4344B14E-62E7-44C1-BB25-CDC12DC66BA6">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>sertraline</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D7398750-DBB1-4277-90FE-0D3B61D9F453">
    <dikbD2R:dose>200</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>mirtazapine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:44C1B3E0-7D35-4769-9BA7-FF9B4301F514">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:11171A22-5D51-461B-A0CB-E73A2E8803E4"/>
    <pav:createdOn>2015-10-14 11:40:13 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E9EAE4A5-B8D4-445A-B9C0-EA6DEABCC480">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-01 10:46:05 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DC54EBE-B2A9-4AE7-A174-F0074ECE4050</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:E07E7166-DC2E-40CF-AF46-5D9373A5FAEA</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="Nc82756b7f2ac4e68aa897bd4216a6461"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8275AC8D-C197-4A2D-B764-130348A5DAFA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D52477D5-F344-4C63-A8C0-B5AB1F5D9A43">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:629E760A-97E8-4496-953A-35F7C6732923"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/617C896F-632E-4E58-8961-67CE84FBB43F">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Rifampin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C0D15D7C-8D72-4FB1-BB34-3C5B3BAC9CB3">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:2273416E-BC9E-4063-B76B-3F3E360EB8AA</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="Nd6f77fd6d9b64259ba10eb25d0257a46"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <pav:createdOn>2015-09-29 11:27:24 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:9A801BEF-346A-4CBF-8E25-8311B9F80BB4"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FE948543-6157-435A-AB3F-21C650D1AF18">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EE774587-230D-4340-8F4D-CD0A0BAA721F">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N9d0124b64339431191a4e7c00e251fb5"/>
    <pav:createdOn>2015-09-03 15:48:58 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <pav:lastSavedOn>2015-10-16 10:35:58 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:2A474977-3F89-40AA-A0C2-387F621CD093"/>
    <pav:previousVersion>urn:domeoserver:annotationset:0C9EA96C-0867-4B4B-A1A5-99A165881EF0</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:556C3C36-929F-4F59-8BB9-033A8897C16D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-13 11:56:52 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:19699AED-4CE3-4185-BFE9-311A3FD87753"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:46B234F0-D68D-4DB4-ABE7-1BFB208B25F2</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdOn>2015-10-13 11:54:56 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CEA7AC21-8597-4116-B24F-06BC1435B56E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>CEA7AC21-8597-4116-B24F-06BC1435B56E</domeo:uuid>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <pav:createdOn>2015-09-29 11:26:20 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CEA7AC21-8597-4116-B24F-06BC1435B56E"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:63EC5040-6FCF-4FDD-B425-5AD274DE6B27">
    <ao:suffix>, antifungals (e.g., fluconazole, itraconazole, ketoconazole), barbiturates, beta-blockers, calcium channel blockers (e.g., diltiazem, nifedipine, verapamil), chloramphenicol, clarithromycin, corticosteroids, cyclosporine, cardiac glycoside preparations,</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>63EC5040-6FCF-4FDD-B425-5AD274DE6B27</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:prefix>), oral </ao:prefix>
    <ao:exact>anticoagulants</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:40:17 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:63EC5040-6FCF-4FDD-B425-5AD274DE6B27"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E7C7BC74-CBB9-4D9C-A253-7ACB76FC97C1">
    <pav:createdOn>2015-10-16 10:38:29 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E7C7BC74-CBB9-4D9C-A253-7ACB76FC97C1"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <domeo:uuid>E7C7BC74-CBB9-4D9C-A253-7ACB76FC97C1</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Ketoconazole    Seven-day treatment with ketoconazole (200 mg per day), a potent inhibitor of CYP3A4, did not affect the steady-state pharmacokinetics of selegiline in subjects who received EMSAM 6 mg per 24 hours for 7 days and no differences in the pharmacokinetics of ketoconazole were observed [see Drug Interactions (7.4) and (7.5)]. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:51966DC5-A020-44D6-BA4E-BE64F3B5564A">
    <dikbD2R:objectFormulation>transdermal</dikbD2R:objectFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2E025747-9707-4E97-A29B-084BD9CAE3DA"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/86B6A6EC-5C8A-4914-A6A1-1E67236D7A2F"/>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectDuration>7</dikbD2R:objectDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C503AA81-1484-4CA2-957C-6CEAAC917A62">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In a clinical study to determine the effects of abiraterone acetate 1,000 mg daily (plus prednisone 5 mg twice daily) on a single 100 mg dose of the CYP1A2 substrate theophylline, no increase in systemic exposure of theophylline was observed.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C503AA81-1484-4CA2-957C-6CEAAC917A62"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-08-20 11:18:41 -0400</pav:createdOn>
    <ao:prefix>[see Drug Interactions (7.2) ] .  </ao:prefix>
    <domeo:uuid>C503AA81-1484-4CA2-957C-6CEAAC917A62</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FDF0015E-54F5-4BAC-A5B5-4239D0E27D0B">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdOn>2015-10-14 11:40:00 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:042A1769-B51E-4433-9B39-4695B177BC75"/>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D0914AB8-595D-4D40-89C9-70508FAEB8EE">
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12Direction>Decrease</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/792786F1-ABE7-4828-81A6-67D1BE2BFC10"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A372E97B-CAD5-41E9-ABBF-9255EB529163"/>
    <dikbD2R:t12Type>Percent</dikbD2R:t12Type>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12>38</dikbD2R:t12>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>14</dikbD2R:preciptDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:auc>25</dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/1BD4841A-9C5B-434D-881F-74944DC3E8AA">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <rdfs:label>warfarin</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EECADA2C-8278-48A0-8F4E-925B892A34EC">
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-14 11:41:33 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:07027AE0-2E44-48AB-82C9-2526F46688AF"/>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B979097E-7BE0-4BBF-8151-F28FB534A2D2">
    <pav:createdOn>2015-10-14 11:40:47 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:4E97D24D-7496-42BD-899B-AA45DC8B7CC9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C1556E7D-4545-45DC-96D4-2458BD08DA75">
    <pav:lastSavedOn>2015-10-20 10:37:41 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:CA805CF0-C494-49D4-B27F-D41ED2CC0827</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:BDE241D3-5592-4D56-9C19-0F16DA68A616"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-20 10:23:28 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:694C8CCE-50B6-4BBE-8E15-E6D2CFF02130">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-14 11:41:51 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:FAAC673D-A43E-4C5A-A12D-BD498046D59B"/>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A6CE7C94-8EC0-416D-9108-4FB58C2FD287">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>levothyroxine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F36BD825-3F71-43D7-926C-C60EDD1D12A3">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>carbamazepine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8A1F4F2B-48FC-473D-BFAA-23C03BE4EEBF">
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:17CFEF69-CCC6-4ACD-8A24-0425991EC98C</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdOn>2015-09-14 11:20:15 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:fc9e17d3-1b0d-4635-9936-0d1d94cb01f9</pav:lineageUri>
    <ao:body rdf:nodeID="N5de6e28ed60044ea90e5d284543ec39c"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8387503E-E4C2-4442-8F5A-ACAC8F2ECB58"/>
    <pav:lastSavedOn>2015-09-14 11:21:10 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CE635F27-A391-4A6B-9D87-339FA2F114B2</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N862d50c2c63a4589a7b52e0b7219076a">
    <domeo:sets rdf:resource="urn:pddi:uuid:0C1A8FF1-1DFF-4A4B-9B20-10F8039A048B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CC0D693F-5965-4DC7-80CD-62DED563C67B">
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DC54EBE-B2A9-4AE7-A174-F0074ECE4050</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:7F5CD015-B229-4833-9E8D-3F33212A7B38"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:08742565-514E-44C0-AA3E-E544A1EAB6EF</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-01 10:43:34 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F6B22400-8582-4873-A0AA-10081BF04B0B">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:F59901AC-BA9C-446F-9A7B-494AC69AA5A7</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-10-09 13:32:08 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N601648739b6647c6bf6520af5e2ef5fe"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:2B81FF77-DF41-49F5-8813-60332DD7F517"/>
    <pav:createdOn>2015-09-16 15:28:56 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0468AC6B-4F06-4CA4-A0DE-A389E3B0E59F</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/515AAF42-C90B-48EF-A376-C25676634272">
    <rdfs:label>phenytoin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/AF4060AA-43C3-4256-83D7-54425C648AF7">
    <rdfs:label>cimetidine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F770A719-12D3-4A36-A8EA-82CFEB6E0821">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1547528A-FC8E-41C2-8483-FC1F707DB8A0"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:14034C0F-5105-40D6-850A-54DA9D8C5316">
    <ao:prefix>7.8 Drugs Metabolized by CYP1A2   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:14034C0F-5105-40D6-850A-54DA9D8C5316"/>
    <domeo:uuid>14034C0F-5105-40D6-850A-54DA9D8C5316</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:hasSource>
    <ao:exact>In vitro drug interaction studies demonstrate that duloxetine does not induce CYP1A2 activity. Therefore, an increase in the metabolism of CYP1A2 substrates (e.g., theophylline, caffeine) resulting from induction is not anticipated, although clinical studies of induction have not been performed. Duloxetine is an inhibitor of the CYP1A2 isoform in in vitro studies, and in two clinical studies the average (90% confidence interval) increase in theophylline AUC was 7% (1% to 15%) and 20% (13% to 27%) when co-administered with duloxetine (60 mg twice daily). </ao:exact>
    <pav:createdOn>2015-09-24 15:53:10 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6CF28FF1-AF53-4495-8FE3-1E29D72C8CEC">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:FA5D4EAE-FA42-40DC-A502-43D9E8F28CDB"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E668CBCE-0E0D-4E1A-AF3B-8103D4E0070E">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>sertraline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:684CDA98-DF01-4945-8AC6-E4E6E9406E57">
    <domeo:uuid>684CDA98-DF01-4945-8AC6-E4E6E9406E57</domeo:uuid>
    <ao:suffix>), digitoxin, antiarrhythmics (e.g., disopyramide, mexiletine, quinidine, tocainide), oral anticoagulants, antifungals (e.g., fluconazole, itraconazole, ketoconazole), barbiturates, beta-blockers, calcium channel blockers (e.g., diltiazem, nifedipine, ve</ao:suffix>
    <ao:prefix> (e.g., </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>phenytoin</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:40:11 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:684CDA98-DF01-4945-8AC6-E4E6E9406E57"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4600E031-72B1-49EA-932D-DF707DFFDA02">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B419800B-96F2-44DE-BEEE-403CE4A82E0D"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E2D98F3E-AF53-4C93-896B-04F390D2B2AB"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6BC11E2A-50E1-4200-BFC5-0613C6D28799">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2E0AD717-67BC-4D7C-AF83-5F1037F99712</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:1C1779F6-3F0B-47ED-B78F-57B4B1A1479E"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-08-20 11:05:44 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>urn:domeoclient:uuid:be10a7b6-9093-4dc5-bd8e-7c1619eb41b9</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:64737b65-8582-4b76-8095-85ad69e2cc47</pav:lineageUri>
    <ao:body rdf:nodeID="N4d9cdbcb6e4e4040a93e0e0fb0167eba"/>
    <pav:lastSavedOn>2015-08-20 11:10:08 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4E0A4FA1-3920-4807-8A68-18A28F4C6438">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4E0A4FA1-3920-4807-8A68-18A28F4C6438"/>
    <domeo:uuid>4E0A4FA1-3920-4807-8A68-18A28F4C6438</domeo:uuid>
    <ao:suffix>.</ao:suffix>
    <ao:exact>Sildenafil (Viagra) :Erythromycin has been reported to increase the systemic exposure (AUC) of sildenafil. A similar interaction may occur with clarithromycin; reduction of sildenafil dosage should be considered. (See Viagra package insert</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-13 12:01:49 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9B16807D-97E9-4B29-81DB-7EE66CEB3FF0">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:284DF760-78C0-4FFE-9481-A7F7A382D926</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:3CF51461-26FF-4F12-A356-422C9C7A5D17"/>
    <pav:lastSavedOn>2015-09-03 16:19:40 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-03 15:57:04 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A964F2E8-199E-48E3-8014-B72819250DE9">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35255</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>cisapride</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2122DCBB-B3C5-4E30-A80B-86AB95C590B3">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <pav:createdOn>2015-09-03 15:40:17 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:88D5A9D8-13C2-4F7C-889C-FE89812C70E5"/>
    <pav:previousVersion>urn:domeoclient:uuid:a7f59b4d-3ada-4384-adb1-665a4a1743c8</pav:previousVersion>
    <ao:body rdf:nodeID="N368db959383c4b2599a5976bdceebab9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1E4E7955-794B-4F58-8836-AA2107BBA675">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:C9895165-E2F7-4FE6-9EDC-FE57A930607C"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/c13b7a77-fc02-4fd8-af6c-68bc656ceab5">
    <pav:createdOn>2015-09-29 16:04:14 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lastSavedOn>2015-09-29 16:04:14 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:78f86ce8-5c0a-4d81-990b-ae1d0753efb2</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:545F2613-2A5E-4333-A651-CBA80268D6ED</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:842c5219-8463-4672-b3ec-075b1aeb2a66"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D13612BD-2F3A-40E4-A107-904240C9AE7C">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E41B5E31-A92A-4182-B110-AE781516CE91"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C7B21BF1-EEB5-49C7-B962-B5FE1B3E6DA3"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:018588CA-C4A7-46FA-84C9-CF146F7504B3">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:EDFF465E-39B4-45A8-9299-D64EC7FD33A0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:39094284-467B-4880-8053-BC4887FD4C6D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:BE71BBF5-9A2D-4EBE-83B0-1E019FA0E0F8</domeo:belongsToSet>
    <pav:lastSavedOn>2015-09-25 10:47:09 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N61238ce31e1d45f888a53839a744161f"/>
    <pav:lineageUri>urn:domeoserver:annotation:9C4E809E-81E1-4BA7-A9C0-05FC59E9D94F</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:2CB05416-6F87-48E4-95B7-9FB7BE3D832E"/>
    <pav:createdOn>2015-09-25 10:38:41 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4D4628C4-27FB-4DDC-B242-E679B66BF887">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-09-29 09:23:52 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:089691B4-E6E8-4B18-A4BF-87D0EADF4EC1</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:62527B5F-7EB9-4A81-9165-73E4FCE2C6F9"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0185AD47-6E7B-4C92-8A3D-A2876CC95002</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2A650F26-E819-46B8-9C4C-7A57863D6C6B">
    <ao:exact>alprazolam </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix>) of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>were approximately twice those observed when alprazolam was administered alone; oral clearance was reduced by about 50%. The elevated plasma alprazolam concentrations resulted in decreased psychomotor performance and memory. This interaction, which has n</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2A650F26-E819-46B8-9C4C-7A57863D6C6B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>2A650F26-E819-46B8-9C4C-7A57863D6C6B</domeo:uuid>
    <pav:createdOn>2015-10-20 09:56:54 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:01EDBAAB-9298-4A59-9A65-0993A50EB1B1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Clinical Pharmacology (12.3) ] .  </ao:prefix>
    <pav:createdOn>2015-09-03 15:42:35 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:01EDBAAB-9298-4A59-9A65-0993A50EB1B1"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/83048926-B546-431F-AE06-982C70406513">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>tamoxifen</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>100</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A4589B70-A162-4462-93A8-A4C5E8552C5E">
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:auc>43</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/875D389D-01B4-4906-88FD-800BA42F7ADD"/>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4886337B-6379-4434-86D1-B467989AB11F"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>8</dikbD2R:cmax>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/AFD0292B-88FF-4D55-937B-B96FBDE3422F">
    <rdfs:label>fluvoxamine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:78443FF3-867A-42A8-9EC4-C2F4C6DD3374">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8616297F-98CA-45F7-B476-9680C4EAA05E"/>
    <dikbD2R:cmax>2.5</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6BE71A2E-E0C7-4AF9-8150-B4C4E55BAA64"/>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12Direction>Increase</dikbD2R:t12Direction>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>Fold</dikbD2R:t12Type>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:auc>6</dikbD2R:auc>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:t12>3</dikbD2R:t12>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>14</dikbD2R:numOfParticipants>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:198D1084-D78B-46D0-BC19-BB2AA690A15F">
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:4C053C89-DFE5-44A8-9EAE-800F5ED72B57</pav:lineageUri>
    <ao:body rdf:nodeID="Ndeb4cd3081b44130b14fc60a433b50b4"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:CEA7AC21-8597-4116-B24F-06BC1435B56E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-09-29 11:26:20 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F4F7005B-B14B-4AE3-97BC-106FAA25D6CA">
    <ao:prefix>    Tacrine   </ao:prefix>
    <pav:createdOn>2015-10-16 10:56:26 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F4F7005B-B14B-4AE3-97BC-106FAA25D6CA"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In a study of 13 healthy, male volunteers, a single 40 mg dose of tacrine added to fluvoxamine 100 mg/day administered at steady-state was associated with 5- and 8-fold increases in tacrine Cmax and AUC, respectively, compared to the administration of tacrine alone. Five subjects experienced nausea, vomiting, sweating, and diarrhea following coadministration, consistent with the cholinergic effects of tacrine. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/69349014-805B-4A65-8A67-2CA6C7BD2BBA">
    <rdfs:label>carbamazepine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>400</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3028A14C-3DC4-4F10-9879-34B89C52406C">
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-20 10:18:41 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:4B2E61CE-7D88-4E5A-A24F-DDB39B423856"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-20 10:19:28 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:6B50E664-BD71-432E-B7FA-E7313EFF76E1</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8BA7FE71-AB20-4F46-A4FC-8B7C9690E175">
    <ao:exact>Because of the pharmacologic similarity of maprotiline hydrochloride to the tricyclic antidepressants, the plasma concentration of maprotiline may be increased when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), as has occurred with tricyclic antidepressants. Adjustment of the dosage of maprotiline hydrochloride may therefore be necessary in such cases.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>8BA7FE71-AB20-4F46-A4FC-8B7C9690E175</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8BA7FE71-AB20-4F46-A4FC-8B7C9690E175"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>is rapidly tapered in patients receiving maprotiline .  </ao:prefix>
    <pav:createdOn>2015-09-30 12:41:17 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B5741E42-9B1C-4C13-B769-E37A56B1019D">
    <ao:exact>Carbamazepine    Carbamazepine is an enzyme inducer and typically causes decreases in drug exposure; however, approximately 2-fold increased systemic exposure of selegiline and its metabolites, L-amphetamine and L-methamphetamine were seen after single application of EMSAM 6 mg per 24 hours in subjects who had received carbamazepine (400 mg per day) for 14 days. Changes in plasma selegiline concentrations were nearly 2-fold and variable across the subject population. Such increases may increase the risk of a hypertensive crisis when carbamazepine is used with EMSAM at any dose [see Contraindications (4), Warnings and Precautions (5.3) and Drug Interaction (7.4)].</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-16 10:36:29 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>   </ao:prefix>
    <domeo:uuid>B5741E42-9B1C-4C13-B769-E37A56B1019D</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B5741E42-9B1C-4C13-B769-E37A56B1019D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BE0D460D-5292-4CD4-82A3-E2116AA49A01">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-01 10:27:16 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:33B17719-DF97-48EA-AFA2-01DE8A8887B4</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:032F7210-DAD4-47BF-9655-9B205218004D"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:1A32255C-91C2-4727-92D3-F15F6C4D3438</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1B360D7B-CD91-4FAF-9476-97FA252DEF85">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-14 11:42:01 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:48E0ECCB-C1F9-4F23-81EA-DCEC3A8AFC9A"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:22F5BE19-3AE3-412C-B0C3-2FE0F519DBCF">
    <ao:context rdf:resource="urn:domeoclient:uuid:295F7AE6-29BA-480B-9EEE-43F4D55E2698"/>
    <pav:previousVersion>urn:domeoserver:annotationset:58BD31E4-F1E7-44DA-87A9-5298EBD36BEA</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-10-13 11:52:15 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-13 11:52:38 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:body rdf:nodeID="N6652f01ba6d046168ba936467087ff17"/>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B0391606-0172-43C1-A1C6-0F166427C843">
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:EAAB95EB-FAF6-4447-BC17-C540B6BDF6A7"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-14 11:41:08 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B91E84F5-BBA4-4AFE-8493-137EC930BE43">
    <pav:createdOn>2015-10-13 12:03:48 -0400</pav:createdOn>
    <ao:exact>There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, and bromocriptine.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <domeo:uuid>B91E84F5-BBA4-4AFE-8493-137EC930BE43</domeo:uuid>
    <ao:prefix>dosage should be considered. (See Viagra package insert .)  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B91E84F5-BBA4-4AFE-8493-137EC930BE43"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CF4E0D8B-79B9-41DB-990C-A041462A7C73">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:A63A8ABF-EA0F-4F82-8C1B-61C0AD358CA9</pav:lineageUri>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="Nc6d350d9011a4849b7d3b175508f1174"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:545F2613-2A5E-4333-A651-CBA80268D6ED</domeo:belongsToSet>
    <pav:createdOn>2015-09-30 10:41:45 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:C306E6D1-CDCA-463F-8574-026E2775C5BA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2BC44E2F-CADA-40E8-BC54-D80528AE0ECA">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2AE52676-E820-413E-AE96-95C645C094B0"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E9149F61-2B07-4356-AAC2-DA0131D2F8B7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:58B9528F-88CB-4330-923E-CCA651B8BD8B">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:98C3B339-EE74-4B6A-A71F-AF2F032CDA0D"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:961DD3B0-9056-4A8E-BA5F-F77A157F7F8F">
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:3D644552-4A06-4136-BA23-8792DC6A153B"/>
    <pav:createdOn>2015-10-20 10:09:23 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/97488CE8-6E35-4D8E-BC8A-AB87E9091B32">
    <rdfs:label>Clarithromycin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>500</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5DA58AA0-7094-43E3-A435-F477D5E05DF4">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CCE4C7E1-27C5-426C-9841-006979CF5915"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/844AD8B0-49CB-4D7B-ACB8-BE504915481B"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B163C0BF-9476-44C8-8119-F9FE4A9488A1">
    <pav:createdOn>2015-10-20 10:09:17 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:2E922CD3-E230-4081-A7F5-E65408CC2E66"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EF1538E4-548C-472D-AE45-ED339B3F42E4">
    <ao:exact>There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, and bromocriptine.</ao:exact>
    <domeo:uuid>EF1538E4-548C-472D-AE45-ED339B3F42E4</domeo:uuid>
    <ao:prefix>dosage should be considered. (See Viagra package insert .)  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EF1538E4-548C-472D-AE45-ED339B3F42E4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-13 12:03:59 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23C4B3E3-1FBE-4693-B0F4-59041161A2DF">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N3f41a57d6e174bd2a34f28b2a721afee"/>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:CD065D6E-4669-4434-B279-2F43F2DEBF09"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:F0670018-EE62-4273-9F7E-1D7A98D94858</pav:lineageUri>
    <pav:createdOn>2015-08-20 13:05:32 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:985767C6-2BB2-44CE-8DE9-89EAD47F6E74">
    <ao:context rdf:resource="urn:domeoclient:uuid:37F97FAF-61B1-48CB-84C5-589051D74CB9"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CE635F27-A391-4A6B-9D87-339FA2F114B2</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="Nddd3438da44e490dab7521b1d2a116ae"/>
    <pav:lineageUri>urn:domeoserver:annotationset:fc9e17d3-1b0d-4635-9936-0d1d94cb01f9</pav:lineageUri>
    <pav:lastSavedOn>2015-09-14 11:31:14 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:CEA4E0A9-4D52-4D06-B7F7-888CAB312880</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-09-14 11:31:11 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F0F48489-70C7-46E0-826B-5B9889312076">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>-</ao:prefix>
    <ao:exact>TCA</ao:exact>
    <pav:createdOn>2015-09-29 08:59:05 -0400</pav:createdOn>
    <ao:suffix> interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F0F48489-70C7-46E0-826B-5B9889312076"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>F0F48489-70C7-46E0-826B-5B9889312076</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0ED52EB7-0AFB-485E-A40E-336F14A14C16">
    <dikbD2R:dose>0.2</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3407</dailymed:activeMoietyRxCUI>
    <rdfs:label>digoxin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/688C3B24-3BA8-4AD9-BF02-CB0426E37FDE">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F321624C-362A-4F2B-ABC9-57424B1311F6">
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/70679951-CE00-4147-844B-B51229C326C6"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:numOfParticipants>24</dikbD2R:numOfParticipants>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cmax>2</dikbD2R:cmax>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:auc>No change</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/111B7914-2953-406F-8FAB-9BBE7433B477"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DDEE74D5-2F0E-453E-9FEB-EC6BE327A439">
    <domeo:uuid>DDEE74D5-2F0E-453E-9FEB-EC6BE327A439</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7-10% of Caucasians are so-called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <pav:createdOn>2015-10-01 10:28:44 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DDEE74D5-2F0E-453E-9FEB-EC6BE327A439"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F9FC75CB-1715-4671-A6A7-A61B56C05A2F">
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:9A31B87A-97EE-4287-9624-F33FCC8141F8"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:createdOn>2015-10-13 12:03:19 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:B51F4BB3-6BDB-45E7-9399-D93DBC4324AC</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-13 12:04:13 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FC81AEC7-EA2B-41F4-BF9B-F01EA42A0D31">
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <ao:body rdf:nodeID="N7599b32acbe1412db6b05a2d7b0bceb0"/>
    <pav:createdOn>2015-10-13 12:02:20 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:552468C6-25B6-4E7F-902D-75255E113D2C"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:B51F4BB3-6BDB-45E7-9399-D93DBC4324AC</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <pav:lastSavedOn>2015-10-13 12:04:13 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8BE1D504-E827-4C18-9964-E3C350BE0A35">
    <ao:exact>Phenylpropanolamine (PPA)    In subjects who had received EMSAM 6 mg per 24 hours for 9 days, co-administration with PPA (25 mg every 4 hours for 24 hours) did not affect the pharmacokinetics of PPA. There was a higher incidence of significant blood pressure elevations with the co-administration of EMSAM and PPA than with PPA alone, suggesting a possible pharmacodynamic interaction [see Drug Interactions (7.4) and (7.5)]. </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-16 10:41:21 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8BE1D504-E827-4C18-9964-E3C350BE0A35"/>
    <domeo:uuid>8BE1D504-E827-4C18-9964-E3C350BE0A35</domeo:uuid>
    <ao:prefix>   </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4269EA24-F80D-475E-9FA8-528F69AD0C63">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:0CA852B0-92E0-48CE-9BDD-232A3BE07FEA"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:FB352093-C695-480E-A176-EB564224C0F2</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-03 16:19:40 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-03 15:57:09 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D25D94B9-2153-47D8-8167-6B4518DB2D98">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:comment>45% plasma concentration increase of mirtazapine</dikbD2R:comment>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:C6F343A8-8EEF-4A92-BF04-F00ED54677CA"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DD09F72C-583B-43BC-A5F5-8F304BD8029A">
    <rdfs:label>cefaclor</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:883D470F-9DE7-4A54-A86F-A2C99D48E398">
    <ao:prefix> capsules is as bioavailable as </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:883D470F-9DE7-4A54-A86F-A2C99D48E398"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <ao:suffix> from a solution. The bioavailability of CMI from capsules is not significantly affected by food.</ao:suffix>
    <pav:createdOn>2015-09-29 09:44:16 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:exact>CMI</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:134D7CB1-E742-45FA-8436-98DA3480170A">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdOn>2015-10-14 11:41:41 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:D4999237-8ABE-40BC-84FD-C56A1401D2D2"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7ECC86B5-29FE-4D9A-B4F6-EDEED30CB6CD">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:DE3050F0-7AD5-4635-AC25-63D207EA01CF</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:33B17719-DF97-48EA-AFA2-01DE8A8887B4</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-10-01 10:27:38 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:B78C3A5A-41DD-451B-A01B-895907B431C6"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:89A7DB66-A53E-4F13-9504-6A1D5CDEC34C">
    <ao:suffix>, there is a strong likelihood of substantial accumulation of both species during chronic coadministration. </ao:suffix>
    <ao:exact>N-desmethyldiazepam</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-20 10:09:01 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>and its active metabolite, </ao:prefix>
    <domeo:uuid>89A7DB66-A53E-4F13-9504-6A1D5CDEC34C</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:89A7DB66-A53E-4F13-9504-6A1D5CDEC34C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5C7A8838-1DAA-4F75-8607-B4E403B17B6C">
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/450B8BE6-DF2D-4179-BEDA-7E0B3280E265"/>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/83048926-B546-431F-AE06-982C70406513"/>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/799316E2-E219-49C9-A05A-7D2C6BA38439">
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:55BC195A-DF24-4614-8873-D7778D3CED9D">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/572370D5-AA12-4E2A-81AD-80A6CB30FB7B"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/551EF4B8-5BA1-4D23-8521-6E6CDCCC6BB2"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C20986B0-BF8C-414E-B090-01961FA50DD5">
    <pav:createdOn>2015-08-20 12:59:16 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>There was an increase in mean repaglinide Cmax and AUC (1.7- and 2.4-fold, respectively), following repeated doses of teriflunomide and a single dose of 0.25 mg repaglinide, suggesting that teriflunomide is an inhibitor of CYP2C8 in vivo. The magnitude of interaction could be higher at the recommended repaglinide dose [see Drug Interactions (7)].</ao:exact>
    <ao:prefix>on Other Drugs    CYP2C8 Substrates  </ao:prefix>
    <domeo:uuid>C20986B0-BF8C-414E-B090-01961FA50DD5</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C20986B0-BF8C-414E-B090-01961FA50DD5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5C2ECBB1-69F9-4B8E-A781-D536164C2025">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:34A2128C-DB02-437A-A05C-C462C499966B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9186EEB3-84FE-4472-A0E2-4B242C8E5310">
    <ao:suffix>and enalapril has resulted in decreased concentrations of enalaprilat, the active metabolite of enalapril. Dosage adjustments should be made if indicated by the patients clinical condition.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>rifampin </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9186EEB3-84FE-4472-A0E2-4B242C8E5310"/>
    <domeo:uuid>9186EEB3-84FE-4472-A0E2-4B242C8E5310</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:41:31 -0400</pav:createdOn>
    <ao:prefix>has resulted in decreased serum concentrations of both drugs. Concurrent use of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EA8E0240-7430-47F3-9565-DD53B447D323">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Lorazepam-There was no pharmacokinetic interaction between a single dose of Savella (50 mg) and lorazepam (1.5 mg). </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <ao:prefix>(100 mg/day) did not affect the pharmacokinetics of lithium .  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-30 10:45:17 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EA8E0240-7430-47F3-9565-DD53B447D323"/>
    <domeo:uuid>EA8E0240-7430-47F3-9565-DD53B447D323</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/992912C3-66C4-49E4-8BC2-1BA9C5F397BE">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/57258</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>tizanidine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:658E7905-3AD1-4F91-9C83-D42021CD0345">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:CA427337-D6E2-475C-A2E7-D66C49285894"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:7084298F-F868-484E-9091-B9ED9E4588DB</pav:previousVersion>
    <pav:createdOn>2015-08-20 11:40:32 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N15640616b619410ca23962fdbffc136f"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-08-20 11:43:54 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A42CEB18-FBDB-4BA4-BF6F-D8F2A839D949">
    <rdfs:label>Carbamazepine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8CE909D8-6F7F-4F40-8D3F-7A494D18C465">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>propafenone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8754</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DB6FC72E-5A20-4A39-9705-9B75B8683BA2">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8331</dailymed:activeMoietyRxCUI>
    <rdfs:label>pimozide</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>2</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:61101688-558B-47B6-AC53-B090085A57C3">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5798A46F-1E12-45C8-942C-2DB0C00480D8"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FA5D4EAE-FA42-40DC-A502-43D9E8F28CDB">
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/349151D0-9CA1-4F4F-8A0A-2B09C91D8963"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cmax>25</dikbD2R:cmax>
    <dikbD2R:auc>17</dikbD2R:auc>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FB3767C5-D6B4-44DF-BBC5-B1CBB19D8547"/>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BE494201-423E-4C4F-A4B0-44644A531896">
    <ao:context rdf:resource="urn:domeoclient:uuid:38F59318-D228-4A94-844A-705774A95918"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:lastSavedOn>2015-10-16 10:55:51 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-16 10:54:08 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N9e43cbb4b1b542749f8f9bed8737edb6"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:0DAF5666-9E53-42D5-B92E-DE2C00764986</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:52CD5AF8-2C2A-4A5A-B02F-0C46D5CE209E">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="Nad58055d7eb94b548da34f1403f13155"/>
    <pav:createdOn>2015-09-29 09:48:15 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:6721D402-6401-4579-92B5-34FA9E72D18B"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:DC7B5751-9DCB-412A-A922-7640BC986FD0</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D1A189B6-4854-4795-870C-B1CE5202D07B">
    <domeo:belongsToSet>urn:domeoserver:annotationset:BE71BBF5-9A2D-4EBE-83B0-1E019FA0E0F8</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:F540D170-24B1-495F-A6E4-EAF8E8AEB6DF"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:74CF51E1-AE4E-4F06-98C4-DEDCB93A623B</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N723fc22ee7b74f9db8412ca3e2d62253"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-09-25 10:47:09 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-25 10:36:44 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D964DDC3-EBB1-45B3-B394-996F56299C7A">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>alprazolam</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:82843431-618B-411A-B745-998E072E8D0F">
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:createdOn>2015-10-20 10:18:16 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-20 10:19:28 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:6B50E664-BD71-432E-B7FA-E7313EFF76E1</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:D55B06C1-5FA9-4183-B0CD-31ECA40F2DE1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:11BF79FC-D4CB-4AA3-A2A5-72A80A25EE56">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7A335060-E227-435C-9FBA-3EEE27499713"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:19AF4B30-4FD9-4C57-9F4D-E97A279AA2CC">
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7D134291-6C7F-46A1-B3CF-3FE92B9EDBCF"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B776F2E5-8021-405F-9B3A-5060D1412128"/>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:objectRegimens>Q12</dikbD2R:objectRegimens>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:auc>6-8</dikbD2R:auc>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmax>3-4</dikbD2R:cmax>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:34EC7320-1B97-46E2-9EA5-319DBD84D27C">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:911A21E8-D947-4D2F-B2C0-7F3B54676A6B"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:600E82E4-DF31-43E8-9BFD-4F6F1242193A">
    <ao:prefix>dosage should be considered. (See Viagra package insert .)  </ao:prefix>
    <ao:exact>There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, and bromocriptine.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:600E82E4-DF31-43E8-9BFD-4F6F1242193A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>600E82E4-DF31-43E8-9BFD-4F6F1242193A</domeo:uuid>
    <pav:createdOn>2015-10-13 12:02:34 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6C5659B2-D52F-4275-8E7B-1BA5BE5FBDE9">
    <ao:prefix>better and had significantly lower steady-state plasma concentrations, compared with subjects over 65 years of age. Children under 15 years of age had significantly lower plasma concentration/dose ratios, compared with adults. Plasma concentrations of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>CMI </ao:exact>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-09-29 09:44:28 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <ao:suffix>were significantly lower in smokers than in nonsmokers.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6C5659B2-D52F-4275-8E7B-1BA5BE5FBDE9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:282346E4-30F0-47C2-98DE-CDAC179DA92A">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:createdOn>2015-09-10 14:50:56 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N0f3a7bb0e3a449728be1b9e6f11ed2b8"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:7780B7F5-6DFC-4C9C-BE10-CC8722E2EB7D"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:FEB7E4F7-5C4F-4762-ACB0-CEC20A48E2B7</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-09-10 15:01:13 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/418F8785-D20D-4023-B357-056AF0EA7F7D">
    <rdfs:label>clarithromycin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8A192ED2-65DB-4545-B76C-04A5EB59DAFD">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>s) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA ).  </ao:prefix>
    <pav:createdOn>2015-09-29 09:01:01 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>8A192ED2-65DB-4545-B76C-04A5EB59DAFD</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8A192ED2-65DB-4545-B76C-04A5EB59DAFD"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:59A8EA1A-1C4A-4895-A91B-B43DCABB6E99">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-09-29 09:46:31 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:581E69E6-17FA-4613-9890-66BD673B94DF</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:57B389D3-D73D-4A28-8728-A45DCC6DD30C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EB3C8A27-42F6-4C05-A445-7D2E722619CF">
    <domeo:uuid>EB3C8A27-42F6-4C05-A445-7D2E722619CF</domeo:uuid>
    <ao:exact>Erythromycin and clarithromycin are substrates and inhibitors of the 3A isoform subfamily of the cytochrome P450 enzyme system (CYP3A). Coadministration of erythromycin or clarithromycin and a drug primarily metabolized by CYP3A may be associated with elevations in drug concentrations that could increase or prolong both the therapeutic and adverse effects of the concomitant drug. Dosage adjustment may be considered, and when possible, serum concentrations of drugs primarily metabolized by CYP3A should be monitored closely in patients concurrently receiving clarithromycin or erythromycin.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-13 11:59:05 -0400</pav:createdOn>
    <ao:prefix>colchicine toxicity. (See WARNINGS .)  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EB3C8A27-42F6-4C05-A445-7D2E722619CF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F190A76C-B483-4803-A6B0-0273FFAE8DB0">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:954C7A68-D34D-4AD1-8DC8-59131ABB7382"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3EB83181-3FB7-4176-BECD-DE59315E46E1">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:364D874B-C00E-4366-B96D-C86896D2A0DD"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6A3F34CE-0ADD-4185-9FD0-AD22A9BC0E52">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <rdfs:label>fluoxetine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F0E70F31-8D78-4692-9F3C-9FB1477F226C">
    <dikbD2R:t12>3</dikbD2R:t12>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:t12Type>Fold</dikbD2R:t12Type>
    <dikbD2R:preciptDuration>4</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>Increase</dikbD2R:t12Direction>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:auc>33</dikbD2R:auc>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9B7671EC-793B-41C5-8394-50352EFBEDE4"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0D2D70AA-0957-49C9-BE8C-67351D16661C"/>
    <dikbD2R:cmax>12</dikbD2R:cmax>
    <dikbD2R:numOfParticipants>10</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4D4EC995-8A3D-480A-B829-70BAB8069C62">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8974378E-D90C-48CD-9BD9-AC7D446F8C75">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>600</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>abiraterone acetate</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C6F343A8-8EEF-4A92-BF04-F00ED54677CA">
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:clDirection>Increase</dikbD2R:clDirection>
    <dikbD2R:cl>2</dikbD2R:cl>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7F22DDD1-4421-4DAA-8D74-D3ACEB9BEBD3"/>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B52ABF0A-47C0-458D-876F-D14942BDF286"/>
    <dikbD2R:numOfParticipants>18</dikbD2R:numOfParticipants>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>Fold</dikbD2R:clType>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/1B999F60-A8D2-45DC-8ABE-2D5478157836">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>bupropion</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:94128D43-4924-4E39-A5F6-73D94E8FB7F4">
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:614A4393-0808-442B-BEBD-2704CCB38BC4</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:741F8D04-9EC1-4483-80FF-2D5626EA5BBC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-29 08:59:10 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:87AA3A89-7CF0-4741-B125-89652FE3943C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>. Daily doses of </ao:prefix>
    <ao:exact>rifampin </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>87AA3A89-7CF0-4741-B125-89652FE3943C</domeo:uuid>
    <pav:createdOn>2015-10-14 11:41:39 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:suffix>should be given at least 1 hour before the ingestion of antacids.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:87AA3A89-7CF0-4741-B125-89652FE3943C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:304864EA-BD6F-4EC5-9F49-5C5264DE6F22">
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-09-03 15:57:07 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>. There was a higher incidence of significant blood pressure elevations with the co-administration of </ao:suffix>
    <ao:prefix> (25mg every 4 hours for 24 hours) did not affect the pharmacokinetics of </ao:prefix>
    <ao:exact>PPA</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:304864EA-BD6F-4EC5-9F49-5C5264DE6F22"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DA8F5609-E389-4064-AF9B-3A3E99BCFC05">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>20</dikbD2R:dose>
    <rdfs:label>paroxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:810BB02B-7CD7-4900-815D-6E14864708DA">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/889A2EB7-30CE-44E6-B019-4A06B7AFA208"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/667F4564-91BB-401E-B9B5-95DF59D58FCF"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B2D07C5D-738B-4B2E-BF50-1CABE0AFDADF">
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N7f7bfd24b6e44b7ab045d30815d9e46f"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:47436655-2C70-4BE4-BDF4-E0E6BEAC2364"/>
    <pav:previousVersion>urn:domeoclient:uuid:a7f59b4d-3ada-4384-adb1-665a4a1743c8</pav:previousVersion>
    <pav:createdOn>2015-09-03 15:41:34 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0A98E6B0-5F59-43E1-B45B-FC2EF0D47705">
    <ao:exact>Because of the pharmacologic similarity of maprotiline hydrochloride to the tricyclic antidepressants, the plasma concentration of maprotiline may be increased when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), as has occurred with tricyclic antidepressants. Adjustment of the dosage of maprotiline hydrochloride may therefore be necessary in such cases.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-30 12:40:24 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>0A98E6B0-5F59-43E1-B45B-FC2EF0D47705</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>is rapidly tapered in patients receiving maprotiline .  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0A98E6B0-5F59-43E1-B45B-FC2EF0D47705"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:840EADA8-9914-479B-86B1-4DD985E78FB3">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-20 09:22:33 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix>and </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:840EADA8-9914-479B-86B1-4DD985E78FB3"/>
    <ao:exact>sulforidazine</ao:exact>
    <domeo:uuid>840EADA8-9914-479B-86B1-4DD985E78FB3</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, increased 3-fold following coadministration of fluvoxamine. </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:873E3BEF-EBFB-46B9-97AA-49963FBF08FF">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <pav:createdOn>2015-10-16 10:38:58 -0400</pav:createdOn>
    <ao:exact>Levothyroxine    In healthy subjects who had received EMSAM 6 mg per 24 hours for 10 days, single dose administration with levothyroxine (150 mcg) did not alter the pharmacokinetics of either selegiline or levothyroxine [see Drug Interactions (7.4) and (7.5)].</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>   </ao:prefix>
    <domeo:uuid>873E3BEF-EBFB-46B9-97AA-49963FBF08FF</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:873E3BEF-EBFB-46B9-97AA-49963FBF08FF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:191DBC90-244E-4B28-85E3-91A0C7D2CA55">
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7D3165AF-E749-42A4-A947-09083737957D"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DF275A70-03F2-44A1-918B-D8D47DBC823E"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E6EB594A-72B4-4617-96D0-2F7BF3A36FE2">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B2BFE0C5-595D-4142-B0E1-1A2851105B5E"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F52BCCB8-8F0D-4897-A41F-8C949DAE470C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2797DF94-AA41-40DA-89AC-2B6FE32F26F4">
    <ao:body rdf:nodeID="N8cb1e4b6916d49d7b8b415ac3dbeb814"/>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:66DC78F6-1E6F-48F0-B139-8FC43168E763</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:545F2613-2A5E-4333-A651-CBA80268D6ED</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:96935610-5DFF-4DC8-9B01-97E4CF2907F9"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-09-30 10:40:50 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:14569B66-469D-40B5-9FED-8E8591F749CD">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:createdOn>2015-10-20 09:23:08 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N0a643efb841748ab8e96182b24f5b66c"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:8D286017-0AEC-46C4-AC51-641E2F31DE1A</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:C2072F35-782E-4BD6-95B8-9588B62D6ADE"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-20 09:23:48 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8094835F-A1DA-4220-AE01-0E94ABD59B3C">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6851</dailymed:activeMoietyRxCUI>
    <rdfs:label>methotrexate</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BC39434E-6268-4632-B349-037247CE7542">
    <pav:createdOn>2015-10-16 10:54:22 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BC39434E-6268-4632-B349-037247CE7542"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin. If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached [see Contraindications (4) and Warnings and Precautions (5)]. </ao:exact>
    <ao:prefix>metabolism have not been studied.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BE062828-3F8A-4772-9461-387A35112F5A">
    <ao:context rdf:resource="urn:domeoclient:uuid:8960E120-1B6A-4612-AC01-B56565F1DBE1"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-13 12:03:13 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <ao:body rdf:nodeID="Nc084ccad551f4744833a6e88f4145375"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-13 12:04:13 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:B51F4BB3-6BDB-45E7-9399-D93DBC4324AC</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7f7bfd24b6e44b7ab045d30815d9e46f">
    <domeo:sets rdf:resource="urn:pddi:uuid:58B9528F-88CB-4330-923E-CCA651B8BD8B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FE241EF8-F507-4CE3-949F-DD4EBE848652">
    <domeo:belongsToSet>urn:domeoserver:annotationset:CE635F27-A391-4A6B-9D87-339FA2F114B2</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-14 10:24:39 -0400</pav:createdOn>
    <ao:body rdf:nodeID="Nac93974c23f04158a96643fe7953862a"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotationset:fc9e17d3-1b0d-4635-9936-0d1d94cb01f9</pav:lineageUri>
    <pav:lastSavedOn>2015-09-14 10:25:07 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:46268AFD-D395-4681-9B22-FD8DD047912D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoclient:uuid:e382d7cf-3db6-429c-b6c0-e231f2492215</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:386BFF23-3BE0-4A07-A386-DE544871D834">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/658B18B6-2CE7-446A-B0E6-7CE8DAA4FB5E"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E98D99C8-6A1F-41AD-BB56-B8F7342D87E8"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C67D2B74-8217-4F94-B27D-58E382DC69CD">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D13DE50A-38BE-447F-ADB1-4CB68F14A56E"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:20C4ECAE-3F46-4EAC-BE3F-94F701047608">
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BDBF6112-1D81-4AC5-97E7-4AD3B72F9DB7"/>
    <dikbD2R:auc>1.3</dikbD2R:auc>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7ADD0A8F-16BD-47D0-B7BF-57D3A7B9C41F"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:600FA2BB-9EC6-4B60-A978-AA928A80FEF5">
    <domeo:uuid>600FA2BB-9EC6-4B60-A978-AA928A80FEF5</domeo:uuid>
    <ao:exact>SSRI </ao:exact>
    <pav:createdOn>2015-09-29 08:58:56 -0400</pav:createdOn>
    <ao:prefix>, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the </ao:prefix>
    <ao:suffix>involved. Nevertheless, caution is indicated in the coadministration of </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:600FA2BB-9EC6-4B60-A978-AA928A80FEF5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:13AB40AB-03FE-40A1-BD82-BFF7637C3EE5">
    <pav:lineageUri>urn:domeoserver:annotation:85AE2F50-DD04-4C32-B792-4804DA16FD80</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-24 15:37:52 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:DAD02F8C-D0CF-4D03-A113-8C242E8A7E4F</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N716dfad114964064aed0ce70c9ff6834"/>
    <pav:lastSavedOn>2015-09-24 15:38:09 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:882DF60F-84B8-422C-8907-B1B444911B5C"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/03C16421-4240-4B16-B6EC-76C440A3D901">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4441</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>flecainide</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:44A560A7-EFB5-49AA-87C3-1DEBD963D38C">
    <ao:exact>The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentrations was evaluated in ten male inpatients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.    Thioridazine administration produces a dose-related prolongation of the QTc interval, which is associated with serious ventricular arrhythmias, such as torsades de pointes-type arrhythmias, and sudden death. It is likely that this experience underestimates the degree of risk that might occur with higher doses of thioridazine. Moreover, the effect of fluvoxamine may be even more pronounced when it is administered at higher doses.    Therefore, fluvoxamine and thioridazine should not be coadministered [see Contraindications (4.1)]. </ao:exact>
    <ao:prefix>5.4 Potential Thioridazine Interaction  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-20 09:23:46 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>44A560A7-EFB5-49AA-87C3-1DEBD963D38C</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:44A560A7-EFB5-49AA-87C3-1DEBD963D38C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:73C70409-2A07-4743-B1C9-4841D5E27EBB">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:5BEA2001-CB06-4507-A35E-7F6F162CB5CE</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:EC10971E-3E24-45DA-A543-556459171054"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-03 15:56:56 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-16 10:42:46 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <ao:body rdf:nodeID="Nf570867ada6249a4a3b501401069f461"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/045663CD-0ECA-496D-9691-E1059CF8C897">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D1CB5FB6-B52C-4C3C-92FE-C19859D7DE37">
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:numOfParticipants>6</dikbD2R:numOfParticipants>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F06FE283-A85B-44B4-92C2-D32E52034960"/>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B8EC1E7A-95F2-4D2D-A178-693D321C57D0"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:84E732E9-EFA8-44B1-ACBD-AC557E774425">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F626D8F1-EA9B-4130-B2D0-0D3B14D5B3DD"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:96935610-5DFF-4DC8-9B01-97E4CF2907F9">
    <domeo:uuid>96935610-5DFF-4DC8-9B01-97E4CF2907F9</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Clomipramine-Switching from clomipramine (75 mg once a day) to milnacipran (100 mg/day) without a washout period did not lead to clinically significant changes in the pharmacokinetics of milnacipran. Because an increase in adverse events (eg, euphoria and postural hypotension) was observed after switching from clomipramine to milnacipran, monitoring of patients during treatment switch is recommended. </ao:exact>
    <pav:createdOn>2015-09-30 10:40:50 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>or its epoxide metabolite due to co-administration with Savella .  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:96935610-5DFF-4DC8-9B01-97E4CF2907F9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9FE667DC-2842-457D-97A1-7440687F7955">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:createdOn>2015-10-20 10:09:13 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:9F652A20-6C92-4C08-BE6B-7D2B2E42E6FE"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:48E0ECCB-C1F9-4F23-81EA-DCEC3A8AFC9A">
    <ao:prefix>sulfasalazine to sulfapyridine and </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:48E0ECCB-C1F9-4F23-81EA-DCEC3A8AFC9A"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>.    </ao:suffix>
    <domeo:uuid>48E0ECCB-C1F9-4F23-81EA-DCEC3A8AFC9A</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>mesalamine</ao:exact>
    <pav:createdOn>2015-10-14 11:42:01 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/f0293991-7014-48da-8dc8-9cd6abfc858b">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-08-27 14:50:16 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-08-27 14:50:16 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:c7ce6e79-6e93-45b7-978e-80ada2f4e509"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/38E4AA8A-B218-4BBD-9772-4DAA2015E3C0">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>abiraterone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A304BF07-A56F-40D4-9D69-89D42C824C17">
    <rdfs:label>clarithromycin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9D6ED403-B05E-4350-803B-C4E18E216987">
    <pav:createdOn>2015-08-20 13:05:43 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), and metoprolol (a CYP2D6 substrate).</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9D6ED403-B05E-4350-803B-C4E18E216987"/>
    <ao:prefix>[see Drug Interactions (7) ] .  </ao:prefix>
    <domeo:uuid>9D6ED403-B05E-4350-803B-C4E18E216987</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A2A2345-C764-4C44-81DA-580C2885BBD7">
    <ao:body rdf:nodeID="N99ec727a9bf24d22b251d50f09b96102"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:6B50E664-BD71-432E-B7FA-E7313EFF76E1</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-20 10:19:28 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-20 10:19:25 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:60CA4623-6D29-464C-B0D8-C1435AF7E973"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CA284E47-850E-461C-96AB-E6C94F44731C">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <rdfs:label>carbamazepine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>400</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AC2087DA-3178-4243-9BA8-82C69F3AAF6C">
    <pav:createdOn>2015-10-14 11:40:08 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>has been reported to accelerate the metabolism of the following drugs: anticonvulsants (e.g., phenytoin), digitoxin, antiarrhythmics (e.g., disopyramide, mexiletine, quinidine, tocainide), oral anticoagulants, antifungals (e.g., fluconazole, itraconazole</ao:suffix>
    <domeo:uuid>AC2087DA-3178-4243-9BA8-82C69F3AAF6C</domeo:uuid>
    <ao:exact>Rifampin </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AC2087DA-3178-4243-9BA8-82C69F3AAF6C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A33C822C-240E-49A9-8879-3E6167E97DC4">
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4ABBFA3B-0EB4-4F06-813B-0A31BDF7073E"/>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:preciptFormulation>transdermal</dikbD2R:preciptFormulation>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/1BD4841A-9C5B-434D-881F-74944DC3E8AA"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7FCEBD33-3E98-4378-968D-722F31455BCE">
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N0665ccc7cbd7404bb86f7f982bc71c14"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-08-20 11:44:17 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:AE6F9626-48AF-4592-938C-2E6217D74167</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:5E769D5F-ECB6-4930-8D97-608D7807119C"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BB4F6AC4-EAA6-4F75-9E87-41B417B2185B">
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:auc>15</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmax>10</dikbD2R:cmax>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/97488CE8-6E35-4D8E-BC8A-AB87E9091B32"/>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/1575541E-207B-4264-8BEB-7DD0D0427ECB"/>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:objectRegimens>Q8</dikbD2R:objectRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A7EDE56B-7E2D-45DD-9B69-71AF93CE4A54">
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-20 09:56:31 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdOn>2015-10-20 09:54:08 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:E5FF8830-7E0E-459E-812B-5C25783EC689"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:659993FA-47A6-4170-A1F4-37E021B93D40</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B93959A7-F648-4609-A26D-030346CEA017">
    <ao:exact>fluoroquinolones </ao:exact>
    <pav:createdOn>2015-10-14 11:40:46 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B93959A7-F648-4609-A26D-030346CEA017"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <domeo:uuid>B93959A7-F648-4609-A26D-030346CEA017</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>(e.g., ciprofloxacin), haloperidol, oral hypoglycemic agents (sulfonylureas) levothyroxine, methadone, narcotic analgesics, progestins, quinine, tacrolimus theophylline, tricyclic antidepressants (e.g., amitriptyline, nortriptyline) and zidovudine. It ma</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BB822C45-55D4-403F-924B-6557AE6B85A4">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>duloxetine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>2</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C50E8ACB-18FB-4CA8-96D7-3DF57419D60C">
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:BF845E15-E0F0-48BA-8A9D-E052826B0B71"/>
    <pav:previousVersion>urn:domeoserver:annotationset:2F0F6A9C-0E38-4924-B1BA-458A4EEDE554</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-13 11:57:45 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-13 11:59:07 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0B50AB0B-35ED-4E43-82DA-CFC072278D08">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:356EE5A3-8AD4-4E58-9F2E-3322D96D63DA"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:comment>Plasma concentration of imipramine may increase</dikbD2R:comment>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E04E68EF-0690-42D3-A066-0A02D642ABDD">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>warfarin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>200</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D55B06C1-5FA9-4183-B0CD-31ECA40F2DE1">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix>(plasma level:dose) ratios have been reported when </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>D55B06C1-5FA9-4183-B0CD-31ECA40F2DE1</domeo:uuid>
    <ao:suffix> was administered to patients receiving maintenance methadone treatment, with symptoms of opioid intoxication in one patient. Opioid withdrawal symptoms were reported following fluvoxamine maleate discontinuation in another patient. </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D55B06C1-5FA9-4183-B0CD-31ECA40F2DE1"/>
    <ao:exact>fluvoxamine maleate</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-20 10:18:16 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:101726AC-4079-4A15-B511-8EB870DB4FF4">
    <pav:lineageUri>urn:domeoserver:annotation:D814EB04-18D2-4C12-924A-E78D1D020AA8</pav:lineageUri>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N9e7d8a4300e74479aff869f87f0290f7"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0185AD47-6E7B-4C92-8A3D-A2876CC95002</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:C7C1E541-536C-41BE-A49D-DCDC6D516DC3"/>
    <pav:createdOn>2015-09-29 09:27:00 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:04B80DF1-D3FE-4E2E-859F-732C816CB3FC">
    <dikbD2R:auc>2.51</dikbD2R:auc>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C9679E02-D4D5-4264-9711-E07F48E32713"/>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F1D8B81F-3833-47C8-89FA-EEBEF48441CC"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmax>2.65</dikbD2R:cmax>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8135BF3B-C859-4C1E-B730-D48B1E7FD2D4">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:BE71BBF5-9A2D-4EBE-83B0-1E019FA0E0F8</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:3E5B3D66-33ED-41B4-9C24-1185F6070F1A</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-09-25 10:43:30 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:5E7AE326-70E8-4110-B6FA-8E17F64A8D46"/>
    <pav:lastSavedOn>2015-09-25 10:47:09 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BDC69264-3F54-4B1A-A8DC-4EEAB55EE6C8">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9303401C-5BCA-46CD-9B7D-8236FF8DBC6D"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2D645FF2-9025-478C-826A-5B62FCD191C6"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/cd9425be-1f3a-4f04-9290-7f3e46a8c14f">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-08-18 11:34:40 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:25e971a8-ce4d-4e5c-a750-8f8a09c85093"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:b0de7462-b5db-4bbf-8a8a-8438b37938a8</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-08-18 11:34:40 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:710D2A05-EC79-4BFC-BC3E-436C7AC80BD5</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6F7DEC5B-F0F1-47F1-9E89-42D1748BDC63">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>. This finding may be the result of alteration in the colonic bacteria responsible for the reduction of sulfasalazine to </ao:prefix>
    <domeo:uuid>6F7DEC5B-F0F1-47F1-9E89-42D1748BDC63</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>sulfapyridine </ao:exact>
    <pav:createdOn>2015-10-14 11:42:00 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6F7DEC5B-F0F1-47F1-9E89-42D1748BDC63"/>
    <ao:suffix>and mesalamine.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:478316AB-63D1-4CCC-8174-F4FA6BF833D9">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:737767C4-4F05-463E-96C7-13F0E2D918F3"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D90EDE5C-86B4-4DA8-A1F6-3088500295D9">
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:createdOn>2015-10-14 11:40:12 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:B41F96C6-E115-46AD-AA76-0646B204DCF2"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:55FCD9DB-B74B-4058-9EE3-E31E5BBA0A4D">
    <pav:lineageUri>urn:domeoserver:annotation:20A59C28-9D07-4E32-A8C8-13310175498C</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:304864EA-BD6F-4EC5-9F49-5C5264DE6F22"/>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-09-03 16:19:40 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-03 15:57:07 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:52478B04-68BB-4BB3-859E-ADC37C8058B8">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DC54EBE-B2A9-4AE7-A174-F0074ECE4050</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:13AD2788-BA98-40EC-B068-29A26FEE5DF6</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:A6DB74B9-8184-4FBD-9651-41DD31268769"/>
    <pav:createdOn>2015-10-01 10:46:36 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="Nce2d499b24ab4ecaa838ab8c74a6b280"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:933A2B5E-1527-47CC-AF30-1F82C9D93E43">
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:E3442E22-8445-4577-A5E2-7CBBAEFE37EB</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:6916DAA3-E315-423E-91FE-B8543860BF1B"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-29 11:25:48 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N0eef503bedbf4a91a1138b848014c80d"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3246EE9D-08F9-4FD7-BEF4-BE9102B9FCAB">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N1ac30af8477c4bc1a9060f703e8e2030"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <pav:lastSavedOn>2015-10-13 12:04:13 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:B51F4BB3-6BDB-45E7-9399-D93DBC4324AC</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-13 12:02:34 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:600E82E4-DF31-43E8-9BFD-4F6F1242193A"/>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BA1E2064-A38B-4525-A6B8-2810448F4E8F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BA1E2064-A38B-4525-A6B8-2810448F4E8F"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>BA1E2064-A38B-4525-A6B8-2810448F4E8F</domeo:uuid>
    <ao:exact>There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, and bromocriptine.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>dosage should be considered. (See Viagra package insert .)  </ao:prefix>
    <pav:createdOn>2015-10-13 12:03:36 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F74FE5C1-B9CC-46B7-90EB-735E4E3F42FA">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:23C921CE-AE9A-4E8B-9815-A9ABE1043C9D"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-25 10:43:25 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-25 10:47:09 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:C0186D9C-793B-4A81-BCDD-B82DA50F70C8</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:BE71BBF5-9A2D-4EBE-83B0-1E019FA0E0F8</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8166155C-393C-45B1-A8D8-E895C20F3D99">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:55BC195A-DF24-4614-8873-D7778D3CED9D"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B97E743C-8DCF-4ADC-A9D7-9A3940861B8A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>natalizumab</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6853CD49-9E30-472A-9DD1-6C5F009A7AC1">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="Nc35c1dcb85624e3aba9ab359582051d9"/>
    <pav:createdOn>2015-09-29 09:24:40 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0185AD47-6E7B-4C92-8A3D-A2876CC95002</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:0862607E-26D8-4D02-BB9E-2ACFDEB07937</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:63E97057-3323-429B-AC74-2866EDAF5AA9"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4DFFE47E-5452-452E-B101-770AFA41F372">
    <ao:context rdf:resource="urn:domeoclient:uuid:931C5400-46C6-479B-B120-F302AB10F763"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-09-03 15:51:47 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <pav:createdOn>2015-09-03 15:47:39 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:FF458BCB-ED21-41C0-8A43-C739664C5F67</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1FFE02F7-0229-4945-8C92-7F816B8FE95F">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:suffix>(e.g., fluconazole, itraconazole, ketoconazole), barbiturates, beta-blockers, calcium channel blockers (e.g., diltiazem, nifedipine, verapamil), chloramphenicol, clarithromycin, corticosteroids, cyclosporine, cardiac glycoside preparations, clofibrate, o</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>1FFE02F7-0229-4945-8C92-7F816B8FE95F</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1FFE02F7-0229-4945-8C92-7F816B8FE95F"/>
    <ao:exact>antifungals </ao:exact>
    <ao:prefix>, </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-14 11:40:18 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1DE064C4-9A25-4A8E-B4A6-03E67FB5C12F">
    <domeo:uuid>1DE064C4-9A25-4A8E-B4A6-03E67FB5C12F</domeo:uuid>
    <ao:prefix>Antineoplastic, Immunosuppressive, or Immune-Modulating Therapies   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1DE064C4-9A25-4A8E-B4A6-03E67FB5C12F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:hasSource>
    <pav:createdOn>2015-08-20 13:55:35 -0400</pav:createdOn>
    <ao:exact>Antineoplastic, immune-modulating, or immunosuppressive therapies, (including corticosteroids) are expected to increase the risk of immunosuppression, and the risk of additive immune system effects must be considered if these therapies are coadministered with GILENYA. When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating GILENYA [see Warnings and Precautions (5.2)].</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D">
    <ao:item rdf:resource="urn:domeoclient:uuid:7202CC73-0AE1-4A33-B3A2-3FE717DFC543"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:3D1ABB80-1DA1-481B-9674-4E4FAE0FA309"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B65A8359-7809-4E61-8900-BB4D603E7E9E"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B7E902CE-7AE0-4D65-B1AD-79D8EF39BE72"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:53286523-B901-42EC-8901-993C4320624D"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7E68B341-4216-465A-8B75-6D6394771A71"/>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="Ncc6d5419f6d94c4c8d17fa999387f0c3"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:7B0DB3A3-8406-401E-8B2A-5754E62D7385"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F85DC19C-09D0-4BD1-B3A7-5DBCFBCE72AD"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:F63AD193-B301-4138-A56A-8F0E9F879B07"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:C91289D7-45EC-44D1-A933-E79E770CFE71</pav:lineageUri>
    <ao:item rdf:resource="urn:domeoclient:uuid:4715C7DD-0005-4C0F-88B4-99A266D94C43"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:EDCA5EA5-9888-43D6-9944-71BD1EFBDDF6"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:B0ECD02E-F340-495E-8CF5-6F1F8786A602"/>
    <pav:lastSavedOn>2015-10-14 12:10:56 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:item rdf:resource="urn:domeoclient:uuid:EBF713BB-1E6D-47A7-8F3E-03103D4DDABB"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:912F4CEC-E545-4E5D-8337-0DBA3B5B6E89"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:11A52C7C-23D0-4A66-9D3B-9B054A8CC4C9"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:annotatesResource>
    <ao:item rdf:resource="urn:domeoclient:uuid:5E28CDF4-912F-4A42-9962-26AB548B421A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:1705FF37-6249-47BE-83EA-0B511345B099"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:0278336C-C287-4150-BBFD-946E7C02463E"/>
    <pav:createdOn>2015-10-14 12:06:07 -0400</pav:createdOn>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:A3A2C53B-E138-40AA-AEFA-2806EF8D3E7B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:BC7FD29D-7CDD-4766-A290-D710E4D0DDE8"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:CADFFF9A-CF8A-4A55-9886-7839B4777B1A"/>
    <pav:previousVersion>urn:domeoclient:uuid:430F4899-112C-41CA-BFEB-BA36C4B2739D</pav:previousVersion>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:2A1BB431-B923-4C57-AA3D-4E5343A75E5B"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:08C8AB4C-4F4F-4616-B072-A9FEC9DDE7F8"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:18202B9F-45FD-4DE0-A36C-EB4CDED5C7F4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2DDE57E8-8DE6-4ED1-ADB7-2F109930DB5D">
    <pav:lineageUri>urn:domeoserver:annotation:C50E7F1C-48E9-4F98-A9E5-68CC7E0BFB32</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2014-02-09 21:22:48 -0500</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:resource="urn:linkedspls:uuid:A0F0B55C-92C3-42AC-BA8B-D25B34B24813"/>
    <pav:createdOn>2014-02-09 21:23:27 -0500</pav:createdOn>
    <domeo:belongsToSet>urn:domeoclient:uuid:6B12D9AC-F09A-4157-8E26-ACDF40ECBB03</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:929BF940-1099-4796-BBA3-341FACCD0F42"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B9E961DB-D430-4F4F-B9A8-070D3943C9B8">
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:90AF36A5-2ECD-446B-A9B6-CEC8F72AB133"/>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:createdOn>2015-10-14 11:39:55 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2d1a4a7f-6ab4-4b36-a625-a116e1deb204">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Desmethyldoxepin</ao:exact>
    <ao:prefix> urinary excretion of the parent drug and its metabolites. </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <pav:createdOn>2015-08-27 14:50:17 -0400</pav:createdOn>
    <ao:suffix> has a half-life that ranges from 28 to 52 hours and is not </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2d1a4a7f-6ab4-4b36-a625-a116e1deb204"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:01836909-A227-4192-B564-D5631329F0C9">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9A92D660-F9DA-49F8-AB31-AC92D01F160F"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4ECC45D7-1009-41EF-81E5-A2A40E7750D7">
    <ao:prefix>   7.2 Inhibitors of CYP2D6   </ao:prefix>
    <ao:exact>Concomitant use of duloxetine (40 mg once daily) with paroxetine (20 mg once daily) increased the concentration of duloxetine AUC by about 60%, and greater degrees of inhibition are expected with higher doses of paroxetine. Similar effects would be expected with other potent CYP2D6 inhibitors (e.g., fluoxetine, quinidine) [see WARNINGS AND PRECAUTIONS (5.12)]. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-24 15:47:21 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:hasSource>
    <domeo:uuid>4ECC45D7-1009-41EF-81E5-A2A40E7750D7</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4ECC45D7-1009-41EF-81E5-A2A40E7750D7"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DFB2591B-62E6-4EBD-8A34-A6273831DB8E">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:748087E9-72A8-4CEB-9184-127F9C7D7CFF"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2BF29D63-16DC-413A-B043-2D784BEE08D7">
    <ao:prefix>[see Drug Interactions (7.1) ] .  </ao:prefix>
    <domeo:uuid>2BF29D63-16DC-413A-B043-2D784BEE08D7</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2BF29D63-16DC-413A-B043-2D784BEE08D7"/>
    <pav:createdOn>2015-08-20 11:31:12 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In a separate clinical pharmacokinetic interaction study of healthy subjects, co-administration of ketoconazole, a strong inhibitor of CYP3A4, had no clinically meaningful effect on the pharmacokinetics of abiraterone [see Drug Interactions (7.1)].</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/53500124-D066-4452-9DFB-FE1A1CCE7B10">
    <rdfs:label>abiraterone acetate</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>30</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/217187CC-6A1C-47B0-B132-35E7CFCFAA9F">
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <rdfs:label>warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4FD4E4F5-61CF-499D-A803-E6FD77E18839">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:355E164D-5258-46CF-934C-DB54FC42D20B"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/c1bdce77-66e3-4473-a4af-d20ec6534ce4">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:148461b1-b4b4-47d1-ac70-e21d1f8f267d</pav:lineageUri>
    <pav:lastSavedOn>2015-08-27 14:50:29 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:cbbf9293-bae7-4f67-abd1-d741d1430373"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-08-27 14:50:29 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3FC8F828-F0E8-444D-B54E-D4D2B5F42B77">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>22</dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A0D9C92E-0E93-453E-972C-8D8CF754228D"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:auc>77</dikbD2R:auc>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E596E732-8428-46A7-9BA4-184EECE6564E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:759B1D09-D228-4234-95A9-1CA416EC3077">
    <ao:exact>TCA</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-29 08:55:54 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <ao:suffix>).</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>759B1D09-D228-4234-95A9-1CA416EC3077</domeo:uuid>
    <ao:prefix>s) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:759B1D09-D228-4234-95A9-1CA416EC3077"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0EE9979A-3981-4AB8-95D5-7D7C96D70345">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:249780A8-45D7-4839-9FB2-EEA2029189E8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:864ED026-5998-4414-A057-6FCA60ABC131">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N70eb7750167843049cdf431a2d667b82"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:fc9e17d3-1b0d-4635-9936-0d1d94cb01f9</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-14 11:21:08 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CE635F27-A391-4A6B-9D87-339FA2F114B2</domeo:belongsToSet>
    <pav:lastSavedOn>2015-09-14 11:21:10 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:17CFEF69-CCC6-4ACD-8A24-0425991EC98C</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:9F436229-A045-46D0-874D-489EC872933C"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EADDCAFC-F127-4D8B-AC67-FA06B0EADDA5">
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-14 11:41:21 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:FE844157-DB14-4D8C-A5BF-15D63AD8C55C"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1C1632B0-E9F8-4E24-B931-122605DEAF64">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:C2D6F93B-C87D-4504-A018-C8EF51417845</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:A3C8F16A-9EA8-482D-8C38-61DBCE45EA93"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-09-29 08:58:55 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ECCC345A-BE75-43BB-88C2-F71C6FDBFC7B">
    <pav:lineageUri>urn:domeoserver:annotation:330FEFC2-4869-4469-9AD7-FB496D648145</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="Nbb5c0fab746940dda295037cfab3639c"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-10-14 11:53:53 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-14 11:57:06 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:DE4DCFF2-608E-4A8E-B5DC-8724F0BC8ADD"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na505db4b0df749ad8fde8108b9b2af8d">
    <domeo:sets rdf:resource="urn:pddi:uuid:25F3877A-D050-4EED-A66C-7DF9A7937D83"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D6F657B5-90BE-4358-9042-5255EA60946F">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8F392652-BCD4-47E9-BCA0-933278AFD587"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:80D2C2AA-4236-485D-92E2-0282A214379B">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-20 10:09:05 -0400</pav:createdOn>
    <ao:suffix>and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam. In these subjects (N = 8), the clearance of diazepam was reduced by 65% and that of N-desmethyldi</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:80D2C2AA-4236-485D-92E2-0282A214379B"/>
    <ao:exact>fluvoxamine </ao:exact>
    <ao:prefix>Evidence supporting the conclusion that it is inadvisable to coadminister </ao:prefix>
    <domeo:uuid>80D2C2AA-4236-485D-92E2-0282A214379B</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/93B149A5-FCBD-48A1-B5CF-8A2639C47CFF">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>lithium</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5DDF6D10-A992-43D4-B1C2-B010E34F248F">
    <ao:suffix> (</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/Clopidogrel-1086a7b4-b89b-4bee-8120-5f752626c046.html</ao:hasSource>
    <domeo:uuid>5DDF6D10-A992-43D4-B1C2-B010E34F248F</domeo:uuid>
    <pav:createdOn>2014-02-19 12:41:37 -0500</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5DDF6D10-A992-43D4-B1C2-B010E34F248F"/>
    <ao:exact>CYP2C19 inhibitors (e.g., omeprazole): Avoid concomitant use.</ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/29CA75DD-696A-44B2-8B2A-1F0107958720">
    <rdfs:label>ritonavir</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85762</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:59ED443A-C2AF-4273-855E-D51D1A91E24A">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8A6FCCBB-798E-4925-8411-69823AC07AB8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9F436229-A045-46D0-874D-489EC872933C">
    <ao:prefix>is coadministered with lithium.  Digoxin  </ao:prefix>
    <pav:createdOn>2015-09-14 11:21:08 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>The steady-state pharmacokinetics of paroxetine was not altered when administered with digoxin at steady state. Mean digoxin AUC at steady state decreased by 15% in the presence of paroxetine. Since there is little clinical experience, the concurrent administration of paroxetine and digoxin should be undertaken with caution.</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9F436229-A045-46D0-874D-489EC872933C"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8b8a3f8d-c9a5-4eb8-9823-d688fe4b13fb">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-08-18 11:35:24 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-08-18 11:35:24 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:a6683e4f-efa6-41ad-b752-0a7d5d07d2cb"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7F22DDD1-4421-4DAA-8D74-D3ACEB9BEBD3">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
    <rdfs:label>phenytoin</rdfs:label>
    <dikbD2R:dose>30</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ADAE5737-442E-4008-BD0B-9B62E45610C2">
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-14 11:40:19 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:00C393BA-0091-449D-A6BE-AD5BEA51DB22"/>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:12B79C6A-D8E7-41BB-A5CC-B2F760C3F0DC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:DA86ED84-44C6-460E-AE8C-B2332FD8F0E7"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BDE241D3-5592-4D56-9C19-0F16DA68A616">
    <pav:createdOn>2015-10-20 10:23:28 -0400</pav:createdOn>
    <ao:exact>fluvoxamine </ao:exact>
    <ao:prefix>When </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BDE241D3-5592-4D56-9C19-0F16DA68A616"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>100 mg twice daily was administered for 3 days prior to single-dose coadministration of ramelteon 16 mg and fluvoxamine, the AUC for ramelteon increased approximately 190-fold and the C</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <domeo:uuid>BDE241D3-5592-4D56-9C19-0F16DA68A616</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AEBD2BB2-1ADA-4FE3-8B12-5993B86C445C">
    <pav:lineageUri>urn:domeoserver:annotation:0B4BBECF-45DF-4CC1-8589-1C9DA3B7CB37</pav:lineageUri>
    <pav:createdOn>2015-09-24 15:54:35 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-09-24 15:55:00 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N6076c4a8137d44f0aaea6178dfc14188"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:6087EDDF-DC67-4E63-A031-8DD850131D3E"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:85AD6EA1-D560-4FFB-A685-3F21B0B4208E</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C2072F35-782E-4BD6-95B8-9588B62D6ADE">
    <ao:prefix>5.4 Potential Thioridazine Interaction  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentrations was evaluated in ten male inpatients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.    Thioridazine administration produces a dose-related prolongation of the QTc interval, which is associated with serious ventricular arrhythmias, such as torsades de pointes-type arrhythmias, and sudden death. It is likely that this experience underestimates the degree of risk that might occur with higher doses of thioridazine. Moreover, the effect of fluvoxamine may be even more pronounced when it is administered at higher doses.    Therefore, fluvoxamine and thioridazine should not be coadministered [see Contraindications (4.1)]. </ao:exact>
    <pav:createdOn>2015-10-20 09:23:08 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>C2072F35-782E-4BD6-95B8-9588B62D6ADE</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C2072F35-782E-4BD6-95B8-9588B62D6ADE"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:166AA3D7-46F5-42AC-9272-8A6A40A86DBE">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">14</pav:versionNumber>
    <pav:createdOn>2015-09-03 15:55:15 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-16 10:40:14 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <ao:body rdf:nodeID="N0cfebc8800a84a6dbc8c22b85987eaec"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:CE124242-AD57-4D32-9A25-1EF5E6126E23</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:873E3BEF-EBFB-46B9-97AA-49963FBF08FF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BB52ED61-3987-4ADE-94FA-3476768CFBBA">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/161F03B9-D79B-4148-B98C-F8C533F5CB23"/>
    <dikbD2R:t12>3</dikbD2R:t12>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:t12Type>Fold</dikbD2R:t12Type>
    <dikbD2R:cmax>2</dikbD2R:cmax>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:t12Direction>Increase</dikbD2R:t12Direction>
    <dikbD2R:auc>5</dikbD2R:auc>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DA8F5609-E389-4064-AF9B-3A3E99BCFC05"/>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:576A1DD4-4A0B-4632-821C-5F4FB1B06214">
    <pav:lastSavedOn>2015-10-13 11:56:52 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:95F45B41-8CBE-45C5-BA13-0C5BFD45D7B0"/>
    <ao:body rdf:nodeID="N920b8608e6d8441faa57d2a49f579df7"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-10-13 11:55:45 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:46B234F0-D68D-4DB4-ABE7-1BFB208B25F2</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3299957A-4DD8-42F0-880B-EFF809AD45A4">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:964748F7-AA2C-4C0F-AEE3-C10C76C04726</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-10-01 10:28:35 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:13398298-6D06-4CA1-8445-B2BD67BADC5C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N52ed874a00d541189c99c2a8912086df"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:33B17719-DF97-48EA-AFA2-01DE8A8887B4</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:31E432CC-C956-474B-A311-ECCAE0A34A4F">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EEEBC110-DCB7-49AD-BEA1-5AD46C23F126"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D8A2AFE3-5BE2-4383-AE8A-5F1AE76CBB64"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5E7AE326-70E8-4110-B6FA-8E17F64A8D46">
    <ao:exact>lithium </ao:exact>
    <ao:prefix>. The effects of higher doses of </ao:prefix>
    <domeo:uuid>5E7AE326-70E8-4110-B6FA-8E17F64A8D46</domeo:uuid>
    <ao:suffix>on the pharmacokinetics of </ao:suffix>
    <pav:createdOn>2015-09-25 10:43:30 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5E7AE326-70E8-4110-B6FA-8E17F64A8D46"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EBB2D315-7C91-408C-8A37-F0A5F6CF4FE1">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B41F96C6-E115-46AD-AA76-0646B204DCF2">
    <ao:exact>digitoxin</ao:exact>
    <ao:prefix>), </ao:prefix>
    <domeo:uuid>B41F96C6-E115-46AD-AA76-0646B204DCF2</domeo:uuid>
    <ao:suffix>, antiarrhythmics (e.g., disopyramide, mexiletine, quinidine, tocainide), oral anticoagulants, antifungals (e.g., fluconazole, itraconazole, ketoconazole), barbiturates, beta-blockers, calcium channel blockers (e.g., diltiazem, nifedipine, verapamil), ch</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-14 11:40:12 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B41F96C6-E115-46AD-AA76-0646B204DCF2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C3156E0B-6985-4638-85C7-5D89C1C6266E">
    <domeo:uuid>C3156E0B-6985-4638-85C7-5D89C1C6266E</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Clinical studies have shown that desvenlafaxine (100 mg daily) does not have a clinically relevant effect on tamoxifen and aripiprazole, compounds that are metabolized by a combination of both CYP2D6 and CYP3A4 enzymes (Figure 2).</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C3156E0B-6985-4638-85C7-5D89C1C6266E"/>
    <ao:prefix>and CYP3A4 substrates (Figure 2).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-24 15:28:54 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N032c31791b6e45f9b7c08f3fd125f575">
    <domeo:sets rdf:resource="urn:pddi:uuid:BFFBA8AD-6CB0-4C7B-BF7A-C52DCC64A4BA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9AE53DD6-BF07-4ED3-925B-66A877E065CC">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdOn>2015-09-03 15:44:23 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:CCB515E3-7272-470E-B7DB-F399A3A49062"/>
    <ao:body rdf:nodeID="N2067834d24524d12b606e8ee94a5aaf7"/>
    <pav:previousVersion>urn:domeoserver:annotationset:55B1C49E-7916-41C7-A208-C65CF240E0B5</pav:previousVersion>
    <pav:lastSavedOn>2015-10-16 10:31:17 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AB12B3EC-41EF-4DDE-98ED-2155A0A4B9B3">
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:DEAE2EA6-BFEB-4C59-AC1F-5CAC23D48A04"/>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-14 11:39:58 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D1291B5E-C283-48C2-BDEE-2E0046415542">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>phenytoin</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E22F4363-3D17-4C39-8B0A-72CEE0B97B5D">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <pav:createdOn>2015-08-20 11:45:38 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E22F4363-3D17-4C39-8B0A-72CEE0B97B5D"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>on organic anion transporter 3 (OAT3) substrates   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:380833A1-5A1B-4EC8-A274-887D3F90E3DE">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:53307188-612A-4951-85F8-934C7D0352EC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:996F160E-19AE-4844-B55D-993B7D6E2615">
    <ao:prefix>, </ao:prefix>
    <pav:createdOn>2015-10-14 11:40:33 -0400</pav:createdOn>
    <ao:suffix>, cyclosporine, cardiac glycoside preparations, clofibrate, oral or other systemic hormonal contraceptives, dapsone, diazepam, doxycycline, fluoroquinolones (e.g., ciprofloxacin), haloperidol, oral hypoglycemic agents (sulfonylureas) levothyroxine, metha</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:996F160E-19AE-4844-B55D-993B7D6E2615"/>
    <domeo:uuid>996F160E-19AE-4844-B55D-993B7D6E2615</domeo:uuid>
    <ao:exact>corticosteroids</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:06C3C17C-03D7-464B-84AF-2AC11924D8E5">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:21E3775E-57FC-4CA1-A666-B5901773B506"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N8da672a253184de39a067fda031c56d0"/>
    <pav:lastSavedOn>2015-08-20 11:38:24 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-08-20 11:36:50 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:7d2027ff-e85b-46f3-befa-3f8f5cf7e88f</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:64A14B71-4AB9-4735-A227-D9A89F23C614">
    <ao:exact>phenothiazines</ao:exact>
    <pav:createdOn>2015-10-01 10:43:31 -0400</pav:createdOn>
    <domeo:uuid>64A14B71-4AB9-4735-A227-D9A89F23C614</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, and the Type 1C antiarrhythmics </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>) and many that are substrates for P450 2D6 (many other antidepressants, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:64A14B71-4AB9-4735-A227-D9A89F23C614"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D205191B-E949-4BF3-B844-951C38D31E80">
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DC54EBE-B2A9-4AE7-A174-F0074ECE4050</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="Ne07e416a2908437f936617e5c3383339"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:D63FFAD6-2B46-4448-A854-4D6C6595A64A"/>
    <pav:lineageUri>urn:domeoserver:annotation:21B75FB4-D1C0-4A24-A19A-5FFB35C13D6C</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-10-01 10:46:50 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2B72E799-44E0-4434-B7E3-346160B5FB5C">
    <ao:exact>methadone </ao:exact>
    <pav:createdOn>2015-10-20 10:18:11 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix>Significantly increased </ao:prefix>
    <domeo:uuid>2B72E799-44E0-4434-B7E3-346160B5FB5C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>(plasma level:dose) ratios have been reported when fluvoxamine maleate was administered to patients receiving maintenance methadone treatment, with symptoms of opioid intoxication in one patient. Opioid withdrawal symptoms were reported following fluvoxa</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2B72E799-44E0-4434-B7E3-346160B5FB5C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EB25F5A2-A93C-4C05-B6D1-40E7412D189B">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BB4F6AC4-EAA6-4F75-9E87-41B417B2185B"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E742A8FE-5600-44EC-A3CD-70667F10AE25">
    <ao:body rdf:nodeID="N0c104681e4dd4b9fb81ae3783d1bd180"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:152B2F3D-4E7D-4FD4-87BE-DE4DCF3F490C"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CE635F27-A391-4A6B-9D87-339FA2F114B2</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-09 13:18:59 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:B4999650-8822-48D4-A157-78F324B6E113</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-09-14 10:51:13 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:fc9e17d3-1b0d-4635-9936-0d1d94cb01f9</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6356DE5E-F188-46C3-8067-EEFE92CABEBB">
    <ao:exact>AUBAGIO may increase the systemic exposures of ethinylestradiol and levonorgestrel. Consideration should be given to the type or dose of contraceptives used in combination with AUBAGIO [see Clinical Pharmacology (12.3)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6356DE5E-F188-46C3-8067-EEFE92CABEBB"/>
    <ao:prefix>AUBAGIO on oral contraceptives   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-08-20 11:39:01 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B0A09D3F-2B66-4107-AC03-967A6FECA31C">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>500</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>Clarithromycin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7215FF49-D455-4A62-98AA-9F3FBD686D8C">
    <ao:prefix>is contraindicated (See CONTRAINDICATIONS ).   </ao:prefix>
    <domeo:uuid>7215FF49-D455-4A62-98AA-9F3FBD686D8C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <pav:createdOn>2015-10-14 12:10:54 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7215FF49-D455-4A62-98AA-9F3FBD686D8C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>CYP 2D6 inhibitors: In healthy subjects, co-administration of pimozide 2 mg (single dose) and paroxetine 60 mg resulted in a 151% increase in pimozide AUC and a 62% increase in pimozide Cmax compared to pimozide administered alone. The increase in pimozide AUC and Cmax is related to the CYP 2D6 inhibitory properties of paroxetine. Concomitant use of pimozide and paroxetine or other strong CYP 2D6 inhibitors are contraindicated (see CONTRAINDICATIONS).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B5034613-24AE-40A1-8866-E2415321B047">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>propafenone</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8754</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E15ADF76-9E3C-4FE3-A2F3-750E2C5B7A0B">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BFABEC76-605B-4A5C-9A08-7BE8CDDE808B"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/15EFADFC-D2D6-4E04-96C7-C3E754B92307"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C7933EAE-B8B1-4F90-A63B-E0A4E34DFAA7">
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-14 11:41:14 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:92C6B48C-4C9D-40DD-AADE-25C9BFCBA081"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42201ABB-753C-491E-9EA9-45A742B4D21B">
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-20 10:08:57 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:8BA15B39-60FF-442D-9D16-49CA28D5964E"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CC573065-1EFB-432F-8729-8E859D2CB33E">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:740F436B-0D0C-4C9D-A54C-E2CB8268CFF1"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-09-24 15:28:24 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:01207605-4e40-4784-b7e8-7c296bff1d72</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoclient:uuid:636b6a9f-a53f-43ee-92d9-1e554d4d58e7</pav:previousVersion>
    <ao:body rdf:nodeID="N42864e4497dc4d31b17c806aacbab59e"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:DAD02F8C-D0CF-4D03-A113-8C242E8A7E4F</domeo:belongsToSet>
    <pav:createdOn>2015-09-24 15:28:23 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A9CBFF9A-EF56-4A42-95EE-9A1D317628A3">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:D8B75604-1C6E-40D4-8862-5A1D62A64D14</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-25 10:02:46 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-09-25 10:05:58 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N24bd94619454445faaf2810ce318cc92"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5808C4F6-3D20-4064-BA30-F1F80E74C108</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:C21B3DF0-F5D5-49BA-AC30-1EA3C3CA8C31"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B1621457-B01E-48A0-A14A-156EBD1B8786">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:78FC1706-B6D7-4F2D-BAAD-579DA6D22143">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:F062BFB0-7D99-4B91-AB15-BCF02C8D9B30"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-14 11:41:00 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/76D7C71E-4FB3-423E-932B-7C159AFAA9FD">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>tipranavir</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CFF7A244-CF86-44AD-A33E-ACF701E2EFFE">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:038C1A42-3DD2-4A7C-9526-355837CAFE20</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N704b853b97944ba08ba3cd4d21b29312"/>
    <pav:createdOn>2015-09-29 09:26:10 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:575EE166-E25C-4355-A63D-3ADB011F3371"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0185AD47-6E7B-4C92-8A3D-A2876CC95002</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:109474B3-F064-428B-8CC5-295B8EB15FD2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4EDAEED2-601E-4BEF-9ED8-F608AB876ED9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AFBB5843-B21C-4B1F-AF5E-5AA60AF92EA4">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:634E3729-1931-469D-85FB-EFC61E128CC8"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C7C1E541-536C-41BE-A49D-DCDC6D516DC3">
    <pav:createdOn>2015-09-29 09:27:00 -0400</pav:createdOn>
    <ao:prefix>hydroxylase) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:hasSource>
    <domeo:uuid>C7C1E541-536C-41BE-A49D-DCDC6D516DC3</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C7C1E541-536C-41BE-A49D-DCDC6D516DC3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:59737256-6A10-41BA-BB40-6E36BA8080A6">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-10-13 12:05:58 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:4AD985E7-FAB2-4973-9C24-6BD1BA3C4C4B</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:17805DE8-0495-48EB-98BB-070226368C2A"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-13 12:06:23 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N14f9f47d66494a448e928fea2b6c71a4"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2861ABC1-22FB-4FD5-88C2-532AD5E8650E">
    <ao:prefix> in patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>2861ABC1-22FB-4FD5-88C2-532AD5E8650E</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2861ABC1-22FB-4FD5-88C2-532AD5E8650E"/>
    <ao:exact>beta blockers</ao:exact>
    <ao:suffix>, </ao:suffix>
    <pav:createdOn>2015-08-20 13:56:48 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B5727900-FDD2-4516-B18B-3022863A9E0B">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:31E432CC-C956-474B-A311-ECCAE0A34A4F"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DE04EA3F-C940-4C88-A879-767D8630FF93">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/71bea6cd-1e47-40c9-935d-423d03992201">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <pav:lastSavedOn>2015-08-27 14:50:03 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:2933b5f6-bb2f-4961-86ed-e09658163628</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:createdOn>2015-08-27 14:50:03 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:7f36157a-84b3-49af-abd6-b11bc5699bc1"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A34BD5C7-51DC-49B8-89D0-61837CDAF19C">
    <pav:createdOn>2015-09-30 10:43:20 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:95787BE2-BCFB-4FAE-AB6E-59B0753207A5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:545F2613-2A5E-4333-A651-CBA80268D6ED</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:89384147-EDD9-4A21-AA03-4ADF2CC64A1B</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3C5E11B4-8675-4671-9460-F973D9BB478F">
    <ao:exact>tacrolimus theophylline</ao:exact>
    <ao:suffix>, tricyclic antidepressants (e.g., amitriptyline, nortriptyline) and zidovudine. It may be necessary to adjust the dosages of these drugs if they are given concurrently with rifampin.</ao:suffix>
    <pav:createdOn>2015-10-14 11:41:03 -0400</pav:createdOn>
    <domeo:uuid>3C5E11B4-8675-4671-9460-F973D9BB478F</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3C5E11B4-8675-4671-9460-F973D9BB478F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FD528EB0-2A80-423E-9AB9-52C00C5FD85B">
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DB6FC72E-5A20-4A39-9705-9B75B8683BA2"/>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmax>40</dikbD2R:cmax>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:auc>40</dikbD2R:auc>
    <dikbD2R:preciptRegimens>QD</dikbD2R:preciptRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0EA27B8B-961F-48C5-87DB-FE608839C5B0"/>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:22DB0824-2A61-4B05-8B21-324FF990CCA0">
    <pav:lineageUri>urn:domeoserver:annotation:7E772008-971C-437B-8976-28C3F56E2AD4</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-29 11:22:06 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:C91D2274-509B-49F5-B5D1-D7C7D0D29F8F"/>
    <ao:body rdf:nodeID="N8a96bbacfd76465c9f255d3aeb661047"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:52165ABE-00FF-41BF-BA2A-5938CA339FD2">
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
    <pav:createdOn>2015-10-20 10:08:58 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:CCC07A28-6FEF-4F41-B9EA-6A9DB36C0D7F"/>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AAE435D9-58B2-446B-A1BD-BF6E4CC64025">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AAE435D9-58B2-446B-A1BD-BF6E4CC64025"/>
    <ao:suffix>or Venlafaxine    Avoid use of PR</ao:suffix>
    <pav:createdOn>2015-09-24 15:29:13 -0400</pav:createdOn>
    <ao:exact>Desvenlafaxine </ao:exact>
    <ao:prefix>   7.6 Other Drugs Containing </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>AAE435D9-58B2-446B-A1BD-BF6E4CC64025</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E7675671-AEC9-4A92-BAF6-0E3954752675">
    <pav:createdOn>2015-09-14 11:31:43 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:77BE48D2-1183-498F-A9E1-E10950AB44AB</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CE635F27-A391-4A6B-9D87-339FA2F114B2</domeo:belongsToSet>
    <ao:body rdf:nodeID="N72c241a453e1485b9559fac45722cd62"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:B6666984-66C9-4A84-B678-A70C9359EECB"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-14 11:32:07 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9729AB6B-8C8D-4365-8A84-25CE10E6AD4C">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>800</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>Mirtazapine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:71B7E81D-B3E4-4CC3-A432-A446DD4BAAA1">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectRegimens>Q12</dikbD2R:objectRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:preciptRegimens>Q12</dikbD2R:preciptRegimens>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BB822C45-55D4-403F-924B-6557AE6B85A4"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5AD6405F-1805-4DB1-A285-A76B2AB51DD7"/>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EF054D06-109D-487A-96EB-1DD52DCD6AD0">
    <rdfs:label>nateglinide</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1202A678-DD4B-44C6-B9E2-78985758EEC2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:comment>Increase TCA plasma levels</dikbD2R:comment>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:16D85653-2369-40BD-80C0-D151FEA01087"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FAE68D9F-031E-4AE3-B4EE-5DF90C7DC714">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:C3D292D1-54B5-4DA5-ABDF-D9633CFCEA22</pav:lineageUri>
    <ao:body rdf:nodeID="N4eff9c0c5c984eb5b43dbfb7a89876a1"/>
    <pav:createdOn>2015-09-30 10:47:34 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:108E830A-C87C-4FA3-9136-6D1ADD9F0C2D"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:545F2613-2A5E-4333-A651-CBA80268D6ED</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6916DAA3-E315-423E-91FE-B8543860BF1B">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6916DAA3-E315-423E-91FE-B8543860BF1B"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <domeo:uuid>6916DAA3-E315-423E-91FE-B8543860BF1B</domeo:uuid>
    <pav:createdOn>2015-09-29 11:25:48 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2C7C66B6-F3DA-4EF5-BA78-4E623595064A">
    <dikbD2R:dose>150</dikbD2R:dose>
    <rdfs:label>fluvoxamine maleate</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/203143</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F70B3E11-F954-4A99-84CF-2D3119D52F6A">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/27E601C5-F766-4F40-A8A9-1569CF0C7575"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BFEBF689-6C4D-4D20-8765-41877C80A56B"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BC7FD29D-7CDD-4766-A290-D710E4D0DDE8">
    <ao:context rdf:resource="urn:domeoclient:uuid:15CC3D23-04EC-4A4B-87A1-5E550679326E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-14 12:06:26 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-14 12:07:40 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:C91289D7-45EC-44D1-A933-E79E770CFE71</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:86D02130-5F65-449C-9315-8E672FDAC7E2">
    <ao:exact>Concomitant use of paroxetine with risperidone, a CYP2D6 substrate has also been evaluated. In 1 study, daily dosing of paroxetine 20 mg in patients stabilized on risperidone (4 to 8 mg/day) increased mean plasma concentrations of risperidone approximately 4-fold, decreased 9-hydroxyrisperidone concentrations approximately 10%, and increased concentrations of the active moiety (the sum of risperidone plus 9-hydroxyrisperidone) approximately 1.4-fold.</ao:exact>
    <pav:createdOn>2015-09-14 11:09:49 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> The effect of</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:86D02130-5F65-449C-9315-8E672FDAC7E2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D9E71616-7D16-4C2B-9A4D-B3AB4AEB4BA1">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdOn>2015-10-14 11:39:59 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:BC7B7477-1771-4742-BF5C-CEC7F77E7F83"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E98D99C8-6A1F-41AD-BB56-B8F7342D87E8">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>clarithromycin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F7D91396-F847-4D3B-8DE6-8BBDAF06324F">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-09-29 09:57:18 -0400</pav:createdOn>
    <ao:body rdf:nodeID="Nf8493fb283a24c8a99f3dd4c9e1974d4"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:95C1F41F-1A9E-48A4-9473-492B2AE05E58"/>
    <pav:lineageUri>urn:domeoserver:annotation:56A88E14-37F2-43CD-9E72-552575895F93</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2EC2B395-2185-4E2D-B7D1-8214768712AA">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5B26DDD8-ECAC-43C2-8187-556E17A58793"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C1CA1E00-6920-4F80-B42D-D1B0F64F3F45">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>9-hydroxyrisperidone</rdfs:label>
    <dikbD2R:dose>4-8</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/679314</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C8874E61-E80C-4C3F-A900-EA53216C53E0">
    <ao:prefix> </ao:prefix>
    <pav:createdOn>2015-09-14 11:12:22 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C8874E61-E80C-4C3F-A900-EA53216C53E0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The effect of paroxetine on the pharmacokinetics of atomoxetine has been evaluated when both drugs were at steady state. In healthy volunteers who were extensive metabolizers of CYP2D6, paroxetine 20 mg daily was given in combination with 20 mg atomoxetine every 12 hours. This resulted in increases in steady state atomoxetine AUC values that were 6- to 8-fold greater and in atomoxetine Cmax values that were 3- to 4-fold greater than when atomoxetine was given alone. Dosage adjustment of atomoxetine may be necessary and it is recommended that atomoxetine be initiated at a reduced dose when it is given with paroxetine.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:324679DC-B5C4-4FAF-B588-1D66C5F18EF5">
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:numOfParticipants>10</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7A9393F1-19B6-4E41-ADB2-31F523C2DE9F"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E3E97E76-5E13-4105-A8EC-99DCC8F4EFBE"/>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:045492A1-0E37-4C8C-9485-7E11134C582A">
    <ao:exact>Under steady-state conditions for duloxetine (60 mg Q 12 hours) and lorazepam (2 mg Q 12 hours), the pharmacokinetics of duloxetine were not affected by co-administration. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>045492A1-0E37-4C8C-9485-7E11134C582A</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>   7.5 Lorazepam   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:045492A1-0E37-4C8C-9485-7E11134C582A"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-24 15:50:22 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D57AC561-50A1-4050-9ACA-FE6D1F2EBB95">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D452A095-9171-4848-9B0B-6E03D7A7A8B7"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8F097540-00DB-4581-BFD8-42B918C17F19"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0E895E85-BDA3-4347-A8DE-4CFC5373CA38">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>ibuprofen</rdfs:label>
    <dikbD2R:dose>800</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F7240EBE-4D25-4D4C-AC9B-8E9B04072967">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:C9067E0C-43A2-40C2-A7D7-E7A9149E6EF0"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0CB55CFA-6EBF-42B8-8F0D-DD87A96935EE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:BA4A4F06-DE8C-4B66-8918-920D0399D744</pav:previousVersion>
    <pav:createdOn>2015-08-20 12:47:24 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <ao:body rdf:nodeID="N80f157dabc07486a985f7f03fc2d03b0"/>
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:27EE5080-B435-458C-B8C4-52DE6E799617"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/11552A09-BA53-4E45-AA92-F279C2AA195F">
    <dikbD2R:dose>6</dikbD2R:dose>
    <rdfs:label>EMSAM</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AC844597-827C-46D7-BC10-F1AAEFD7FCDB">
    <pav:lineageUri>urn:domeoserver:annotation:F4CCB04A-7C27-4564-83C4-34A998700A8E</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-25 10:47:09 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:BE71BBF5-9A2D-4EBE-83B0-1E019FA0E0F8</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-25 10:44:45 -0400</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:32560457-99DD-4B35-A385-F90F0661CE60"/>
    <ao:body rdf:nodeID="Nfc0a9a891d504b508717cb1b4eb26a3c"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A33EAE5A-8DB5-4457-BF16-9974AE27B18F">
    <pav:createdOn>2015-09-03 15:46:36 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-10-16 10:36:45 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:B5741E42-9B1C-4C13-B769-E37A56B1019D"/>
    <ao:body rdf:nodeID="Nd0446fa6a97e48e198e4cb0cbfe66dd0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:9908DBC1-0CC6-4CAC-BB52-A25ECABCF67A</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AC05F8B2-F9F9-49D3-A70F-921EA23EA476">
    <ao:context rdf:resource="urn:domeoclient:uuid:9861DC11-56A0-4E77-9F46-AB7EBF4F623E"/>
    <pav:lastSavedOn>2015-10-16 10:55:51 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdOn>2015-10-16 10:52:42 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:0DAF5666-9E53-42D5-B92E-DE2C00764986</pav:previousVersion>
    <ao:body rdf:nodeID="N8dd28c7185ff490293abf79bac9cf4fe"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/887B6FD9-1A19-43E4-B4E8-6FA71FC202BD">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E1CA8CCE-BC2F-433E-BABF-7DDD6537C722">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <rdfs:label>fluoxetine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7CCF7600-624B-4E6D-983F-C36DF12B9B2D">
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:E06B776E-DD21-4AD5-B7E8-A6F06A196197</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:0E0A4DC0-6734-478B-AC97-93CC2B52C521"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-29 09:02:32 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A5842844-FD5D-4B2D-A1EB-A81881AB399E">
    <ao:exact>Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See CONTRAINDICATIONS.) </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>with drugs that undergo biotransformation through these metabolic pathways may accelerate elimination of coadministered drugs. To maintain optimum therapeutic blood levels, dosages of drugs metabolized by these enzymes may require adjustment when starting or stopping concomitantly administered rifampin.  </ao:prefix>
    <pav:createdOn>2015-10-14 11:54:07 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>A5842844-FD5D-4B2D-A1EB-A81881AB399E</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A5842844-FD5D-4B2D-A1EB-A81881AB399E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:18E274E9-2A42-4B5A-9D95-37B595098FE2">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-01 10:27:29 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:F6444A9A-E301-4604-B754-A508722522F3</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:33B17719-DF97-48EA-AFA2-01DE8A8887B4</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:68F33E48-4A8D-49FD-91B4-DFA00C9E1732"/>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8A1A74BA-5924-4B41-96D0-B7199CD1CFE9">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N66e10cb983de4c1bad0f75f90c2fb04e"/>
    <pav:lastSavedOn>2015-10-13 12:04:13 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-13 12:03:48 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:B51F4BB3-6BDB-45E7-9399-D93DBC4324AC</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:B91E84F5-BBA4-4AFE-8493-137EC930BE43"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9BEA3577-72E8-4C8C-AADE-04F58083C1B9">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>9BEA3577-72E8-4C8C-AADE-04F58083C1B9</domeo:uuid>
    <ao:suffix>have been reported to increase the blood level of rifampin.</ao:suffix>
    <ao:prefix>and </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9BEA3577-72E8-4C8C-AADE-04F58083C1B9"/>
    <pav:createdOn>2015-10-14 11:41:43 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>cotrimoxazole </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4FCD805B-0264-4B9B-BC69-F31623FBBAC6">
    <dikbD2R:dose>600</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>mirtazapine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:657BFDCD-CAF7-4E5E-9671-C1747114E769">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:111E0CE7-7420-49E7-A976-43E417CA03FD"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>urn:domeoserver:annotationset:0DAF5666-9E53-42D5-B92E-DE2C00764986</pav:previousVersion>
    <pav:createdOn>2015-10-16 10:51:45 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="Nd7bc74455c0942fdb2d9f8cfa16a2a82"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:lastSavedOn>2015-10-16 10:55:51 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:39CA0CAB-310A-4E0C-98E1-1C2424A54469">
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E30682F1-8894-4215-891B-A1AFEC04BD44"/>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:auc>0</dikbD2R:auc>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/10724B60-7F03-4798-8C06-530A4F0C6687"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EFB0903F-21FF-4FB3-A116-4DC0F441A4E6">
    <domeo:uuid>EFB0903F-21FF-4FB3-A116-4DC0F441A4E6</domeo:uuid>
    <ao:suffix>, fluoroquinolones (e.g., ciprofloxacin), haloperidol, oral hypoglycemic agents (sulfonylureas) levothyroxine, methadone, narcotic analgesics, progestins, quinine, tacrolimus theophylline, tricyclic antidepressants (e.g., amitriptyline, nortriptyline) an</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>, </ao:prefix>
    <ao:exact>doxycycline</ao:exact>
    <pav:createdOn>2015-10-14 11:40:45 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EFB0903F-21FF-4FB3-A116-4DC0F441A4E6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:538F9D58-A743-4EA9-93D6-A980C871E977">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:12DBF8CB-DE55-4304-982A-ED3753583A2A"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0799F45C-AB26-4C6A-A508-17349BB26B01">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>50 to 200</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:02CF245D-EC65-40F4-9D8C-206EB92D5651">
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:auc>1.54</dikbD2R:auc>
    <dikbD2R:cmax>1.43</dikbD2R:cmax>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/854504A7-A33C-4183-9492-6B338E175CA5"/>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DD09F72C-583B-43BC-A5F5-8F304BD8029A"/>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:26716B9A-81D7-435A-B33A-D6B56849F816">
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:ABDB3F0E-3768-4FCC-A328-2E9C2D56FEE2"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-14 11:41:42 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5C322BE1-EE43-410D-AA68-801F3BF3F67D">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>GILENYA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:55511E97-34AB-41C6-A461-E5D7312F99C8">
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5d103551-978f-472a-9c62-51e6e4dea068.html</ao:hasSource>
    <ao:suffix>and antacids produced no clinically relevant changes in plasma rabeprazole concentrations.</ao:suffix>
    <pav:createdOn>2015-08-26 16:11:47 -0400</pav:createdOn>
    <ao:prefix>. Co-administration of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>rabeprazole </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:55511E97-34AB-41C6-A461-E5D7312F99C8"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B2B52CA8-8E9F-4EF1-BC60-4C0C672DFABD">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:01207605-4e40-4784-b7e8-7c296bff1d72</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:90494AC1-B993-41E7-8727-362CD90821B0"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:DAD02F8C-D0CF-4D03-A113-8C242E8A7E4F</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:636b6a9f-a53f-43ee-92d9-1e554d4d58e7</pav:previousVersion>
    <pav:createdOn>2015-09-24 15:27:08 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-09-24 15:28:24 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:751E61B0-AEF5-4076-A23C-E7295C3E518E">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <pav:createdOn>2015-10-01 10:46:20 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>751E61B0-AEF5-4076-A23C-E7295C3E518E</domeo:uuid>
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so-called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:751E61B0-AEF5-4076-A23C-E7295C3E518E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:50F3FA34-07BC-42B4-A034-5917E4C79B90">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-03 15:59:17 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-16 10:42:46 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:5BEA2001-CB06-4507-A35E-7F6F162CB5CE</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N5603255c5dae4f219ff2ceefacbfbabd"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:8BE1D504-E827-4C18-9964-E3C350BE0A35"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:11A52C7C-23D0-4A66-9D3B-9B054A8CC4C9">
    <pav:createdOn>2015-10-14 12:06:24 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:C91289D7-45EC-44D1-A933-E79E770CFE71</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:B2B35601-1AB1-4715-8483-63B09D394B71"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-14 12:07:40 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:681BADBA-A7DA-414A-9E7A-F48859411242">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-09-29 09:47:39 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:764C3740-FD65-4B29-B8A9-76436266890F"/>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:4B38B6D4-EBA9-4CD8-B6FB-6EC6E871BBB9</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6E1C4379-985E-4A39-B253-07A55A93BFCE">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:948ADEC5-BE5C-417D-B3E9-CBBE68C184F6"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6087EDDF-DC67-4E63-A031-8DD850131D3E">
    <pav:createdOn>2015-09-24 15:54:35 -0400</pav:createdOn>
    <ao:exact>Results of in vitro studies demonstrate that duloxetine does not inhibit activity. In a clinical study, the pharmacokinetics of S-warfarin, a CYP2C9 substrate, were not significantly affected by duloxetine [see DRUG INTERACTIONS (7.4)]. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>7.10 Drugs Metabolized by CYP2C9   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6087EDDF-DC67-4E63-A031-8DD850131D3E"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>6087EDDF-DC67-4E63-A031-8DD850131D3E</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C3FFAA74-97B8-4C05-8DD1-D5CD4AB8EFFB">
    <rdfs:label>quinidine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9068</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8FE246CE-5429-489B-A255-1BC9C23AA17E">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>sertraline</rdfs:label>
    <dikbD2R:dose>100</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D75C7F62-CC9A-4600-8009-82D778F5EF67">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A0A9E06E-7395-4665-ABB3-4C779A9747CF"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4A04CDE4-D2EB-43B5-8A0F-ACB912CEA762">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:24DCF383-153B-4640-8043-7C4632C5F4AA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:659993FA-47A6-4170-A1F4-37E021B93D40</pav:previousVersion>
    <pav:createdOn>2015-10-20 09:54:44 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N77dc8b84efcb48999b14b3b3caa1ee13"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-10-20 09:56:31 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D1506DE0-38C5-44C2-A094-5E512962C351">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-09-16 15:31:12 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:113747B9-5C5D-4307-8820-565251C9A736</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0468AC6B-4F06-4CA4-A0DE-A389E3B0E59F</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-16 15:19:52 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:E34DCA29-F2E0-4985-A084-C94BE7317FA3"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N8dc96ff55de7453d8340b1264c113d58"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F3F07E2E-E25B-424B-AA80-B08BAD54201F">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6C4DFA91-EA88-42F6-B8FF-A57CAF81EDC4"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:auc>2.9</dikbD2R:auc>
    <dikbD2R:cmax>2.8</dikbD2R:cmax>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F3C5F26C-D9B0-4BD8-B3F1-895B266B8F19"/>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/AADE7CB7-E435-496B-B17E-356F55E52666">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>levothyroxine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/667F4564-91BB-401E-B9B5-95DF59D58FCF">
    <rdfs:label>ciprofloxacin</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D93184E6-2126-4874-BB5B-16B99244195C">
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="Nb2718ba3935a4f369425c1a275c700fb"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DC54EBE-B2A9-4AE7-A174-F0074ECE4050</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:BEBEC3AC-7C36-4E2B-A26D-DDF84DCF6384</pav:lineageUri>
    <pav:createdOn>2015-10-01 10:49:17 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:460FF567-9498-4139-B837-750F5B71C8E1"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/111B7914-2953-406F-8FAB-9BBE7433B477">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11413</dailymed:activeMoietyRxCUI>
    <rdfs:label>zidovudine</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B91C9D9B-7F7A-45C2-B412-779E4ED0B89F">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:EAB351E9-0B37-4AB3-8A05-81214FE5B573"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0CCAA492-719D-47DE-AA19-07E516423E35">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-29 11:27:40 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0CCAA492-719D-47DE-AA19-07E516423E35"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <domeo:uuid>0CCAA492-719D-47DE-AA19-07E516423E35</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D4999237-8ABE-40BC-84FD-C56A1401D2D2">
    <domeo:uuid>D4999237-8ABE-40BC-84FD-C56A1401D2D2</domeo:uuid>
    <pav:createdOn>2015-10-14 11:41:41 -0400</pav:createdOn>
    <ao:prefix>Concomitant </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:suffix>administration may reduce the absorption of </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D4999237-8ABE-40BC-84FD-C56A1401D2D2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>antacid </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4956715B-3516-4F6B-88A7-D02C6FF49410">
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <pav:createdOn>2015-09-29 11:27:58 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>4956715B-3516-4F6B-88A7-D02C6FF49410</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4956715B-3516-4F6B-88A7-D02C6FF49410"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D61A1061-76F8-4260-8644-9EAD2CB79E2D">
    <pav:lineageUri>urn:domeoserver:annotation:637CCD0C-C350-46F9-83FF-CA310D62AE41</pav:lineageUri>
    <ao:body rdf:nodeID="Nbe5d2e8b2a804815826a1de8597b6530"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-13 12:06:23 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-13 12:05:41 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:4DAD0D87-6F37-4D74-A08E-92E60EF28FC2"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9140882ddcf54c1f8c7b84d3cd98177b">
    <domeo:sets rdf:resource="urn:pddi:uuid:9EF12F1F-E2EE-4CA1-BCB7-F585C3CEE70F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B74E0947-30D8-4BF5-8A3D-3FA2A563D6F4">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-24 15:51:20 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B74E0947-30D8-4BF5-8A3D-3FA2A563D6F4"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>B74E0947-30D8-4BF5-8A3D-3FA2A563D6F4</domeo:uuid>
    <ao:exact>Under steady-state conditions for duloxetine (20 mg qhs) and temazepam (30 mg qhs), the pharmacokinetics of duloxetine were not affected by co-administration. </ao:exact>
    <ao:prefix>   7.6 Temazepam   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EDD4DE44-60E0-4BF7-9358-79D622BDEFA1">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-01 10:47:47 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:0E651153-623D-4039-82E6-625B00CEEB3C"/>
    <ao:body rdf:nodeID="N4b3eff938be543eeaf8c0ab984e89adf"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:4D7FC115-7AD4-4309-A99B-A1F704274134</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DC54EBE-B2A9-4AE7-A174-F0074ECE4050</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0E42BE9D-B2A1-4386-8950-C7CAB5B597C4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Clinical studies have not shown any drug interactions between bicalutamide and LHRH analogs (goserelin or leuprolide). There is no evidence that bicalutamide induces hepatic enzymes</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0E42BE9D-B2A1-4386-8950-C7CAB5B597C4"/>
    <domeo:uuid>0E42BE9D-B2A1-4386-8950-C7CAB5B597C4</domeo:uuid>
    <pav:createdOn>2015-08-20 10:19:11 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7c295b64-ec39-42ec-9f02-da5b42e775e1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0A70CC02-9A9C-4466-8795-549262C22BD3">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3750C2AF-6026-4CF2-A9F2-7BF65EADDC13">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>milnacipran</rdfs:label>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E7A45CEA-7937-491F-B3A3-4881D2AFA749">
    <pav:createdOn>2015-08-20 12:46:56 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E7A45CEA-7937-491F-B3A3-4881D2AFA749"/>
    <domeo:uuid>E7A45CEA-7937-491F-B3A3-4881D2AFA749</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>on BCRP and organic anion transporting polypeptide B1 and B3 (OATP1B1/1B3) substrates   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2E5FECF6-16DC-4945-8E25-05D048937F3D">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/38400</dailymed:activeMoietyRxCUI>
    <rdfs:label>atomoxetine</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3E13D693-2C73-45B2-B2BC-9FE20BA414C4">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Rifampin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9303401C-5BCA-46CD-9B7D-8236FF8DBC6D">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>ketoconazole</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0693FC56-21C5-448E-A068-8F71FB6D5E24">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin. If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached [see Contraindications (4) and Warnings and Precautions (5)]. </ao:exact>
    <ao:prefix>metabolism have not been studied.  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0693FC56-21C5-448E-A068-8F71FB6D5E24"/>
    <pav:createdOn>2015-10-16 10:53:33 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:77E5C5F7-F081-480C-88EC-AE783CBA6721">
    <pav:lineageUri>urn:domeoserver:annotation:3999A0C9-95C2-4FB6-BF0E-AF9A7861046F</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:6A520B73-CABB-446D-A745-518C38326EE8"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-29 11:26:42 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:042A1769-B51E-4433-9B39-4695B177BC75">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See </ao:suffix>
    <ao:exact>saquinavir</ao:exact>
    <ao:prefix>, </ao:prefix>
    <domeo:uuid>042A1769-B51E-4433-9B39-4695B177BC75</domeo:uuid>
    <pav:createdOn>2015-10-14 11:40:00 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:042A1769-B51E-4433-9B39-4695B177BC75"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:50448CFC-87BB-4F11-9507-87FA713CD169">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:nodeID="N862d50c2c63a4589a7b52e0b7219076a"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <pav:createdOn>2015-09-03 15:40:30 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:BF104FC9-4328-4D52-96EB-84787C485B64"/>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>urn:domeoclient:uuid:a7f59b4d-3ada-4384-adb1-665a4a1743c8</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0AA7C57A-C28F-4C48-BC86-A8B2F1DDC411">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:57A59D65-4528-4D1E-957A-2E6348B38F4D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B96BE6A9-C9A5-46A2-9EEA-CFC9F7788F2E">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5C7A8838-1DAA-4F75-8607-B4E403B17B6C"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BFF23E68-FE10-45CB-9065-88EBB1D41D71">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>BFF23E68-FE10-45CB-9065-88EBB1D41D71</domeo:uuid>
    <pav:createdOn>2015-09-25 10:43:10 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BFF23E68-FE10-45CB-9065-88EBB1D41D71"/>
    <ao:prefix>  Amitriptyline  </ao:prefix>
    <ao:exact>In healthy, CYP2D6 extensive metabolizer patients (n=32), amitriptyline (75 mg daily), at steady state, did not cause relevant changes in the pharmacokinetics of steady state mirtazapine (30 mg daily); mirtazapine also did not cause relevant changes to the pharmacokinetics of amitriptyline.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0EB5CB42-9D8F-4FB8-844D-205FA00A437B">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>ketoconazole</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>200</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:828ADF4C-8F84-4AE2-BB18-82DCC3BFEE8E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:comment>plasma concentration of imipramine may decrease</dikbD2R:comment>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F0C18349-F3A3-4E26-8CE9-BF9ABD45297A"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:736AE15B-A2FB-4A1B-837E-E60FC4298542">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <ao:prefix>) and many that are substrates for P450 2D6 (many other antidepressants, </ao:prefix>
    <ao:suffix>, and the Type 1C antiarrhythmics </ao:suffix>
    <domeo:uuid>736AE15B-A2FB-4A1B-837E-E60FC4298542</domeo:uuid>
    <ao:exact>phenothiazines</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:736AE15B-A2FB-4A1B-837E-E60FC4298542"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-01 10:30:31 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BFFBA8AD-6CB0-4C7B-BF7A-C52DCC64A4BA">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A48D457C-C4DA-41E4-9B8B-37D2AF09F492"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/19D299D1-2568-4788-8A52-79F3B46873DB">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/0</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>phenothiazines</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:18202B9F-45FD-4DE0-A36C-EB4CDED5C7F4">
    <ao:body rdf:nodeID="N129e82459ed24b188ac34885f682cf28"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:FBE40000-71A9-4A4B-82B7-04B4172DDA4C</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-10-14 12:10:54 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:7215FF49-D455-4A62-98AA-9F3FBD686D8C"/>
    <pav:lastSavedOn>2015-10-14 12:10:56 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/39E54E44-CA4A-4506-890C-C71468CB0071">
    <rdfs:label>phenobarbital</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8134</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E5B17E24-8354-4EB7-BCE1-276BD496416C">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10438</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>6.5 or 12 mg/kg</dikbD2R:dose>
    <rdfs:label>theophylline</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3908dc2259d242f091573a59d6525eb2">
    <domeo:sets rdf:resource="urn:pddi:uuid:CEA91607-0BA5-49A7-8FEE-F739EA74F261"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FC641720-6E94-4C53-951F-25C1172B97B8">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>FC641720-6E94-4C53-951F-25C1172B97B8</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FC641720-6E94-4C53-951F-25C1172B97B8"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In a CYP2C8 drug-drug interaction trial in healthy subjects, the AUC of pioglitazone (CYP2C8 substrate) was increased by 46% when pioglitazone was given together with a single dose of 1,000 mg abiraterone acetate. Therefore, patients should be monitored closely for signs of toxicity related to a CYP2C8 substrate with a narrow therapeutic index if used concomitantly with ZYTIGA [see Clinical Pharmacology (12.3)].</ao:exact>
    <ao:prefix>Clinical Pharmacology (12.3) ] .  </ao:prefix>
    <pav:createdOn>2015-08-20 11:08:37 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:90D0ECD1-D2C8-4CCE-A552-0576C3C2A783">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:27930AA1-7502-491C-B456-7D079712EC2C"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1EAD1B21-BE15-4960-B81D-9B59CFD37A6E">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-09-29 09:44:24 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:53835F6B-C832-443C-BC55-21D245D31C42"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:3114014C-95D3-4DBC-8924-1E0CC318D2B2</pav:lineageUri>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:15766629-36ED-4174-9263-26C964E1791C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>atovaquone </ao:exact>
    <domeo:uuid>15766629-36ED-4174-9263-26C964E1791C</domeo:uuid>
    <pav:createdOn>2015-10-14 11:41:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:15766629-36ED-4174-9263-26C964E1791C"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:prefix>When the two drugs were taken concomitantly, decreased concentrations of </ao:prefix>
    <ao:suffix>and increased concentrations of rifampin were observed.</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:61DE5E52-F63C-4CA7-AE6A-4442B330D15F">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7877A319-101E-4CC2-90ED-DEAC61D4C354"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2D6B6138-C5FF-4667-AF3D-AEF8EFB27C66">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>400</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>desvenlafaxine succinate</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3C34201F-1651-4A2A-B927-94C1E3EC79BC">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F4722E24-22E4-4C54-A2FE-EB7888ED53DF"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:431F3FB0-9ED9-4DCB-9738-492413431665">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E47B0D2D-E792-4A25-9141-4236C7ED5483"/>
    <dikbD2R:comment>Reduced plasma concentration of saquinavir</dikbD2R:comment>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B9988126-6B74-45A7-89BE-556C38D6B120">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/0</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>Benzodiazepines</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:60383C47-9637-4716-B18F-42EABF19C871">
    <ao:prefix>and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>rifampin </ao:exact>
    <pav:createdOn>2015-10-14 11:41:29 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:60383C47-9637-4716-B18F-42EABF19C871"/>
    <domeo:uuid>60383C47-9637-4716-B18F-42EABF19C871</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>has resulted in decreased serum concentrations of both drugs. Concurrent use of rifampin and enalapril has resulted in decreased concentrations of enalaprilat, the active metabolite of enalapril. Dosage adjustments should be made if indicated by the pati</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D4C98CB4-FEB5-4061-B1B8-36CE8BD2B5FE">
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptRegimens>Q8</dikbD2R:preciptRegimens>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B0A09D3F-2B66-4107-AC03-967A6FECA31C"/>
    <dikbD2R:t12Direction>Increase</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:auc>89</dikbD2R:auc>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12>34</dikbD2R:t12>
    <dikbD2R:cmax>30</dikbD2R:cmax>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7354A25D-D05D-4C91-BB76-5928D1D5DE96"/>
    <dikbD2R:t12Type>Percent</dikbD2R:t12Type>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectRegimens>Q8</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:760D0D9E-F966-4419-95C3-5DB2977A9CD8">
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmax>1.5</dikbD2R:cmax>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EE863A57-ECAA-42C6-9176-A28AEE4CA1B0"/>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6488D76E-6BAD-424B-AF80-2CD63E0D8E94"/>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:auc>1.9</dikbD2R:auc>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9A16A252-5C55-4B94-91E9-2F665BF72296">
    <ao:prefix>did not significantly alter steady-state lithium levels or the renal clearance of </ao:prefix>
    <pav:createdOn>2015-09-16 15:22:45 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9A16A252-5C55-4B94-91E9-2F665BF72296"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>lithium</ao:exact>
    <ao:suffix>.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0971333E-F8EA-459F-9907-212F5277738C">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>160</dikbD2R:dose>
    <rdfs:label>propranolol</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8787</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A906518C-A45F-43E6-88EF-1DCB10E013E1">
    <ao:prefix>   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-16 10:42:43 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <domeo:uuid>A906518C-A45F-43E6-88EF-1DCB10E013E1</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A906518C-A45F-43E6-88EF-1DCB10E013E1"/>
    <ao:exact>Risperidone    In subjects who had received EMSAM 6 mg per 24 hours for 10 days, co-administration with risperidone (2 mg per day for 7 days), a substrate for CYP2D6, did not affect the pharmacokinetics of selegiline or risperidone [see Drug Interactions (7.4) and (7.5)].    Warfarin</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:49746603-5E54-4D89-8C88-A0A5870FA4E2">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:6B50E664-BD71-432E-B7FA-E7313EFF76E1</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:612A9701-97C1-4777-9126-4DB30D220898"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-20 10:17:43 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-20 10:19:28 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E295FB18-445C-46DC-A345-CA0DD6C242E7">
    <ao:exact>Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See CONTRAINDICATIONS.) </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>with drugs that undergo biotransformation through these metabolic pathways may accelerate elimination of coadministered drugs. To maintain optimum therapeutic blood levels, dosages of drugs metabolized by these enzymes may require adjustment when starting or stopping concomitantly administered rifampin.  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>E295FB18-445C-46DC-A345-CA0DD6C242E7</domeo:uuid>
    <pav:createdOn>2015-10-14 11:54:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E295FB18-445C-46DC-A345-CA0DD6C242E7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B4FE1A5F-829C-4CC5-BE0B-4AEA61773EC2">
    <domeo:uuid>B4FE1A5F-829C-4CC5-BE0B-4AEA61773EC2</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B4FE1A5F-829C-4CC5-BE0B-4AEA61773EC2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-29 11:27:03 -0400</pav:createdOn>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2B6DC982-E12E-48B2-ADAE-398E867DB33B">
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:CD125CC8-4856-4783-915D-FBF10607155C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:fc9e17d3-1b0d-4635-9936-0d1d94cb01f9</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CE635F27-A391-4A6B-9D87-339FA2F114B2</domeo:belongsToSet>
    <pav:createdOn>2015-09-14 11:05:46 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:17CFEF69-CCC6-4ACD-8A24-0425991EC98C</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-09-14 11:21:10 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N2bd056353cd648f59518ad341749e9ac"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:115D5A34-6458-49C4-877C-C47E0DF5BDBB">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:FF54DED3-0DAD-48FA-89EC-483B19DA2272"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7993A459-EE66-4E96-8A86-86C5B2BB1378">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>bicalutamide</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A9729445-9798-4C2A-83D8-20CA3981A6AA">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BFBA4537-CED4-4AF7-B0C1-888C3022EEE9"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FA376B57-1C54-4E13-9401-6D5DA4BC8B21">
    <dikbD2R:comment>TCA plasma levels decreased</dikbD2R:comment>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:97943AA2-332D-4556-8948-4D75AFC7615D"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:48CBCF3A-2676-4D9E-8A2A-3E1ABC922C14">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:406A52AA-3726-4E58-981B-A95F7F133543</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:1EE1AB5E-8FFE-42C9-92E5-AAE6F8056F8D"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:33B17719-DF97-48EA-AFA2-01DE8A8887B4</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-01 10:27:31 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8784e7551f604001a50ec1b139326131">
    <domeo:sets rdf:resource="urn:pddi:uuid:5FFC5498-009C-4E07-8452-B0F49319598D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3FF5F418-AF79-4A81-A155-A741E18FA662">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4D4EC995-8A3D-480A-B829-70BAB8069C62"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/1BB95734-B178-4799-AF06-C9F9B16FCFF5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F87055E3-1DB3-43ED-9639-5EE3B5AD76E4">
    <ao:exact>Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F87055E3-1DB3-43ED-9639-5EE3B5AD76E4"/>
    <pav:createdOn>2015-08-20 11:45:06 -0400</pav:createdOn>
    <ao:prefix>on organic anion transporter 3 (OAT3) substrates   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23F1AAA6-DEFE-4DC7-BBDA-BF4E31C4CF53">
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DC54EBE-B2A9-4AE7-A174-F0074ECE4050</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:34F72160-DA4C-44B3-8929-42E3BE9A47B9</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:70D88A1D-C8FC-4808-B566-E45FDA68E548"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-10-01 10:48:35 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N6fb2a40ec1e2482cadaffb63019ed838"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3E3F5537-2CCB-43FE-9963-2617094F1725">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-13 11:12:39 -0400</pav:createdOn>
    <ao:exact>The metabolism of saquinavir is mediated primarily by CYP3A. Additionally, saquinavir is a substrate for P-glycoprotein (P-gp). Therefore, drugs that affect CYP3A and/or P-gp may modify the pharmacokinetics of saquinavir. Coadministration with drugs that are potent inducers of CYP3A (e.g., phenobarbital, phenytoin, carbamazepine) may result in decreased plasma concentrations of saquinavir and reduced therapeutic effect.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c00d1607-ac36-457b-a34b-75ad74f9cf0a.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>7.2 Potential for Other Drugs to Affect INVIRASE  </ao:prefix>
    <domeo:uuid>3E3F5537-2CCB-43FE-9963-2617094F1725</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3E3F5537-2CCB-43FE-9963-2617094F1725"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9966E472-7F69-441E-900C-832EE2412A01">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-01 10:29:37 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9966E472-7F69-441E-900C-832EE2412A01"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7-10% of Caucasians are so-called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).  </ao:prefix>
    <domeo:uuid>9966E472-7F69-441E-900C-832EE2412A01</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:979614C6-94A5-490B-A19B-F12114DD0DAC">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-03 15:39:46 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>Clinical Pharmacology (12.3) ] .  </ao:prefix>
    <ao:exact>No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:979614C6-94A5-490B-A19B-F12114DD0DAC"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/865E4C7F-47D5-45C4-AB41-489475A35229">
    <rdfs:label>TCA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:99AACB16-26B2-48A8-A0C4-B33A03BB516E">
    <ao:body rdf:nodeID="Nafb244aa071544abad24a1117aefd082"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:fc9e17d3-1b0d-4635-9936-0d1d94cb01f9</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:CEA4E0A9-4D52-4D06-B7F7-888CAB312880</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CE635F27-A391-4A6B-9D87-339FA2F114B2</domeo:belongsToSet>
    <pav:lastSavedOn>2015-09-14 11:31:14 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:createdOn>2015-09-14 11:27:16 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:B19C53E8-0CF6-4AD1-8709-E55FCCF854C9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DB76C2E5-8252-49A4-BFA1-4F1701011171">
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FC30EFD3-8B33-4D31-8F77-295276999DDB"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/32B97A0F-D811-4EE0-8AAE-809811B56CA2"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectFormulation>transdermal</dikbD2R:objectFormulation>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:objectDuration>7</dikbD2R:objectDuration>
    <dikbD2R:auc>Unk</dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DDEB9FF7-9051-4C5C-B5F5-3024924A4C1A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:942E45EF-3423-4659-B2DE-B4AD453CDAA3</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:body rdf:nodeID="Naf47738a2353418c8d674520dfab0d57"/>
    <pav:lastSavedOn>2015-09-14 11:00:37 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:fc9e17d3-1b0d-4635-9936-0d1d94cb01f9</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:F3B380E6-A0A2-495E-9596-D1BB480F7139"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CE635F27-A391-4A6B-9D87-339FA2F114B2</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-09-14 11:00:35 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/189177B9-2F94-4FE1-9AA7-B39DD8C54FF3">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>astemizole</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CF22FF83-C1EE-443C-8E6C-7FF613D550D2">
    <pav:createdOn>2015-10-20 10:18:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>methadone </ao:exact>
    <ao:suffix>treatment, with symptoms of opioid intoxication in one patient. Opioid withdrawal symptoms were reported following fluvoxamine maleate discontinuation in another patient. </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CF22FF83-C1EE-443C-8E6C-7FF613D550D2"/>
    <ao:prefix> was administered to patients receiving maintenance </ao:prefix>
    <domeo:uuid>CF22FF83-C1EE-443C-8E6C-7FF613D550D2</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EBF713BB-1E6D-47A7-8F3E-03103D4DDABB">
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:C91289D7-45EC-44D1-A933-E79E770CFE71</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-14 12:06:18 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-14 12:07:40 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:D90EB4B6-E985-43E3-95F8-50682DE27976"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/AD48AD7C-557A-4CB1-AA9B-6A3B71F41DD3">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>lithium</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D14AD1F5-2795-478C-B8D7-016316593E1D">
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-14 11:40:56 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:18B599FF-6A4D-4DA0-ACE9-6D889D08EF91"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3B64C840-21D5-4CE4-8EC2-93996F21CDBE">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0216D85F-E05A-4F90-9F6E-C044A9A60534"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2DCB43A8-8406-477E-81DA-8D31F9114345">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5C474472-3F94-474B-8730-D2B30165E24B"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:cmaxDirection>Decrease</dikbD2R:cmaxDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmax>16</dikbD2R:cmax>
    <dikbD2R:auc>31</dikbD2R:auc>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/285EAC7B-9DBA-4700-B619-67A16BEA39A1"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7C5552C6-29B8-4ED1-9F08-13DBD5700F83">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>paroxetine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/51B5EF7C-E93D-4C1C-BC56-CB80905FE771">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>30</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>cimetidine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:21FFFD1F-27FA-48ED-9946-A15455B6663F">
    <ao:suffix>, e.g., </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <ao:exact>SSRIs</ao:exact>
    <domeo:uuid>21FFFD1F-27FA-48ED-9946-A15455B6663F</domeo:uuid>
    <pav:createdOn>2015-09-29 11:24:12 -0400</pav:createdOn>
    <ao:prefix>, and the Type IC antiarrhythmics propafenone and flecainide ). While all the </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:21FFFD1F-27FA-48ED-9946-A15455B6663F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6E461CD6-F6B6-4B30-AB90-8DDD1F8359BC">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>6E461CD6-F6B6-4B30-AB90-8DDD1F8359BC</domeo:uuid>
    <ao:exact>Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam, etc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine. The clearance of benzodiazepines metabolized by glucuronidation (e.g., lorazepam, oxazepam, temazepam) is unlikely to be affected by fluvoxamine. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix>    Benzodiazepines   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-20 09:54:55 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6E461CD6-F6B6-4B30-AB90-8DDD1F8359BC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1FE06F45-1F25-4B8A-BCC6-643822373F72">
    <ao:prefix>s) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA ).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-29 09:04:23 -0400</pav:createdOn>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <domeo:uuid>1FE06F45-1F25-4B8A-BCC6-643822373F72</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1FE06F45-1F25-4B8A-BCC6-643822373F72"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E9E731BC-5E28-4A8A-8D61-8F51D24308C2">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:578FFC0A-4CDA-4416-BFFC-A3FAE69D7251"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E4DB9111-A9D8-47D5-ACE0-D3115A4EFD3E">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:87BD3438-6149-4E4C-8BF3-06DA4B3C606F"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:765E9F86-0CF5-4A87-A414-84F349811B56">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D1CB5FB6-B52C-4C3C-92FE-C19859D7DE37"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2FAF8BCF-F265-4F1D-8051-5D46B4ECB7DB">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6904B5FE-0AB5-4344-9576-006B816BB934"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/63B9442A-C267-404B-B347-4599E7805D8C">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <rdfs:label>carbamazepine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/57A6491F-ECEC-432E-80B5-4DDD07163F42">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>50</dikbD2R:dose>
    <rdfs:label>duloxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C6AA5EA2-3B4B-43F6-AB33-C888E340ADBA">
    <ao:exact>pimozide </ao:exact>
    <domeo:uuid>C6AA5EA2-3B4B-43F6-AB33-C888E340ADBA</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <ao:prefix>administered alone. The increase in </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>AUC and C</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C6AA5EA2-3B4B-43F6-AB33-C888E340ADBA"/>
    <pav:createdOn>2015-10-14 12:08:06 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:444EB9F5-84A6-404E-8D80-D5B360E815F8">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:ECA01409-8751-4283-B80A-3D7F33F3AD0D"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8FDA1CCB-9373-49CD-A744-492499262BC8">
    <rdfs:label>rosiglitazone</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/84108</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4EDAEED2-601E-4BEF-9ED8-F608AB876ED9">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C4028117-2B50-48F6-B563-925853DCA6D2"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/23A9B45E-3F21-4526-A6C9-6E0EA480729C"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:017082FB-C40B-493A-B2B5-09825691F4C8">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-10-14 11:53:41 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:9A189470-8B19-4E49-801A-71BB695D839D</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N3ae82a846ef0407d8ceb51cf8ab2cd25"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:E4FDFAA3-782F-4615-9FCD-54B42668753C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-14 11:57:06 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A39CA8D6-8728-4BBC-92CC-0C2F2A887E44">
    <pav:createdOn>2015-10-14 12:06:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A39CA8D6-8728-4BBC-92CC-0C2F2A887E44"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>citalopram </ao:exact>
    <ao:suffix>did not alter the mean AUC or C</ao:suffix>
    <domeo:uuid>A39CA8D6-8728-4BBC-92CC-0C2F2A887E44</domeo:uuid>
    <ao:prefix>given alone. Racemic </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:84ECF375-4665-4E02-9C87-C3E902230404">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:exact>enalapril </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:84ECF375-4665-4E02-9C87-C3E902230404"/>
    <ao:prefix>and </ao:prefix>
    <pav:createdOn>2015-10-14 11:41:32 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>has resulted in decreased concentrations of enalaprilat, the active metabolite of enalapril. Dosage adjustments should be made if indicated by the patients clinical condition.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>84ECF375-4665-4E02-9C87-C3E902230404</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E68B0DFB-C662-44AB-8D18-073EB1AC2659">
    <rdfs:label>fluvoxamine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:93703B81-928E-4914-8CD8-F441879EC8E3">
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D7B35CE6-E8F3-4D41-AFF4-8D0B71C1EA9D"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/38909539-9756-4591-9D9B-919942FEC53A"/>
    <dikbD2R:cl>2</dikbD2R:cl>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:numOfParticipants>24</dikbD2R:numOfParticipants>
    <dikbD2R:clType>Fold</dikbD2R:clType>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:clDirection>Increase</dikbD2R:clDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2F5CD38D-ACDF-497A-B31B-191BD5E31A57">
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-29 09:25:18 -0400</pav:createdOn>
    <ao:prefix>hydroxylase) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2F5CD38D-ACDF-497A-B31B-191BD5E31A57"/>
    <domeo:uuid>2F5CD38D-ACDF-497A-B31B-191BD5E31A57</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:96356D4B-BE9C-4D1B-A933-FE5531AAEBD2">
    <pav:createdOn>2015-09-29 08:59:21 -0400</pav:createdOn>
    <ao:suffix> or the other drug. Furthermore, whenever one of these other drugs is withdrawn from cotherapy, an increased dose of tricyclic antidepressant may be required. It is desirable to monitor TCA plasma levels whenever a TCA is going to be coadministered with </ao:suffix>
    <ao:prefix> with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:96356D4B-BE9C-4D1B-A933-FE5531AAEBD2"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <domeo:uuid>96356D4B-BE9C-4D1B-A933-FE5531AAEBD2</domeo:uuid>
    <ao:exact>tricyclic antidepressant</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/ae020e7f-0797-4a91-b8b9-d041676f17d3">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CE635F27-A391-4A6B-9D87-339FA2F114B2</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-08-27 14:50:27 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-08-27 14:50:27 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:fc9e17d3-1b0d-4635-9936-0d1d94cb01f9</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:1e1181d5-903c-4c15-b5b0-40539c6cefa8"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc45b52497fe54dbfaf9c19b10aafffb7">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D118C509-DE8C-4A8E-BB86-21CFE1955841">
    <pav:createdOn>2015-10-14 11:41:45 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:134605F4-D17D-4BB9-9F01-8B55B07ECC2D"/>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C9EFCE7A-9214-4308-A7B3-CE8E69647709">
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5230D4C8-6846-4BBF-9B52-C9DE46AEA077"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants>6</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E72ECA10-90B7-4236-9644-A6CFEAF3BE5E"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N661dbbfdab73461bba3cfde7ffcaab04">
    <domeo:sets rdf:resource="urn:pddi:uuid:B92ABAA1-4178-40A5-B402-750AF29F1F5A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C0B10178-37CF-42CE-A06A-8A0898C76D4F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>concentrations resulted in decreased psychomotor performance and memory. This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is coadministered, particularly since fluvoxamine </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <domeo:uuid>C0B10178-37CF-42CE-A06A-8A0898C76D4F</domeo:uuid>
    <pav:createdOn>2015-10-20 09:56:57 -0400</pav:createdOn>
    <ao:prefix>was administered alone; oral clearance was reduced by about 50%. The elevated plasma </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C0B10178-37CF-42CE-A06A-8A0898C76D4F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>alprazolam </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CC1E8980-8CD3-4995-B3AA-F252FF147351">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:33788CB0-C207-4240-952C-9CF5BB6A4E8A"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:424C6CE5-EDF5-4A96-BB21-222F75EB72FC">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:90CC2977-9DCD-4239-AA94-3A12FFC5DDD0"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C53210CC-8E79-4DEA-B11A-B10AF0BF8EDE">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:CF7387C9-0803-4113-B425-440E35501B08"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8070CCDE-FB1C-4EFF-BF7E-3FEA17B3EB0A">
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/107EDD01-3DB7-41CE-B570-FA04C3B4DF7F"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/552431F0-DFBD-48DB-8DA4-9133DD2E8A85"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:auc>1.7</dikbD2R:auc>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B2DA9535-7AB8-4F96-83AC-D65C091E22F1">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>repaglinide</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/73044</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:28071b68-eb46-415c-b53c-52b3a4a35218">
    <ao:exact>cimetidine</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>, fluoxetine</ao:suffix>
    <ao:prefix>e.g., </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-08-27 14:50:14 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:28071b68-eb46-415c-b53c-52b3a4a35218"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1EE1AB5E-8FFE-42C9-92E5-AAE6F8056F8D">
    <ao:prefix>-</ao:prefix>
    <ao:exact>TCA</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>1EE1AB5E-8FFE-42C9-92E5-AAE6F8056F8D</domeo:uuid>
    <ao:suffix> interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficien</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1EE1AB5E-8FFE-42C9-92E5-AAE6F8056F8D"/>
    <pav:createdOn>2015-10-01 10:27:31 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9793E575-E9F3-4454-A73F-F38F27E06168">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:760D0D9E-F966-4419-95C3-5DB2977A9CD8"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/1A2B9EE2-F5E7-40AD-ABD4-D303AD3ECB8B">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
    <rdfs:label>clarithromycin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:59AA3350-6C71-4B9C-83AC-E3303FC1EFC3">
    <pav:createdOn>2015-10-20 09:54:10 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:659993FA-47A6-4170-A1F4-37E021B93D40</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:lastSavedOn>2015-10-20 09:56:31 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:4A194B83-BBD0-4A1F-830E-1D3CE2352E73"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3C958806-DB41-436F-9C02-EE13E739606D">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:7084298F-F868-484E-9091-B9ED9E4588DB</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:lastSavedOn>2015-08-20 11:43:54 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:4B5DC0ED-67F7-4CE7-8F52-9E71B436F48C"/>
    <pav:createdOn>2015-08-20 11:40:48 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:body rdf:nodeID="N8d49210c58304e228a7b47e0f2751bd1"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8844EE85-76AF-4E48-94F9-5AC9DCB442C7">
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N29ab4e70046e4ef0a085d5c17bd8c724"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-13 11:47:41 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-13 11:52:38 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:58BD31E4-F1E7-44DA-87A9-5298EBD36BEA</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:BB16C304-6BBB-4B51-8956-EE514F98D7D7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A7312858-A9CC-433D-B9AC-C691A114786C">
    <pav:lineageUri>urn:domeoserver:annotationset:fc9e17d3-1b0d-4635-9936-0d1d94cb01f9</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CE635F27-A391-4A6B-9D87-339FA2F114B2</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:lastSavedOn>2015-09-14 11:21:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N60166b5fcfd9443384ec451f7eb77326"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E8A26B3A-BA52-4768-BB64-F9A0C1CB4C22"/>
    <pav:createdOn>2015-09-14 11:11:20 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:17CFEF69-CCC6-4ACD-8A24-0425991EC98C</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B549982E-B184-45EA-8F52-24E289C3EB5A">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="Nd248526e4c5d445eb101b296dce075a8"/>
    <pav:lastSavedOn>2015-09-10 15:01:13 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:9582478F-9CF2-410C-B418-3FB608E47263</pav:lineageUri>
    <pav:createdOn>2015-09-10 15:00:51 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:EF2539F7-AF31-4FEC-AD07-2E959071466F"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E3622504-BDE4-4E34-8683-CA6EFB71F1D3">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5D90DAB9-EA1D-400B-9D40-5E1082910AEE">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:33788CB0-C207-4240-952C-9CF5BB6A4E8A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FB5D506C-FC3B-48A7-9037-1D864C45087A"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/78983CA4-8DC3-4283-A4DD-692E1A2EF9AC"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8EDCFE51-FD29-4AEE-9B50-B418C03E22F1">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>25</dikbD2R:dose>
    <rdfs:label>milnacipran</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C20EF95A-DAE3-4E18-9A61-1035A52F81F2">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-10-14 11:57:06 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:02B840EE-7DB4-4691-8E69-BD0CFCBB8013</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="Nfff1808984d9417a8639d4c00ac5e6a5"/>
    <pav:createdOn>2015-10-14 11:54:18 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:E295FB18-445C-46DC-A345-CA0DD6C242E7"/>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6503C8AA-225C-4574-B860-C4FC53740246">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B853D0D5-2744-4039-91BC-E2D7933A2A5A">
    <ao:context rdf:resource="urn:domeoclient:uuid:15E194A1-3A60-40F1-9A3C-66824617A1C4"/>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdOn>2015-10-14 11:41:17 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FBFC7A2E-312A-4BC0-9A3A-832DBFC6DE79">
    <ao:context rdf:resource="urn:domeoclient:uuid:BD9CF53E-3C56-43E2-97D4-04E1EB146127"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-14 11:40:14 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0FCEDCED-41C1-4198-8B22-0EC7ABCC4985">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:90833F3C-9567-46EC-B92C-320ACABC3374"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:328B72FE-B10D-4804-A1C1-8D2A1FDFD05C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N46c21e06b0c64cc2a2994805fbd89c51"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:8A192ED2-65DB-4545-B76C-04A5EB59DAFD"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-29 09:01:01 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:B7072277-427E-4BD1-A52A-8E9A5627B126</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:778D6A47-413C-47A1-8778-A751B97ABDC2">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:845C5817-1226-427E-B875-634AAB8A4166"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:comment>Increased plasma level</dikbD2R:comment>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7A6AE117-70A3-463F-9A39-4FA23E86E199">
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7-10% of Caucasians are so-called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).  </ao:prefix>
    <pav:createdOn>2015-10-01 10:29:56 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>7A6AE117-70A3-463F-9A39-4FA23E86E199</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7A6AE117-70A3-463F-9A39-4FA23E86E199"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:715D4106-C790-47A3-8A5C-4C871F409FC1">
    <ao:context rdf:resource="urn:domeoclient:uuid:F78D2650-630F-40EA-B7AC-235F8798B509"/>
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="Nc8650a50db2d4bd98428956293b1d420"/>
    <pav:lineageUri>urn:domeoserver:annotation:75273578-2E1A-4745-9F5D-85005F292ED1</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-08-20 11:44:30 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8AEDE37A-F06B-40BE-82F5-302935994D48">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:7CCF3FB2-179D-475F-A019-4B26715301BB"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-29 08:59:08 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:FEED225E-0D8F-4F06-8270-3B141D572DB3</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:249780A8-45D7-4839-9FB2-EEA2029189E8">
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FBDB7A20-21BD-4AA1-BF39-1C4B84B2F8E4"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C0B51BBF-1076-4E1E-B22D-E07C0777D467"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DD376E9C-4957-41AC-8F13-1EED67D1A071">
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptDuration>14</dikbD2R:preciptDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CA284E47-850E-461C-96AB-E6C94F44731C"/>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6BD1AA26-D041-4913-8305-AB000DB6F5B5"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:auc>2</dikbD2R:auc>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:46D60EAD-7099-4467-8AD4-8B299E24C6F6">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="Nd4b872b20d944392ac6617d19df36f00"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-10-20 09:54:55 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:659993FA-47A6-4170-A1F4-37E021B93D40</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-20 09:56:31 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:6E461CD6-F6B6-4B30-AB90-8DDD1F8359BC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:606EFCDA-E3C6-4BAA-AC91-61A3C06FE137">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:606EFCDA-E3C6-4BAA-AC91-61A3C06FE137"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>606EFCDA-E3C6-4BAA-AC91-61A3C06FE137</domeo:uuid>
    <pav:createdOn>2015-08-20 11:19:49 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Abiraterone is a substrate of CYP3A4, in vitro. In a clinical pharmacokinetic interaction study of healthy subjects pretreated with a strong CYP3A4 inducer (rifampin, 600 mg daily for 6 days) followed by a single dose of abiraterone acetate 1,000 mg, the mean plasma AUC of abiraterone was decreased by 55% [see Drug Interactions (7.1)].</ao:exact>
    <ao:prefix>, no increase in systemic exposure of theophylline was observed.  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A82B1C2D-CBC6-4B0F-A77B-5C0B065E335F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>AUBAGIO on CYP2C8 substrates   </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <pav:createdOn>2015-08-20 11:36:33 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A82B1C2D-CBC6-4B0F-A77B-5C0B065E335F"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Teriflunomide is an inhibitor of CYP2C8 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP2C8 as required [see Clinical Pharmacology (12.3)].</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:15CC3D23-04EC-4A4B-87A1-5E550679326E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>. The mechanism of this pharmacodynamic interaction is not known. Concomitant use of Pimozide and Celexa or Lexapro is contraindicated (See </ao:suffix>
    <ao:exact>pimozide</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:15CC3D23-04EC-4A4B-87A1-5E550679326E"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <domeo:uuid>15CC3D23-04EC-4A4B-87A1-5E550679326E</domeo:uuid>
    <pav:createdOn>2015-10-14 12:06:26 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C9877559-D342-4808-A74C-952B3EEC7DC5">
    <rdfs:label>cimetidine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8F380AE4-6978-4D85-8A47-F39014CE091E">
    <pav:createdOn>2015-09-29 08:55:52 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <ao:exact>TCA</ao:exact>
    <domeo:uuid>8F380AE4-6978-4D85-8A47-F39014CE091E</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8F380AE4-6978-4D85-8A47-F39014CE091E"/>
    <ao:suffix>s) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> (</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9B7671EC-793B-41C5-8394-50352EFBEDE4">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <rdfs:label>fluvoxamine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>100</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:29B8806B-B5D6-4242-81BF-2BC2D594B831">
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:BE71BBF5-9A2D-4EBE-83B0-1E019FA0E0F8</domeo:belongsToSet>
    <pav:createdOn>2015-09-25 10:45:07 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-09-25 10:47:09 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:59BC1102-9FDE-4B9B-8654-3C9208A97571</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:1641A711-8F00-44AE-B015-B108EA45AD99"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FB5D506C-FC3B-48A7-9037-1D864C45087A">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>cimetidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A0F0B55C-92C3-42AC-BA8B-D25B34B24813">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#metabolism-decrease</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8728E81F-1288-4E58-86BB-05EB3FFB80F2">
    <rdfs:label>paroxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1C6BED4B-513C-498D-BF7D-7A9355D90DE2">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1C6BED4B-513C-498D-BF7D-7A9355D90DE2"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <ao:exact>Co-administration of CMI with phenobarbital increases plasma concentrations of phenobarbital </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-29 09:45:37 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>with CMI increases plasma concentrations of CMI . </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B65A8359-7809-4E61-8900-BB4D603E7E9E">
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <pav:createdOn>2015-10-14 12:08:07 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-14 12:10:56 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:EF9B9DFB-0591-4732-ABA1-5EDB6CA4C1E1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:7DFF4B77-D3A4-452C-B9E6-2ED385DF4D4A</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F62DAECF-B521-4072-903B-105D028FA312">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42330</dailymed:activeMoietyRxCUI>
    <rdfs:label>terfenadine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1E80249C-6FF0-4079-9846-1144F568ADA5">
    <pav:createdOn>2015-10-14 12:08:01 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>CYP 2D6 inhibitors: In healthy subjects, co-administration of </ao:prefix>
    <ao:suffix>2 mg (single dose) and paroxetine 60 mg resulted in a 151% increase in pimozide AUC and a 62% increase in pimozide C</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1E80249C-6FF0-4079-9846-1144F568ADA5"/>
    <domeo:uuid>1E80249C-6FF0-4079-9846-1144F568ADA5</domeo:uuid>
    <ao:exact>pimozide </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8B2229F0-4792-48AD-AC4D-ED3A99C1FEF5">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/86615DF7-F19A-437E-9B9A-993DFFAE632E"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/688C3B24-3BA8-4AD9-BF02-CB0426E37FDE"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0092DA02-6EBA-4DCF-9402-22C327ADEE16">
    <rdfs:label>fluvoxamine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:85AD7C92-23BA-409A-88A0-4C9FF4A6A25B">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:DF394C97-B9F6-4B73-8E8B-9C6DC8A7F9C2</pav:lineageUri>
    <pav:createdOn>2015-10-14 11:54:29 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-14 11:57:06 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <ao:body rdf:nodeID="Na7880cd1f2ea49ca82c325887616fce3"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:5FEFDED8-D960-4190-87B0-F4EFBAB2463A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9F652A20-6C92-4C08-BE6B-7D2B2E42E6FE">
    <domeo:uuid>9F652A20-6C92-4C08-BE6B-7D2B2E42E6FE</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-20 10:09:13 -0400</pav:createdOn>
    <ao:exact>N-desmethyldiazepam</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9F652A20-6C92-4C08-BE6B-7D2B2E42E6FE"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix>was reduced by 65% and that of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> to a level that was too low to measure over the course of the 2 week long study. </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:27DB7F57-5D1E-4E42-83C6-CF8E80B12686">
    <ao:suffix>metabolized by hepatic oxidation (e.g., </ao:suffix>
    <ao:exact>Benzodiazepines </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-20 09:54:06 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>27DB7F57-5D1E-4E42-83C6-CF8E80B12686</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:27DB7F57-5D1E-4E42-83C6-CF8E80B12686"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5D602923-348F-43D6-9140-86EFFC84570D">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D5353CCD-7B5F-41E1-8B6A-BE4C0729D4C7"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8D650328-BA5C-4D2C-96C2-FD196454F8FD">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <domeo:uuid>8D650328-BA5C-4D2C-96C2-FD196454F8FD</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8D650328-BA5C-4D2C-96C2-FD196454F8FD"/>
    <ao:exact>SSRI </ao:exact>
    <ao:suffix>involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient bein</ao:suffix>
    <pav:createdOn>2015-09-29 11:24:26 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C2D1A9E2-B506-4537-B5A2-2EEF27B55BF1">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-29 08:59:05 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:F0F48489-70C7-46E0-826B-5B9889312076"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:CC8D0863-D4FD-4188-B2D7-891FC70C0335</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3ECB7CC0-8270-4447-8B64-0A0EA6011D97">
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-10-13 12:03:36 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-13 12:04:13 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:B51F4BB3-6BDB-45E7-9399-D93DBC4324AC</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="Na8cbce6f4c2e47f8b0be020eedf963c4"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:BA1E2064-A38B-4525-A6B8-2810448F4E8F"/>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9444B9C5-5E86-416E-9833-D136BC2A2458">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5F179590-78B5-4217-A441-7F5608C0DA39"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/79DF7AA8-5F91-4E74-8FB2-F99518CA0CBC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:58900B65-A479-4EC9-9B5C-D08181AEBB76">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:1B382E42-FA07-45A2-8026-2219D9D03E43"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-09-03 16:19:40 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:B1EADCBC-C313-4654-A821-F05ED825AC54</pav:lineageUri>
    <pav:createdOn>2015-09-03 15:57:10 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:946DE5A8-F174-4332-A17C-C1B1D458457F">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0BAD7033-27BD-4FC8-BB76-051526757B61"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DEF93588-2EC9-41DC-A3ED-F69C039BBCA9">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:36705A85-66C6-4A44-95B1-23CFC807CAC6"/>
    <pav:createdOn>2015-10-14 11:40:32 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3987E061-22F1-4E39-8C8B-35A9C4BB0A1A">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2E7A875D-C094-4C0A-8F23-05E683DED388">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:254C54C9-FE6A-4B90-9E27-B8DAFFA5CE3D"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A23AA743-97C6-4DEB-8331-DD3025461806">
    <ao:prefix>Clinical Pharmacology (12.3) ] .  </ao:prefix>
    <pav:createdOn>2015-09-03 15:39:19 -0400</pav:createdOn>
    <ao:exact>No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A23AA743-97C6-4DEB-8331-DD3025461806"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EA793A2B-1519-4053-B8E2-E9076266C705">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-13 12:02:49 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="Ne533b0ec15b24a228758832ded86c082"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:B51F4BB3-6BDB-45E7-9399-D93DBC4324AC</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-10-13 12:04:13 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:FD12FFE9-C878-4697-B0D7-AF4D13B28A10"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeo:software:id:Domeo-2.1alpha-050">
    <foafx:name>Domeo Annotation Toolkit</foafx:name>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Software"/>
    <foafx:version>2.1alpha</foafx:version>
    <foafx:build>050</foafx:build>
    <rdfs:label>Domeo Annotation Toolkit</rdfs:label>
    <foafx:homepage></foafx:homepage>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8B8ED38F-25A3-4CF1-9385-E137098DB26E">
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdOn>2015-10-14 11:40:21 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:46998416-3B6D-44C3-817E-2ABF94C39647"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/775c860a-4753-45b9-a371-85faaac32a56">
    <pav:lastSavedOn>2015-09-29 16:04:18 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-29 16:04:18 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:39fc80e2-49c4-440e-bd50-1aa2413f2f32</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6F5C24D1-EA99-48CF-B498-A0D89C02B290</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:bea6ab45-b167-4aa7-899d-2dad3f303256"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6B4D7751-1D0A-4847-A1B2-6E0366E2003C">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6904B5FE-0AB5-4344-9576-006B816BB934">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/863F7B25-4328-4C31-A28D-89A3FFD2642E"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/59C70A53-ECAE-4EDE-8CE8-1A4CE4A2CF8B"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:58AF5A91-0D92-4C34-8B7B-E2AB8D21A53A">
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5DF6AE9B-949E-46A3-A206-985DB924A453"/>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CA8EBA33-B837-45E1-B0DE-6F6214286335"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:numOfParticipants>12</dikbD2R:numOfParticipants>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9CEDBF4C-4695-47F9-9724-88EEA750A041">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-25 10:36:05 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:EE3ED664-DC9E-4190-B021-13E58E1157F5"/>
    <pav:lineageUri>urn:domeoserver:annotation:AA4C0729-E731-4AAE-8459-69C0C1F0259A</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-25 10:47:09 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:BE71BBF5-9A2D-4EBE-83B0-1E019FA0E0F8</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N6e5ba7c64c8841a091b5367d508ef847"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CBAB79B3-8313-41B5-999B-25D4F9959A13">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:body rdf:nodeID="N83d8cd20b639458cadf39b8c7b688808"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:0DAF5666-9E53-42D5-B92E-DE2C00764986</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-16 10:51:04 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:252FCE71-378C-4956-9688-A804BE47B43A"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-16 10:55:51 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A157546F-42C1-4855-AE82-E4CD1FDCCBA3">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:3519E134-7F5A-48D2-B805-99B992459417"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E4462C4A-DCA8-486D-9F68-B5E79858E901">
    <rdfs:label>didanosine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3364</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:19CCE768-6894-484E-BE0C-E22478C924A2">
    <pav:previousVersion>urn:domeoserver:annotationset:7AD36F12-4658-4A93-AF58-4FBAE2379926</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-10-16 10:57:21 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-09-10 14:51:24 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:31618939-6349-45FF-B3FD-2B7AB66C2111"/>
    <ao:body rdf:nodeID="Nbbb7234ff838498c8238668259c311b6"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9f5b2469596a452cbf0f8ea661a1004e">
    <domeo:sets rdf:resource="urn:pddi:uuid:BBD6701A-D6BD-4EEC-9666-1F50FE3FFEB6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CED8BF4E-8391-4512-AEA7-FEB082C4D59F">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:89A7DB66-A53E-4F13-9504-6A1D5CDEC34C"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-20 10:09:01 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5603255c5dae4f219ff2ceefacbfbabd">
    <domeo:sets rdf:resource="urn:pddi:uuid:AAE42D5F-9364-403B-8D0D-8000D1C73EDD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6A520B73-CABB-446D-A745-518C38326EE8">
    <pav:createdOn>2015-09-29 11:26:42 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6A520B73-CABB-446D-A745-518C38326EE8"/>
    <ao:prefix>) and many that are substrates for P450 2D6 (many other antidepressants, </ao:prefix>
    <ao:exact>phenothiazines</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>6A520B73-CABB-446D-A745-518C38326EE8</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:612A9701-97C1-4777-9126-4DB30D220898">
    <ao:suffix>have been reported in patients taking fluvoxamine maleate and clozapine. Since clozapine-related seizures and orthostatic hypotension appear to be dose related, the risk of these adverse events may be higher when fluvoxamine and clozapine are coadministe</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>612A9701-97C1-4777-9126-4DB30D220898</domeo:uuid>
    <ao:exact>clozapine </ao:exact>
    <pav:createdOn>2015-10-20 10:17:43 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Elevated serum levels of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:612A9701-97C1-4777-9126-4DB30D220898"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F4340BF5-2166-4478-8A2E-AD0222BFC3E1">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In a CYP2C8 drug-drug interaction trial in healthy subjects, the AUC of pioglitazone was increased by 46% when pioglitazone was given together with a single dose of 1,000 mg abiraterone acetate [see Drug Interactions (7.2)].</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F4340BF5-2166-4478-8A2E-AD0222BFC3E1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>F4340BF5-2166-4478-8A2E-AD0222BFC3E1</domeo:uuid>
    <ao:prefix>[see Drug Interactions (7.1) ] .  </ao:prefix>
    <pav:createdOn>2015-08-20 11:32:01 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0683C2AA-5C90-4CA7-B517-F5C39E62CCE2">
    <domeo:uuid>0683C2AA-5C90-4CA7-B517-F5C39E62CCE2</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0683C2AA-5C90-4CA7-B517-F5C39E62CCE2"/>
    <pav:createdOn>2015-10-20 10:09:07 -0400</pav:createdOn>
    <ao:suffix> were administered a single oral dose of 10 mg of diazepam. In these subjects (N = 8), the clearance of diazepam was reduced by 65% and that of N-desmethyldiazepam to a level that was too low to measure over the course of the 2 week long study. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>fluvoxamine</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix>is derived from a study in which healthy volunteers taking 150 mg/day of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AD1790AB-13B7-460E-B97D-F2C2BD5365A5">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B1830459-C328-439D-A1E8-CCB65A945C9B"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/91D3B9F1-7A05-4728-9595-10D2EC4D8DE8"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A3A2C53B-E138-40AA-AEFA-2806EF8D3E7B">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-14 12:07:40 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:C91289D7-45EC-44D1-A933-E79E770CFE71</pav:lineageUri>
    <pav:createdOn>2015-10-14 12:06:29 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:29BAE9CE-A490-411B-8D51-D180C758A333"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:21C5AF10-BD7A-4667-9B9A-6DFB1A3BB881">
    <pav:createdOn>2015-10-20 10:17:48 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:6B50E664-BD71-432E-B7FA-E7313EFF76E1</pav:previousVersion>
    <pav:lastSavedOn>2015-10-20 10:19:28 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:2EC218B9-538E-4C65-83F9-FF609C0D4C12"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B3D228DE-074E-4B6A-B6E5-4AD387F1C150">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>concentrations should be carefully monitored while patients are receiving digoxin and clarithromycin simultaneously.  </ao:prefix>
    <domeo:uuid>B3D228DE-074E-4B6A-B6E5-4AD387F1C150</domeo:uuid>
    <ao:exact>Colchicine is a substrate for both CYP3A and the efflux transporter, P-glycoprotein (Pgp). Clarithromycin and other macrolides are known to inhibit CYP3A and Pgp. When clarithromycin and colchicine are administered together, inhibition of Pgp and/or CYP3A by clarithromycin may lead to increased exposure to colchicine. Patients should be monitored for clinical symptoms of colchicine toxicity. (See WARNINGS.)</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-13 11:58:32 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B3D228DE-074E-4B6A-B6E5-4AD387F1C150"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D04F3D8D-1B33-4FA9-B0E8-7D32C2B5B39D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:hasSource>
    <ao:prefix>Inhibitors of CYP3A4 ( ketoconazole )   </ao:prefix>
    <ao:exact>CYP3A4 is a minor pathway for the metabolism of desvenlafaxine. In a clinical study, ketoconazole (200 mg BID) increased the area under the concentration vs. time curve (AUC) of desvenlafaxine (400 mg single dose) by about 43% and Cmax by about 8%. Concomitant use of desvenlafaxine with potent inhibitors of CYP3A4 may result in higher concentrations of desvenlafaxine. </ao:exact>
    <domeo:uuid>D04F3D8D-1B33-4FA9-B0E8-7D32C2B5B39D</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-24 15:33:08 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D04F3D8D-1B33-4FA9-B0E8-7D32C2B5B39D"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C9667511-312E-4D0D-BB07-553CDFA26DF5">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>penicillin G</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7C1C174C-14D5-469B-8D3C-57A63B16E0E6">
    <pav:createdOn>2015-10-14 11:40:16 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>7C1C174C-14D5-469B-8D3C-57A63B16E0E6</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>), oral anticoagulants, antifungals (e.g., fluconazole, itraconazole, ketoconazole), barbiturates, beta-blockers, calcium channel blockers (e.g., diltiazem, nifedipine, verapamil), chloramphenicol, clarithromycin, corticosteroids, cyclosporine, cardiac g</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7C1C174C-14D5-469B-8D3C-57A63B16E0E6"/>
    <ao:exact>tocainide</ao:exact>
    <ao:prefix>, </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D47B67A6-F253-4F81-A37E-89462D176513">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, verapamil), chloramphenicol, clarithromycin, corticosteroids, cyclosporine, cardiac glycoside preparations, clofibrate, oral or other systemic hormonal contraceptives, dapsone, diazepam, doxycycline, fluoroquinolones (e.g., ciprofloxacin), haloperidol,</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <pav:createdOn>2015-10-14 11:40:29 -0400</pav:createdOn>
    <ao:exact>nifedipine</ao:exact>
    <ao:prefix>, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D47B67A6-F253-4F81-A37E-89462D176513"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>D47B67A6-F253-4F81-A37E-89462D176513</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:76A0A4B9-D178-4060-963F-C58B74C12622">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N4c91f3fae62e46f98df763131b7c49f2"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:710D2A05-EC79-4BFC-BC3E-436C7AC80BD5</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:0E42BE9D-B2A1-4386-8950-C7CAB5B597C4"/>
    <pav:createdOn>2015-08-20 10:19:11 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:69668BF0-57FC-44E8-9743-63D637403A06</pav:lineageUri>
    <pav:lastSavedOn>2015-08-20 10:29:59 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BEDC3045-C5EC-49D7-A08E-F5208415E81B">
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/69349014-805B-4A65-8A67-2CA6C7BD2BBA"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptDuration>14</dikbD2R:preciptDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:auc>2</dikbD2R:auc>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/18A4B509-B850-400E-8EE9-780AA264AFDF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AEC0D894-25D8-45C6-B259-D0D000221245">
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>urn:domeoclient:uuid:a7f59b4d-3ada-4384-adb1-665a4a1743c8</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N8897f4766e494588bd27e2cd25bb6257"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:979614C6-94A5-490B-A19B-F12114DD0DAC"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-03 15:39:46 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E1870C1A-8789-40F2-B9E4-E786F91FF161">
    <rdfs:label>quinidine</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9068</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C7D731E9-DEA5-4D63-891D-A09D631C9A48">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>100</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>duloxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/519D3E74-400D-4120-8E9A-19D15499DE3F">
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6E810DEC-906B-4BEC-8621-DAB36D645A70">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:nodeID="N75a27fb842b64d4eaf70212ac5f32862"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoclient:uuid:a7f59b4d-3ada-4384-adb1-665a4a1743c8</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-03 15:39:04 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:1199069D-F2BD-463E-9B5E-59F14DE43EBF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C21B3DF0-F5D5-49BA-AC30-1EA3C3CA8C31">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Dose adjustment is recommended when FETZIMA is co-administered with strong inhibitors of CYP3A4 (e.g. ketoconazole) [see Dosage and Administration (2.7)]. An in vivo study showed a clinically meaningful increase in levomilnacipran exposure when FETZIMA was co-administered with the CYP3A4 inhibitor ketoconazole (see Figure 1). </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>7.4 Potential for Other Drugs to Affect FETZIMA   </ao:prefix>
    <domeo:uuid>C21B3DF0-F5D5-49BA-AC30-1EA3C3CA8C31</domeo:uuid>
    <pav:createdOn>2015-09-25 10:02:46 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/f371258d-91b3-4b6a-ac99-434a1964c3af.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C21B3DF0-F5D5-49BA-AC30-1EA3C3CA8C31"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/86F2CF71-06FA-4328-AEFA-C0D7D5193FA7">
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:46998416-3B6D-44C3-817E-2ABF94C39647">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>), </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <domeo:uuid>46998416-3B6D-44C3-817E-2ABF94C39647</domeo:uuid>
    <ao:exact>barbiturates</ao:exact>
    <ao:suffix>, beta-blockers, calcium channel blockers (e.g., diltiazem, nifedipine, verapamil), chloramphenicol, clarithromycin, corticosteroids, cyclosporine, cardiac glycoside preparations, clofibrate, oral or other systemic hormonal contraceptives, dapsone, diaze</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:40:21 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:46998416-3B6D-44C3-817E-2ABF94C39647"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:103D0088-07B3-4E41-8B47-BBD96100B99C">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/418F8785-D20D-4023-B357-056AF0EA7F7D"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/871315CB-D598-45DE-A773-6C2656001BB6"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CF7387C9-0803-4113-B425-440E35501B08">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E881763B-51F8-43BC-951D-E3A87053E98B"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5719DA99-A90C-4BAD-8084-5DDF731EFEFA"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4FA88695-3425-4FFC-8204-2DCA6F7DE6C9">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7D9C4662-D5AD-40D5-8386-2B97BF54F4D4"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E628D4CB-EC21-4420-BF42-AF61D6850848">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C7E772F6-875F-4637-94E9-DE4BCB9AAF16">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-10-20 09:53:20 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-20 09:56:31 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:78ABC7AE-C998-440B-93E0-9979080145F2"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <ao:body rdf:nodeID="N87abe59af3a949148ae5e13e9c3db9d5"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:659993FA-47A6-4170-A1F4-37E021B93D40</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D960C312-4566-45E1-8A58-E9EDCE19C1BC">
    <pav:lineageUri>urn:domeoserver:annotation:D16FCD54-1431-4B00-A497-C3367D5A3B17</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0185AD47-6E7B-4C92-8A3D-A2876CC95002</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-09-29 09:26:45 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:C3AFC81E-A721-4020-94AF-09350E7CB555"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E6EE8106-6DE2-4E80-BA46-2BFB8DD87999">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-13 11:56:23 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:46B234F0-D68D-4DB4-ABE7-1BFB208B25F2</pav:previousVersion>
    <ao:body rdf:nodeID="N78632914b245462d8cca75a00c2bcc8d"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-10-13 11:56:52 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:60A0F07C-2172-4677-A782-F6408A598554"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:14A50529-D7FE-4475-8383-CB1135DDAF7D">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:lastSavedOn>2015-10-20 09:56:31 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N874cf99474264e91b5e93fcd3d89b262"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:D3B8EC67-D49E-45E0-8AA0-7991FAC4D15B"/>
    <pav:previousVersion>urn:domeoserver:annotationset:659993FA-47A6-4170-A1F4-37E021B93D40</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-10-20 09:54:31 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:47322827-ADED-4C7A-AA4D-868F6BE857D6">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:E9753FC0-E930-437A-8438-D9405D59629D"/>
    <pav:createdOn>2015-08-26 16:11:45 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7C3ED630-095E-46C1-9254-E12EC01A6C0B</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-08-26 16:14:07 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB05F5-AF88-4B04-87DC-5826864F9BE3</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/46BB7B1D-CA69-484C-A2CF-827E4D97C26E">
    <rdfs:label>teriflunomide</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:894C77C9-A108-4EBD-8BE3-CB27499155EF">
    <domeo:uuid>894C77C9-A108-4EBD-8BE3-CB27499155EF</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <pav:createdOn>2015-10-13 11:23:28 -0400</pav:createdOn>
    <ao:prefix> was administered alone. Similar results were seen for </ao:prefix>
    <ao:exact>14-hydroxy-clarithromycin</ao:exact>
    <ao:suffix>, the mean </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:894C77C9-A108-4EBD-8BE3-CB27499155EF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7F71D02A-84F3-48F9-82AC-6317FBAB63B0">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:595D8B80-0709-42C5-8A0C-43FDA50313C4">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8B2229F0-4792-48AD-AC4D-ED3A99C1FEF5"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:70D88A1D-C8FC-4808-B566-E45FDA68E548">
    <ao:prefix>Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required. It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.  </ao:prefix>
    <domeo:uuid>70D88A1D-C8FC-4808-B566-E45FDA68E548</domeo:uuid>
    <pav:createdOn>2015-10-01 10:48:35 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:70D88A1D-C8FC-4808-B566-E45FDA68E548"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A412671E-469E-4847-B67C-FD0A8860D9A2">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>A412671E-469E-4847-B67C-FD0A8860D9A2</domeo:uuid>
    <ao:suffix>.</ao:suffix>
    <pav:createdOn>2015-10-14 11:41:40 -0400</pav:createdOn>
    <ao:exact>antacids</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A412671E-469E-4847-B67C-FD0A8860D9A2"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:prefix>should be given at least 1 hour before the ingestion of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0C2D9A2F-489B-4509-9364-A8B5F2617D8B">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluoxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/889A2EB7-30CE-44E6-B019-4A06B7AFA208">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E4FDFAA3-782F-4615-9FCD-54B42668753C">
    <ao:exact>Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See CONTRAINDICATIONS.) </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:prefix>with drugs that undergo biotransformation through these metabolic pathways may accelerate elimination of coadministered drugs. To maintain optimum therapeutic blood levels, dosages of drugs metabolized by these enzymes may require adjustment when starting or stopping concomitantly administered rifampin.  </ao:prefix>
    <pav:createdOn>2015-10-14 11:53:41 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>E4FDFAA3-782F-4615-9FCD-54B42668753C</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E4FDFAA3-782F-4615-9FCD-54B42668753C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:8EBC3A86-CAF7-4AEB-8718-D2C34C496981">
    <poc:TestRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#required</poc:TestRecommendation>
    <sio:SIO_000563>poc:TestRecommendation</sio:SIO_000563>
    <rdfs:label>Required</rdfs:label>
    <dct:description>A required test is related to the biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:59432D4C-310C-4958-A609-270395DC845D">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-14 11:41:44 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:A8AD9ECE-1FA4-428F-A3D9-7F741AA06D78"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:62506EF3-9D76-4B58-90B6-F9B7468545D2">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4FA59759-19EA-4EF8-88E3-6C759192CE8C"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6AE59F0B-03A0-4731-8439-9C5065EB73EC">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DC54EBE-B2A9-4AE7-A174-F0074ECE4050</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:1109F941-1C3B-4F3E-8852-4533203DF3B8</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:7D918661-6CD5-48B3-AD72-A11F18451883"/>
    <ao:body rdf:nodeID="N43b7d14915654cb4974c6a6e13d4ce18"/>
    <pav:createdOn>2015-10-01 10:47:23 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3489FFF6-AA10-402E-86E6-88F51D8C1556">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>SSRIs</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:56796674-1FE0-4010-A3FE-6DA9ED404E88">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:B627103B-63D6-44FC-8F4D-CE5F66D98218"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:comment>Maprotiline plasma concentrations may be decreased</dikbD2R:comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F2B9732E-515B-496E-A7E7-DE29A9A9B53F">
    <ao:prefix>was increased by approximately 2-fold, whereas the AUC was unaffected.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-13 11:51:17 -0400</pav:createdOn>
    <domeo:uuid>F2B9732E-515B-496E-A7E7-DE29A9A9B53F</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F2B9732E-515B-496E-A7E7-DE29A9A9B53F"/>
    <ao:exact>Simultaneous administration of clarithromycin tablets and didanosine to 12 HIV-infected adult patients resulted in no statistically significant change in didanosine pharmacokinetics.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:091ADEE2-BD39-4316-9D9D-D0737D6F7CBE">
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:86D02130-5F65-449C-9315-8E672FDAC7E2"/>
    <pav:createdOn>2015-09-14 11:09:49 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:fc9e17d3-1b0d-4635-9936-0d1d94cb01f9</pav:lineageUri>
    <ao:body rdf:nodeID="N11675b0f61894626bb6caa6d0718d97d"/>
    <pav:previousVersion>urn:domeoserver:annotationset:17CFEF69-CCC6-4ACD-8A24-0425991EC98C</pav:previousVersion>
    <pav:lastSavedOn>2015-09-14 11:21:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CE635F27-A391-4A6B-9D87-339FA2F114B2</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FA3561E2-736C-4AB3-AD83-336362809C34">
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FCE857AC-CF2E-43D2-BA6E-43F6D066C40E"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/569C4B4D-A75C-459C-9AEF-2AFCEB1FE2B0"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:82A680C3-86DA-43A2-8F39-634A52062B54">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Clinical studies have not shown any drug interactions between bicalutamide and LHRH analogs (goserelin or leuprolide). There is no evidence that bicalutamide induces hepatic enzymes.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-08-20 10:18:58 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:82A680C3-86DA-43A2-8F39-634A52062B54"/>
    <domeo:uuid>82A680C3-86DA-43A2-8F39-634A52062B54</domeo:uuid>
    <ao:prefix>   </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7c295b64-ec39-42ec-9f02-da5b42e775e1.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F54D24C5-5C64-439C-A1EE-5F4449E965EE">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:C2DAAC63-7E05-4EDC-A282-BB2EEA69091F"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:195D49D1-2E5F-403D-9BB9-0471ADA92D3A">
    <ao:context rdf:resource="urn:domeoclient:uuid:898943E1-8373-4EAD-AD6E-A4B90C2E9F95"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N74ac6ecb45014a3194d1bcb6ce73aaa8"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0185AD47-6E7B-4C92-8A3D-A2876CC95002</domeo:belongsToSet>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:7CA54A57-9B18-438D-9F09-6AF75B8FAAF9</pav:lineageUri>
    <pav:createdOn>2015-09-29 09:25:58 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/814FE517-D865-4846-BA0B-338F630FF375">
    <dikbD2R:dose>75</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>milnacipran</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:962077F2-FB00-4675-9E3B-C57F6D350EF9">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D653CC99-F2D9-471F-AC2A-74FF25660717"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/03C16421-4240-4B16-B6EC-76C440A3D901"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5f8f7830-34e2-4a38-9ee0-8113b6f2c0af">
    <pav:createdOn>2015-10-12 13:20:27 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-12 13:20:27 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:6221399c-7475-4504-b9cb-e9341e023700"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1D5A6A7E-B5A8-4307-8524-83E87C344BCB">
    <ao:context rdf:resource="urn:domeoclient:uuid:EC868F67-3A3C-45C9-BB1E-ACAD5E32C6C6"/>
    <pav:lineageUri>urn:domeoserver:annotation:E1806AD1-8408-46B7-88C4-E14C4D21D767</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-29 11:19:00 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1705FF37-6249-47BE-83EA-0B511345B099">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:C91289D7-45EC-44D1-A933-E79E770CFE71</pav:lineageUri>
    <pav:createdOn>2015-10-14 12:07:39 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:32DAEE61-E8FE-47A7-8507-2DECEE9F5520"/>
    <pav:lastSavedOn>2015-10-14 12:07:40 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N41578232d9c2418ba95f769cdd266a53"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0665ccc7cbd7404bb86f7f982bc71c14">
    <domeo:sets rdf:resource="urn:pddi:uuid:DED98394-4ADE-4292-BB18-1466CDDAED6F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CBC29E8F-3018-4FB3-9D06-66D1FC3641AB">
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#none</poc:PharmacodynamicImpact>
    <rdfs:label>None</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>none.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:088CBC7A-07AE-43E0-881D-4C1B0A051F3A">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CE635F27-A391-4A6B-9D87-339FA2F114B2</domeo:belongsToSet>
    <ao:body rdf:nodeID="N0a4727c4c0364af2ba4b52da245f94eb"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:E8FB27B7-E3BA-4267-9A34-138ED9926C19</pav:previousVersion>
    <pav:lastSavedOn>2015-09-14 11:03:10 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:fc9e17d3-1b0d-4635-9936-0d1d94cb01f9</pav:lineageUri>
    <pav:createdOn>2015-09-14 11:03:03 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:BCBBE1C3-02EB-4C98-9173-F038FE053254"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F0A8DF45-E947-4CC6-90D2-D34891139FF5">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-14 11:40:42 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:5024CBC4-FDB8-4C66-8337-0AA2E58C4067"/>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:47F05620-DDA9-487E-A23B-0B8B4ED83049">
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:clType>Percent</dikbD2R:clType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:clDirection>Decrease</dikbD2R:clDirection>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cl>65</dikbD2R:cl>
    <dikbD2R:numOfParticipants>8</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2C7C66B6-F3DA-4EF5-BA78-4E623595064A"/>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BACBBDD8-DC86-4CD8-8ADC-182369AB917C"/>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2BB3420C-77A4-4FB0-8BA2-850970373666">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:3399DE83-1B0E-4217-A3E7-CCE40D4B4C7D"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4CD9A258-C2B7-483E-B951-7206B4F86B0C">
    <domeo:uuid></domeo:uuid>
    <ao:exact>An in vivo interaction study involving the coadministration under steady-state conditions of paroxetine and terfenadine, a substrate for cytochrome CYP3A4, revealed no effect of paroxetine on terfenadine pharmacokinetics.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:suffix> In addition,</ao:suffix>
    <pav:createdOn>2015-09-14 11:13:09 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4CD9A258-C2B7-483E-B951-7206B4F86B0C"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/51F74AD9-CFE6-402E-9742-65FA5B4711E2">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>zidovudine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11413</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:39ECB635-1D7A-41B0-802B-6080D29F84FC">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-20 09:55:27 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:39ECB635-1D7A-41B0-802B-6080D29F84FC"/>
    <ao:exact>Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam, etc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine. The clearance of benzodiazepines metabolized by glucuronidation (e.g., lorazepam, oxazepam, temazepam) is unlikely to be affected by fluvoxamine. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix>    Benzodiazepines   </ao:prefix>
    <domeo:uuid>39ECB635-1D7A-41B0-802B-6080D29F84FC</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DD604848-4BDA-4DA2-97ED-ABCA8265DA7A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>selegiline</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D0F4A4A2-C1A4-4864-8E03-1598F140F312">
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/11586B9B-E685-4F91-A4D8-9DBCB95A126D"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0ED52EB7-0AFB-485E-A40E-336F14A14C16"/>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D87BF910-1BDA-4084-9519-918C66EC040C">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <domeo:uuid>D87BF910-1BDA-4084-9519-918C66EC040C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D87BF910-1BDA-4084-9519-918C66EC040C"/>
    <ao:exact>There was an increase in mean cefaclor Cmax and AUC (1.43- and 1.54-fold, respectively), following repeated doses of teriflunomide, suggesting that teriflunomide is an inhibitor of organic anion transporter 3 (OAT3) in vivo [see Drug Interactions (7)].</ao:exact>
    <pav:createdOn>2015-08-20 13:01:38 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>may be a weak inducer of CYP1A2 in vivo .   OAT3 Substrates  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:506C9915-D18D-4399-B1C9-71B99BF34F78">
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:numOfParticipants>24</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/992391BB-66BE-4EB6-8F0C-F9FFB5F6C8C0"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:auc>50</dikbD2R:auc>
    <dikbD2R:cmax>40</dikbD2R:cmax>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6A939209-7E68-435F-BA58-C4A802640148"/>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:preciptDuration>6.5</dikbD2R:preciptDuration>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7B364074-734F-49C7-88BE-71539BF01FD7">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:CB0AC331-18FB-427B-A1D4-544494DE0FE5"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8C4505F8-A67B-48DF-AD0B-0C0AF2E89651">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1E97C862-CD4B-4655-AA5A-73C5C1C3260D"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9B62559A-7BF8-4CF1-882E-ED54C0B36733">
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdOn>2015-10-14 11:40:28 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:66ABB5E5-7E59-429A-A3CD-1D0F8266AA22"/>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C6D0AC43-7A5B-4C6E-86CE-8E858ED62EFE">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptDuration>11</dikbD2R:preciptDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6449CD69-4460-487F-BBC6-FA0B9AD8DF9E"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation>transdermal</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C67B7283-20BE-427C-86F2-7D5C4E9D5799"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/86B6A6EC-5C8A-4914-A6A1-1E67236D7A2F">
    <rdfs:label>EMSAM</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dikbD2R:dose>6</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/552431F0-DFBD-48DB-8DA4-9133DD2E8A85">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>ketoconazole</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:954C7A68-D34D-4AD1-8DC8-59131ABB7382">
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:preciptRegimens>QD</dikbD2R:preciptRegimens>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>Increase</dikbD2R:t12Direction>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectRegimens>QID</dikbD2R:objectRegimens>
    <dikbD2R:t12>2</dikbD2R:t12>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/282344C2-0768-4AA8-9215-172E8AA44E83"/>
    <dikbD2R:t12Type>Fold</dikbD2R:t12Type>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:auc>2</dikbD2R:auc>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:cmax>2</dikbD2R:cmax>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E84C0F84-E2D6-4F78-BC1E-CEA53FF4912E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:518FD360-703E-4F95-B396-CCB179716873">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <domeo:uuid>518FD360-703E-4F95-B396-CCB179716873</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:518FD360-703E-4F95-B396-CCB179716873"/>
    <ao:prefix>1.6  0.8    Lung  8.8  1.7      </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Clarithromycin 500 mg every 8 hours was given in combination with omeprazole 40 mg daily to healthy adult males. The plasma levels of clarithromycin and 14-hydroxy-clarithromycin were increased by the concomitant administration of omeprazole. For clarithromycin, the mean Cmax was 10% greater, the mean Cmin was 27% greater, and the mean AUC0-8 was 15% greater when clarithromycin was administered with omeprazole than when clarithromycin was administered alone. Similar results were seen for 14-hydroxy-clarithromycin, the mean Cmax was 45% greater, the mean Cmin was 57% greater, and the mean AUC0-8 was 45% greater. Clarithromycin concentrations in the gastric tissue and mucus were also increased by concomitant administration of omeprazole.</ao:exact>
    <pav:createdOn>2015-10-13 11:24:27 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8EF41540-288B-43F6-A276-6896A2A6EA80">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DEC969CC-2B9D-4652-8E5C-A90AB60063D5"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/AD48AD7C-557A-4CB1-AA9B-6A3B71F41DD3"/>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:292DDE04-C612-4FA1-8DEB-1912DE56BEC2">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Drugs Metabolized by P450 3A4In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertralines extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).</ao:exact>
    <pav:createdOn>2015-09-16 15:26:37 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:292DDE04-C612-4FA1-8DEB-1912DE56BEC2"/>
    <ao:prefix>CONTRAINDICATIONS, WARNINGS, andDOSAGE AND ADMINISTRATION .   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E8D5C85E-AD89-4E93-B371-0678DA230E33">
    <ao:body rdf:nodeID="Nfa2dea0e56df4cbb815ea2b3344da591"/>
    <pav:lastSavedOn>2015-10-16 10:55:51 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:FEF90AD1-0B74-4259-90AA-EC27812E1C91"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-10-16 10:51:31 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:0DAF5666-9E53-42D5-B92E-DE2C00764986</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/96535AFF-63A2-4ECA-A193-C044A8E5A042">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>clarithromycin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0EA27B8B-961F-48C5-87DB-FE608839C5B0">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>sertraline</rdfs:label>
    <dikbD2R:dose>200</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E62C93E3-E9D2-4338-BF38-206615042C69">
    <domeo:uuid>E62C93E3-E9D2-4338-BF38-206615042C69</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/Clopidogrel-1086a7b4-b89b-4bee-8120-5f752626c046.html</ao:hasSource>
    <ao:exact>Effectiveness of Plavix depends on activation to an active metabolite by the cytochrome P450 (CYP) system, principally CYP2C19</ao:exact>
    <ao:suffix>. (</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-02-19 12:27:56 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E62C93E3-E9D2-4338-BF38-206615042C69"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A2EA9703-A708-4572-8D00-D5F3074A2E43">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <ao:body rdf:nodeID="N4d3c8255261d4da791f8cf199bb47a75"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-08-20 12:48:10 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:6A0828EA-848D-489C-981C-06A04B2D9DB0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:BA4A4F06-DE8C-4B66-8918-920D0399D744</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9479B4BD-59A7-4AC9-B221-E9869B952571">
    <ao:body rdf:nodeID="N3134d59ae9f84af9b9cd19c22a9e5921"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-09-25 10:47:09 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:BE71BBF5-9A2D-4EBE-83B0-1E019FA0E0F8</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:D36B886A-85E8-40FE-B1D1-660175A622C5</pav:lineageUri>
    <pav:createdOn>2015-09-25 10:45:51 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:8A9A0D3A-8B5C-44D9-8261-0984AABA8AC7"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9D96C168-8C96-49B8-BE24-FFF9F32265AE">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-29 08:59:30 -0400</pav:createdOn>
    <ao:exact>TCA</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <domeo:uuid>9D96C168-8C96-49B8-BE24-FFF9F32265AE</domeo:uuid>
    <ao:suffix> plasma levels whenever a TCA is going to be coadministered with another drug known to be an inhibitor of P450 2D6.</ao:suffix>
    <ao:prefix> may be required. It is desirable to monitor </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9D96C168-8C96-49B8-BE24-FFF9F32265AE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:17106EA7-F424-413F-88DB-537091B65B25">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/673EE000-8A6B-4E34-B918-C8977C061DE0"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3445C449-56D0-4244-9004-CCC744F4CF2F"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N852e2b072c224ca982a367b08175c17d">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A9746444-48D7-4D24-AA87-51BAD09C5DC4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:hasSource>
    <domeo:uuid>A9746444-48D7-4D24-AA87-51BAD09C5DC4</domeo:uuid>
    <ao:prefix>Drugs That Slow Heart Rate or Atrioventricular Conduction (e.g., beta blockers or diltiazem )   </ao:prefix>
    <ao:exact>Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited. Because initiation of GILENYA treatment may result in an additional decrease in heart rate, concomitant use of these drugs during GILENYA initiation may be associated with severe bradycardia or heart block. Seek advice from the prescribing physician regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating GILENYA. Patients who cannot switch, should have overnight continuous ECG monitoring after the first dose [see Dosage and Administration (2) and Warnings and Precautions (5.1)].</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A9746444-48D7-4D24-AA87-51BAD09C5DC4"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-08-20 13:56:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C5DFAF2F-C905-4201-BE99-FBC74F059988">
    <ao:prefix>group compared to a 20% decrease in the placebo group (p &lt; 0.03). The clinical significance of these changes is unknown.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In a placebo-controlled trial in normal volunteers, the administration of two doses of sertraline did not significantly alter steady-state lithium levels or the renal clearance of lithium.</ao:exact>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-09-16 15:22:57 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C5DFAF2F-C905-4201-BE99-FBC74F059988"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:563B4DF4-2A90-4A3F-BF5D-40F5E36A5D8F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N61620abfea634fe58f3eff9365d18db5"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:EC1CD113-5851-48C8-A5D0-FA72A7594C47</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-10 15:00:02 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:F900845F-B29D-42EA-8707-2DD6BAE279C9"/>
    <pav:lastSavedOn>2015-10-16 11:00:06 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FE5041E0-D597-4A36-BF97-FC9EBBDB6AC9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>FE5041E0-D597-4A36-BF97-FC9EBBDB6AC9</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Simultaneous administration of clarithromycin tablets and didanosine to 12 HIV-infected adult patients resulted in no statistically significant change in didanosine pharmacokinetics.  </ao:prefix>
    <pav:createdOn>2015-10-13 11:52:57 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:exact>Concomitant administration of fluconazole 200 mg daily and clarithromycin 500 mg twice daily to 21 healthy volunteers led to increases in the mean steady-state clarithromycin Cmin and AUC of 33% and 18%, respectively. Steady-state concentrations of 14-OH clarithromycin were not significantly affected by concomitant administration of fluconazole.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FE5041E0-D597-4A36-BF97-FC9EBBDB6AC9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:78BD474F-2894-4999-851D-7B58FDA38108">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:FA3561E2-736C-4AB3-AD83-336362809C34"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A5789EB7-E220-4F2D-9D56-323B392EAC5C">
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:3ABCA7AE-0EF6-44D5-8F82-AE7C89B7ECF6"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:createdOn>2015-10-14 11:40:37 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DE34F6E2-312D-4B3A-890B-150922997A86">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <pav:createdOn>2015-10-01 10:27:44 -0400</pav:createdOn>
    <ao:prefix>s. Of particular importance, sufficient time must elapse before initiating </ao:prefix>
    <domeo:uuid>DE34F6E2-312D-4B3A-890B-150922997A86</domeo:uuid>
    <ao:exact>TCA</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DE34F6E2-312D-4B3A-890B-150922997A86"/>
    <ao:suffix> treatment in a patient being withdrawn from </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N50ce90acbbbb4490bff71ed0bb22fe6a">
    <domeo:sets rdf:resource="urn:pddi:uuid:F4C72415-4D8C-49A5-9EA5-4D620EDEDC0F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7C1B5957-4396-4B3A-BC64-186F5A95193F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <ao:prefix>on BCRP and organic anion transporting polypeptide B1 and B3 (OATP1B1/1B3) substrates   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7C1B5957-4396-4B3A-BC64-186F5A95193F"/>
    <domeo:uuid>7C1B5957-4396-4B3A-BC64-186F5A95193F</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-08-20 12:48:39 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:00E9D06D-C90C-4069-974A-596169F16DF5">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:2CF02C33-209E-4704-9E54-9C3A34E27E59</pav:lineageUri>
    <pav:createdOn>2015-09-25 10:03:05 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:5808C4F6-3D20-4064-BA30-F1F80E74C108</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-09-25 10:05:58 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="Nd1efd8b5bc5441ed9de4dfb27929f262"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:07CA9796-0E8D-4505-828E-323AC16E6EFD"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FC26A947-68C1-439E-97CB-A4B892DD45AE">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfb7ae8caada24b9d97d8b87bace2b373">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:75EB9D3A-7581-4BF9-AC53-3752B9011C68">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6E0A7B57-FF63-4A7C-9391-BBD7FECA3B05"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N29ab4e70046e4ef0a085d5c17bd8c724">
    <domeo:sets rdf:resource="urn:pddi:uuid:1033C46E-C444-4DA3-A5E8-0C570A912181"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0DE7B5FD-A576-45AC-9469-74E35BE93A3C">
    <dikbD2R:dose>6</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>selegiline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7CCF3FB2-179D-475F-A019-4B26715301BB">
    <ao:suffix>s and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from </ao:suffix>
    <domeo:uuid>7CCF3FB2-179D-475F-A019-4B26715301BB</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>s with any of the </ao:prefix>
    <pav:createdOn>2015-09-29 08:59:08 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>SSRI</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7CCF3FB2-179D-475F-A019-4B26715301BB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:47BBF50A-23F6-445E-BDDC-661B7E310349">
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9DB2C984-BCE7-4269-9A59-D64A78C3F92B"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptDuration>7</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6866B193-7C66-4494-8005-FFC7D20665B3"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:numOfParticipants>10</dikbD2R:numOfParticipants>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5460F551-AC63-4535-973D-D0F058F9518A">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:23C51101-74AD-4D98-B40F-6E13A74A4065"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/030EAAE2-16C8-48EA-9D9F-4438CD491120">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>atorvastatin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/83367</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2D4B4751-6FCB-4C88-9179-CBB2EE796D26">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:FF63AE48-3767-4170-B8D4-9949D561C3B9"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:comment>Increased concentrations</dikbD2R:comment>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/28590323-92ED-4F77-820A-CFD9FF7E1D99">
    <rdfs:label>Savella</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>0.2</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D14B1B36-8511-4465-9615-06E0A268F4C9">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>is contraindicated (see CONTRAINDICATIONS .)  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In addition, there have been reports of interactions of erythromycin or clarithromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate.</ao:exact>
    <pav:createdOn>2015-10-13 12:06:09 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D14B1B36-8511-4465-9615-06E0A268F4C9"/>
    <domeo:uuid>D14B1B36-8511-4465-9615-06E0A268F4C9</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FE6DBDC0-66B5-4B58-A384-A1B072592EB0">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/822451DB-387F-4E83-99E3-9CD58089D772"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EA32C547-8F7F-4528-A359-6BB8CBA78596"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:68AE10BB-FBC8-40C9-BEBC-132102208892">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:8C508480-BCE8-48F1-9553-E240DF7F0C24</pav:lineageUri>
    <ao:body rdf:nodeID="Na121ec03031f4e9ba60cccacafe160f0"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-08-20 13:57:26 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2ABE5FA2-BA00-4AF9-A2EA-1305FAECF3DF</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:191021CF-DC3E-4994-AD75-04A2F2BEF987"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0C61A3F4-A4B7-4756-BF49-512FAED37378">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:44696D7C-10B2-4F4B-AECE-CD7E954AEF97"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:DD53EE65-079D-4C5D-8248-EE332FEE3EDA</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-13 11:24:28 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-13 11:23:22 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EAF4BEDE-3D55-4DED-A7E8-9DE3062888F0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-20 09:22:33 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <domeo:uuid>EAF4BEDE-3D55-4DED-A7E8-9DE3062888F0</domeo:uuid>
    <ao:exact>mesoridazine </ao:exact>
    <ao:prefix>and its two active metabolites, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EAF4BEDE-3D55-4DED-A7E8-9DE3062888F0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>and sulforidazine, increased 3-fold following coadministration of fluvoxamine. </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6B12D9AC-F09A-4157-8E26-ACDF40ECBB03">
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:lineageUri>urn:domeoserver:annotationset:97462094-EB47-4D8E-A3F1-3B41A3ABEFF5</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/Clopidogrel-1086a7b4-b89b-4bee-8120-5f752626c046.html</ao:annotatesResource>
    <rdfs:label>Default Set</rdfs:label>
    <permissions:permissions rdf:nodeID="N72954efd0d024935a2b5402cea44250c"/>
    <pav:createdOn>2014-02-09 21:22:24 -0500</pav:createdOn>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2014-02-09 21:22:48 -0500</pav:lastSavedOn>
    <domeo:deleted>false</domeo:deleted>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:item rdf:resource="urn:domeoclient:uuid:2DDE57E8-8DE6-4ED1-ADB7-2F109930DB5D"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F20A7A91-F667-4DE8-ABD5-A85862436E18">
    <rdfs:label>diazepam</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3322</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2056EE88-B9C4-43AF-A3D5-B309CF4BED47">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:71B7E81D-B3E4-4CC3-A432-A446DD4BAAA1"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A35E54E2-7FB2-4533-9409-F9BF2CBC38B9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:ED8D1FE9-B200-42D0-9B06-3F2EED68B302"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E41B5E31-A92A-4182-B110-AE781516CE91">
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5000D962-57F1-4EEE-9643-6544E28C0C68">
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:6CDB2B96-4DA8-44C1-8B35-3E8DA8E089D9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-14 11:40:48 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9060017D-193D-4DE8-9E11-175889E42400">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:18C6017F-70AF-422C-893F-CF25B4092807"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>urn:domeoserver:annotationset:5D7970E2-6A55-4380-A2F7-06C554DD3F1F</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2E0AD717-67BC-4D7C-AF83-5F1037F99712</domeo:belongsToSet>
    <pav:createdOn>2015-08-20 11:11:53 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-08-20 11:17:13 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:64737b65-8582-4b76-8095-85ad69e2cc47</pav:lineageUri>
    <ao:body rdf:nodeID="N0ea41d88915d490aade5ba4096825879"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BB1AF37E-3BB3-44CC-A127-077E63066586">
    <ao:prefix>. It may be necessary to adjust the dosages of these drugs if they are given concurrently with </ao:prefix>
    <ao:exact>rifampin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>BB1AF37E-3BB3-44CC-A127-077E63066586</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BB1AF37E-3BB3-44CC-A127-077E63066586"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>.</ao:suffix>
    <pav:createdOn>2015-10-14 11:41:11 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5BA89E2E-8665-4836-BD65-19BCDA7CFA7F">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1AEAE481-2177-4FCD-B21C-21C091519858"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A953940F-4A5E-4451-8F60-7585A9F3A6B8">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:6CE672D3-0B6E-4638-A191-01BBB207588C"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-20 10:09:08 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N01dc3ee44d12415ea8a38ca18db3d50f">
    <domeo:sets rdf:resource="urn:pddi:uuid:C00F04F3-F660-405D-ADB3-DE86F16D1ABC"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/928E1D5F-0BF8-4B1F-9F2E-56E2EE706494">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdfs:label>paroxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F7FECC4C-1169-430B-AF75-887972E7499C">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>ibuprofen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1F6DA055-110E-4D41-9532-29387C6567CD">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>. This finding may be the result of alteration in the colonic bacteria responsible for the reduction of sulfasalazine to sulfapyridine and mesalamine.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1F6DA055-110E-4D41-9532-29387C6567CD"/>
    <domeo:uuid>1F6DA055-110E-4D41-9532-29387C6567CD</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:41:55 -0400</pav:createdOn>
    <ao:prefix>and </ao:prefix>
    <ao:exact>rifampin</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8EAC845C-01E6-475A-9CB1-AA2A4E51AC22">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9E2AD1DF-7F91-4C9E-9C40-7AF729A924F3"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D07DC343-AB19-40CC-A629-36FC562D0314"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A372E97B-CAD5-41E9-ABBF-9255EB529163">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8134</dailymed:activeMoietyRxCUI>
    <rdfs:label>phenobarbital</rdfs:label>
    <dikbD2R:dose>100</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:11CFFF93-99D0-4CF8-A9EB-EE1BEDF2137B">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:DFB7BB80-D245-46D2-8E46-4C4F9E081D08"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdOn>2015-10-14 11:39:57 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:46268AFD-D395-4681-9B22-FD8DD047912D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-09-14 10:24:39 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:46268AFD-D395-4681-9B22-FD8DD047912D"/>
    <ao:exact>In vitro drug interaction studies reveal that paroxetine inhibits CYP2D6. Clinical drug interaction studies have been performed with substrates of CYP2D6 and show that paroxetine can inhibit the metabolism of drugs metabolized by CYP2D6 including desipramine, risperidone, and atomoxetine (see PRECAUTIONS: Drug Interactions).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>DOSAGE AND ADMINISTRATION ).  Drug-Drug Interactions   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C09825F3-B6D6-40D0-BE32-57E20F5E9CDF">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>quinidine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9068</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FA9F1823-1C25-4EAF-AEB0-2D9EFD1A628A">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:5CA6C59B-25DC-4905-AF3C-A4F6570B9620</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-29 09:04:09 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:8759B758-2E09-414E-B1DC-69359DCD909B"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N7753a5d9a1d74c8ba2958b81ff650e61"/>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A1611C67-8AB8-4E31-BE48-22AA3DC3C4AC">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:C86626A1-C299-4F5F-85F2-A0BC4F64FA7E"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8172FAF8-BA4C-4D30-966D-6B6A0E21D44E">
    <pav:previousVersion>urn:domeoserver:annotationset:5849C28E-25DD-46CF-8E18-8F16D54151B4</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-08-20 12:53:31 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-08-20 12:53:42 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N3850506bbabe483cbb0d87eed5d0f4a2"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:746371A2-AA31-425D-96A0-947D5E301EB4"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncaf5e839ddfb43039aa5188559dbc0c7">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5C474472-3F94-474B-8730-D2B30165E24B">
    <rdfs:label>desvenlafaxine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>4</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/71B44EFE-3F93-4792-A233-4250F63845BC">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C6032A1D-A583-41DE-A677-CB9F1CBBFA3A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-16 10:37:18 -0400</pav:createdOn>
    <ao:exact>Ibuprofen    In subjects who had received EMSAM 6 mg per 24 hours for 11 days, combined administration with the CYP2C9 substrate ibuprofen (800 mg single dose) did not affect the pharmacokinetics of either selegiline or ibuprofen [see Drug Interactions (7.4) and (7.5)]. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C6032A1D-A583-41DE-A677-CB9F1CBBFA3A"/>
    <domeo:uuid>C6032A1D-A583-41DE-A677-CB9F1CBBFA3A</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>   </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C21EEA0C-88D7-44F4-B790-38B97282D2BF">
    <ao:suffix>has been reported to be increased by the concomitant administration of </ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>The plasma concentration of </ao:prefix>
    <ao:exact>CMI </ao:exact>
    <pav:createdOn>2015-09-29 09:46:21 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C21EEA0C-88D7-44F4-B790-38B97282D2BF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97E4CDE7-633E-4188-9846-10A00E9A78AB">
    <ao:prefix> 6mg per 24 hours for 9 days, co-administration with </ao:prefix>
    <pav:createdOn>2015-09-03 15:57:06 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>PPA</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:97E4CDE7-633E-4188-9846-10A00E9A78AB"/>
    <ao:suffix> (25mg every 4 hours for 24 hours) did not affect the pharmacokinetics of PPA. There was a higher incidence of significant blood pressure elevations with the co-administration of </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndeb4cd3081b44130b14fc60a433b50b4">
    <domeo:sets rdf:resource="urn:pddi:uuid:F63EFF39-F44C-4772-A071-82F0F184DDB9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:252FCE71-378C-4956-9688-A804BE47B43A">
    <pav:createdOn>2015-10-16 10:51:04 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:252FCE71-378C-4956-9688-A804BE47B43A"/>
    <ao:exact>Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds. The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available. Based on a finding of substantial interactions of fluvoxamine with certain of these drugs [see later parts of this section and also Warnings and Precautions (5)] and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>7.1 Potential Interactions with Drugs that Inhibit or are Metabolized by Cytochrome P450 Isoenzymes  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D333F5B1-1DBC-435B-BA4E-8EEAC5D7230F">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N6311a602ca6a49df9ae31d7afb27a515"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-13 12:06:23 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-13 12:05:31 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:1F0F4AD3-668A-44E0-8EA8-A016AF9D49EC"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:362D0BFC-93F0-401F-A043-34940980D95F</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:46887215-EBC0-4819-B453-E97722BC8960">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-20 09:22:29 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>steady-state concentrations was evaluated in ten male inpatients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine. </ao:suffix>
    <ao:prefix>(25 mg b.i.d. for one week) on </ao:prefix>
    <ao:exact>thioridazine </ao:exact>
    <domeo:uuid>46887215-EBC0-4819-B453-E97722BC8960</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:46887215-EBC0-4819-B453-E97722BC8960"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B9BB7E96-2A41-4A24-8F51-A1E0B53EC77F">
    <pav:createdOn>2015-10-16 10:51:17 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix>7.1 Potential Interactions with Drugs that Inhibit or are Metabolized by Cytochrome P450 Isoenzymes  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B9BB7E96-2A41-4A24-8F51-A1E0B53EC77F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds. The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available. Based on a finding of substantial interactions of fluvoxamine with certain of these drugs [see later parts of this section and also Warnings and Precautions (5)] and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9F260B07-A582-4AC8-B337-2561E714CB8B">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <ao:prefix>   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-16 10:42:10 -0400</pav:createdOn>
    <ao:exact>Pseudoephedrine    EMSAM 6 mg per 24 hours for 10 days, co-administered with pseudoephedrine (60 mg, 3 times a day) did not affect the pharmacokinetics of pseudoephedrine. There were no clinically significant changes in blood pressure during pseudoephedrine administration alone, or in combination with EMSAM [see Drug Interactions (7.4) and (7.5)]. </ao:exact>
    <domeo:uuid>9F260B07-A582-4AC8-B337-2561E714CB8B</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9F260B07-A582-4AC8-B337-2561E714CB8B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:145CADDF-092E-409D-83DB-7E09303108D6">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:4ED8CAF5-0FBD-49C2-91AC-A04538BEB712</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:D6BB0AFD-5321-4A71-9BB3-01FF5D9ADF51"/>
    <pav:createdOn>2015-09-10 14:44:43 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-09-10 15:01:13 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/72BE13CC-4F08-423C-B7F9-CC4465B469B3">
    <rdfs:label>mirtazapine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>40</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:66FF0DF3-C777-4A3D-971F-8E83B304FDCC">
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:357321A7-5793-4DE5-BB38-BF5FA7A5D72C</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:body rdf:resource="urn:linkedspls:uuid:C0D4F41F-0FCC-446B-A746-DAED97C65270"/>
    <pav:createdOn>2014-02-19 12:27:56 -0500</pav:createdOn>
    <ao:body rdf:resource="urn:linkedspls:uuid:33F29679-E217-4D93-9174-2D69A0E1B032"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E62C93E3-E9D2-4338-BF38-206615042C69"/>
    <pav:lastSavedOn>2014-02-19 12:28:11 -0500</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E9F13BFE-1A17-4FDF-99A7-13B89F697635</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6D3CE614-A965-411F-A271-16DB31F2442E">
    <domeo:uuid>6D3CE614-A965-411F-A271-16DB31F2442E</domeo:uuid>
    <ao:suffix>concurrently, it is recommended that the prothrombin time be performed daily or as frequently as necessary to establish and maintain the required dose of anticoagulant.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:exact>rifampin </ao:exact>
    <ao:prefix>and </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6D3CE614-A965-411F-A271-16DB31F2442E"/>
    <pav:createdOn>2015-10-14 11:41:18 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5639E7F7-47BE-4F6B-A2CD-C2D4930B731D">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:CD39430C-CE63-414F-9F43-1F592CD3E105</pav:lineageUri>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:C8296470-B24E-4940-9418-4184085A32EA"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="Nca892a7f58ba443dab103ba4152a631a"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:545F2613-2A5E-4333-A651-CBA80268D6ED</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-30 10:42:16 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/42C2A2DD-0DF0-4E6C-B6EB-E9D5C3923DE2">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dikbD2R:dose>1.5</dikbD2R:dose>
    <rdfs:label>Savella</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B8304FDE-AD6F-4F41-B61B-4F88031B0A85">
    <pav:lineageUri>urn:domeoserver:annotation:8F9A9100-79F0-4E79-A9F3-75AD8E41E63F</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N4a294291cddf4d84ae71ec8454a7411e"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-09-29 11:20:15 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:CFC0FDEB-61EF-4D3D-B8EB-CDA68B521721"/>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:87A3A1EE-D987-4F2B-8DFB-B24B9B5DE85A">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:73751559-D18E-4DA7-BFC2-99E35DB4EDF4"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:842c5219-8463-4672-b3ec-075b1aeb2a66">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <ao:suffix>                                     </ao:suffix>
    <ao:exact>digoxin</ao:exact>
    <pav:createdOn>2015-09-29 16:04:14 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:842c5219-8463-4672-b3ec-075b1aeb2a66"/>
    <ao:prefix> and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8897DB69-A04A-4BBC-8B42-D8F0B553B267">
    <rdfs:label>mesoridazine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6779</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BFEBF689-6C4D-4D20-8765-41877C80A56B">
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:47711889-AF38-45A8-A424-6E73BA96C377">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:C00BC986-BF47-4D92-BBAD-0DCD5DA063A1</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:F3F5DBC3-EA59-4083-9F58-186A56D29143"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-29 09:44:25 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8E6B2E9F-FE08-436B-A0D4-1A6618990FA1">
    <rdfs:label>psychostimulants</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9EF12F1F-E2EE-4CA1-BCB7-F585C3CEE70F">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:654B2AAF-79AD-47F5-BD08-D71977DBCDA3"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6DA584D7-1D33-4C8D-8B04-084023087CC5">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>clarithromycin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8F89DD01-5204-4190-BBC4-A5F41E491CE0">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <rdfs:label>fluvoxamine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/06A3E8C6-059D-4578-8210-CA5CE45CAE53">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/73044</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>repaglinide</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3BF1679F-DD54-4851-9764-2A7B020C5DB4">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>phenytoin</rdfs:label>
    <dikbD2R:dose>30</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8759B758-2E09-414E-B1DC-69359DCD909B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <pav:createdOn>2015-09-29 09:04:09 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>s) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA ).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>8759B758-2E09-414E-B1DC-69359DCD909B</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8759B758-2E09-414E-B1DC-69359DCD909B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1D1F4E1A-B9D4-460F-AC11-4ABA88DA72D8">
    <pav:createdOn>2015-10-14 11:41:32 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:84ECF375-4665-4E02-9C87-C3E902230404"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:03b8ad99-26c1-4c2f-8490-b2dbbdb04280">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>erone sulphate and SULT2A1 is involved in the formation of </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> sulphate.                                                  </ao:suffix>
    <pav:createdOn>2015-08-18 11:34:40 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:hasSource>
    <ao:exact>abiraterone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:03b8ad99-26c1-4c2f-8490-b2dbbdb04280"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:96BAC859-5CB1-4963-A12C-9E45F0A17F1F">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9D1C1206-9096-4B3A-ABDF-BA78B56F1359"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BF221115-C0FE-46B1-96DB-A85C6065A7D7">
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-09-29 09:02:21 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:F56177AE-AD85-4ACD-ABCF-CAA3053E242E</pav:lineageUri>
    <ao:body rdf:nodeID="Na505db4b0df749ad8fde8108b9b2af8d"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:FC3BDA4B-6797-4E69-B2A2-8D02E551D5DE"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D1FBAABA-EF88-4FD0-8C4A-3447C135D2E1">
    <pav:lineageUri>urn:domeoserver:annotationset:fc9e17d3-1b0d-4635-9936-0d1d94cb01f9</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-09-14 11:01:50 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N10f55e7f47524292949b2ad8e84c4902"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CE635F27-A391-4A6B-9D87-339FA2F114B2</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-14 11:03:10 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:E8FB27B7-E3BA-4267-9A34-138ED9926C19</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:2C0CC855-B0BF-4638-8FCD-B61F16128202"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C1ED112D-54FC-4EED-9310-75DAA13EFFBD">
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:040AAC68-C089-4D0C-82F0-E37CEE99917B"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:E089588A-45EB-43B4-A29E-D3301BEED860</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-29 09:46:34 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8A6FCCBB-798E-4925-8411-69823AC07AB8">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8728E81F-1288-4E58-86BB-05EB3FFB80F2"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D288D74F-9708-49AC-B474-30F89F6775D3"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N45499dc0bb9d4ba58f69059ccd27aaf5">
    <domeo:sets rdf:resource="urn:pddi:uuid:7CD64C84-E54F-4060-9C56-5839875C957D"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2E38DDF5-FA53-4F16-AD2E-CAD2A4E4393C">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4FC117E6-6D99-4A02-88CF-028C55B050BC">
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-13 12:03:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:B51F4BB3-6BDB-45E7-9399-D93DBC4324AC</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-13 12:04:13 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:CF5E3D34-4BFF-41D7-83EC-62FDB08127EA"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/42DCD145-8643-440F-BB86-FC11DCEFA544">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>60 or 120</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>duloxetine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C20B4AA7-0F63-48A6-865C-3902B3EF9049">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0B8718D5-B552-4BCA-8C1E-BD9B06924E3A"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E34039C1-F715-482F-A942-0A1E1B944DB6"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9C1A8D37-D67F-40E5-AD1B-123DEF9844C1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix>and </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9C1A8D37-D67F-40E5-AD1B-123DEF9844C1"/>
    <pav:createdOn>2015-10-20 10:09:24 -0400</pav:createdOn>
    <domeo:uuid>9C1A8D37-D67F-40E5-AD1B-123DEF9844C1</domeo:uuid>
    <ao:suffix>should not ordinarily be coadministered. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>fluvoxamine </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/66A95A4C-FA60-43FE-ABFB-A6C892784BBC">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A43FD6B2-3C37-43F7-BDA0-4CD8367D4DDC">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:37625BBF-2140-442F-87E5-A81B89AADD1E"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Neb13e42d900240deae3092573c8c79c7">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:383EAF23-ABAB-4AA4-BDB3-988974B6D1ED">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="Nead26cc7f37e44a79f2f1bd4f645fde9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:7AD36F12-4658-4A93-AF58-4FBAE2379926</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:0CF842B2-78B2-4174-B769-2CDF44397186"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-10 14:52:28 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:lastSavedOn>2015-10-16 11:00:06 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4E9A3236-5738-496E-91EE-4C23AF5C9EB2">
    <ao:prefix>, </ao:prefix>
    <ao:suffix>, temazepam) is unlikely to be affected by fluvoxamine. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>4E9A3236-5738-496E-91EE-4C23AF5C9EB2</domeo:uuid>
    <ao:exact>oxazepam</ao:exact>
    <pav:createdOn>2015-10-20 09:54:09 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4E9A3236-5738-496E-91EE-4C23AF5C9EB2"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FC1DDD53-7473-431E-8950-A5A9D07425CD">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>amitriptyline</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>30</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/704</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E773DAFA-3AB4-468F-AF00-DB4F5DE42B6C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:EAB51D08-C5E4-414E-AE31-C67CFC40A051"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EC868F67-3A3C-45C9-BB1E-ACAD5E32C6C6">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <domeo:uuid>EC868F67-3A3C-45C9-BB1E-ACAD5E32C6C6</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>tricyclic antidepressant</ao:exact>
    <pav:createdOn>2015-09-29 11:19:00 -0400</pav:createdOn>
    <ao:prefix>and alcohol, induce liver enzyme activity and thereby reduce </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> plasma levels. Similar effects have been reported with tobacco smoke.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EC868F67-3A3C-45C9-BB1E-ACAD5E32C6C6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:382B9488-A266-4EAF-8082-A95DC2BBF526">
    <pav:createdOn>2015-10-20 10:18:28 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:exact>Significantly increased methadone (plasma level:dose) ratios have been reported when fluvoxamine maleate was administered to patients receiving maintenance methadone treatment, with symptoms of opioid intoxication in one patient. Opioid withdrawal symptoms were reported following fluvoxamine maleate discontinuation in another patient. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:382B9488-A266-4EAF-8082-A95DC2BBF526"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>382B9488-A266-4EAF-8082-A95DC2BBF526</domeo:uuid>
    <ao:prefix>    Methadone   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N636778f2c58b42e29276fd20ed255a92">
    <domeo:sets rdf:resource="urn:pddi:uuid:FED6DBC4-B992-4231-9B50-CD74271FF94D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CCBB1912-2615-4C30-A634-859FECE23236">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine. </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-20 09:22:32 -0400</pav:createdOn>
    <ao:prefix>steady-state concentrations was evaluated in ten male inpatients with schizophrenia. Concentrations of </ao:prefix>
    <ao:exact>thioridazine </ao:exact>
    <domeo:uuid>CCBB1912-2615-4C30-A634-859FECE23236</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CCBB1912-2615-4C30-A634-859FECE23236"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:07027AE0-2E44-48AB-82C9-2526F46688AF">
    <pav:createdOn>2015-10-14 11:41:33 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:07027AE0-2E44-48AB-82C9-2526F46688AF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:suffix>, the active metabolite of enalapril. Dosage adjustments should be made if indicated by the patients clinical condition.</ao:suffix>
    <ao:prefix>has resulted in decreased concentrations of </ao:prefix>
    <domeo:uuid>07027AE0-2E44-48AB-82C9-2526F46688AF</domeo:uuid>
    <ao:exact>enalaprilat</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:08D9F2FC-8AD3-4B76-8722-A9EEEF1233AB">
    <ao:context rdf:resource="urn:domeoclient:uuid:BF3B52AD-C540-4014-83D2-FE29BD13CA56"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-14 11:40:06 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B19C53E8-0CF6-4AD1-8709-E55FCCF854C9">
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-09-14 11:27:16 -0400</pav:createdOn>
    <ao:prefix>were not evaluated.  Procyclidine  </ao:prefix>
    <ao:exact>Daily oral dosing of paroxetine (30 mg once daily) increased steady-state AUC0-24, Cmax, and Cmin values of procyclidine (5 mg oral once daily) by 35%, 37%, and 67%, respectively, compared to procyclidine alone at steady state. If anticholinergic effects are seen, the dose of procyclidine should be reduced.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B19C53E8-0CF6-4AD1-8709-E55FCCF854C9"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3D1ABB80-1DA1-481B-9674-4E4FAE0FA309">
    <pav:createdOn>2015-10-14 12:08:02 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:976A02BC-A9C7-4255-B03F-629AF63BF598"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:5C564FC5-26AA-44D3-A770-FC251BA9C939</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-10-14 12:10:56 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A5236F24-CD6E-4FFA-9D2D-4F7D5C440691">
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <ao:body rdf:nodeID="Na4403ec5e5284f7c922273a5e9806c1d"/>
    <pav:createdOn>2015-08-20 13:01:38 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:42339FDA-47CB-445D-81BE-BD6C66B9F436</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:D87BF910-1BDA-4084-9519-918C66EC040C"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ED38BE9F-16E3-44A2-9EBD-E2E7309A6222">
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:92955C64-5220-4751-A1F6-3F652B2D59BD</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-08-20 13:00:41 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:52704A93-092F-4145-ADFC-C9DDB39BC2E0"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N7537fda7e8794a8197b8590892d938ee"/>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9A74732C-FABE-471C-972C-0CC6549B2961">
    <pav:createdOn>2015-10-14 11:40:53 -0400</pav:createdOn>
    <domeo:uuid>9A74732C-FABE-471C-972C-0CC6549B2961</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>oral hypoglycemic agents</ao:exact>
    <ao:suffix> (sulfonylureas) levothyroxine, methadone, narcotic analgesics, progestins, quinine, tacrolimus theophylline, tricyclic antidepressants (e.g., amitriptyline, nortriptyline) and zidovudine. It may be necessary to adjust the dosages of these drugs if they </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9A74732C-FABE-471C-972C-0CC6549B2961"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/624F46A3-BE9C-4290-9DCD-A0B3EA43C782">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>100</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/203143</dailymed:activeMoietyRxCUI>
    <rdfs:label>fluvoxamine maleate</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BE750539-471D-46E1-8B1E-8CE651934F5A">
    <ao:prefix>cilostazol , and bromocriptine .  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-13 12:05:05 -0400</pav:createdOn>
    <ao:exact>Concomitant administration of clarithromycin with cisapride, pimozide, astemizole, or terfenadine is contraindicated (see CONTRAINDICATIONS.)</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>BE750539-471D-46E1-8B1E-8CE651934F5A</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BE750539-471D-46E1-8B1E-8CE651934F5A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CAB63AF9-D23A-4109-A615-275C9421E6CB">
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to increase the dose of the drug from the recommended baseline.</dct:description>
    <poc:DoseSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#increase-from-recommended-baseline</poc:DoseSelectionRecommendation>
    <sio:SIO_000563>poc:DoseSelectionRecommendation</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Increase from baseline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FAF53196-24EB-417F-B2F5-4037FD5B9F20">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:73161045-082A-4C78-A0EB-AB263AC05E44"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:comment>Plasma concentration of imipramine may increase.</dikbD2R:comment>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FB6B82F4-1EBF-4EB5-AB9F-F7E58FF8DE43">
    <rdfs:label>SSRIs</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:925378B3-0BCB-4EA3-AC47-5DD55DEF8970">
    <ao:prefix>5.5 Potential Tizanidine Interaction  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:925378B3-0BCB-4EA3-AC47-5DD55DEF8970"/>
    <pav:createdOn>2015-10-20 09:49:36 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Fluvoxamine is a potent inhibitor of CYP1A2 and tizanidine is a CYP1A2 substrate. The effect of fluvoxamine (100 mg daily for 4 days) on the pharmacokinetics and pharmacodynamics of a single 4 mg dose of tizanidine has been studied in ten healthy male subjects. Tizanidine Cmax was increased approximately 12-fold (range 5-fold to 32-fold), elimination half-life was increased by almost 3-fold, and AUC increased 33-fold (range 14-fold to 103-fold). The mean maximal effect on blood pressure was a 35 mm Hg decrease in systolic blood pressure, a 20 mm Hg decrease in diastolic blood pressure, and a 4 beat/min decrease in heart rate. Drowsiness was significantly increased and performance on the psychomotor task was significantly impaired. Fluvoxamine and tizanidine should not be used together [see Contraindications (4.1)].</ao:exact>
    <domeo:uuid>925378B3-0BCB-4EA3-AC47-5DD55DEF8970</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4A1F947D-E4F9-4B43-9991-96915301A3C1">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-20 10:18:00 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:B3AD5EB9-79E0-4CA2-B026-05BA753A2E7A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-20 10:19:28 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="Nccee0c039f2942dbb6d912e75825d22f"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:6B50E664-BD71-432E-B7FA-E7313EFF76E1</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D5F8EFD7-FCCA-4828-9DD4-C359C19E5F66">
    <domeo:uuid>D5F8EFD7-FCCA-4828-9DD4-C359C19E5F66</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:41:53 -0400</pav:createdOn>
    <ao:exact>sulfapyridine </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>may be reduced following the concomitant administration of sulfasalazine and rifampin. This finding may be the result of alteration in the colonic bacteria responsible for the reduction of sulfasalazine to sulfapyridine and mesalamine.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:prefix>Plasma concentrations of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D5F8EFD7-FCCA-4828-9DD4-C359C19E5F66"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/910AFC45-5DD4-4BA5-899D-4A8448711B1D">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2626</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>clozapine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FBDB7A20-21BD-4AA1-BF39-1C4B84B2F8E4">
    <dikbD2R:dose>25</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>Savella</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ECF9BE3A-3729-4936-9391-499AE1D37C57">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:C5D43AE6-6354-4E16-825D-D76367957266"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2B5070FD-9D65-4C0B-B084-C8BC8912D195">
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-09-03 15:45:09 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="Nd5649aadb483419295f6a3eca1e37d8a"/>
    <pav:lastSavedOn>2015-10-16 10:35:58 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:6D3709FE-1151-4CCD-8ED5-6577EE09D4D5"/>
    <pav:previousVersion>urn:domeoserver:annotationset:0C9EA96C-0867-4B4B-A1A5-99A165881EF0</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:493863A5-4C9E-4F9A-8147-FB5D77E06771">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <pav:createdOn>2015-09-29 08:59:15 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:A6944C7D-6432-4774-9637-C6CB84C61FE1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:2DC3E46B-8A95-44B3-8EC9-447CBA0265D7</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:79A8DE39-E57A-4966-B6CC-4915B089F4CB">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-09-24 15:38:09 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:CEB45259-CC25-499A-890E-4140F225B186</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:DAD02F8C-D0CF-4D03-A113-8C242E8A7E4F</domeo:belongsToSet>
    <pav:createdOn>2015-09-24 15:29:13 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:AAE435D9-58B2-446B-A1BD-BF6E4CC64025"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B49657E4-FB9E-49F2-94A4-CE875B099051">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-25 10:41:44 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N3df2c4137ea447b1b024520cb73f4590"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:BE71BBF5-9A2D-4EBE-83B0-1E019FA0E0F8</domeo:belongsToSet>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:2D35B71D-2E14-4C03-8659-4167834A149E</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:1BDA7B55-D91B-4590-9E64-FDB6FF77928B"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-09-25 10:47:09 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6DBDAF96-E906-41FD-B5E7-3E9C3D83709C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>azole antifungal agents</ao:exact>
    <ao:suffix> and protease inhibitor drugs (see CONTRAINDICATIONS).</ao:suffix>
    <pav:createdOn>2015-10-14 12:06:12 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6DBDAF96-E906-41FD-B5E7-3E9C3D83709C"/>
    <ao:prefix>is partly metabolized via CYP 3A4, it should not be administered concomitantly with inhibitors of this metabolic system, such as </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>6DBDAF96-E906-41FD-B5E7-3E9C3D83709C</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8678E0CA-6432-40E2-8C6F-78AB05431252">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E4B45313-0C87-4DCE-8BD7-9BFB14E5BC4E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:552468C6-25B6-4E7F-902D-75255E113D2C">
    <pav:createdOn>2015-10-13 12:02:20 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:552468C6-25B6-4E7F-902D-75255E113D2C"/>
    <ao:exact>There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, and bromocriptine.</ao:exact>
    <ao:prefix>dosage should be considered. (See Viagra package insert .)  </ao:prefix>
    <domeo:uuid>552468C6-25B6-4E7F-902D-75255E113D2C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1EE51B7B-C0DE-4E81-AB02-AA8498593241">
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DD2C6134-AE70-455E-A541-EE9425AFB951"/>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9C3B3ED1-A359-4D30-8BB0-4EC7EE74A4D8"/>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:auc>7-20</dikbD2R:auc>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:80427841-8733-4D31-B75E-C7B5AC762B29">
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdfs:label>None</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dct:description>none</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#none</poc:PharmacokineticImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C8B13C68-DA2F-459D-B4E3-A4ABBDFF42DC">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>milnacipran and 150mg pregabalin .  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C8B13C68-DA2F-459D-B4E3-A4ABBDFF42DC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>C8B13C68-DA2F-459D-B4E3-A4ABBDFF42DC</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <ao:exact>Warfarin-Steady-state milnacipran (200 mg/day) did not affect the pharmacokinetics of R-warfarin and S-warfarin or the pharmacodynamics (as assessed by measurement of prothrombin INR) of a single dose of 25 mg warfarin. The pharmacokinetics of Savella were not altered by warfarin. </ao:exact>
    <pav:createdOn>2015-09-30 10:48:09 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:27EE5080-B435-458C-B8C4-52DE6E799617">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:27EE5080-B435-458C-B8C4-52DE6E799617"/>
    <pav:createdOn>2015-08-20 12:47:24 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>27EE5080-B435-458C-B8C4-52DE6E799617</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <ao:prefix>on BCRP and organic anion transporting polypeptide B1 and B3 (OATP1B1/1B3) substrates   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1820958B-AD16-486F-81C4-001769B9695A">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:comment>Subjects were male</dikbD2R:comment>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:78443FF3-867A-42A8-9EC4-C2F4C6DD3374"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4620AEC8-472B-4E1E-A5CA-85E870C2B430">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>sertraline</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FD12FFE9-C878-4697-B0D7-AF4D13B28A10">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-13 12:02:49 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>dosage should be considered. (See Viagra package insert .)  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, and bromocriptine.</ao:exact>
    <domeo:uuid>FD12FFE9-C878-4697-B0D7-AF4D13B28A10</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FD12FFE9-C878-4697-B0D7-AF4D13B28A10"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/940d0fc9-6876-4714-abf6-541abdf7fa67">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-08-27 14:50:19 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-08-27 14:50:19 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:feec2ab0-71a1-46f3-88e8-bac41a3f6a17"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:282837CD-372D-4A39-ACC1-B9E420E7A591">
    <pav:createdOn>2015-09-30 10:39:28 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>The drug interaction studies described in this section were conducted in healthy adult subjects.  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>282837CD-372D-4A39-ACC1-B9E420E7A591</domeo:uuid>
    <ao:exact>Carbamazepine-There were no clinically significant changes in the pharmacokinetics of milnacipran following co-administration of Savella (100 mg/day) and carbamazepine (200 mg twice a day). No changes were observed in the pharmacokinetics of carbamazepine or its epoxide metabolite due to co-administration with Savella. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:282837CD-372D-4A39-ACC1-B9E420E7A591"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:560ED62D-D32F-4146-B047-7AB9DBB6F516">
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:0683C2AA-5C90-4CA7-B517-F5C39E62CCE2"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-20 10:09:07 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A7694551-D141-4557-87D6-A195E8F76B82">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <rdfs:label>cimetidine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A75C324F-9F88-48E2-884F-44D03DA0A982">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>sertraline</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>200</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:00F6D7A8-ADDC-4EEF-8B54-2538CCE00AAF">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6FAEBB86-7CA0-42CA-92E4-DF055A567659"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8897f4766e494588bd27e2cd25bb6257">
    <domeo:sets rdf:resource="urn:pddi:uuid:3C34201F-1651-4A2A-B927-94C1E3EC79BC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A358E38F-FA15-494B-949C-44D37D23BE49">
    <ao:exact>Because of the pharmacologic similarity of maprotiline hydrochloride to the tricyclic antidepressants, the plasma concentration of maprotiline may be increased when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), as has occurred with tricyclic antidepressants. Adjustment of the dosage of maprotiline hydrochloride may therefore be necessary in such cases.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-30 12:40:07 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A358E38F-FA15-494B-949C-44D37D23BE49"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>A358E38F-FA15-494B-949C-44D37D23BE49</domeo:uuid>
    <ao:prefix>is rapidly tapered in patients receiving maprotiline .  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FF57A4B9-CC79-451C-9234-D39598D4703F">
    <rdfs:label>olanzapine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3A225FC5-5620-450A-9EE4-3DFE36E2CA3B">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-14 11:40:33 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:996F160E-19AE-4844-B55D-993B7D6E2615"/>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A98E10B7-3877-4E84-BB0A-2738C21E4CDD">
    <ao:context rdf:resource="urn:domeoclient:uuid:8D650328-BA5C-4D2C-96C2-FD196454F8FD"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <pav:createdOn>2015-09-29 11:24:26 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:5986F106-9877-451D-82D5-EC7156BABA14</pav:lineageUri>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B419800B-96F2-44DE-BEEE-403CE4A82E0D">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10438</dailymed:activeMoietyRxCUI>
    <rdfs:label>theophylline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ABA54D79-4C89-44D4-AC22-ADBD65C7097E">
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmax>5</dikbD2R:cmax>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9B0F9D3A-740F-4C2E-8BB9-79934B636019"/>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0971333E-F8EA-459F-9907-212F5277738C"/>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0D254072-7664-47FE-9C53-FD89886AF61C">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F8C460B6-A830-41FF-BB18-F647DD001A02"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B7E725AA-4265-4E0B-959E-57A4D8586321"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C0EAD6FC-7563-4352-8B33-AA84146C6C74">
    <pav:createdOn>2015-10-16 10:51:17 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-16 10:55:51 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="Nfe41af0e32fe411faf69071727977348"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:0DAF5666-9E53-42D5-B92E-DE2C00764986</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:B9BB7E96-2A41-4A24-8F51-A1E0B53EC77F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2918AAD1-E59E-4604-8CD5-016C5F8C0ACB">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7D6CC28B-39F2-46E5-9AC4-F618BCA73D55"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/1A2B9EE2-F5E7-40AD-ABD4-D303AD3ECB8B"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:845C5817-1226-427E-B875-634AAB8A4166">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/76FDF091-BF17-4173-8FBA-154825C19086"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/36844AF9-84CB-4AEB-8971-46D7EAF727F5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:18B599FF-6A4D-4DA0-ACE9-6D889D08EF91">
    <ao:suffix>, narcotic analgesics, progestins, quinine, tacrolimus theophylline, tricyclic antidepressants (e.g., amitriptyline, nortriptyline) and zidovudine. It may be necessary to adjust the dosages of these drugs if they are given concurrently with rifampin.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>18B599FF-6A4D-4DA0-ACE9-6D889D08EF91</domeo:uuid>
    <ao:exact>methadone</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-14 11:40:56 -0400</pav:createdOn>
    <ao:prefix>, </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:18B599FF-6A4D-4DA0-ACE9-6D889D08EF91"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B0521F1D-1BA2-40FA-86D3-1A8F950933A9">
    <ao:suffix> may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (</ao:suffix>
    <pav:createdOn>2015-09-29 09:24:02 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of </ao:prefix>
    <domeo:uuid>B0521F1D-1BA2-40FA-86D3-1A8F950933A9</domeo:uuid>
    <ao:exact>TCA</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B0521F1D-1BA2-40FA-86D3-1A8F950933A9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:839915E5-0351-4036-A7A5-DEBBE27B137B">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C733351C-24EF-4F5F-A079-2ED71A363CD5"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:numOfParticipants>12</dikbD2R:numOfParticipants>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F40AC04D-7DAE-4958-B524-1B01C3E34506"/>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:preciptDuration>1</dikbD2R:preciptDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptRegimens>SD</dikbD2R:preciptRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:objectRegimens>BID</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:911E45A5-C8CB-408F-A048-AE764254BB06">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/AA998DF5-8EF7-4A04-9300-EBC4A4CFC4DB"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A7694551-D141-4557-87D6-A195E8F76B82"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:54AFBACD-5A69-405B-A5F3-BDD53D7377F3">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:B7C2144D-8452-4A0D-AE4C-F4BD352AC755"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1D5A637D-5D0D-4828-BA8F-B06362C87321">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>or other strong CYP 2D6 inhibitors are contraindicated (see </ao:suffix>
    <domeo:uuid>1D5A637D-5D0D-4828-BA8F-B06362C87321</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1D5A637D-5D0D-4828-BA8F-B06362C87321"/>
    <ao:exact>paroxetine </ao:exact>
    <pav:createdOn>2015-10-14 12:08:09 -0400</pav:createdOn>
    <ao:prefix> and </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:96C2E3DD-CFC0-4B5C-A927-479839774169">
    <ao:body rdf:nodeID="N661dbbfdab73461bba3cfde7ffcaab04"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-08-20 11:45:38 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:E22F4363-3D17-4C39-8B0A-72CEE0B97B5D"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:1D1C5AFE-04AC-4339-AAB1-AF00405BC90F</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4950B5DA-2438-44CB-8130-B993D496F58B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, mexiletine, quinidine, tocainide), oral anticoagulants, antifungals (e.g., fluconazole, itraconazole, ketoconazole), barbiturates, beta-blockers, calcium channel blockers (e.g., diltiazem, nifedipine, verapamil), chloramphenicol, clarithromycin, cortic</ao:suffix>
    <ao:prefix>(e.g., </ao:prefix>
    <pav:createdOn>2015-10-14 11:40:14 -0400</pav:createdOn>
    <domeo:uuid>4950B5DA-2438-44CB-8130-B993D496F58B</domeo:uuid>
    <ao:exact>disopyramide</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4950B5DA-2438-44CB-8130-B993D496F58B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CE37B0DD-63CD-4244-97C1-41BECC806657">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>sertraline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:27930AA1-7502-491C-B456-7D079712EC2C">
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E6E5E2BF-110F-4222-A780-5EA92CB0DA45"/>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptDuration>10</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4FCD805B-0264-4B9B-BC69-F31623FBBAC6"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A0D9C92E-0E93-453E-972C-8D8CF754228D">
    <rdfs:label>ritonavir</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85762</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:536084E1-4894-4FC8-8485-806ECB576ABF">
    <pav:createdOn>2015-10-14 11:40:10 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:B8BF66D0-3ECC-4CAE-8D2A-060A2E0912AB"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1885A697-957C-4329-B524-9B683EC6620F">
    <pav:previousVersion>urn:domeoserver:annotationset:2F0F6A9C-0E38-4924-B1BA-458A4EEDE554</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N4e948442a4c14a21b7d2910a5e8cab41"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-10-13 11:59:07 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-13 11:58:14 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:F559702E-86B5-4B89-9DBF-F04A75B3360B"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/49C7B63E-79ED-4915-B479-BFD5C26EA7F2">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>pimozide</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8331</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1FFAB7BB-4578-4DF0-AA0D-E551841F103D">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A9FB662B-B83B-4917-B9B9-EA3D95D5A7B3"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A8E2E3A5-6930-4C86-8E84-38677FB9541E"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B6766B06-895F-4173-AC6D-9B856461E828">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-08-20 13:55:35 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N656de6243a454912a021b18f4fc011d1"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:1DE064C4-9A25-4A8E-B4A6-03E67FB5C12F"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2ABE5FA2-BA00-4AF9-A2EA-1305FAECF3DF</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:C6A0EC6E-7A1B-4416-A6DA-E9D694F595AD</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0D5B628D-9A8E-4485-92C6-6327D739FE2B">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/57258</dailymed:activeMoietyRxCUI>
    <rdfs:label>tizanidine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:973101FF-2CCF-4B2B-981D-8B49DF14D876">
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N2cea5e0ca10345dfac1b59c8b4525f00"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:913DB6C1-AA04-4858-A117-A7C1269443E2"/>
    <pav:lineageUri>urn:domeoserver:annotation:313B4B53-EFB7-44CD-91A9-7C7A8235FFE1</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:545F2613-2A5E-4333-A651-CBA80268D6ED</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-30 10:44:33 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/391382AD-9D4A-4BCC-92B4-3DE625E5234B">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>imipramine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/5691</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:26AC1AC5-7BF2-4256-BC61-4CA271F577C9">
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/53500124-D066-4452-9DFB-FE1A1CCE7B10"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E1C3313D-4AD7-4D8E-900B-D7C2D6E43D83"/>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmax>2.8</dikbD2R:cmax>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucType>Fold</dikbD2R:aucType>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:cmaxType>Fold</dikbD2R:cmaxType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:auc>2.9</dikbD2R:auc>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:06E2ACC0-7263-4C16-ADEC-327CE225CD4F">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:06E2ACC0-7263-4C16-ADEC-327CE225CD4F"/>
    <ao:exact> tricyclic antidepressants</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-29 11:18:49 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> have been reported upon discontinuation of </ao:suffix>
    <ao:prefix> can produce clinically significant increases in the plasma concentrations of the tricyclic antidepressants. Conversely, decreases in plasma levels of the</ao:prefix>
    <domeo:uuid>06E2ACC0-7263-4C16-ADEC-327CE225CD4F</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2D645FF2-9025-478C-826A-5B62FCD191C6">
    <rdfs:label>levomilnacipran</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:53034F06-01D0-456B-B27F-C45D6327886E">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D05C560B-0A2A-45F3-8B4B-34CECB64AB75"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:97C72BF5-EFD6-4BFB-8E87-3F00FE3995F1">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/30B562BD-11DC-47B0-A4BA-65B20C3A5A8B"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/63424F66-F81A-4FE6-A06D-1FD33D4C0A09"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:544F1A0B-6C64-4B6C-B623-DF98000D3F29">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:03E18AD1-EFAA-4E41-A6B0-D5FE7C8C9BC5"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CD065D6E-4669-4434-B279-2F43F2DEBF09">
    <domeo:uuid>CD065D6E-4669-4434-B279-2F43F2DEBF09</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-08-20 13:05:32 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>[see Drug Interactions (7) ] .  </ao:prefix>
    <ao:exact>Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), and metoprolol (a CYP2D6 substrate).</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CD065D6E-4669-4434-B279-2F43F2DEBF09"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D0977829-85CF-48FD-9F4E-40132B488710">
    <ao:prefix>, metoprolol , atomoxetine )   </ao:prefix>
    <pav:createdOn>2015-09-24 15:36:49 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>D0977829-85CF-48FD-9F4E-40132B488710</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In vitro studies showed minimal inhibitory effect of desvenlafaxine on CYP2D6. Clinical studies have shown that desvenlafaxine does not have a clinically relevant effect on CYP2D6 metabolism at the dose of 100 mg daily. When desvenlafaxine succinate was administered at a dose of 100 mg daily in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the Cmax and AUC of desipramine increased approximately 25% and 17%, respectively. When 400 mg (8 times the recommended 50 mg dose) was administered, the Cmax and AUC of desipramine increased approximately 50% and 90%, respectively. Concomitant use of desvenlafaxine with a drug metabolized by CYP2D6 can result in higher concentrations of that drug [see Drug Interactions (7.5)].</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D0977829-85CF-48FD-9F4E-40132B488710"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4E3F940B-842C-4B25-B4CE-F3012B81FFE3">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8331</dailymed:activeMoietyRxCUI>
    <rdfs:label>pimozide</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:345461F7-EDAF-4FC6-9989-9C08C90A9BEB">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:52BD9C60-3B4E-45B9-8AF0-3435FD2293B6"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3df2c4137ea447b1b024520cb73f4590">
    <domeo:sets rdf:resource="urn:pddi:uuid:93B475C7-75F1-4743-8FFA-D944D75B1713"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:867AE862-C429-41C4-A327-DC5851C4562E">
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/75C13C61-5E7D-4445-AB25-C7C9FEA47925"/>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxDirection>Decrease</dikbD2R:cmaxDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:auc>35</dikbD2R:auc>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:cmax>35</dikbD2R:cmax>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:preciptRegimens>QD</dikbD2R:preciptRegimens>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A964F2E8-199E-48E3-8014-B72819250DE9"/>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:58655709-DAF3-46BE-9EE2-996808369DAA">
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-08-20 13:03:26 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N835d10a036d94426a4fd933225b08698"/>
    <pav:lineageUri>urn:domeoserver:annotation:6C1E59DA-FA49-4E62-A835-0FD929EFF2B1</pav:lineageUri>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:56F89889-24B7-4AC1-8383-B649A34A92FD"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/35783469-A903-4427-96C8-B2BB98648CE2">
    <rdfs:label>levomilnacipran</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A016C3D6-7FFC-4901-9BB0-E99C37F139D2">
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:numOfParticipants>32</dikbD2R:numOfParticipants>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/454565FB-E40E-4EDB-9577-DF831C122D0D"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/1EC2CBC5-EDF8-453A-B3A2-C7955EBBC3AF"/>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:53286523-B901-42EC-8901-993C4320624D">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:C91289D7-45EC-44D1-A933-E79E770CFE71</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-14 12:06:07 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5EE070F1-3108-4ADB-BC2D-46939EAADB10"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-14 12:07:40 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8192C38C-8A64-4095-93F3-6ABB76394412">
    <domeo:uuid>8192C38C-8A64-4095-93F3-6ABB76394412</domeo:uuid>
    <ao:exact>Spontaneous reports in the postmarketing period suggest that concomitant administration of clarithromycin and oral anticoagulants may potentiate the effects of the oral anticoagulants. Prothrombin times should be carefully monitored while patients are receiving clarithromycin and oral anticoagulants simultaneously.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-13 11:57:58 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8192C38C-8A64-4095-93F3-6ABB76394412"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>should be reduced by 50%. For patients with CLCR &lt; 30 mL/min, the dose of clarithromycin should be decreased by 75%.  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1C418A3B-A13B-4CCF-A73C-F688A08DBC67">
    <ao:prefix>casians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of </ao:prefix>
    <domeo:uuid>1C418A3B-A13B-4CCF-A73C-F688A08DBC67</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>tricyclic antidepressants</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1C418A3B-A13B-4CCF-A73C-F688A08DBC67"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-29 08:55:49 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <ao:suffix> (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1e1181d5-903c-4c15-b5b0-40539c6cefa8">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-08-27 14:50:27 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1e1181d5-903c-4c15-b5b0-40539c6cefa8"/>
    <ao:suffix> </ao:suffix>
    <ao:prefix> with </ao:prefix>
    <ao:exact>clomipramine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5FC3A0F4-2409-4406-82D2-08ECEF04A6BE">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0331BE00-9791-4997-932F-FAB3E4507C8F"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0D2D70AA-0957-49C9-BE8C-67351D16661C">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/57258</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>4</dikbD2R:dose>
    <rdfs:label>tizanidine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A39C05D9-C1FF-4348-B163-BEEEF07CDD0F">
    <rdfs:label>fluvoxamine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:652B60BC-66CA-4374-AD8E-3EE0BEA4543C">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>is contraindicated. (See CONTRAINDICATIONS .)  </ao:prefix>
    <pav:createdOn>2015-10-13 11:38:07 -0400</pav:createdOn>
    <ao:exact>Clarithromycin 500 mg every 8 hours was given in combination with omeprazole 40 mg daily to healthy adult subjects. The steady-state plasma concentrations of omeprazole were increased (Cmax, AUC0-24, and T1/2 increases of 30%, 89%, and 34%, respectively), by the concomitant administration of clarithromycin. The mean 24-hour gastric pH value was 5.2 when omeprazole was administered alone and 5.7 when coadministered with clarithromycin.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>652B60BC-66CA-4374-AD8E-3EE0BEA4543C</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:652B60BC-66CA-4374-AD8E-3EE0BEA4543C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AAE42D5F-9364-403B-8D0D-8000D1C73EDD">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:51ADF4A4-36F4-4036-8C39-A4E2F13682BD"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:comment>Object drug given every 4 hours - nothing represents that in the regimen</dikbD2R:comment>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F3C5F26C-D9B0-4BD8-B3F1-895B266B8F19">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>dextromethorphan</rdfs:label>
    <dikbD2R:dose>1000</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:18C6017F-70AF-422C-893F-CF25B4092807">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>18C6017F-70AF-422C-893F-CF25B4092807</domeo:uuid>
    <pav:createdOn>2015-08-20 11:11:53 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:hasSource>
    <ao:exact>In an in vivo drug-drug interaction trial, the Cmax and AUC of dextromethorphan (CYP2D6 substrate) were increased 2.8- and 2.9-fold, respectively when dextromethorphan 30 mg was given with abiraterone acetate 1,000 mg daily (plus prednisone 5 mg twice daily). The AUC for dextrorphan, the active metabolite of dextromethorphan, increased approximately 1.3 fold [see Drug Interactions (7.2)].</ao:exact>
    <ao:prefix>has the potential to inhibit CYP1A2, CYP2D6, CYP2C8 and to a lesser extent CYP2C9, CYP2C19 and CYP3A4/5.  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:18C6017F-70AF-422C-893F-CF25B4092807"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6C4DFA91-EA88-42F6-B8FF-A57CAF81EDC4">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>abiraterone acetate</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B14EF34E-916A-4CB4-8766-72FB1F5DA995">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/5691</dailymed:activeMoietyRxCUI>
    <rdfs:label>imipramine</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/408F26AF-FCE9-4E71-8A05-5723857C96AE">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>clarithromycin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DE595579-2726-43AE-BE6A-8D48C30C5CFD">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:3A25B883-250F-4B02-840F-4193D0A046CA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C9DE974E-8A48-4DD5-B1FF-FEF3E4AFB8AA">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <ao:prefix>Drug Interactions (7) ] .   Oral Contraceptives  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-08-20 13:05:10 -0400</pav:createdOn>
    <ao:exact>There was an increase in mean ethinylestradiol Cmax and AUC024 (1.58- and 1.54-fold, respectively) and levonorgestrel Cmax and AUC024 (1.33- and 1.41-fold, respectively) following repeated doses of teriflunomide [see Drug Interactions (7)].</ao:exact>
    <domeo:uuid>C9DE974E-8A48-4DD5-B1FF-FEF3E4AFB8AA</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C9DE974E-8A48-4DD5-B1FF-FEF3E4AFB8AA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4488333E-90FB-4227-A529-CB398D9751C8">
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-20 09:23:48 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:8D286017-0AEC-46C4-AC51-641E2F31DE1A</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:EAF4BEDE-3D55-4DED-A7E8-9DE3062888F0"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-20 09:22:33 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B67C5EED-18A2-4EE9-81EC-2B539F5A4F12">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <domeo:uuid>B67C5EED-18A2-4EE9-81EC-2B539F5A4F12</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-29 11:24:22 -0400</pav:createdOn>
    <ao:suffix>interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class </ao:suffix>
    <ao:prefix>SSRI </ao:prefix>
    <ao:exact>TCA </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B67C5EED-18A2-4EE9-81EC-2B539F5A4F12"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6a84c164e37847a8ba32d652a5c61eb9">
    <domeo:sets rdf:resource="urn:pddi:uuid:78BB9141-0159-4703-BA9D-BD34CB79F242"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/ADFB4A66-76E9-4663-8777-15964EB91687">
    <rdfs:label>paroxetine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8BA15B39-60FF-442D-9D16-49CA28D5964E">
    <pav:createdOn>2015-10-20 10:08:57 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix> tablets and </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8BA15B39-60FF-442D-9D16-49CA28D5964E"/>
    <domeo:uuid>8BA15B39-60FF-442D-9D16-49CA28D5964E</domeo:uuid>
    <ao:suffix>is generally not advisable. Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic coadministration. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>diazepam </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/36552645-2A49-4B3F-A83B-AD6CC9F3BA5B">
    <dikbD2R:dose>20</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>rabeprazole</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BD891937-2C4A-475C-9F12-D68CA41C44BB">
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-16 10:31:17 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:55B1C49E-7916-41C7-A208-C65CF240E0B5</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="Nd6e1d7a1f8d647fd978db86fc0afe9f2"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdOn>2015-09-03 15:42:58 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:CCEEA6AE-2E77-4C46-AD3D-D81508E6C690"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/64A6C4D4-5FE7-41A7-AD26-1E0B9ECE7502">
    <rdfs:label>paroxetine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3F373F2F-E720-4F70-A0CE-36E72CEB3FCE">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:324585FC-3C7D-4ECD-A8FD-34EFC3850977"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8FDD37CC-61CA-46A4-BB15-912B0623A178">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="Ne4b98f5e139b4bfb8b438ee2a21a7a31"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:7075CCC9-1A63-43E3-8BA3-C9050AAD5898"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:BE71BBF5-9A2D-4EBE-83B0-1E019FA0E0F8</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:7C54AB9A-1029-4E70-B215-41C356CF7949</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-09-25 10:42:31 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-09-25 10:47:09 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EBC7D022-C17F-4F68-99DD-1C481A89BA04">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-09-03 15:40:59 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:3E8F5287-A48D-41C3-9170-862531EB5307"/>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:55B1C49E-7916-41C7-A208-C65CF240E0B5</pav:previousVersion>
    <pav:lastSavedOn>2015-10-16 10:31:17 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N19f478ab592841d785e358ff6f52aa7e"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CB70CFDA-E17D-4A6C-8B95-CB742B5D4532">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:74E02DD6-AA1B-4C0B-A182-800A00272FFB"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:81E726EE-AA8D-4B55-8C48-986ACFF5AECC">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix>metabolism have not been studied.  </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-16 10:54:35 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:81E726EE-AA8D-4B55-8C48-986ACFF5AECC"/>
    <ao:exact>A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin. If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached [see Contraindications (4) and Warnings and Precautions (5)]. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E040159D-8A6C-4851-BA28-4759203426F5">
    <ao:context rdf:resource="urn:domeoclient:uuid:A08093DA-3EE1-44F9-9238-92BB02F21D62"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
    <pav:createdOn>2015-08-20 11:41:02 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:7084298F-F868-484E-9091-B9ED9E4588DB</pav:previousVersion>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N88b10d7887604c56801f7963217b65f7"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-08-20 11:43:54 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DEC213F1-5C66-4AC5-9443-03F6A2229756">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>abiraterone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8CB0EAF5-2143-4515-B447-2EA1A8508235">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-10-13 12:03:59 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:lastSavedOn>2015-10-13 12:04:13 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N48097d6a75674e1ebf2a8fcb3a13c211"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:B51F4BB3-6BDB-45E7-9399-D93DBC4324AC</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:EF1538E4-548C-472D-AE45-ED339B3F42E4"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2EC218B9-538E-4C65-83F9-FF609C0D4C12">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:exact>clozapine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2EC218B9-538E-4C65-83F9-FF609C0D4C12"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-20 10:17:48 -0400</pav:createdOn>
    <domeo:uuid>2EC218B9-538E-4C65-83F9-FF609C0D4C12</domeo:uuid>
    <ao:prefix> and </ao:prefix>
    <ao:suffix>. Since clozapine-related seizures and orthostatic hypotension appear to be dose related, the risk of these adverse events may be higher when fluvoxamine and clozapine are coadministered. Patients should be closely monitored when fluvoxamine maleate and </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FA277D75-02D4-452E-80B4-9F36CF1CF573">
    <dikbD2R:comment>Warfarin dose was titrated to clinical levels of anticoagulation, so different for each person.</dikbD2R:comment>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A33C822C-240E-49A9-8879-3E6167E97DC4"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1A5D8A4A-106F-41F1-8E35-559596E80901">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0022E1AF-245D-40B1-A071-ADD4C967A8D2"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E61A3EB0-57D7-4D36-A9CD-E265FEE0C538">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, methadone, narcotic analgesics, progestins, quinine, tacrolimus theophylline, tricyclic antidepressants (e.g., amitriptyline, nortriptyline) and zidovudine. It may be necessary to adjust the dosages of these drugs if they are given concurrently with ri</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <pav:createdOn>2015-10-14 11:40:55 -0400</pav:createdOn>
    <ao:exact>levothyroxine</ao:exact>
    <domeo:uuid>E61A3EB0-57D7-4D36-A9CD-E265FEE0C538</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>) </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E61A3EB0-57D7-4D36-A9CD-E265FEE0C538"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ACE81FE6-2F4B-4734-AB4B-497D5C50F2A1">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4D4B1447-4736-45FE-8790-101F65AAE150"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:comment>Reduced plasma concentration of saquinavir</dikbD2R:comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CFC0FDEB-61EF-4D3D-B8EB-CDA68B521721">
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2015-09-29 11:20:15 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>CFC0FDEB-61EF-4D3D-B8EB-CDA68B521721</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <ao:suffix>Concurrent administration of</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CFC0FDEB-61EF-4D3D-B8EB-CDA68B521721"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Certain drugs, particularly the psychostimulants and the phenothiazines, increase plasma levels of concomitantly administered tricyclic antidepressants through competition for the same metabolic enzyme systems. </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:56F89889-24B7-4AC1-8383-B649A34A92FD">
    <domeo:uuid>56F89889-24B7-4AC1-8383-B649A34A92FD</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <ao:prefix>BCRP and OATP1B1/1B3 Substrates  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:56F89889-24B7-4AC1-8383-B649A34A92FD"/>
    <ao:exact>There was an increase in mean rosuvastatin Cmax and AUC (2.65- and 2.51-fold, respectively), following repeated doses of teriflunomide , suggesting that teriflunomide is an inhibitor of BCRP transporter and organic anion transporting polypeptide 1B1 and 1B3 (OATP1B1/1B3) [see Drug Interactions (7)].</ao:exact>
    <pav:createdOn>2015-08-20 13:03:26 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E7183CA1-C2BE-48A3-B739-A4EAFA4C115B">
    <pav:createdOn>2015-09-29 11:19:53 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:D0CCAC05-2FD9-4C0D-B712-4B325A19A640"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:F938FAD4-2257-4A3B-B7F1-E9AE7B048EAA</pav:lineageUri>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D3363696-62ED-4C7C-916C-75F08DDF9E4B">
    <ao:exact>rifampin</ao:exact>
    <ao:prefix>Concomitant antacid administration may reduce the absorption of </ao:prefix>
    <pav:createdOn>2015-10-14 11:41:38 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D3363696-62ED-4C7C-916C-75F08DDF9E4B"/>
    <domeo:uuid>D3363696-62ED-4C7C-916C-75F08DDF9E4B</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:suffix>. Daily doses of rifampin should be given at least 1 hour before the ingestion of antacids.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E34DCA29-F2E0-4985-A084-C94BE7317FA3">
    <ao:exact>CimetidineIn a study assessing disposition of sertraline (100 mg) on the second of 8 days of cimetidine administration (800 mg daily), there were significant increases in sertraline mean AUC (50%), Cmax (24%) and half-life (26%) compared to the placebo group. The clinical significance of these changes is unknown.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>therapy is initiated or stopped.   </ao:prefix>
    <pav:createdOn>2015-09-16 15:19:52 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E34DCA29-F2E0-4985-A084-C94BE7317FA3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:17805DE8-0495-48EB-98BB-070226368C2A">
    <pav:createdOn>2015-10-13 12:05:58 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In addition, there have been reports of interactions of erythromycin or clarithromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate.</ao:exact>
    <ao:prefix>is contraindicated (see CONTRAINDICATIONS .)  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:17805DE8-0495-48EB-98BB-070226368C2A"/>
    <domeo:uuid>17805DE8-0495-48EB-98BB-070226368C2A</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3C11326F-F54A-4B3F-8354-557EC02AF851">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:103D0088-07B3-4E41-8B47-BBD96100B99C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:58572AE4-2116-4E49-8AF2-509D75B729C3">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:3FC8F828-F0E8-444D-B54E-D4D2B5F42B77"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CA8EBA33-B837-45E1-B0DE-6F6214286335">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluvoxamine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>50</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/50540ab3-4d5b-436c-afe5-9e16c16ef1fe">
    <ao:context rdf:resource="urn:domeoclient:uuid:03b8ad99-26c1-4c2f-8490-b2dbbdb04280"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-08-18 11:34:40 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:64737b65-8582-4b76-8095-85ad69e2cc47</pav:lineageUri>
    <pav:createdOn>2015-08-18 11:34:40 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2E0AD717-67BC-4D7C-AF83-5F1037F99712</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A820C708-DD9F-4B42-9652-BC89E5BCFF0F">
    <ao:exact>CMI</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <pav:createdOn>2015-09-29 09:44:23 -0400</pav:createdOn>
    <ao:prefix> with CMI increases plasma concentrations of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>. Co-administration of CMI with </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A820C708-DD9F-4B42-9652-BC89E5BCFF0F"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E30682F1-8894-4215-891B-A1AFEC04BD44">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10438</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>theophylline</rdfs:label>
    <dikbD2R:dose>1000</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BE63D747-8C0B-431D-AA2A-307559C30C3E">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6F803812-6959-41B2-ABE3-03310CF96EEB"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C09825F3-B6D6-40D0-BE32-57E20F5E9CDF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:16FDB844-0908-4D9D-9647-601A4C547C45">
    <sio:SIO_000338>poc:TestResult</sio:SIO_000338>
    <poc:TestResult>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#gene-haplotype-positive</poc:TestResult>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>gene-haplotype-positive</rdfs:label>
    <dct:description>A test result that is somehow related to the biomarker.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4D7DBAA1-48DE-4BE6-BBEA-286BD33E89EF">
    <ao:suffix> involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <ao:exact>SSRI</ao:exact>
    <domeo:uuid>4D7DBAA1-48DE-4BE6-BBEA-286BD33E89EF</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-01 10:27:35 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4D7DBAA1-48DE-4BE6-BBEA-286BD33E89EF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N683a9b09a9b149bcb25a0733a3e15ab1">
    <domeo:sets rdf:resource="urn:pddi:uuid:B81D5E26-E66A-4C11-9AC2-C774F994E2AE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1039BA00-71C9-437E-A17F-D5BD526D0B58">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BEDC3045-C5EC-49D7-A08E-F5208415E81B"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2A474977-3F89-40AA-A0C2-387F621CD093">
    <domeo:uuid>2A474977-3F89-40AA-A0C2-387F621CD093</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Carbamazepine    Carbamazepine is an enzyme inducer and typically causes decreases in drug exposure; however, approximately 2-fold increased systemic exposure of selegiline and its metabolites, L-amphetamine and L-methamphetamine were seen after single application of EMSAM 6 mg per 24 hours in subjects who had received carbamazepine (400 mg per day) for 14 days. Changes in plasma selegiline concentrations were nearly 2-fold and variable across the subject population. Such increases may increase the risk of a hypertensive crisis when carbamazepine is used with EMSAM at any dose [see Contraindications (4), Warnings and Precautions (5.3) and Drug Interaction (7.4)].</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-16 10:35:39 -0400</pav:createdOn>
    <ao:prefix>   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2A474977-3F89-40AA-A0C2-387F621CD093"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0238857E-C0B0-435F-A609-C3760073ADB4">
    <rdfs:label>warfarin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B2109108-581E-4CB0-9BAA-BCB518613C2C">
    <domeo:uuid>B2109108-581E-4CB0-9BAA-BCB518613C2C</domeo:uuid>
    <pav:createdOn>2015-09-29 11:28:11 -0400</pav:createdOn>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B2109108-581E-4CB0-9BAA-BCB518613C2C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FEF90AD1-0B74-4259-90AA-EC27812E1C91">
    <ao:prefix>7.1 Potential Interactions with Drugs that Inhibit or are Metabolized by Cytochrome P450 Isoenzymes  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Multiple hepatic cytochrome P450 isoenzymes are involved in the oxidative biotransformation of a large number of structurally different drugs and endogenous compounds. The available knowledge concerning the relationship of fluvoxamine and the cytochrome P450 isoenzyme system has been obtained mostly from pharmacokinetic interaction studies conducted in healthy volunteers, but some preliminary in vitro data are also available. Based on a finding of substantial interactions of fluvoxamine with certain of these drugs [see later parts of this section and also Warnings and Precautions (5)] and limited in vitro data for CYP3A4, it appears that fluvoxamine inhibits several cytochrome P450 isoenzymes that are known to be involved in the metabolism of other drugs such as: CYP1A2 (e.g., warfarin, theophylline, propranolol, tizanidine), CYP2C9 (e.g., warfarin), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., omeprazole).</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FEF90AD1-0B74-4259-90AA-EC27812E1C91"/>
    <pav:createdOn>2015-10-16 10:51:31 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:31B4775C-E1FD-47C1-9784-61826CFD3E23">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so-called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).  </ao:prefix>
    <pav:createdOn>2015-10-01 10:45:55 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:31B4775C-E1FD-47C1-9784-61826CFD3E23"/>
    <domeo:uuid>31B4775C-E1FD-47C1-9784-61826CFD3E23</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/871315CB-D598-45DE-A773-6C2656001BB6">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/136411</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>Sildenafil</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:44046A29-7959-4E62-9332-5C8CAF559886">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:2F0F6A9C-0E38-4924-B1BA-458A4EEDE554</pav:previousVersion>
    <ao:body rdf:nodeID="Nd2e1c1cf2e9e491d97e9c4b59875f2f0"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <pav:createdOn>2015-10-13 11:59:05 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-13 11:59:07 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:EB3C8A27-42F6-4C05-A445-7D2E722619CF"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2032BEFB-374A-48C8-A3C3-A86CD4A90B1A">
    <rdfs:label>phenobarbital</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8134</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7202CC73-0AE1-4A33-B3A2-3FE717DFC543">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:1E80249C-6FF0-4079-9846-1144F568ADA5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-10-14 12:08:01 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-14 12:10:56 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:AC0C5ADB-2009-49C8-A666-A5870EB11A51</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nca5ea678456441639a1c0324168e17e3">
    <domeo:sets rdf:resource="urn:pddi:uuid:185FBCB4-5BB3-497B-B52D-9F4A70A4A4DA"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A42C5CEA-C711-448C-B236-8FAFC70BB6DF">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A6319AE3-2857-4629-9C16-E0537BBAA400">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>GILENYA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8B1939F6-6CDE-49BB-B048-194206B6B33F">
    <domeo:uuid>8B1939F6-6CDE-49BB-B048-194206B6B33F</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-08-20 12:47:11 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8B1939F6-6CDE-49BB-B048-194206B6B33F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>on BCRP and organic anion transporting polypeptide B1 and B3 (OATP1B1/1B3) substrates   </ao:prefix>
    <ao:exact>Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)]</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:00F17E52-DA80-479D-A14C-5E2CD0F791CB">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:62385118-7FDC-4740-8C67-BDAE631F3391"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A0B15123-D4BE-4F0C-85C9-0CE36D987D85">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/09DAC383-A901-4BF7-8CAF-796BA2EA439A"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FC26A947-68C1-439E-97CB-A4B892DD45AE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:25F3877A-D050-4EED-A66C-7DF9A7937D83">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0B2844E8-5711-43D4-966A-07E43CB1D1E5"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B79542B8-A1FC-4568-BFE5-E7A58198BFCC">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1109D905-1CFB-4B3D-8D2B-2302F68D62D3">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:40:05 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1109D905-1CFB-4B3D-8D2B-2302F68D62D3"/>
    <ao:exact>antiviral drugs</ao:exact>
    <ao:prefix>. These </ao:prefix>
    <domeo:uuid>1109D905-1CFB-4B3D-8D2B-2302F68D62D3</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> must not be co-administered with rifampin. (See </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:17EDF22D-388A-48A8-A8D8-ED030D4251D3">
    <pav:createdOn>2015-09-29 11:21:43 -0400</pav:createdOn>
    <ao:prefix>. Other substances, particularly </ao:prefix>
    <domeo:uuid>17EDF22D-388A-48A8-A8D8-ED030D4251D3</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:17EDF22D-388A-48A8-A8D8-ED030D4251D3"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <ao:exact>barbiturates</ao:exact>
    <ao:suffix> and alcohol, induce liver enzy</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7679B49A-D35E-4A97-9BB5-8E51FE97FA85">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:suffix>and halothane should be avoided. Patients receiving both rifampin and isoniazid should be monitored closely for hepatotoxicity.</ao:suffix>
    <pav:createdOn>2015-10-14 11:41:49 -0400</pav:createdOn>
    <ao:exact>rifampin </ao:exact>
    <domeo:uuid>7679B49A-D35E-4A97-9BB5-8E51FE97FA85</domeo:uuid>
    <ao:prefix>, the potential for hepatotoxicity is increased. The concomitant use of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7679B49A-D35E-4A97-9BB5-8E51FE97FA85"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CCF3DB31-ADF0-4361-A2CF-40577E0CC470">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:C38B82D1-3D17-47AC-9D1B-AFB34D78E462"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdOn>2015-10-14 11:40:23 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6C74F45B-5AF2-428C-8F42-7060B0272693">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BE06FB39-1B13-4BA9-9ED4-B1668C339202"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/74817592-9344-43E3-B8EE-DF8381C29BE5">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>clarithromycin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>500</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/38909539-9756-4591-9D9B-919942FEC53A">
    <rdfs:label>carbamazepine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>15</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:58E0485C-4FEC-4D50-87A7-1419620F57EE">
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>s) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA ).  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:58E0485C-4FEC-4D50-87A7-1419620F57EE"/>
    <domeo:uuid>58E0485C-4FEC-4D50-87A7-1419620F57EE</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-29 09:02:08 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9B6AB25B-F52E-4B8D-A2F0-9BB0DB36E039">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>abiraterone acetate</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0022E1AF-245D-40B1-A071-ADD4C967A8D2">
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D7398750-DBB1-4277-90FE-0D3B61D9F453"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:numOfParticipants>18</dikbD2R:numOfParticipants>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3BF1679F-DD54-4851-9764-2A7B020C5DB4"/>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D84D66E4-56B1-4333-8E42-46365A7662F6">
    <ao:exact>chloramphenicol</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, clarithromycin, corticosteroids, cyclosporine, cardiac glycoside preparations, clofibrate, oral or other systemic hormonal contraceptives, dapsone, diazepam, doxycycline, fluoroquinolones (e.g., ciprofloxacin), haloperidol, oral hypoglycemic agents (su</ao:suffix>
    <pav:createdOn>2015-10-14 11:40:31 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D84D66E4-56B1-4333-8E42-46365A7662F6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>), </ao:prefix>
    <domeo:uuid>D84D66E4-56B1-4333-8E42-46365A7662F6</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:400DB10E-975D-40DC-8BBE-672C89C7A710">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdOn>2015-10-14 11:41:46 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:3013C7EA-F549-441B-A296-8D4B57503429"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/792786F1-ABE7-4828-81A6-67D1BE2BFC10">
    <dikbD2R:dose>30</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdfs:label>paroxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:247EEF24-F836-468A-B1C2-DECCED9FDEC5">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:810BB02B-7CD7-4900-815D-6E14864708DA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B4BB6C7-ACA6-48F0-BA61-967A67720DED">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:exact>Rifampin </ao:exact>
    <domeo:uuid>3B4BB6C7-ACA6-48F0-BA61-967A67720DED</domeo:uuid>
    <ao:suffix>is known to induce certain cytochrome P-450 enzymes. Administration of rifampin with drugs that undergo biotransformation through these metabolic pathways may accelerate elimination of coadministered drugs. To maintain optimum therapeutic blood levels, d</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:39:50 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3B4BB6C7-ACA6-48F0-BA61-967A67720DED"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/86615DF7-F19A-437E-9B9A-993DFFAE632E">
    <rdfs:label>theophylline</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10438</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FF54DED3-0DAD-48FA-89EC-483B19DA2272">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6C8F0D8B-7E49-44AF-88CF-7D094E41B894"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3EE86021-4C3B-4CDA-A24A-F58D969923C5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E01D6A81-E98C-4BA7-936C-B4D6127192C7">
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-29 09:24:02 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:95761FFD-A883-47E6-B3A0-C59B9F70E1E0</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:B0521F1D-1BA2-40FA-86D3-1A8F950933A9"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0185AD47-6E7B-4C92-8A3D-A2876CC95002</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:817F1189-E5B6-4610-A044-B745728634D9">
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:9009A542-077B-4E59-90E4-B89CB4F865D4"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-14 11:41:55 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F2FF4BAA-E6D7-4190-A266-56C578E40ACB">
    <pav:createdOn>2015-10-01 10:27:40 -0400</pav:createdOn>
    <ao:prefix>s with any of the </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>s. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <domeo:uuid>F2FF4BAA-E6D7-4190-A266-56C578E40ACB</domeo:uuid>
    <ao:exact>SSRI</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F2FF4BAA-E6D7-4190-A266-56C578E40ACB"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nef87126d43a8431ebe77b1e291ef3f73">
    <domeo:sets rdf:resource="urn:pddi:uuid:A021DA3A-E5BE-407C-AF76-360319A511B8"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BDBF6112-1D81-4AC5-97E7-4AD3B72F9DB7">
    <rdfs:label>abiraterone acetate</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:650291E4-CD2C-4F63-8D8B-5FE81B6C6AA2">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-08-20 13:56:54 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:454518AA-5617-4ED1-85DF-11BF34E8E45B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2ABE5FA2-BA00-4AF9-A2EA-1305FAECF3DF</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:CCF3CC6E-A046-49BA-BC8B-6A9DEE88B4FD</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/454565FB-E40E-4EDB-9577-DF831C122D0D">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>amitriptyline</rdfs:label>
    <dikbD2R:dose>30</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/704</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0BFF1C7C-23AF-4B59-AA57-05DB5F5EEEAD">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:16F09385-3309-4F83-961C-BC477C26E817"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CF0071BF-34C3-47B5-9CA8-023BB8BA35BE">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:084ACFBE-6C19-4F8C-BF54-035F58B7A68F">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:F4340BF5-2166-4478-8A2E-AD0222BFC3E1"/>
    <pav:lineageUri>urn:domeoserver:annotation:8268B13F-B972-4B8B-BD3F-F11C11121401</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-08-20 11:32:01 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-08-20 11:32:27 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="Nc6391147289c4003abd5aa682cb89b60"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2E0AD717-67BC-4D7C-AF83-5F1037F99712</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D85E6C65-A039-4EF9-A805-FDF3D9518789">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0DDB20E4-E308-4E87-AFF2-1B88539001C1"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Naa2e7d7a337642edb4054b417e240f43">
    <domeo:sets rdf:resource="urn:pddi:uuid:1D7580AB-8752-466C-A439-C8E0D9F02120"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9D13FD7D-56D6-4D7B-BC33-67B4C98F472C">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:652B60BC-66CA-4374-AD8E-3EE0BEA4543C"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>urn:domeoserver:annotationset:58BD31E4-F1E7-44DA-87A9-5298EBD36BEA</pav:previousVersion>
    <ao:body rdf:nodeID="N41cce41e35184bdc974ddae9d769102d"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-10-13 11:38:07 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-13 11:52:38 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AF1A8348-FE16-499F-A909-18EF8BA4B3BD">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N53732b23cdd742259b132a46f0c850a4"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:9A09E6E2-D2C1-4F2D-A046-BD34E07FB684</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-08-20 12:59:16 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:C20986B0-BF8C-414E-B090-01961FA50DD5"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc69313f8dd254f9d8ab8dc27a4722ecc">
    <domeo:sets rdf:resource="urn:pddi:uuid:3B7BC994-0AD3-4AB6-8772-CF4F3FEF6C4D"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/20775C9A-854C-4232-8CF1-D088BD273635">
    <rdfs:label>phenothiazines</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/0</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6C7C7983-18BD-4457-87BC-590968958908">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:031D9FFC-DBC7-457A-AF73-FF8ABED1AA23"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9B40C1CD-AF57-4FD1-BED1-66F8053F15DF">
    <domeo:uuid>9B40C1CD-AF57-4FD1-BED1-66F8053F15DF</domeo:uuid>
    <ao:prefix>is rapidly tapered in patients receiving maprotiline .  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9B40C1CD-AF57-4FD1-BED1-66F8053F15DF"/>
    <pav:createdOn>2015-09-30 12:41:42 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Because of the pharmacologic similarity of maprotiline hydrochloride to the tricyclic antidepressants, the plasma concentration of maprotiline may be increased when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), as has occurred with tricyclic antidepressants. Adjustment of the dosage of maprotiline hydrochloride may therefore be necessary in such cases.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:CBE2B329-4E6C-4915-91A7-775A43D4D87E">
    <rdfs:label>Absorption Increase</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is associated with a increase in absorption of the drug.</dct:description>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#absorption-increase</poc:PharmacokineticImpact>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BEE6C688-7A67-42B6-A24F-6CA2B7894CF3">
    <rdfs:label>pravastatin</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42463</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:995850CB-4152-4213-9360-B739CC078262">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:B690CCB5-1067-4435-BF81-418A58CE39E2"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-29 09:46:33 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:48F61E84-935B-4FFE-8329-25FC21E9D5FD</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97020E1A-6E28-45D5-A4DA-64A1B59C3BF9">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/Clopidogrel-1086a7b4-b89b-4bee-8120-5f752626c046.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Poor metabolizers treated with Plavix at recommended doses exhibit higher cardiovascular event rates following acute coronary syndrome (ACS) or percutaneous coronary intervention (PCI) than patients with normal CYP2C19 function</ao:exact>
    <domeo:uuid>97020E1A-6E28-45D5-A4DA-64A1B59C3BF9</domeo:uuid>
    <ao:prefix>xsd:String</ao:prefix>
    <pav:createdOn>2014-02-19 12:35:40 -0500</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:97020E1A-6E28-45D5-A4DA-64A1B59C3BF9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>. (</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E49ECA25-B2B5-4EC3-B3DA-562B43C387B4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="Nb087eaa8c040492ca166cf58e7832c86"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-30 10:46:40 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:545F2613-2A5E-4333-A651-CBA80268D6ED</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:95C9BC91-F173-4DEE-BB26-1A7E789A3C91"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotation:6BF8BBBB-53E4-4895-8F79-EAF985826539</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/56F26685-0744-419E-BE42-AEF9BAEBF7CE">
    <rdfs:label>oxazepam</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DE16DE17-5423-4599-A22C-72CD49682241">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:40:15 -0400</pav:createdOn>
    <domeo:uuid>DE16DE17-5423-4599-A22C-72CD49682241</domeo:uuid>
    <ao:prefix>, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DE16DE17-5423-4599-A22C-72CD49682241"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:exact>quinidine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, tocainide), oral anticoagulants, antifungals (e.g., fluconazole, itraconazole, ketoconazole), barbiturates, beta-blockers, calcium channel blockers (e.g., diltiazem, nifedipine, verapamil), chloramphenicol, clarithromycin, corticosteroids, cyclosporine</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F57E349E-B634-4B2E-8428-042582074328">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3987E061-22F1-4E39-8C8B-35A9C4BB0A1A"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7F90A120-AAFD-4F01-B9A3-07D0FC51015F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd378fd2dffd04831b6a8d1cb826cd7e5">
    <domeo:sets rdf:resource="urn:pddi:uuid:2BB3420C-77A4-4FB0-8BA2-850970373666"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FAAC673D-A43E-4C5A-A12D-BD498046D59B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>FAAC673D-A43E-4C5A-A12D-BD498046D59B</domeo:uuid>
    <ao:exact>rifampin </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FAAC673D-A43E-4C5A-A12D-BD498046D59B"/>
    <ao:prefix>should be avoided. Patients receiving both </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:41:51 -0400</pav:createdOn>
    <ao:suffix>and isoniazid should be monitored closely for hepatotoxicity.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:21E3775E-57FC-4CA1-A666-B5901773B506">
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-08-20 11:36:50 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>AUBAGIO on CYP2C8 substrates   </ao:prefix>
    <ao:exact>Teriflunomide is an inhibitor of CYP2C8 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP2C8 (e.g., paclitaxel, pioglitazone, repaglinide, rosiglitazone) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP2C8 as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:21E3775E-57FC-4CA1-A666-B5901773B506"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C3D5761B-F1E9-43C2-9D22-5854F1ED38ED">
    <pav:createdOn>2014-02-19 12:41:17 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/Clopidogrel-1086a7b4-b89b-4bee-8120-5f752626c046.html</ao:hasSource>
    <ao:exact>Reduced effectiveness in impaired CYP2C19 function: Avoid concomitant use with drugs that inhibit CYP2C19 (e.g., omeprazole)</ao:exact>
    <ao:suffix>. (</ao:suffix>
    <domeo:uuid>C3D5761B-F1E9-43C2-9D22-5854F1ED38ED</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>xsd:String</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C3D5761B-F1E9-43C2-9D22-5854F1ED38ED"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B55EDFB0-3526-472E-8B0B-8583AFB2A081">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B55EDFB0-3526-472E-8B0B-8583AFB2A081"/>
    <pav:createdOn>2015-10-16 10:53:55 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin. If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached [see Contraindications (4) and Warnings and Precautions (5)]. </ao:exact>
    <ao:prefix>metabolism have not been studied.  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:317AD3F8-0D57-4139-8BB0-76A296E48D86">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-20 09:23:48 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-20 09:22:19 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:4F574216-3440-43A0-9611-75D6F91A9696"/>
    <ao:body rdf:nodeID="N92a68b64a6df4649be026a7a48ac7453"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>urn:domeoserver:annotationset:8D286017-0AEC-46C4-AC51-641E2F31DE1A</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:711DC06D-073B-492E-84BE-F4D429C68659">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <ao:body rdf:nodeID="Ne2bb17e9bca24080a1bc9763ddd9e9b4"/>
    <pav:createdOn>2015-10-20 09:56:15 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:lastSavedOn>2015-10-20 09:56:31 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:659993FA-47A6-4170-A1F4-37E021B93D40</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:4BC94603-2CAA-4991-8D85-B103CC78103F"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D27274BE-720D-44F5-B604-55E09E9A68B0">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>rosuvastatin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/93A96470-7019-4F6D-9B18-20CF725E8044">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
    <rdfs:label>clarithromycin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1C1779F6-3F0B-47ED-B78F-57B4B1A1479E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>1C1779F6-3F0B-47ED-B78F-57B4B1A1479E</domeo:uuid>
    <ao:exact>Based on in vitro data, ZYTIGA is a substrate of CYP3A4.    In a dedicated drug interaction trial, co-administration of rifampin, a strong CYP3A4 inducer, decreased exposure of abiraterone by 55%. Avoid concomitant strong CYP3A4 inducers during ZYTIGA treatment. If a strong CYP3A4 inducer must be co-administered, increase the ZYTIGA dosing frequency [see Dosage and Administration (2.3) and Clinical Pharmacology (12.3)].</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:hasSource>
    <ao:prefix>7.1 Drugs that Inhibit or Induce CYP3A4 Enzymes  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-08-20 11:05:44 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1C1779F6-3F0B-47ED-B78F-57B4B1A1479E"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/277BE7D5-53BD-4070-8A37-193202BDA762">
    <dikbD2R:dose>1</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85248</dailymed:activeMoietyRxCUI>
    <rdfs:label>alosetron</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5EFEE67C-83D9-4028-B5EA-AF8C3696A1C4">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>75</dikbD2R:dose>
    <rdfs:label>mirtazapine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0AEC087A-B27C-4CAE-83EC-666698AECFBD">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <domeo:uuid>0AEC087A-B27C-4CAE-83EC-666698AECFBD</domeo:uuid>
    <ao:suffix>. It may be necessary to adjust the dosages of these drugs if they are given concurrently with rifampin.</ao:suffix>
    <ao:exact>zidovudine</ao:exact>
    <pav:createdOn>2015-10-14 11:41:09 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0AEC087A-B27C-4CAE-83EC-666698AECFBD"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>) and </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/992391BB-66BE-4EB6-8F0C-F9FFB5F6C8C0">
    <rdfs:label>ketoconazole</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>30</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nead26cc7f37e44a79f2f1bd4f645fde9">
    <domeo:sets rdf:resource="urn:pddi:uuid:1CE8369A-1BEC-46FC-BFDD-F90CB13F40B3"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8a96bbacfd76465c9f255d3aeb661047">
    <domeo:sets rdf:resource="urn:pddi:uuid:12DF3D2B-C272-47FD-8375-DF92D6588DDF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6C8BD137-AC6D-41F9-8440-594ADEBF162A">
    <ao:suffix>or Lexapro is contraindicated (See </ao:suffix>
    <domeo:uuid>6C8BD137-AC6D-41F9-8440-594ADEBF162A</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>. The mechanism of this pharmacodynamic interaction is not known. Concomitant use of Pimozide and </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <ao:exact>Celexa </ao:exact>
    <pav:createdOn>2015-10-14 12:06:28 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6C8BD137-AC6D-41F9-8440-594ADEBF162A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:feec2ab0-71a1-46f3-88e8-bac41a3f6a17">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>                                      In in vitro studies, </ao:prefix>
    <pav:createdOn>2015-08-27 14:50:19 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>fluvoxamine maleate</ao:exact>
    <ao:suffix> had no significant affinity for histaminergic, alpha or bet</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:feec2ab0-71a1-46f3-88e8-bac41a3f6a17"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:134605F4-D17D-4BB9-9F01-8B55B07ECC2D">
    <ao:prefix>When </ao:prefix>
    <ao:suffix>is given concomitantly with either halothane or isoniazid, the potential for hepatotoxicity is increased. The concomitant use of rifampin and halothane should be avoided. Patients receiving both rifampin and isoniazid should be monitored closely for hepa</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:exact>rifampin </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:134605F4-D17D-4BB9-9F01-8B55B07ECC2D"/>
    <domeo:uuid>134605F4-D17D-4BB9-9F01-8B55B07ECC2D</domeo:uuid>
    <pav:createdOn>2015-10-14 11:41:45 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:75A2813A-8AB3-4071-ADBF-240FB84F8727">
    <domeo:belongsToSet>urn:domeoserver:annotationset:0468AC6B-4F06-4CA4-A0DE-A389E3B0E59F</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:B7B13A80-C001-4C0F-A3B2-68C41351BC5B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-09 13:32:08 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-16 15:24:10 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N163e9fbb440547eca1b9e1d7a01cbed0"/>
    <pav:lineageUri>urn:domeoserver:annotation:2A6F79BD-A1A7-4C03-8136-F00A8F2CC240</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3757690F-00EB-4283-B082-ABE1C19FD5EF">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>sertraline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2B81FF77-DF41-49F5-8813-60332DD7F517">
    <domeo:uuid>2B81FF77-DF41-49F5-8813-60332DD7F517</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2B81FF77-DF41-49F5-8813-60332DD7F517"/>
    <pav:createdOn>2015-10-09 13:32:03 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Sertraline (100 mg) when administered to 10 healthy male subjects had no effect on the beta-adrenergic blocking ability of atenolol .   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>DigoxinIn a placebo-controlled trial in normal volunteers, administration of sertraline for 17 days (including 200 mg/day for the last 10 days) did not change serum digoxin levels or digoxin renal clearance.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9A9C6311-750C-4A5B-AEC1-96022DC1FE62">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:327B818F-44B0-45BB-AC8D-060ABB62590E</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:4956715B-3516-4F6B-88A7-D02C6FF49410"/>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N3ec7df7a327b455baa54d89a7abd2d4d"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-29 11:27:58 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:93080012-4C3E-4C4D-B2F2-4D326EFC7211">
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:58E0485C-4FEC-4D50-87A7-1419620F57EE"/>
    <pav:lineageUri>urn:domeoserver:annotation:A5B1F9FB-8268-4C26-BBFA-0A3FBD0AB2EF</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N221ec74960f54ec08cbdeaeec4768f6c"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-29 09:02:08 -0400</pav:createdOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/00F49CCE-6AB1-4D5C-B8ED-3AF52B48CEF4">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>diltiazem</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3443</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B89FBECC-35DF-4F80-A180-33F0F5532E13">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:comment>Plasma concentration of imipramine may decrease</dikbD2R:comment>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E9533FA8-F131-43DB-B55B-C68F0C211CEA"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CBE88E8B-BA5E-48D1-858D-E9D3F589421A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>imipramine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/5691</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:60CA4623-6D29-464C-B0D8-C1435AF7E973">
    <domeo:uuid>60CA4623-6D29-464C-B0D8-C1435AF7E973</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>The effect of steady-state fluvoxamine (50 mg b.i.d. for 7 days) on the single dose pharmacokinetics of mexiletine (200 mg) was evaluated in six healthy Japanese males. The clearance of mexiletine was reduced by 38% following coadministration with fluvoxamine compared to mexiletine alone. If fluvoxamine and mexiletine are coadministered, serum mexiletine levels should be monitored. </ao:exact>
    <ao:prefix>    Mexiletine   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:60CA4623-6D29-464C-B0D8-C1435AF7E973"/>
    <pav:createdOn>2015-10-20 10:19:25 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:578FF25A-B6C6-474F-8C61-2BA421EF9F4B">
    <ao:body rdf:nodeID="N1e8e09fec2fa46948209dd60bb6a42fa"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:B826528F-BE54-468B-A83C-E0BDE1010787</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-09-30 12:41:52 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-30 12:39:40 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6F5C24D1-EA99-48CF-B498-A0D89C02B290</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:A358E38F-FA15-494B-949C-44D37D23BE49"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E42630A7-EC0A-4840-A981-7D700D64CB85">
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-20 09:56:31 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:27DB7F57-5D1E-4E42-83C6-CF8E80B12686"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:createdOn>2015-10-20 09:54:06 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:659993FA-47A6-4170-A1F4-37E021B93D40</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1ef67243-4467-4109-8d15-a36c39140f24">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/f371258d-91b3-4b6a-ac99-434a1964c3af.html</ao:hasSource>
    <ao:suffix> ER was 92% when compared to oral solution. Levomilnacipran </ao:suffix>
    <pav:createdOn>2015-08-27 14:50:08 -0400</pav:createdOn>
    <ao:exact>FETZIMA</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1ef67243-4467-4109-8d15-a36c39140f24"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>bioavailability of levomilnacipran after administration of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5A2D7417-45A8-47CB-B886-B517A1F862EE">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/19D299D1-2568-4788-8A52-79F3B46873DB"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A42C5CEA-C711-448C-B236-8FAFC70BB6DF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B1ED0446-7473-4E86-95CF-113D6813129E">
    <pav:createdOn>2015-10-16 10:59:03 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:A3BEC454-A0B4-4596-8478-0FD7334B1BF2</pav:lineageUri>
    <pav:lastSavedOn>2015-10-16 11:00:06 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:F024E7A6-2941-478E-B52D-5C30CA60FCE6"/>
    <ao:body rdf:nodeID="Nb0da1bbff58c42b09fbc0da9d512d6a9"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/AA998DF5-8EF7-4A04-9300-EBC4A4CFC4DB">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:056CA2C9-322E-45AA-81BC-D781489782F3">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1FFAB7BB-4578-4DF0-AA0D-E551841F103D"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B776F2E5-8021-405F-9B3A-5060D1412128">
    <dikbD2R:dose>20</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>atomoxetine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/38400</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1199069D-F2BD-463E-9B5E-59F14DE43EBF">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1199069D-F2BD-463E-9B5E-59F14DE43EBF"/>
    <ao:prefix>Clinical Pharmacology (12.3) ] .  </ao:prefix>
    <ao:exact>No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs. </ao:exact>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-09-03 15:39:04 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5F55ADCB-AA08-466C-A32E-2740BFF6F508">
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdOn>2015-10-14 11:40:31 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:D84D66E4-56B1-4333-8E42-46365A7662F6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4E812EE5-3B86-412B-99DB-84E15DEFF8C6">
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:2C2C0A17-3046-4824-B927-60431EF09B62"/>
    <pav:previousVersion>urn:domeoserver:annotationset:659993FA-47A6-4170-A1F4-37E021B93D40</pav:previousVersion>
    <pav:createdOn>2015-10-20 09:54:06 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-20 09:56:31 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D765C020-2D34-4D0C-8D4F-8E19DF6E645D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdOn>2015-10-14 11:41:00 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:A9F76EB7-C4FE-41DE-ACD1-B9A7AE8B5D1A"/>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:863DE1C9-E2E5-4CE7-A179-42F1E8032660">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:98150954-C90C-4F0D-BD9D-19FF8DBB874D"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0F83DB94-0B3F-435A-A490-4E7CF44C29C5">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>phenytoin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CDDC9E8D-62CB-4BF0-9812-9185A18E1C54">
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>CDDC9E8D-62CB-4BF0-9812-9185A18E1C54</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Concomitant use of tricyclic antidepressants with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Furthermore, whenever one of these other drugs is withdrawn from co-therapy, an increased dose of tricyclic antidepressant may be required. It is desirable to monitor TCA plasma levels whenever a TCA is going to be co-administered with another drug known to be an inhibitor of P450 2D6.  </ao:prefix>
    <pav:createdOn>2015-10-01 10:48:53 -0400</pav:createdOn>
    <ao:exact>The plasma concentration of imipramine may increase when the drug is given concomitantly with hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decrease by concomitant administration with hepatic enzyme inducers (e.g., barbiturates, phenytoin), and adjustment of the dosage of imipramine may therefore be necessary.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CDDC9E8D-62CB-4BF0-9812-9185A18E1C54"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A2972AD3-DCB1-4A60-AF1E-7FA59D903AC9">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:B15A7631-78AE-4404-A560-C8500665DC4E</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:33B17719-DF97-48EA-AFA2-01DE8A8887B4</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:DE34F6E2-312D-4B3A-890B-150922997A86"/>
    <pav:createdOn>2015-10-01 10:27:44 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B7E902CE-7AE0-4D65-B1AD-79D8EF39BE72">
    <pav:lastSavedOn>2015-10-14 12:07:40 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-14 12:06:28 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:C91289D7-45EC-44D1-A933-E79E770CFE71</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:3855DAFA-7CA1-473C-84D0-9686D6BEA028"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:578FFC0A-4CDA-4416-BFFC-A3FAE69D7251">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/79BF090F-C54F-4CF8-A3CD-86ABA82B1EDC"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/21E43179-3B84-42D4-9293-AD4C1E0470DA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FAA59BBF-F495-4115-A3D4-7A5302A3CEFC">
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:63EC5040-6FCF-4FDD-B425-5AD274DE6B27"/>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-14 11:40:17 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B2B35601-1AB1-4715-8483-63B09D394B71">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>pimozide </ao:exact>
    <ao:suffix>given alone. Racemic citalopram did not alter the mean AUC or C</ao:suffix>
    <ao:prefix>40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B2B35601-1AB1-4715-8483-63B09D394B71"/>
    <pav:createdOn>2015-10-14 12:06:24 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <domeo:uuid>B2B35601-1AB1-4715-8483-63B09D394B71</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0CE28007-B024-43C8-906A-836ED3FB7ADA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>0CE28007-B024-43C8-906A-836ED3FB7ADA</domeo:uuid>
    <ao:prefix>, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <pav:createdOn>2015-09-29 11:40:55 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0CE28007-B024-43C8-906A-836ED3FB7ADA"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C96BD073-4D70-44BE-928E-B22F63FC0265">
    <rdfs:label>theophylline</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10438</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B2C1921F-B346-41F3-8ED1-A8E19B7280D4">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:createdOn>2015-08-20 13:04:28 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:9DB1BBFA-A85C-4000-BC1E-A8549108577C</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="Nff4d5c0bd0c947728d50312dcb8a4c7e"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:0CD9E330-14C2-4177-B31F-C986B1635D81"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/36844AF9-84CB-4AEB-8971-46D7EAF727F5">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>methylphenidate</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5275F184-7DF1-4DF3-B8B6-A543AE2EDAE7">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <domeo:uuid>5275F184-7DF1-4DF3-B8B6-A543AE2EDAE7</domeo:uuid>
    <ao:prefix>   Alprazolam  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5275F184-7DF1-4DF3-B8B6-A543AE2EDAE7"/>
    <pav:createdOn>2015-10-20 09:58:05 -0400</pav:createdOn>
    <ao:exact>When fluvoxamine maleate (100 mg q.d.) and alprazolam (1 mg q.i.d.) were coadministered to steady state, plasma concentrations and other pharmacokinetic parameters (AUC, Cmax, T) of alprazolam were approximately twice those observed when alprazolam was administered alone; oral clearance was reduced by about 50%. The elevated plasma alprazolam concentrations resulted in decreased psychomotor performance and memory. This interaction, which has not been investigated using higher doses of fluvoxamine, may be more pronounced if a 300 mg daily dose is coadministered, particularly since fluvoxamine exhibits non-linear pharmacokinetics over the dosage range 100 mg to 300 mg. If alprazolam is coadministered with fluvoxamine maleate tablets, the initial alprazolam dosage should be at least halved and titration to the lowest effective dose is recommended. No dosage adjustment is required for fluvoxamine maleate tablets. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D24A23D0-90E2-4CD2-8DD1-8062096192B9">
    <domeo:uuid>D24A23D0-90E2-4CD2-8DD1-8062096192B9</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-20 10:09:06 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>and </ao:prefix>
    <ao:exact>diazepam </ao:exact>
    <ao:suffix>is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam. In these subjects (N = 8), the clearance of diazepam was reduced by 65% and that of N-desmethyldiazepam to a l</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D24A23D0-90E2-4CD2-8DD1-8062096192B9"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb0da1bbff58c42b09fbc0da9d512d6a9">
    <domeo:sets rdf:resource="urn:pddi:uuid:3F373F2F-E720-4F70-A0CE-36E72CEB3FCE"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/854504A7-A33C-4183-9492-6B338E175CA5">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F63EFF39-F44C-4772-A071-82F0F184DDB9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F70B3E11-F954-4A99-84CF-2D3119D52F6A"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1547528A-FC8E-41C2-8483-FC1F707DB8A0">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/89425384-D20C-461C-8FA5-1C9A7A0348B7"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F24B102B-A1DC-4C9C-B227-BC36875F31B7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1922C8FD-FDAD-4FE8-ABD0-4CF2A15D66F2">
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:7672B2F3-AFE2-459D-9FB8-91BDF351CC66"/>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-14 11:41:07 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/39C4C7DB-94E1-481E-BBD5-D5081A9637DD">
    <dikbD2R:dose>1000</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>pioglitazone</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7B5B546E-8776-4EB6-BF76-E5B762E84322">
    <ao:exact>Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), and metoprolol (a CYP2D6 substrate).</ao:exact>
    <ao:prefix>[see Drug Interactions (7) ] .  </ao:prefix>
    <domeo:uuid>7B5B546E-8776-4EB6-BF76-E5B762E84322</domeo:uuid>
    <pav:createdOn>2015-08-20 13:05:57 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7B5B546E-8776-4EB6-BF76-E5B762E84322"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/161F03B9-D79B-4148-B98C-F8C533F5CB23">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>desipramine</rdfs:label>
    <dikbD2R:dose>100</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3247</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E84C0F84-E2D6-4F78-BC1E-CEA53FF4912E">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>alprazolam</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>1</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7DF66C96-E6C1-4D67-886F-3A5C59D7E087">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3135C6CA-7184-43E8-B660-771A5C984C77"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C0C0EEFD-733A-4E66-8517-A205FC022AEE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A1828EE5-809D-4FD1-AF38-3101C913DC5E">
    <pav:lineageUri>urn:domeoserver:annotation:863ACF92-9FBA-4D18-8E62-A163D315C380</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="Nef155112b5624b51a22244c0f7bfc80a"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-09-29 11:26:07 -0400</pav:createdOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:B9DC837C-AB49-496D-9AA3-389E4BDF49F3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:206594A1-662D-4501-BCA2-DBA71CD719C3">
    <domeo:uuid>206594A1-662D-4501-BCA2-DBA71CD719C3</domeo:uuid>
    <ao:prefix>7.2 Potential for Other Drugs to Affect INVIRASE  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c00d1607-ac36-457b-a34b-75ad74f9cf0a.html</ao:hasSource>
    <pav:createdOn>2015-10-13 11:12:12 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:206594A1-662D-4501-BCA2-DBA71CD719C3"/>
    <ao:exact>The metabolism of saquinavir is mediated primarily by CYP3A. Additionally, saquinavir is a substrate for P-glycoprotein (P-gp). Therefore, drugs that affect CYP3A and/or P-gp may modify the pharmacokinetics of saquinavir. Coadministration with drugs that are potent inducers of CYP3A (e.g., phenobarbital, phenytoin, carbamazepine) may result in decreased plasma concentrations of saquinavir and reduced therapeutic effect.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EAB351E9-0B37-4AB3-8A05-81214FE5B573">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FFF7068E-F234-4C9C-AE2F-87BB57C02E7B"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FE36B559-7A41-4F16-BA6B-EED9B64147C7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5FFC5498-009C-4E07-8452-B0F49319598D">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:24BE6835-72DA-46D2-92DD-53AB9733080E"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:93272F80-7133-4FFD-819B-B60FB135C380">
    <pav:lineageUri>urn:domeoserver:annotation:6DE0D3AD-0B8B-49CB-A9F3-54DEB238572A</pav:lineageUri>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-29 09:44:23 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:A820C708-DD9F-4B42-9652-BC89E5BCFF0F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/54678AA6-BFB7-48C6-8897-15C79F6F0476">
    <rdfs:label>CMI</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5CBE087A-CCD5-48AB-A2A5-02B7E65BF8AE">
    <pav:createdOn>2015-09-29 08:59:03 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:3844B79F-439A-48FB-AF88-12C049A4766C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotation:5A2294CD-0382-4C73-9348-4904CF2AD82B</pav:lineageUri>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DED98394-4ADE-4292-BB18-1466CDDAED6F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A0B15123-D4BE-4F0C-85C9-0CE36D987D85"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2DCBAB84-202D-41C3-B8EB-9CD9D668C3DF">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#none</poc:PharmacokineticImpact>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <dct:description>none</dct:description>
    <rdfs:label>None</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DB4D4254-04A2-4C48-9D60-BFF38A50B47C">
    <ao:exact>Under steady-state conditions, diazepam does not appear to affect paroxetine kinetics. The effects of paroxetine on diazepam were not evaluated.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-14 11:26:11 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DB4D4254-04A2-4C48-9D60-BFF38A50B47C"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>should be undertaken with caution.  Diazepam  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/73E7122C-D90A-47DC-B2F0-9405E668ECF5">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4441</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>flecainide</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/51FDDB98-A5CE-47B1-A192-61AC33B13E17">
    <rdfs:label>PPA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>25</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BA69F573-0461-4317-A288-E3C95B8A9D33">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B5034613-24AE-40A1-8866-E2415321B047"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4193FEF6-81CC-421D-8342-A5481CFF1DC5"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EB001177-4AAF-4272-8E73-2F1A77A14CBC">
    <pav:lastSavedOn>2015-08-20 10:29:59 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:710D2A05-EC79-4BFC-BC3E-436C7AC80BD5</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="Ndd8f8fe56a4a49cabbf518a5cb84521f"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-08-20 10:18:58 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:82A680C3-86DA-43A2-8F39-634A52062B54"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:C486CF5B-2163-45B9-976B-F4483F28D236</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FF5BE84E-7934-4808-AD2F-6F207D312D09">
    <rdfs:label>barbiturates</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:89B0316F-0588-408C-A123-319062AB06EE">
    <domeo:uuid>89B0316F-0588-408C-A123-319062AB06EE</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> were not significantly affected by concomitant administration of fluconazole</ao:suffix>
    <ao:exact>14-OH clarithromycin</ao:exact>
    <pav:createdOn>2015-10-13 11:52:24 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:89B0316F-0588-408C-A123-319062AB06EE"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:prefix> and AUC of 33% and 18%, respectively. Steady-state concentrations of </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:69C234A4-460B-4AD6-A14A-389E8556B5B6">
    <domeo:belongsToSet>urn:domeoserver:annotationset:0468AC6B-4F06-4CA4-A0DE-A389E3B0E59F</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:E4ACFF9D-86D9-4F4A-BB16-5D12239445AC</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-16 15:22:41 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:187D03F8-A554-4DA6-B127-77407C0BBC17"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-16 15:31:12 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2D74C846-D521-4E4D-ABB4-735D9E78A6FC">
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:382B9488-A266-4EAF-8082-A95DC2BBF526"/>
    <pav:previousVersion>urn:domeoserver:annotationset:6B50E664-BD71-432E-B7FA-E7313EFF76E1</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-20 10:19:28 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="Ne04e25770e614d28b5bb5f31c595edd4"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:createdOn>2015-10-20 10:18:28 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3545E07C-1260-4EE4-B446-28CBDB1E6555">
    <ao:prefix>, metoprolol , atomoxetine )   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In vitro studies showed minimal inhibitory effect of desvenlafaxine on CYP2D6. Clinical studies have shown that desvenlafaxine does not have a clinically relevant effect on CYP2D6 metabolism at the dose of 100 mg daily. When desvenlafaxine succinate was administered at a dose of 100 mg daily in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the Cmax and AUC of desipramine increased approximately 25% and 17%, respectively. When 400 mg (8 times the recommended 50 mg dose) was administered, the Cmax and AUC of desipramine increased approximately 50% and 90%, respectively. Concomitant use of desvenlafaxine with a drug metabolized by CYP2D6 can result in higher concentrations of that drug [see Drug Interactions (7.5)].</ao:exact>
    <pav:createdOn>2015-09-24 15:35:57 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:hasSource>
    <domeo:uuid>3545E07C-1260-4EE4-B446-28CBDB1E6555</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3545E07C-1260-4EE4-B446-28CBDB1E6555"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B46528F5-973A-43B6-85F6-03CCE7BD44A1">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/11586B9B-E685-4F91-A4D8-9DBCB95A126D">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Savella</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2C1DEA9E-A8E5-482A-8B56-78ADB9F83C02">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdfs:label>paroxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>30</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:76B0AB90-74E8-4301-9405-FD66E7216D08">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3CAAD5EA-82E3-473E-89AE-2DCD5CEF403B"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6035449E-44B5-4AC2-B5D8-E1F87722C1D1"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/e2c85362-b41b-4e30-b3ec-3e9a1e57d381">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-12 13:20:28 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-12 13:20:28 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:BDA149A4-7480-419D-95B4-B8534B0D597B</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:fc1d9c11-3031-4808-8a0d-d822dcc8c05e"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:2dde803e-2aa6-412f-b00d-eae0772b9fcf</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F7AA104A-110D-4EA9-88E0-99F6DE345461">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:8D286017-0AEC-46C4-AC51-641E2F31DE1A</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N56b18acc653446e9bd721d59d49de50a"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:44A560A7-EFB5-49AA-87C3-1DEBD963D38C"/>
    <pav:lastSavedOn>2015-10-20 09:23:48 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-20 09:23:46 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A63FF147-259B-46E0-8A9F-F286872F35DF">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2E0AD717-67BC-4D7C-AF83-5F1037F99712</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-08-20 11:06:07 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:be10a7b6-9093-4dc5-bd8e-7c1619eb41b9</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:64737b65-8582-4b76-8095-85ad69e2cc47</pav:lineageUri>
    <ao:body rdf:nodeID="Ne81a4e23382443a48e622e37420fed55"/>
    <pav:lastSavedOn>2015-08-20 11:10:08 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:EBDB43FF-AE87-4F7A-851A-39FD29796105"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7C08FED6-33A1-4C10-865C-CCEAE36D672C">
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/03B8BB68-3CA6-493F-8394-D11B2B03C71D"/>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:preciptDuration>18</dikbD2R:preciptDuration>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/624F46A3-BE9C-4290-9DCD-A0B3EA43C782"/>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:aucDirection>UNK</dikbD2R:aucDirection>
    <dikbD2R:auc>Unk</dikbD2R:auc>
    <dikbD2R:aucType>UNK</dikbD2R:aucType>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:numOfParticipants>8</dikbD2R:numOfParticipants>
    <dikbD2R:objectFormulation>IV</dikbD2R:objectFormulation>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7A4989DB-C1B1-42C6-B4A6-0AAAD2673ED4">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>CMI</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BD9E51FD-D663-4C35-8EAB-B6AB4DFC3DB2">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:386BFF23-3BE0-4A07-A386-DE544871D834"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5719DA99-A90C-4BAD-8084-5DDF731EFEFA">
    <rdfs:label>fluvoxamine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A689156C-7D60-4A20-9DD0-285100C9AF39">
    <rdfs:label>clarithromycin</rdfs:label>
    <dikbD2R:dose>250 or 500</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A4F26A0D-380A-4D5D-9B97-3201413D165B">
    <pav:createdOn>2015-08-26 16:11:33 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:A3511B53-47E5-4DC5-8429-E8BAC40EE89E"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:7C3ED630-095E-46C1-9254-E12EC01A6C0B</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:98EB05F5-AF88-4B04-87DC-5826864F9BE3</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-08-26 16:14:07 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3399DE83-1B0E-4217-A3E7-CCE40D4B4C7D">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/043DEF26-B53C-4843-A330-523CF5CD1AE5"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F3ED089E-E6C1-4A17-9C53-58315607CF2A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4DAD0D87-6F37-4D74-A08E-92E60EF28FC2">
    <ao:prefix>cilostazol , and bromocriptine .  </ao:prefix>
    <pav:createdOn>2015-10-13 12:05:41 -0400</pav:createdOn>
    <ao:exact>Concomitant administration of clarithromycin with cisapride, pimozide, astemizole, or terfenadine is contraindicated (see CONTRAINDICATIONS.)</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4DAD0D87-6F37-4D74-A08E-92E60EF28FC2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>4DAD0D87-6F37-4D74-A08E-92E60EF28FC2</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CAE8468A-B375-41C4-89B1-057EB6FF0781">
    <pav:lastSavedOn>2015-09-14 10:25:07 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:FA20D9EF-8F4E-40C9-B23A-B82C96DB4038"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:e382d7cf-3db6-429c-b6c0-e231f2492215</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:CE635F27-A391-4A6B-9D87-339FA2F114B2</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:fc9e17d3-1b0d-4635-9936-0d1d94cb01f9</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:body rdf:nodeID="Nd48eaf0394fc41b2b5268d4ef35ed004"/>
    <pav:createdOn>2015-09-14 10:24:54 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:08E23EDA-057E-46A0-B028-3EF188F39525">
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:4950B5DA-2438-44CB-8130-B993D496F58B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-14 11:40:14 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BB406C06-1C8B-4C33-9266-D068ACCCA992">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>. This finding may be the result of alteration in the colonic bacteria responsible for the reduction of </ao:prefix>
    <domeo:uuid>BB406C06-1C8B-4C33-9266-D068ACCCA992</domeo:uuid>
    <ao:suffix>to sulfapyridine and mesalamine.</ao:suffix>
    <pav:createdOn>2015-10-14 11:41:59 -0400</pav:createdOn>
    <ao:exact>sulfasalazine </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BB406C06-1C8B-4C33-9266-D068ACCCA992"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4CDCD183-F333-4860-B0EE-7193B548395E">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>maprotiline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:37CD58F2-C7ED-41F7-869E-313B8FF59EBF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:17106EA7-F424-413F-88DB-537091B65B25"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:13398298-6D06-4CA1-8445-B2BD67BADC5C">
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <pav:createdOn>2015-10-01 10:28:35 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>13398298-6D06-4CA1-8445-B2BD67BADC5C</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:13398298-6D06-4CA1-8445-B2BD67BADC5C"/>
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7-10% of Caucasians are so-called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:750C3B61-90C0-4208-9060-F6C9E7875830">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <pav:createdOn>2015-08-20 11:44:41 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>on organic anion transporter 3 (OAT3) substrates   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:750C3B61-90C0-4208-9060-F6C9E7875830"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne07e416a2908437f936617e5c3383339">
    <domeo:sets rdf:resource="urn:pddi:uuid:626DDD90-C0D5-4D91-BC8E-D7772144A881"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DEF3C7AE-E9D3-41C3-A16A-F50BAE3C2CD1">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/617C896F-632E-4E58-8961-67CE84FBB43F"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6D60F4F4-6285-4CA2-A2C0-3E7FF2C60F9A"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/21D219EA-6DC6-4522-9154-9E0ECFE1705A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdfs:label>paroxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ED0570CC-A3F9-493A-8A74-1A7C60C8F3DB">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-24 15:28:54 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-09-24 15:28:55 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N15a4773be7bd473594d205e24729e8a1"/>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:C3156E0B-6985-4638-85C7-5D89C1C6266E"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:BC4B710E-6FB5-42E1-B92F-94A55FCECEB9</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:DAD02F8C-D0CF-4D03-A113-8C242E8A7E4F</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:01207605-4e40-4784-b7e8-7c296bff1d72</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AFF477E1-4F09-4E06-A825-1632395DB0AC">
    <ao:context rdf:resource="urn:domeoclient:uuid:BE750539-471D-46E1-8B1E-8CE651934F5A"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:79592E89-A787-4F07-BADD-3188C5850209</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N658d48d73e144f2b8b58465c35d46f60"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-10-13 12:06:23 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-13 12:05:05 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:586ED5FE-8D6E-43EE-B342-B85C076133ED">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:561CF841-9DB6-49E0-9798-A297976A2336"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7DC95F37-31D6-41FA-934B-50B98ED51CE9">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-01 10:48:58 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:1BF64D5B-66AB-4144-9607-FBF90369D554</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:2DF1511E-C967-4532-AE40-EE4DE4EA8451"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DC54EBE-B2A9-4AE7-A174-F0074ECE4050</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6E37F34F-43A6-4730-9D49-4EDD55028BA3">
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:4E0A4FA1-3920-4807-8A68-18A28F4C6438"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N5f30a8cb37974fc492ec20ec64906d37"/>
    <pav:lastSavedOn>2015-10-13 12:04:13 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdOn>2015-10-13 12:01:49 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:B51F4BB3-6BDB-45E7-9399-D93DBC4324AC</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc084ccad551f4744833a6e88f4145375">
    <domeo:sets rdf:resource="urn:pddi:uuid:863DE1C9-E2E5-4CE7-A179-42F1E8032660"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B00FB515-BCD9-4CDA-92E1-542F90AA2984">
    <ao:context rdf:resource="urn:domeoclient:uuid:31B4775C-E1FD-47C1-9784-61826CFD3E23"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="Nac71ad29dfbd4f7d827893804f8c7159"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-10-01 10:45:55 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:33495E0F-9A28-46A6-9B4A-94140719698C</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DC54EBE-B2A9-4AE7-A174-F0074ECE4050</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:913DB6C1-AA04-4858-A117-A7C1269443E2">
    <domeo:uuid>913DB6C1-AA04-4858-A117-A7C1269443E2</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-30 10:44:33 -0400</pav:createdOn>
    <ao:prefix>(100 mg/day) did not affect the pharmacokinetics of lithium .  </ao:prefix>
    <ao:exact>Lorazepam-There was no pharmacokinetic interaction between a single dose of Savella (50 mg) and lorazepam (1.5 mg). </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:913DB6C1-AA04-4858-A117-A7C1269443E2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B5BE8416-9D18-4716-A9B6-856792123329">
    <pav:createdOn>2015-10-14 11:40:59 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:711B5807-B1E3-4D14-8643-F10FED5E3371"/>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FF2D351F-C7C7-416A-98F1-1B1F25B71F66">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>EMSAM</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8829FC35-C588-40E5-A075-03B89B92A252">
    <ao:prefix>Drugs That Slow Heart Rate or Atrioventricular Conduction (e.g., beta blockers or diltiazem )   </ao:prefix>
    <domeo:uuid>8829FC35-C588-40E5-A075-03B89B92A252</domeo:uuid>
    <ao:exact>Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited. Because initiation of GILENYA treatment may result in an additional decrease in heart rate, concomitant use of these drugs during GILENYA initiation may be associated with severe bradycardia or heart block. Seek advice from the prescribing physician regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating GILENYA. Patients who cannot switch, should have overnight continuous ECG monitoring after the first dose [see Dosage and Administration (2) and Warnings and Precautions (5.1)].</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-08-20 13:56:05 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8829FC35-C588-40E5-A075-03B89B92A252"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A3C8F16A-9EA8-482D-8C38-61DBCE45EA93">
    <ao:prefix>y vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of </ao:prefix>
    <pav:createdOn>2015-09-29 08:58:55 -0400</pav:createdOn>
    <ao:suffix>s with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <ao:exact>TCA</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A3C8F16A-9EA8-482D-8C38-61DBCE45EA93"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>A3C8F16A-9EA8-482D-8C38-61DBCE45EA93</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1E892F99-BD17-4A3B-BDCD-58AA050D0BAB">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>1E892F99-BD17-4A3B-BDCD-58AA050D0BAB</domeo:uuid>
    <pav:createdOn>2015-09-25 10:46:33 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1E892F99-BD17-4A3B-BDCD-58AA050D0BAB"/>
    <ao:prefix>  Diazepam  </ao:prefix>
    <ao:exact>Concomitant administration of diazepam (15 mg) had a minimal effect on plasma levels of mirtazapine (15 mg) in 12 healthy subjects. However, the impairment of motor skills produced by REMERON has been shown to be additive with those caused by diazepam. Accordingly, patients should be advised to avoid diazepam and other similar drugs while taking REMERON.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/82F5D709-515F-4442-95C8-DD289F45E850">
    <rdfs:label>fluvoxamine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/21E43179-3B84-42D4-9293-AD4C1E0470DA">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6960</dailymed:activeMoietyRxCUI>
    <rdfs:label>midazolam</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/158BBB77-5CB2-4D1E-B6AE-C1D5F5B22362">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>30</dikbD2R:dose>
    <rdfs:label>paroxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3EE86021-4C3B-4CDA-A24A-F58D969923C5">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>clarithromycin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0DDB20E4-E308-4E87-AFF2-1B88539001C1">
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9BDECE31-1737-44ED-AAF7-892459C4A105"/>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/67910508-7CDE-4E07-AF24-4132328BEA61"/>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:preciptRegimens>UNK</dikbD2R:preciptRegimens>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:objectFormulation>UNK</dikbD2R:objectFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptFormulation>UNK</dikbD2R:preciptFormulation>
    <dikbD2R:auc>15</dikbD2R:auc>
    <dikbD2R:objectRegimens>UNK</dikbD2R:objectRegimens>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:185FBCB4-5BB3-497B-B52D-9F4A70A4A4DA">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:33AFB702-15A9-4F37-809C-1652993A46D6"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7f36157a-84b3-49af-abd6-b11bc5699bc1">
    <ao:prefix>e.g., chlordiazepoxide or </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7f36157a-84b3-49af-abd6-b11bc5699bc1"/>
    <pav:createdOn>2015-08-27 14:50:03 -0400</pav:createdOn>
    <ao:exact>diazepam</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EA9DEED5-5AA7-4986-8D55-2BC114A21609">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Co-administration of haloperidol with CMI increases plasma concentrations of CMI. </ao:exact>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-09-29 09:45:10 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EA9DEED5-5AA7-4986-8D55-2BC114A21609"/>
    <ao:suffix>Co-administration of</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1641A711-8F00-44AE-B015-B108EA45AD99">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>1641A711-8F00-44AE-B015-B108EA45AD99</domeo:uuid>
    <pav:createdOn>2015-09-25 10:45:07 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1641A711-8F00-44AE-B015-B108EA45AD99"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>(30 mg daily) at steady state did not influence the pharmacokinetics of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>risperidone</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5917C0F8-C7F3-436E-9D49-46C5F4C600CB">
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="N7491d5ceb3634cf6a1320315e1532817"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:E19D2025-EB93-4F07-9C83-7950D34A6BA5"/>
    <pav:lastSavedOn>2015-10-16 10:42:46 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">15</pav:versionNumber>
    <pav:createdOn>2015-09-03 16:17:47 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:5BEA2001-CB06-4507-A35E-7F6F162CB5CE</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0170eb3e769341579de44a9f948555d2">
    <domeo:sets rdf:resource="urn:pddi:uuid:018588CA-C4A7-46FA-84C9-CF146F7504B3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1F07C92E-D96B-4283-8F92-81EDB88E913D">
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-14 11:40:33 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:812BEA3E-86E1-4BC2-A64B-D744B33A1D15"/>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:26D05FD2-9BAC-491C-95B4-B87DEFD0FF0D">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C944B079-003C-4856-9E7D-3BE44ED45093"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
    <dikbD2R:preciptDuration>14</dikbD2R:preciptDuration>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C7255E3A-928A-4A5D-A862-248B7CCDA86E"/>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:aucDirection>Decrease</dikbD2R:aucDirection>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:auc>12</dikbD2R:auc>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DE55F02D-63B4-42D7-B53B-C851E6782F76">
    <dikbD2R:dose>6</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <rdfs:label>EMSAM</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A6DB74B9-8184-4FBD-9651-41DD31268769">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-01 10:46:36 -0400</pav:createdOn>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so-called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A6DB74B9-8184-4FBD-9651-41DD31268769"/>
    <domeo:uuid>A6DB74B9-8184-4FBD-9651-41DD31268769</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:61B625CB-8C56-4E12-A6F4-0DC653A10AC0">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N7c89e5d32ea94247bf15a32e747c17d6"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:EA8E0240-7430-47F3-9565-DD53B447D323"/>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:545F2613-2A5E-4333-A651-CBA80268D6ED</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:E0DB2E95-152C-413F-86CE-CE5F076C0112</pav:lineageUri>
    <pav:createdOn>2015-09-30 10:45:17 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B26CD913-F144-4BFF-8967-7F740FF37133">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SPLAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:97020E1A-6E28-45D5-A4DA-64A1B59C3BF9"/>
    <pav:lineageUri>urn:domeoserver:annotationset:357321A7-5793-4DE5-BB38-BF5FA7A5D72C</pav:lineageUri>
    <pav:createdOn>2014-02-19 12:35:40 -0500</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:8803D2BD-5758-4131-9F54-9AEAC91645F8</pav:previousVersion>
    <rdfs:label>SPL Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E9F13BFE-1A17-4FDF-99A7-13B89F697635</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">2</pav:versionNumber>
    <pav:lastSavedOn>2014-02-19 12:35:49 -0500</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:567622C8-3CF7-4D00-B6DE-58E98EC87767">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:E8D32CF0-DC1F-47F2-B985-33994B162AA1</pav:lineageUri>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N4c863206311642cf8f47e3859809062b"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:7B5B546E-8776-4EB6-BF76-E5B762E84322"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-08-20 13:05:57 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9DF6A73F-A12D-4E35-8150-87A99531211A">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluvoxamine maleate</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/203143</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7877A319-101E-4CC2-90ED-DEAC61D4C354">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4344B14E-62E7-44C1-BB25-CDC12DC66BA6"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8A842890-2CC5-4CAB-BB40-13D9F1AD35C4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:fd835697-0f94-4dea-8117-8b676123d889">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> is initiated or discontinued [see Warnings and Precautions </ao:suffix>
    <pav:createdOn>2015-08-27 14:50:21 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>PRISTIQ</ao:exact>
    <ao:prefix>eiving warfarin therapy should be carefully monitored when </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:fd835697-0f94-4dea-8117-8b676123d889"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FF12F8C1-BC48-49A1-B32D-D9539B1A5BE9">
    <rdfs:label>cimetidine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23572555-6B65-422D-90E6-045BE62D49C1">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> produced no clinically relevant changes in plasma rabeprazole concentrations.</ao:suffix>
    <pav:createdOn>2015-08-26 16:11:50 -0400</pav:createdOn>
    <ao:prefix>and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:23572555-6B65-422D-90E6-045BE62D49C1"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5d103551-978f-472a-9c62-51e6e4dea068.html</ao:hasSource>
    <ao:exact>antacids</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:78ABC7AE-C998-440B-93E0-9979080145F2">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-20 09:53:20 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:78ABC7AE-C998-440B-93E0-9979080145F2"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>5.7 Potential Alosetron Interaction  </ao:prefix>
    <domeo:uuid>78ABC7AE-C998-440B-93E0-9979080145F2</domeo:uuid>
    <ao:exact>Because alosetron is metabolized by a variety of hepatic CYP drug metabolizing enzymes, inducers or inhibitors of these enzymes may change the clearance of alosetron. Fluvoxamine is a known potent inhibitor of CYP1A2 and also inhibits CYP3A4, CYP2C9, and CYP2C19. In a pharmacokinetic study, 40 healthy female subjects received fluvoxamine in escalating doses from 50 mg to 200 mg a day for 16 days, with coadministration of alosetron 1 mg on the last day. Fluvoxamine increased mean alosetron plasma concentration (AUC) approximately 6-fold and prolonged the half-life by approximately 3-fold [see Contraindications (4.1)] and Lotronex (alosetron) package insert. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/080CCBD5-3FFB-4024-918C-A27D97A96282">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>terfenadine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42330</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EE3ED664-DC9E-4190-B021-13E58E1157F5">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In healthy male patients (n=18), phenytoin (200 mg daily) increased mirtazapine (30 mg daily) clearance about 2-fold, resulting in a decrease in average plasma mirtazapine concentrations of 45%. Mirtazapine did not significantly affect the pharmacokinetics of phenytoin.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-25 10:36:05 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <ao:prefix>  Phenytoin  </ao:prefix>
    <domeo:uuid>EE3ED664-DC9E-4190-B021-13E58E1157F5</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EE3ED664-DC9E-4190-B021-13E58E1157F5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1ED20ED1-FB0C-422E-8105-1ED7D0D52049">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#none</poc:PharmacokineticImpact>
    <dct:description>none</dct:description>
    <rdfs:label>None</rdfs:label>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3CD92FB3-F293-4A2C-9F16-10772321FFDD">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>paroxetine</rdfs:label>
    <dikbD2R:dose>20</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/990A8EFD-9234-41D3-A475-48D0CA0DB9D7">
    <rdfs:label>lorazepam</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6470</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1CD72A3B-02EF-47C0-BB78-1E8CA3D998CA">
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:createdOn>2015-10-14 11:40:29 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:3E6CAB50-964C-47A1-B775-F60E5AB0BC0C"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/06D751E5-D380-434D-9CDF-03B12807E7F6">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8787</dailymed:activeMoietyRxCUI>
    <rdfs:label>propranolol</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BC7B7477-1771-4742-BF5C-CEC7F77E7F83">
    <ao:prefix>, </ao:prefix>
    <pav:createdOn>2015-10-14 11:39:59 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:suffix>, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>fosamprenavir</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>BC7B7477-1771-4742-BF5C-CEC7F77E7F83</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BC7B7477-1771-4742-BF5C-CEC7F77E7F83"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:091FB1B6-AFD7-417A-B142-19C55B590655">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">7</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:2F0F6A9C-0E38-4924-B1BA-458A4EEDE554</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <pav:createdOn>2015-10-13 11:58:32 -0400</pav:createdOn>
    <ao:body rdf:nodeID="N4f233366e74948d194515daa501377d4"/>
    <pav:lastSavedOn>2015-10-13 11:59:07 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:B3D228DE-074E-4B6A-B6E5-4AD387F1C150"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/AF18B468-A219-4E1A-9219-4955E1D0702F">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:19D9C218-A991-40F9-BE73-9CC7580ADDC8">
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <dikbD2R:preciptFormulation>Oral</dikbD2R:preciptFormulation>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:objectFormulation>Oral</dikbD2R:objectFormulation>
    <dikbD2R:cmaxDirection>Increase</dikbD2R:cmaxDirection>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:numOfParticipants>Unk</dikbD2R:numOfParticipants>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:auc>151</dikbD2R:auc>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptRegimens>Daily</dikbD2R:preciptRegimens>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/81F515F9-20CA-4FC8-A307-63D0B35D7C23"/>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:cmaxType>Percent</dikbD2R:cmaxType>
    <dikbD2R:objectRegimens>SD</dikbD2R:objectRegimens>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/79C3BB1C-2898-42E4-BFE2-56F60B52E2C7"/>
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <dikbD2R:cmax>62</dikbD2R:cmax>
    <dikbD2R:objectDuration>1</dikbD2R:objectDuration>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DD2C6134-AE70-455E-A541-EE9425AFB951">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>theophylline</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10438</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AE5043A5-A6D7-408B-8086-D164EAE3A3F0">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FFF175C6-9F56-4383-8B68-F3EF6EDC7D96"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/28037A94-46A8-4D58-A8BD-BC8A0B20411F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D6BB0AFD-5321-4A71-9BB3-01FF5D9ADF51">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix>), CYP2C9 (e.g., </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>warfarin</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D6BB0AFD-5321-4A71-9BB3-01FF5D9ADF51"/>
    <pav:createdOn>2015-09-10 14:44:43 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>), CYP3A4 (e.g., alprazolam), and CYP2C19 (e.g., </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0E651153-623D-4039-82E6-625B00CEEB3C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so-called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-01 10:47:47 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0E651153-623D-4039-82E6-625B00CEEB3C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>0E651153-623D-4039-82E6-625B00CEEB3C</domeo:uuid>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0E0AED6D-A358-46BB-B7DD-FFDDAEC30073">
    <rdfs:label>CMI</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D3BA1581-32CA-4E00-81DC-2B8825244D7A">
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-14 11:40:11 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:684CDA98-DF01-4945-8AC6-E4E6E9406E57"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8C2AB037-A9A0-4C62-A473-F7A147EA3C04">
    <domeo:uuid>8C2AB037-A9A0-4C62-A473-F7A147EA3C04</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8C2AB037-A9A0-4C62-A473-F7A147EA3C04"/>
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7-10% of Caucasians are so-called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-01 10:29:06 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:032F7210-DAD4-47BF-9655-9B205218004D">
    <ao:exact>TCA</ao:exact>
    <domeo:uuid>032F7210-DAD4-47BF-9655-9B205218004D</domeo:uuid>
    <ao:prefix>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dosage regimen of a </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:032F7210-DAD4-47BF-9655-9B205218004D"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
    <pav:createdOn>2015-10-01 10:27:16 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BDEEA462-887A-41B3-88C9-0A13E5638CEC">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>hexobarbital</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E3E97E76-5E13-4105-A8EC-99DCC8F4EFBE">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>sulforidazine</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9B8FBF72-9A52-4632-A51A-8B711C78D73A">
    <domeo:uuid>9B8FBF72-9A52-4632-A51A-8B711C78D73A</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-20 09:56:51 -0400</pav:createdOn>
    <ao:prefix> (100 mg q.d.) and </ao:prefix>
    <ao:exact>alprazolam </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>(1 mg q.i.d.) were coadministered to steady state, plasma concentrations and other pharmacokinetic parameters (AUC, C</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9B8FBF72-9A52-4632-A51A-8B711C78D73A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A1B4D05A-19F5-4ABC-A27B-6B9CFCDE1FF9">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:77D3CA28-823A-4BC7-8DFD-034B9C5C8959"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:comment>Increased Cmin by 67%</dikbD2R:comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:80D2A1C4-6072-405B-A4F4-2432E0B3EB53">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-09-30 10:48:18 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:545F2613-2A5E-4333-A651-CBA80268D6ED</domeo:belongsToSet>
    <pav:createdOn>2015-09-30 10:39:45 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:907BF48E-9086-4099-91DE-21B4E18B2535</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:DC123E69-3401-4E56-B96A-77AF52AFAA21"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:454F6C27-43B6-4A9B-897D-8EFBA3FD1A99">
    <ao:prefix>as well.</ao:prefix>
    <domeo:uuid>454F6C27-43B6-4A9B-897D-8EFBA3FD1A99</domeo:uuid>
    <ao:suffix> </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:454F6C27-43B6-4A9B-897D-8EFBA3FD1A99"/>
    <ao:exact> Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <pav:createdOn>2015-09-29 11:41:49 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C331A888-80A8-4A77-8B8B-9B4659235EBF">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:prefix>hydroxylase) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:hasSource>
    <domeo:uuid>C331A888-80A8-4A77-8B8B-9B4659235EBF</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C331A888-80A8-4A77-8B8B-9B4659235EBF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-29 09:25:46 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8798FEA7-9B12-4A71-A25B-7AA5A785F4C1">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:596EF7A4-A1DA-43AD-98A2-505C04A492A6"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:518BED41-7283-4522-8D89-FF422D1D8A85">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5F377576-4DBC-4316-BC46-1E324C1A4648"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N723fc22ee7b74f9db8412ca3e2d62253">
    <domeo:sets rdf:resource="urn:pddi:uuid:1A5D8A4A-106F-41F1-8E35-559596E80901"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:175D6051-88AC-4656-9272-BBF63B1F9C81">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:AC8664C2-5E79-4ED0-A167-3C8B25CE6CDF</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:6C5659B2-D52F-4275-8E7B-1BA5BE5FBDE9"/>
    <pav:createdOn>2015-09-29 09:44:28 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6E19CC03-E03E-4213-8EA8-46AEFDCE0AEB">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E68B0DFB-C662-44AB-8D18-073EB1AC2659"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C96BD073-4D70-44BE-928E-B22F63FC0265"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E0701F46-8C28-4A8D-886B-270DAC63BB62">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9DE57A2D-FCE6-45AA-AC64-6FA9C1DBB165"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/008259E3-59A1-4EC0-B54F-8C531B562044"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:108E830A-C87C-4FA3-9136-6D1ADD9F0C2D">
    <domeo:uuid>108E830A-C87C-4FA3-9136-6D1ADD9F0C2D</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-30 10:47:34 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <ao:prefix>milnacipran and 150mg pregabalin .  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:108E830A-C87C-4FA3-9136-6D1ADD9F0C2D"/>
    <ao:exact>Warfarin-Steady-state milnacipran (200 mg/day) did not affect the pharmacokinetics of R-warfarin and S-warfarin or the pharmacodynamics (as assessed by measurement of prothrombin INR) of a single dose of 25 mg warfarin. The pharmacokinetics of Savella were not altered by warfarin. </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BACBBDD8-DC86-4CD8-8ADC-182369AB917C">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3322</dailymed:activeMoietyRxCUI>
    <rdfs:label>diazepam</rdfs:label>
    <dikbD2R:dose>10</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FB7C3E1A-9374-4DF5-80E7-43CE698CF7A9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:5375D007-B052-4318-B373-403930670985</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6F5C24D1-EA99-48CF-B498-A0D89C02B290</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-09-30 12:41:17 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:8BA7FE71-AB20-4F46-A4FC-8B7C9690E175"/>
    <ao:body rdf:nodeID="N5016ad2a1779422aa23395ee25eabdf9"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-09-30 12:41:52 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BCA7C5D9-76C4-4313-B0F4-D885A239D20C">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D9DFF99C-370B-4655-9E62-B8B725F31F30">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-14 11:41:09 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:81101CB5-AABA-43BC-A7A7-CFCE0ED9C538"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E0A97148-5D07-470C-82E0-B363A9DDE5C1">
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <domeo:uuid>E0A97148-5D07-470C-82E0-B363A9DDE5C1</domeo:uuid>
    <pav:createdOn>2015-09-29 11:28:28 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E0A97148-5D07-470C-82E0-B363A9DDE5C1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E73D6B7D-A3A8-4817-A2C4-32DE510299C5">
    <ao:exact>Consider alternative treatment or treatment strategies in patients identified as CYP2C19 poor metabolizers. </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/Clopidogrel-1086a7b4-b89b-4bee-8120-5f752626c046.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>E73D6B7D-A3A8-4817-A2C4-32DE510299C5</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E73D6B7D-A3A8-4817-A2C4-32DE510299C5"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>(</ao:suffix>
    <pav:createdOn>2014-02-19 12:38:23 -0500</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:711EDF9D-6E35-49AC-AA7D-D0B9DA61AED9">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/99E8881C-1ED6-4ED9-A748-04DA06BDF07D"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BEE6C688-7A67-42B6-A24F-6CA2B7894CF3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:47308EE3-1269-4178-8530-2A71DABC486B">
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-13 12:04:13 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-13 12:03:21 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:2EE97ADE-F18C-48A2-9F22-4B314409ED08"/>
    <pav:previousVersion>urn:domeoserver:annotationset:B51F4BB3-6BDB-45E7-9399-D93DBC4324AC</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7E68B341-4216-465A-8B75-6D6394771A71">
    <pav:lastSavedOn>2015-10-14 12:07:40 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:C91289D7-45EC-44D1-A933-E79E770CFE71</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-10-14 12:06:18 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:322EB9EE-02D4-4A14-930C-8B461AFD4B02"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2880880C-966F-4482-BBCD-B24A39E8870E">
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:1D5515B8-366D-4B1E-9626-0B9C6E83246F"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdOn>2015-08-20 11:38:01 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoclient:uuid:7d2027ff-e85b-46f3-befa-3f8f5cf7e88f</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="N82e15d891a8345cb854ce95add64ef39"/>
    <pav:lastSavedOn>2015-08-20 11:38:24 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:ED1DC53A-6D91-4B39-9733-9EB4AE8830AF">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-14 11:40:55 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:E61A3EB0-57D7-4D36-A9CD-E265FEE0C538"/>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E0B63912-C3DD-4CBB-9094-C6C18ED87698">
    <ao:suffix>should be monitored closely for hepatotoxicity.</ao:suffix>
    <ao:prefix>and </ao:prefix>
    <pav:createdOn>2015-10-14 11:41:52 -0400</pav:createdOn>
    <ao:exact>isoniazid </ao:exact>
    <domeo:uuid>E0B63912-C3DD-4CBB-9094-C6C18ED87698</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E0B63912-C3DD-4CBB-9094-C6C18ED87698"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4B590F9A-D21F-41D1-93B2-7EF2747AFDC4">
    <ao:context rdf:resource="urn:domeoclient:uuid:9C1A8D37-D67F-40E5-AD1B-123DEF9844C1"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:createdOn>2015-10-20 10:09:24 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C8525E3E-20A2-4497-88CF-376153FB353D">
    <dikbD2R:dose>30</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdfs:label>paroxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F062BFB0-7D99-4B91-AB15-BCF02C8D9B30">
    <domeo:uuid>F062BFB0-7D99-4B91-AB15-BCF02C8D9B30</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:prefix>, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F062BFB0-7D99-4B91-AB15-BCF02C8D9B30"/>
    <pav:createdOn>2015-10-14 11:41:00 -0400</pav:createdOn>
    <ao:suffix>, tacrolimus theophylline, tricyclic antidepressants (e.g., amitriptyline, nortriptyline) and zidovudine. It may be necessary to adjust the dosages of these drugs if they are given concurrently with rifampin.</ao:suffix>
    <ao:exact>quinine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1B142529-AD77-4271-A130-905880ABE202">
    <ao:prefix>cilostazol , and bromocriptine .  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-13 12:05:17 -0400</pav:createdOn>
    <ao:exact>Concomitant administration of clarithromycin with cisapride, pimozide, astemizole, or terfenadine is contraindicated (see CONTRAINDICATIONS.)</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>1B142529-AD77-4271-A130-905880ABE202</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1B142529-AD77-4271-A130-905880ABE202"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:897BE155-74FF-42F2-801E-97BC586FF1AB">
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-14 11:40:46 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:B93959A7-F648-4609-A26D-030346CEA017"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/35096440-E02C-4177-B446-A1169CA8838F">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>cimetidine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>300</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:03A604B0-BFEA-4C22-A99A-F043C16F0A0A">
    <pav:createdOn>2015-10-20 10:08:53 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>maleate tablets and diazepam is generally not advisable. Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic co</ao:suffix>
    <ao:exact>fluvoxamine </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:03A604B0-BFEA-4C22-A99A-F043C16F0A0A"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix>The coadministration of </ao:prefix>
    <domeo:uuid>03A604B0-BFEA-4C22-A99A-F043C16F0A0A</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:976A02BC-A9C7-4255-B03F-629AF63BF598">
    <pav:createdOn>2015-10-14 12:08:02 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>976A02BC-A9C7-4255-B03F-629AF63BF598</domeo:uuid>
    <ao:suffix>60 mg resulted in a 151% increase in pimozide AUC and a 62% increase in pimozide C</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:976A02BC-A9C7-4255-B03F-629AF63BF598"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>paroxetine </ao:exact>
    <ao:prefix>2 mg (single dose) and </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8457BA6E-641E-4DB2-9E03-728451CB6CD6">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>ketoconazole</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3E018E90-4D51-4344-AD05-A49492C9B566">
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdOn>2015-10-14 11:41:43 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:9BEA3577-72E8-4C8C-AADE-04F58083C1B9"/>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1B6C697E-067C-46AF-9C37-2EC0D7B07E53">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:body rdf:nodeID="N78e90197bf524297b354678097a1d99d"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:4128C0CD-6C3E-4991-99E0-2AA0424C733F</pav:lineageUri>
    <pav:createdOn>2015-08-20 13:05:43 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:9D6ED403-B05E-4350-803B-C4E18E216987"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7ADD0A8F-16BD-47D0-B7BF-57D3A7B9C41F">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dikbD2R:dose>1000</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>dextrorphan</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/740001AD-822F-4815-B1EC-95234A0FFEFB">
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <rdfs:label>warfarin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:11171A22-5D51-461B-A0CB-E73A2E8803E4">
    <ao:exact>antiarrhythmics </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:11171A22-5D51-461B-A0CB-E73A2E8803E4"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <domeo:uuid>11171A22-5D51-461B-A0CB-E73A2E8803E4</domeo:uuid>
    <ao:suffix>(e.g., disopyramide, mexiletine, quinidine, tocainide), oral anticoagulants, antifungals (e.g., fluconazole, itraconazole, ketoconazole), barbiturates, beta-blockers, calcium channel blockers (e.g., diltiazem, nifedipine, verapamil), chloramphenicol, cla</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:40:13 -0400</pav:createdOn>
    <ao:prefix>, </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D6FC87AF-703F-412F-B64A-DDC21D3C4AA9">
    <domeo:belongsToSet>urn:domeoserver:annotationset:7C3ED630-095E-46C1-9254-E12EC01A6C0B</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:C79E0778-23A4-4684-B599-182D4BA0B6F3"/>
    <pav:lineageUri>urn:domeoserver:annotation:10E15785-F32B-44DE-9B28-49F52FCA1865</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-10-09 13:39:25 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N6af460554a2442bc9072b10502416f8a"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-09 13:36:49 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DA473F3A-1EA1-4A12-9DE2-F3829DF3154F">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:AD1790AB-13B7-460E-B97D-F2C2BD5365A5"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AB525967-9BA3-4C51-91D6-7D8F6B0AE214">
    <pav:createdOn>2015-09-24 15:46:01 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:hasSource>
    <ao:prefix>   7.1 Inhibitors of CYP1A2   </ao:prefix>
    <domeo:uuid>AB525967-9BA3-4C51-91D6-7D8F6B0AE214</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>When duloxetine 60 mg was co-administered with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to male subjects (n=14) duloxetine AUC was increased approximately 6-fold, the Cmax was increased about 2.5-fold, and duloxetine t1/2 was increased approximately 3-fold. Other drugs that inhibit CYP1A2 metabolism include cimetidine and quinolone antimicrobials such as ciprofloxacin and enoxacin [see WARNINGS AND PRECAUTIONS (5.12)]. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AB525967-9BA3-4C51-91D6-7D8F6B0AE214"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:59142E57-1816-4AB7-B582-C415EBDF37D4">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:894C77C9-A108-4EBD-8BE3-CB27499155EF"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:DD53EE65-079D-4C5D-8248-EE332FEE3EDA</pav:previousVersion>
    <pav:createdOn>2015-10-13 11:23:28 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-13 11:24:28 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C22B15D4-ED74-40DF-92C3-16732E7180BC">
    <ao:suffix> treatment in a patient being withdrawn from </ao:suffix>
    <pav:createdOn>2015-09-29 11:24:52 -0400</pav:createdOn>
    <ao:prefix>involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C22B15D4-ED74-40DF-92C3-16732E7180BC"/>
    <ao:exact>TCA</ao:exact>
    <domeo:uuid>C22B15D4-ED74-40DF-92C3-16732E7180BC</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7625FFE2-5AD2-45D5-B529-281159B83AF9">
    <pav:createdOn>2015-09-16 15:22:28 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-16 15:31:12 -0400</pav:lastSavedOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="Nbac83f10c9344ac0babcb5c491e07b78"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0468AC6B-4F06-4CA4-A0DE-A389E3B0E59F</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:B685076F-09F4-4C5C-8A80-FBB9B399649C</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:218A1970-F7A1-4D9E-890F-6C4552091879"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BBB2B0E0-A5E7-4820-AFA7-2E6B6CA080E3">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:createdOn>2015-08-20 12:48:25 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:1CBC63B2-8B2E-4ADB-B5BB-A9F2750B2A50"/>
    <ao:body rdf:nodeID="N3cfe156636f3438cb8d0ae98a70e2d08"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:BA4A4F06-DE8C-4B66-8918-920D0399D744</pav:previousVersion>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8F76EE37-C22C-4ECE-9F52-CC13D26D2DE0">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:exact>hormonal contraceptives</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, dapsone, diazepam, doxycycline, fluoroquinolones (e.g., ciprofloxacin), haloperidol, oral hypoglycemic agents (sulfonylureas) levothyroxine, methadone, narcotic analgesics, progestins, quinine, tacrolimus theophylline, tricyclic antidepressants (e.g., </ao:suffix>
    <ao:prefix>, oral or other systemic </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8F76EE37-C22C-4ECE-9F52-CC13D26D2DE0"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:40:41 -0400</pav:createdOn>
    <domeo:uuid>8F76EE37-C22C-4ECE-9F52-CC13D26D2DE0</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9D207858-AC88-4FB3-970F-5EA02E8D2555">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:55170CF8-8D68-4114-B3E6-DDA4F59726CC"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16EF1A8D-F411-462D-B908-B935CB267C22">
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:body rdf:nodeID="Nf842cdbdebbf4abbb69a9f65318ce4ba"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:5B9289C4-6EAC-44C9-9AC8-BB5217DE4EBB"/>
    <pav:previousVersion>urn:domeoclient:uuid:a7f59b4d-3ada-4384-adb1-665a4a1743c8</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-09-03 15:42:21 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/66C174F9-3E19-45E9-8797-706347DCF898">
    <rdfs:label>fluvoxamine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6e60f74aff7c4797877c83ea8d8efdd1">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7512BAA3-D70D-40E3-926F-0CCE4EC533DD">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-29 09:03:38 -0400</pav:createdOn>
    <ao:body rdf:nodeID="Ncbe4c4c7cc8544d4ab766138652e0ac4"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:FAE837A8-903B-4407-AD74-E675B6006E05</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:812800E2-CCBF-4D26-B127-DE7CAF212FBE"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16EA135F-CDB0-4142-91AA-B23FC38A3199">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-14 11:41:59 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:BB406C06-1C8B-4C33-9266-D068ACCCA992"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C00F04F3-F660-405D-ADB3-DE86F16D1ABC">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8EF41540-288B-43F6-A276-6896A2A6EA80"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F70B463D-A444-4115-9390-AABA778F2FE2">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1B29206A-BBA8-4584-BB32-267808C9854A">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-09-29 09:24:17 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-29 09:27:10 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0185AD47-6E7B-4C92-8A3D-A2876CC95002</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N6c445ed610fa4fdd8aff39c273172b38"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:EDE73783-D2A3-424F-B7A2-32EBDF087819</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:7E8BB1FA-609D-4431-A230-12A374C72B5A"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/79C3BB1C-2898-42E4-BFE2-56F60B52E2C7">
    <rdfs:label>pimozide</rdfs:label>
    <dikbD2R:dose>2</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8331</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E9FC935E-A71B-4526-809B-94CC04024810">
    <ao:context rdf:resource="urn:domeoclient:uuid:116A5D25-45A4-4CDE-9D8A-D91DE2762CF2"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:7D8E880F-7FB0-4CEC-B70E-D27EAC272657</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-03 16:19:18 -0400</pav:createdOn>
    <ao:body rdf:nodeID="Nf32bcb0983bd4f96adb03287c5c59066"/>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <pav:lastSavedOn>2015-10-16 10:43:23 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">16</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9F35ECA3-9A50-47BB-90FF-F0352719F403">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:62CFF391-05E7-402D-96DB-3D69E36FBCE0"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:47795914-06B1-4C55-864C-EBC32AE4358E">
    <pav:lineageUri>urn:domeoserver:annotation:BC2F685B-DF0D-4947-9CBC-44653B4AF56C</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-09-29 09:44:09 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:009F8EE9-A45D-4768-B436-EB845104C124"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:55E33A88-4EAA-4FB5-A3A9-0E1542B3AA85">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:comment>DELETE</dikbD2R:comment>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0040B2A4-9CD1-49A8-B3D4-BC8547FC2363"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/57BF8DDB-2F8F-4E27-9FD5-634619584FB6">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>carbamazepine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CEB4345E-465D-4401-B785-B85E1D649721">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4603</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>furosemide</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F4722E24-22E4-4C54-A2FE-EB7888ED53DF">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FF57A4B9-CC79-451C-9234-D39598D4703F"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5B620FFB-C1CB-4133-9D9C-4C13AE1899D9"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C471FFF4-C39A-4E02-8A38-863CF7D75C91">
    <ao:prefix>Drugs That Slow Heart Rate or Atrioventricular Conduction (e.g., beta blockers or diltiazem )   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited. Because initiation of GILENYA treatment may result in an additional decrease in heart rate, concomitant use of these drugs during GILENYA initiation may be associated with severe bradycardia or heart block. Seek advice from the prescribing physician regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating GILENYA. Patients who cannot switch, should have overnight continuous ECG monitoring after the first dose [see Dosage and Administration (2) and Warnings and Precautions (5.1)].</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>C471FFF4-C39A-4E02-8A38-863CF7D75C91</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C471FFF4-C39A-4E02-8A38-863CF7D75C91"/>
    <pav:createdOn>2015-08-20 13:56:39 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0551D423-1699-48B1-BBE9-B1E946BDEEAA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>0551D423-1699-48B1-BBE9-B1E946BDEEAA</domeo:uuid>
    <ao:prefix>and </ao:prefix>
    <ao:exact>halothane </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0551D423-1699-48B1-BBE9-B1E946BDEEAA"/>
    <ao:suffix>should be avoided. Patients receiving both rifampin and isoniazid should be monitored closely for hepatotoxicity.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <pav:createdOn>2015-10-14 11:41:49 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C5B99ECC-158C-4392-B2C6-F4CFDB242160">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/13F71DE0-2757-4052-A155-FCE0A8CB2936"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DC9E04A3-A623-4BA9-8BE7-BA422822DCB1"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3013C7EA-F549-441B-A296-8D4B57503429">
    <domeo:uuid>3013C7EA-F549-441B-A296-8D4B57503429</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:suffix>or isoniazid, the potential for hepatotoxicity is increased. The concomitant use of rifampin and halothane should be avoided. Patients receiving both rifampin and isoniazid should be monitored closely for hepatotoxicity.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3013C7EA-F549-441B-A296-8D4B57503429"/>
    <ao:prefix>is given concomitantly with either </ao:prefix>
    <ao:exact>halothane </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-14 11:41:46 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E6E5E2BF-110F-4222-A780-5EA92CB0DA45">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>30</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>lithium</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4B3F18EE-DFF2-417A-86A9-A1C3C40B55A1">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:39CA0CAB-310A-4E0C-98E1-1C2424A54469"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FCE857AC-CF2E-43D2-BA6E-43F6D066C40E">
    <rdfs:label>aripiprazole</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>100</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:82EE3E7D-2A34-4402-ADF2-A3E0372E3BEA">
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-10-14 11:54:07 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-14 11:57:06 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="N91d8420f400646e59632dccd56dbd34a"/>
    <pav:lineageUri>urn:domeoserver:annotation:46DEFFEA-EC78-47A5-97B8-374D1B38F10D</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:A5842844-FD5D-4B2D-A1EB-A81881AB399E"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/75B841AC-9362-40F7-8C11-26139D521425">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>paclitaxel</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/56946</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/333460FC-6A5E-44AD-91DD-FF5BFD1588EA">
    <rdfs:label>clarithromycin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EE531387-2630-404A-90E4-6A4B382FFD4F">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-20 10:09:09 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:AB9646D0-69B7-463F-B535-B0682D7E6F8A"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C7B21BF1-EEB5-49C7-B962-B5FE1B3E6DA3">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9068</dailymed:activeMoietyRxCUI>
    <rdfs:label>quinidine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne70e30db8a9a45759ff3699348fb0808">
    <domeo:sets rdf:resource="urn:pddi:uuid:DC5C770C-A40B-4EE0-9B1C-5DEB06A5D3B2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:cbbf9293-bae7-4f67-abd1-d741d1430373">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <ao:exact>clomipramine hydrochloride</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> capsules is as bioavailable as CMI from a solution. The bio</ao:suffix>
    <pav:createdOn>2015-08-27 14:50:29 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>                                                  CMI from </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:cbbf9293-bae7-4f67-abd1-d741d1430373"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FA20D9EF-8F4E-40C9-B23A-B82C96DB4038">
    <pav:createdOn>2015-09-14 10:24:54 -0400</pav:createdOn>
    <ao:prefix>DOSAGE AND ADMINISTRATION ).  Drug-Drug Interactions   </ao:prefix>
    <ao:exact>In vitro drug interaction studies reveal that paroxetine inhibits CYP2D6. Clinical drug interaction studies have been performed with substrates of CYP2D6 and show that paroxetine can inhibit the metabolism of drugs metabolized by CYP2D6 including desipramine, risperidone, and atomoxetine (see PRECAUTIONS: Drug Interactions).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:FA20D9EF-8F4E-40C9-B23A-B82C96DB4038"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6CE672D3-0B6E-4638-A191-01BBB207588C">
    <ao:suffix>. In these subjects (N = 8), the clearance of diazepam was reduced by 65% and that of N-desmethyldiazepam to a level that was too low to measure over the course of the 2 week long study. </ao:suffix>
    <ao:exact>diazepam</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-20 10:09:08 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6CE672D3-0B6E-4638-A191-01BBB207588C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> were administered a single oral dose of 10 mg of </ao:prefix>
    <domeo:uuid>6CE672D3-0B6E-4638-A191-01BBB207588C</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BBBB362C-93B8-4C16-81FD-F1789157CC67">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BBBB362C-93B8-4C16-81FD-F1789157CC67"/>
    <pav:createdOn>2015-09-25 10:39:34 -0400</pav:createdOn>
    <domeo:uuid>BBBB362C-93B8-4C16-81FD-F1789157CC67</domeo:uuid>
    <ao:prefix>  Cimetidine  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In healthy male patients (n=12), when cimetidine, a weak inhibitor of CYP1A2, CYP2D6, and CYP3A4, given at 800 mg b.i.d. at steady state was coadministered with mirtazapine (30 mg daily) at steady state, the Area Under the Curve (AUC) of mirtazapine increased more than 50%. Mirtazapine did not cause relevant changes in the pharmacokinetics of cimetidine. The mirtazapine dose may have to be decreased when concomitant treatment with cimetidine is started, or increased when cimetidine treatment is discontinued.</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DC9E04A3-A623-4BA9-8BE7-BA422822DCB1">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3407</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>digoxin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:116A5D25-45A4-4CDE-9D8A-D91DE2762CF2">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-16 10:43:10 -0400</pav:createdOn>
    <ao:prefix>   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Warfarin    Warfarin is a substrate for CYP2C9 and CYP3A4 metabolism pathways. In healthy volunteers titrated with Coumadin# (warfarin sodium) to clinical levels of anticoagulation (INR of 1.5 to 2), co-administration with EMSAM 6 mg per 24 hours for 7 days did not affect the pharmacokinetics of the individual warfarin enantiomers. EMSAM did not alter the clinical pharmacodynamic effects of warfarin as measured by INR, Factor VII or Factor X levels [see Drug Interactions (7.4) and (7.5)].</ao:exact>
    <domeo:uuid>116A5D25-45A4-4CDE-9D8A-D91DE2762CF2</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:116A5D25-45A4-4CDE-9D8A-D91DE2762CF2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2B412587-C38D-429C-82F8-6FA6FF610C62">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-29 09:44:16 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:F69BD261-D534-45DA-A326-9C3B61D503AF</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:883D470F-9DE7-4A54-A86F-A2C99D48E398"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E1C3313D-4AD7-4D8E-900B-D7C2D6E43D83">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>dextromethorphan</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>1000</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8E7ABB1C-FA5F-4991-B571-7869CB72CA87">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:BFF23E68-FE10-45CB-9065-88EBB1D41D71"/>
    <ao:body rdf:nodeID="N8482e424900f482db4a3daec10e4ea62"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:BF45E615-6760-4FB9-BD37-DCB9C89AB8C0</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-25 10:47:09 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-25 10:43:10 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:BE71BBF5-9A2D-4EBE-83B0-1E019FA0E0F8</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/759E5BCD-B74C-472F-A849-36EAF4A6B901">
    <dikbD2R:dose>400</dikbD2R:dose>
    <rdfs:label>carbamazepine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2CADD952-DDB0-48B5-B41F-CD6F96CDC186">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FF2D351F-C7C7-416A-98F1-1B1F25B71F66"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/89732B3A-74A8-4C41-AEDC-A88F844360CD"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E19DE6D4-EB73-440B-B7AC-CF7AED46AD2C">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>omeprazole</rdfs:label>
    <dikbD2R:dose>40</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/7646</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1432A4AA-FDB4-4896-B1E8-282338FA3F4F">
    <dikbD2R:comment>Switching from clompipramine to mlnacipran with no washout period.</dikbD2R:comment>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A2DE45B0-9514-40B5-B411-F5FC6B9D395D"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2FA865F9-7395-4DC0-AF33-84D72F77EA3F">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="N4892cc1c43ba46cbb67c5c8f08ac6d88"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:createdOn>2015-10-20 09:55:09 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-20 09:56:31 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>urn:domeoserver:annotationset:659993FA-47A6-4170-A1F4-37E021B93D40</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:41D04F07-F1A4-4984-92BF-64D621B5DF2A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B079047A-8D2F-4E32-BDE4-963FB269A9E6">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6DE261AC-3364-4AC2-985F-E44D2C662600"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4E825338-5822-401F-8440-DD2F9EEC6845">
    <rdfs:label>rifampin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>1000</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BBA6E0E7-69CB-4291-BCDF-DE962787E606">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9122E29C-7A46-4528-95FC-A1AD9EC754EE"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:comment>Steady state plasma concentrations of propanolol unaltered</dikbD2R:comment>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:94217DDD-9B20-4E77-8235-8C45672E523C">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:FCA82051-9E94-4750-8F5F-03AFC2261654"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EDF1BCD1-0EA0-41C0-AF73-88FEC7DE58F4">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">6</pav:versionNumber>
    <pav:createdOn>2015-08-20 12:46:42 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:5C7BDA17-45D7-4DC3-AEF2-44850B6F0D70"/>
    <pav:previousVersion>urn:domeoserver:annotationset:BA4A4F06-DE8C-4B66-8918-920D0399D744</pav:previousVersion>
    <ao:body rdf:nodeID="N855af5e56bae48f983922a82beafa8b3"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-08-20 12:50:04 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F1A26F99-9F60-4059-AA7F-419F4852F52C">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>Clinical Pharmacology (12.3) ] .  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F1A26F99-9F60-4059-AA7F-419F4852F52C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>No dose adjustment for EMSAM is needed when EMSAM is used concomitantly with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and CYP3A4 inhibitors (e.g., ketoconazole). No clinically meaningful change in selegiline exposure was seen when EMSAM was co-administered with alcohol, alprazolam, ibuprofen, olanzapine, risperidone, levothyroxine, and ketoconazole [see Clinical Pharmacology (12.3)]. </ao:exact>
    <pav:createdOn>2015-09-03 15:41:17 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0ACB8BDE-E592-4270-9AC7-42A62B893693">
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:149774FA-0B95-4FC6-B3B4-604D4FE97060"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-20 10:09:18 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EA099A9E-EE38-4634-8CDC-59117F9587EA">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/73E7122C-D90A-47DC-B2F0-9405E668ECF5"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4FB3483D-36F7-4ABD-BE96-8AED148EF544"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E5FF8830-7E0E-459E-812B-5C25783EC689">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>lorazepam</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E5FF8830-7E0E-459E-812B-5C25783EC689"/>
    <ao:prefix>metabolized by glucuronidation (e.g., </ao:prefix>
    <pav:createdOn>2015-10-20 09:54:08 -0400</pav:createdOn>
    <domeo:uuid>E5FF8830-7E0E-459E-812B-5C25783EC689</domeo:uuid>
    <ao:suffix>, oxazepam, temazepam) is unlikely to be affected by fluvoxamine. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6449CD69-4460-487F-BBC6-FA0B9AD8DF9E">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>ibuprofen</rdfs:label>
    <dikbD2R:dose>800</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8A9A0D3A-8B5C-44D9-8261-0984AABA8AC7">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>  Risperidone  </ao:prefix>
    <pav:createdOn>2015-09-25 10:45:51 -0400</pav:createdOn>
    <domeo:uuid>8A9A0D3A-8B5C-44D9-8261-0984AABA8AC7</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8A9A0D3A-8B5C-44D9-8261-0984AABA8AC7"/>
    <ao:exact>In an in vivo, nonrandomized, interaction study, subjects (n=6) in need of treatment with an antipsychotic and antidepressant drug, showed that mirtazapine (30 mg daily) at steady state did not influence the pharmacokinetics of risperidone (up to 3 mg b.i.d.).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:42FE8003-EA53-433E-852F-817D0BE4BDD8">
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-10 14:51:09 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:exact>Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine. Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:42FE8003-EA53-433E-852F-817D0BE4BDD8"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Tricyclic Antidepressants (TCAs)   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0CD9E330-14C2-4177-B31F-C986B1635D81">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <pav:createdOn>2015-08-20 13:04:28 -0400</pav:createdOn>
    <ao:prefix>Drug Interactions (7) ] .   Oral Contraceptives  </ao:prefix>
    <ao:exact>There was an increase in mean ethinylestradiol Cmax and AUC024 (1.58- and 1.54-fold, respectively) and levonorgestrel Cmax and AUC024 (1.33- and 1.41-fold, respectively) following repeated doses of teriflunomide [see Drug Interactions (7)].</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0CD9E330-14C2-4177-B31F-C986B1635D81"/>
    <domeo:uuid>0CD9E330-14C2-4177-B31F-C986B1635D81</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1A62DFA9-A3EA-44F0-938A-C311F8F17963">
    <ao:prefix>   </ao:prefix>
    <pav:createdOn>2015-10-16 10:45:35 -0400</pav:createdOn>
    <ao:exact>Olanzapine    In subjects who had received EMSAM 6 mg per 24 hours for 10 days, co-administration with olanzapine, a substrate for CYP1A2, CYP2D6, and possibly CYP2A6, did not affect the pharmacokinetics of selegiline or olanzapine [see Drug Interactions (7.4) and (7.5)].</ao:exact>
    <domeo:uuid>1A62DFA9-A3EA-44F0-938A-C311F8F17963</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1A62DFA9-A3EA-44F0-938A-C311F8F17963"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:06BC474E-3024-4DCB-97FA-F3A2B0984C23">
    <domeo:belongsToSet>urn:domeoserver:annotationset:85AD6EA1-D560-4FFB-A685-3F21B0B4208E</domeo:belongsToSet>
    <ao:body rdf:nodeID="N1c27b48856f74687a3a0c4b7714fa501"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-24 15:55:00 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:C3A42A96-23BA-4C83-AFB6-58A6917F54D8</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:14034C0F-5105-40D6-850A-54DA9D8C5316"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-24 15:53:10 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A08093DA-3EE1-44F9-9238-92BB02F21D62">
    <ao:exact>Teriflunomide may be a weak inducer of CYP1A2 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP1A2 as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <ao:prefix>AUBAGIO on CYP1A2 substrates   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A08093DA-3EE1-44F9-9238-92BB02F21D62"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-08-20 11:41:02 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1004CB50-F4B2-47A8-8632-F333D20F2E67">
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-14 11:40:05 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:1109D905-1CFB-4B3D-8D2B-2302F68D62D3"/>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nff262b54d49641179b6e64b202db20e2">
    <domeo:sets rdf:resource="urn:pddi:uuid:63A76675-C58E-4CF3-9C9E-588174E52742"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CADFFF9A-CF8A-4A55-9886-7839B4777B1A">
    <ao:context rdf:resource="urn:domeoclient:uuid:4F6D9D8B-BFDC-48A8-8B68-2FBD87B23A1C"/>
    <pav:lineageUri>urn:domeoserver:annotation:804D0C45-A5D0-4F7E-A05E-A3426954C34E</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-10-14 12:08:04 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-14 12:10:56 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B7EFF992-8B0B-4FED-AF3A-20623D38AF4F">
    <pav:createdOn>2015-10-20 10:09:21 -0400</pav:createdOn>
    <ao:prefix>, the effect of </ao:prefix>
    <ao:suffix>may even be more pronounced when it is administered at higher doses. </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>B7EFF992-8B0B-4FED-AF3A-20623D38AF4F</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>fluvoxamine </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B7EFF992-8B0B-4FED-AF3A-20623D38AF4F"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/25C1054A-69CC-44B3-A4B2-040328EB3E72">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/7646</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>omeprazole</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8616297F-98CA-45F7-B476-9680C4EAA05E">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>100</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>duloxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2C2C0A17-3046-4824-B927-60431EF09B62">
    <ao:exact>benzodiazepines </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>metabolized by glucuronidation (e.g., lorazepam, oxazepam, temazepam) is unlikely to be affected by fluvoxamine. </ao:suffix>
    <domeo:uuid>2C2C0A17-3046-4824-B927-60431EF09B62</domeo:uuid>
    <ao:prefix>. The clearance of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2C2C0A17-3046-4824-B927-60431EF09B62"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-20 09:54:06 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EFB0657A-BCA1-4AFF-9956-FC6062842A6A">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/83395</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>saquinavir</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CD125CC8-4856-4783-915D-FBF10607155C">
    <pav:createdOn>2015-09-14 11:05:46 -0400</pav:createdOn>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CD125CC8-4856-4783-915D-FBF10607155C"/>
    <ao:exact>Many drugs, including most drugs effective in the treatment of major depressive disorder (paroxetine, other SSRIs and many tricyclics), are metabolized by the cytochrome P450 isozyme CYP2D6. Like other agents that are metabolized by CYP2D6, paroxetine may significantly inhibit the activity of this isozyme. In most patients (&gt;90%), this CYP2D6 isozyme is saturated early during dosing with paroxetine. In 1 study, daily dosing of paroxetine (20 mg once daily) under steady-state conditions increased single dose desipramine (100 mg) Cmax, AUC, and T by an average of approximately 2-, 5-, and 3-fold, respectively. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>Concomitant use of</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:764C3740-FD65-4B29-B8A9-76436266890F">
    <pav:createdOn>2015-09-29 09:47:39 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>hepatic enzyme inhibitors</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> (e.g., </ao:suffix>
    <ao:prefix> or </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:764C3740-FD65-4B29-B8A9-76436266890F"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7C41DBCD-AA4C-4ED7-AF69-4530146C1BCF">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>Rifampin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:88DA3795-F8CF-499E-A0E6-2C02E577312F">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:50707EE2-1666-4851-9265-5CDF0B590D9B"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D3B8EC67-D49E-45E0-8AA0-7991FAC4D15B">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <domeo:uuid>D3B8EC67-D49E-45E0-8AA0-7991FAC4D15B</domeo:uuid>
    <ao:exact>Benzodiazepines metabolized by hepatic oxidation (e.g., alprazolam, midazolam, triazolam, etc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine. The clearance of benzodiazepines metabolized by glucuronidation (e.g., lorazepam, oxazepam, temazepam) is unlikely to be affected by fluvoxamine. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-20 09:54:31 -0400</pav:createdOn>
    <ao:prefix>    Benzodiazepines   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D3B8EC67-D49E-45E0-8AA0-7991FAC4D15B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:06C60C4D-FF6C-4152-BA7D-6DDDE37671E0">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A6CE7C94-8EC0-416D-9108-4FB58C2FD287"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9948AB52-A0F6-4592-9E56-14E7E74068CE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:532FFB8D-A0B2-44DD-8521-C58EE3F8B271">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2A949489-DB98-4A6B-BEFA-0D28605554CF"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D9D0C350-E217-4D24-B455-4D6BFDC3CF79">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A70238ED-3B41-4B29-A0BD-932D1A199E36">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>ketoconazole (see Figure 1 ).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/f371258d-91b3-4b6a-ac99-434a1964c3af.html</ao:hasSource>
    <pav:createdOn>2015-09-25 10:03:31 -0400</pav:createdOn>
    <ao:exact>No dose adjustment of FETZIMA is needed when co-administered with a CYP3A4 inducer or substrate. In vivo studies showed no clinically meaningful change in levomilnacipran exposure when co-administered with the CYP3A4 inducer carbamazepine or the CYP3A4 substrate alprazolam (see Figure 1). </ao:exact>
    <domeo:uuid>A70238ED-3B41-4B29-A0BD-932D1A199E36</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A70238ED-3B41-4B29-A0BD-932D1A199E36"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4655D30A-B652-44FA-9DC7-0015C67E66B7">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-29 11:24:21 -0400</pav:createdOn>
    <ao:prefix>, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which </ao:prefix>
    <ao:exact>SSRI </ao:exact>
    <ao:suffix>TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one cl</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <domeo:uuid>4655D30A-B652-44FA-9DC7-0015C67E66B7</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4655D30A-B652-44FA-9DC7-0015C67E66B7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:92457D2D-BB01-4342-9F4C-B8414696872A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:160855D9-B2DC-4D5C-84F9-D3F0F4046EEE"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-09-29 09:03:52 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:B5012AF7-189F-42AB-B521-DE5DCADFBC0F</pav:lineageUri>
    <ao:body rdf:nodeID="Nca0d7e00e2ba4225892d37d8ab4a3f56"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6D60F4F4-6285-4CA2-A2C0-3E7FF2C60F9A">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fosamprenavir</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/358262</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9C3B3ED1-A359-4D30-8BB0-4EC7EE74A4D8">
    <dikbD2R:dose>60</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>duloxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A68DDD07-EF29-4F4C-9784-72EADBCD7BA5">
    <ao:exact>Serotonin release by platelets plays an important role in hemostasis. Epidemiological studies of the case-control and cohort design that have demonstrated an association between use of psychotropic drugs that interfere with serotonin reuptake and the occurrence of upper gastrointestinal bleeding have also shown that concurrent use of an NSAID or aspirin may potentiate this risk of bleeding. Altered anticoagulant effects, including increased bleeding, have been reported when SSRIs or SNRIs are co-administered with warfarin. Concomitant administration of warfarin (2 to 9 mg once daily) under steady state conditions with duloxetine 60 or 120 mg once daily for up to 14 days in healthy subjects (n=15) did not significantly change INR from baseline (mean INR changes ranged from 0.05 to +0.07). The total warfarin (protein bound plus free drug) pharmacokinetics (AUC,ss, Cmax,ss or tmax,ss) for both R- and S-warfarin were not altered by duloxetine. Because of the potential effect of duloxetine on platelets, patients receiving warfarin therapy should be carefully monitored when duloxetine is initiated or discontinued [see WARNINGS AND PRECAUTIONS (5.5)]. </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:hasSource>
    <ao:prefix>7.4 Drugs that Interfere with Hemostasis (e.g., NSAIDs, Aspirin, and Warfarin)   </ao:prefix>
    <domeo:uuid>A68DDD07-EF29-4F4C-9784-72EADBCD7BA5</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-24 15:49:35 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A68DDD07-EF29-4F4C-9784-72EADBCD7BA5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1CEB3C6B-7B47-4609-9F0D-697A3AF5EBC5">
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-10-16 10:54:35 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:81E726EE-AA8D-4B55-8C48-986ACFF5AECC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="Nca5ea678456441639a1c0324168e17e3"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:previousVersion>urn:domeoserver:annotationset:0DAF5666-9E53-42D5-B92E-DE2C00764986</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-10-16 10:55:51 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D0021CCC-FA29-4F5E-BFAC-724F661BFE63">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D0F4A4A2-C1A4-4864-8E03-1598F140F312"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B8EC1E7A-95F2-4D2D-A178-693D321C57D0">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>3</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>mirtazapine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E4B45313-0C87-4DCE-8BD7-9BFB14E5BC4E">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/68158035-A75F-4817-A8AF-B67C8EF43857"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F3181AE2-E041-4E56-9E33-9A4C89FB7FEB"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CEA03631-9D8A-43C6-B7D6-B3C014AFC833">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:770C9DBF-86C8-4FC9-ABEA-6B185AB873D5"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FFF175C6-9F56-4383-8B68-F3EF6EDC7D96">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
    <rdfs:label>phenytoin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:33F29679-E217-4D93-9174-2D69A0E1B032">
    <dct:description>none.</dct:description>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#none</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <rdfs:label>None</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:626DDD90-C0D5-4D91-BC8E-D7772144A881">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:038D22CB-99BD-44B8-B516-E1EA64EA74E9"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:47BD9F20-D410-407C-907C-9E1251E71081">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:comment>Increased concentrations</dikbD2R:comment>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:324679DC-B5C4-4FAF-B588-1D66C5F18EF5"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E596E732-8428-46A7-9BA4-184EECE6564E">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>clarithromycin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/AF23E222-97FD-45FB-875D-197B209CA9FB">
    <rdfs:label>fluvoxamine maleate</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/203143</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1e8e09fec2fa46948209dd60bb6a42fa">
    <domeo:sets rdf:resource="urn:pddi:uuid:9FBF0953-E4A6-4D88-871C-A8C2A86A89AB"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E7AD763E-7B7F-4BE5-82B7-24A3FCBA74B6">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/83395</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>saquinavir</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/48E4EE2E-ECE1-4646-8833-535FB2396C55">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>fluvoxamine maleate</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/203143</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2CDA503C-6EC4-4CF6-A75D-1C18D768462D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1D7EC3DC-6FC8-4E76-BCE7-3E2D375182CF"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8D0D303B-689D-4CE2-A583-0D91BF2D57F0">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/189177B9-2F94-4FE1-9AA7-B39DD8C54FF3"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4CAB82EB-7168-4782-BE64-4BFDB88A1168"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6D04824F-3FE0-4EDC-853E-99A452259A65">
    <rdfs:label>olanzapine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6C8F0D8B-7E49-44AF-88CF-7D094E41B894">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3008</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>cyclosporine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/551EF4B8-5BA1-4D23-8521-6E6CDCCC6BB2">
    <rdfs:label>pregabalin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>50</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/950759E6-F9E3-48D0-8AFA-7A8C5114B86E">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>150</dikbD2R:dose>
    <rdfs:label>pregabalin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D7C2D90D-6D05-4C42-8B82-0733CAA32B4C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:6356DE5E-F188-46C3-8067-EEFE92CABEBB"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:7084298F-F868-484E-9091-B9ED9E4588DB</pav:previousVersion>
    <pav:createdOn>2015-08-20 11:39:01 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:body rdf:nodeID="N6a84c164e37847a8ba32d652a5c61eb9"/>
    <pav:lastSavedOn>2015-08-20 11:43:54 -0400</pav:lastSavedOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8ED2A29D-3A2F-42D3-8D3B-6BD914065936">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:28996346-6515-4892-84BA-92E5CB541BEF"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C9EAFF5D-297F-4B36-9AAA-08FC1EAFE82F">
    <rdfs:label>goserelin</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BFDA94B6-C3E3-4254-B29F-1D8EE09A501D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <dailymed:pharmgxBiomarker>http://fakeuri.org/CYP2C9</dailymed:pharmgxBiomarker>
    <dct:description>The selected biomarker.</dct:description>
    <sio:SIO_000628>dailymed:pharmgxBiomarker</sio:SIO_000628>
    <rdfs:label>CYP2C19</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F28D6516-9703-406F-96F8-5B421154E605">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:8754B1EE-5CF3-4B07-B663-694229AB8CE6"/>
    <pav:createdOn>2015-10-14 11:41:27 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ECDD3130-2EB6-47EB-BBA3-C6BE4B38C054">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:24B18E20-1A2F-4A93-914F-835938109D3A"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EC181D09-9FBE-4D67-B527-812C5BD1E031">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>milnacipran</rdfs:label>
    <dikbD2R:dose>20</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E9533FA8-F131-43DB-B55B-C68F0C211CEA">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3E2FDD29-E848-4894-A2E0-F79CFB2AEE6A"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A21F5BB7-9E1D-4264-9C8E-DF791E04BFCF"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5a72ffe47737455c9f06df07895ceba8">
    <domeo:sets rdf:resource="urn:pddi:uuid:F220C296-D1D9-4D82-932B-3F2E3AA73B32"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BD3C6BF3-0975-4B55-AA20-C3F17DEE6EE6">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/76D7C71E-4FB3-423E-932B-7C159AFAA9FD"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/AB7E1905-302D-461F-9971-C03F4AC9E028"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EF2539F7-AF31-4FEC-AD07-2E959071466F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>tablets, a reduction in the initial beta-blocker dose and more cautious dose titration are recommended. No dosage adjustment is required for fluvoxamine maleate tablets.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-10 15:00:51 -0400</pav:createdOn>
    <ao:exact>Coadministration of fluvoxamine maleate 100 mg per day with atenolol 100 mg per day (N = 6) did not affect the plasma concentrations of atenolol. Unlike propranolol and metoprolol which undergo hepatic metabolism, atenolol is eliminated primarily by renal excretion. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EF2539F7-AF31-4FEC-AD07-2E959071466F"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6721D402-6401-4579-92B5-34FA9E72D18B">
    <ao:exact>The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6721D402-6401-4579-92B5-34FA9E72D18B"/>
    <ao:prefix>, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-29 09:48:15 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3E418AD-A782-4293-B4D8-8CB1E09D8D1A">
    <domeo:uuid>F3E418AD-A782-4293-B4D8-8CB1E09D8D1A</domeo:uuid>
    <ao:exact>Carbamazepine    Carbamazepine is an enzyme inducer and typically causes decreases in drug exposure; however, approximately 2-fold increased systemic exposure of selegiline and its metabolites, L-amphetamine and L-methamphetamine were seen after single application of EMSAM 6 mg per 24 hours in subjects who had received carbamazepine (400 mg per day) for 14 days. Changes in plasma selegiline concentrations were nearly 2-fold and variable across the subject population. Such increases may increase the risk of a hypertensive crisis when carbamazepine is used with EMSAM at any dose [see Contraindications (4), Warnings and Precautions (5.3) and Drug Interaction (7.4)].</ao:exact>
    <ao:prefix>   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-16 10:35:57 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F3E418AD-A782-4293-B4D8-8CB1E09D8D1A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E919E880-47EB-483C-855A-01488949B792">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:51FA01A1-09E3-4C6A-BCCB-682D02F9460E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-08-20 11:48:50 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N0d594dc80f9642e58b0c9aa68d1a2870"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:createdOn>2015-08-20 11:45:52 -0400</pav:createdOn>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:F6E8A65B-FB38-43C1-AF04-4DDAA1B18FF8</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:85BE2C40-7BBF-47B9-B0F0-0C4F3E9176A6">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:711EDF9D-6E35-49AC-AA7D-D0B9DA61AED9"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N15a6777be34a41c2b1cd7efb166ae35c">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F67BC663-6A59-481D-AF2C-EDB9936FBFD4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:B7EFF992-8B0B-4FED-AF3A-20623D38AF4F"/>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:createdOn>2015-10-20 10:09:21 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7bbf62d7-595f-481e-b910-419c53446301">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:d5d1f96a-f1c4-422f-a8db-6afb741bb0fc</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-08-27 14:50:34 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-08-27 14:50:34 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:85AD6EA1-D560-4FFB-A685-3F21B0B4208E</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:57b4dcfd-71d6-4b6b-9263-9e309570bb86"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.1alpha-050</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:29BAE9CE-A490-411B-8D51-D180C758A333">
    <ao:prefix>. The mechanism of this pharmacodynamic interaction is not known. Concomitant use of Pimozide and Celexa or </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <domeo:uuid>29BAE9CE-A490-411B-8D51-D180C758A333</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>is contraindicated (See </ao:suffix>
    <pav:createdOn>2015-10-14 12:06:29 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:29BAE9CE-A490-411B-8D51-D180C758A333"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Lexapro </ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F540D170-24B1-495F-A6E4-EAF8E8AEB6DF">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <ao:exact>In healthy male patients (n=18), phenytoin (200 mg daily) increased mirtazapine (30 mg daily) clearance about 2-fold, resulting in a decrease in average plasma mirtazapine concentrations of 45%. Mirtazapine did not significantly affect the pharmacokinetics of phenytoin.</ao:exact>
    <domeo:uuid>F540D170-24B1-495F-A6E4-EAF8E8AEB6DF</domeo:uuid>
    <pav:createdOn>2015-09-25 10:36:44 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F540D170-24B1-495F-A6E4-EAF8E8AEB6DF"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>  Phenytoin  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C3AFC81E-A721-4020-94AF-09350E7CB555">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>phenothiazines</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C3AFC81E-A721-4020-94AF-09350E7CB555"/>
    <pav:createdOn>2015-09-29 09:26:45 -0400</pav:createdOn>
    <ao:suffix>, and the Type 1C antiarrhythmics </ao:suffix>
    <ao:prefix>) and many that are substrates for P450 2D6 (many other antidepressants, </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>C3AFC81E-A721-4020-94AF-09350E7CB555</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb7b43f8781ad4837a26849f73605cdfd">
    <domeo:sets rdf:resource="urn:pddi:uuid:5C2ECBB1-69F9-4B8E-A781-D536164C2025"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/56F00D8F-5E03-4E1A-BA19-7863443A321D">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>haloperidol</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E47B0D2D-E792-4A25-9141-4236C7ED5483">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2032BEFB-374A-48C8-A3C3-A86CD4A90B1A"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EFB0657A-BCA1-4AFF-9956-FC6062842A6A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9AD5F276-76A1-4489-A1E5-B9B85E27029E">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D4D6F8F4-C4E3-4D62-81AB-AD4AEE2D078B"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:783BEAD9-A5E3-4C83-964D-B264DA1D580D">
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:03A604B0-BFEA-4C22-A99A-F043C16F0A0A"/>
    <pav:createdOn>2015-10-20 10:08:53 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D8A2AFE3-5BE2-4383-AE8A-5F1AE76CBB64">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>alprazolam</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7E489E1F-6E43-458C-BBF5-3C3B620C3CEB">
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-14 11:41:18 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:6D3CE614-A965-411F-A271-16DB31F2442E"/>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E7D49F0F-4C2F-403D-B408-E33808B2D70C">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-09-25 10:47:09 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-25 10:39:34 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:BE71BBF5-9A2D-4EBE-83B0-1E019FA0E0F8</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:BBBB362C-93B8-4C16-81FD-F1789157CC67"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:2FA14080-ABCA-49A4-BF38-FB5985746439</pav:lineageUri>
    <ao:body rdf:nodeID="Ndc1b31e0d0d143d48962c538cedca47e"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:15B838BA-9B8E-469B-94DB-33151EE847D0">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-09-29 08:55:54 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:6E806245-53A9-4829-B33A-099ECEF58ADD</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:759B1D09-D228-4234-95A9-1CA416EC3077"/>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc30c99df41c64bb4970ec8f94a53a9b8">
    <domeo:sets rdf:resource="urn:pddi:uuid:A1611C67-8AB8-4E31-BE48-22AA3DC3C4AC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E2A044D2-76E2-4DBD-9969-C882DC1E4E30">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E1411FBD-7BA8-4C1A-AD74-656CDDAE9450"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DBE96F34-0BBB-401F-B1E6-F9FD5237E978"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:25e971a8-ce4d-4e5c-a750-8f8a09c85093">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:25e971a8-ce4d-4e5c-a750-8f8a09c85093"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> and LHRH analogs </ao:suffix>
    <ao:prefix>nical studies have not shown any drug interactions between </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-08-18 11:34:40 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/7c295b64-ec39-42ec-9f02-da5b42e775e1.html</ao:hasSource>
    <ao:exact>bicalutamide</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F78D2650-630F-40EA-B7AC-235F8798B509">
    <ao:prefix>on organic anion transporter 3 (OAT3) substrates   </ao:prefix>
    <ao:exact>Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <pav:createdOn>2015-08-20 11:44:30 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F78D2650-630F-40EA-B7AC-235F8798B509"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:065AC336-D88B-438F-86C0-C1846BB09A35">
    <ao:context rdf:resource="urn:domeoclient:uuid:BC39434E-6268-4632-B349-037247CE7542"/>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:lastSavedOn>2015-10-16 10:55:51 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:0DAF5666-9E53-42D5-B92E-DE2C00764986</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdOn>2015-10-16 10:54:22 -0400</pav:createdOn>
    <ao:body rdf:nodeID="Na8792dcd0dd2459f90426069e71d5d22"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BCBBE1C3-02EB-4C98-9173-F038FE053254">
    <ao:exact>When a single oral 30 mg dose of paroxetine was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T were reduced (by an average of 50% and 35%, respectively) compared to paroxetine administered alone. In a separate study, when a single oral 300 mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone. Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed. No initial dosage adjustments are considered necessary when these drugs are coadministered; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS: Postmarketing Reports).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-14 11:03:03 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BCBBE1C3-02EB-4C98-9173-F038FE053254"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>; any subsequent adjustment should be guided by clinical effect.  Phenytoin  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:331EA73A-B17C-4129-8E97-A6D6195AE89E">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdOn>2015-10-01 10:47:08 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:93418194-554C-4709-AEFD-4DD3FAF682A7"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:7F75A012-F476-48CD-BB26-C1E4A0CA1229</pav:lineageUri>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DC54EBE-B2A9-4AE7-A174-F0074ECE4050</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:body rdf:nodeID="N698b13365cb3486eb8c871d8679a8eba"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:32560457-99DD-4B35-A385-F90F0661CE60">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>  Lithium  </ao:prefix>
    <ao:exact>No relevant clinical effects or significant changes in pharmacokinetics have been observed in healthy male subjects on concurrent treatment with subtherapeutic levels of lithium (600 mg/day for 10 days) at steady state and a single 30-mg dose of mirtazapine. The effects of higher doses of lithium on the pharmacokinetics of mirtazapine are unknown.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:32560457-99DD-4B35-A385-F90F0661CE60"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <pav:createdOn>2015-09-25 10:44:45 -0400</pav:createdOn>
    <domeo:uuid>32560457-99DD-4B35-A385-F90F0661CE60</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:364D874B-C00E-4366-B96D-C86896D2A0DD">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8094835F-A1DA-4220-AE01-0E94ABD59B3C"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8BEE3797-8082-4D79-A3D7-CF3F5CD96F5D"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N58f1f52ff4ce4d998d644c9ea6c3f301">
    <domeo:sets rdf:resource="urn:pddi:uuid:38C04CDC-DC8F-4124-8366-315F41D3B360"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ED8D1FE9-B200-42D0-9B06-3F2EED68B302">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4620AEC8-472B-4E1E-A5CA-85E870C2B430"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3AFEFADC-BCC5-4367-B259-1F4164F8FB2B"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3B380E6-A0A2-495E-9596-D1BB480F7139">
    <ao:prefix>may be affected by the induction or inhibition of drug-metabolizing enzymes.  Cimetidine  </ao:prefix>
    <ao:exact>Cimetidine inhibits many cytochrome P450 (oxidative) enzymes. In a study where paroxetine (30 mg once daily) was dosed orally for 4 weeks, steady-state plasma concentrations of paroxetine were increased by approximately 50% during coadministration with oral cimetidine (300 mg three times daily) for the final week. Therefore, when these drugs are administered concurrently, dosage adjustment of paroxetine after the 20 mg starting dose should be guided by clinical effect. The effect of paroxetine on cimetidines pharmacokinetics was not studied.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F3B380E6-A0A2-495E-9596-D1BB480F7139"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-14 11:00:35 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B52ABF0A-47C0-458D-876F-D14942BDF286">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>mirtazapine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9d0124b64339431191a4e7c00e251fb5">
    <domeo:sets rdf:resource="urn:pddi:uuid:1039BA00-71C9-437E-A17F-D5BD526D0B58"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B94CA21-324F-4FD5-9C09-51793E04D748">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3B94CA21-324F-4FD5-9C09-51793E04D748"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>; any subsequent adjustment should be guided by clinical effect.  Phenytoin  </ao:prefix>
    <ao:exact>When a single oral 30 mg dose of paroxetine was administered at phenytoin steady state (300 mg once daily for 14 days), paroxetine AUC and T were reduced (by an average of 50% and 35%, respectively) compared to paroxetine administered alone. In a separate study, when a single oral 300 mg dose of phenytoin was administered at paroxetine steady state (30 mg once daily for 14 days), phenytoin AUC was slightly reduced (12% on average) compared to phenytoin administered alone. Since both drugs exhibit nonlinear pharmacokinetics, the above studies may not address the case where the 2 drugs are both being chronically dosed. No initial dosage adjustments are considered necessary when these drugs are coadministered; any subsequent adjustments should be guided by clinical effect (see ADVERSE REACTIONS: Postmarketing Reports).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-14 11:04:17 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4a04021bc8ef4b5aa69cf3cf5737dbc2">
    <domeo:sets rdf:resource="urn:pddi:uuid:8ED2A29D-3A2F-42D3-8D3B-6BD914065936"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N92629cea59bb4759806d7d6b965cd158">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/628C73B2-2620-4BC1-AA54-BDE1133DE537">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>sertraline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/62F445E6-CD27-4A77-9D0F-EBBCDB1EE9E5">
    <rdfs:label>fluoxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97D20613-ACA2-4122-9E8A-62810E745B08">
    <ao:prefix>) and decreased by concomitant administration with hepatic enzyme inducers (e.g., </ao:prefix>
    <ao:exact>barbiturates</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>97D20613-ACA2-4122-9E8A-62810E745B08</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c3ca69e6-1ea0-4c2c-abcb-7264b2e79a87.html</ao:hasSource>
    <ao:suffix>, </ao:suffix>
    <pav:createdOn>2015-09-30 12:40:33 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:97D20613-ACA2-4122-9E8A-62810E745B08"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:12DF3D2B-C272-47FD-8375-DF92D6588DDF">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:comment>Reduce TCA plasma levels</dikbD2R:comment>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BA3E44F7-5E41-42CE-BB2F-E0110DE96C1B"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5F185723-E6EF-4140-8D04-86779721BF6E">
    <dikbD2R:cl>Unk</dikbD2R:cl>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4930EBB3-3D03-4029-9517-6530523FAD61"/>
    <dikbD2R:aucDirection>Increase</dikbD2R:aucDirection>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <dikbD2R:cmaxType>UNK</dikbD2R:cmaxType>
    <dikbD2R:objectRegimens>Daily</dikbD2R:objectRegimens>
    <dikbD2R:t12Type>UNK</dikbD2R:t12Type>
    <dikbD2R:preciptDuration>Unk</dikbD2R:preciptDuration>
    <dikbD2R:aucType>Percent</dikbD2R:aucType>
    <dikbD2R:t12Direction>UNK</dikbD2R:t12Direction>
    <dikbD2R:cmax>Unk</dikbD2R:cmax>
    <dikbD2R:objectFormulation>tablet</dikbD2R:objectFormulation>
    <dikbD2R:t12>Unk</dikbD2R:t12>
    <dikbD2R:preciptFormulation>tablet</dikbD2R:preciptFormulation>
    <dikbD2R:cmaxDirection>UNK</dikbD2R:cmaxDirection>
    <dikbD2R:clType>UNK</dikbD2R:clType>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/40FF46B3-70F7-45A8-82AE-ED83632A18F8"/>
    <dikbD2R:preciptRegimens>BID</dikbD2R:preciptRegimens>
    <dikbD2R:objectDuration>Unk</dikbD2R:objectDuration>
    <dikbD2R:clDirection>UNK</dikbD2R:clDirection>
    <dikbD2R:numOfParticipants>12</dikbD2R:numOfParticipants>
    <dikbD2R:auc>50</dikbD2R:auc>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8E78D0B8-F0A9-4839-9685-C656C6D46C26">
    <dikbD2R:comment>Increase TCA plasma concentration</dikbD2R:comment>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8F4DE2DB-B2FA-480F-9386-47911CAD218D"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BACA411A-57BF-4DAA-A840-AE001F4F029B">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/77FD8774-B176-4E5B-A87B-ADDC76548A56"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/030EAAE2-16C8-48EA-9D9F-4438CD491120"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B78C3A5A-41DD-451B-A01B-895907B431C6">
    <ao:exact>TCA</ao:exact>
    <ao:suffix>s with any of the SSRIs. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from </ao:suffix>
    <domeo:uuid>B78C3A5A-41DD-451B-A01B-895907B431C6</domeo:uuid>
    <pav:createdOn>2015-10-01 10:27:38 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B78C3A5A-41DD-451B-A01B-895907B431C6"/>
    <ao:prefix> involved. Nevertheless, caution is indicated in the co-administration of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c66a11c1-3093-45ef-b348-3b196c05ba0c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8F4DE2DB-B2FA-480F-9386-47911CAD218D">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FF12F8C1-BC48-49A1-B32D-D9539B1A5BE9"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/887B6FD9-1A19-43E4-B4E8-6FA71FC202BD"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FB739724-7344-4810-BDFC-5B0A97A5F4BA">
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/117D065F-EB05-4E4F-BEFC-57F37CF5611D">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>propafenone</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8754</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7A6ED409-6373-4CB8-9789-8A728A13C5CF">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>20</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>temazepam</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:53835F6B-C832-443C-BC55-21D245D31C42">
    <ao:suffix>with </ao:suffix>
    <pav:createdOn>2015-09-29 09:44:24 -0400</pav:createdOn>
    <ao:prefix>with CMI increases plasma concentrations of CMI . Co-administration of </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>CMI </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:53835F6B-C832-443C-BC55-21D245D31C42"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/67910508-7CDE-4E07-AF24-4132328BEA61">
    <rdfs:label>digoxin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3407</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DEC969CC-2B9D-4652-8E5C-A90AB60063D5">
    <rdfs:label>Savella</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>100</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0E6D27D1-BB58-44E7-A985-E844B9108BFC">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <pav:createdOn>2015-10-20 10:18:39 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:94197DC2-E08A-4657-9AF3-3A137868DE30"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-20 10:19:28 -0400</pav:lastSavedOn>
    <pav:previousVersion>urn:domeoserver:annotationset:6B50E664-BD71-432E-B7FA-E7313EFF76E1</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A047300E-DCE0-4EA4-BBE4-81DA58D32E2D">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3407</dailymed:activeMoietyRxCUI>
    <rdfs:label>digoxin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E1411FBD-7BA8-4C1A-AD74-656CDDAE9450">
    <rdfs:label>hepatic enzyme inducers</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/70679951-CE00-4147-844B-B51229C326C6">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>clarithromycin</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3BCE2870-5D15-464D-9540-1F124B4548AB">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>EMSAM</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3EB5B0BD-9D35-4A8D-841B-4134C25EEC8D">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:7679B49A-D35E-4A97-9BB5-8E51FE97FA85"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-14 11:41:49 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:356EE5A3-8AD4-4E58-9F2E-3322D96D63DA">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CBE88E8B-BA5E-48D1-858D-E9D3F589421A"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C9877559-D342-4808-A74C-952B3EEC7DC5"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D9CBCC96-4A9B-4EE2-85E4-4D13991AF59F">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C2915845-B6D5-41CF-9AA1-083F459B7EB1">
    <ao:context rdf:resource="urn:domeoclient:uuid:1F6DA055-110E-4D41-9532-29387C6567CD"/>
    <pav:createdOn>2015-10-14 11:41:55 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D39AD412-5269-4737-9C8A-D705002B9E48">
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <ao:context rdf:resource="urn:domeoclient:uuid:1FFE02F7-0229-4945-8C92-7F816B8FE95F"/>
    <pav:createdOn>2015-10-14 11:40:18 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne85bc6278ff5488788452d54420a24fb">
    <domeo:sets rdf:resource="urn:pddi:uuid:2153A09C-668C-4682-AD1B-DCC2EACB7797"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7CF755C5-9CAC-44FE-840F-3DD0BB4B3260">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>ibuprofen</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F220C296-D1D9-4D82-932B-3F2E3AA73B32">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:B6FED040-B249-4D05-9B5E-3F9E803BE417"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7A335060-E227-435C-9FBA-3EEE27499713">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/AFEEA39C-D805-4CD9-8B57-D9547F6C801E"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A8E93953-0B7B-4984-90DD-EF7F2278F39D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6A0828EA-848D-489C-981C-06A04B2D9DB0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <ao:prefix>on BCRP and organic anion transporting polypeptide B1 and B3 (OATP1B1/1B3) substrates   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6A0828EA-848D-489C-981C-06A04B2D9DB0"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)]</ao:exact>
    <domeo:uuid>6A0828EA-848D-489C-981C-06A04B2D9DB0</domeo:uuid>
    <pav:createdOn>2015-08-20 12:48:10 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2E0F624B-1BE7-43A4-9ED7-25412422C615">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0D254072-7664-47FE-9C53-FD89886AF61C"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:71317DF3-7CAF-4895-8E25-163954DE9D62">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:DB76C2E5-8252-49A4-BFA1-4F1701011171"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B4202C0D-92E5-4602-874E-FAC955BFF448">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:02CF245D-EC65-40F4-9D8C-206EB92D5651"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc6d350d9011a4849b7d3b175508f1174">
    <domeo:sets rdf:resource="urn:pddi:uuid:151B7CA5-9C49-4293-A093-7744FE253510"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AC689554-C03A-4E24-ADC7-2A36E35E8454">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-14 12:08:04 -0400</pav:createdOn>
    <ao:exact>pimozide </ao:exact>
    <domeo:uuid>AC689554-C03A-4E24-ADC7-2A36E35E8454</domeo:uuid>
    <ao:prefix>60 mg resulted in a 151% increase in pimozide AUC and a 62% increase in </ao:prefix>
    <ao:suffix>C</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AC689554-C03A-4E24-ADC7-2A36E35E8454"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BD7B24E5-5A0E-4E40-9F53-E994B2428043">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>alosetron</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/85248</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:37F97FAF-61B1-48CB-84C5-589051D74CB9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>In a study where propranolol (80 mg twice daily) was dosed orally for 18 days, the established steady-state plasma concentrations of propranolol were unaltered during coadministration with paroxetine (30 mg once daily) for the final 10 days. The effects of propranolol on paroxetine have not been evaluated (see ADVERSE REACTIONS: Postmarketing Reports).</ao:exact>
    <pav:createdOn>2015-09-14 11:31:11 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:37F97FAF-61B1-48CB-84C5-589051D74CB9"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>should be reduced.  Beta-Blockers  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4B5DC0ED-67F7-4CE7-8F52-9E71B436F48C">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4B5DC0ED-67F7-4CE7-8F52-9E71B436F48C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>AUBAGIO on CYP1A2 substrates   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <pav:createdOn>2015-08-20 11:40:48 -0400</pav:createdOn>
    <ao:exact>Teriflunomide may be a weak inducer of CYP1A2 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP1A2 as required [see Clinical Pharmacology (12.3)].</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:63E97057-3323-429B-AC74-2866EDAF5AA9">
    <ao:prefix>hydroxylase) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:63E97057-3323-429B-AC74-2866EDAF5AA9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-29 09:24:40 -0400</pav:createdOn>
    <domeo:uuid>63E97057-3323-429B-AC74-2866EDAF5AA9</domeo:uuid>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EA32C547-8F7F-4528-A359-6BB8CBA78596">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>ethinylestradiol</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:a6683e4f-efa6-41ad-b752-0a7d5d07d2cb">
    <ao:prefix>          In a population analysis, the clearance rate for </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <ao:exact>teriflunomide</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix> is 23% less in females than in males.                      </ao:suffix>
    <pav:createdOn>2015-08-18 11:35:24 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:a6683e4f-efa6-41ad-b752-0a7d5d07d2cb"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4E97D24D-7496-42BD-899B-AA45DC8B7CC9">
    <ao:prefix>(e.g., </ao:prefix>
    <pav:createdOn>2015-10-14 11:40:47 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4E97D24D-7496-42BD-899B-AA45DC8B7CC9"/>
    <domeo:uuid>4E97D24D-7496-42BD-899B-AA45DC8B7CC9</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:exact>ciprofloxacin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>), haloperidol, oral hypoglycemic agents (sulfonylureas) levothyroxine, methadone, narcotic analgesics, progestins, quinine, tacrolimus theophylline, tricyclic antidepressants (e.g., amitriptyline, nortriptyline) and zidovudine. It may be necessary to ad</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:57b4dcfd-71d6-4b6b-9263-9e309570bb86">
    <ao:exact>duloxetine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-08-27 14:50:34 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:hasSource>
    <ao:suffix> dose appears in the urine as metabolites of duloxetine; abo</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> of the </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:57b4dcfd-71d6-4b6b-9263-9e309570bb86"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:702A8854-7BC5-430E-87FF-62B857C38A13">
    <pav:lineageUri>urn:domeoserver:annotation:35F0D310-6A0D-481E-95DC-9668004B3812</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N472a760b1b704e05972b1f159e4bc8ac"/>
    <pav:createdOn>2015-10-01 10:47:37 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:9D0406D5-79FA-4622-B9BC-962FFE2A50B9"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:8DC54EBE-B2A9-4AE7-A174-F0074ECE4050</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lastSavedOn>2015-10-01 10:49:57 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D7B35CE6-E8F3-4D41-AFF4-8D0B71C1EA9D">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>400</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>mirtazapine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F416F666-81A3-4F10-81DE-F6B6E34655AB">
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">12</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:F8A4A60F-D73B-49D9-B507-647F30F97129"/>
    <pav:previousVersion>urn:domeoserver:annotationset:6B50E664-BD71-432E-B7FA-E7313EFF76E1</pav:previousVersion>
    <pav:lastSavedOn>2015-10-20 10:19:28 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-20 10:17:47 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:172F8373-6543-4D18-B064-EBAD6491B449">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:277F51B2-4AD3-4BE4-9460-4E4FB0C3B86A"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C4DC6294-3B81-4921-9633-75583A1E42C5">
    <pav:createdOn>2015-09-10 14:44:45 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-09-10 15:01:13 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotation:2A28E11B-E045-4DBE-AF3B-D6A091F8C80A</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:CFAE29BC-FF25-428D-B782-0D804503CEE7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B57F40FB-83F6-4E9D-A5C6-0BEDE1CC6D92">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:CE1FA3D4-E8F4-4DC0-B989-6DC0656AB8AE"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:comment>DELETE</dikbD2R:comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FF895082-0B10-4D32-ABF2-77A3ABFE3D80">
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:context rdf:resource="urn:domeoclient:uuid:C8BE2022-72F9-4691-863A-1C67FE32A041"/>
    <pav:createdOn>2015-10-20 09:56:29 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="N507a6d45c5114087ab0df006d9a150b1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>urn:domeoserver:annotationset:659993FA-47A6-4170-A1F4-37E021B93D40</pav:previousVersion>
    <pav:lastSavedOn>2015-10-20 09:56:31 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D5B61AB4-5131-46A7-AC6F-A47FE2DAFDF7">
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoserver:annotationset:E9F13BFE-1A17-4FDF-99A7-13B89F697635">
    <rdfs:label>Default Set</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#AnnotationSet"/>
    <domeo:agents rdf:resource="urn:person:uuid:080e143043ef9cf90143f8ea240c0005"/>
    <domeo:agents rdf:resource="urn:domeo:software:id:Domeo-2.0alpha-040"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <ao:item rdf:resource="urn:domeoclient:uuid:66FF0DF3-C777-4A3D-971F-8E83B304FDCC"/>
    <pav:lineageUri>urn:domeoserver:annotationset:357321A7-5793-4DE5-BB38-BF5FA7A5D72C</pav:lineageUri>
    <domeo:deleted>false</domeo:deleted>
    <ao:item rdf:resource="urn:domeoclient:uuid:B26CD913-F144-4BFF-8967-7F740FF37133"/>
    <ao:annotatesResource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/Clopidogrel-1086a7b4-b89b-4bee-8120-5f752626c046.html</ao:annotatesResource>
    <dct:description>The default set is created automatically by Domeo when no other set is existing.</dct:description>
    <ao:item rdf:resource="urn:domeoclient:uuid:18CB9938-6266-493E-A282-DB819CD3E51A"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:633CA52C-A1B8-4DA1-936D-70D2F0106564"/>
    <pav:lastSavedOn>2014-02-19 12:41:40 -0500</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:item rdf:resource="urn:domeoclient:uuid:8B9CE845-DC5C-4C1A-B610-A49E5EABC515"/>
    <ao:item rdf:resource="urn:domeoclient:uuid:37DDEDB4-2423-46DF-880E-A2D411563078"/>
    <pav:previousVersion>urn:domeoserver:annotationset:47A2106C-5354-420D-9E05-D9E4F945B6D0</pav:previousVersion>
    <permissions:permissions rdf:nodeID="Nfe7262cda6a6466bbb2325569e923029"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2014-02-19 12:23:10 -0500</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6F803812-6959-41B2-ABE3-03310CF96EEB">
    <rdfs:label>clarithromycin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C5B78899-CFE3-472C-B57D-E64D78A48245">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:99F81799-FA1E-454E-8912-AF54614E5794"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/51D59424-383C-4008-AC25-65FDA87F2768">
    <rdfs:label>rosuvastatin</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1944F90F-7575-4ECA-A8EF-A70D96EA6057">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0E0AED6D-A358-46BB-B7DD-FFDDAEC30073"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/790BC479-B26F-4F08-A851-B17265810340"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8A9DD9CA-AD6B-41AA-9EB3-37DD8E6B1448">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C906081F-115B-4532-B6DB-49330D1E7159">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>milnacipran</rdfs:label>
    <dikbD2R:dose>50</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/77CB0730-59F7-4027-A81E-4B5C160CAA4B">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>CMI</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4955F310-1A47-4B4F-8110-8835D9A41A0D">
    <rdfs:label>colchicine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0ea41d88915d490aade5ba4096825879">
    <domeo:sets rdf:resource="urn:pddi:uuid:D4B0B3A5-C93F-4A95-98BB-819649B7497D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9D0406D5-79FA-4622-B9BC-962FFE2A50B9">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so-called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).  </ao:prefix>
    <domeo:uuid>9D0406D5-79FA-4622-B9BC-962FFE2A50B9</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9D0406D5-79FA-4622-B9BC-962FFE2A50B9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <pav:createdOn>2015-10-01 10:47:37 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F4CE75DE-435B-4BD2-BAB4-D4FBC5DD1286">
    <rdfs:label>levomilnacipran</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A2159AAA-99B0-4620-89AB-88E988542AD3">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0238857E-C0B0-435F-A609-C3760073ADB4"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7F71D02A-84F3-48F9-82AC-6317FBAB63B0"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C01F7ADD-2F57-4B50-8835-5CE1DF41F6AD">
    <rdfs:label>caffeine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/1886</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N82b2db7d810e437fab5859ee4db2e95f">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N56b18acc653446e9bd721d59d49de50a">
    <domeo:sets rdf:resource="urn:pddi:uuid:47BD9F20-D410-407C-907C-9E1251E71081"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A13D3801-36D7-4149-A012-C359E457F596">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9948AB52-A0F6-4592-9E56-14E7E74068CE">
    <rdfs:label>EMSAM</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7B448242-40AA-4BE3-BC6B-DD6ABF8F5FDB">
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-14 11:41:40 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:A412671E-469E-4847-B67C-FD0A8860D9A2"/>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:66ABB5E5-7E59-429A-A3CD-1D0F8266AA22">
    <ao:suffix>, nifedipine, verapamil), chloramphenicol, clarithromycin, corticosteroids, cyclosporine, cardiac glycoside preparations, clofibrate, oral or other systemic hormonal contraceptives, dapsone, diazepam, doxycycline, fluoroquinolones (e.g., ciprofloxacin), </ao:suffix>
    <domeo:uuid>66ABB5E5-7E59-429A-A3CD-1D0F8266AA22</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> (e.g., </ao:prefix>
    <ao:exact>diltiazem</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:66ABB5E5-7E59-429A-A3CD-1D0F8266AA22"/>
    <pav:createdOn>2015-10-14 11:40:28 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0C8A8CBC-D82D-4B57-90F2-3B6A5EAE5CBA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-13 12:06:09 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:07A327F1-0F1E-4614-8FE7-9CE140618CD2</pav:lineageUri>
    <pav:lastSavedOn>2015-10-13 12:06:23 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D14B1B36-8511-4465-9615-06E0A268F4C9"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:body rdf:nodeID="Nd295e3fb57864c72b0c1c1ba19558ac1"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E576AC12-1B3A-4ACC-A6EF-3F991AD36B57">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:06C60C4D-FF6C-4152-BA7D-6DDDE37671E0"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3135C6CA-7184-43E8-B660-771A5C984C77">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>GILENYA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7075CCC9-1A63-43E3-8BA3-C9050AAD5898">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In healthy, CYP2D6 extensive metabolizer patients (n=32), amitriptyline (75 mg daily), at steady state, did not cause relevant changes in the pharmacokinetics of steady state mirtazapine (30 mg daily); mirtazapine also did not cause relevant changes to the pharmacokinetics of amitriptyline.</ao:exact>
    <domeo:uuid>7075CCC9-1A63-43E3-8BA3-C9050AAD5898</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-25 10:42:31 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7075CCC9-1A63-43E3-8BA3-C9050AAD5898"/>
    <ao:prefix>  Amitriptyline  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:66EBEC3F-5FA6-40F3-AE9F-8F714C95AB68">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:71e36154-5414-4578-8341-237fb761a4ba</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:40DBE3FA-1806-43A1-A070-B9CFB893221F</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:C2DFE403-9A62-41B5-A780-CA8820026119"/>
    <pav:previousVersion>urn:domeoclient:uuid:a7f59b4d-3ada-4384-adb1-665a4a1743c8</pav:previousVersion>
    <pav:lastSavedOn>2015-09-03 15:42:22 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdOn>2015-09-03 15:40:01 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:fc1d9c11-3031-4808-8a0d-d822dcc8c05e">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-12 13:20:28 -0400</pav:createdOn>
    <ao:suffix> was 7 hours </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>nous doses of 6, 36, and 72 mg. The mean residence time of </ao:prefix>
    <ao:exact>saquinavir</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c00d1607-ac36-457b-a34b-75ad74f9cf0a.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:fc1d9c11-3031-4808-8a0d-d822dcc8c05e"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:52704A93-092F-4145-ADFC-C9DDB39BC2E0">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Repeated doses of teriflunomide decreased mean Cmax and AUC of caffeine by 18% and 55%, respectively, suggesting that teriflunomide may be a weak inducer of CYP1A2 in vivo.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-08-20 13:00:41 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>52704A93-092F-4145-ADFC-C9DDB39BC2E0</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <ao:prefix>Drug Interactions (7) ] .   CYP1A2 Substrates  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:52704A93-092F-4145-ADFC-C9DDB39BC2E0"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3AFEFADC-BCC5-4367-B259-1F4164F8FB2B">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>TCA</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/76463211-BEC6-4BF7-80D8-E889485548E8">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>EMSAM</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dikbD2R:dose>6</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/59C70A53-ECAE-4EDE-8CE8-1A4CE4A2CF8B">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B3CB5756-91BE-46FD-8A2F-18EB0E55096E">
    <ao:body rdf:nodeID="N7ab544a8311a4991a26d9bad63974630"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:56088436-63FD-438F-8741-AF502F09A53E"/>
    <pav:lineageUri>urn:domeoserver:annotation:D22ECCBA-72B2-4BA3-B4BA-E81EBEF7D0B1</pav:lineageUri>
    <pav:lastSavedOn>2015-10-14 11:57:06 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-14 11:54:42 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F40AC04D-7DAE-4958-B524-1B01C3E34506">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluvoxamine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>50</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:538E06C0-D3EE-4DD3-BE7D-E3BA133FC18E">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:71829FB0-93DE-41B8-8545-74963379E255"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-29 09:46:27 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotation:0E329ABF-6680-4FBB-A54E-E98B349EE900</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2323BFC3-8379-4C7A-8617-A93A9B3A33BE">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>protease inhibitor drugs</ao:exact>
    <ao:prefix> and </ao:prefix>
    <ao:suffix> (see CONTRAINDICATIONS).</ao:suffix>
    <pav:createdOn>2015-10-14 12:06:17 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2323BFC3-8379-4C7A-8617-A93A9B3A33BE"/>
    <domeo:uuid>2323BFC3-8379-4C7A-8617-A93A9B3A33BE</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FB8D4A98-F29A-423C-891A-788B00C52757">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>phenothiazines</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/0</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E34039C1-F715-482F-A942-0A1E1B944DB6">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E3E66202-09AD-48C3-BFA0-E00BD8C9C48F">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F0E70F31-8D78-4692-9F3C-9FB1477F226C"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd15e0f008d6248e896039a9b95a43715">
    <domeo:sets rdf:resource="urn:pddi:uuid:4608515E-EFDE-40EC-A3C5-637B96ADD28F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F3F5DBC3-EA59-4083-9F58-186A56D29143">
    <pav:createdOn>2015-09-29 09:44:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F3F5DBC3-EA59-4083-9F58-186A56D29143"/>
    <ao:exact>CMI </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>better and had significantly lower steady-state plasma concentrations, compared with subjects over 65 years of age. Children under 15 years of age had significantly lower plasma concentration/dose ratios, compared with adults. Plasma concentrations of CM</ao:suffix>
    <ao:prefix>). Younger subjects (18 to 40 years of age) tolerated </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:68710CB3-2621-4C81-8B39-86CF50BE9127">
    <ao:suffix> may be required. It is desirable to monitor TCA plasma levels whenever a TCA is going to be coadministered with another drug known to be an inhibitor of P450 2D6.</ao:suffix>
    <pav:createdOn>2015-09-29 08:59:27 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <domeo:uuid>68710CB3-2621-4C81-8B39-86CF50BE9127</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>tricyclic antidepressant</ao:exact>
    <ao:prefix> or the other drug. Furthermore, whenever one of these other drugs is withdrawn from cotherapy, an increased dose of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:68710CB3-2621-4C81-8B39-86CF50BE9127"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:32F5147E-4676-4CAC-951A-8B4BB95F96F4">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/33A27A6C-1E00-4665-A76F-16BD9ACE8082"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E9BFF3CB-C96C-405B-B94A-6A06395D24B2"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:03CF6241-C331-40D5-BC34-DB9E7915F464">
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <domeo:belongsToSet>urn:domeoserver:annotationset:710D2A05-EC79-4BFC-BC3E-436C7AC80BD5</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:27CDD1F9-58C1-4AE2-982C-582882E7AE76"/>
    <pav:createdOn>2015-08-20 10:29:57 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:A7C406B1-2E2F-44C6-8A9B-4DE62C0F95D1</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-08-20 10:29:59 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <ao:body rdf:nodeID="Naf0ffb03383246adb3167a43b6dc738b"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc82756b7f2ac4e68aa897bd4216a6461">
    <domeo:sets rdf:resource="urn:pddi:uuid:CC1E8980-8CD3-4995-B3AA-F252FF147351"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7F9CF7B8-2195-48E6-B19C-7A9F0E1EC342">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8070CCDE-FB1C-4EFF-BF7E-3FEA17B3EB0A"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na802d4991e9f4c43a8582d13da4a79b1">
    <domeo:sets rdf:resource="urn:pddi:uuid:EC6731E5-3BC9-4D46-9885-9EA2C74CB23B"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7A07B4CA-31C3-4C02-85CD-DE48739EC30C">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:08C8AB4C-4F4F-4616-B072-A9FEC9DDE7F8">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:C91289D7-45EC-44D1-A933-E79E770CFE71</pav:lineageUri>
    <pav:lastSavedOn>2015-10-14 12:07:40 -0400</pav:lastSavedOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:6C8BD137-AC6D-41F9-8440-594ADEBF162A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-14 12:06:28 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5A9E8858-8558-48B2-BFFB-0A0517EC153B">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluoxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/668924AB-96EF-4B98-80A9-29AFE755C7ED">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>EMSAM</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1F3F4371-FBB9-439C-AB77-55AA1CAF8655">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2CADD952-DDB0-48B5-B41F-CD6F96CDC186"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/178AEACD-1341-47E8-B148-E838EA4A19D2">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>14-OH clarithromycin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DC5C770C-A40B-4EE0-9B1C-5DEB06A5D3B2">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:32F5147E-4676-4CAC-951A-8B4BB95F96F4"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:51E0AB1D-2630-4365-A160-6B6184C2158C">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B79542B8-A1FC-4568-BFE5-E7A58198BFCC"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/62F445E6-CD27-4A77-9D0F-EBBCDB1EE9E5"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:34C21368-2A4D-43BE-A6BC-F2D131B07F2D">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5C322BE1-EE43-410D-AA68-801F3BF3F67D"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B97E743C-8DCF-4ADC-A9D7-9A3940861B8A"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/13F71DE0-2757-4052-A155-FCE0A8CB2936">
    <rdfs:label>clarithromycin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B0A8E9B5-6F46-4FA6-AD7B-5C9526B9DB21">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:exact>fluvoxamine</ao:exact>
    <domeo:uuid>B0A8E9B5-6F46-4FA6-AD7B-5C9526B9DB21</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-20 09:54:04 -0400</pav:createdOn>
    <ao:suffix>. The clearance of benzodiazepines metabolized by glucuronidation (e.g., lorazepam, oxazepam, temazepam) is unlikely to be affected by fluvoxamine. </ao:suffix>
    <ao:prefix>, etc.) should be used with caution because the clearance of these drugs is likely to be reduced by </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B0A8E9B5-6F46-4FA6-AD7B-5C9526B9DB21"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0DDCC14D-1691-4186-9766-064E8F5C0851">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0DDCC14D-1691-4186-9766-064E8F5C0851"/>
    <pav:createdOn>2015-08-20 11:44:53 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>on organic anion transporter 3 (OAT3) substrates   </ao:prefix>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:81101CB5-AABA-43BC-A7A7-CFCE0ED9C538">
    <ao:prefix>, </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-14 11:41:09 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <domeo:uuid>81101CB5-AABA-43BC-A7A7-CFCE0ED9C538</domeo:uuid>
    <ao:exact>nortriptyline</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>) and zidovudine. It may be necessary to adjust the dosages of these drugs if they are given concurrently with rifampin.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:81101CB5-AABA-43BC-A7A7-CFCE0ED9C538"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4c91f3fae62e46f98df763131b7c49f2">
    <domeo:sets rdf:resource="urn:pddi:uuid:18A635A9-C899-49F2-9EA4-19AD44838712"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne2bb17e9bca24080a1bc9763ddd9e9b4">
    <domeo:sets rdf:resource="urn:pddi:uuid:7C45F870-951A-49F5-9A73-F41F546A8D5E"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8E94CF5B-6E88-499B-A71A-8E750E941BF4">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>alprazolam</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5522FC9F-6AFE-4610-91FA-84A7249FF0B9">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>14-hydroxy-clarithromycin</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2153A09C-668C-4682-AD1B-DCC2EACB7797">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2BC44E2F-CADA-40E8-BC54-D80528AE0ECA"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3962E670-2F06-46D6-A0E5-063E8F06D917">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7C41DBCD-AA4C-4ED7-AF69-4530146C1BCF"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D4D62777-76E7-4FDA-83C4-0D64C053920E"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:911A21E8-D947-4D2F-B2C0-7F3B54676A6B">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/86F2CF71-06FA-4328-AEFA-C0D7D5193FA7"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6E116C9B-C1FA-4B60-97FB-F04CA639E7BA"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F1D8B81F-3833-47C8-89FA-EEBEF48441CC">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>rosuvastatin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3C3D5B64-6A65-4CBD-82E4-8EBB9BF0F6F0">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-14 11:41:17 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:C6F6583D-9C15-411E-A389-3E7455E515BA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/844AD8B0-49CB-4D7B-ACB8-BE504915481B">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BFABEC76-605B-4A5C-9A08-7BE8CDDE808B">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluvoxamine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1CE8369A-1BEC-46FC-BFDD-F90CB13F40B3">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:7C08FED6-33A1-4C10-865C-CCEAE36D672C"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23C921CE-AE9A-4E8B-9815-A9ABE1043C9D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <ao:suffix>      No relevant clinical eff</ao:suffix>
    <ao:prefix>  </ao:prefix>
    <pav:createdOn>2015-09-25 10:43:25 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Lithium</ao:exact>
    <domeo:uuid>23C921CE-AE9A-4E8B-9815-A9ABE1043C9D</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:23C921CE-AE9A-4E8B-9815-A9ABE1043C9D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3B7E6C06-0481-460E-9625-E6C11AD727AB">
    <pav:lastSavedOn>2015-09-24 15:38:09 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:DAD02F8C-D0CF-4D03-A113-8C242E8A7E4F</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:4CC0902C-9539-4E6A-8825-68769AED696A</pav:lineageUri>
    <pav:createdOn>2015-09-24 15:32:02 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:5A2106C1-9FB8-4E59-BCA1-1E2909B77C1B"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4F2A9C24-89DE-431D-B9A0-9DB593BD82C5">
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-20 09:56:57 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:C0B10178-37CF-42CE-A06A-8A0898C76D4F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:439B2109-3D9C-4904-9DF7-41D812AC5AC7">
    <ao:exact>Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].</ao:exact>
    <domeo:uuid>439B2109-3D9C-4904-9DF7-41D812AC5AC7</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>on BCRP and organic anion transporting polypeptide B1 and B3 (OATP1B1/1B3) substrates   </ao:prefix>
    <pav:createdOn>2015-08-20 12:47:40 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:439B2109-3D9C-4904-9DF7-41D812AC5AC7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D2922D3F-3CFA-4786-B2D2-F1EDB6C89271">
    <ao:exact>Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>on BCRP and organic anion transporting polypeptide B1 and B3 (OATP1B1/1B3) substrates   </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-08-20 12:47:54 -0400</pav:createdOn>
    <domeo:uuid>D2922D3F-3CFA-4786-B2D2-F1EDB6C89271</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D2922D3F-3CFA-4786-B2D2-F1EDB6C89271"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B09769E1-4079-4AD7-8C38-999FD9B34833">
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:622DD637-8168-499D-8D4A-1980552D5F2A</pav:lineageUri>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-10-09 13:32:08 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-09-16 15:28:36 -0400</pav:createdOn>
    <ao:body rdf:nodeID="Nbca81144016e428985fd093cdeb4c421"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0468AC6B-4F06-4CA4-A0DE-A389E3B0E59F</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:C264D646-7C64-4346-92EA-657FF860711E"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AE0DD04E-5F6C-4F42-A871-E61AF88ED79B">
    <ao:suffix>(600 mg/day for 10 days) at steady state and a single 30-mg dose of </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/010f9162-9f7f-4b6d-a6e4-4f832f26f38e.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-25 10:43:28 -0400</pav:createdOn>
    <ao:prefix>No relevant clinical effects or significant changes in pharmacokinetics have been observed in healthy male subjects on concurrent treatment with subtherapeutic levels of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>AE0DD04E-5F6C-4F42-A871-E61AF88ED79B</domeo:uuid>
    <ao:exact>lithium </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:AE0DD04E-5F6C-4F42-A871-E61AF88ED79B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E4A17105-DC85-42EE-858F-047500667634">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:80C8EF97-2A80-46BF-BFA4-46DA997B10CB"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:comment>Increased plasma concentration of phenobarbital</dikbD2R:comment>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:A26A390E-AB65-462C-81C3-438BDBA41B70">
    <rdfs:label>None</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#none</poc:PharmacodynamicImpact>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>none.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CE393762-B4C3-4ED9-AC81-0E79CAD266FD">
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:18A635A9-C899-49F2-9EA4-19AD44838712">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A72BD722-4ABC-4E15-8572-3DEEEBD77214"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FCA82051-9E94-4750-8F5F-03AFC2261654">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B1621457-B01E-48A0-A14A-156EBD1B8786"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B0BC9D66-9909-49A4-B565-1CA4A5CCFF6B"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/02C6A4C3-181E-469F-8BC8-C562E075204E">
    <rdfs:label>TCA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:36705A85-66C6-4A44-95B1-23CFC807CAC6">
    <ao:prefix>, </ao:prefix>
    <ao:exact>clarithromycin</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-14 11:40:32 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:36705A85-66C6-4A44-95B1-23CFC807CAC6"/>
    <ao:suffix>, corticosteroids, cyclosporine, cardiac glycoside preparations, clofibrate, oral or other systemic hormonal contraceptives, dapsone, diazepam, doxycycline, fluoroquinolones (e.g., ciprofloxacin), haloperidol, oral hypoglycemic agents (sulfonylureas) lev</ao:suffix>
    <domeo:uuid>36705A85-66C6-4A44-95B1-23CFC807CAC6</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/761B93B7-4499-4FEC-9288-AE7AB258656A">
    <rdfs:label>fluvoxamine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2FB934B1-2DF6-465A-B442-CEC008ABBBFB">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:552412E5-F74C-439C-82B7-DF5A550A2778"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:29C9F4E5-4A2A-4693-AF94-46A5CC1A21D0">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:0DAF5666-9E53-42D5-B92E-DE2C00764986</pav:previousVersion>
    <ao:body rdf:nodeID="Na802d4991e9f4c43a8582d13da4a79b1"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:CBD3826C-96BE-496D-94F7-B5EAD1383423"/>
    <rdfs:label>ddi Annotation</rdfs:label>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-10-16 10:55:51 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-10 14:48:45 -0400</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5FEFDED8-D960-4190-87B0-F4EFBAB2463A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <pav:createdOn>2015-10-14 11:54:29 -0400</pav:createdOn>
    <domeo:uuid>5FEFDED8-D960-4190-87B0-F4EFBAB2463A</domeo:uuid>
    <ao:exact>Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See CONTRAINDICATIONS.) </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>with drugs that undergo biotransformation through these metabolic pathways may accelerate elimination of coadministered drugs. To maintain optimum therapeutic blood levels, dosages of drugs metabolized by these enzymes may require adjustment when starting or stopping concomitantly administered rifampin.  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5FEFDED8-D960-4190-87B0-F4EFBAB2463A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:00D52F79-36F4-4CE9-B2F3-9F7D012B88E5">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:CDEFF0EB-79DD-493B-A381-6343E24BCF9C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:80C8EF97-2A80-46BF-BFA4-46DA997B10CB">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/39E54E44-CA4A-4506-890C-C71468CB0071"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/54678AA6-BFB7-48C6-8897-15C79F6F0476"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1DD7B543-078B-4F0E-8C2B-7D10EF933612">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4EB2A056-F504-40BD-A358-6042884B62DA"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:89BEEE9E-FD9A-463B-9C3B-DF66ABFD0923">
    <domeo:uuid>89BEEE9E-FD9A-463B-9C3B-DF66ABFD0923</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:40:27 -0400</pav:createdOn>
    <ao:suffix> (e.g., diltiazem, nifedipine, verapamil), chloramphenicol, clarithromycin, corticosteroids, cyclosporine, cardiac glycoside preparations, clofibrate, oral or other systemic hormonal contraceptives, dapsone, diazepam, doxycycline, fluoroquinolones (e.g.,</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:89BEEE9E-FD9A-463B-9C3B-DF66ABFD0923"/>
    <ao:prefix>, </ao:prefix>
    <ao:exact>calcium channel blockers</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/41B61282-12A0-4568-8B59-D93188A41363">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>quinidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9068</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EE25ADE9-3E14-4953-AF7B-200DFF38B286">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:AA119F40-3DF5-414B-A9BA-D5DA54DF8259"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfff1808984d9417a8639d4c00ac5e6a5">
    <domeo:sets rdf:resource="urn:pddi:uuid:B91C9D9B-7F7A-45C2-B412-779E4ED0B89F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9861DC11-56A0-4E77-9F46-AB7EBF4F623E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-16 10:52:42 -0400</pav:createdOn>
    <ao:exact>Approximately 7% of the normal population has a genetic code that leads to reduced levels of activity of CYP2D6. Such individuals have been referred to as poor metabolizers (PM) of drugs such as debrisoquin, dextromethorphan, and tricyclic antidepressants. While none of the drugs studied for drug interactions significantly affected the pharmacokinetics of fluvoxamine, an in vivo study of fluvoxamine single-dose pharmacokinetics in 13 PM subjects demonstrated altered pharmacokinetic properties compared to 16 extensive metabolizers (EM): mean Cmax, AUC, and half-life were increased by 52%, 200%, and 62%, respectively, in the PM compared to the EM group. This suggests that fluvoxamine is metabolized, at least in part, by CYP2D6. Caution is indicated in patients known to have reduced levels of CYP2D6 activity and those receiving concomitant drugs known to inhibit this cytochrome P450 isoenzyme (e.g., quinidine).</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9861DC11-56A0-4E77-9F46-AB7EBF4F623E"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>is a relatively weak inhibitor of CYP2D6.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/AD400125-E032-4FB8-AEF2-3E88944E5B79">
    <rdfs:label>GILENYA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/673EE000-8A6B-4E34-B918-C8977C061DE0">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>AUBAGIO</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7D9785A9-6383-44E5-8DB7-0E1C0D3A7283">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1D6FB298-54BE-445A-852F-BC90F8821EF0"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F85DC19C-09D0-4BD1-B3A7-5DBCFBCE72AD">
    <pav:lineageUri>urn:domeoserver:annotation:D8E194CA-B4FD-4C3B-94DB-550B2F0DEFD0</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <pav:createdOn>2015-10-14 12:09:47 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:83F941D4-E688-4E2C-8F5D-9129F179A240"/>
    <pav:lastSavedOn>2015-10-14 12:10:56 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B0ECD02E-F340-495E-8CF5-6F1F8786A602">
    <pav:lineageUri>urn:domeoserver:annotationset:C91289D7-45EC-44D1-A933-E79E770CFE71</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:E92268FB-0334-40ED-88C2-3C9DA7E99028"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-14 12:06:20 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-14 12:07:40 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BD9CF53E-3C56-43E2-97D4-04E1EB146127">
    <ao:prefix>, </ao:prefix>
    <pav:createdOn>2015-10-14 11:40:14 -0400</pav:createdOn>
    <ao:exact>mexiletine</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:suffix>, quinidine, tocainide), oral anticoagulants, antifungals (e.g., fluconazole, itraconazole, ketoconazole), barbiturates, beta-blockers, calcium channel blockers (e.g., diltiazem, nifedipine, verapamil), chloramphenicol, clarithromycin, corticosteroids, c</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>BD9CF53E-3C56-43E2-97D4-04E1EB146127</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BD9CF53E-3C56-43E2-97D4-04E1EB146127"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:93418194-554C-4709-AEFD-4DD3FAF682A7">
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so-called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).  </ao:prefix>
    <domeo:uuid>93418194-554C-4709-AEFD-4DD3FAF682A7</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-01 10:47:08 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:93418194-554C-4709-AEFD-4DD3FAF682A7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AED9E760-9BFE-446A-9218-8F3850610388">
    <pav:lastSavedOn>2015-09-30 12:41:52 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-30 12:41:42 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N683a9b09a9b149bcb25a0733a3e15ab1"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6F5C24D1-EA99-48CF-B498-A0D89C02B290</domeo:belongsToSet>
    <ao:context rdf:resource="urn:domeoclient:uuid:9B40C1CD-AF57-4FD1-BED1-66F8053F15DF"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotation:799611E8-4316-46E8-A62C-78FFBACE380F</pav:lineageUri>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/1C466545-9969-4647-BA61-B32FAD73D045">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>flecainide</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4441</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N14f9f47d66494a448e928fea2b6c71a4">
    <domeo:sets rdf:resource="urn:pddi:uuid:7DCEBA9E-178D-4402-AE75-34205645FFE2"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncbe4c4c7cc8544d4ab766138652e0ac4">
    <domeo:sets rdf:resource="urn:pddi:uuid:62506EF3-9D76-4B58-90B6-F9B7468545D2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:740F436B-0D0C-4C9D-A54C-E2CB8268CFF1">
    <ao:prefix>and CYP3A4 substrates (Figure 2).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>740F436B-0D0C-4C9D-A54C-E2CB8268CFF1</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Clinical studies have shown that desvenlafaxine (100 mg daily) does not have a clinically relevant effect on tamoxifen and aripiprazole, compounds that are metabolized by a combination of both CYP2D6 and CYP3A4 enzymes (Figure 2).</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:740F436B-0D0C-4C9D-A54C-E2CB8268CFF1"/>
    <pav:createdOn>2015-09-24 15:28:23 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F8C460B6-A830-41FF-BB18-F647DD001A02">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>clarithromycin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3cfe156636f3438cb8d0ae98a70e2d08">
    <domeo:sets rdf:resource="urn:pddi:uuid:1E4E7955-794B-4F58-8836-AA2107BBA675"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:39368375-C994-4FD6-8A23-3C959B1AE025">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:600FA2BB-9EC6-4B60-A978-AA928A80FEF5"/>
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-09-29 08:58:56 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:DA269A9E-1621-4067-816E-56E416DB97D0</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6F48A090-E4BB-49EA-BD4B-621FCACB423E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:BD68DA44-7F86-4048-99B9-16558FF32E07"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-20 09:56:55 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F024E7A6-2941-478E-B52D-5C30CA60FCE6">
    <pav:createdOn>2015-10-16 10:59:03 -0400</pav:createdOn>
    <ao:exact>Elevated carbamazepine levels and symptoms of toxicity have been reported with the coadministration of fluvoxamine maleate and carbamazepine. </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:prefix>    Carbamazepine   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:F024E7A6-2941-478E-B52D-5C30CA60FCE6"/>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6C3D8967-44BA-4108-AFBB-CF1B7B82A16F">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:704B3892-EB73-430B-BBF8-9AF87186D376"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6076c4a8137d44f0aaea6178dfc14188">
    <domeo:sets rdf:resource="urn:pddi:uuid:15FEFE05-3C55-48D9-896D-1D0CCBE9FB9E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4ADCCB67-AA24-4C5E-A116-A1A8EDA0C259">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>on organic anion transporter 3 (OAT3) substrates   </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-08-20 11:45:24 -0400</pav:createdOn>
    <ao:exact>Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4ADCCB67-AA24-4C5E-A116-A1A8EDA0C259"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5DC9BCDE-EDCD-4F10-A071-050134EF1449">
    <rdfs:label>EMSAM</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:160855D9-B2DC-4D5C-84F9-D3F0F4046EEE">
    <domeo:uuid>160855D9-B2DC-4D5C-84F9-D3F0F4046EEE</domeo:uuid>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the coadministration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <pav:createdOn>2015-09-29 09:03:52 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:160855D9-B2DC-4D5C-84F9-D3F0F4046EEE"/>
    <ao:prefix>s) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA ).  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:84DFF0F1-308C-49E0-9779-B1A53D49590C">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:587D1E52-C317-475F-8553-B0F5340F9437"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:15FEFE05-3C55-48D9-896D-1D0CCBE9FB9E">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BE9C0041-BC8D-43A3-994A-A07CF600971A"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:53307188-612A-4951-85F8-934C7D0352EC">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D9CBCC96-4A9B-4EE2-85E4-4D13991AF59F"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EF054D06-109D-487A-96EB-1DD52DCD6AD0"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1D5515B8-366D-4B1E-9626-0B9C6E83246F">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>AUBAGIO may increase the systemic exposures of ethinylestradiol and levonorgestrel. Consideration should be given to the type or dose of contraceptives used in combination with AUBAGIO [see Clinical Pharmacology (12.3)].</ao:exact>
    <pav:createdOn>2015-08-20 11:38:01 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1D5515B8-366D-4B1E-9626-0B9C6E83246F"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <ao:prefix>AUBAGIO on oral contraceptives   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/66B73E5C-5979-4966-8079-A2F5CA13ADF5">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>ketoconazole</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7D1823C4-97DD-4615-A703-A22221EE4B5E">
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:createdOn>2015-08-20 11:37:19 -0400</pav:createdOn>
    <ao:body rdf:nodeID="Ne2fab5ce8b3f4596bfa25e1e5a87fea9"/>
    <pav:previousVersion>urn:domeoclient:uuid:7d2027ff-e85b-46f3-befa-3f8f5cf7e88f</pav:previousVersion>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:9C8684F9-A126-455C-B66F-EB4598A5F120"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lastSavedOn>2015-08-20 11:38:24 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N78e90197bf524297b354678097a1d99d">
    <domeo:sets rdf:resource="urn:pddi:uuid:E9E731BC-5E28-4A8A-8D61-8F51D24308C2"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/44BF1E7D-5B5C-4EE2-82A4-C7F3283EABA1">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>propafenone</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8754</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1E80309A-5BCC-4DD4-8CFF-B1EFB59AF65E">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <ao:suffix> (e.g., </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>hepatic enzyme inducers</ao:exact>
    <ao:prefix>) and decreased by the concomitant administration of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1E80309A-5BCC-4DD4-8CFF-B1EFB59AF65E"/>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-09-29 09:57:35 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:56088436-63FD-438F-8741-AF502F09A53E">
    <domeo:uuid>56088436-63FD-438F-8741-AF502F09A53E</domeo:uuid>
    <ao:prefix>with drugs that undergo biotransformation through these metabolic pathways may accelerate elimination of coadministered drugs. To maintain optimum therapeutic blood levels, dosages of drugs metabolized by these enzymes may require adjustment when starting or stopping concomitantly administered rifampin.  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Rifampin has been reported to substantially decrease the plasma concentrations of the following antiviral drugs: atazanavir, darunavir, fosamprenavir, saquinavir, and tipranavir. These antiviral drugs must not be co-administered with rifampin. (See CONTRAINDICATIONS.) </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:56088436-63FD-438F-8741-AF502F09A53E"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-14 11:54:42 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DA322BDB-92B7-4631-8DCB-DC725BBAC9ED">
    <ao:exact>Teriflunomide did not affect the pharmacokinetics of bupropion (a CYP2B6 substrate), midazolam (a CYP3A4 substrate), S-warfarin (a CYP2C9 substrate), omeprazole (a CYP2C19 substrate), and metoprolol (a CYP2D6 substrate).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>DA322BDB-92B7-4631-8DCB-DC725BBAC9ED</domeo:uuid>
    <pav:createdOn>2015-08-20 13:06:08 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>[see Drug Interactions (7) ] .  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DA322BDB-92B7-4631-8DCB-DC725BBAC9ED"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DBBE404A-7D3A-4CA2-9EA1-F8E8E9BD41C9">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, triazolam, etc.) should be used with caution because the clearance of these drugs is likely to be reduced by fluvoxamine. The clearance of benzodiazepines metabolized by glucuronidation (e.g., lorazepam, oxazepam, temazepam) is unlikely to be affected </ao:suffix>
    <pav:createdOn>2015-10-20 09:54:01 -0400</pav:createdOn>
    <ao:prefix>, </ao:prefix>
    <domeo:uuid>DBBE404A-7D3A-4CA2-9EA1-F8E8E9BD41C9</domeo:uuid>
    <ao:exact>midazolam</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DBBE404A-7D3A-4CA2-9EA1-F8E8E9BD41C9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6652f01ba6d046168ba936467087ff17">
    <domeo:sets rdf:resource="urn:pddi:uuid:BF807C1C-F7D1-4CFA-9875-6A7C6630DD4F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:550727B8-CA74-41DC-AB41-81D12CB47BD0">
    <ao:prefix>   Diazepam  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <domeo:uuid>550727B8-CA74-41DC-AB41-81D12CB47BD0</domeo:uuid>
    <ao:exact>The coadministration of fluvoxamine maleate tablets and diazepam is generally not advisable. Because fluvoxamine reduces the clearance of both diazepam and its active metabolite, N-desmethyldiazepam, there is a strong likelihood of substantial accumulation of both species during chronic coadministration.    Evidence supporting the conclusion that it is inadvisable to coadminister fluvoxamine and diazepam is derived from a study in which healthy volunteers taking 150 mg/day of fluvoxamine were administered a single oral dose of 10 mg of diazepam. In these subjects (N = 8), the clearance of diazepam was reduced by 65% and that of N-desmethyldiazepam to a level that was too low to measure over the course of the 2 week long study.    It is likely that this experience significantly underestimates the degree of accumulation that might occur with repeated diazepam administration. Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses.    Accordingly, diazepam and fluvoxamine should not ordinarily be coadministered. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:550727B8-CA74-41DC-AB41-81D12CB47BD0"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-20 10:10:31 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1CD5ECF1-16A3-4A48-91CD-C57508FC1162">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:821C0209-1F80-4A54-BC99-9AAA00055E98"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5E508224-86F3-41FE-8BD5-64E8A8463CAD">
    <rdfs:label>teriflunomide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:DC4A9FC2-1018-4E06-8B45-3BBBB5D59DE7">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>risperdione</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-09-03 15:39:59 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, </ao:suffix>
    <ao:prefix>ibuprofen , levothyroxine , olanzapine , </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:DC4A9FC2-1018-4E06-8B45-3BBBB5D59DE7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:FE761BDC-F49F-4756-8D07-F41A55DC5220">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:B824E163-D969-4C79-B059-3656EF961DBA"/>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <pav:createdOn>2015-10-14 11:41:28 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4B2E61CE-7D88-4E5A-A24F-DDB39B423856">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>(50 mg b.i.d. for 7 days) on the single dose pharmacokinetics of </ao:prefix>
    <ao:exact>mexiletine </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <pav:createdOn>2015-10-20 10:18:41 -0400</pav:createdOn>
    <domeo:uuid>4B2E61CE-7D88-4E5A-A24F-DDB39B423856</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>(200 mg) was evaluated in six healthy Japanese males. The clearance of mexiletine was reduced by 38% following coadministration with fluvoxamine compared to mexiletine alone. If fluvoxamine and mexiletine are coadministered, serum mexiletine levels shoul</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4B2E61CE-7D88-4E5A-A24F-DDB39B423856"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AC99C46C-859B-46C2-AE16-9C1D260E1BDC">
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:659993FA-47A6-4170-A1F4-37E021B93D40</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <ao:context rdf:resource="urn:domeoclient:uuid:B0A8E9B5-6F46-4FA6-AD7B-5C9526B9DB21"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdOn>2015-10-20 09:54:04 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:lastSavedOn>2015-10-20 09:56:31 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbe8b1a59a50747a4971bfdf0f3eb4482">
    <domeo:sets rdf:resource="urn:pddi:uuid:380833A1-5A1B-4EC8-A274-887D3F90E3DE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:F429D0CF-A31E-4429-8092-5584CF47A264">
    <ao:context rdf:resource="urn:domeoclient:uuid:DBBE404A-7D3A-4CA2-9EA1-F8E8E9BD41C9"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:659993FA-47A6-4170-A1F4-37E021B93D40</pav:previousVersion>
    <pav:lastSavedOn>2015-10-20 09:56:31 -0400</pav:lastSavedOn>
    <pav:createdOn>2015-10-20 09:54:01 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8F9227EB-64B6-48B6-9996-6D860AB88B63">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>100</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluoxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D62F7837-84F3-40D9-B4C6-C37715C61B6A">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:76B0AB90-74E8-4301-9405-FD66E7216D08"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/1C17697D-A00B-4699-9B4E-956A463E764D">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>levothyroxine</rdfs:label>
    <dikbD2R:dose>0.15</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B0BC9D66-9909-49A4-B565-1CA4A5CCFF6B">
    <rdfs:label>fluoxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4493</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3CAAD5EA-82E3-473E-89AE-2DCD5CEF403B">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdfs:label>paroxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BD81BD31-90E5-4609-93C7-7E22524EEC3E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix> (</ao:suffix>
    <domeo:uuid>BD81BD31-90E5-4609-93C7-7E22524EEC3E</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <ao:exact>selective serotonin reuptake inhibitors</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BD81BD31-90E5-4609-93C7-7E22524EEC3E"/>
    <ao:prefix>). While all the </ao:prefix>
    <pav:createdOn>2015-09-29 09:00:38 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5fcf5887708c4c10ae00f8ef21237ab1">
    <domeo:sets rdf:resource="urn:pddi:uuid:2C2CF26D-06E9-49D5-9141-8C8D332BC314"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:841A93FF-C9A7-4ED4-9B08-BBB942ED30A4">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-16 15:26:50 -0400</pav:createdOn>
    <ao:exact>Drugs Metabolized by P450 3A4In three separate in vivo interaction studies, sertraline was co-administered with cytochrome P450 3A4 substrates, terfenadine, carbamazepine, or cisapride under steady-state conditions. The results of these studies indicated that sertraline did not increase plasma concentrations of terfenadine, carbamazepine, or cisapride. These data indicate that sertralines extent of inhibition of P450 3A4 activity is not likely to be of clinical significance. Results of the interaction study with cisapride indicate that sertraline 200 mg (q.d.) induces the metabolism of cisapride (cisapride AUC and Cmax were reduced by about 35%).</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:841A93FF-C9A7-4ED4-9B08-BBB942ED30A4"/>
    <ao:prefix>CONTRAINDICATIONS, WARNINGS, andDOSAGE AND ADMINISTRATION .   </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:1135EFA3-67D9-4B8E-B010-CD51438236F7">
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <dct:description>none.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>None</rdfs:label>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#none</poc:PharmacodynamicImpact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CB5CD621-E9E3-4987-B430-DAD1C01273E1">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:7102B134-6D68-4372-BF73-14FF38765EEA</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:56ABE48E-674F-4C83-AF35-5A83F88C35E9"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-09-29 11:18:37 -0400</pav:createdOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2EEED366-8AEC-4F5F-9D3C-F9C491200753">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluvoxamine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0BAD7033-27BD-4FC8-BB76-051526757B61">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B2DA9535-7AB8-4F96-83AC-D65C091E22F1"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/519C269B-F197-4169-9CC0-1BC57D07146D"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/AB94710B-440E-41E2-9FD0-6A5EBBC5576C">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>abiraterone acetate</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B01BB01D-87CB-4E43-B8BE-582A25B5B6D6">
    <rdfs:label>TCA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0C1A8FF1-1DFF-4A4B-9B20-10F8039A048B">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:9EA2AE2B-0305-4AD7-B154-4BFC69BFA513"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7E62BBC1-074D-4EF0-8E18-207BD15D07C8">
    <pav:createdOn>2015-10-13 12:03:01 -0400</pav:createdOn>
    <ao:prefix>dosage should be considered. (See Viagra package insert .)  </ao:prefix>
    <ao:exact>There have been spontaneous or published reports of CYP3A based interactions of erythromycin and/or clarithromycin with cyclosporine, carbamazepine, tacrolimus, alfentanil, disopyramide, rifabutin, quinidine, methylprednisolone, cilostazol, and bromocriptine.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>7E62BBC1-074D-4EF0-8E18-207BD15D07C8</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7E62BBC1-074D-4EF0-8E18-207BD15D07C8"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:19699AED-4CE3-4185-BFE9-311A3FD87753">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>14-OH clarithromycin</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:suffix>.</ao:suffix>
    <ao:prefix> AUC and a 100% decrease in the AUC of </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:19699AED-4CE3-4185-BFE9-311A3FD87753"/>
    <domeo:uuid>19699AED-4CE3-4185-BFE9-311A3FD87753</domeo:uuid>
    <pav:createdOn>2015-10-13 11:54:56 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3774f0c52ae44c3892768487ed9b6b3e">
    <domeo:sets rdf:resource="urn:pddi:uuid:778D6A47-413C-47A1-8778-A751B97ABDC2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3002A6AB-D0C6-4851-8086-5F1EA0F6A084">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>AUBAGIO on CYP1A2 substrates   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3002A6AB-D0C6-4851-8086-5F1EA0F6A084"/>
    <pav:createdOn>2015-08-20 11:41:14 -0400</pav:createdOn>
    <ao:exact>Teriflunomide may be a weak inducer of CYP1A2 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP1A2 as required [see Clinical Pharmacology (12.3)]</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5AEFC4D4-5364-48F0-969E-09164EA86C60">
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F4C72415-4D8C-49A5-9EA5-4D620EDEDC0F">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A5922FD4-A159-4019-89E2-289342604349"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4930EBB3-3D03-4029-9517-6530523FAD61">
    <rdfs:label>mirtazapine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>800</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A5FABFA9-8E2F-49A9-ABBC-32FC70990532">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>phenothiazines</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/0</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4C8F7669-6070-492F-8BF7-54DFF7BD7341">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4C8F7669-6070-492F-8BF7-54DFF7BD7341"/>
    <ao:prefix>7.3 Dual Inhibition of CYP1A2 and CYP2D6   </ao:prefix>
    <domeo:uuid>4C8F7669-6070-492F-8BF7-54DFF7BD7341</domeo:uuid>
    <ao:exact>Concomitant administration of duloxetine 40 mg twice daily with fluvoxamine 100 mg, a potent CYP1A2 inhibitor, to CYP2D6 poor metabolizer subjects (n=14) resulted in a 6-fold increase in duloxetine AUC and Cmax.</ao:exact>
    <pav:createdOn>2015-09-24 15:48:28 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5E769D5F-ECB6-4930-8D97-608D7807119C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-08-20 11:44:17 -0400</pav:createdOn>
    <ao:prefix>on organic anion transporter 3 (OAT3) substrates   </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5E769D5F-ECB6-4930-8D97-608D7807119C"/>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Teriflunomide inhibits the activity of OAT3 in vivo. In patients taking AUBAGIO, exposure of drugs which are OAT3 substrates (e.g., cefaclor, cimetidine, ciprofloxacin, penicillin G, ketoprofen, furosemide, methotrexate, zidovudine) may be increased. Monitor these patients and adjust the dose of the concomitant drug(s) which are OAT3 substrates as required [see Clinical Pharmacology (12.3)].</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:449680C4-EDC0-497D-8F7B-7F0CDE1A79C7">
    <domeo:uuid>449680C4-EDC0-497D-8F7B-7F0CDE1A79C7</domeo:uuid>
    <pav:createdOn>2015-09-24 15:53:57 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/829a4f51-c882-4b64-81f3-abfb03a52ebe.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>7.9 Drugs Metabolized by CYP2D6   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Duloxetine is a moderate inhibitor of CYP2D6. When duloxetine was administered (at a dose of 60 mg twice daily) in conjunction with a single 50 mg dose of desipramine, a CYP2D6 substrate, the AUC of desipramine increased 3-fold [see WARNINGS AND PRECAUTIONS (5.12)]. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:449680C4-EDC0-497D-8F7B-7F0CDE1A79C7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C79E0778-23A4-4684-B599-182D4BA0B6F3">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5d103551-978f-472a-9c62-51e6e4dea068.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Due to its effects on gastric acid secretion, rabeprazole can reduce the absorption of drugs where gastric pH is an important determinant of their bioavailability. Like with other drugs that decrease the intragastric acidity, the absorption of drugs such as ketoconazole, atazanavir, iron salts, erlotinib, and mycophenolate mofetil (MMF) can decrease, while the absorption of drugs such as digoxin can increase during treatment with ACIPHEX.  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C79E0778-23A4-4684-B599-182D4BA0B6F3"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>Concomitant treatment with rabeprazole (20 mg daily) and ketoconazole in healthy subjects decreased the bioavailability of ketoconazole by 30% and increased the AUC and Cmax for digoxin by 19% and 29%, respectively. Therefore, patients may need to be monitored when such drugs are taken concomitantly with rabeprazole. Co-administration of rabeprazole and antacids produced no clinically relevant changes in plasma rabeprazole concentrations.</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>C79E0778-23A4-4684-B599-182D4BA0B6F3</domeo:uuid>
    <pav:createdOn>2015-10-09 13:38:39 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:bae50ce2-5965-493d-becf-e26e57748704">
    <ao:exact>Aspirin</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <ao:suffix>, Warfarin, etc.</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <pav:createdOn>2015-08-27 14:50:28 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:bae50ce2-5965-493d-becf-e26e57748704"/>
    <ao:prefix>Non-selective NSAIDs, </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BEC10150-F68D-44FD-A3BA-397D82FE20D7">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1CE9BEA9-9313-46A3-B873-855AD934D9D4"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:comment>Increased plasma levels</dikbD2R:comment>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D7A9CF59-FA8D-4C9C-B9B1-11165D8D02AA">
    <ao:exact>sulfonylureas</ao:exact>
    <ao:suffix>) levothyroxine, methadone, narcotic analgesics, progestins, quinine, tacrolimus theophylline, tricyclic antidepressants (e.g., amitriptyline, nortriptyline) and zidovudine. It may be necessary to adjust the dosages of these drugs if they are given concu</ao:suffix>
    <ao:prefix> (</ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:40:54 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <domeo:uuid>D7A9CF59-FA8D-4C9C-B9B1-11165D8D02AA</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D7A9CF59-FA8D-4C9C-B9B1-11165D8D02AA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:931C5400-46C6-479B-B120-F302AB10F763">
    <pav:createdOn>2015-09-03 15:47:39 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>and its metabolites, L-amphetamine  and </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>L-methamphetamine</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:931C5400-46C6-479B-B120-F302AB10F763"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0B737F90-D900-4EBF-A944-99042ABD0DBC">
    <pav:createdOn>2015-10-14 11:41:47 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>, the potential for hepatotoxicity is increased. The concomitant use of rifampin and halothane should be avoided. Patients receiving both rifampin and isoniazid should be monitored closely for hepatotoxicity.</ao:suffix>
    <domeo:uuid>0B737F90-D900-4EBF-A944-99042ABD0DBC</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:exact>isoniazid</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0B737F90-D900-4EBF-A944-99042ABD0DBC"/>
    <ao:prefix>or </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4f9c82096f7e449885747a57995cc781">
    <domeo:sets rdf:resource="urn:pddi:uuid:4FA88695-3425-4FFC-8204-2DCA6F7DE6C9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A5922FD4-A159-4019-89E2-289342604349">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F70B463D-A444-4115-9390-AABA778F2FE2"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E806EFAE-67D4-4B3E-AD71-F92EAA4792CE"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6947206C-641A-4D07-8C99-0099CAA79C39">
    <dikbD2R:dose>6</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <rdfs:label>EMSAM</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:95787BE2-BCFB-4FAE-AB6E-59B0753207A5">
    <ao:suffix>-Multiple doses of </ao:suffix>
    <domeo:uuid>95787BE2-BCFB-4FAE-AB6E-59B0753207A5</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Lithium</ao:exact>
    <pav:createdOn>2015-09-30 10:43:20 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:95787BE2-BCFB-4FAE-AB6E-59B0753207A5"/>
    <ao:prefix>(100 mg/day) without a washout period did not affect the pharmacokinetics of milnacipran .  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/875D389D-01B4-4906-88FD-800BA42F7ADD">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>desvenlafaxine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BE2C964A-CE58-4522-ACC9-84E4B2D79E01">
    <pav:lastSavedOn>2015-09-29 09:04:36 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:465F7364-0CE5-4129-ABDA-35391C66B447</domeo:belongsToSet>
    <pav:createdOn>2015-09-29 08:55:52 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lineageUri>urn:domeoserver:annotation:9C46E5BB-04F6-4F07-A52F-A47A04F8CB1B</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:8F380AE4-6978-4D85-8A47-F39014CE091E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A1E7BA95-6EEA-404F-81F6-3A9069FBAC9B">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/58ABF8B0-22B5-41E9-8E53-F8B7B2752222"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5E8D0ED9-202F-4A41-9961-E4207967C162"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BF845E15-E0F0-48BA-8A9D-E052826B0B71">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>anticoagulants</ao:exact>
    <ao:prefix> and oral </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <pav:createdOn>2015-10-13 11:57:45 -0400</pav:createdOn>
    <ao:suffix> may potentiate the effects of the oral anticoagulants. </ao:suffix>
    <domeo:uuid>BF845E15-E0F0-48BA-8A9D-E052826B0B71</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BF845E15-E0F0-48BA-8A9D-E052826B0B71"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0ED91940-C0DD-4195-AE7F-B43AB1E4E117">
    <ao:context rdf:resource="urn:domeoclient:uuid:63C4B236-094B-4C60-BF4B-DBE1FBD6A88C"/>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-10-13 12:03:22 -0400</pav:createdOn>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-10-13 12:04:13 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:B51F4BB3-6BDB-45E7-9399-D93DBC4324AC</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0278336C-C287-4150-BBFD-946E7C02463E">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-10-14 12:06:12 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:C91289D7-45EC-44D1-A933-E79E770CFE71</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:6DBDAF96-E906-41FD-B5E7-3E9C3D83709C"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-14 12:07:40 -0400</pav:lastSavedOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7E8BB1FA-609D-4431-A230-12A374C72B5A">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine, cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <pav:createdOn>2015-09-29 09:24:17 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a16297df-3158-48db-85e5-5cd506885556.html</ao:hasSource>
    <domeo:uuid>7E8BB1FA-609D-4431-A230-12A374C72B5A</domeo:uuid>
    <ao:prefix>hydroxylase) is reduced in a subset of the caucasian population (about 7 to 10% of caucasians are so called poor metabolizers); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7E8BB1FA-609D-4431-A230-12A374C72B5A"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/96425A47-B57A-4120-9BE9-A9BB35F407E3">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
    <rdfs:label>phenytoin</rdfs:label>
    <dikbD2R:dose>300</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:187D03F8-A554-4DA6-B127-77407C0BBC17">
    <ao:prefix> did not significantly alter steady-state </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>levels or the renal clearance of lithium.</ao:suffix>
    <pav:createdOn>2015-09-16 15:22:41 -0400</pav:createdOn>
    <ao:exact>lithium </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:187D03F8-A554-4DA6-B127-77407C0BBC17"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B15BE827-BE10-4A89-942D-4F762E070FB9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:27E99368-C12A-4070-8F13-575F3DDF977B"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F0A4ABF0-CAF2-4D6B-887C-049168E8677F">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>GILENYA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7F90A120-AAFD-4F01-B9A3-07D0FC51015F">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>duloxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C6618B4E-98E0-4726-B821-3577879C7B57">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>EMSAM</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A134645E-BBB8-42E1-9301-F5D2F49E8B6F">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1A5D2B03-C402-4744-9427-79753A2FAD8D">
    <ao:context rdf:resource="urn:domeoclient:uuid:06E2ACC0-7263-4C16-ADEC-327CE225CD4F"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-09-29 11:18:49 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:61CB1A4B-9EA2-48FB-B8B7-DDED8B43296B</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5A188DF2-F157-4BF3-9AAF-8E3A3754BAF4">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F1128F8F-18DC-4316-92C0-B87A646AA1CC">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:76846948-A201-4FB8-8CA0-B7E0EF641A9F"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:16C6B0FF-0B69-479C-82CC-438323CF8CF9">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A587FCF9-0C88-4D93-AB10-FF3AB8EBC24F"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/56B626A1-FA5F-41C3-941C-7FC2F0DFA6B6">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2556</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>citalopram</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>40</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DA6380EB-F552-4705-BC0B-02B1DDE88B31">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A6319AE3-2857-4629-9C16-E0537BBAA400"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/00F49CCE-6AB1-4D5C-B8ED-3AF52B48CEF4"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:674AB29D-91D0-4A79-BA72-9E21D8D67D3B">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:C20B4AA7-0F63-48A6-865C-3902B3EF9049"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F0CE3DA6-955D-446E-9A5E-15F4DDD90DB6">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>leuprolide</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc35c1dcb85624e3aba9ab359582051d9">
    <domeo:sets rdf:resource="urn:pddi:uuid:9FEFD555-E9E8-4B1A-B12C-48A113EC841D"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/29181E2A-72A8-41CB-8C25-96A40C0E2471">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A9549B26-0A6B-471C-A032-3E08F002D474">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4CDCD183-F333-4860-B0EE-7193B548395E"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/655C69F9-AAD6-4BDD-B6CE-34CD426FF16E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:AF31D033-4AD7-4A2C-B1DF-ED88AA603171">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6DA584D7-1D33-4C8D-8B04-084023087CC5"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BDEEA462-887A-41B3-88C9-0A13E5638CEC"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D139441C-B779-463A-AD5E-2E77ACEB3547">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2CC9C924-9A66-42D9-899D-A6C742155727"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E7AD763E-7B7F-4BE5-82B7-24A3FCBA74B6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0D552947-8625-4606-9AD7-7BF6071BDBA9">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A1E7BA95-6EEA-404F-81F6-3A9069FBAC9B"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5bdb3440ca47451ca905e91e6c4a6209">
    <domeo:sets rdf:resource="urn:pddi:uuid:E629B9F8-3220-400A-AE7D-6DA8A37A88CF"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/28037A94-46A8-4D58-A8BD-BC8A0B20411F">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:16A0844E-3F03-4029-B7C2-1E174B6032F3">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B62FAB60-E745-424E-B505-33F14FF73D9A"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C9667511-312E-4D0D-BB07-553CDFA26DF5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B1388FFF-1D80-4A68-B45E-724DC48B5687">
    <ao:body rdf:nodeID="Nb8be16dcbdd04188a97ec872db17dc85"/>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotation:0D1C8E3C-2829-479F-9407-120BA4F69018</pav:lineageUri>
    <pav:lastSavedOn>2015-09-30 12:41:52 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:0A98E6B0-5F59-43E1-B45B-FC2EF0D47705"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-30 12:39:27 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:6F5C24D1-EA99-48CF-B498-A0D89C02B290</domeo:belongsToSet>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2BB39737-8A55-4CBA-A991-8E44E5F10B70">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <rdfs:label>sertraline</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:12DBF8CB-DE55-4304-982A-ED3753583A2A">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E3622504-BDE4-4E34-8683-CA6EFB71F1D3"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D8E5FDE3-5360-4F9F-97FE-300D2A53DB18"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BFBA4537-CED4-4AF7-B0C1-888C3022EEE9">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8E94CF5B-6E88-499B-A71A-8E750E941BF4"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2E38DDF5-FA53-4F16-AD2E-CAD2A4E4393C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf842cdbdebbf4abbb69a9f65318ce4ba">
    <domeo:sets rdf:resource="urn:pddi:uuid:E576AC12-1B3A-4ACC-A6EF-3F991AD36B57"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C38B82D1-3D17-47AC-9D1B-AFB34D78E462">
    <pav:createdOn>2015-10-14 11:40:23 -0400</pav:createdOn>
    <domeo:uuid>C38B82D1-3D17-47AC-9D1B-AFB34D78E462</domeo:uuid>
    <ao:suffix>, calcium channel blockers (e.g., diltiazem, nifedipine, verapamil), chloramphenicol, clarithromycin, corticosteroids, cyclosporine, cardiac glycoside preparations, clofibrate, oral or other systemic hormonal contraceptives, dapsone, diazepam, doxycyclin</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:exact>beta-blockers</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C38B82D1-3D17-47AC-9D1B-AFB34D78E462"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:056BEDA8-97D1-403C-B251-9FA6D7AC07F5">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:9A16A252-5C55-4B94-91E9-2F665BF72296"/>
    <pav:createdOn>2015-09-16 15:22:45 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotation:0D0A0ACB-978E-41D4-B85E-617AC2A8DBC1</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0468AC6B-4F06-4CA4-A0DE-A389E3B0E59F</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-16 15:31:12 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd152913a9f13445f93efeecd6f93e8f5">
    <domeo:sets rdf:resource="urn:pddi:uuid:C546DCD8-3F2C-4E34-BF95-7720097AE8F3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7B0DB3A3-8406-401E-8B2A-5754E62D7385">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:F4D9193F-6630-4EDC-8181-3955EE5FA89E"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotationset:C91289D7-45EC-44D1-A933-E79E770CFE71</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-14 12:07:40 -0400</pav:lastSavedOn>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdOn>2015-10-14 12:06:21 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/417F2F75-2B44-4BF4-9806-C46D316D1935">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/ECBE5A65-EB0C-47B1-953D-BB063498E57E">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:151B7CA5-9C49-4293-A093-7744FE253510">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E60849B6-3467-49C6-8A41-614417EF3801"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/17ED197A-2F4E-465C-ACD3-4034B90AE12A">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9068</dailymed:activeMoietyRxCUI>
    <rdfs:label>quinidine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E981CBE5-D5AD-42E0-92B0-575E5C5F6F24">
    <rdfs:label>CMI</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:191021CF-DC3E-4994-AD75-04A2F2BEF987">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:hasSource>
    <pav:createdOn>2015-08-20 13:57:26 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>191021CF-DC3E-4994-AD75-04A2F2BEF987</domeo:uuid>
    <ao:prefix>Drugs That Slow Heart Rate or Atrioventricular Conduction (e.g., beta blockers or diltiazem )   </ao:prefix>
    <ao:exact>Experience with GILENYA in patients receiving concurrent therapy with drugs that slow the heart rate or atrioventricular conduction (e.g., beta blockers, digoxin, or heart rate-slowing calcium channel blockers such as diltiazem or verapamil) is limited. Because initiation of GILENYA treatment may result in an additional decrease in heart rate, concomitant use of these drugs during GILENYA initiation may be associated with severe bradycardia or heart block. Seek advice from the prescribing physician regarding the possibility to switch to drugs that do not slow the heart rate or atrioventricular conduction before initiating GILENYA. Patients who cannot switch, should have overnight continuous ECG monitoring after the first dose [see Dosage and Administration (2) and Warnings and Precautions (5.1)]</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:191021CF-DC3E-4994-AD75-04A2F2BEF987"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nafb244aa071544abad24a1117aefd082">
    <domeo:sets rdf:resource="urn:pddi:uuid:A1B4D05A-19F5-4ABC-A27B-6B9CFCDE1FF9"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/91D3B9F1-7A05-4728-9595-10D2EC4D8DE8">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>TCA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5BDCB383-7EA9-42BB-A1ED-476F28689D49">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/49322C7D-5199-461A-9BC8-3217A9EEB92B">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>bicalutamide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0d594dc80f9642e58b0c9aa68d1a2870">
    <domeo:sets rdf:resource="urn:pddi:uuid:2FAF8BCF-F265-4F1D-8051-5D46B4ECB7DB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:83F3CE35-1D1E-40F7-AFD0-669A8DC32134">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).</ao:exact>
    <ao:prefix>, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-29 09:47:31 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:83F3CE35-1D1E-40F7-AFD0-669A8DC32134"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:71829FB0-93DE-41B8-8545-74963379E255">
    <ao:suffix> have been reported to be increased by the concomitant administration of </ao:suffix>
    <pav:createdOn>2015-09-29 09:46:27 -0400</pav:createdOn>
    <ao:prefix>; plasma levels of several closely related </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:71829FB0-93DE-41B8-8545-74963379E255"/>
    <ao:exact>tricyclic antidepressants</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E72ECA10-90B7-4236-9644-A6CFEAF3BE5E">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/1202</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>100</dikbD2R:dose>
    <rdfs:label>atenolol</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EC0DCB16-B5A8-4E6B-85E2-B89C1EDEE563">
    <rdfs:label>barbiturates</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:764395F8-5AFD-4E44-BF9C-0E47552B204F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:506C9915-D18D-4399-B1C9-71B99BF34F78"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:593F9136-50EF-4080-9407-79BC9D1D95EF">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:ABA54D79-4C89-44D4-AC22-ADBD65C7097E"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:16F09385-3309-4F83-961C-BC477C26E817">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CF0071BF-34C3-47B5-9CA8-023BB8BA35BE"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5A5AD0EF-537C-4948-8F42-62843FC47E81"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CB0AC331-18FB-427B-A1D4-544494DE0FE5">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/89C8796C-7343-4696-8BBD-1B695E02F81E"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D5B61AB4-5131-46A7-AC6F-A47FE2DAFDF7"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:109EA3A8-973A-4DA9-80A8-7662CE097F39">
    <pav:createdOn>2015-10-13 12:06:19 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>is contraindicated (see CONTRAINDICATIONS .)  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:109EA3A8-973A-4DA9-80A8-7662CE097F39"/>
    <domeo:uuid>109EA3A8-973A-4DA9-80A8-7662CE097F39</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In addition, there have been reports of interactions of erythromycin or clarithromycin with drugs not thought to be metabolized by CYP3A, including hexobarbital, phenytoin, and valproate.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1D47EB00-D7BC-4588-9793-29047B520FE8">
    <ao:body rdf:nodeID="N359701b5d9c649529b0cd5fd2d76032a"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:612CD415-340B-4E39-AB07-DD25B9DDDAAA"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-10-01 10:30:18 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:lineageUri>urn:domeoserver:annotation:F37E8124-800F-4FFA-9A6B-BADF8AE82194</pav:lineageUri>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:33B17719-DF97-48EA-AFA2-01DE8A8887B4</domeo:belongsToSet>
    <rdfs:label>ddi Annotation</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0CF842B2-78B2-4174-B769-2CDF44397186">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0CF842B2-78B2-4174-B769-2CDF44397186"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-16 10:59:55 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>    Digoxin   </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:exact>Administration of fluvoxamine maleate 100 mg daily for 18 days (N = 8) did not significantly affect the pharmacokinetics of a 1.25 mg single intravenous dose of digoxin. </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0FDEDBD9-15D7-4853-9AFC-81D6084B22D7">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>TCA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/1EC2CBC5-EDF8-453A-B3A2-C7955EBBC3AF">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>75</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>mirtazapine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0b9e880cd9154cb5a167fd952f5daf90">
    <domeo:sets rdf:resource="urn:pddi:uuid:115D5A34-6458-49C4-877C-C47E0DF5BDBB"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6311a602ca6a49df9ae31d7afb27a515">
    <domeo:sets rdf:resource="urn:pddi:uuid:91B40C9C-0C58-4D0A-B7D0-F7E974544009"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:444270ED-51A4-488D-82AF-C401D6B8D636">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BE63D747-8C0B-431D-AA2A-307559C30C3E"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:105CF640-753B-43C5-957A-87EA5C5586D1">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:B9D9BEC9-E143-442C-83CE-5C9C581F8A91"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:comment>Increased CMI plasma concentration</dikbD2R:comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2DEF71E7-518E-4AA5-92AC-A020B088D299">
    <dikbD2R:dose>100</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>carbamazepine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B0209F2A-C65D-4890-9D82-B304338F4E6E">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>warfarin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1F4995A3-461C-4944-8BDA-B9103E6977BC">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdOn>2015-10-01 10:27:23 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:33B17719-DF97-48EA-AFA2-01DE8A8887B4</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-10-01 10:31:02 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:D2128AEB-ADBD-4C8D-921B-A08DE5625871"/>
    <pav:lineageUri>urn:domeoserver:annotation:CCDF9841-50DB-4E4D-B9C5-6620D6182867</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6FAEBB86-7CA0-42CA-92E4-DF055A567659">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/045663CD-0ECA-496D-9691-E1059CF8C897"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/AD400125-E032-4FB8-AEF2-3E88944E5B79"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:13C01E54-2C05-46E0-9405-B5481F5383A4">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/992912C3-66C4-49E4-8BC2-1BA9C5F397BE"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/22E36239-AB3D-4676-9AEC-B6576A60A79B"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:218A1970-F7A1-4D9E-890F-6C4552091879">
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-16 15:22:28 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/c25f968b-7037-4f60-9a02-2189769b0cbf.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>In a study comparing the disposition of intravenously administered diazepam before and after 21 days of dosing with either sertraline (50 to 200 mg/day escalating dose) or placebo, there was a 32% decrease relative to baseline in diazepam clearance for the sertraline group compared to a 19% decrease relative to baseline for the placebo group (p &lt; 0.03). There was a 23% increase in Tmax for desmethyldiazepam in the sertraline group compared to a 20% decrease in the placebo group (p &lt; 0.03). The clinical significance of these changes is unknown.</ao:exact>
    <ao:prefix>(24%) and half-life (26%) compared to the placebo group. The clinical significance of these changes is unknown.   CNS Active Drugs </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:218A1970-F7A1-4D9E-890F-6C4552091879"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2365DEAC-00CA-4928-8DE6-495C26047070">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:3FF5F418-AF79-4A81-A155-A741E18FA662"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5AD6405F-1805-4DB1-A285-A76B2AB51DD7">
    <rdfs:label>lorazepam</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6470</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>60</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:20DCDD14-451F-4CB1-9298-CDF9CE771F69">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:839915E5-0351-4036-A7A5-DEBBE27B137B"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:61884F07-2FBB-4359-A9E4-B4846ADBB0F0">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:81318619-7AC8-45CC-8689-2D147CE9F211"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:41DBC941-97B7-4F69-B88D-FB36F19C347A">
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:B74E0947-30D8-4BF5-8A3D-3FA2A563D6F4"/>
    <pav:lineageUri>urn:domeoserver:annotation:B185BA20-AB66-403C-A113-377C4684A899</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-09-24 15:51:20 -0400</pav:createdOn>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:85AD6EA1-D560-4FFB-A685-3F21B0B4208E</domeo:belongsToSet>
    <pav:lastSavedOn>2015-09-24 15:55:00 -0400</pav:lastSavedOn>
    <ao:body rdf:nodeID="Nbbbb7e5af7a1480091b4e3da8f8202b5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0B2844E8-5711-43D4-966A-07E43CB1D1E5">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A134645E-BBB8-42E1-9301-F5D2F49E8B6F"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/64047647-342E-418F-B80F-5F03217AE2D4"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/91E89437-3D47-4B7F-B4B2-43FBAEFEF1F1">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>cilostazol</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:99ACBB97-47CE-47E6-9BD3-808EDED1ECF7">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F57E349E-B634-4B2E-8428-042582074328"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2CE45FE3-827E-44F2-B60A-EE526B4D1203">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:933223C7-983E-49F8-9C5E-9729630CBD5D"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:comment>Active moiety concentration increased 1.4 fold</dikbD2R:comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/840BE60C-29AC-4826-BF18-E10A79E5054B">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>2</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
    <rdfs:label>risperidone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:15E194A1-3A60-40F1-9A3C-66824617A1C4">
    <ao:exact>coumarin </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>type. In patients receiving anticoagulants and rifampin concurrently, it is recommended that the prothrombin time be performed daily or as frequently as necessary to establish and maintain the required dose of anticoagulant.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:15E194A1-3A60-40F1-9A3C-66824617A1C4"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <domeo:uuid>15E194A1-3A60-40F1-9A3C-66824617A1C4</domeo:uuid>
    <pav:createdOn>2015-10-14 11:41:17 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>has been observed to increase the requirements for anticoagulant drugs of the </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/348DA3E2-EC77-40B7-9C88-EE9DF41C8397">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>0.25</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd2415601d5354e6ea3d0aa6834999adb">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5C7BDA17-45D7-4DC3-AEF2-44850B6F0D70">
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <domeo:uuid>5C7BDA17-45D7-4DC3-AEF2-44850B6F0D70</domeo:uuid>
    <pav:createdOn>2015-08-20 12:46:42 -0400</pav:createdOn>
    <ao:prefix>on BCRP and organic anion transporting polypeptide B1 and B3 (OATP1B1/1B3) substrates   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)].</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5C7BDA17-45D7-4DC3-AEF2-44850B6F0D70"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7EFBE050-F23D-4AD7-9613-BEDEC8EE79D8">
    <ao:context rdf:resource="urn:domeoclient:uuid:D24A23D0-90E2-4CD2-8DD1-8062096192B9"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdOn>2015-10-20 10:09:06 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B853C546-5169-4BDE-A71E-82BB708405C8">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1C941DD3-7D28-477E-8CB2-B25161FAC382">
    <pav:lastSavedOn>2015-08-20 13:06:41 -0400</pav:lastSavedOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:29C81FA3-6B09-43AD-A17B-ED50BCB3873D</pav:lineageUri>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:createdOn>2015-08-20 13:06:38 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <ao:body rdf:nodeID="N40a77f6c69cc4ce8bab1d1552a026732"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:64AA2313-E589-4938-99DC-2A49A60E0242"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0A2D817D-4EA6-4B9D-91A5-3EF21D457EE1">
    <ao:exact>diazepam</ao:exact>
    <pav:createdOn>2015-10-14 11:40:43 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0A2D817D-4EA6-4B9D-91A5-3EF21D457EE1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:suffix>, doxycycline, fluoroquinolones (e.g., ciprofloxacin), haloperidol, oral hypoglycemic agents (sulfonylureas) levothyroxine, methadone, narcotic analgesics, progestins, quinine, tacrolimus theophylline, tricyclic antidepressants (e.g., amitriptyline, nort</ao:suffix>
    <domeo:uuid>0A2D817D-4EA6-4B9D-91A5-3EF21D457EE1</domeo:uuid>
    <ao:prefix>, </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6BE71A2E-E0C7-4AF9-8150-B4C4E55BAA64">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluvoxamine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>60</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9DE57A2D-FCE6-45AA-AC64-6FA9C1DBB165">
    <rdfs:label>fluvoxamine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5989B15D-72CA-4DF4-96C0-D41D0D41C034">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>beta blockers</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/28AABF38-58C8-4949-AFF2-702FAC5913CD">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>mexiletine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6926</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B824E163-D969-4C79-B059-3656EF961DBA">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <pav:createdOn>2015-10-14 11:41:28 -0400</pav:createdOn>
    <ao:prefix>Concurrent use of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>ketoconazole </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B824E163-D969-4C79-B059-3656EF961DBA"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>and rifampin has resulted in decreased serum concentrations of both drugs. Concurrent use of rifampin and enalapril has resulted in decreased concentrations of enalaprilat, the active metabolite of enalapril. Dosage adjustments should be made if indicate</ao:suffix>
    <domeo:uuid>B824E163-D969-4C79-B059-3656EF961DBA</domeo:uuid>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EAAF690D-73CA-4E97-9ABA-228A16082AA5">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>selegiline</rdfs:label>
    <dikbD2R:dose>6</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfe7262cda6a6466bbb2325569e923029">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/03B8BB68-3CA6-493F-8394-D11B2B03C71D">
    <rdfs:label>digoxin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3407</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>1.25</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/73EB24BB-86D5-496E-9768-2CE6A3B494A6">
    <dikbD2R:dose>0.15</dikbD2R:dose>
    <rdfs:label>levothyroxine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:2615D048-46FA-4557-B691-24297A4787D9">
    <poc:MedicalCondition>tmc</poc:MedicalCondition>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>MedicalCondition</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CD3A7AE7-5E99-4E1E-A75B-5E0A94EBD675">
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:9186EEB3-84FE-4472-A0E2-4B242C8E5310"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-14 11:41:31 -0400</pav:createdOn>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:28996346-6515-4892-84BA-92E5CB541BEF">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F4CE75DE-435B-4BD2-BAB4-D4FBC5DD1286"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/07F75683-487F-4E5B-A891-FDEADC1E8A0B"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/1C28BB6C-3609-4CB3-A98F-B198460C640B">
    <dikbD2R:dose>100</dikbD2R:dose>
    <rdfs:label>fluvoxamine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/729B9B6A-B7AE-43A1-9ED9-2662E8DCC53F">
    <rdfs:label>risperdione</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/569C4B4D-A75C-459C-9AEF-2AFCEB1FE2B0">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>desvenlafaxine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:821C0209-1F80-4A54-BC99-9AAA00055E98">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/71B44EFE-3F93-4792-A233-4250F63845BC"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8FDA1CCB-9373-49CD-A744-492499262BC8"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/AB7E1905-302D-461F-9971-C03F4AC9E028">
    <rdfs:label>Rifampin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9D339366-5C9E-4A0B-A282-FD01A8D970EF">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:C5B99ECC-158C-4392-B2C6-F4CFDB242160"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E9149F61-2B07-4356-AAC2-DA0131D2F8B7">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2597</dailymed:activeMoietyRxCUI>
    <rdfs:label>clomipramine</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9e7d8a4300e74479aff869f87f0290f7">
    <domeo:sets rdf:resource="urn:pddi:uuid:2FB934B1-2DF6-465A-B442-CEC008ABBBFB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A6944C7D-6432-4774-9637-C6CB84C61FE1">
    <ao:exact>tricyclic antidepressants</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <ao:suffix> with drugs that can inhibit cytochrome P450 2D6 may require lower doses than usually prescribed for either the tricyclic antidepressant or the other drug. Furthermore, whenever one of these other drugs is withdrawn from cotherapy, an increased dose of t</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A6944C7D-6432-4774-9637-C6CB84C61FE1"/>
    <domeo:uuid>A6944C7D-6432-4774-9637-C6CB84C61FE1</domeo:uuid>
    <ao:prefix>Concomitant use of </ao:prefix>
    <pav:createdOn>2015-09-29 08:59:15 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EF9B9DFB-0591-4732-ABA1-5EDB6CA4C1E1">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> is related to the CYP 2D6 inhibitory properties of </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <ao:exact>paroxetine</ao:exact>
    <pav:createdOn>2015-10-14 12:08:07 -0400</pav:createdOn>
    <domeo:uuid>EF9B9DFB-0591-4732-ABA1-5EDB6CA4C1E1</domeo:uuid>
    <ao:suffix>. Concomitant use of pimozide and paroxetine or other strong CYP 2D6 inhibitors are contraindicated (see </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EF9B9DFB-0591-4732-ABA1-5EDB6CA4C1E1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:06CA4F5E-AE2F-4CAE-8104-B4DBFD00AF22">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:C6D0AC43-7A5B-4C6E-86CE-8E858ED62EFE"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A65865D9-F393-4D2A-BA99-A5CE604B3F8A">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>6</dikbD2R:dose>
    <rdfs:label>EMSAM</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncc6d5419f6d94c4c8d17fa999387f0c3">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9BC80BE8-ABC9-4678-B052-80482D209D83">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:0340691A-566D-462A-991D-4B1EB2FC98B2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F1933D6D-9F3E-4BF7-80E7-B20BFDA0CC04">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:640B975C-9A37-4C61-94BF-4F6DC0BB40FF"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:comment>Switching from fluoxetine to milnacipran with no wash out period</dikbD2R:comment>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:03B26142-76BF-4602-9917-090D6E864169">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix> for </ao:prefix>
    <ao:suffix> by 19% and 29%, respectively. Therefore, patients may need to be monitored when such drugs are taken concomitantly with </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5d103551-978f-472a-9c62-51e6e4dea068.html</ao:hasSource>
    <ao:exact>digoxin</ao:exact>
    <pav:createdOn>2015-08-26 16:11:55 -0400</pav:createdOn>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:03B26142-76BF-4602-9917-090D6E864169"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6E116C9B-C1FA-4B60-97FB-F04CA639E7BA">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>selective serotonin reuptake inhibitors</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5E28CDF4-912F-4A42-9962-26AB548B421A">
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:lastSavedOn>2015-10-14 12:10:56 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:18BF074B-1F38-43EC-966D-283527BF6E0D</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:01610A50-69B8-4086-8D3E-44B99316E079</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:C6AA5EA2-3B4B-43F6-AB33-C888E340ADBA"/>
    <pav:createdOn>2015-10-14 12:08:06 -0400</pav:createdOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/310BEEAB-EAAB-488D-B985-148A11FEDFAE">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>alfentanil</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EDFF465E-39B4-45A8-9299-D64EC7FD33A0">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/AF4060AA-43C3-4256-83D7-54425C648AF7"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/865E4C7F-47D5-45C4-AB41-489475A35229"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N19f433bce14f4f9ea5c2551540b3ad07">
    <domeo:sets rdf:resource="urn:pddi:uuid:3F52ABFF-9B48-4938-86DF-78B3DEE83425"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6375C633-8839-4C08-8AC2-6241A31D44CC">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdfs:label>paroxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3E6CAB50-964C-47A1-B775-F60E5AB0BC0C">
    <ao:exact>verapamil</ao:exact>
    <ao:suffix>), chloramphenicol, clarithromycin, corticosteroids, cyclosporine, cardiac glycoside preparations, clofibrate, oral or other systemic hormonal contraceptives, dapsone, diazepam, doxycycline, fluoroquinolones (e.g., ciprofloxacin), haloperidol, oral hypog</ao:suffix>
    <domeo:uuid>3E6CAB50-964C-47A1-B775-F60E5AB0BC0C</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:40:29 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3E6CAB50-964C-47A1-B775-F60E5AB0BC0C"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Naf47738a2353418c8d674520dfab0d57">
    <domeo:sets rdf:resource="urn:pddi:uuid:7E7F4E8D-E33F-46C2-BAA8-8364523ED1DC"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N74ac6ecb45014a3194d1bcb6ce73aaa8">
    <domeo:sets rdf:resource="urn:pddi:uuid:2730D7B3-31C9-4A50-B560-5142B96A3A23"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:009F8EE9-A45D-4768-B436-EB845104C124">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> is presumed to influence obsessive and compulsive behaviors through its effects on serotonergic neuronal transmission. The actual neurochemical mechanism is unknown, but CMI's capacity to inhibit the reuptake of </ao:suffix>
    <ao:prefix> (</ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <domeo:uuid></domeo:uuid>
    <ao:exact>CMI)</ao:exact>
    <pav:createdOn>2015-09-29 09:44:09 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:009F8EE9-A45D-4768-B436-EB845104C124"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9A801BEF-346A-4CBF-8E25-8311B9F80BB4">
    <domeo:uuid>9A801BEF-346A-4CBF-8E25-8311B9F80BB4</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-09-29 11:27:24 -0400</pav:createdOn>
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8 fold increase in plasma AUC of the TCA).  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9A801BEF-346A-4CBF-8E25-8311B9F80BB4"/>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type IC antiarrhythmics propafenone and flecainide). While all the SSRIs, e.g., fluoxetine, sertraline, paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:260378E5-F4CE-4282-BADB-45604F318D7E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:19D9C218-A991-40F9-BE73-9CC7580ADDC8"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nddd3438da44e490dab7521b1d2a116ae">
    <domeo:sets rdf:resource="urn:pddi:uuid:BBA6E0E7-69CB-4291-BCDF-DE962787E606"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8B1C920F-48AF-42CB-B4DA-DEBE5FB38829">
    <pav:createdOn>2015-09-29 08:59:33 -0400</pav:createdOn>
    <ao:prefix> plasma levels whenever a </ao:prefix>
    <domeo:uuid>8B1C920F-48AF-42CB-B4DA-DEBE5FB38829</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8B1C920F-48AF-42CB-B4DA-DEBE5FB38829"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix> is going to be coadministered with another drug known to be an inhibitor of P450 2D6.</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/ea35caf8-c8c8-481a-97a2-25f68cbc240b.html</ao:hasSource>
    <ao:exact>TCA</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:443A925E-DA00-466F-A718-C63993B4B2E5">
    <dikbD2R:comment>Drug regimen was listed as QHS</dikbD2R:comment>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:58248057-768C-4323-B6B0-8DCF7930B044"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A8E2E3A5-6930-4C86-8E84-38677FB9541E">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>clarithromycin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:C0D4F41F-0FCC-446B-A746-DAED97C65270">
    <poc:PharmacokineticImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#not-important</poc:PharmacokineticImpact>
    <rdfs:label>Not Important</rdfs:label>
    <dct:description>The pharmacogenomic biomarker is not associated any clinically relevant pharmacokinetic with respect to the drug.</dct:description>
    <sio:SIO_000563>poc:PharmacokineticImpact</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7D6CC28B-39F2-46E5-9AC4-F618BCA73D55">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>disopyramide</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7780B7F5-6DFC-4C9C-BE10-CC8722E2EB7D">
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Tricyclic Antidepressants (TCAs)   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-10 14:50:56 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine. Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced. </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7780B7F5-6DFC-4C9C-BE10-CC8722E2EB7D"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1ce14d6bd7334650b1bd7ed53f17effd">
    <domeo:sets rdf:resource="urn:pddi:uuid:3359C2F5-9A93-4692-8C07-2D98F900E929"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:98150954-C90C-4F0D-BD9D-19FF8DBB874D">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FDBC2BB8-0140-4D15-93D3-FBC56FC49844"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/93A96470-7019-4F6D-9B18-20CF725E8044"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EEEBC110-DCB7-49AD-BEA1-5AD46C23F126">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>EMSAM</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:EBCEFCFC-427C-49EF-AFE9-1274D4001C7D">
    <pav:createdOn>2015-08-20 11:07:28 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>EBCEFCFC-427C-49EF-AFE9-1274D4001C7D</domeo:uuid>
    <ao:exact>ZYTIGA is an inhibitor of the hepatic drug-metabolizing enzymes CYP2D6 and CYP2C8. In a CYP2D6 drug-drug interaction trial, the Cmax and AUC of dextromethorphan (CYP2D6 substrate) were increased 2.8- and 2.9-fold, respectively, when dextromethorphan was given with abiraterone acetate 1,000 mg daily and prednisone 5 mg twice daily. Avoid co-administration of abiraterone acetate with substrates of CYP2D6 with a narrow therapeutic index (e.g., thioridazine). If alternative treatments cannot be used, exercise caution and consider a dose reduction of the concomitant CYP2D6 substrate drug [see Clinical Pharmacology (12.3)].</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>7.2 Effects of Abiraterone on Drug Metabolizing Enzymes  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4e338e89-3cf2-48eb-b6e2-a06c608c6513.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:EBCEFCFC-427C-49EF-AFE9-1274D4001C7D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FB837169-4577-475A-9C8C-F9E8B826D304">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1579053D-B51B-4EF6-A468-58C48DBFB64E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C83ADD65-1FE4-472E-ADC9-CB830E45EC4F">
    <pav:createdOn>2015-09-29 11:21:05 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/3e593725-3fc9-458e-907d-19d51d5a7f9c.html</ao:hasSource>
    <ao:prefix>xsd:String</ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C83ADD65-1FE4-472E-ADC9-CB830E45EC4F"/>
    <domeo:uuid>C83ADD65-1FE4-472E-ADC9-CB830E45EC4F</domeo:uuid>
    <ao:suffix> Conversely, decreases in plasma levels of th</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>Concurrent administration of cimetidine and tricyclic antidepressants can produce clinically significant increases in the plasma concentrations of the tricyclic antidepressants.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4a294291cddf4d84ae71ec8454a7411e">
    <domeo:sets rdf:resource="urn:pddi:uuid:1202A678-DD4B-44C6-B9E2-78985758EEC2"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8A8A6EC7-7E6E-4019-9747-DA99D46ECB77">
    <rdfs:label>barbiturates</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4d9cdbcb6e4e4040a93e0e0fb0167eba">
    <domeo:sets rdf:resource="urn:pddi:uuid:96BAC859-5CB1-4963-A12C-9E45F0A17F1F"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/37DB1277-310C-4C5E-8D84-E9DF2198342B">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7AB37698-54BD-4A66-919F-A123A6569141">
    <ao:prefix>Antineoplastic, Immunosuppressive, or Immune-Modulating Therapies   </ao:prefix>
    <ao:exact>Antineoplastic, immune-modulating, or immunosuppressive therapies, (including corticosteroids) are expected to increase the risk of immunosuppression, and the risk of additive immune system effects must be considered if these therapies are coadministered with GILENYA. When switching from drugs with prolonged immune effects, such as natalizumab, teriflunomide or mitoxantrone, the duration and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects when initiating GILENYA [see Warnings and Precautions (5.2)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-08-20 13:55:21 -0400</pav:createdOn>
    <domeo:uuid>7AB37698-54BD-4A66-919F-A123A6569141</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7AB37698-54BD-4A66-919F-A123A6569141"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:13CEB6A6-B8D0-40B6-955E-B735CF08F32E">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:93703B81-928E-4914-8CD8-F441879EC8E3"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:comment>60% plasma concentration increase of mirtazapine</dikbD2R:comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:33DCD3EA-1199-4A8F-A11A-7A31E00D95D5">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/64A6C4D4-5FE7-41A7-AD26-1E0B9ECE7502"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/080CCBD5-3FFB-4024-918C-A27D97A96282"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D9DD0FED-8CAA-4C72-9C92-E76BA43781CA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid>D9DD0FED-8CAA-4C72-9C92-E76BA43781CA</domeo:uuid>
    <pav:createdOn>2015-08-20 13:53:27 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:exact>The blood levels of fingolimod and fingolimod-phosphate are increased by 1.7-fold when used concomitantly with ketoconazole. Patients who use GILENYA and systemic ketoconazole concomitantly should be closely monitored, as the risk of adverse reactions is greater.</ao:exact>
    <ao:prefix>[see Dosage and Administration (2) and Warnings and Precautions (5.1)] .   Ketoconazole   </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/cc9e1c8c-0e2b-44e2-878b-27057f786be9.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D9DD0FED-8CAA-4C72-9C92-E76BA43781CA"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9DB2C984-BCE7-4269-9A59-D64A78C3F92B">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>25</dikbD2R:dose>
    <rdfs:label>fluvoxamine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C0C0EEFD-733A-4E66-8517-A205FC022AEE">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>calcium channel blockers</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1B382E42-FA07-45A2-8026-2219D9D03E43">
    <ao:prefix>than with </ao:prefix>
    <ao:exact>PPA </ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:suffix>alone, suggesting a possible pharmacodynamic interaction </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-03 15:57:10 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1B382E42-FA07-45A2-8026-2219D9D03E43"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D6350C48-AC2A-4106-82F4-E2F7CF2F561B">
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:8D286017-0AEC-46C4-AC51-641E2F31DE1A</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <ao:context rdf:resource="urn:domeoclient:uuid:46887215-EBC0-4819-B453-E97722BC8960"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-10-20 09:23:48 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">8</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-20 09:22:29 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0DC742B1-BF20-4178-B00E-C8EFC639DD44">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D57AC561-50A1-4050-9ACA-FE6D1F2EBB95"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:149774FA-0B95-4FC6-B3B4-604D4FE97060">
    <pav:createdOn>2015-10-20 10:09:18 -0400</pav:createdOn>
    <ao:exact>alprazolam</ao:exact>
    <ao:suffix>, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses. </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:149774FA-0B95-4FC6-B3B4-604D4FE97060"/>
    <domeo:uuid>149774FA-0B95-4FC6-B3B4-604D4FE97060</domeo:uuid>
    <ao:prefix>administration. Moreover, as noted with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:254C54C9-FE6A-4B90-9E27-B8DAFFA5CE3D">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EABE5D0F-6780-45CF-939C-CEC95D686754"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0D5B628D-9A8E-4485-92C6-6327D739FE2B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:948ADEC5-BE5C-417D-B3E9-CBBE68C184F6">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F270973E-DB55-40D2-8C87-2E60338AD366"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7CF755C5-9CAC-44FE-840F-3DD0BB4B3260"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfc0a9a891d504b508717cb1b4eb26a3c">
    <domeo:sets rdf:resource="urn:pddi:uuid:90D0ECD1-D2C8-4CCE-A552-0576C3C2A783"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EABE5D0F-6780-45CF-939C-CEC95D686754">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7599b32acbe1412db6b05a2d7b0bceb0">
    <domeo:sets rdf:resource="urn:pddi:uuid:F1128F8F-18DC-4316-92C0-B87A646AA1CC"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2a382ee0360b4ef78da0a27bdee45686">
    <domeo:sets rdf:resource="urn:pddi:uuid:9D1B526F-267F-4ADD-A3FA-F70A535B6D24"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C4028117-2B50-48F6-B563-925853DCA6D2">
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5CB3F5BE-D8EE-4652-A953-E8A1DC770705">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5798CBE8-708E-45A1-88F9-BB02BD866FEE"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D653CC99-F2D9-471F-AC2A-74FF25660717">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BB16C304-6BBB-4B51-8956-EE514F98D7D7">
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <domeo:uuid>BB16C304-6BBB-4B51-8956-EE514F98D7D7</domeo:uuid>
    <pav:createdOn>2015-10-13 11:47:41 -0400</pav:createdOn>
    <ao:exact>Simultaneous oral administration of clarithromycin tablets and zidovudine to HIV infected adult patients resulted in decreased steady-state zidovudine concentrations. When 500 mg of clarithromycin were administered twice daily, steady-state zidovudine AUC was reduced by a mean of 12% (n=4). Individual values ranged from a decrease of 34% to an increase of 14%. Based on limited data in 24 patients, when clarithromycin tablets were administered two to four hours prior to oral zidovudine, the steady-state zidovudine Cmax was increased by approximately 2-fold, whereas the AUC was unaffected.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14-hydroxyclarithromycin plasma concentrations (31%). These effects are clinically insignificant.  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BB16C304-6BBB-4B51-8956-EE514F98D7D7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:32DAEE61-E8FE-47A7-8507-2DECEE9F5520">
    <domeo:uuid>32DAEE61-E8FE-47A7-8507-2DECEE9F5520</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:32DAEE61-E8FE-47A7-8507-2DECEE9F5520"/>
    <ao:prefix>protease inhibitor drugs (see CONTRAINDICATIONS).   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <pav:createdOn>2015-10-14 12:07:39 -0400</pav:createdOn>
    <ao:exact>Pimozide and Celexa: In a controlled study, a single dose of pimozide 2 mg coadministered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Racemic citalopram did not alter the mean AUC or Cmax of pimozide. The mechanism of this pharmacodynamic interaction is not known. Concomitant use of Pimozide and Celexa or Lexapro is contraindicated (See CONTRAINDICATIONS).</ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:C8296470-B24E-4940-9418-4184085A32EA">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>C8296470-B24E-4940-9418-4184085A32EA</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/16a4a314-f97e-4e91-95e9-576a3773d284.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, monitoring of patients during treatment switch is recommended.  </ao:prefix>
    <pav:createdOn>2015-09-30 10:42:16 -0400</pav:createdOn>
    <ao:exact>Digoxin-There was no pharmacokinetic interaction between Savella (200 mg/day) and digoxin    (0.2 mg/day Lanoxicaps) following multiple-dose administration to healthy subjects. </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:C8296470-B24E-4940-9418-4184085A32EA"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N656de6243a454912a021b18f4fc011d1">
    <domeo:sets rdf:resource="urn:pddi:uuid:B5DE11DD-2736-44CF-BA0E-E3E353A295AD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:574FF5F7-13AA-497F-8060-12A8C869458F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5F185723-E6EF-4140-8D04-86779721BF6E"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1ae090ec8f9c471da7836b9872e575e1">
    <domeo:sets rdf:resource="urn:pddi:uuid:7B0F5D3A-BDC8-442E-8D89-EC9B654C9953"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FE447885-52AC-4622-86F7-CE9C9246D9BF">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:97961C84-B101-47B0-9F36-4124A7C5BB29">
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotation:F91FDE45-0A4E-4B9E-8DF8-E2193EF2D959</pav:lineageUri>
    <pav:createdOn>2015-09-29 11:24:22 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:B67C5EED-18A2-4EE9-81EC-2B539F5A4F12"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:31618939-6349-45FF-B3FD-2B7AB66C2111">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-16 10:56:46 -0400</pav:createdOn>
    <ao:exact>Significantly increased plasma TCA levels have been reported with the coadministration of fluvoxamine maleate and amitriptyline, clomipramine or imipramine. Caution is indicated with the coadministration of fluvoxamine maleate tablets and TCAs; plasma TCA concentrations may need to be monitored, and the dose of TCA may need to be reduced.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>Tricyclic Antidepressants (TCAs)   </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:31618939-6349-45FF-B3FD-2B7AB66C2111"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DA86ED84-44C6-460E-AE8C-B2332FD8F0E7">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/13864D12-9E66-48A1-997D-86524B01BA2A"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/45B77EF0-BBF9-48C0-A832-B0B49A30671A"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/81F515F9-20CA-4FC8-A307-63D0B35D7C23">
    <dikbD2R:dose>60</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <rdfs:label>paroxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:74319367-2778-4836-A36D-C8518AEC7C9D">
    <ao:prefix>. Concomitant use of </ao:prefix>
    <domeo:uuid>74319367-2778-4836-A36D-C8518AEC7C9D</domeo:uuid>
    <pav:createdOn>2015-10-14 12:08:08 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:74319367-2778-4836-A36D-C8518AEC7C9D"/>
    <ao:exact>pimozide</ao:exact>
    <ao:suffix> and paroxetine or other strong CYP 2D6 inhibitors are contraindicated (see </ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nea4583a18e6846d5981d0a3ca717aad9">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne04e25770e614d28b5bb5f31c595edd4">
    <domeo:sets rdf:resource="urn:pddi:uuid:F54D24C5-5C64-439C-A1EE-5F4449E965EE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C5762CDA-09BB-47D3-A83B-0B1BC127AAA0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4B720508-6AFE-4212-BD22-96430132AA78"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7E008BC6-EC9B-4F1E-B537-D4CF660033C7">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>DOSAGE AND ADMINISTRATION ).  Drug-Drug Interactions   </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7E008BC6-EC9B-4F1E-B537-D4CF660033C7"/>
    <ao:exact>In vitro drug interaction studies reveal that paroxetine inhibits CYP2D6. Clinical drug interaction studies have been performed with substrates of CYP2D6 and show that paroxetine can inhibit the metabolism of drugs metabolized by CYP2D6 including desipramine, risperidone, and atomoxetine (see PRECAUTIONS: Drug Interactions)</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/326e8ab0-6886-4749-9544-885b37070051.html</ao:hasSource>
    <pav:createdOn>2015-09-14 10:25:06 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E92268FB-0334-40ED-88C2-3C9DA7E99028">
    <ao:prefix>: In a controlled study, a single dose of </ao:prefix>
    <ao:suffix>2 mg coadministered with racemic citalopram 40 mg given once daily for 11 days was associated with a mean increase in QTc values of approximately 10 msec compared to pimozide given alone. Racemic citalopram did not alter the mean AUC or C</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/70b079e2-a1f7-4a93-8685-d60a4d7c1280.html</ao:hasSource>
    <pav:createdOn>2015-10-14 12:06:20 -0400</pav:createdOn>
    <domeo:uuid>E92268FB-0334-40ED-88C2-3C9DA7E99028</domeo:uuid>
    <ao:exact>pimozide </ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E92268FB-0334-40ED-88C2-3C9DA7E99028"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne5e50011ec9841728b0502ce9511293e">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B63A0C41-F68B-48AB-A2FC-BB05571545D8">
    <rdfs:label>clarithromycin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1056244F-7147-456A-9240-D224C911F3B0">
    <ao:body rdf:nodeID="Nb55889e61020446a944f53770fdfec96"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:assertionType>DDI-clinical-trial</dikbD2R:assertionType>
    <pav:lastSavedOn>2015-10-13 11:52:38 -0400</pav:lastSavedOn>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">5</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:F2B9732E-515B-496E-A7E7-DE29A9A9B53F"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:547DC888-0D3F-489E-9152-DACDED489EA8</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:26c9faea-4e7c-436c-8be8-0f9e3de431df</pav:lineageUri>
    <pav:previousVersion>urn:domeoserver:annotationset:58BD31E4-F1E7-44DA-87A9-5298EBD36BEA</pav:previousVersion>
    <pav:createdOn>2015-10-13 11:51:17 -0400</pav:createdOn>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EAC5533B-4DCB-4C46-AADE-0F32094343E0">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A9549B26-0A6B-471C-A032-3E08F002D474"/>
    <dikbD2R:comment>Maprotiline plasma concentration may be increased</dikbD2R:comment>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E806EFAE-67D4-4B3E-AD71-F92EAA4792CE">
    <rdfs:label>flecainide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4441</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1BE4CA5F-EDFB-4059-A4C9-35914BF2ADF4">
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:351D2822-3970-49BE-A42B-2DB8E7DE6EB8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3359C2F5-9A93-4692-8C07-2D98F900E929">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:20C4ECAE-3F46-4EAC-BE3F-94F701047608"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2A949489-DB98-4A6B-BEFA-0D28605554CF">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/AADE7CB7-E435-496B-B17E-356F55E52666"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5DC9BCDE-EDCD-4F10-A071-050134EF1449"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7672B2F3-AFE2-459D-9FB8-91BDF351CC66">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:exact>tricyclic antidepressants</ao:exact>
    <pav:createdOn>2015-10-14 11:41:07 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7672B2F3-AFE2-459D-9FB8-91BDF351CC66"/>
    <ao:suffix> (e.g., amitriptyline, nortriptyline) and zidovudine. It may be necessary to adjust the dosages of these drugs if they are given concurrently with rifampin.</ao:suffix>
    <domeo:uuid>7672B2F3-AFE2-459D-9FB8-91BDF351CC66</domeo:uuid>
    <ao:prefix>, </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:CA427337-D6E2-475C-A2E7-D66C49285894">
    <ao:exact>Teriflunomide may be a weak inducer of CYP1A2 in vivo. In patients taking AUBAGIO, exposure of drugs metabolized by CYP1A2 (e.g., alosetron, duloxetine, theophylline, tizanidine) may be reduced. Monitor these patients and adjust the dose of the concomitant drug(s) metabolized by CYP1A2 as required [see Clinical Pharmacology (12.3)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-08-20 11:40:32 -0400</pav:createdOn>
    <ao:prefix>AUBAGIO on CYP1A2 substrates   </ao:prefix>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:CA427337-D6E2-475C-A2E7-D66C49285894"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4E539308-4FB5-4CB6-814C-CFEA1D7EF6B9">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>teriflunomide</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:91B40C9C-0C58-4D0A-B7D0-F7E974544009">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8D0D303B-689D-4CE2-A583-0D91BF2D57F0"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5BD0DA29-2766-4691-8D00-FD038555ED08">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3BCE2870-5D15-464D-9540-1F124B4548AB"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7FCC43CF-62FF-48AE-8A6E-7E6699DA1F59"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7FCC43CF-62FF-48AE-8A6E-7E6699DA1F59">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>risperidone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:552412E5-F74C-439C-82B7-DF5A550A2778">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A5FABFA9-8E2F-49A9-ABBC-32FC70990532"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/417F2F75-2B44-4BF4-9806-C46D316D1935"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F3ED089E-E6C1-4A17-9C53-58315607CF2A">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:19AFE8C0-5725-4424-B244-8E729452C0A4">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:comment>TCA plasma levels increased</dikbD2R:comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5D449E83-868F-4EDF-8430-2B29B4C014FC"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F9897809-1242-44CB-AC4A-03EDD6A34BDB">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>60</dikbD2R:dose>
    <rdfs:label>paroxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:person:uuid:080e143043ef9cf90143f8ea240c0005">
    <foafx:name>Katrina</foafx:name>
    <foafx:firstname>Katrina</foafx:firstname>
    <foafx:lastname>Romagnoli</foafx:lastname>
    <rdf:type rdf:resource="http://xmlns.com/foaf/0.1/Person"/>
    <foafx:title></foafx:title>
    <foafx:email>kak59@pitt.edu</foafx:email>
    <foafx:homepage></foafx:homepage>
    <rdfs:label>Katrina</rdfs:label>
    <foafx:picture>http://www.hcklab.org/images/me/paolo%20ciccarese-boston.jpg</foafx:picture>
    <foafx:middlename></foafx:middlename>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N24a4f3a6a618470899b3ee88060a6760">
    <domeo:sets rdf:resource="urn:pddi:uuid:9E39C9A0-7D4C-4A57-B963-787FA1EC899A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:c7ce6e79-6e93-45b7-978e-80ada2f4e509">
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>ns in blood pressure. Therefore, monitor blood pressure if </ao:prefix>
    <pav:createdOn>2015-08-27 14:50:16 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:c7ce6e79-6e93-45b7-978e-80ada2f4e509"/>
    <ao:exact>EMSAM</ao:exact>
    <ao:suffix> is used with any of the following drugs: buspirone, ampheta</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CB82B7D7-65F5-47DB-B759-FD272307C843">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2DCB43A8-8406-477E-81DA-8D31F9114345"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DBE96F34-0BBB-401F-B1E6-F9FD5237E978">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:ECA01409-8751-4283-B80A-3D7F33F3AD0D">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/49322C7D-5199-461A-9BC8-3217A9EEB92B"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C9EAFF5D-297F-4B36-9AAA-08FC1EAFE82F"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8F097540-00DB-4581-BFD8-42B918C17F19">
    <rdfs:label>clarithromycin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/282344C2-0768-4AA8-9215-172E8AA44E83">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/203143</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>100</dikbD2R:dose>
    <rdfs:label>fluvoxamine maleate</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A2A62E19-E90B-4C15-8F9E-E89CCBFD218F">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>maprotiline</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/13FBEF08-83AE-43FF-9833-5915D7776D0D">
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BDCEACD0-98B1-4AB9-A3E9-72B4C3E4FB45">
    <rdfs:label>clomipramine</rdfs:label>
    <dikbD2R:dose>100</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2597</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbbbb7e5af7a1480091b4e3da8f8202b5">
    <domeo:sets rdf:resource="urn:pddi:uuid:443A925E-DA00-466F-A718-C63993B4B2E5"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/40D0E198-1AC4-473D-8BB1-FE2877A636AC">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>propafenone</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8754</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:704B3892-EB73-430B-BBF8-9AF87186D376">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C72F97A8-3245-47CA-97B3-91682D7B0A05"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/51D59424-383C-4008-AC25-65FDA87F2768"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8BEE3797-8082-4D79-A3D7-CF3F5CD96F5D">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>Teriflunomide</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C944B079-003C-4856-9E7D-3BE44ED45093">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>300</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8183</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>phenytoin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:24B18E20-1A2F-4A93-914F-835938109D3A">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3489FFF6-AA10-402E-86E6-88F51D8C1556"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7FA8FD4A-5E33-4537-A903-16639AE0421F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N874cf99474264e91b5e93fcd3d89b262">
    <domeo:sets rdf:resource="urn:pddi:uuid:53034F06-01D0-456B-B27F-C45D6327886E"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2067834d24524d12b606e8ee94a5aaf7">
    <domeo:sets rdf:resource="urn:pddi:uuid:61047704-2B5D-467F-8EA8-1BEC048D756B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9A92D660-F9DA-49F8-AB31-AC92D01F160F">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/310BEEAB-EAAB-488D-B985-148A11FEDFAE"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B63A0C41-F68B-48AB-A2FC-BB05571545D8"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N40a77f6c69cc4ce8bab1d1552a026732">
    <domeo:sets rdf:resource="urn:pddi:uuid:84DFF0F1-308C-49E0-9779-B1A53D49590C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A4688FBD-C9C3-49C1-8E9A-89A838425C26">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8512C3A6-C183-4355-A260-B5264ABB5227"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A2B36B62-4E42-4EFF-82B7-1B9A77823B1B">
    <rdfs:label>tricyclic antidepressant</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B9D9BEC9-E143-442C-83CE-5C9C581F8A91">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C45AD04D-3270-4CC3-863B-3DC449CE3508"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/77CB0730-59F7-4027-A81E-4B5C160CAA4B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7CD64C84-E54F-4060-9C56-5839875C957D">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:19AF4B30-4FD9-4C57-9F4D-E97A279AA2CC"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/62FC9A11-0C8E-45AF-A806-C55FA3506D96">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:748087E9-72A8-4CEB-9184-127F9C7D7CFF">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/ADFB4A66-76E9-4663-8777-15964EB91687"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/29CA75DD-696A-44B2-8B2A-1F0107958720"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/112AC08E-3C63-4C04-8E28-AA93CC8EDA26">
    <rdfs:label>TCA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:D557BF69-26AB-4E39-B394-E926CC17D66C">
    <domeo:uuid></domeo:uuid>
    <ao:prefix>, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <pav:createdOn>2015-09-29 09:58:01 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:D557BF69-26AB-4E39-B394-E926CC17D66C"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C9679E02-D4D5-4264-9711-E07F48E32713">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>teriflunomide</rdfs:label>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C551FD48-3DFB-43BB-8FCD-511F078199DC">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0CA852B0-92E0-48CE-9BDD-232A3BE07FEA">
    <pav:createdOn>2015-09-03 15:57:09 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <domeo:uuid></domeo:uuid>
    <ao:exact>PPA </ao:exact>
    <ao:prefix> and </ao:prefix>
    <ao:suffix>than with PPA alone, suggesting a possible pharmacodynamic interaction </ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0CA852B0-92E0-48CE-9BDD-232A3BE07FEA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5D449E83-868F-4EDF-8430-2B29B4C014FC">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/799316E2-E219-49C9-A05A-7D2C6BA38439"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/26BAC204-CD2B-49BC-B2C6-3A5AB3B24726"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/89425384-D20C-461C-8FA5-1C9A7A0348B7">
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/704</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>amitriptyline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:87BD3438-6149-4E4C-8BF3-06DA4B3C606F">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D1291B5E-C283-48C2-BDEE-2E0046415542"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/333460FC-6A5E-44AD-91DD-FF5BFD1588EA"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:66C219E4-EC64-425E-8265-823A7EB39E06">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5A2D7417-45A8-47CB-B886-B517A1F862EE"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4B720508-6AFE-4212-BD22-96430132AA78">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EBB2D315-7C91-408C-8A37-F0A5F6CF4FE1"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/1B999F60-A8D2-45DC-8ABE-2D5478157836"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8B2AEBA4-2FFE-4044-8357-29D8859AF7D7">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8B2AEBA4-2FFE-4044-8357-29D8859AF7D7"/>
    <ao:exact>cardiac glycoside preparations</ao:exact>
    <pav:createdOn>2015-10-14 11:40:36 -0400</pav:createdOn>
    <domeo:uuid>8B2AEBA4-2FFE-4044-8357-29D8859AF7D7</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>, clofibrate, oral or other systemic hormonal contraceptives, dapsone, diazepam, doxycycline, fluoroquinolones (e.g., ciprofloxacin), haloperidol, oral hypoglycemic agents (sulfonylureas) levothyroxine, methadone, narcotic analgesics, progestins, quinine</ao:suffix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:prefix>, </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:E9753FC0-E930-437A-8438-D9405D59629D">
    <pav:createdOn>2015-08-26 16:11:45 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix> for digoxin by 19% and 29%, respectively. Therefore, patients may need to be monitored when such drugs are taken concomitantly with </ao:prefix>
    <ao:exact>rabeprazole</ao:exact>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/5d103551-978f-472a-9c62-51e6e4dea068.html</ao:hasSource>
    <ao:suffix>. Co-administration of rabeprazole and antacids produced no clinically relevant changes in plasma rabeprazole concentrations.</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:E9753FC0-E930-437A-8438-D9405D59629D"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CCBD88D5-62C4-4179-AA6D-7DD3626FB431">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>paroxetine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F13DDBBD-0D4A-4433-8F3E-F2DE519D5368">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:191DBC90-244E-4B28-85E3-91A0C7D2CA55"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B92ABAA1-4178-40A5-B402-750AF29F1F5A">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5DA58AA0-7094-43E3-A435-F477D5E05DF4"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:52DB4DDD-6B99-4C2A-B8AE-C74F18D1C9C8">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/98DF7C52-806D-4BBC-B646-D50272400CDF"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/408F26AF-FCE9-4E71-8A05-5723857C96AE"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:80A2D9C2-BBE3-4073-A25D-8B748388D720">
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>metabolism have not been studied.  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>A clinically significant fluvoxamine interaction is possible with drugs having a narrow therapeutic ratio such as pimozide, warfarin, theophylline, certain benzodiazepines, omeprazole and phenytoin. If fluvoxamine maleate tablets are to be administered together with a drug that is eliminated via oxidative metabolism and has a narrow therapeutic window, plasma levels and/or pharmacodynamic effects of the latter drug should be monitored closely, at least until steady-state conditions are reached [see Contraindications (4) and Warnings and Precautions (5)]. </ao:exact>
    <pav:createdOn>2015-10-16 10:53:43 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:80A2D9C2-BBE3-4073-A25D-8B748388D720"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:33AFB702-15A9-4F37-809C-1652993A46D6">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0F83DB94-0B3F-435A-A490-4E7CF44C29C5"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2EEED366-8AEC-4F5F-9D3C-F9C491200753"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:90494AC1-B993-41E7-8727-362CD90821B0">
    <ao:exact>desvenlafaxine </ao:exact>
    <domeo:uuid>90494AC1-B993-41E7-8727-362CD90821B0</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-24 15:27:08 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/a9ff32c4-3bcf-4e51-ae8c-81ff0191ec35.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:90494AC1-B993-41E7-8727-362CD90821B0"/>
    <ao:prefix>Clinical studies have shown that </ao:prefix>
    <ao:suffix>(100 mg daily) does not have a clinically relevant effect on </ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0B8718D5-B552-4BCA-8C1E-BD9B06924E3A">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>sertraline</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:669A4336-8FAC-4F68-8C83-5C820CEE68E7">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C5E6C8F3-37BA-4D4E-AF52-4A413FF5AC2C"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/38E4AA8A-B218-4BBD-9772-4DAA2015E3C0"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1E167070-34E0-487B-8906-3D4713302363">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E4C87AB6-53E6-476A-8DF3-B503643E6E29"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9E2AD1DF-7F91-4C9E-9C40-7AF729A924F3">
    <rdfs:label>Rifampin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0D671E14-0A06-4713-9A7D-04E9773C855A">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BA69F573-0461-4317-A288-E3C95B8A9D33"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/ADDBF2EC-65E3-4DD5-A161-4E2BA5648C57">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>EMSAM</rdfs:label>
    <dikbD2R:dose>6</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0b46291164f44de2ac3f50ba4e03f1db">
    <domeo:sets rdf:resource="urn:pddi:uuid:7B364074-734F-49C7-88BE-71539BF01FD7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:812BEA3E-86E1-4BC2-A64B-D744B33A1D15">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>812BEA3E-86E1-4BC2-A64B-D744B33A1D15</domeo:uuid>
    <ao:exact>cyclosporine</ao:exact>
    <ao:suffix>, cardiac glycoside preparations, clofibrate, oral or other systemic hormonal contraceptives, dapsone, diazepam, doxycycline, fluoroquinolones (e.g., ciprofloxacin), haloperidol, oral hypoglycemic agents (sulfonylureas) levothyroxine, methadone, narcotic</ao:suffix>
    <ao:prefix>, </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:812BEA3E-86E1-4BC2-A64B-D744B33A1D15"/>
    <pav:createdOn>2015-10-14 11:40:33 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E3F0AA8A-350C-4D5B-8049-DB04CC917E7C">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:DD376E9C-4957-41AC-8F13-1EED67D1A071"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6BD1AA26-D041-4913-8305-AB000DB6F5B5">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>L-amphetamine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:726B758C-5D4A-423D-B28E-4C51148D9F39">
    <pav:createdOn>2015-09-29 11:21:43 -0400</pav:createdOn>
    <domeo:belongsToSet>urn:domeoserver:annotationset:E5FB5E7F-6083-48AA-B949-4BE79B41C354</domeo:belongsToSet>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <ao:context rdf:resource="urn:domeoclient:uuid:17EDF22D-388A-48A8-A8D8-ED030D4251D3"/>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lastSavedOn>2015-09-29 11:28:40 -0400</pav:lastSavedOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lineageUri>urn:domeoserver:annotation:748A868D-0E3F-4580-82C2-679E3A3299CE</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:58D5488E-7332-43C8-8E54-6584C2EA6074">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:97C72BF5-EFD6-4BFB-8E87-3F00FE3995F1"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N10f55e7f47524292949b2ad8e84c4902">
    <domeo:sets rdf:resource="urn:pddi:uuid:B4234013-1118-4769-8D2D-47E93AB98ED1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9112C7A2-148B-4685-8FEC-6415F27EA7B1">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E0701F46-8C28-4A8D-886B-270DAC63BB62"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6D0CC975-6BE7-431D-9466-39ED14B3EE0E">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:27542EC3-2E5D-4711-97F9-3700D71B59D2"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D8E5FDE3-5360-4F9F-97FE-300D2A53DB18">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6960</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>midazolam</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2AD0F96C-ABDC-46F3-B9C5-6E19DD3A7B92">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:createdOn>2015-08-20 13:55:05 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:91941771-D879-47D4-A033-6E979797C3BE"/>
    <pav:lastSavedOn>2015-08-20 13:57:35 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <domeo:belongsToSet>urn:domeoserver:annotationset:2ABE5FA2-BA00-4AF9-A2EA-1305FAECF3DF</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <ao:body rdf:nodeID="Nc69313f8dd254f9d8ab8dc27a4722ecc"/>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <rdfs:label>ddi Annotation</rdfs:label>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <pav:lineageUri>urn:domeoserver:annotation:972FE382-D454-419C-B490-DC0E383B46C7</pav:lineageUri>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/043DEF26-B53C-4843-A330-523CF5CD1AE5">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>SSRIs</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1CC84A84-9696-46C0-A082-51EDC82C931B">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:51E0AB1D-2630-4365-A160-6B6184C2158C"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:6D353708-61D5-4483-9392-C64EE4CE14E1">
    <domeo:uuid>6D353708-61D5-4483-9392-C64EE4CE14E1</domeo:uuid>
    <ao:exact>tipranavir</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:6D353708-61D5-4483-9392-C64EE4CE14E1"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:suffix>. These antiviral drugs must not be co-administered with rifampin. (See </ao:suffix>
    <pav:createdOn>2015-10-14 11:40:00 -0400</pav:createdOn>
    <ao:prefix>, and </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N72954efd0d024935a2b5402cea44250c">
    <permissions:accessType>urn:domeo:access:public</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7F58F36E-9F7A-4CD6-9AF2-A18AC685705E">
    <domeo:uuid>7F58F36E-9F7A-4CD6-9AF2-A18AC685705E</domeo:uuid>
    <ao:prefix>The effect of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:suffix>(25 mg b.i.d. for one week) on thioridazine steady-state concentrations was evaluated in ten male inpatients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coa</ao:suffix>
    <pav:createdOn>2015-10-20 09:22:28 -0400</pav:createdOn>
    <ao:exact>fluvoxamine </ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7F58F36E-9F7A-4CD6-9AF2-A18AC685705E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6E803E7E-A17A-45EB-B29A-24A2605495C8">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E8F6706A-E20A-4DBA-8CE1-B71E6F17FEA6"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FE447885-52AC-4622-86F7-CE9C9246D9BF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8F392652-BCD4-47E9-BCA0-933278AFD587">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6B951705-7BDF-467E-B106-ECB07C4F2575"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DE04EA3F-C940-4C88-A879-767D8630FF93"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9FEFD555-E9E8-4B1A-B12C-48A113EC841D">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D13612BD-2F3A-40E4-A107-904240C9AE7C"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EE863A57-ECAA-42C6-9176-A28AEE4CA1B0">
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6960</dailymed:activeMoietyRxCUI>
    <rdfs:label>midazolam</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2AE52676-E820-413E-AE96-95C645C094B0">
    <rdfs:label>fluvoxamine maleate</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/203143</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:9A31B87A-97EE-4287-9624-F33FCC8141F8">
    <domeo:uuid>9A31B87A-97EE-4287-9624-F33FCC8141F8</domeo:uuid>
    <ao:suffix>, cilostazol, and bromocriptine.</ao:suffix>
    <pav:createdOn>2015-10-13 12:03:19 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, </ao:prefix>
    <ao:exact>methylprednisolone</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:9A31B87A-97EE-4287-9624-F33FCC8141F8"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F70B12B8-16F0-428C-853D-84AEE83FCC4F">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B95EF06F-2E7B-4ADD-BAA5-16482A25FC49"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F0A4ABF0-CAF2-4D6B-887C-049168E8677F"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/23A9B45E-3F21-4526-A6C9-6E0EA480729C">
    <rdfs:label>quinidine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9068</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nac71ad29dfbd4f7d827893804f8c7159">
    <domeo:sets rdf:resource="urn:pddi:uuid:FF456A41-9E7C-4E63-AA74-8071591A99CA"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3A80C62B-7836-44FF-B64E-77DA92F605DE">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>procyclidine</rdfs:label>
    <dikbD2R:dose>5</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:FDB5E8CF-B1ED-4248-B148-8CD7C377E595">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/AFD0292B-88FF-4D55-937B-B96FBDE3422F"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E1870C1A-8789-40F2-B9E4-E786F91FF161"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D3E06232-E03C-4122-AA3F-16AF5BA22690">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdfs:label>sertraline</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7D9C4662-D5AD-40D5-8386-2B97BF54F4D4">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F20A7A91-F667-4DE8-ABD5-A85862436E18"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6375C633-8839-4C08-8AC2-6241A31D44CC"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2E025747-9707-4E97-A29B-084BD9CAE3DA">
    <dikbD2R:dose>15</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>alprazolam</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:7F46AEEA-D7F6-4F1F-A426-9F20EDEB76A3">
    <dct:description>The drug of interest.</dct:description>
    <rdfs:label>Abacivir</rdfs:label>
    <sio:SIO_000628>dailymed:pharmgxDrug</sio:SIO_000628>
    <dailymed:pharmgxDrug>http://fakeuri.org/Aripiprazole</dailymed:pharmgxDrug>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne2fab5ce8b3f4596bfa25e1e5a87fea9">
    <domeo:sets rdf:resource="urn:pddi:uuid:1CD5ECF1-16A3-4A48-91CD-C57508FC1162"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:A8AD9ECE-1FA4-428F-A3D9-7F741AA06D78">
    <ao:exact>rifampin</ao:exact>
    <ao:prefix>have been reported to increase the blood level of </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-14 11:41:44 -0400</pav:createdOn>
    <domeo:uuid>A8AD9ECE-1FA4-428F-A3D9-7F741AA06D78</domeo:uuid>
    <ao:suffix>.</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:A8AD9ECE-1FA4-428F-A3D9-7F741AA06D78"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfcfb4a62b7b8452ea7101d5ef807a955">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/99F4DC31-8BF6-4A47-9616-EDDAF0783C76">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>fluvoxamine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N885e26abebba4112b1955044b7d7b4a8">
    <domeo:sets rdf:resource="urn:pddi:uuid:005201C9-318D-430E-87E5-46A87DF5B164"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:BF104FC9-4328-4D52-96EB-84787C485B64">
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>Clinical Pharmacology (12.3) ] .  </ao:prefix>
    <pav:createdOn>2015-09-03 15:40:30 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:exact>No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs.</ao:exact>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:BF104FC9-4328-4D52-96EB-84787C485B64"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:16D85653-2369-40BD-80C0-D151FEA01087">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8E6B2E9F-FE08-436B-A0D4-1A6618990FA1"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/13FBEF08-83AE-43FF-9833-5915D7776D0D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4D4B1447-4736-45FE-8790-101F65AAE150">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8A87388D-69CF-46EA-98B2-17F5863DF318"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D4F8EA01-8DCA-4715-AF5B-0ABFCF10DFA4"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7227be347b9644bf916a13a2745a3247">
    <permissions:isLocked>false</permissions:isLocked>
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/16368547-3DC1-476D-BEE4-4DCB59549293">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3247</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>100</dikbD2R:dose>
    <rdfs:label>desipramine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:587D1E52-C317-475F-8553-B0F5340F9437">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3E13D693-2C73-45B2-B2BC-9FE20BA414C4"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5E508224-86F3-41FE-8BD5-64E8A8463CAD"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/89C8796C-7343-4696-8BBD-1B695E02F81E">
    <rdfs:label>omeprazole</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/7646</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2DC230E7-7D25-49FC-8899-90D905A84DC4">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">10</pav:versionNumber>
    <pav:createdOn>2015-10-20 09:54:02 -0400</pav:createdOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:659993FA-47A6-4170-A1F4-37E021B93D40</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <ao:context rdf:resource="urn:domeoclient:uuid:427D6518-2858-4799-A74C-646C32A98582"/>
    <pav:lastSavedOn>2015-10-20 09:56:31 -0400</pav:lastSavedOn>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:722C7B42-FBCE-42D9-A86A-C13624023A28">
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:createdOn>2015-10-14 11:41:53 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:D5F8EFD7-FCCA-4828-9DD4-C359C19E5F66"/>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <rdfs:label>Highlight</rdfs:label>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:23530D0B-F4A5-407A-AED0-EE99C0B30E6D">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:23530D0B-F4A5-407A-AED0-EE99C0B30E6D"/>
    <domeo:uuid>23530D0B-F4A5-407A-AED0-EE99C0B30E6D</domeo:uuid>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>Warfarin reduces the regeneration of vitamin K from vitamin K epoxide in the vitamin K cycle through inhibition of VKOR, a multiprotein enzyme complex. Certain single nucleotide polymorphisms in the VKORC1 gene (e.g., 1639G&gt;A) have been associated with variable warfarin dose requirements. VKORC1 and CYP2C9 gene variants generally explain the largest proportion of known variability in warfarin dose requirements.</ao:exact>
    <ao:prefix>% and 7% for CYP2C9*2 and CYP2C9*3, respectively. Other CYP2C9 alleles associated with reduced enzymatic activity occur at lower frequencies, including *5, *6, and *11 alleles in populations of African ancestry and *5, *9, and *11 alleles in Caucasians. </ao:prefix>
    <pav:createdOn>2014-02-20 13:49:37 -0500</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:2020/SPL-annotation/Warfarin-ab047628-67d0-4a64-8d77-36b054969b44.html </ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N920b8608e6d8441faa57d2a49f579df7">
    <domeo:sets rdf:resource="urn:pddi:uuid:58572AE4-2116-4E49-8AF2-509D75B729C3"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf5aedc926fef4936925ecbe51cb2c67a">
    <domeo:sets rdf:resource="urn:pddi:uuid:1820958B-AD16-486F-81C4-001769B9695A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3ae82a846ef0407d8ceb51cf8ab2cd25">
    <domeo:sets rdf:resource="urn:pddi:uuid:58D5488E-7332-43C8-8E54-6584C2EA6074"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9FBF0953-E4A6-4D88-871C-A8C2A86A89AB">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:comment>Maprotiline plasma concentration may be increased</dikbD2R:comment>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:805CB069-7975-4076-9068-35EB8BF59994"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:16EF4E16-7784-4EB0-8FE0-6A31A48EB623">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-09-03 15:39:33 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:16EF4E16-7784-4EB0-8FE0-6A31A48EB623"/>
    <ao:prefix>Clinical Pharmacology (12.3) ] .  </ao:prefix>
    <domeo:uuid></domeo:uuid>
    <ao:exact>No dose adjustment of alprazolam, ibuprofen, levothyroxine, olanzapine, risperdione, warfarin, or strong CYP3A4 inhibitors (e.g., ketoconazole) is necessary when these drugs are used in combination with EMSAM. EMSAM had no clinically relevant effect on pharmacokinetics of these drugs.</ao:exact>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndd982fd9e8044af4a717251246ceb697">
    <domeo:sets rdf:resource="urn:pddi:uuid:D6F657B5-90BE-4358-9042-5255EA60946F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:CB01354B-0B3C-435A-AE84-FB2C130E6745">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A2159AAA-99B0-4620-89AB-88E988542AD3"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/863F7B25-4328-4C31-A28D-89A3FFD2642E">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>zidovudine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11413</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7D134291-6C7F-46A1-B3CF-3FE92B9EDBCF">
    <dikbD2R:dose>20</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>paroxetine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A4621498-3014-44FF-A863-4D9667907AA0">
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:5BD0DA29-2766-4691-8D00-FD038555ED08"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7DB97C61-75F4-4C62-9D15-4FDB96A0D78F">
    <dikbD2R:dose>2</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>risperidone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4EB2A056-F504-40BD-A358-6042884B62DA">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/44BF1E7D-5B5C-4EE2-82A4-C7F3283EABA1"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/37DB1277-310C-4C5E-8D84-E9DF2198342B"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1D7EC3DC-6FC8-4E76-BCE7-3E2D375182CF">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/49C7B63E-79ED-4915-B479-BFD5C26EA7F2"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/259BC540-3D43-4F99-B96B-5CD172299B1D"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9FDA56C9-1247-4921-B59B-E5A47EC1011D">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>paroxetine</rdfs:label>
    <dikbD2R:dose>20</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A21F5BB7-9E1D-4264-9C8E-DF791E04BFCF">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>barbiturates</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/75C13C61-5E7D-4445-AB25-C7C9FEA47925">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/36437</dailymed:activeMoietyRxCUI>
    <rdfs:label>sertraline</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>200</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf8493fb283a24c8a99f3dd4c9e1974d4">
    <domeo:sets rdf:resource="urn:pddi:uuid:19AFE8C0-5725-4424-B244-8E729452C0A4"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8b00c7a1223d42a3be4be3486cd2e2b5">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:746371A2-AA31-425D-96A0-947D5E301EB4">
    <ao:prefix>on BCRP and organic anion transporting polypeptide B1 and B3 (OATP1B1/1B3) substrates   </ao:prefix>
    <ao:exact>Teriflunomide inhibits the activity of BCRP and OATP1B1/1B3 in vivo. For a patient taking AUBAGIO, the dose of rosuvastatin should not exceed 10 mg once daily. For other substrates of BCRP (e.g., mitoxantrone) and drugs in the OATP family (e.g., methotrexate, rifampin), especially HMG-Co reductase inhibitors (e.g., atorvastatin, nateglinide, pravastatin, repaglinide, and simvastatin), consider reducing the dose of these drugs and monitor patients closely for signs and symptoms of increased exposures to the drugs while patients are taking AUBAGIO [see Clinical Pharmacology (12.3)]</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:746371A2-AA31-425D-96A0-947D5E301EB4"/>
    <pav:createdOn>2015-08-20 12:53:31 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>746371A2-AA31-425D-96A0-947D5E301EB4</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/4650d12c-b9c8-4525-b07f-a2d773eca155.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/7D3165AF-E749-42A4-A947-09083737957D">
    <rdfs:label>lorazepam</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6470</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>50</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D5353CCD-7B5F-41E1-8B6A-BE4C0729D4C7">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A6B2FC51-C9DA-42D2-90FA-0DF0DBCE925F"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/729B9B6A-B7AE-43A1-9ED9-2662E8DCC53F"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:AD69FEE2-142E-4170-A583-B4791A2C9D5B">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoclient:uuid:f3f3e898-d8dc-4745-8fb5-22596e7fa89b</pav:previousVersion>
    <ao:context rdf:resource="urn:domeoclient:uuid:2C5BC3F9-D707-470F-AE11-8D6ADC1C72A9"/>
    <pav:createdOn>2015-10-14 11:39:52 -0400</pav:createdOn>
    <pav:lastSavedOn>2015-10-14 11:42:10 -0400</pav:lastSavedOn>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <domeo:belongsToSet>urn:domeoserver:annotationset:0F2720B1-7312-40B5-AAD3-4B71A4D2C7C0</domeo:belongsToSet>
    <pav:lineageUri>urn:domeoserver:annotationset:1e5ecef0-8e23-4649-9781-eff10b1be2f8</pav:lineageUri>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">3</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N82e15d891a8345cb854ce95add64ef39">
    <domeo:sets rdf:resource="urn:pddi:uuid:37CD58F2-C7ED-41F7-869E-313B8FF59EBF"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:7D918661-6CD5-48B3-AD72-A11F18451883">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>7D918661-6CD5-48B3-AD72-A11F18451883</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <ao:exact>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of TCA may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (quinidine; cimetidine) and many that are substrates for P450 2D6 (many other antidepressants, phenothiazines, and the Type 1C antiarrhythmics propafenone and flecainide). While all the selective serotonin reuptake inhibitors (SSRIs), e.g., fluoxetine, sertraline, and paroxetine, inhibit P450 2D6, they may vary in the extent of inhibition. The extent to which SSRI-TCA interactions may pose clinical problems will depend on the degree of inhibition and the pharmacokinetics of the SSRI involved. Nevertheless, caution is indicated in the co-administration of TCAs with any of the SSRIs and also in switching from one class to the other. Of particular importance, sufficient time must elapse before initiating TCA treatment in a patient being withdrawn from fluoxetine, given the long half-life of the parent and active metabolite (at least 5 weeks may be necessary).</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:prefix>hydroxylase) is reduced in a subset of the Caucasian population (about 7% to 10% of Caucasians are so-called "poor metabolizers"); reliable estimates of the prevalence of reduced P450 2D6 isozyme activity among Asian, African, and other populations are not yet available. Poor metabolizers have higher than expected plasma concentrations of tricyclic antidepressants (TCAs) when given usual doses. Depending on the fraction of drug metabolized by P450 2D6, the increase in plasma concentration may be small, or quite large (8-fold increase in plasma AUC of the TCA).  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-01 10:47:23 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:7D918661-6CD5-48B3-AD72-A11F18451883"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1F0F4AD3-668A-44E0-8EA8-A016AF9D49EC">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>cilostazol , and bromocriptine .  </ao:prefix>
    <ao:exact>Concomitant administration of clarithromycin with cisapride, pimozide, astemizole, or terfenadine is contraindicated (see CONTRAINDICATIONS.)</ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>1F0F4AD3-668A-44E0-8EA8-A016AF9D49EC</domeo:uuid>
    <pav:createdOn>2015-10-13 12:05:31 -0400</pav:createdOn>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1F0F4AD3-668A-44E0-8EA8-A016AF9D49EC"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N41578232d9c2418ba95f769cdd266a53">
    <domeo:sets rdf:resource="urn:pddi:uuid:2EC2B395-2185-4E2D-B7D1-8214768712AA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:73161045-082A-4C78-A0EB-AB263AC05E44">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5A9E8858-8558-48B2-BFFB-0A0517EC153B"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/391382AD-9D4A-4BCC-92B4-3DE625E5234B"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E9BFF3CB-C96C-405B-B94A-6A06395D24B2">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/11289</dailymed:activeMoietyRxCUI>
    <rdfs:label>warfarin</rdfs:label>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb6330ddf9113434d998c0dc43fee3a23">
    <domeo:sets rdf:resource="urn:pddi:uuid:D95D2B8F-17FC-4A88-971D-B666AB43725E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BFA6410B-1C67-4B5F-AF2C-525757EC91DC">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D4075F76-8042-4477-9D20-5D1A7749FAC9"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F06FE283-A85B-44B4-92C2-D32E52034960">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/35636</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>30</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>risperidone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/22E36239-AB3D-4676-9AEC-B6576A60A79B">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluvoxamine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:5024CBC4-FDB8-4C66-8337-0AA2E58C4067">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:5024CBC4-FDB8-4C66-8337-0AA2E58C4067"/>
    <ao:prefix>, </ao:prefix>
    <ao:suffix>, diazepam, doxycycline, fluoroquinolones (e.g., ciprofloxacin), haloperidol, oral hypoglycemic agents (sulfonylureas) levothyroxine, methadone, narcotic analgesics, progestins, quinine, tacrolimus theophylline, tricyclic antidepressants (e.g., amitripty</ao:suffix>
    <pav:createdOn>2015-10-14 11:40:42 -0400</pav:createdOn>
    <ao:exact>dapsone</ao:exact>
    <domeo:uuid>5024CBC4-FDB8-4C66-8337-0AA2E58C4067</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8A3DD1C2-0404-4AB4-ABB3-83155933D3E4">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/56F00D8F-5E03-4E1A-BA19-7863443A321D"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E981CBE5-D5AD-42E0-92B0-575E5C5F6F24"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:94611C47-47D7-4D38-8EEF-17379EF5BB78">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:DrugSelectionRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#alternative-recommended</poc:DrugSelectionRecommendation>
    <sio:SIO_000563>poc:DrugSelectionRecommendation</sio:SIO_000563>
    <dct:description>The pharmacogenomic biomarker is related to a recommendation to use an alternative drug.</dct:description>
    <rdfs:label>Alternative Recommended</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:0B998C8C-A7B7-4E62-9960-0D6A6C27D6D3">
    <ao:prefix>In addition, certain drugs inhibit the activity of this isozyme and make normal metabolizers resemble poor metabolizers. An individual who is stable on a given dose of </ao:prefix>
    <domeo:uuid>0B998C8C-A7B7-4E62-9960-0D6A6C27D6D3</domeo:uuid>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/75bf3473-2d70-4d41-93cd-afa1015e45bb.html</ao:hasSource>
    <ao:exact>TCA</ao:exact>
    <pav:createdOn>2015-10-01 10:43:25 -0400</pav:createdOn>
    <ao:suffix> may become abruptly toxic when given one of these inhibiting drugs as concomitant therapy. The drugs that inhibit cytochrome P450 2D6 include some that are not metabolized by the enzyme (</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:0B998C8C-A7B7-4E62-9960-0D6A6C27D6D3"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8A842890-2CC5-4CAB-BB40-13D9F1AD35C4">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E629B9F8-3220-400A-AE7D-6DA8A37A88CF">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BACA411A-57BF-4DAA-A840-AE001F4F029B"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:95C1F41F-1A9E-48A4-9473-492B2AE05E58">
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:95C1F41F-1A9E-48A4-9473-492B2AE05E58"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <pav:createdOn>2015-09-29 09:57:18 -0400</pav:createdOn>
    <ao:exact>The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).</ao:exact>
    <ao:prefix>, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.  </ao:prefix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E777B05F-C229-40C7-8566-C6DF7886F462">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:201A57BB-94B3-4FE8-942E-4EE00AF39EB8"/>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2E43AF44-F0BD-44A5-9C65-D35E3D54601F">
    <pav:createdOn>2015-10-20 10:08:59 -0400</pav:createdOn>
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:4D463EE4-B17B-4CA9-909F-2363279F7740"/>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <rdfs:label>Highlight</rdfs:label>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/23E27A87-DE2D-420E-9D6D-98BD122107FF">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/3322</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdfs:label>diazepam</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N90b6b580ee124c4ab59fdc9cb13eb53e">
    <domeo:sets rdf:resource="urn:pddi:uuid:61101688-558B-47B6-AC53-B090085A57C3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:20B499B4-2C14-4656-9B9F-3B37ECC304FE">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8EAC845C-01E6-475A-9CB1-AA2A4E51AC22"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E4C87AB6-53E6-476A-8DF3-B503643E6E29">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4955F310-1A47-4B4F-8110-8835D9A41A0D"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FAD581CA-962D-4430-9B87-BF3BEEDC8518"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1ac30af8477c4bc1a9060f703e8e2030">
    <domeo:sets rdf:resource="urn:pddi:uuid:10D95FA3-6B6D-4F9C-ACC0-0B6692EDAB63"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0a4727c4c0364af2ba4b52da245f94eb">
    <domeo:sets rdf:resource="urn:pddi:uuid:86BE9337-A28D-474B-88DB-D20A43681D40"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B62FAB60-E745-424E-B505-33F14FF73D9A">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E52534C7-60CA-4A9C-9977-3877A0274FA3">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>tricyclic antidepressants</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:2E922CD3-E230-4081-A7F5-E65408CC2E66">
    <ao:exact>diazepam </ao:exact>
    <pav:createdOn>2015-10-20 10:09:17 -0400</pav:createdOn>
    <ao:suffix>administration. Moreover, as noted with alprazolam, the effect of fluvoxamine may even be more pronounced when it is administered at higher doses. </ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:2E922CD3-E230-4081-A7F5-E65408CC2E66"/>
    <ao:prefix>It is likely that this experience significantly underestimates the degree of accumulation that might occur with repeated </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <domeo:uuid>2E922CD3-E230-4081-A7F5-E65408CC2E66</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:E1A13E6B-FEC0-4B30-A55E-08FABDACB329">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BB52ED61-3987-4ADE-94FA-3476768CFBBA"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:4F574216-3440-43A0-9611-75D6F91A9696">
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:4F574216-3440-43A0-9611-75D6F91A9696"/>
    <domeo:uuid>4F574216-3440-43A0-9611-75D6F91A9696</domeo:uuid>
    <pav:createdOn>2015-10-20 09:22:19 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix>5.4 Potential Thioridazine Interaction  </ao:prefix>
    <ao:exact>The effect of fluvoxamine (25 mg b.i.d. for one week) on thioridazine steady-state concentrations was evaluated in ten male inpatients with schizophrenia. Concentrations of thioridazine and its two active metabolites, mesoridazine and sulforidazine, increased 3-fold following coadministration of fluvoxamine.    Thioridazine administration produces a dose-related prolongation of the QTc interval, which is associated with serious ventricular arrhythmias, such as torsades de pointes-type arrhythmias, and sudden death. It is likely that this experience underestimates the degree of risk that might occur with higher doses of thioridazine. Moreover, the effect of fluvoxamine may be even more pronounced when it is administered at higher doses.    Therefore, fluvoxamine and thioridazine should not be coadministered [see Contraindications (4.1)]. </ao:exact>
    <ao:suffix>xsd:String</ao:suffix>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3434A6E3-7B0B-4EB8-B5C1-C85AB7A49A6C">
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">4</pav:versionNumber>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <ao:context rdf:resource="urn:domeoclient:uuid:8FEA5EE6-6737-4181-AE96-5FBC6B3F9EF7"/>
    <rdfs:label>Highlight</rdfs:label>
    <pav:previousVersion>urn:domeoserver:annotationset:7084298F-F868-484E-9091-B9ED9E4588DB</pav:previousVersion>
    <pav:lineageUri>urn:domeoserver:annotationset:f27b0e7c-cb50-4d0f-beb8-d28df2703767</pav:lineageUri>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EC6D4111-C748-434F-ACE8-BE629911FB11</domeo:belongsToSet>
    <pav:createdOn>2015-08-20 11:38:44 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:lastSavedOn>2015-08-20 11:43:54 -0400</pav:lastSavedOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/77B85D6B-14C5-474E-B9E1-1D425AFB1FF6">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose>200</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/4450</dailymed:activeMoietyRxCUI>
    <rdfs:label>fluconazole</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:29473796-19E7-4D38-9560-AA88C28F9FD8">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:13C01E54-2C05-46E0-9405-B5481F5383A4"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C72F97A8-3245-47CA-97B3-91682D7B0A05">
    <rdfs:label>Teriflunomide</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5B620FFB-C1CB-4133-9D9C-4C13AE1899D9">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>EMSAM</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6B951705-7BDF-467E-B106-ECB07C4F2575">
    <rdfs:label>phenothiazines</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/0</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6C2CDE1C-3327-4F5A-9E88-D6B10FDAD89F">
    <rdfs:label>cimetidine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>800</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F9F9E840-AE21-47EB-8034-EBEBE33B89CB">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:A50A7597-EF00-47D2-84A0-934DA6C9A4E5"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:005201C9-318D-430E-87E5-46A87DF5B164">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:8A3DD1C2-0404-4AB4-ABB3-83155933D3E4"/>
    <dikbD2R:comment>Increased plasma concentration</dikbD2R:comment>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nca892a7f58ba443dab103ba4152a631a">
    <domeo:sets rdf:resource="urn:pddi:uuid:D0021CCC-FA29-4F5E-BFAC-724F661BFE63"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne4b98f5e139b4bfb8b438ee2a21a7a31">
    <domeo:sets rdf:resource="urn:pddi:uuid:2453256F-56D4-4235-89E1-77477041E2D7"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N359701b5d9c649529b0cd5fd2d76032a">
    <domeo:sets rdf:resource="urn:pddi:uuid:0FCEDCED-41C1-4198-8B22-0EC7ABCC4985"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0F8843A3-78E9-4700-99C6-6261D97D5E8F">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F2C6F9E4-8CE7-4261-BFC5-E81DFEE2EB11"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9D1EE414-DD79-41FD-89D1-F4D250EAC251">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>TCA</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd3a86f2ce691499eaeb58c290157d5a6">
    <domeo:sets rdf:resource="urn:pddi:uuid:5ACB2517-A52D-4E82-AC3A-47C6A5641B6C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:355E164D-5258-46CF-934C-DB54FC42D20B">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F62DAECF-B521-4072-903B-105D028FA312"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E668CBCE-0E0D-4E1A-AF3B-8103D4E0070E"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2d08b2c0616449dbb9a5d3a342b2cef3">
    <domeo:sets rdf:resource="urn:pddi:uuid:2365DEAC-00CA-4928-8DE6-495C26047070"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:40DAB383-D55F-4575-9AFD-BAF1EDCEBB4F">
    <rdfs:label>Highlight</rdfs:label>
    <domeo:belongsToSet>urn:domeoserver:annotationset:EB61713F-98B8-4950-B8CE-4DC0EDCB9A49</domeo:belongsToSet>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <pav:lineageUri>urn:domeoserver:annotationset:f3c5be53-27fb-441d-b100-ab1fce7598a9</pav:lineageUri>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#Highlight"/>
    <pav:previousVersion>urn:domeoserver:annotationset:C83FEB89-21C7-463A-912F-EB5C5913F3D0</pav:previousVersion>
    <pav:lastSavedOn>2015-10-20 10:10:33 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">11</pav:versionNumber>
    <pav:createdOn>2015-10-20 10:09:05 -0400</pav:createdOn>
    <ao:context rdf:resource="urn:domeoclient:uuid:80D2C2AA-4236-485D-92E2-0282A214379B"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd5649aadb483419295f6a3eca1e37d8a">
    <domeo:sets rdf:resource="urn:pddi:uuid:DA9E702B-0D60-4D59-A24C-4E056166C97D"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C733351C-24EF-4F5F-A079-2ED71A363CD5">
    <rdfs:label>lorazepam</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6470</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>4</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:038D22CB-99BD-44B8-B516-E1EA64EA74E9">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C114DF72-D510-44D5-BB77-FE602EB2056C"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FB739724-7344-4810-BDFC-5B0A97A5F4BA"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:52BD9C60-3B4E-45B9-8AF0-3435FD2293B6">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/48E4EE2E-ECE1-4646-8833-535FB2396C55"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/910AFC45-5DD4-4BA5-899D-4A8448711B1D"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:1898BF1E-CE40-436B-968F-1154C1CF097C">
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:prefix>, or similar agents, and such an effect may be anticipated with CMI because of its structural similarity to other tricyclic antidepressants.  </ao:prefix>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <pav:createdOn>2015-09-29 11:40:20 -0400</pav:createdOn>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:exact>The plasma concentration of CMI has been reported to be increased by the concomitant administration of haloperidol; plasma levels of several closely related tricyclic antidepressants have been reported to be increased by the concomitant administration of methylphenidate or hepatic enzyme inhibitors (e.g., cimetidine, fluoxetine) and decreased by the concomitant administration of hepatic enzyme inducers (e.g., barbiturates, phenytoin), and such an effect may be anticipated with CMI as well. Administration of CMI has been reported to increase the plasma levels of phenobarbital, if given concomitantly (see CLINICAL PHARMACOLOGY, Interactions).</ao:exact>
    <domeo:uuid>1898BF1E-CE40-436B-968F-1154C1CF097C</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:1898BF1E-CE40-436B-968F-1154C1CF097C"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5EBA6AC6-09E9-4AA0-BE58-CDE431CC0CC8">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BD3C6BF3-0975-4B55-AA20-C3F17DEE6EE6"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0ee07473d75c487090f7f6c667a1835d">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:32239FB5-C87B-4DAD-9EFE-23D013750E32">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:680BB734-E110-4953-A6ED-937A50138C7D"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4CAB82EB-7168-4782-BE64-4BFDB88A1168">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>clarithromycin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N160b709ba9744be9a26078ce9762bf88">
    <domeo:sets rdf:resource="urn:pddi:uuid:3EB83181-3FB7-4176-BECD-DE59315E46E1"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/1BB95734-B178-4799-AF06-C9F9B16FCFF5">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>metoprolol</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6918</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BF807C1C-F7D1-4CFA-9875-6A7C6630DD4F">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:6F80331D-77B9-473C-9E85-DFDA8F1062C4"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:20A4F13C-F9D0-424D-9960-73CDCA576AD1">
    <ao:exact>Levothyroxine    In healthy subjects who had received EMSAM 6 mg per 24 hours for 10 days, single dose administration with levothyroxine (150 mcg) did not alter the pharmacokinetics of either selegiline or levothyroxine [see Drug Interactions (7.4) and (7.5)].</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/b891bd9f-fdb8-4862-89c5-ecdd700398a3.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <domeo:uuid>20A4F13C-F9D0-424D-9960-73CDCA576AD1</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:20A4F13C-F9D0-424D-9960-73CDCA576AD1"/>
    <pav:createdOn>2015-10-16 10:39:24 -0400</pav:createdOn>
    <ao:prefix>   </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FFF7068E-F234-4C9C-AE2F-87BB57C02E7B">
    <rdfs:label>Rifampin</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/9384</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3445C449-56D0-4244-9004-CCC744F4CF2F">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6373</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>levonorgestrel</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1fa0d25fb1ad46a4ad7f514b67f3f06c">
    <domeo:sets rdf:resource="urn:pddi:uuid:5FC3A0F4-2409-4406-82D2-08ECEF04A6BE"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8d49210c58304e228a7b47e0f2751bd1">
    <domeo:sets rdf:resource="urn:pddi:uuid:99ACBB97-47CE-47E6-9BD3-808EDED1ECF7"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B5DE11DD-2736-44CF-BA0E-E3E353A295AD">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:E6EB594A-72B4-4617-96D0-2F7BF3A36FE2"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B7C2144D-8452-4A0D-AE4C-F4BD352AC755">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/454FDA85-31D5-4267-A049-34D9A53C6A8E"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/117D065F-EB05-4E4F-BEFC-57F37CF5611D"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/70D5F376-877B-4127-9822-34F169B5B9CA">
    <rdfs:label>EMSAM</rdfs:label>
    <dikbD2R:dose>6</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne1ef6f53310740c699aca737730e391b">
    <domeo:sets rdf:resource="urn:pddi:uuid:00F17E52-DA80-479D-A14C-5E2CD0F791CB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:295F7AE6-29BA-480B-9EEE-43F4D55E2698">
    <ao:exact>Concomitant administration of fluconazole 200 mg daily and clarithromycin 500 mg twice daily to 21 healthy volunteers led to increases in the mean steady-state clarithromycin Cmin and AUC of 33% and 18%, respectively. Steady-state concentrations of 14-OH clarithromycin were not significantly affected by concomitant administration of fluconazole.</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-13 11:52:14 -0400</pav:createdOn>
    <domeo:uuid>295F7AE6-29BA-480B-9EEE-43F4D55E2698</domeo:uuid>
    <ao:prefix>Simultaneous administration of clarithromycin tablets and didanosine to 12 HIV-infected adult patients resulted in no statistically significant change in didanosine pharmacokinetics.  </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:suffix>xsd:String</ao:suffix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:295F7AE6-29BA-480B-9EEE-43F4D55E2698"/>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DA6F7D85-DD9E-4845-BF51-0263865BEDD4">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5AEFC4D4-5364-48F0-969E-09164EA86C60"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EFA928C7-C58C-4CE6-B9F7-4B61069AEC50"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:DA9E702B-0D60-4D59-A24C-4E056166C97D">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:51966DC5-A020-44D6-BA4E-BE64F3B5564A"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:3D644552-4A06-4136-BA23-8792DC6A153B">
    <ao:suffix>and fluvoxamine should not ordinarily be coadministered. </ao:suffix>
    <ao:exact>diazepam </ao:exact>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/53664f8d-3a93-9f2b-daee-380707e4062c.html</ao:hasSource>
    <ao:prefix>Accordingly, </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:3D644552-4A06-4136-BA23-8792DC6A153B"/>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-10-20 10:09:23 -0400</pav:createdOn>
    <domeo:uuid>3D644552-4A06-4136-BA23-8792DC6A153B</domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/07F75683-487F-4E5B-A891-FDEADC1E8A0B">
    <rdfs:label>alprazolam</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FDBC2BB8-0140-4D15-93D3-FBC56FC49844">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>rifabutin</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:9EA2AE2B-0305-4AD7-B154-4BFC69BFA513">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E37C0FB8-8BF3-4E5D-9C4D-76A95F6FE4A2"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/217187CC-6A1C-47B0-B132-35E7CFCFAA9F"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BBD6701A-D6BD-4EEC-9666-1F50FE3FFEB6">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:F70B12B8-16F0-428C-853D-84AEE83FCC4F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:805CB069-7975-4076-9068-35EB8BF59994">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E1CA8CCE-BC2F-433E-BABF-7DDD6537C722"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B1712E9C-0C41-4680-B97E-4A8DE5131457"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:64DF4E01-7FD9-4C44-BD7E-89C3DAB13158">
    <domeo:belongsToSet>urn:domeoserver:annotationset:0C66E149-27D5-4A0D-95AB-15407AB60EA7</domeo:belongsToSet>
    <pav:createdWith>urn:domeo:software:id:Domeo-2.0alpha-040</pav:createdWith>
    <dikbD2R:evidenceType>evidence-supports</dikbD2R:evidenceType>
    <rdfs:label>ddi Annotation</rdfs:label>
    <pav:previousVersion>xsd:String</pav:previousVersion>
    <pav:createdBy>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</pav:createdBy>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#ddiAnnotation"/>
    <dikbD2R:assertionType>drug-drug-interaction</dikbD2R:assertionType>
    <ao:context rdf:resource="urn:domeoclient:uuid:1C6BED4B-513C-498D-BF7D-7A9355D90DE2"/>
    <ao:body rdf:nodeID="N7129b903b70347e68815889b06021fb2"/>
    <pav:lineageUri>urn:domeoserver:annotation:7D35AFBD-C1B3-45D8-8F24-CF3FFF683091</pav:lineageUri>
    <pav:lastSavedOn>2015-09-29 09:58:27 -0400</pav:lastSavedOn>
    <pav:versionNumber rdf:datatype="http://www.w3.org/2001/XMLSchema#integer">1</pav:versionNumber>
    <pav:createdOn>2015-09-29 09:45:37 -0400</pav:createdOn>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DF9B1097-2090-453D-AF71-6310D301DA86">
    <rdfs:label>ketoconazole</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4edd194f0db44a5a8305511b5046df5c">
    <domeo:sets rdf:resource="urn:pddi:uuid:ACE81FE6-2F4B-4734-AB4B-497D5C50F2A1"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:EAB51D08-C5E4-414E-AE31-C67CFC40A051">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0092DA02-6EBA-4DCF-9402-22C327ADEE16"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/06D751E5-D380-434D-9CDF-03B12807E7F6"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C53DC362-8533-4B85-8AA7-6D92A5C9C174">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>paroxetine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:24BE6835-72DA-46D2-92DD-53AB9733080E">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/0FDEDBD9-15D7-4853-9AFC-81D6084B22D7"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/625296F7-1267-4ACF-B45F-0D20A05D262B"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/89732B3A-74A8-4C41-AEDC-A88F844360CD">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>alprazolam</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N42864e4497dc4d31b17c806aacbab59e">
    <domeo:sets rdf:resource="urn:pddi:uuid:B96BE6A9-C9A5-46A2-9EEA-CFC9F7788F2E"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/008259E3-59A1-4EC0-B54F-8C531B562044">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8331</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>pimozide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2E88862A-E48A-4E4D-9585-9598A488A431">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>80</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8787</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>propranolol</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:737767C4-4F05-463E-96C7-13F0E2D918F3">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/41B61282-12A0-4568-8B59-D93188A41363"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2BB9235C-F6FC-4F92-A5DB-3F6E5F01D13D"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:45BEC177-C8EC-4C18-A85D-871A6FD0B5B1">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:D139441C-B779-463A-AD5E-2E77ACEB3547"/>
    <dikbD2R:comment>Reduced plasma concentration of saquinavir</dikbD2R:comment>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/658B18B6-2CE7-446A-B0E6-7CE8DAA4FB5E">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>anticoagulants</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5F07294B-DDE9-4785-BAD5-2E3C0D58F502">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/metabolite"/>
    <dikbD2R:dose></dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>14-OH clarithromycin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncd934dce7d34452b97c1a9852c232ee7">
    <domeo:sets rdf:resource="urn:pddi:uuid:AD775091-85D8-4B77-9121-BF7A457ACD7E"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2CC9C924-9A66-42D9-899D-A6C742155727">
    <rdfs:label>carbamazepine</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2002</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N13fc23429b9b42838f46ef83c8ada125">
    <domeo:sets rdf:resource="urn:pddi:uuid:12B79C6A-D8E7-41BB-A5CC-B2F760C3F0DC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:78BB9141-0159-4703-BA9D-BD34CB79F242">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:FE6DBDC0-66B5-4B58-A384-A1B072592EB0"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:8F8E9C64-8696-4ACD-9B24-35D4C06DD4F5">
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/38642D80-AAA6-4196-A033-3977FF35B48A.html</ao:hasSource>
    <ao:suffix>xsd:String</ao:suffix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <domeo:uuid>8F8E9C64-8696-4ACD-9B24-35D4C06DD4F5</domeo:uuid>
    <ao:prefix>concentrations (57%), increased plasma bismuth trough concentrations (48%), and increased 14-hydroxyclarithromycin plasma concentrations (31%). These effects are clinically insignificant.  </ao:prefix>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:8F8E9C64-8696-4ACD-9B24-35D4C06DD4F5"/>
    <ao:exact>Simultaneous oral administration of clarithromycin tablets and zidovudine to HIV infected adult patients resulted in decreased steady-state zidovudine concentrations. When 500 mg of clarithromycin were administered twice daily, steady-state zidovudine AUC was reduced by a mean of 12% (n=4). Individual values ranged from a decrease of 34% to an increase of 14%. Based on limited data in 24 patients, when clarithromycin tablets were administered two to four hours prior to oral zidovudine, the steady-state zidovudine Cmax was increased by approximately 2-fold, whereas the AUC was unaffected.</ao:exact>
    <pav:createdOn>2015-10-13 11:43:21 -0400</pav:createdOn>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CBE54F32-8CD8-43A0-9C0B-347A34E16D47">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>1000</dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>pioglitazone</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4eff9c0c5c984eb5b43dbfb7a89876a1">
    <domeo:sets rdf:resource="urn:pddi:uuid:8C4505F8-A67B-48DF-AD0B-0C0AF2E89651"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:596EF7A4-A1DA-43AD-98A2-505C04A492A6">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/15706B7B-7757-4106-93E6-5173979D3824"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A13D3801-36D7-4149-A012-C359E457F596"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:56EA7F48-3179-452B-BB6A-F74C96533A0D">
    <rdfs:label>Required</rdfs:label>
    <dct:description>A required monitoring recommendation is related to the pharmacogenomic biomarker.</dct:description>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <poc:MonitoringRecommendation>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#required</poc:MonitoringRecommendation>
    <sio:SIO_000563>poc:MonitoringRecommendation</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/519C269B-F197-4169-9CC0-1BC57D07146D">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>Teriflunomide</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BC555E53-2CF4-4F52-8C38-A251F6E5B05D">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/25C1054A-69CC-44B3-A4B2-040328EB3E72"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/66C174F9-3E19-45E9-8797-706347DCF898"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc394ce39837a42e7894e92d63c546a3d">
    <domeo:sets rdf:resource="urn:pddi:uuid:385F758F-56E4-4CEF-B518-C20BF7DCCF03"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N698b13365cb3486eb8c871d8679a8eba">
    <domeo:sets rdf:resource="urn:pddi:uuid:F182EC31-7982-40C0-85FC-6107B586545C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbbb7234ff838498c8238668259c311b6">
    <domeo:sets rdf:resource="urn:pddi:uuid:F9F9E840-AE21-47EB-8034-EBEBE33B89CB"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:63A76675-C58E-4CF3-9C9E-588174E52742">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:negative</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BF9602B4-C193-49D9-B91D-95A5DB4FEC73"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2488D451-0C05-404A-AE57-E5B272F707DE">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <rdfs:label>phenothiazines</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/0</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:82327B05-8BB1-401E-ACB4-42C3E0930D57">
    <dct:description>The pharmacogenomic biomarker is associated with an increased risk of toxicity.</dct:description>
    <sio:SIO_000563>poc:PharmacodynamicImpact</sio:SIO_000563>
    <poc:PharmacodynamicImpact>http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#drug-toxicity-risk-increased</poc:PharmacodynamicImpact>
    <rdfs:label>Increased Toxicity Risk</rdfs:label>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F0C18349-F3A3-4E26-8CE9-BF9ABD45297A">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/40256306-A3CF-446C-9E11-97451E784EEE"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9CCD590F-A14D-4E82-9365-527B1627BB84"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D2ADEC8E-3FB1-43F1-9101-6807EA638559">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:comment>Two studies performed, with average increase of 7% and 20%</dikbD2R:comment>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1EE51B7B-C0DE-4E81-AB02-AA8498593241"/>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FC4D49AA-F064-4D14-8330-B58B8930B171">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>mitoxantrone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F5FCFDEA-A058-4B82-B10D-81427E8E5243">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>fluvoxamine</rdfs:label>
    <dikbD2R:dose>50</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/EB23C209-ED58-4EFD-BDBB-82B5E438C421">
    <dikbD2R:dose>500</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>clarithromycin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4537cd741edd4782bd34faae3e12d1f4">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5A5AD0EF-537C-4948-8F42-62843FC47E81">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>cimetidine</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na4403ec5e5284f7c922273a5e9806c1d">
    <domeo:sets rdf:resource="urn:pddi:uuid:B4202C0D-92E5-4602-874E-FAC955BFF448"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N321e7762d7ab45389edf893ea84cf636">
    <domeo:sets rdf:resource="urn:pddi:uuid:946DE5A8-F174-4332-A17C-C1B1D458457F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na1229c9b766d4ac38a11fc1d734d73e8">
    <domeo:sets rdf:resource="urn:pddi:uuid:4FD4E4F5-61CF-499D-A803-E6FD77E18839"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F7688443-E658-446B-95E1-BD1EFCD05CC4">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/8331</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>2</dikbD2R:dose>
    <rdfs:label>pimozide</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbca81144016e428985fd093cdeb4c421">
    <domeo:sets rdf:resource="urn:pddi:uuid:9F3C3FE4-7308-4AB5-AFD4-095B9C07E8B3"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D510FF59-847E-4C27-A3FF-FC8F654AAC36">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:47F05620-DDA9-487E-A23B-0B8B4ED83049"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7DCEBA9E-178D-4402-AE75-34205645FFE2">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:AF31D033-4AD7-4A2C-B1DF-ED88AA603171"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/30B562BD-11DC-47B0-A4BA-65B20C3A5A8B">
    <dikbD2R:dose></dikbD2R:dose>
    <rdfs:label>atazanavir</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/343047</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb2718ba3935a4f369425c1a275c700fb">
    <domeo:sets rdf:resource="urn:pddi:uuid:B89FBECC-35DF-4F80-A180-33F0F5532E13"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8dd28c7185ff490293abf79bac9cf4fe">
    <domeo:sets rdf:resource="urn:pddi:uuid:2A85AB94-C993-4CA7-BB35-A605E1007165"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:7B0F5D3A-BDC8-442E-8D89-EC9B654C9953">
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:EA099A9E-EE38-4634-8CDC-59117F9587EA"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N66e10cb983de4c1bad0f75f90c2fb04e">
    <domeo:sets rdf:resource="urn:pddi:uuid:056CA2C9-322E-45AA-81BC-D781489782F3"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N92a68b64a6df4649be026a7a48ac7453">
    <domeo:sets rdf:resource="urn:pddi:uuid:235D11AE-12F2-493E-AA97-F800206B2FFC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:8F8A29D9-1378-48CD-8E5F-EAEBE68D2E8F">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2BC02782-DDAC-4C90-AC4F-75A613530F88"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N87abe59af3a949148ae5e13e9c3db9d5">
    <domeo:sets rdf:resource="urn:pddi:uuid:32239FB5-C87B-4DAD-9EFE-23D013750E32"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/35269557-A44C-490F-BBB2-239DF98060A2">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>TCA</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N43b7d14915654cb4974c6a6e13d4ce18">
    <domeo:sets rdf:resource="urn:pddi:uuid:94217DDD-9B20-4E77-8235-8C45672E523C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N88b10d7887604c56801f7963217b65f7">
    <domeo:sets rdf:resource="urn:pddi:uuid:595D8B80-0709-42C5-8A0C-43FDA50313C4"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/79DF7AA8-5F91-4E74-8FB2-F99518CA0CBC">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>clarithromycin</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A50A7597-EF00-47D2-84A0-934DA6C9A4E5">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9DF6A73F-A12D-4E35-8150-87A99531211A"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B14EF34E-916A-4CB4-8766-72FB1F5DA995"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7129b903b70347e68815889b06021fb2">
    <domeo:sets rdf:resource="urn:pddi:uuid:E4A17105-DC85-42EE-858F-047500667634"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb8be16dcbdd04188a97ec872db17dc85">
    <domeo:sets rdf:resource="urn:pddi:uuid:EAC5533B-4DCB-4C46-AADE-0F32094343E0"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8c003dc6a2d740f287117c5cd5756f73">
    <domeo:sets rdf:resource="urn:pddi:uuid:B15BE827-BE10-4A89-942D-4F762E070FB9"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N51188617479245079c00b9949eecf225">
    <domeo:sets rdf:resource="urn:pddi:uuid:A35E54E2-7FB2-4533-9409-F9BF2CBC38B9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:00C393BA-0091-449D-A6BE-AD5BEA51DB22">
    <ao:suffix>, itraconazole, ketoconazole), barbiturates, beta-blockers, calcium channel blockers (e.g., diltiazem, nifedipine, verapamil), chloramphenicol, clarithromycin, corticosteroids, cyclosporine, cardiac glycoside preparations, clofibrate, oral or other syste</ao:suffix>
    <ao:exact>fluconazole</ao:exact>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <ao:prefix>(e.g., </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <pav:createdOn>2015-10-14 11:40:19 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/55816042-946d-4bec-9461-bd998628ff45.html</ao:hasSource>
    <domeo:uuid>00C393BA-0091-449D-A6BE-AD5BEA51DB22</domeo:uuid>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:00C393BA-0091-449D-A6BE-AD5BEA51DB22"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne81a4e23382443a48e622e37420fed55">
    <domeo:sets rdf:resource="urn:pddi:uuid:01727474-D904-451D-8C6B-E656DAC891F1"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E3C63644-36C5-476F-826C-B41250DC99E4">
    <rdfs:label>repaglinide</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/73044</dailymed:activeMoietyRxCUI>
    <dikbD2R:dose>Unk</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9434E333-272E-47B3-AD13-C606E857797B">
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6813</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dikbD2R:dose></dikbD2R:dose>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>methadone</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/BCEC36F1-A3A6-4CAB-A507-D8DA9D9D2228">
    <rdfs:label>clarithromycin</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N77dc8b84efcb48999b14b3b3caa1ee13">
    <domeo:sets rdf:resource="urn:pddi:uuid:A9729445-9798-4C2A-83D8-20CA3981A6AA"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na8792dcd0dd2459f90426069e71d5d22">
    <domeo:sets rdf:resource="urn:pddi:uuid:C53210CC-8E79-4DEA-B11A-B10AF0BF8EDE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:05E6D336-7414-4C4F-AC25-BF6E922A2CAD">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:4600E031-72B1-49EA-932D-DF707DFFDA02"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/49A838BE-6459-4679-85D0-F66AA6EEA5B2">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-product"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
    <rdfs:label>GILENYA</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C2DAAC63-7E05-4EDC-A282-BB2EEA69091F">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9434E333-272E-47B3-AD13-C606E857797B"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DBDCACDA-3C0B-4215-BB82-5C7F301BB787"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/78983CA4-8DC3-4283-A4DD-692E1A2EF9AC">
    <rdfs:label>TCA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F8ED774F-FF92-4E0A-8F8A-A921A3B0C159">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/515AAF42-C90B-48EF-A376-C25676634272"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/A2A62E19-E90B-4C15-8F9E-E89CCBFD218F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A021DA3A-E5BE-407C-AF76-360319A511B8">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:BC555E53-2CF4-4F52-8C38-A251F6E5B05D"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Naf0ffb03383246adb3167a43b6dc738b">
    <domeo:sets rdf:resource="urn:pddi:uuid:9793E575-E9F3-4454-A73F-F38F27E06168"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N11675b0f61894626bb6caa6d0718d97d">
    <domeo:sets rdf:resource="urn:pddi:uuid:2CE45FE3-827E-44F2-B60A-EE526B4D1203"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0a5610e932214c25879ce499e927f6b3">
    <domeo:sets rdf:resource="urn:pddi:uuid:247EEF24-F836-468A-B1C2-DECCED9FDEC5"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:domeoclient:uuid:B690CCB5-1067-4435-BF81-418A58CE39E2">
    <ao:suffix>as well. Administration of CMI has been reported to increase the plasma levels of </ao:suffix>
    <domeo:uuid></domeo:uuid>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#PrefixSuffixTextSelector"/>
    <pav:createdOn>2015-09-29 09:46:33 -0400</pav:createdOn>
    <ao:hasSource>http://dbmi-icode-01.dbmi.pitt.edu:80/DDI-labels/1809bcb4-5fcc-45ca-986a-4fa5edcd4b5e.html</ao:hasSource>
    <ao:exact>CMI </ao:exact>
    <ao:prefix>), and such an effect may be anticipated with </ao:prefix>
    <rdf:type rdf:resource="http://www.w3.org/ns/oa#SpecificResource"/>
    <ao:hasSelector rdf:resource="urn:domeoclient:uuid:B690CCB5-1067-4435-BF81-418A58CE39E2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:B15CEE3F-DFB6-4C26-92A9-6BC508FA3986">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/20775C9A-854C-4232-8CF1-D088BD273635"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E52534C7-60CA-4A9C-9977-3877A0274FA3"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6866B193-7C66-4494-8005-FFC7D20665B3">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdfs:label>Thioridazine</rdfs:label>
    <dikbD2R:dose>Unkhttp://arpinotrattoria.com/</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/10502</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nca59f240375e46828239339903e74612">
    <domeo:sets rdf:resource="urn:pddi:uuid:B57F40FB-83F6-4E9D-A5C6-0BEDE1CC6D92"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/40FF46B3-70F7-45A8-82AE-ED83632A18F8">
    <rdfs:label>cimetidine</rdfs:label>
    <dikbD2R:dose>30</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/33A27A6C-1E00-4665-A76F-16BD9ACE8082">
    <rdfs:label>fluvoxamine</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/42355</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C7255E3A-928A-4A5D-A862-248B7CCDA86E">
    <rdfs:label>paroxetine</rdfs:label>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/32937</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose>30</dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N633f1fc2e80348c39edaa213b91ccc69">
    <domeo:sets rdf:resource="urn:pddi:uuid:9AD5F276-76A1-4489-A1E5-B9B85E27029E"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndc1b31e0d0d143d48962c538cedca47e">
    <domeo:sets rdf:resource="urn:pddi:uuid:DE595579-2726-43AE-BE6A-8D48C30C5CFD"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:A48D457C-C4DA-41E4-9B8B-37D2AF09F492">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CE393762-B4C3-4ED9-AC81-0E79CAD266FD"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/CEB4345E-465D-4401-B785-B85E1D649721"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0c104681e4dd4b9fb81ae3783d1bd180">
    <domeo:sets rdf:resource="urn:pddi:uuid:260378E5-F4CE-4282-BADB-45604F318D7E"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D05C560B-0A2A-45F3-8B4B-34CECB64AB75">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8F89DD01-5204-4190-BBC4-A5F41E491CE0"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B9988126-6B74-45A7-89BE-556C38D6B120"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1CE9BEA9-9313-46A3-B873-855AD934D9D4">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E332D54E-7DD7-464B-B67C-B0A710888D13"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/D9D0C350-E217-4D24-B455-4D6BFDC3CF79"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:5798A46F-1E12-45C8-942C-2DB0C00480D8">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/4E3F940B-842C-4B25-B4CE-F3012B81FFE3"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/761B93B7-4499-4FEC-9288-AE7AB258656A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2631e625a678462d9291c12e4677d0c9">
    <domeo:sets rdf:resource="urn:pddi:uuid:3B64C840-21D5-4CE4-8EC2-93996F21CDBE"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C9067E0C-43A2-40C2-A7D7-E7A9149E6EF0">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FC4D49AA-F064-4D14-8330-B58B8930B171"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5BDCB383-7EA9-42BB-A1ED-476F28689D49"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:D4B0B3A5-C93F-4A95-98BB-819649B7497D">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:26AC1AC5-7BF2-4256-BC61-4CA271F577C9"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:statement>ncit:quantitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/13864D12-9E66-48A1-997D-86524B01BA2A">
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>clarithromycin</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/21212</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na7880cd1f2ea49ca82c325887616fce3">
    <domeo:sets rdf:resource="urn:pddi:uuid:5EBA6AC6-09E9-4AA0-BE58-CDE431CC0CC8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2BC02782-DDAC-4C90-AC4F-75A613530F88">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8CE909D8-6F7F-4F40-8D3F-7A494D18C465"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C551FD48-3DFB-43BB-8FCD-511F078199DC"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1c6512802de44c9783a76192729e400e">
    <domeo:sets rdf:resource="urn:pddi:uuid:B079047A-8D2F-4E32-BDE4-963FB269A9E6"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3ec7df7a327b455baa54d89a7abd2d4d">
    <domeo:sets rdf:resource="urn:pddi:uuid:DA473F3A-1EA1-4A12-9DE2-F3829DF3154F"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E965E51E-54F7-4BC3-BA85-B2BE1A92A6A1">
    <dikbD2R:dose>30</dikbD2R:dose>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>duloxetine</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6c445ed610fa4fdd8aff39c273172b38">
    <domeo:sets rdf:resource="urn:pddi:uuid:9730CBBB-7089-4CCE-82A1-294E965F9063"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:C86626A1-C299-4F5F-85F2-A0BC4F64FA7E">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/E9EF0517-2E1D-4217-8D3E-05CF7B6973EA"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8457BA6E-641E-4DB2-9E03-728451CB6CD6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:25AAB2BB-7B3C-4E9D-BA17-0E800465FE42">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6A2C2680-8895-4D3E-941E-1212437B892A"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C3FFAA74-97B8-4C05-8DD1-D5CD4AB8EFFB"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4c863206311642cf8f47e3859809062b">
    <domeo:sets rdf:resource="urn:pddi:uuid:CB01354B-0B3C-435A-AE84-FB2C130E6745"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N61120de9a93941ddb85ef30afa63453e">
    <domeo:sets rdf:resource="urn:pddi:uuid:C5B78899-CFE3-472C-B57D-E64D78A48245"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/FE36B559-7A41-4F16-BA6B-EED9B64147C7">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>saquinavir</rdfs:label>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/83395</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd431148f817448108b584b102427c9c9">
    <domeo:sets rdf:resource="urn:pddi:uuid:586ED5FE-8D6E-43EE-B342-B85C076133ED"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N15640616b619410ca23962fdbffc136f">
    <domeo:sets rdf:resource="urn:pddi:uuid:071BC921-234F-46F2-B81F-373E3EBB5348"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd295e3fb57864c72b0c1c1ba19558ac1">
    <domeo:sets rdf:resource="urn:pddi:uuid:E4DB9111-A9D8-47D5-ACE0-D3115A4EFD3E"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/15EFADFC-D2D6-4E04-96C7-C3E754B92307">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>benzodiazepines</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/0</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dikbD2R:dose></dikbD2R:dose>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/1575541E-207B-4264-8BEB-7DD0D0427ECB">
    <rdfs:label>omeprazole</rdfs:label>
    <dikbD2R:dose>40</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/7646</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd2e1c1cf2e9e491d97e9c4b59875f2f0">
    <domeo:sets rdf:resource="urn:pddi:uuid:E777B05F-C229-40C7-8566-C6DF7886F462"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na0bfd2f416534568ac32f244cd9a90e2">
    <domeo:sets rdf:resource="urn:pddi:uuid:20DCDD14-451F-4CB1-9298-CDF9CE771F69"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N221ec74960f54ec08cbdeaeec4768f6c">
    <domeo:sets rdf:resource="urn:pddi:uuid:5BA89E2E-8665-4836-BD65-19BCDA7CFA7F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3873be13859a4697998c760b17f4f3df">
    <domeo:sets rdf:resource="urn:pddi:uuid:720E94FB-4CCF-4CF2-A511-AD69BD8F84EE"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6af460554a2442bc9072b10502416f8a">
    <domeo:sets rdf:resource="urn:pddi:uuid:D75C7F62-CC9A-4600-8009-82D778F5EF67"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N53732b23cdd742259b132a46f0c850a4">
    <domeo:sets rdf:resource="urn:pddi:uuid:518BED41-7283-4522-8D89-FF422D1D8A85"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:65665911-B22B-4DA8-838A-23259BE53C9B">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5989B15D-72CA-4DF4-96C0-D41D0D41C034"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/49A838BE-6459-4679-85D0-F66AA6EEA5B2"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8482e424900f482db4a3daec10e4ea62">
    <domeo:sets rdf:resource="urn:pddi:uuid:9B156F67-B49D-47AE-AE7B-FD05838799AB"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F924CECD-3BCA-4F07-B76D-4F30EB2A95EA">
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <dikbD2R:dose>Unk</dikbD2R:dose>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6373</dailymed:activeMoietyRxCUI>
    <rdfs:label>levonorgestrel</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N70eb7750167843049cdf431a2d667b82">
    <domeo:sets rdf:resource="urn:pddi:uuid:D85E6C65-A039-4EF9-A805-FDF3D9518789"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:3F52ABFF-9B48-4938-86DF-78B3DEE83425">
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:65665911-B22B-4DA8-838A-23259BE53C9B"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6e5ba7c64c8841a091b5367d508ef847">
    <domeo:sets rdf:resource="urn:pddi:uuid:D25D94B9-2153-47D8-8167-6B4518DB2D98"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8da672a253184de39a067fda031c56d0">
    <domeo:sets rdf:resource="urn:pddi:uuid:701DB538-7BEA-4445-90B8-94717DA942D2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:720E94FB-4CCF-4CF2-A511-AD69BD8F84EE">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:02603A02-9277-416E-802B-D18E2636893E"/>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/27E601C5-F766-4F40-A8A9-1569CF0C7575">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/2541</dailymed:activeMoietyRxCUI>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <rdfs:label>cimetidine</rdfs:label>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:62385118-7FDC-4740-8C67-BDAE631F3391">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B46528F5-973A-43B6-85F6-03CCE7BD44A1"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8CB716C6-3DD1-4088-8B37-038F3FF1F8F9"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0992d2909649421baf18c58eaaae728f">
    <domeo:sets rdf:resource="urn:pddi:uuid:D510FF59-847E-4C27-A3FF-FC8F654AAC36"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4608515E-EFDE-40EC-A3C5-637B96ADD28F">
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:1944F90F-7575-4ECA-A8EF-A70D96EA6057"/>
    <dikbD2R:comment>Increased phenobarbital plasma levels</dikbD2R:comment>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5a337b328ade444ea37a8e239a9411e3">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N1d328f4b8f0245f89fe440d3342b4261">
    <domeo:sets rdf:resource="urn:pddi:uuid:75EB9D3A-7581-4BF9-AC53-3752B9011C68"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8407dba312a64477bccbd16e58e48fdf">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N91d8420f400646e59632dccd56dbd34a">
    <domeo:sets rdf:resource="urn:pddi:uuid:7B300AA8-9780-472A-8138-C7B919A828B9"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:F182EC31-7982-40C0-85FC-6107B586545C">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2B21D2D6-E6EE-4F7B-8F60-4AA923FC48D2"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nabe39f57d83c425b979bb56129ee537a">
    <domeo:sets rdf:resource="urn:pddi:uuid:EB25F5A2-A93C-4C05-B6D1-40E7412D189B"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N74f190382db54789a03f29e6ba19ca5b">
    <domeo:sets rdf:resource="urn:pddi:uuid:F190A76C-B483-4803-A6B0-0273FFAE8DB0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:BF13ABBA-974C-4D13-B3D9-09EF5A6BB2FA">
    <rdfs:label>Alleles</rdfs:label>
    <ns1:Alleles>ta</ns1:Alleles>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:4FA59759-19EA-4EF8-88E3-6C759192CE8C">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/5A188DF2-F157-4BF3-9AAF-8E3A3754BAF4"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/1C466545-9969-4647-BA61-B32FAD73D045"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C7F050D4-7AEF-4BE7-81F0-6B5109D78143">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/drug-group"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>TCA</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndd8f8fe56a4a49cabbf518a5cb84521f">
    <domeo:sets rdf:resource="urn:pddi:uuid:444EB9F5-84A6-404E-8D80-D5B360E815F8"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BE06FB39-1B13-4BA9-9ED4-B1668C339202">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/928E1D5F-0BF8-4B1F-9F2E-56E2EE706494"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2E5FECF6-16DC-4945-8E25-05D048937F3D"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbb5c0fab746940dda295037cfab3639c">
    <domeo:sets rdf:resource="urn:pddi:uuid:D81E0F3F-E93F-4A23-9E72-F8450AA979D6"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd6f77fd6d9b64259ba10eb25d0257a46">
    <domeo:sets rdf:resource="urn:pddi:uuid:A876D8F6-552D-4874-AE4D-80EF6F76EEF0"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:6E0A7B57-FF63-4A7C-9391-BBD7FECA3B05">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/3757690F-00EB-4283-B082-ABE1C19FD5EF"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/93B149A5-FCBD-48A1-B5CF-8A2639C47CFF"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd7bc74455c0942fdb2d9f8cfa16a2a82">
    <domeo:sets rdf:resource="urn:pddi:uuid:61884F07-2FBB-4359-A9E4-B4846ADBB0F0"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5493b2edd21b497aaca51d8a66e04fc7">
    <domeo:sets rdf:resource="urn:pddi:uuid:D52477D5-F344-4C63-A8C0-B5AB1F5D9A43"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1AEAE481-2177-4FCD-B21C-21C091519858">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/29181E2A-72A8-41CB-8C25-96A40C0E2471"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/17ED197A-2F4E-465C-ACD3-4034B90AE12A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5f30a8cb37974fc492ec20ec64906d37">
    <domeo:sets rdf:resource="urn:pddi:uuid:3C11326F-F54A-4B3F-8354-557EC02AF851"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N642afa43b37d4d489844a9925543a6b0">
    <domeo:sets rdf:resource="urn:pddi:uuid:FA376B57-1C54-4E13-9401-6D5DA4BC8B21"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C5E6C8F3-37BA-4D4E-AF52-4A413FF5AC2C">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>ketoconazole</rdfs:label>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/6135</dailymed:activeMoietyRxCUI>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N60166b5fcfd9443384ec451f7eb77326">
    <domeo:sets rdf:resource="urn:pddi:uuid:87A3A1EE-D987-4F2B-8DFB-B24B9B5DE85A"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DBDCACDA-3C0B-4215-BB82-5C7F301BB787">
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/203143</dailymed:activeMoietyRxCUI>
    <rdfs:label>fluvoxamine maleate</rdfs:label>
    <sio:SIO_000228>dikbD2R:precipitant-drug-of-interaction</sio:SIO_000228>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3f1b59dc267c4c09b31b8bf5ab553020">
    <domeo:sets rdf:resource="urn:pddi:uuid:A4688FBD-C9C3-49C1-8E9A-89A838425C26"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4d3c8255261d4da791f8cf199bb47a75">
    <domeo:sets rdf:resource="urn:pddi:uuid:85BE2C40-7BBF-47B9-B0F0-0C4F3E9176A6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:379E5FD5-5C78-435D-9C03-E9A46CD3F77F">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/F36BD825-3F71-43D7-926C-C60EDD1D12A3"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/35783469-A903-4427-96C8-B2BB98648CE2"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N80b54cbfb19f44c696c6b51dfa2d4e6b">
    <domeo:sets rdf:resource="urn:pddi:uuid:13CEB6A6-B8D0-40B6-955E-B735CF08F32E"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N163e9fbb440547eca1b9e1d7a01cbed0">
    <domeo:sets rdf:resource="urn:pddi:uuid:98F48C7E-A6A2-4BEB-B11D-0403BA73E069"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2bc3b068ecf4443492ab9ab282a8b80e">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0d052c11e4f1402584b8ad2ecda40e61">
    <domeo:sets rdf:resource="urn:pddi:uuid:8CC6D2D9-EC12-46A9-A31E-545B24323940"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N9e43cbb4b1b542749f8f9bed8737edb6">
    <domeo:sets rdf:resource="urn:pddi:uuid:3B88446F-BBBE-4200-B520-7533B65271BB"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N75a27fb842b64d4eaf70212ac5f32862">
    <domeo:sets rdf:resource="urn:pddi:uuid:B5727900-FDD2-4516-B18B-3022863A9E0B"/>
  </rdf:Description>
  <rdf:Description rdf:about="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/27D73D78-3872-4F3B-B360-73FB6DD1644D">
    <dikbD2R:dose>15</dikbD2R:dose>
    <dailymed:activeMoietyRxCUI>http://purl.bioontology.org/ontology/RXNORM/596</dailymed:activeMoietyRxCUI>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/active-ingredient"/>
    <sio:SIO_000228>dikbD2R:object-drug-of-interaction</sio:SIO_000228>
    <rdfs:label>alprazolam</rdfs:label>
    <dct:description>Referred to the drug in the interaction.</dct:description>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N61238ce31e1d45f888a53839a744161f">
    <domeo:sets rdf:resource="urn:pddi:uuid:574FF5F7-13AA-497F-8060-12A8C869458F"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:62CFF391-05E7-402D-96DB-3D69E36FBCE0">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/6416BB2E-E31D-401D-80C0-9136D4AAEC24"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/99F4DC31-8BF6-4A47-9616-EDDAF0783C76"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na19b0dd402df4cfeb76b22632a46c8f9">
    <domeo:sets rdf:resource="urn:pddi:uuid:DE5DD0C7-8157-4179-B542-7367D2140BB7"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na8cbce6f4c2e47f8b0be020eedf963c4">
    <domeo:sets rdf:resource="urn:pddi:uuid:444270ED-51A4-488D-82AF-C401D6B8D636"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:0216D85F-E05A-4F90-9F6E-C044A9A60534">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/2488D451-0C05-404A-AE57-E5B272F707DE"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/B01BB01D-87CB-4E43-B8BE-582A25B5B6D6"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:2A85AB94-C993-4CA7-BB35-A605E1007165">
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:FDB5E8CF-B1ED-4248-B148-8CD7C377E595"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nac93974c23f04158a96643fe7953862a">
    <domeo:sets rdf:resource="urn:pddi:uuid:59ED443A-C2AF-4273-855E-D51D1A91E24A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7a98df939d53483b863c5db71965bd3a">
    <domeo:sets rdf:resource="urn:pddi:uuid:9D207858-AC88-4FB3-970F-5EA02E8D2555"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:836A9ED8-3168-46A8-8BFD-D0B77AB5A1E1">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/9D1EE414-DD79-41FD-89D1-F4D250EAC251"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/628C73B2-2620-4BC1-AA54-BDE1133DE537"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6e330c49c5ac4ea0ac3dae1c1925cc1f">
    <domeo:sets rdf:resource="urn:pddi:uuid:8678E0CA-6432-40E2-8C6F-78AB05431252"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2bd056353cd648f59518ad341749e9ac">
    <domeo:sets rdf:resource="urn:pddi:uuid:E1A13E6B-FEC0-4B30-A55E-08FABDACB329"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N78632914b245462d8cca75a00c2bcc8d">
    <domeo:sets rdf:resource="urn:pddi:uuid:CB70CFDA-E17D-4A6C-8B95-CB742B5D4532"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndf5c7015115a486da6516c5be87cb76f">
    <domeo:sets rdf:resource="urn:pddi:uuid:2E7A875D-C094-4C0A-8F23-05E683DED388"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N81c54f25f6ef4bcaa93b1ea0607c2c4d">
    <domeo:sets rdf:resource="urn:pddi:uuid:828ADF4C-8F84-4AE2-BB18-82DCC3BFEE8E"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne533b0ec15b24a228758832ded86c082">
    <domeo:sets rdf:resource="urn:pddi:uuid:01836909-A227-4192-B564-D5631329F0C9"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N62ced0d0f7ae4f37aee621edfdf09715">
    <domeo:sets rdf:resource="urn:pddi:uuid:6CF28FF1-AF53-4495-8FE3-1E29D72C8CEC"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:linkedspls:uuid:0768CA5A-42B5-4AEE-898D-336AADC10B13">
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#PharmacogenomicsStatement"/>
    <rdfs:label>Comment</rdfs:label>
    <poc:Comment>what an awesome annotation!</poc:Comment>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:561CF841-9DB6-49E0-9798-A297976A2336">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DF9B1097-2090-453D-AF71-6310D301DA86"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/DEC213F1-5C66-4AC5-9443-03F6A2229756"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N472a760b1b704e05972b1f159e4bc8ac">
    <domeo:sets rdf:resource="urn:pddi:uuid:2A1F7A1E-6D01-428F-B598-26E80043C4C2"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:1D7580AB-8752-466C-A439-C8E0D9F02120">
    <dikbD2R:statement>ncit:Qualitative</dikbD2R:statement>
    <sio:SIO_000563>dikbD2R:modality</sio:SIO_000563>
    <sio:SIO_000628 rdf:resource="urn:pddi:uuid:2918AAD1-E59E-4604-8CD5-016C5F8C0ACB"/>
    <dikbD2R:modality>ncit:positive</dikbD2R:modality>
    <rdf:type rdf:resource="http://purl.org/net/nlprepository/spl-pharmgx-annotation-poc#DrugDrugInteractionStatement"/>
    <sio:SIO_000205>dikbD2R:statement</sio:SIO_000205>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0a643efb841748ab8e96182b24f5b66c">
    <domeo:sets rdf:resource="urn:pddi:uuid:2D4B4751-6FCB-4C88-9179-CBB2EE796D26"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd6e1d7a1f8d647fd978db86fc0afe9f2">
    <domeo:sets rdf:resource="urn:pddi:uuid:55E33A88-4EAA-4FB5-A3A9-0E1542B3AA85"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N19f478ab592841d785e358ff6f52aa7e">
    <domeo:sets rdf:resource="urn:pddi:uuid:1F3F4371-FBB9-439C-AB77-55AA1CAF8655"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5de6e28ed60044ea90e5d284543ec39c">
    <domeo:sets rdf:resource="urn:pddi:uuid:D62F7837-84F3-40D9-B4C6-C37715C61B6A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0df7b1d117e04bf7b85d0c07d4c0900e">
    <domeo:sets rdf:resource="urn:pddi:uuid:115D6BEA-61FB-408B-BE9D-158A3C4A672C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfe41af0e32fe411faf69071727977348">
    <domeo:sets rdf:resource="urn:pddi:uuid:E773DAFA-3AB4-468F-AF00-DB4F5DE42B6C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2993ba8f20054a72a7958d1dc10a61f6">
    <domeo:sets rdf:resource="urn:pddi:uuid:431F3FB0-9ED9-4DCB-9738-492413431665"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N15a4773be7bd473594d205e24729e8a1">
    <domeo:sets rdf:resource="urn:pddi:uuid:78BD474F-2894-4999-851D-7B58FDA38108"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N855af5e56bae48f983922a82beafa8b3">
    <domeo:sets rdf:resource="urn:pddi:uuid:6C3D8967-44BA-4108-AFBB-CF1B7B82A16F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N507a6d45c5114087ab0df006d9a150b1">
    <domeo:sets rdf:resource="urn:pddi:uuid:544F1A0B-6C64-4B6C-B623-DF98000D3F29"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd42aad590fa44dc3a399324cbb36ebce">
    <domeo:sets rdf:resource="urn:pddi:uuid:F1933D6D-9F3E-4BF7-80E7-B20BFDA0CC04"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4892cc1c43ba46cbb67c5c8f08ac6d88">
    <domeo:sets rdf:resource="urn:pddi:uuid:9F35ECA3-9A50-47BB-90FF-F0352719F403"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:02603A02-9277-416E-802B-D18E2636893E">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8A9DD9CA-AD6B-41AA-9EB3-37DD8E6B1448"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/55569A80-4A18-47C6-804A-8B13AAF0A793"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0d554189f939461d8ce6d9abf7e93c22">
    <domeo:sets rdf:resource="urn:pddi:uuid:6E1C4379-985E-4A39-B253-07A55A93BFCE"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N129e82459ed24b188ac34885f682cf28">
    <domeo:sets rdf:resource="urn:pddi:uuid:A157546F-42C1-4855-AE82-E4CD1FDCCBA3"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf570867ada6249a4a3b501401069f461">
    <domeo:sets rdf:resource="urn:pddi:uuid:F8FEA01F-5802-49B2-9B99-748333B3B90F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4c1b798e95a44a2292ecba7934d2be7b">
    <domeo:sets rdf:resource="urn:pddi:uuid:C67D2B74-8217-4F94-B27D-58E382DC69CD"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4fee2038a0bc49d7bac96c39d604c780">
    <domeo:sets rdf:resource="urn:pddi:uuid:5460F551-AC63-4535-973D-D0F058F9518A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7537fda7e8794a8197b8590892d938ee">
    <domeo:sets rdf:resource="urn:pddi:uuid:0CE9B7E7-ABBF-4E8E-ABC8-DB03865B9C2A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nef155112b5624b51a22244c0f7bfc80a">
    <domeo:sets rdf:resource="urn:pddi:uuid:478316AB-63D1-4CCC-8174-F4FA6BF833D9"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc375534964cd457ca8e489679bcd7b1c">
    <domeo:sets rdf:resource="urn:pddi:uuid:EE25ADE9-3E14-4953-AF7B-200DFF38B286"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7ab544a8311a4991a26d9bad63974630">
    <domeo:sets rdf:resource="urn:pddi:uuid:20B499B4-2C14-4656-9B9F-3B37ECC304FE"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N29fc2e1686d2481da9aa49a4d1fdb237">
    <domeo:sets rdf:resource="urn:pddi:uuid:FB837169-4577-475A-9C8C-F9E8B826D304"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6327cf99c497425ca63616d61f499a55">
    <domeo:sets rdf:resource="urn:pddi:uuid:FAF53196-24EB-417F-B2F5-4037FD5B9F20"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N919d44e7323a46adaead59f8b626312b">
    <domeo:sets rdf:resource="urn:pddi:uuid:6C7C7983-18BD-4457-87BC-590968958908"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nda150563f7e74340897874a7daa865f5">
    <domeo:sets rdf:resource="urn:pddi:uuid:6E11779D-86CD-474D-B2C3-EE46C71E6B66"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nce2d499b24ab4ecaa838ab8c74a6b280">
    <domeo:sets rdf:resource="urn:pddi:uuid:8F8A29D9-1378-48CD-8E5F-EAEBE68D2E8F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3f41a57d6e174bd2a34f28b2a721afee">
    <domeo:sets rdf:resource="urn:pddi:uuid:C5762CDA-09BB-47D3-A83B-0B1BC127AAA0"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7c89e5d32ea94247bf15a32e747c17d6">
    <domeo:sets rdf:resource="urn:pddi:uuid:F13DDBBD-0D4A-4433-8F3E-F2DE519D5368"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N99ec727a9bf24d22b251d50f09b96102">
    <domeo:sets rdf:resource="urn:pddi:uuid:BFA6410B-1C67-4B5F-AF2C-525757EC91DC"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Na121ec03031f4e9ba60cccacafe160f0">
    <domeo:sets rdf:resource="urn:pddi:uuid:EE8109C6-F996-4992-83CA-022BC0576074"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nff4d5c0bd0c947728d50312dcb8a4c7e">
    <domeo:sets rdf:resource="urn:pddi:uuid:6D0CC975-6BE7-431D-9466-39ED14B3EE0E"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3c2cade066c843d7b58bad795b5e7586">
    <domeo:sets rdf:resource="urn:pddi:uuid:A4621498-3014-44FF-A863-4D9667907AA0"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2cea5e0ca10345dfac1b59c8b4525f00">
    <domeo:sets rdf:resource="urn:pddi:uuid:0AA7C57A-C28F-4C48-BC86-A8B2F1DDC411"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ncebeea2da3cf4a46bcffcbc18cecaa1e">
    <domeo:sets rdf:resource="urn:pddi:uuid:77CF1A27-F7DB-4B5F-9F59-6E2E483DEA12"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3f9bd300206e4ba6a647274b686f2d88">
    <domeo:sets rdf:resource="urn:pddi:uuid:7F9CF7B8-2195-48E6-B19C-7A9F0E1EC342"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N70d230cb157b4f2fa4772ce0f7e8c0f5">
    <domeo:sets rdf:resource="urn:pddi:uuid:6C74F45B-5AF2-428C-8F42-7060B0272693"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb6874c23d10746bb889eadebdc134433">
    <domeo:sets rdf:resource="urn:pddi:uuid:1BE4CA5F-EDFB-4059-A4C9-35914BF2ADF4"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:03E18AD1-EFAA-4E41-A6B0-D5FE7C8C9BC5">
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/8D611268-C3CA-4B8B-8BE5-CCEE1B802599"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/22ADA332-6E7E-4B45-8F2C-28B248EFAFCB"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndbb83f681f364abdac51215ebbb878ef">
    <domeo:sets rdf:resource="urn:pddi:uuid:109474B3-F064-428B-8CC5-295B8EB15FD2"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6c1c41f3b7fd40babadd6c298bd1e72f">
    <domeo:sets rdf:resource="urn:pddi:uuid:532FFB8D-A0B2-44DD-8521-C58EE3F8B271"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7023dca4c49f439082bf1b793c2bc17a">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5016ad2a1779422aa23395ee25eabdf9">
    <domeo:sets rdf:resource="urn:pddi:uuid:56796674-1FE0-4010-A3FE-6DA9ED404E88"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf01dc4fda0b540caa80ac44411374836">
    <domeo:sets rdf:resource="urn:pddi:uuid:41A964F8-890F-418E-9391-8D77BE8A2F18"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N736cb82c7897487a88e42e0f6f2ae419">
    <domeo:sets rdf:resource="urn:pddi:uuid:BD9E51FD-D663-4C35-8EAB-B6AB4DFC3DB2"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3134d59ae9f84af9b9cd19c22a9e5921">
    <domeo:sets rdf:resource="urn:pddi:uuid:765E9F86-0CF5-4A87-A414-84F349811B56"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N3850506bbabe483cbb0d87eed5d0f4a2">
    <domeo:sets rdf:resource="urn:pddi:uuid:BED03FA5-9E57-4FE6-B474-FBD6C633C54F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N46c21e06b0c64cc2a2994805fbd89c51">
    <domeo:sets rdf:resource="urn:pddi:uuid:34EC7320-1B97-46E2-9EA5-319DBD84D27C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2c8b797d6bb644a2b915c60b9c8c7fd8">
    <permissions:accessType>urn:person:uuid:080e143043ef9cf90143f8ea240c0005</permissions:accessType>
    <permissions:isLocked>false</permissions:isLocked>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N658d48d73e144f2b8b58465c35d46f60">
    <domeo:sets rdf:resource="urn:pddi:uuid:2E0F624B-1BE7-43A4-9ED7-25412422C615"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb55889e61020446a944f53770fdfec96">
    <domeo:sets rdf:resource="urn:pddi:uuid:5CB3F5BE-D8EE-4652-A953-E8A1DC770705"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfa2dea0e56df4cbb815ea2b3344da591">
    <domeo:sets rdf:resource="urn:pddi:uuid:29473796-19E7-4D38-9560-AA88C28F9FD8"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N24bd94619454445faaf2810ce318cc92">
    <domeo:sets rdf:resource="urn:pddi:uuid:B48B1E77-F1D1-4DD5-8343-F0BDDFEF55BB"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4a0128b05aeb4778a4499bf1f87fe130">
    <domeo:sets rdf:resource="urn:pddi:uuid:424C6CE5-EDF5-4A96-BB21-222F75EB72FC"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N724f723091d44a39ae1549104b0b234f">
    <domeo:sets rdf:resource="urn:pddi:uuid:105CF640-753B-43C5-957A-87EA5C5586D1"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N64bebd049c334ff7a5fbb50431b9d964">
    <domeo:sets rdf:resource="urn:pddi:uuid:DFB2591B-62E6-4EBD-8A34-A6273831DB8E"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc8650a50db2d4bd98428956293b1d420">
    <domeo:sets rdf:resource="urn:pddi:uuid:0BFF1C7C-23AF-4B59-AA57-05DB5F5EEEAD"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N33c8677f23454807bb0dda53702cf9de">
    <domeo:sets rdf:resource="urn:pddi:uuid:11BF79FC-D4CB-4AA3-A2A5-72A80A25EE56"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N41cce41e35184bdc974ddae9d769102d">
    <domeo:sets rdf:resource="urn:pddi:uuid:CD253487-2236-4233-8018-9CDB85F89040"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd0446fa6a97e48e198e4cb0cbfe66dd0">
    <domeo:sets rdf:resource="urn:pddi:uuid:7D9785A9-6383-44E5-8DB7-0E1C0D3A7283"/>
  </rdf:Description>
  <rdf:Description rdf:about="urn:pddi:uuid:BFE2309E-0451-4F6F-B065-4457A24B1C0E">
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/21D219EA-6DC6-4522-9154-9E0ECFE1705A"/>
    <sio:SIO_000132 rdf:resource="file:///var/opt/Downloads/domeo/DomeoClient/Design/python-SPL-connector/C7F050D4-7AEF-4BE7-81F0-6B5109D78143"/>
    <rdf:type rdf:resource="http://dbmi-icode-01.dbmi.pitt.edu:2020/vocab/resource/PK_DDI"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd248526e4c5d445eb101b296dce075a8">
    <domeo:sets rdf:resource="urn:pddi:uuid:6E2F72BD-DCE6-4B9F-8A11-C0C47CD56B18"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N835d10a036d94426a4fd933225b08698">
    <domeo:sets rdf:resource="urn:pddi:uuid:45E2683D-3B8E-46A3-B025-28C2F533D051"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc8ec8707c16148949c59626a7ff6e857">
    <domeo:sets rdf:resource="urn:pddi:uuid:00F6D7A8-ADDC-4EEF-8B54-2538CCE00AAF"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7491d5ceb3634cf6a1320315e1532817">
    <domeo:sets rdf:resource="urn:pddi:uuid:ECF9BE3A-3729-4936-9391-499AE1D37C57"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nea286e88440846f186e68cb78198880f">
    <domeo:sets rdf:resource="urn:pddi:uuid:E3E66202-09AD-48C3-BFA0-E00BD8C9C48F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfe77b05c35d84781b7fba6f8f954a96e">
    <domeo:sets rdf:resource="urn:pddi:uuid:10303B76-B21D-40E5-86E2-AC2A99F114BC"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4c37bf8217334902b2f65314fcd39920">
    <domeo:sets rdf:resource="urn:pddi:uuid:4B3F18EE-DFF2-417A-86A9-A1C3C40B55A1"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N5bcb65e85b9d41f3b42b12cfb1d9b7d6">
    <domeo:sets rdf:resource="urn:pddi:uuid:0D671E14-0A06-4713-9A7D-04E9773C855A"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbe5d2e8b2a804815826a1de8597b6530">
    <domeo:sets rdf:resource="urn:pddi:uuid:0DC742B1-BF20-4178-B00E-C8EFC639DD44"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ne6b115537dd64ecca390f3c189617d86">
    <domeo:sets rdf:resource="urn:pddi:uuid:AFBB5843-B21C-4B1F-AF5E-5AA60AF92EA4"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N80f157dabc07486a985f7f03fc2d03b0">
    <domeo:sets rdf:resource="urn:pddi:uuid:8798FEA7-9B12-4A71-A25B-7AA5A785F4C1"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4e948442a4c14a21b7d2910a5e8cab41">
    <domeo:sets rdf:resource="urn:pddi:uuid:9D339366-5C9E-4A0B-A282-FD01A8D970EF"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0cfebc8800a84a6dbc8c22b85987eaec">
    <domeo:sets rdf:resource="urn:pddi:uuid:51BD9699-910E-4FD0-A63A-D68388FDA719"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N08a343800fd4450fbc90450a7acae9a4">
    <domeo:sets rdf:resource="urn:pddi:uuid:CEA03631-9D8A-43C6-B7D6-B3C014AFC833"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8dc96ff55de7453d8340b1264c113d58">
    <domeo:sets rdf:resource="urn:pddi:uuid:2CEEDAA8-C06E-4CF2-BC26-160763C76B7B"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N72c241a453e1485b9559fac45722cd62">
    <domeo:sets rdf:resource="urn:pddi:uuid:0D552947-8625-4606-9AD7-7BF6071BDBA9"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4f233366e74948d194515daa501377d4">
    <domeo:sets rdf:resource="urn:pddi:uuid:1E167070-34E0-487B-8906-3D4713302363"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbac83f10c9344ac0babcb5c491e07b78">
    <domeo:sets rdf:resource="urn:pddi:uuid:9BC80BE8-ABC9-4678-B052-80482D209D83"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0f3a7bb0e3a449728be1b9e6f11ed2b8">
    <domeo:sets rdf:resource="urn:pddi:uuid:F770A719-12D3-4A36-A8EA-82CFEB6E0821"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N2579bc32cc3b48cc8b8e42a205c43b23">
    <domeo:sets rdf:resource="urn:pddi:uuid:45BEC177-C8EC-4C18-A85D-871A6FD0B5B1"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N8cb1e4b6916d49d7b8b415ac3dbeb814">
    <domeo:sets rdf:resource="urn:pddi:uuid:1432A4AA-FDB4-4896-B1E8-282338FA3F4F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N368db959383c4b2599a5976bdceebab9">
    <domeo:sets rdf:resource="urn:pddi:uuid:5D602923-348F-43D6-9140-86EFFC84570D"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N31235d9575214181b73cae0ec93105b4">
    <domeo:sets rdf:resource="urn:pddi:uuid:2F258F00-52DA-4240-8817-2F94CB72286D"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nb087eaa8c040492ca166cf58e7832c86">
    <domeo:sets rdf:resource="urn:pddi:uuid:8166155C-393C-45B1-A8D8-E895C20F3D99"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N716dfad114964064aed0ce70c9ff6834">
    <domeo:sets rdf:resource="urn:pddi:uuid:CB82B7D7-65F5-47DB-B759-FD272307C843"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf32bcb0983bd4f96adb03287c5c59066">
    <domeo:sets rdf:resource="urn:pddi:uuid:FA277D75-02D4-452E-80B4-9F36CF1CF573"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd85fd1cb75074465be16877532c01d53">
    <domeo:sets rdf:resource="urn:pddi:uuid:54AFBACD-5A69-405B-A5F3-BDD53D7377F3"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6ee84d643f974750940e775c5dbd8205">
    <domeo:sets rdf:resource="urn:pddi:uuid:9112C7A2-148B-4685-8FEC-6415F27EA7B1"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nc6391147289c4003abd5aa682cb89b60">
    <domeo:sets rdf:resource="urn:pddi:uuid:0F8843A3-78E9-4700-99C6-6261D97D5E8F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nad58055d7eb94b548da34f1403f13155">
    <domeo:sets rdf:resource="urn:pddi:uuid:BEC10150-F68D-44FD-A3BA-397D82FE20D7"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N08dadf9cb8c64c588148c0641d0edcfe">
    <domeo:sets rdf:resource="urn:pddi:uuid:764395F8-5AFD-4E44-BF9C-0E47552B204F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0e7d2ecdfdb740989cc612c342351af5">
    <domeo:sets rdf:resource="urn:pddi:uuid:F7240EBE-4D25-4D4C-AC9B-8E9B04072967"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N83d8cd20b639458cadf39b8c7b688808">
    <domeo:sets rdf:resource="urn:pddi:uuid:05E6D336-7414-4C4F-AC25-BF6E922A2CAD"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N601648739b6647c6bf6520af5e2ef5fe">
    <domeo:sets rdf:resource="urn:pddi:uuid:A43FD6B2-3C37-43F7-BDA0-4CD8367D4DDC"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nca0d7e00e2ba4225892d37d8ab4a3f56">
    <domeo:sets rdf:resource="urn:pddi:uuid:1CC84A84-9696-46C0-A082-51EDC82C931B"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd4b872b20d944392ac6617d19df36f00">
    <domeo:sets rdf:resource="urn:pddi:uuid:538F9D58-A743-4EA9-93D6-A980C871E977"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd48eaf0394fc41b2b5268d4ef35ed004">
    <domeo:sets rdf:resource="urn:pddi:uuid:172F8373-6543-4D18-B064-EBAD6491B449"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nf3ddbea522b24c04bfee0ef13daa9900">
    <domeo:sets rdf:resource="urn:pddi:uuid:2CDA503C-6EC4-4CF6-A75D-1C18D768462D"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfe1978203f6d4b7fbf8618845abddddf">
    <domeo:sets rdf:resource="urn:pddi:uuid:88DA3795-F8CF-499E-A0E6-2C02E577312F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4b3eff938be543eeaf8c0ab984e89adf">
    <domeo:sets rdf:resource="urn:pddi:uuid:F15CC0C5-8322-4829-AE1E-EDD48EC6F753"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N4d3d0bcc6e264aa8bc5a66aa73fc61e0">
    <domeo:sets rdf:resource="urn:pddi:uuid:E3F0AA8A-350C-4D5B-8049-DB04CC917E7C"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nfa4ed7eb852f4f488795fae3a5c71e06">
    <domeo:sets rdf:resource="urn:pddi:uuid:66C219E4-EC64-425E-8265-823A7EB39E06"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N6fb2a40ec1e2482cadaffb63019ed838">
    <domeo:sets rdf:resource="urn:pddi:uuid:0B50AB0B-35ED-4E43-82DA-CFC072278D08"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nccee0c039f2942dbb6d912e75825d22f">
    <domeo:sets rdf:resource="urn:pddi:uuid:345461F7-EDAF-4FC6-9989-9C08C90A9BEB"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N7753a5d9a1d74c8ba2958b81ff650e61">
    <domeo:sets rdf:resource="urn:pddi:uuid:674AB29D-91D0-4A79-BA72-9E21D8D67D3B"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N48097d6a75674e1ebf2a8fcb3a13c211">
    <domeo:sets rdf:resource="urn:pddi:uuid:CFFE1E34-CEED-4DA5-B793-B7016EED59B8"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N246ac54b0cb7495ba8289a2ebb7874b7">
    <domeo:sets rdf:resource="urn:pddi:uuid:61DE5E52-F63C-4CA7-AE6A-4442B330D15F"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nbccee63e20f24a9c939eb0ff73202072">
    <domeo:sets rdf:resource="urn:pddi:uuid:8E78D0B8-F0A9-4839-9685-C656C6D46C26"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N17aed261ab2c4946b850e66d7878dfa0">
    <domeo:sets rdf:resource="urn:pddi:uuid:71317DF3-7CAF-4895-8E25-163954DE9D62"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Nd1efd8b5bc5441ed9de4dfb27929f262">
    <domeo:sets rdf:resource="urn:pddi:uuid:FEA679D5-C7D7-4859-BA01-6F91997B0C9B"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N704b853b97944ba08ba3cd4d21b29312">
    <domeo:sets rdf:resource="urn:pddi:uuid:00D52F79-36F4-4CE9-B2F3-9F7D012B88E5"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N0eef503bedbf4a91a1138b848014c80d">
    <domeo:sets rdf:resource="urn:pddi:uuid:ECDD3130-2EB6-47EB-BBA3-C6BE4B38C054"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="N61620abfea634fe58f3eff9365d18db5">
    <domeo:sets rdf:resource="urn:pddi:uuid:593F9136-50EF-4080-9407-79BC9D1D95EF"/>
  </rdf:Description>
  <rdf:Description rdf:nodeID="Ndde8c450a967474ba5386e60b15d3738">
    <domeo:sets rdf:resource="urn:pddi:uuid:16C6B0FF-0B69-479C-82CC-438323CF8CF9"/>
  </rdf:Description>
</rdf:RDF>
